0001178913-24-002281.txt : 20240724 0001178913-24-002281.hdr.sgml : 20240724 20240724160554 ACCESSION NUMBER: 0001178913-24-002281 CONFORMED SUBMISSION TYPE: 20-F/A PUBLIC DOCUMENT COUNT: 135 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240724 DATE AS OF CHANGE: 20240724 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHL TELEMEDICINE LTD CENTRAL INDEX KEY: 0001166834 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 20-F/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41641 FILM NUMBER: 241138118 BUSINESS ADDRESS: STREET 1: 90 YIGAL ALON STREET CITY: TEL AVIV ISRAEL STATE: L3 ZIP: 67891 BUSINESS PHONE: 972-3-5612212 MAIL ADDRESS: STREET 1: 90 YIGAL ALON STREET CITY: TEL AVIV ISRAEL STATE: L3 ZIP: 67891 20-F/A 1 zk2431705.htm 20 F/A SHL TELEMEDICINE LTD - 1166834 - 2024
The terms of billed accounts receivable are generally 30-60 days. As of December 31, 2023 and 2022, there were no material billed receivables that were past due. 0001166834FYtrueILThe Prime rate as of December 31, 2023 – 6.25% (December 31, 2022 – 4.75%). $159 presented in other comprehensive income. The index on an average basis of 1993 = 100. Represents an amount lower than $1. The recoverable amount of the cash generating units to which the goodwill mainly relates has been determined based on a value in use calculation using cash flow projections from financial budgets approved by senior management covering a five-year period. Including expenses related to employee benefits and other direct expenditures arising from the restructuring. See Note 22b for information on fair value measurement. 0001166834 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMember 2022-12-31 0001166834ifrs-full:AccumulatedImpairmentMember 2022-12-31 0001166834 2023-12-31 0001166834 2022-12-31 0001166834ifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:AccumulatedImpairmentMember 2023-12-31 0001166834 2022-01-01 2022-12-31 0001166834 2021-01-01 2021-12-31 0001166834ifrs-full:PresentValueOfDefinedBenefitObligationMember 2022-12-31 0001166834ifrs-full:PresentValueOfDefinedBenefitObligationMember 2023-01-01 2023-12-31 0001166834ifrs-full:PlanAssetsMember 2023-12-31 0001166834ifrs-full:PlanAssetsMember 2022-12-31 0001166834ifrs-full:BottomOfRangeMember 2023-12-31 0001166834ifrs-full:TopOfRangeMember 2023-12-31 0001166834ifrs-full:BottomOfRangeMember 2022-12-31 0001166834ifrs-full:TopOfRangeMember 2022-12-31 0001166834ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2022-12-31 0001166834ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2022-01-01 2022-12-31 0001166834ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2022-12-31 0001166834ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2023-12-31 0001166834ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2023-12-31 0001166834ifrs-full:PresentValueOfDefinedBenefitObligationMember 2023-12-31 0001166834ifrs-full:PlanAssetsMember 2023-01-01 2023-12-31 0001166834ifrs-full:PresentValueOfDefinedBenefitObligationMember 2022-01-01 2022-12-31 0001166834ifrs-full:PresentValueOfDefinedBenefitObligationMember 2021-12-31 0001166834ifrs-full:PlanAssetsMember 2022-01-01 2022-12-31 0001166834ifrs-full:PlanAssetsMember 2021-12-31 0001166834 2021-12-31 0001166834ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2023-01-01 2023-12-31 0001166834dei:BusinessContactMember 2023-01-01 2023-12-31 0001166834shlt:AmericanDepositarySharesMember 2023-01-01 2023-12-31 0001166834ifrs-full:OrdinarySharesMember 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember 2021-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:MedicalEquipmentMember 2021-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember 2021-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember 2021-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember 2021-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:DevicesOnLoanMember 2021-12-31 0001166834ifrs-full:GrossCarryingAmountMember 2021-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember 2022-01-01 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember 2022-01-01 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember 2022-01-01 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:DevicesOnLoanMember 2022-01-01 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMember 2022-01-01 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:MedicalEquipmentMember 2022-01-01 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:MedicalEquipmentMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:DevicesOnLoanMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:MedicalEquipmentMember 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:DevicesOnLoanMember 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMember 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:MedicalEquipmentMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:DevicesOnLoanMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerEquipmentMember 2021-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:MedicalEquipmentMember 2021-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember 2021-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:VehiclesMember 2021-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember 2021-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:DevicesOnLoanMember 2021-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2021-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerEquipmentMember 2022-01-01 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:MedicalEquipmentMember 2022-01-01 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember 2022-01-01 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:VehiclesMember 2022-01-01 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:DevicesOnLoanMember 2022-01-01 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2022-01-01 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerEquipmentMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:MedicalEquipmentMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:VehiclesMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:DevicesOnLoanMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerEquipmentMember 2023-01-01 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:MedicalEquipmentMember 2023-01-01 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember 2023-01-01 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:VehiclesMember 2023-01-01 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember 2023-01-01 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:DevicesOnLoanMember 2023-01-01 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2023-01-01 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerEquipmentMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:MedicalEquipmentMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:VehiclesMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:DevicesOnLoanMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2023-12-31 0001166834ifrs-full:ComputerEquipmentMember 2023-12-31 0001166834shlt:MedicalEquipmentMember 2023-12-31 0001166834ifrs-full:OfficeEquipmentMember 2023-12-31 0001166834ifrs-full:VehiclesMember 2023-12-31 0001166834ifrs-full:LeaseholdImprovementsMember 2023-12-31 0001166834shlt:DevicesOnLoanMember 2023-12-31 0001166834ifrs-full:ComputerEquipmentMember 2022-12-31 0001166834shlt:MedicalEquipmentMember 2022-12-31 0001166834ifrs-full:OfficeEquipmentMember 2022-12-31 0001166834ifrs-full:VehiclesMember 2022-12-31 0001166834ifrs-full:LeaseholdImprovementsMember 2022-12-31 0001166834shlt:DevicesOnLoanMember 2022-12-31 0001166834 2021-01-07 0001166834 2021-01-21 2021-01-21 0001166834ifrs-full:IssuedCapitalMember 2021-01-21 2021-01-21 0001166834shlt:LiabilityForShareOptionsMember 2021-01-21 0001166834shlt:LiabilityForShareOptionsMember 2021-01-21 2021-01-21 0001166834ifrs-full:IssuedCapitalMember 2021-02-17 2021-02-17 0001166834shlt:LiabilityForShareOptionsMember 2021-02-17 0001166834shlt:LiabilityForShareOptionsMember 2021-02-17 2021-02-17 0001166834ifrs-full:OptionPricingModelMember 2023-01-01 2023-12-31 0001166834shlt:LiabilityForShareOptionsMemberifrs-full:OptionPricingModelMember 2022-01-01 2022-12-31 0001166834shlt:LiabilityForShareOptionsMemberifrs-full:BottomOfRangeMemberifrs-full:OptionPricingModelMember 2022-01-01 2022-12-31 0001166834shlt:LiabilityForShareOptionsMemberifrs-full:TopOfRangeMemberifrs-full:OptionPricingModelMember 2022-01-01 2022-12-31 0001166834ifrs-full:IssuedCapitalMember 2022-12-31 0001166834ifrs-full:IssuedCapitalMember 2023-01-01 2023-12-31 0001166834ifrs-full:IssuedCapitalMember 2022-01-01 2022-12-31 0001166834shlt:LiabilityForShareOptionsMember 2022-01-01 2022-12-31 0001166834shlt:LiabilityForShareOptionsMember 2022-12-31 0001166834shlt:LiabilityForShareOptionsMember 2023-01-01 2023-12-31 0001166834shlt:LiabilityForShareOptionsMember 2023-12-31 0001166834ifrs-full:IssuedCapitalMembershlt:IfrsOverAllotmentOptionMember 2023-01-01 2023-12-31 0001166834shlt:MonteCarloOptionPricingModelMember 2023-01-01 2023-12-31 0001166834ifrs-full:IssuedCapitalMembershlt:ExpectedDividendMeasurementInputMembershlt:MonteCarloOptionPricingModelMember 2022-01-01 2022-12-31 0001166834ifrs-full:IssuedCapitalMemberifrs-full:InterestRateMeasurementInputMembershlt:MonteCarloOptionPricingModelMember 2022-01-01 2022-12-31 0001166834ifrs-full:IssuedCapitalMembershlt:ExpectedAverageLifeOfOptionsMeasurementInputMembershlt:MonteCarloOptionPricingModelMember 2022-01-01 2022-12-31 0001166834shlt:LiabilityForShareOptionsMembershlt:SharePriceMeasurementInputMembershlt:MonteCarloOptionPricingModelMember 2022-01-01 2022-12-31 0001166834ifrs-full:IssuedCapitalMembershlt:IfrsOverAllotmentOptionMember 2023-12-31 0001166834shlt:IfrsRestrictedStockUnitsRsusMember 2021-12-20 2021-12-20 0001166834shlt:IfrsRestrictedStockUnitsRsusMember 2021-12-20 0001166834shlt:LiabilityForShareOptionsMember 2023-02-01 2023-02-28 0001166834shlt:LiabilityForShareOptionsMember 2021-02-01 2021-02-28 0001166834shlt:LiabilityForShareOptionsMember 2021-12-31 0001166834shlt:LiabilityForShareOptionsMembershlt:IfrsOverAllotmentOptionMember 2023-01-01 2023-12-31 0001166834ifrs-full:IssuedCapitalMembershlt:IfrsOverAllotmentOptionMember 2023-03-01 2023-03-31 0001166834shlt:LiabilityForShareOptionsMemberifrs-full:OptionPricingModelMember 2023-01-01 2023-12-31 0001166834ifrs-full:ReserveOfSharebasedPaymentsMember 2023-01-01 2023-12-31 0001166834shlt:ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2015Member 2022-01-02 2022-01-02 0001166834shlt:ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2015Member 2022-02-15 2022-02-15 0001166834shlt:ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2015Member 2022-06-20 2022-06-20 0001166834shlt:ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2015Member 2023-01-01 2023-01-02 0001166834shlt:ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2015Member 2023-05-01 2023-05-15 0001166834shlt:ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2015Member 2023-06-01 2023-06-18 0001166834shlt:ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2015Member 2021-10-31 0001166834shlt:ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2021Member 2023-01-01 2023-12-31 0001166834shlt:ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2021Member 2022-01-01 2022-12-31 0001166834ifrs-full:OptionPricingModelMembershlt:IfrsOverAllotmentOptionMember 2023-01-01 2023-12-31 0001166834shlt:ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2021Member 2021-01-01 2021-12-31 0001166834ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2023-12-31 0001166834ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2022-12-31 0001166834ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2023-01-01 2023-12-31 0001166834ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2022-01-01 2022-12-31 0001166834ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2021-12-31 0001166834ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2021-01-01 2021-12-31 0001166834 2020-12-31 0001166834ifrs-full:CountryOfDomicileMember 2023-01-01 2023-12-31 0001166834ifrs-full:CountryOfDomicileMember 2022-01-01 2022-12-31 0001166834ifrs-full:ForeignCountriesMembercountry:US 2023-01-01 2023-12-31 0001166834ifrs-full:ForeignCountriesMembercountry:DE 2023-01-01 2023-12-31 0001166834shlt:FixedAndIntangibleAssetsMember 2021-12-31 0001166834shlt:EmployeeBenefitLiabilitiesMember 2021-12-31 0001166834ifrs-full:UnusedTaxLossesMember 2021-12-31 0001166834shlt:FixedAndIntangibleAssetsMember 2022-01-01 2022-12-31 0001166834ifrs-full:UnusedTaxLossesMember 2022-01-01 2022-12-31 0001166834shlt:FixedAndIntangibleAssetsMember 2022-12-31 0001166834shlt:EmployeeBenefitLiabilitiesMember 2022-12-31 0001166834ifrs-full:UnusedTaxLossesMember 2022-12-31 0001166834shlt:FixedAndIntangibleAssetsMember 2023-01-01 2023-12-31 0001166834shlt:EmployeeBenefitLiabilitiesMember 2023-01-01 2023-12-31 0001166834ifrs-full:UnusedTaxLossesMember 2023-01-01 2023-12-31 0001166834shlt:FixedAndIntangibleAssetsMember 2023-12-31 0001166834shlt:EmployeeBenefitLiabilitiesMember 2023-12-31 0001166834ifrs-full:UnusedTaxLossesMember 2023-12-31 0001166834country:IL 2023-12-31 0001166834country:IL 2022-12-31 0001166834srt:EuropeMember 2023-12-31 0001166834srt:EuropeMember 2022-12-31 0001166834country:US 2023-12-31 0001166834country:US 2022-12-31 0001166834shlt:EmployeeBenefitLiabilitiesMember 2022-01-01 2022-12-31 0001166834shlt:ShortTermInvestmentsMember 2021-12-31 0001166834shlt:ShortTermInvestmentsMember 2022-01-01 2022-12-31 0001166834shlt:ShortTermInvestmentsMember 2022-12-31 0001166834shlt:ShortTermInvestmentsMember 2023-01-01 2023-12-31 0001166834shlt:ShortTermInvestmentsMember 2023-12-31 0001166834country:IL 2021-12-31 0001166834srt:EuropeMember 2021-12-31 0001166834country:US 2021-12-31 0001166834ifrs-full:ShareOptionsMember 2023-01-01 2023-12-31 0001166834ifrs-full:ShareOptionsMember 2022-01-01 2022-12-31 0001166834ifrs-full:MotorVehiclesMemberifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:MotorVehiclesMemberifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:MotorVehiclesMembersrt:WeightedAverageMember 2023-01-01 2023-12-31 0001166834ifrs-full:BuildingsMemberifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:BuildingsMemberifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:BuildingsMembersrt:WeightedAverageMember 2023-01-01 2023-12-31 0001166834shlt:MedicalEquipmentMemberifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001166834shlt:MedicalEquipmentMemberifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001166834shlt:MedicalEquipmentMembersrt:WeightedAverageMember 2023-01-01 2023-12-31 0001166834ifrs-full:VehiclesMemberifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:VehiclesMemberifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:VehiclesMembersrt:WeightedAverageMember 2023-01-01 2023-12-31 0001166834ifrs-full:OfficeEquipmentMemberifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:OfficeEquipmentMemberifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:OfficeEquipmentMembersrt:WeightedAverageMember 2023-01-01 2023-12-31 0001166834ifrs-full:ComputerEquipmentMemberifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:ComputerEquipmentMemberifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:ComputerEquipmentMembersrt:WeightedAverageMember 2023-01-01 2023-12-31 0001166834shlt:DevicesOnLoanMember 2023-01-01 2023-12-31 0001166834ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001166834ifrs-full:ComputerSoftwareMember 2023-01-01 2023-12-31 0001166834shlt:ContractsMember 2023-01-01 2023-12-31 0001166834ifrs-full:CustomerrelatedIntangibleAssetsMember 2023-01-01 2023-12-31 0001166834ifrs-full:TechnologybasedIntangibleAssetsMember 2023-01-01 2023-12-31 0001166834currency:ILS 2023-12-31 0001166834currency:EUR 2023-12-31 0001166834currency:USD 2023-12-31 0001166834currency:CHF 2023-12-31 0001166834currency:ILS 2022-12-31 0001166834currency:EUR 2022-12-31 0001166834currency:USD 2022-12-31 0001166834currency:CHF 2022-12-31 0001166834currency:ILS 2021-12-31 0001166834currency:EUR 2021-12-31 0001166834currency:USD 2021-12-31 0001166834currency:CHF 2021-12-31 0001166834currency:ILS 2023-01-01 2023-12-31 0001166834currency:EUR 2023-01-01 2023-12-31 0001166834currency:USD 2023-01-01 2023-12-31 0001166834currency:CHF 2023-01-01 2023-12-31 0001166834currency:ILS 2022-01-01 2022-12-31 0001166834currency:EUR 2022-01-01 2022-12-31 0001166834currency:USD 2022-01-01 2022-12-31 0001166834currency:CHF 2022-01-01 2022-12-31 0001166834currency:CHF 2021-01-01 2021-12-31 0001166834currency:USD 2021-01-01 2021-12-31 0001166834currency:EUR 2021-01-01 2021-12-31 0001166834currency:ILS 2021-01-01 2021-12-31 0001166834srt:EuropeMembershlt:InstitutionsAndPayersMember 2023-01-01 2023-12-31 0001166834srt:EuropeMember 2023-01-01 2023-12-31 0001166834country:ILshlt:IndividualsAndCommunitiesMember 2023-01-01 2023-12-31 0001166834country:ILshlt:InstitutionsAndPayersMember 2023-01-01 2023-12-31 0001166834country:ILshlt:OtherSegmentMember 2023-01-01 2023-12-31 0001166834country:IL 2023-01-01 2023-12-31 0001166834shlt:OtherGeographicalAreasMembershlt:OtherSegmentMember 2023-01-01 2023-12-31 0001166834shlt:OtherGeographicalAreasMember 2023-01-01 2023-12-31 0001166834shlt:IndividualsAndCommunitiesMember 2023-01-01 2023-12-31 0001166834shlt:InstitutionsAndPayersMember 2023-01-01 2023-12-31 0001166834shlt:OtherSegmentMember 2023-01-01 2023-12-31 0001166834srt:EuropeMembershlt:InstitutionsAndPayersMember 2022-01-01 2022-12-31 0001166834srt:EuropeMember 2022-01-01 2022-12-31 0001166834country:ILshlt:IndividualsAndCommunitiesMember 2022-01-01 2022-12-31 0001166834country:ILshlt:InstitutionsAndPayersMember 2022-01-01 2022-12-31 0001166834country:ILshlt:OtherSegmentMember 2022-01-01 2022-12-31 0001166834country:IL 2022-01-01 2022-12-31 0001166834shlt:OtherGeographicalAreasMembershlt:OtherSegmentMember 2022-01-01 2022-12-31 0001166834shlt:OtherGeographicalAreasMember 2022-01-01 2022-12-31 0001166834shlt:IndividualsAndCommunitiesMember 2022-01-01 2022-12-31 0001166834shlt:InstitutionsAndPayersMember 2022-01-01 2022-12-31 0001166834shlt:OtherSegmentMember 2022-01-01 2022-12-31 0001166834srt:EuropeMemberifrs-full:OperatingSegmentsMember 2022-01-01 2022-12-31 0001166834srt:EuropeMemberifrs-full:OperatingSegmentsMember 2021-01-01 2021-12-31 0001166834country:ILifrs-full:OperatingSegmentsMember 2022-01-01 2022-12-31 0001166834country:ILifrs-full:OperatingSegmentsMember 2021-01-01 2021-12-31 0001166834shlt:OtherGeographicalAreasMemberifrs-full:OperatingSegmentsMember 2022-01-01 2022-12-31 0001166834shlt:OtherGeographicalAreasMemberifrs-full:OperatingSegmentsMember 2021-01-01 2021-12-31 0001166834ifrs-full:OperatingSegmentsMember 2022-01-01 2022-12-31 0001166834ifrs-full:OperatingSegmentsMember 2021-01-01 2021-12-31 0001166834ifrs-full:UnallocatedAmountsMember 2022-01-01 2022-12-31 0001166834ifrs-full:UnallocatedAmountsMember 2021-01-01 2021-12-31 0001166834srt:EuropeMembershlt:IndividualsAndCommunitiesMember 2023-01-01 2023-12-31 0001166834shlt:OtherGeographicalAreasMembershlt:IndividualsAndCommunitiesMember 2023-01-01 2023-12-31 0001166834shlt:OtherGeographicalAreasMembershlt:InstitutionsAndPayersMember 2023-01-01 2023-12-31 0001166834srt:EuropeMembershlt:OtherSegmentMember 2023-01-01 2023-12-31 0001166834srt:EuropeMembershlt:OtherSegmentMember 2022-01-01 2022-12-31 0001166834srt:EuropeMembershlt:IndividualsAndCommunitiesMember 2022-01-01 2022-12-31 0001166834shlt:OtherGeographicalAreasMembershlt:IndividualsAndCommunitiesMember 2022-01-01 2022-12-31 0001166834shlt:OtherGeographicalAreasMembershlt:InstitutionsAndPayersMember 2022-01-01 2022-12-31 0001166834srt:EuropeMember 2021-01-01 2021-12-31 0001166834srt:EuropeMembershlt:OtherSegmentMember 2021-01-01 2021-12-31 0001166834srt:EuropeMembershlt:InstitutionsAndPayersMember 2021-01-01 2021-12-31 0001166834srt:EuropeMembershlt:IndividualsAndCommunitiesMember 2021-01-01 2021-12-31 0001166834country:IL 2021-01-01 2021-12-31 0001166834country:ILshlt:OtherSegmentMember 2021-01-01 2021-12-31 0001166834country:ILshlt:InstitutionsAndPayersMember 2021-01-01 2021-12-31 0001166834country:ILshlt:IndividualsAndCommunitiesMember 2021-01-01 2021-12-31 0001166834shlt:OtherGeographicalAreasMember 2021-01-01 2021-12-31 0001166834shlt:OtherGeographicalAreasMembershlt:OtherSegmentMember 2021-01-01 2021-12-31 0001166834shlt:OtherGeographicalAreasMembershlt:InstitutionsAndPayersMember 2021-01-01 2021-12-31 0001166834shlt:OtherGeographicalAreasMembershlt:IndividualsAndCommunitiesMember 2021-01-01 2021-12-31 0001166834shlt:OtherSegmentMember 2021-01-01 2021-12-31 0001166834shlt:InstitutionsAndPayersMember 2021-01-01 2021-12-31 0001166834shlt:IndividualsAndCommunitiesMember 2021-01-01 2021-12-31 0001166834srt:EuropeMemberifrs-full:OperatingSegmentsMember 2023-01-01 2023-12-31 0001166834country:ILifrs-full:OperatingSegmentsMember 2023-01-01 2023-12-31 0001166834shlt:OtherGeographicalAreasMemberifrs-full:OperatingSegmentsMember 2023-01-01 2023-12-31 0001166834ifrs-full:OperatingSegmentsMember 2023-01-01 2023-12-31 0001166834ifrs-full:UnallocatedAmountsMember 2023-01-01 2023-12-31 0001166834shlt:OtherSegmentMember 2023-01-01 2023-12-31 0001166834shlt:OtherSegmentMember 2022-01-01 2022-12-31 0001166834shlt:OtherSegmentMember 2021-01-01 2021-12-31 0001166834srt:EuropeMember 2023-12-31 0001166834ifrs-full:UnallocatedAmountsMember 2023-12-31 0001166834shlt:OtherGeographicalAreasMember 2023-12-31 0001166834country:IL 2023-12-31 0001166834ifrs-full:UnallocatedAmountsMember 2022-12-31 0001166834shlt:OtherGeographicalAreasMember 2022-12-31 0001166834country:IL 2022-12-31 0001166834srt:EuropeMember 2022-12-31 0001166834ifrs-full:UnallocatedAmountsMember 2021-12-31 0001166834shlt:OtherGeographicalAreasMember 2021-12-31 0001166834country:IL 2021-12-31 0001166834srt:EuropeMember 2021-12-31 0001166834ifrs-full:IssuedCapitalMember 2021-12-31 0001166834ifrs-full:AdditionalPaidinCapitalMember 2021-12-31 0001166834ifrs-full:TreasurySharesMember 2021-12-31 0001166834ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-31 0001166834ifrs-full:ReserveOfSharebasedPaymentsMember 2021-12-31 0001166834ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2021-12-31 0001166834ifrs-full:RetainedEarningsMember 2021-12-31 0001166834ifrs-full:EquityAttributableToOwnersOfParentMember 2021-12-31 0001166834ifrs-full:NoncontrollingInterestsMember 2021-12-31 0001166834ifrs-full:AdditionalPaidinCapitalMember 2022-01-01 2022-12-31 0001166834ifrs-full:EquityAttributableToOwnersOfParentMember 2022-01-01 2022-12-31 0001166834ifrs-full:TreasurySharesMember 2022-01-01 2022-12-31 0001166834ifrs-full:NoncontrollingInterestsMember 2022-01-01 2022-12-31 0001166834ifrs-full:RetainedEarningsMember 2022-01-01 2022-12-31 0001166834ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-01-01 2022-12-31 0001166834ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2022-01-01 2022-12-31 0001166834ifrs-full:ReserveOfSharebasedPaymentsMember 2022-01-01 2022-12-31 0001166834ifrs-full:NoncontrollingInterestsMember 2022-12-31 0001166834ifrs-full:EquityAttributableToOwnersOfParentMember 2022-12-31 0001166834ifrs-full:RetainedEarningsMember 2022-12-31 0001166834ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2022-12-31 0001166834ifrs-full:ReserveOfSharebasedPaymentsMember 2022-12-31 0001166834ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-12-31 0001166834ifrs-full:TreasurySharesMember 2022-12-31 0001166834ifrs-full:AdditionalPaidinCapitalMember 2022-12-31 0001166834ifrs-full:NoncontrollingInterestsMember 2023-01-01 2023-12-31 0001166834ifrs-full:EquityAttributableToOwnersOfParentMember 2023-01-01 2023-12-31 0001166834ifrs-full:RetainedEarningsMember 2023-01-01 2023-12-31 0001166834ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2023-01-01 2023-12-31 0001166834ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-01-01 2023-12-31 0001166834ifrs-full:TreasurySharesMember 2023-01-01 2023-12-31 0001166834ifrs-full:AdditionalPaidinCapitalMember 2023-01-01 2023-12-31 0001166834ifrs-full:NoncontrollingInterestsMember 2023-12-31 0001166834ifrs-full:EquityAttributableToOwnersOfParentMember 2023-12-31 0001166834ifrs-full:RetainedEarningsMember 2023-12-31 0001166834ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2023-12-31 0001166834ifrs-full:ReserveOfSharebasedPaymentsMember 2023-12-31 0001166834ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-12-31 0001166834ifrs-full:TreasurySharesMember 2023-12-31 0001166834ifrs-full:AdditionalPaidinCapitalMember 2023-12-31 0001166834ifrs-full:IssuedCapitalMember 2023-12-31 0001166834ifrs-full:CapitalisedDevelopmentExpenditureMember 2022-12-31 0001166834shlt:CustomerRelationsMember 2022-12-31 0001166834ifrs-full:TechnologybasedIntangibleAssetsMember 2022-12-31 0001166834ifrs-full:GoodwillMember 2022-12-31 0001166834ifrs-full:CapitalisedDevelopmentExpenditureMember 2023-01-01 2023-12-31 0001166834shlt:CustomerRelationsMember 2023-01-01 2023-12-31 0001166834ifrs-full:TechnologybasedIntangibleAssetsMember 2023-01-01 2023-12-31 0001166834ifrs-full:GoodwillMember 2023-01-01 2023-12-31 0001166834ifrs-full:CapitalisedDevelopmentExpenditureMember 2023-12-31 0001166834shlt:CustomerRelationsMember 2023-12-31 0001166834ifrs-full:TechnologybasedIntangibleAssetsMember 2023-12-31 0001166834ifrs-full:GoodwillMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:CapitalisedDevelopmentExpenditureMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:ContractsAndOthersMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:CustomerRelationsMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:TechnologybasedIntangibleAssetsMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:GoodwillMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:CapitalisedDevelopmentExpenditureMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:ContractsAndOthersMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:CustomerRelationsMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:TechnologybasedIntangibleAssetsMember 2023-12-31 0001166834ifrs-full:CapitalisedDevelopmentExpenditureMember 2021-12-31 0001166834ifrs-full:GoodwillMember 2021-12-31 0001166834ifrs-full:CapitalisedDevelopmentExpenditureMember 2022-01-01 2022-12-31 0001166834shlt:CustomerRelationsMember 2022-01-01 2022-12-31 0001166834ifrs-full:TechnologybasedIntangibleAssetsMember 2022-01-01 2022-12-31 0001166834shlt:ContractsAndOthersMember 2022-01-01 2022-12-31 0001166834ifrs-full:GoodwillMember 2022-01-01 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:CapitalisedDevelopmentExpenditureMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:ContractsAndOthersMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMembershlt:CustomerRelationsMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:TechnologybasedIntangibleAssetsMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:GoodwillMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:CapitalisedDevelopmentExpenditureMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:ContractsAndOthersMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembershlt:CustomerRelationsMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:TechnologybasedIntangibleAssetsMember 2022-12-31 0001166834shlt:IsraelTelemedicineCguMember 2023-12-31 0001166834shlt:IsraelTelemedicineCguMember 2022-12-31 0001166834shlt:IsraelMeditonCguMember 2023-12-31 0001166834shlt:IsraelMeditonCguMember 2022-12-31 0001166834shlt:InternationalCguMember 2023-12-31 0001166834shlt:InternationalCguMember 2022-12-31 0001166834shlt:CustomerRelationsMember 2021-12-31 0001166834ifrs-full:TechnologybasedIntangibleAssetsMember 2021-12-31 0001166834shlt:IsraelTelemedicineCguMembershlt:FiveYearForecastPeriodMember 2023-12-31 0001166834shlt:IsraelMeditonCguMembershlt:FiveYearForecastPeriodMember 2023-12-31 0001166834shlt:InternationalCguMembershlt:FiveYearForecastPeriodMember 2023-12-31 0001166834shlt:IsraelTelemedicineCguMembershlt:FiveYearForecastPeriodMember 2022-12-31 0001166834shlt:IsraelMeditonCguMembershlt:FiveYearForecastPeriodMember 2022-12-31 0001166834shlt:InternationalCguMembershlt:FiveYearForecastPeriodMember 2022-12-31 0001166834shlt:SalariesAndRelatedBenefitsMember 2023-01-01 2023-12-31 0001166834shlt:SalariesAndRelatedBenefitsMember 2022-01-01 2022-12-31 0001166834shlt:MedicalServicesMember 2023-01-01 2023-12-31 0001166834shlt:MedicalServicesMember 2022-01-01 2022-12-31 0001166834shlt:RentalFeesAndMaintenanceMember 2023-01-01 2023-12-31 0001166834shlt:RentalFeesAndMaintenanceMember 2022-01-01 2022-12-31 0001166834shlt:DepreciationAndAmortizationMember 2023-01-01 2023-12-31 0001166834shlt:DepreciationAndAmortizationMember 2022-01-01 2022-12-31 0001166834shlt:CostOfDevicesMember 2023-01-01 2023-12-31 0001166834shlt:CostOfDevicesMember 2022-01-01 2022-12-31 0001166834shlt:OthersMember 2023-01-01 2023-12-31 0001166834shlt:OthersMember 2022-01-01 2022-12-31 0001166834shlt:AmortizationOfDevelopmentCostsMember 2023-01-01 2023-12-31 0001166834shlt:AmortizationOfDevelopmentCostsMember 2022-01-01 2022-12-31 0001166834shlt:MarketingAndRelatedExpensesMember 2023-01-01 2023-12-31 0001166834shlt:MarketingAndRelatedExpensesMember 2022-01-01 2022-12-31 0001166834shlt:MaintenanceOfVehiclesMember 2023-01-01 2023-12-31 0001166834shlt:MaintenanceOfVehiclesMember 2022-01-01 2022-12-31 0001166834shlt:RentalFeesAndOfficeExpensesMember 2023-01-01 2023-12-31 0001166834shlt:RentalFeesAndOfficeExpensesMember 2022-01-01 2022-12-31 0001166834shlt:ProfessionalFeesMember 2023-01-01 2023-12-31 0001166834shlt:ProfessionalFeesMember 2022-01-01 2022-12-31 0001166834shlt:SalariesAndRelatedBenefitsMember 2021-01-01 2021-12-31 0001166834shlt:MedicalServicesMember 2021-01-01 2021-12-31 0001166834shlt:RentalFeesAndMaintenanceMember 2021-01-01 2021-12-31 0001166834shlt:DepreciationAndAmortizationMember 2021-01-01 2021-12-31 0001166834shlt:CostOfDevicesMember 2021-01-01 2021-12-31 0001166834shlt:OthersMember 2021-01-01 2021-12-31 0001166834shlt:AmortizationOfDevelopmentCostsMember 2021-01-01 2021-12-31 0001166834shlt:MarketingAndRelatedExpensesMember 2021-01-01 2021-12-31 0001166834shlt:MaintenanceOfVehiclesMember 2021-01-01 2021-12-31 0001166834shlt:RentalFeesAndOfficeExpensesMember 2021-01-01 2021-12-31 0001166834shlt:ProfessionalFeesMember 2021-01-01 2021-12-31 0001166834shlt:AgreementWithBankInIsraelMember 2021-08-29 0001166834shlt:AgreementWithBankInIsraelMember 2021-08-29 2021-08-29 0001166834ifrs-full:MotorVehiclesMember 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:MotorVehiclesMember 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:MotorVehiclesMember 2023-01-01 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:MotorVehiclesMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MotorVehiclesMember 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember 2023-01-01 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MotorVehiclesMember 2023-01-01 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember 2023-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MotorVehiclesMember 2023-12-31 0001166834ifrs-full:BuildingsMember 2023-12-31 0001166834ifrs-full:MotorVehiclesMember 2023-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember 2021-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:MotorVehiclesMember 2021-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember 2022-01-01 2022-12-31 0001166834ifrs-full:GrossCarryingAmountMemberifrs-full:MotorVehiclesMember 2022-01-01 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember 2021-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MotorVehiclesMember 2021-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember 2022-01-01 2022-12-31 0001166834ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MotorVehiclesMember 2022-01-01 2022-12-31 0001166834ifrs-full:BuildingsMember 2022-12-31 0001166834ifrs-full:MotorVehiclesMember 2022-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembershlt:CashAndCashEquivalentMember 2023-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembershlt:CashAndCashEquivalentMember 2022-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembershlt:ShortTermDepositsMember 2023-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberifrs-full:TradeReceivablesMember 2023-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberifrs-full:TradeReceivablesMember 2022-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembershlt:OtherAccountsReceivableMember 2023-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembershlt:OtherAccountsReceivableMember 2022-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembershlt:LongTermDepositsMember 2023-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembershlt:LongTermDepositsMember 2022-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2023-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2022-12-31 0001166834ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembershlt:CallOptionFromNonControllingInterestsMember 2023-12-31 0001166834ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembershlt:ShortTermInvestmentMember 2023-12-31 0001166834ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembershlt:ShortTermInvestmentMember 2022-12-31 0001166834ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember 2023-12-31 0001166834ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember 2022-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembershlt:CreditFromBanksAndOthersMember 2023-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembershlt:CreditFromBanksAndOthersMember 2022-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembershlt:TradePayablesMember 2023-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembershlt:TradePayablesMember 2022-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembershlt:OtherPayablesMember 2023-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembershlt:OtherPayablesMember 2022-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembershlt:LoansFromBanksMember 2023-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembershlt:LoansFromBanksMember 2022-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberifrs-full:LeaseLiabilitiesMember 2023-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberifrs-full:LeaseLiabilitiesMember 2022-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2023-12-31 0001166834ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2022-12-31 0001166834ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembershlt:LiabilityForShareOptionsMember 2023-12-31 0001166834ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembershlt:LiabilityForShareOptionsMember 2022-12-31 0001166834ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembershlt:LiabilityToUnderwritersMember 2023-12-31 0001166834ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembershlt:LiabilityToUnderwritersMember 2022-12-31 0001166834ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2023-12-31 0001166834ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2022-12-31 0001166834ifrs-full:CurrencyRiskMember 2023-01-01 2023-12-31 0001166834ifrs-full:CurrencyRiskMembercurrency:USD 2023-12-31 0001166834ifrs-full:CurrencyRiskMembercurrency:USD 2022-12-31 0001166834ifrs-full:CurrencyRiskMembercurrency:EUR 2023-12-31 0001166834ifrs-full:CurrencyRiskMembercurrency:EUR 2022-12-31 0001166834ifrs-full:EquityPriceRiskMember 2023-01-01 2023-12-31 0001166834shlt:TradePayablesMemberifrs-full:NotLaterThanOneYearMember 2023-12-31 0001166834shlt:TradePayablesMember 2023-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:NotLaterThanOneYearMember 2023-12-31 0001166834shlt:AccruedExpensesMember 2023-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2023-12-31 0001166834shlt:PutOptionToNonControllingInterestsMember 2023-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:NotLaterThanOneYearMember 2023-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2023-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2023-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2023-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanFiveYearsMember 2023-12-31 0001166834ifrs-full:LeaseLiabilitiesMember 2023-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:NotLaterThanOneYearMember 2023-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2023-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2023-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2023-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:LaterThanFiveYearsMember 2023-12-31 0001166834shlt:LoansAndCreditsFromBanksMember 2023-12-31 0001166834ifrs-full:NotLaterThanOneYearMember 2023-12-31 0001166834ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2023-12-31 0001166834ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2023-12-31 0001166834ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2023-12-31 0001166834ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001166834ifrs-full:LaterThanFiveYearsMember 2023-12-31 0001166834shlt:TradePayablesMemberifrs-full:NotLaterThanOneYearMember 2022-12-31 0001166834shlt:TradePayablesMember 2022-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:NotLaterThanOneYearMember 2022-12-31 0001166834shlt:AccruedExpensesMember 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMember 2022-12-31 0001166834shlt:LiabilityToUnderwritersMemberifrs-full:NotLaterThanOneYearMember 2022-12-31 0001166834shlt:LiabilityToUnderwritersMember 2022-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:NotLaterThanOneYearMember 2022-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2022-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2022-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2022-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001166834ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanFiveYearsMember 2022-12-31 0001166834ifrs-full:LeaseLiabilitiesMember 2022-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:NotLaterThanOneYearMember 2022-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2022-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2022-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2022-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001166834shlt:LoansAndCreditsFromBanksMemberifrs-full:LaterThanFiveYearsMember 2022-12-31 0001166834shlt:LoansAndCreditsFromBanksMember 2022-12-31 0001166834ifrs-full:NotLaterThanOneYearMember 2022-12-31 0001166834ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2022-12-31 0001166834ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2022-12-31 0001166834ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2022-12-31 0001166834ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001166834ifrs-full:LaterThanFiveYearsMember 2022-12-31 0001166834ifrs-full:LeaseLiabilitiesMember 2022-12-31 0001166834ifrs-full:LeaseLiabilitiesMember 2023-01-01 2023-12-31 0001166834ifrs-full:LeaseLiabilitiesMember 2023-12-31 0001166834shlt:LiabilityToUnderwritersMember 2022-12-31 0001166834shlt:LiabilityToUnderwritersMember 2023-01-01 2023-12-31 0001166834shlt:LiabilityToUnderwritersMember 2023-12-31 0001166834ifrs-full:LongtermBorrowingsMember 2022-12-31 0001166834ifrs-full:LongtermBorrowingsMember 2023-01-01 2023-12-31 0001166834ifrs-full:LongtermBorrowingsMember 2023-12-31 0001166834ifrs-full:LeaseLiabilitiesMember 2021-12-31 0001166834ifrs-full:LeaseLiabilitiesMember 2022-01-01 2022-12-31 0001166834shlt:LiabilityToUnderwritersMember 2022-01-01 2022-12-31 0001166834ifrs-full:LongtermBorrowingsMember 2022-01-01 2022-12-31 0001166834shlt:LiabilityForShareOptionsMemberifrs-full:Level3OfFairValueHierarchyMember 2022-12-31 0001166834shlt:LiabilityToUnderwritersMemberifrs-full:Level3OfFairValueHierarchyMember 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:Level3OfFairValueHierarchyMember 2022-12-31 0001166834ifrs-full:Level3OfFairValueHierarchyMember 2022-12-31 0001166834shlt:LiabilityForShareOptionsMemberifrs-full:Level3OfFairValueHierarchyMember 2023-01-01 2023-12-31 0001166834shlt:LiabilityToUnderwritersMemberifrs-full:Level3OfFairValueHierarchyMember 2023-01-01 2023-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:Level3OfFairValueHierarchyMember 2023-01-01 2023-12-31 0001166834ifrs-full:Level3OfFairValueHierarchyMember 2023-01-01 2023-12-31 0001166834shlt:LiabilityForShareOptionsMemberifrs-full:Level3OfFairValueHierarchyMember 2023-12-31 0001166834shlt:LiabilityToUnderwritersMemberifrs-full:Level3OfFairValueHierarchyMember 2023-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:Level3OfFairValueHierarchyMember 2023-12-31 0001166834ifrs-full:Level3OfFairValueHierarchyMember 2023-12-31 0001166834shlt:LiabilityForShareOptionsMemberifrs-full:Level3OfFairValueHierarchyMember 2021-12-31 0001166834shlt:LiabilityToUnderwritersMemberifrs-full:Level3OfFairValueHierarchyMember 2021-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:Level3OfFairValueHierarchyMember 2021-12-31 0001166834ifrs-full:Level3OfFairValueHierarchyMember 2021-12-31 0001166834shlt:LiabilityForShareOptionsMemberifrs-full:Level3OfFairValueHierarchyMember 2022-01-01 2022-12-31 0001166834shlt:LiabilityToUnderwritersMemberifrs-full:Level3OfFairValueHierarchyMember 2022-01-01 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:Level3OfFairValueHierarchyMember 2022-01-01 2022-12-31 0001166834ifrs-full:Level3OfFairValueHierarchyMember 2022-01-01 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMember 2023-01-01 2023-12-31 0001166834shlt:PutOptionToNonControllingInterestsMember 2022-01-01 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:BottomOfRangeMember 2022-01-01 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:TopOfRangeMember 2022-01-01 2022-12-31 0001166834ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembershlt:ShortTermDepositsMember 2022-12-31 0001166834ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembershlt:CallOptionFromNonControllingInterestsMember 2022-12-31 0001166834shlt:TradePayablesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2023-12-31 0001166834shlt:TradePayablesMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2023-12-31 0001166834shlt:TradePayablesMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2023-12-31 0001166834shlt:TradePayablesMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001166834shlt:TradePayablesMemberifrs-full:LaterThanFiveYearsMember 2023-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2023-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2023-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2023-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:LaterThanFiveYearsMember 2023-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2023-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:NotLaterThanOneYearMember 2023-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2023-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:LaterThanFiveYearsMember 2023-12-31 0001166834shlt:TradePayablesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2022-12-31 0001166834shlt:TradePayablesMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2022-12-31 0001166834shlt:TradePayablesMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2022-12-31 0001166834shlt:TradePayablesMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001166834shlt:TradePayablesMemberifrs-full:LaterThanFiveYearsMember 2022-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2022-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2022-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2022-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001166834shlt:AccruedExpensesMemberifrs-full:LaterThanFiveYearsMember 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:NotLaterThanOneYearMember 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001166834shlt:PutOptionToNonControllingInterestsMemberifrs-full:LaterThanFiveYearsMember 2022-12-31 0001166834shlt:LiabilityToUnderwritersMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2022-12-31 0001166834shlt:LiabilityToUnderwritersMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2022-12-31 0001166834shlt:LiabilityToUnderwritersMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2022-12-31 0001166834shlt:LiabilityToUnderwritersMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001166834shlt:LiabilityToUnderwritersMemberifrs-full:LaterThanFiveYearsMember 2022-12-31 0001166834ifrs-full:CurrencyRiskMembercurrency:USD 2023-01-01 2023-12-31 0001166834ifrs-full:CurrencyRiskMembercurrency:USD 2022-01-01 2022-12-31 0001166834ifrs-full:CurrencyRiskMembercurrency:EUR 2023-01-01 2023-12-31 0001166834ifrs-full:CurrencyRiskMembercurrency:EUR 2022-01-01 2022-12-31 0001166834shlt:LiabilityToUnderwritersMember 2021-12-31 0001166834ifrs-full:LongtermBorrowingsMember 2021-12-31 shlt:Capital_Increases iso4217:ILSxbrli:shares shlt:Share iso4217:CHFxbrli:shares iso4217:USDxbrli:shares iso4217:CHF iso4217:EUR iso4217:ILS iso4217:USD utr:Y shlt:Unit_Standard_item_uchMkKGtLkOnxpJzjI5Eyg xbrli:pure xbrli:shares shlt:Years

 

As filed with the Securities and Exchange Commission on July 24, 2024
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 20-F/A

(Amendment No. 1)

 
 
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
 
OR
 
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
   
For the fiscal year ended December 31, 2023
 
OR
 
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
OR
 
 
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
   
Date of event requiring this shell company report ________
 
For the transition period from ________ to ________
 
Commission file number 001-41641
 
SHL TELEMEDICINE LTD.
(Exact name of Registrant as specified in its charter and translation of Registrant’s name into English)
ISRAEL
(Jurisdiction of incorporation or organization)
90 Yigal Alon Street
Tel Aviv 67891, Israel
(Address of principal executive offices)
 Erez Nachtomy, Chief Executive Officer
Tel.: +972 (3) 561‑2212
90 Yigal Alon Street
Tel Aviv 67891, Israel
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
 
Securities registered or to be registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange
on which registered
American Depositary Shares, each representing one (1) ordinary share, nominal value NIS 0.01 per share
 
SHLT
 
Nasdaq Capital Market
 
 
 
 
 
Ordinary shares, nominal value NIS 0.01 per share*
 
 
 
 
*Not for trading, but only in connection with the registration of the American Depositary Shares.
 

Securities registered or to be registered pursuant to Section 12(g) of the Act:
 
None
(Title of Class)
 
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
 
None
(Title of Class)
 
Indicate the number of outstanding shares of each of the issuer’s class of capital or common stock as of the close of the period covered by the annual report: 16,392,754 as of December 31, 2023.
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
 
Yes  No 
 
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
 
Yes  No 
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
Yes  No 
 
Indicate by check mark whether registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
 
Yes  No 
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.
 
Large accelerated filer
Accelerated filer
Non-accelerated filer
Emerging growth company
 
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
 
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
 
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D‑1(b).
 
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
 
U.S. GAAP
International Financial Reporting Standards as issued by the International Accounting Standards Board 
Other ☐
 
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.
 
Item 17 Item 18
 
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act).
 
Yes  No 
 

EXPLANATORY NOTE
 
This Amendment No. 1 on Form 20-F/A (this “Amendment”) is being filed by SHL Telemedicine Ltd. to amend its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, originally filed with the U.S. Securities Exchange Commission (the “SEC”) on April 18, 2024 (the “Original Filing”). All references in this Amendment to the “Annual Report on Form 20-F” shall be deemed to refer to this Amendment. SHL Telemedicine Ltd. is filing this Amendment solely to (a) amend the disclosure set forth in Item 15(a) of the Original Filing regarding management’s conclusions regarding the effectiveness of disclosure controls and procedures; (b) amend the disclosure set forth in Item 15(b) to include Management’s Report on Internal Control over Financial Reporting; (c) amend the disclosure set forth in Item 15(d) related to changes in internal control over financial reporting; (d) include new and updated Section 302 Certifications as Exhibits 12.1 and 12.2 containing corresponding amendments to the language set forth in paragraph 4 thereof with respect to internal control over financial reporting; (e) include new and updated Section 906 Certifications furnished as Exhibits 13.1 and 13.2, which inadvertently referred to the incorrect fiscal year in the Original Filing; and (f) correct typographical errors in the Exhibit Index contained in the Original Filing.
 
Although this Amendment includes all of the Parts, Items, information, disclosures and Exhibits contained in the Original Filing as required by the SEC’s rules, it speaks as of the original filing date of the Original Filing and does not, and does not purport to, amend, modify, update, restate or change in any way any of such Parts, Items, information, disclosure or Exhibits contained in the Original Fling, including the previously reported consolidated financial statements, except as described above, nor does it reflect events occurring after the date of the Original Filing. Among other things, forward-looking statements made in the Original Filing have not been revised to reflect events that occurred or facts that became known to us after the date of the filing of the Original Filing, and such forward-looking statements should be read in their historical context. Accordingly, this Amendment should be read in conjunction with the Company's other filings made with the SEC subsequent to the filing of the Original Filing.
 


Table of Contents
 
 
 
Page
3
3
3
16
29
29
42
55
57
57
58
67
70
72
72
72
74
74
74
74
75
75
75
75
75
75
75
75
76
76
77


CONVENTIONS USED IN THIS ANNUAL REPORT
 
In this Annual Report on Form 20‑F, unless the context otherwise requires:
 

“SHL,” “the company,” “us,” “we” and “our” refer to SHL Telemedicine Ltd. and its subsidiaries;
 

“SHL Telemedicine” refers only to SHL Telemedicine Ltd., and
 

“Mediton” refers to the Mediton Group, in which we acquired a 70% interest on August 31, 2021.
 
Additionally, in this Annual Report:
 

“CHF” and “Swiss francs” refer to the legal currency of Switzerland;
 

“NIS” refers to New Israeli Shekels, the legal currency of the State of Israel;
 

“$” and “U.S. dollars” refer to the legal currency of the United States;
 

“ADSs” refers to our American Depositary Shares, each representing one (1) of our ordinary shares;
 

“IFRS” refers to International Financial Reporting Standards as issued by the International Accounting Standards Board;
 

“Ordinary shares” refers to our ordinary shares, nominal value NIS 0.01 per share;
 

“Nasdaq” refers to the Nasdaq Capital Market;
 

“SEC” refers to the United States Securities and Exchange Commission; and
 

“SIX” refers to the SIX Swiss Exchange Ltd.
 
Our reporting currency is the U.S. dollar. In this Annual Report, unless otherwise specified, all monetary amounts are in U.S. dollars. We prepare our financial statements in accordance with IFRS as issued by the International Accounting Standards Board.
 
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
 
This Annual Report on Form 20‑F contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, including, among others, statements regarding SHL and its business, financial condition and results of operations and the industry in which it operates, are forward-looking statements. Certain of these forward-looking statements are identifiable by use of the following words and other similar expressions: “anticipates,” “believes,” “budgets,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “might,” “will,” “plans,” “predicts,” “projects,” “scheduled,” “should” or similar phrases, although the absence of such words does not necessarily mean that a statement is not forward looking.
 
Readers are cautioned that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are beyond our control and could cause actual results to differ materially from historical results or any future results expressed or implied by forward-looking statements. Factors that can cause actual results to differ from expectations and those contained in forward-looking statements include those risks described in Item 3.D. “Key Information—Risk Factors” contained in this Annual Report, including, but not limited to, our ability to operate and comply with the complex and evolving regulations in the highly regulated healthcare industry; continued development, consumer acceptance and market adoption in the relatively new, unproven and volatile and rapidly changing telehealth market; our ability to develop and introduce new products and solutions and enhancements to existing ones; the significant and increasing levels of competition in the telemedicine market; the impacts of pandemics and epidemics; our ability to continue to attract and retain key employees and personal in the highly competitive healthcare industry; the loss or breach of our proprietary rights and data security and privacy risks; political, judicial, legal, economic and military conditions in Israel and the surrounding region; global economic and financial market conditions and our ability to adapt to and comply with the different business and market factors, conditions, requirements and laws and regulations in the various countries in which we operate internationally; currency fluctuations; labor disputes; our ability to manage growth and integrate acquired businesses and expanding operations; our ability to obtain adequate levels of insurance to cover potential losses; our dependence on key suppliers and sub-contractors and other third parties; and other matters and risks not yet known to us or not currently considered material by us.
 
2

You should not place undue reliance on these forward-looking statements. All written and oral forward-looking statements, attributable to us, or persons acting on our behalf, are qualified in their entirety by these cautionary statements. Unless required by law, SHL undertakes no obligation to publicly update or revise any forward-looking statements.
 
PART I
 
ITEM 1.
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
 
Not applicable.
 
ITEM 2.
OFFER STATISTICS AND EXPECTED TIMETABLE
 
Not applicable.
 
ITEM 3.
KEY INFORMATION
 
A.
[RESERVED]
 
B.
CAPITALIZATION AND INDEBTEDNESS
 
Not applicable.
 
C.
REASONS FOR THE OFFER AND USE OF PROCEEDS
 
Not applicable.
 
D.
RISK FACTORS
 
The realization of one or more of the events described below may have a material adverse effect on our cash flows, results of operations, financial condition, growth prospects and the trading price of our ADSs on Nasdaq and of our ordinary shares on the SIX. You should note that the risks discussed below are not the only risks to which we are exposed. Additional risks, which are not presently known to us or which we currently believe to be immaterial, could likewise result in a material adverse effect on our cash flows, results of operations, financial condition or growth prospects and the trading prices of our ADSs and ordinary shares. This section also contains forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors, including the risks described below and elsewhere in this Annual Report. The order in which the following risks are presented does not necessarily reflect the likelihood of their occurrence or the relative magnitude of their potential material adverse effects on our cash flows, results of operations, financial condition or growth prospects or the trading prices of our ADSs and ordinary shares.
 
Industry-specific Risks
 
We operate in a highly regulated industry and failure to comply with the complex regulations applicable to us could result in investigations, legal judgments or penalties, which could materially adversely affect our business.
 
Our ability to conduct telehealth services and medical services is subject to a variety of laws and regulatory regimes of the countries and jurisdictions in which we operate and provide our services, including a variety of labor laws, privacy regulations, anti-corruption, anti-competition or financial relationships of healthcare providers with service providers. Such regulatory requirements can vary from country to country and new requirements may be imposed on us from time to time. In a regulatory climate that is uncertain and constantly changing, our operations may be subject to direct and indirect adoption, expansion or reinterpretation of various laws and regulations. Compliance with these laws and regulations may require us to change our practices at an undeterminable and possibly significant initial monetary and recurring expense.
 
3

In addition, failure to properly adhere to these and other applicable laws and regulations could result in investigations, the imposition of penalties or adverse legal judgments by public or private plaintiffs, significant adverse publicity and reputational harm, suspension or revocation of licenses, fines, civil and/or administrative penalties, criminal penalties or other disciplinary actions, which could have a material adverse effect on our business, financial condition or results of operations.
 
We depend on evolving governmental regulation in and around the health care industry and failure to comply with these and other laws and regulations could have a material adverse effect on our business, financial condition and results of operations.
 
As a general matter, the healthcare industry is highly regulated. Regulations are constantly evolving and tend to be highly dependent on political developments as well as developments in the health insurance industry and in public finance. We are unable to predict future regulations and governmental decisions that might impact our business in the future with any certainty. Our business, financial condition and results of operations could be adversely affected by the failure to obtain required licenses and governmental approvals, comply with applicable regulations, or comply with existing or future laws, rules or regulations or their interpretations.
 
We and our business customers are subject to various laws governing privacy protection, confidentiality information and security laws. Because we and the Mediton Group retain personal and medical information of patients or other persons, we are also subject to data privacy protection and security laws, which require that owners of databases containing such information to meet certain obligations such as appointing a database administrator who shall supervise the use of the information only for its original purposes.
 
In various countries (such as Israel) a special authorization is needed to process and store personal data, such as patient medical data. The transmission of personal medical data via telecommunications, especially cross border transfer via internet, is a relatively new development, and patient and health care industry concerns regarding the confidentiality of such information could lead to further legislation and regulations that govern the methods of transmitting and storing patient medical data. Failure to comply with these and other laws and regulations could have a material adverse effect on our business, financial condition and results of operations.
 
In many countries, we are also subject to laws prohibiting the corporate practice of medicine and to laws that govern financial and other arrangements between health care providers and payers which are designed to induce the referral of a patient to a particular provider for medical products and services. Although we believe that we are in compliance with these laws, there can be no assurance that certain countries’ governments will not determine that our operations comprise a violation of the prohibition on corporate practice of medicine, and force us to restructure, alter or terminate our operations in those countries.
 
In Israel, we operate under legislations and regulations that apply to the provision of the telemedicine services provided by us and the healthcare services provided by the Mediton Group. In addition, medical equipment laws apply to the medical devices being used by our private pay subscribers and by the Mediton Group in providing its healthcare services. These laws provide that medical equipment may only be manufactured and marketed in Israel, if it is registered as medical equipment in the “AMR register,” in accordance with the Israeli registration conditions. In addition, certain regulations and Ministry of Health procedures apply to the provision of our telemedicine services and the use, operation, calibration and maintenance of certain medical devices or equipment and pharmaceutical products being used or operated by us or by the Mediton Group. The marketing and sale of our telemedicine services to our private pay consumers in Israel are also subject to the Consumer Protection Law and regulations, the goal of which is to protect customers that are individuals from misleading sales methods.
 
Our business environment is volatile and rapidly changing.
 
With respect to our telehealth services, the telehealth market is still relatively new and unproven and rapidly changing, and it is uncertain whether it will achieve and sustain high levels of demand in the various markets, consumer acceptance and market adoption. Our success will depend to a substantial extent on the willingness of our clients to use, and to increase the frequency and extent of their utilization of, our solutions, as well as on our ability to demonstrate the value of telehealth to employers, health plans, government agencies and other purchasers of healthcare for beneficiaries.
 
4

We must continually develop and introduce new products, product enhancements and/or solutions and there is no guarantee that our investments in research and development will yield the desired results.
 
Our success depends, in large part, on our ability to anticipate future customer needs with respect to product quality, price and functionality and to continue to design, manufacture and deploy new innovative products, solutions and services along with enhancements to sustain the performance of our existing products in response to such requirements. We have made, and expect to continue to make, substantial investments in the development of our products and related solutions, software and related solutions, to address new market needs and enhance customer engagement. It is critical for our success to be able to analyze and understand our markets and our customers’ needs, and to maintain a roadmap for our research and development program that allows for its swift implementation.
 
We compete in a highly competitive market, and our competitors constantly show competitive solutions to some of our technologies and services we offer, which may adversely affect demand for our services.
 
In the last few years and particularly during the COVID‑19 pandemic, we have experienced rapidly growing competition within the field of telemedicine services and products. Our main competitors include small companies providing focused solutions for a limited number of specific healthcare conditions, as well as larger companies providing comprehensive healthcare services. Competition from specialized software providers or device manufacturers, which may facilitate the collection of data but offer limited interpretation, feedback or guidance, and from other parties will result in continued pricing pressures, which are likely to lead to price declines in certain product segments, which could in turn negatively impact our sales, profitability and market share.
 
Our ability to compete effectively depends on our ability to distinguish ourselves and our services from our competitors and their products, and includes factors such as: long-term outcomes, ease of use, price, brand recognition, longer operating history, greater market penetration, established client channels and strong customer relationships, larger marketing budgets and quality of services.
 
There can be no assurance that we will be able to continue to sell our products and services or maintain profitability in the face of this competition. Failure to compete successfully as a result of the above factors or for other reasons would have a material adverse effect on our business, financial condition and results of operations.
 
Our proprietary rights may be challenged, which could have a material adverse effect on our business, financial condition and results of operations.
 
Our ability to compete successfully will depend, in part, on our ability to protect our proprietary rights, including the source code of our software. Although we continue implementing protective measures, including patents and trademarks, to defend our proprietary rights, these measures may not be successful, and our patents may not provide meaningful protection against potential competitors developing substantially similar products and services. Moreover, any patents issued to us may be challenged, invalidated or circumvented and the rights granted thereunder may not provide a competitive advantage to us.
 
We also rely on trade secrets and proprietary knowledge, which we protect, in part, through confidentiality agreements with employees, consultants and other parties. There can be no assurance that these agreements will not be breached, that we will have adequate remedies for any breach or that our trade secrets will not otherwise become known to, or independently developed by, competitors. If we were to be unsuccessful in defending our proprietary rights, or if our trade secrets or proprietary knowledge were breached, it could have a material adverse effect on our business, financial condition and results of operations.
 
If we fail to retain our key personnel and attract and retain additional qualified healthcare and management personnel, we may not be able to pursue our growth strategy.
 
Our success depends to a significant degree upon the continued contributions of our management team and our technical, marketing and sales personnel, and our ability to attract and retain additional highly qualified management, and technical, marketing and sales personnel. Competition for highly skilled management, technical, marketing and sales personnel, and other employees in the healthcare industry is intense. We may not be able to attract or retain highly qualified personnel in the future. The members of our senior management are at-will employees and therefore they may terminate their employment with us at any time with no advance notice. The replacement of our key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives. If any of our key employees leave or are terminated, and we fail to attract and retain qualified and experienced professionals on acceptable terms to replace them, the loss of their services could have a material adverse effect on our business, financial condition and results of operations.
 
5

We must also attract and retain additional highly skilled healthcare personnel in order to continue to execute our growth strategy. Our ability to attract and retain qualified healthcare personnel depends on several factors, including our ability to provide competitive benefits and wages. If we do not increase benefits and wages in response to increases by our competitors, we could face difficulties attracting and retaining qualified management and healthcare personnel. In addition, if we raise wages in response to our competitors’ wage increases and are unable to pass such increases on to our clients, our margins and net profits could decline, which could adversely affect our business, financial condition and results of operations.
 
Risks Related to Our Operations in Israel
 
Conditions in Israel and relations between Israel and other countries could adversely affect our business.
 
Many of our employees and suppliers, including most of the members of our management team, are located in Israel. In addition, a number of our officers and directors are residents of Israel. Accordingly, military instability in Israel and the political, economic and military conditions in Israel and the surrounding region may directly affect our business and operations.
 
Since the State of Israel was established in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors and terrorist organizations active in the region, including Hamas, an Islamist terrorist group that controls the Gaza Strip, with Hezbollah, an Islamist terrorist group that controls large portions of southern Lebanon, and with Iranian-backed military forces in Syria. In addition, Iran has threatened to attack Israel and may be developing nuclear weapons. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations. In addition, in the event that our facilities are damaged as a result of hostile action or hostilities otherwise disrupt the ongoing operation of its facilities, our ability to continue our operations could be materially adversely affected.
 
In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries, and, in addition, Hamas kidnapped many Israeli civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas in parallel to Hamas’ continued rocket and other terror attacks.
 
Following the attack by Hamas on Israel’s southern border, Hezbollah in Lebanon has also launched missile, rocket, and shooting attacks against Israeli military sites, troops, and civilian areas in northern Israel. In response to these attacks, the Israeli army has carried out a number of targeted strikes on Hezbollah in southern Lebanon. It is possible that other terrorist organizations, including those located in the West Bank, as well as other countries hostile to Israel, such as Iran, will join the hostilities.
 
Furthermore, the Israeli government has recently been pursuing legislative changes that, if adopted, would alter the current state of separation of powers among the three branches of government, and that have sparked considerable political debate. These changes could have negative consequences on the business and economic conditions in Israel that may include, among others, a downgrade in Israel’s sovereign credit rating, increased interest rates, currency fluctuations, inflation, civil unrest and volatility in securities markets, which could have an adverse effect on our business.
 
Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.
 
Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition and the expansion of our business. Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts, divestment and sanctions have been undertaken against Israel, which could also adversely impact our business.
 
6

Service of process upon our directors and officers may be difficult to effect in non-Israeli jurisdictions such as the United States.
 
Service of process upon our directors and officers, most of whom reside in Israel, may be difficult to effect in a non-Israeli jurisdiction such as the United States.
 
Foreign judgments against us and our directors or officers may not be enforceable.
 
We are incorporated in Israel and substantially all of our assets are located outside the United States. Substantially all of our directors and officers are non-U.S. citizens and most of their assets are also located outside of the United States. Accordingly, the enforceability of judgments against us and our directors and officers may be limited outside Israel. Specifically, Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against us or our officers and directors. Israeli courts will not enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of Israel.
 
Many of our employees and independent contractors in Israel are required to perform military reserve duty, which may disrupt their work for us.
 
Many Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they reach the age of 40 (or older for reservists who are military officers or who have certain occupations) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups in the future. In connection with the Israeli security cabinet’s declaration of war against Hamas and possible hostilities with other organizations, the Israeli military called up several hundred thousand of its reserves for active service. As of December 31, 2023, some of our employees in Israel (mainly members of our healthcare staff) were called up. Additional employees, including members of management, may be called up for service in the current or any future military conflict. Although to date our operations have not been disrupted by such call-ups, we cannot assure that this will be the case in the future. Our operations could be disrupted by such call-ups, particularly if such call-ups include members of our management, and given the current shortage of highly qualified personnel in our industry in Israel due to the recent acceleration of activity in startups, especially in the technology space. Such disruption could materially and adversely affect our business, financial condition and results of operations.
 
The rights and responsibilities of our shareholders are governed by Israeli law, which differ in certain respects from the rights and responsibilities of shareholders of U.S. corporations.
 
Since we are incorporated under Israeli law, the rights and responsibilities of our shareholders are governed by our Articles of Association as in effect from time to time and Israeli law. These rights and responsibilities differ in certain respects from the rights and responsibilities of shareholders of U.S. corporations. In particular, shareholders of Israeli companies have a duty to act in good faith and in a customary manner in exercising their rights and performing their obligations towards their and other shareholders and to refrain from abusing their power in the companies, including, among other things, in voting at general meetings of shareholders on certain matters, such as amendments to their articles of association, an increase of companies’ authorized share capital, mergers and approval of related party transactions. A shareholder also has a general duty to refrain from discriminating against other shareholders. In addition, a controlling shareholder or a shareholder who knows that it possesses the power to determine the outcome of a shareholders’ vote or to appoint or prevent the appointment of an office holder in the company has a duty to act in fairness towards the company. These provisions may be interpreted to impose additional obligations and liabilities on our shareholders that are not typically imposed on shareholders of U.S. corporations.
 
Provisions of Israeli and Swiss law and our Articles of Association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, which could prevent a change of control, even if the terms of such a transaction are favorable to us and our shareholders.
 
Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to mergers and acquisition transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date on which a merger proposal is filed by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the date on which the shareholders of both merging companies have approved the merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover, a tender offer for all of a company’s issued and outstanding shares can only be completed if the acquirer receives positive responses from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless, following consummation of the tender offer, the acquirer would hold at least 98% of the company’s outstanding shares. In addition, shareholders, including those who indicated their acceptance of a tender offer, may, at any time within six months following the completion of the tender offer, claim that the consideration for the acquisition of their shares does not reflect their fair market value, and petition an Israeli court to alter the consideration for the acquisition accordingly, unless the acquirer stipulated in its tender offer that shareholders accepting the offer may not seek such appraisal rights, and the acquirer or the company published all required information with respect to the tender offer prior to the tender offer’s response date.
 
7

Israeli tax considerations may also make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax.
 
These and other similar provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.
 
Due to our listing on the SIX Swiss Exchange, Swiss takeover law applies, which could also restrict or discourage mergers, acquisition and change of control of us. For respective provisions affecting mergers, acquisitions and changes of control applicable to us as a result of our SIX Swiss Exchange listing, see Item 10.B. “Memorandum and Articles of Association – Swiss Laws Applicable with Respect to Our Ordinary Shares”.
 
The ability of any Israeli company to pay dividends is subject to Israeli law and the amount of cash dividends payable may be subject to devaluation in the Israeli currency.
 
The ability of an Israeli company to pay dividends is governed by Israeli law, which provides that cash dividends may be paid only out of retained earnings or earnings derived over the two most recent fiscal years, whichever is higher, as determined for statutory purposes in Israeli currency, provided that there is no reasonable concern that payment of a dividend will prevent a company from satisfying its existing and foreseeable obligations as they become due. In the event of a devaluation of the Israeli currency against the U.S. dollar, the amount in U.S. dollars available for payment of cash dividends out of prior years’ earnings will decrease.
 
Operational Risks
 
The global nature of our operations exposes us to a variety of risks resulting from organizational, logistical, legal, political and cultural as well as other related challenges.
 
Our international business is subject to risks resulting from differing legal and regulatory requirements, political, social and economic conditions and unforeseeable developments in a variety of jurisdictions. Our international operations are subject to particular risks in addition to those faced by our domestic operations, including the following: the need to localize and adapt our solutions for specific countries, requirements of foreign laws and other governmental controls over our services (including employment, healthcare, tax, privacy and data protection laws and regulations), new and different sources of competition, local business and cultural factors that differ from our normal standards and practices, adverse tax consequences, fluctuations in currency exchange rates which could make our solutions more expensive or increase our costs of doing business in certain countries, limitations on future growth or inability to maintain current levels of revenues from international sales, difficulties in staffing, managing and operating our international operations, difficulties in coordinating the activities of our geographically dispersed and culturally diverse operations and political unrest, war, pandemics, terrorism or regional natural disasters, all of which could adversely affect our business, financial condition and results of operations.
 
8

Labor disputes may disrupt our operations or lead to higher labor costs.
 
Employee costs represent a significant cost for our business. Such costs could increase following wage negotiations. Our personnel in certain countries benefit from more favorable laws. In the event our relationships with our personnel, workers, representatives and unions deteriorate or labor laws become more stringent, we could face strikes or similar interruptions to our business as well as significantly increased wage and non-wage labor costs.
 
Significant growth may challenge our operations.
 
We may expand significantly in the coming years. Our successful growth will be dependent on our ability to manage our rapidly expanding operations, including, among other things, our ability to integrate new personnel on a timely basis, to improve continually our financial and management controls, reporting systems and procedures and to outsource a substantial portion of our manufacturing successfully. This growth could place significant strain on our operations. If our controls, systems or procedures, or the sub-contractors to whom we outsource our production, prove inadequate to support our operations, we may be unable to achieve our goals for growth. Any failure to manage growth effectively would have a material adverse effect upon our business, financial condition and results of operations.
 
Acquisitions, substantial investments or absence of suitable acquisitions may negatively affect our financial performance.
 
We may acquire or make substantial investments in complementary businesses, distribution channels, technologies or products in the future. Any such acquisition or investment would entail various risks, including the difficulty of assimilating the technologies, operations and personnel of the acquired business, the potential disruption of our ongoing business and, generally, our potential inability to obtain the desired financial and strategic benefits from the acquisition or investment. Future acquisitions and investments could also result in substantial cash expenditures, potentially dilutive issuances of equity securities, the incurrence of additional debt and contingent liabilities, and amortization expenses related to goodwill and other intangible assets, which could adversely affect our business, financial condition or results of operations.
 
We may be negatively affected by the failure of key suppliers and sub-contractors.
 
We believe that the expansion of our manufacturing capabilities and the manufacturing of component parts can be most effectively accomplished through outside sources. Because of our dependence on manufacturers and suppliers, we may experience logistical problems in our supply chain, including long lead times for receipt of products or components, inventory shortages or related difficulties. Moreover, third party manufacturers and suppliers may fail to produce products or components that meet our quality standards or to deliver such products or components in a timely manner.
 
We may be unable to locate a sufficient number of additional qualified manufacturers or suppliers to meet the demand for our products. Although we believe that we can find alternative manufacturers and suppliers for these externally sourced components, there is no guarantee that we will be able to find alternative manufacturers and suppliers or make cost-effective alternative arrangements in a timely manner. Any failure of outside manufacturers or suppliers to meet our needs could have a material adverse effect on our business, financial condition and results of operations.
 
We may be affected by other third-party risks.
 
In providing our services, we use third parties for certain services, such as cloud services and external data hosting services. Although we engage in due diligence, closely scrutinizing our third-party providers, sometimes these third parties may not perform as contractually required or expected. This may adversely impact our services and may lead to client attrition and could have a material adverse effect on our business, financial condition, results of operations and reputation.
 
We may encounter data security and privacy risks.
 
We are heavily dependent on critical, complex and interdependent information technology systems, including Internet-based systems, to support our business processes. In addition, we gather information, which can include personal sensitive information. We are also increasingly seeking to develop technology-based products to improve patient welfare in a variety of ways, which could also result in us gathering personal information about patients and others electronically.
 
9

Our technology systems may be exposed to external or internal security incidents, breakdowns, malicious intrusions, cyberattacks and cybercrimes, including state-sponsored cybercrimes, malware, misplaced or lost data, programming or human errors, or other similar events. Like other companies, we have been the subject of cyberattacks in the past. As the external cyber-attack threat keeps growing, impacting globally and across different industries, we expect to be subject to additional cyberattacks in the future. Although cyberattacks have not had a material adverse impact on the Company to date and the Company has invested, and continues to invest, in improved cybersecurity processes and technology designed to protect against such attacks, we may not be able to prevent future breakdowns or breaches of our systems and we may not be able to prevent such events from having a material adverse effect on our business, financial condition, results of operations or reputation.
 
Our financial results may be affected by fluctuations in exchange rates.
 
Our functional currency in Israel is the NIS and our reporting currency is the U.S. dollar. An important part of our revenues and expenses are currently paid in NIS, euros and U.S. dollars. As a result, our business is generally exposed to transactional and translational currency exchange risks caused by fluctuations in exchange rates among those different currencies. We do not currently engage in foreign currency hedging transactions to manage foreign currency exchange risks.
 
Liability may arise that may not or, not fully, be covered by insurance.
 
We are not insured against all risks and our insurance could prove insufficient to cover certain losses. Generally, health care companies are subject to claims alleging negligence, product liability, breach of warranty or malpractice that may involve large claims and significant defense costs whether or not such liability is imposed.
 
While we have been able to obtain liability insurance in the past, there is no guarantee that such insurance will be available in the future on terms acceptable to us, if at all. Moreover, a successful claim in excess of the limits of our insurance coverage could have a material adverse effect on our business, financial condition and results of operations. Such claims, regardless of their merit or eventual outcome, may also have a material adverse effect on our reputation.
 
Other Risks
 
Recent global events caused volatility and disruption of financial markets could affect our access to credit.
 
The current economic market environment has caused contraction in the availability of credit in the marketplace. This could potentially reduce our sources of liquidity. While there have not been changes to date regarding our ability to access credit, future volatility could have a negative impact on our financial position and performance which could put us in default of the credit conditions and impact our ability to access credit. Additionally, future volatility and financial market disruptions could impact lenders’ ability to provide new loans or honor the terms of credit agreements.
 
We must comply with tax laws in several jurisdictions.
 
We conduct operations in multiple tax jurisdictions, and the tax laws of those jurisdictions generally require that the transfer prices between affiliated companies shall be the same as those between unrelated companies dealing at arm’s length, and that such prices are supported by contemporaneous documentation. While we believe that we operate in compliance with applicable tax laws (including transfer pricing laws) and we intend to continue to do so, if tax authorities in any of these jurisdictions were to successfully challenge our tax policies, they could require us to make adjustments to our tax policies, which could result in a higher overall tax liability to us, and possibly interest and penalties, and could adversely affect our business, results of operations and financial condition.
 
Additionally, the integrated nature of our worldwide operations can produce conflicting claims from tax authorities in different countries as to the profits to be taxed in the individual countries. The majority of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains. However, mechanisms developed to resolve such conflicting claims are largely untested and can be expected to be very lengthy.
 
10

Risks Related to our ADSs and Ordinary Shares
 
Restrictions on the shares held by certain principal shareholders may be removed which could mean such principal shareholders may have a significant influence on decisions by our shareholders.
 
In January 2018 the Swiss Takeover Board found that Mengke Cai, Xiang Xu, Himalaya (Cayman Islands) TMT Fund, Himalaya Asset Management Ltd. and Kun Shen, who in the aggregate hold approximately 36.4% of the issued shares of SHL as of May 5, 2023, were acting in concert and should have published a tender offer for all of the SHL shares in accordance with Swiss law governing companies traded on the SIX. Subsequently, the relevant Swiss authorities suspended all of these shareholders’ voting rights and prohibited them from disposing of their shares without the court’s prior approval or from purchasing any additional shares until they make a tender offer for all of the SHL shares. Although we are not aware of any intention by the relevant authorities in Switzerland to overturn this decision, if they were to do so, these shareholders would regain all of the rights associated with their shares and would have a significant influence on decisions by our shareholders.
 
An active trading market for the ADSs may fail to develop and continue after the Nasdaq listing and the market prices for our ADSs and our ordinary shares may be volatile.
 
There was no public market for our securities in the United States prior to the listing of our ADSs on Nasdaq. An active trading market may not develop now that our ADSs are listed on the Nasdaq. If an active trading market for the ADSs fails to develop and continue, you may not be able to resell your ADSs quickly or at the market price you expect due to lack of sufficient liquidity.
 
The market prices of our ADSs on Nasdaq and our ordinary shares on the SIX may be highly volatile and could also be negatively influenced by adverse developments affecting the general economic or investment climate. In addition, geopolitical factors such as war, pandemics or acts of terrorism may indirectly adversely affect the market prices of our ADSs on Nasdaq and of our ordinary shares on the SIX.
 
Our securities are traded on more than one market or exchange and this may result in price variations.
 
Our ADSs were listed for trading on Nasdaq on April 3, 2023. Our ordinary shares have been trading on the SIX since November 15, 2000. Trading in our ADSs and ordinary shares on these markets takes place in different currencies (U.S. dollars on Nasdaq and Swiss francs on the SIX), and at different times (resulting from different time zones, trading days, and public holidays in the United States and Switzerland). The trading prices of our ADSs and ordinary shares on these two markets may differ due to these and other factors. Any decrease in the price of our ordinary shares on the SIX could cause a decrease in the trading price of our ADSs on Nasdaq. In addition, the current price of our ADSs may have little or no relationship to the historical sales prices of our ordinary shares on the SIX. The trading price of our ADSs may also fluctuate over time, particularly given our recent initial listing on Nasdaq.
 
Future sales or issuances, or the possibility or perception of future sales or issuances, of a substantial number of ADSs or ordinary shares or other securities that are convertible into our equity securities could cause the market prices of our ADSs or ordinary shares to fall.
 
The market prices of our ADSs and ordinary shares could decline as a result of sales of a large number of ADSs or ordinary shares in the public markets in the future or the possibility or perception that such sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to issue equity securities in the future at a time and price that we deem appropriate.

11

The issuance of equity or other securities that are convertible into equity, including options, or the exercise of options on ADSs or ordinary shares could immediately and substantially dilute the ownership interest and rights of our shareholders.
 
We may choose to raise additional capital in the future, depending on market conditions or strategic considerations and subject to any applicable shareholder approval or other requirements under Israeli law or the listing rules of Nasdaq or the SIX. To the extent that additional capital is raised through the issuance of ADSs, ordinary shares or other securities that are convertible into our equity, the issuance of these securities will dilute the proportional holding of our ADSs and ordinary shares by our investors, and the terms may include liquidation or other preferences that adversely affect the rights of our shareholders. The Board of Directors has granted and may in the future grant options to investors and employees, consultants, directors and officers of the company and other third parties to acquire ADSs and ordinary shares. For example, in January and February 2021, in connection with a private placement of 3,588,889 ordinary shares mainly to Israel based institutional investors, we issued options to purchase 1,944,444 ordinary shares, exercisable until January 20, 2023, and February 16, 2023, respectively, at an exercise price of CHF 11.00. Out of such options, options to purchase 1,914,478 newly issued shares were exercised.
 
As of April 15, 2024, we also had options outstanding for the issuance of up to 1,205,244 ordinary shares under our Share Option Plan. Pursuant to our Share Option Plan, all option exercises are on a net cash basis (i.e., require cashless exercise). For further information please refer to Item 6.B. “Compensation – Share Option Plan”.
 
Sales of substantial numbers of our ADSs and ordinary shares and changes in our shareholder structure may adversely affect the price of our ADSs and ordinary shares as well as the position of our shareholders.
 
Certain of our shareholders hold a significant number of our ordinary shares, as further described under Item 6.E, “Directors, Senior Management and Employees—Share Ownership.” Block sales of significant shareholdings and other changes in our shareholder structure may adversely affect the trading prices of our ADSs and our ordinary shares, may result in a change of control and may adversely impact the trading price of our ADSs and ordinary shares.
 
Whether we will pay dividends to our shareholders is uncertain.
 
We do not have a dividend policy. Our Board declared a dividend in 2019, but did not declare a dividend in 2020, 2021, 2022 or 2023. There can be no assurance that our Board will declare a dividend in any given financial year. If we do not declare dividends, capital appreciation, if any, of our ADSs and ordinary shares will be your sole source of gain.
 
Analyst reports and recommendations may impact the trading price and volume of our ADSs and ordinary shares and cause them to decline.
 
The trading markets for our ADSs and our ordinary shares will likely be influenced by the equity research and reports that industry or security analysts publish about us or our industry after our listing. We do not control these analysts. If one or more of the analysts who cover us downgrade their recommendation regarding our ADSs or ordinary shares, the trading prices of our ADSs and our ordinary shares would likely decline. In addition, if one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the market, which could, in turn, cause the trading volume or the trading prices of our ADSs and our ordinary shares to decline.
 
Market conditions may cause the market price of our ADSs and ordinary shares to fluctuate substantially.
 
The market price of our ADSs and ordinary shares may experience high volatility. Our year-end operating results, changes in general conditions in the economy or the financial markets and other developments affecting us or our competitors could cause the market price of our ADSs and ordinary shares to fluctuate substantially. The capital markets have experienced extreme volatility and disruption over the past years. In some cases, trading markets have produced downward pressure on stock prices for certain issuers seemingly without regard to those issuers’ underlying financial strength.

12

As a foreign private issuer, we are exempt from certain public disclosure requirements, which may afford less protection to the holders of our ADSs and ordinary shares than they would enjoy if we were a domestic U.S. company.
 
We are a foreign private issuer and are not subject to the same disclosure and other requirements that are imposed upon U.S. domestic issuers by the SEC. As a foreign private issuer, we will be exempt from the rules and regulations under the Exchange Act, related to the furnishing and content of proxy statements, and our officers, directors, and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. Furthermore, as a foreign private issuer we are not required to disclose the compensation of our five most highly compensated officers on an individual basis as is required of U.S. domestic reporting companies. In addition, we will not be required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic reporting companies whose securities are registered under the Exchange Act. Moreover, we will not be required to comply with Regulation FD, which restricts the selective disclosure of material information. These exemptions and leniencies will reduce the frequency and scope of information and protections to which you may otherwise have been eligible in relation to a U.S. domestic issuer.
 
If we cease to qualify as a foreign private issuer, we would be required to comply fully with the reporting requirements of the Exchange Act applicable to U.S. domestic issuers. We would lose our foreign private issuer status if a majority of our shares are owned by U.S. residents and a majority of our directors or executive officers are U.S. citizens or residents or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status.
 
As a foreign private issuer, we are permitted to rely on exemptions from certain corporate governance standards.
 
While our ADSs are listed on Nasdaq, we are permitted to follow certain home country corporate governance practices instead of certain Nasdaq corporate governance standards. We are required to provide a brief description of the significant differences between our corporate governance practices and the corporate governance practices required to be followed by domestic U.S. companies listed on Nasdaq. The standards applicable to us are considerably different than the standards applied to domestic U.S. issuers. For instance, under our home country rules, we are not required to maintain a majority of independent directors and a compensation committee comprised of independent directors, and the charters of our board committees do not necessarily contain all of the Nasdaq charter requirements for such committees of U.S. domestic companies.
 
We have relied on and intend to continue to rely on some of these exemptions. As a result, as a holder of our ADSs or ordinary shares, you may not be provided with the benefits of certain Nasdaq corporate governance standards.
 
We are an “emerging growth company,” and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies may make our ADSs and ordinary shares less attractive to investors and, as a result, adversely affect the price of our ADSs and ordinary shares and result in a less active trading market for our ADSs and ordinary shares.
 
We are an “emerging growth company” as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. For example, we have elected to rely on an exemption from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, relating to internal control over financial reporting, and we will not provide such an attestation from our auditors. We cannot predict whether investors will find our ADSs and ordinary shares less attractive because of our reliance on some or all of these exemptions. If investors find our ADSs and ordinary shares less attractive, it may adversely affect the price of our ADSs and ordinary shares and there may be a less active trading market for the ADSs.
 
ADS holders do not have the same rights as our shareholders.
 
ADS holders do not have the same rights as our shareholders. For example, ADS holders may not attend shareholders’ meetings or directly exercise the voting rights attaching to our ordinary shares. ADS holders may vote only by instructing the depositary to vote on their behalf. If we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders’ meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of Israel and the provisions of our Articles of Association or similar documents, to vote or to have its agents vote the deposited ordinary shares as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, the depositary is not required to do so. Except by instructing the depositary as described above, you will not be able to exercise voting rights unless you surrender your ADSs and withdraw the ordinary shares. However, you may not know about the meeting enough in advance to withdraw the ordinary shares. We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your ordinary shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise voting rights and there may be nothing you can do if your ordinary shares are not voted as you requested. In addition, ADS holders have no right to call a shareholders’ meeting unless ADS holders cancel their ADS and hold the ordinary shares underlying such ADSs directly.
 
13

The deposit agreement may be amended or terminated without the ADS holder’s consent.
 
We and the depositary may amend or terminate the deposit agreement without your consent. Holders of the ADSs are entitled to a prior notice in the event of a materially prejudicial amendment or termination thereof or if the amendment adds or increases fees or charges. If you continue to hold your ADSs after an amendment to the deposit agreement, you agree to be bound by the deposit agreement as amended.
 
The deposit agreement may be terminated at any time upon prior written notice to holders of the ADSs. Upon the termination of the deposit agreement, our company will be discharged from all obligations under the deposit agreement except for its obligations to the depositary thereunder. At any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. After the termination date and before the depositary sells all of the securities, the depositary may refuse to accept a surrender of ADSs by a holder for the purpose of withdrawing deposited securities if it would interfere with the selling process. During this time, the depositary will not be required to register any transfer or ADSs or distribute any dividends or other distributions, give any notices or perform any other duties under the deposit agreement.
 
Holders of ADSs may be subject to limitations on transfer of their ADSs.
 
Your ADSs will be transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deem it advisable to do so because of any requirement of law or of any government or governmental body, under any provision of the deposit agreement, or for any other reason in accordance with the terms of the deposit agreement.
 
You may not receive the same distributions or dividends as those we make to the holders of our ordinary shares, and, in certain limited circumstances, you may not receive dividends or other distributions on our ordinary shares, if it is illegal or impractical to make them available to you.
 
The depositary for the ADSs has agreed to pay to you the cash dividends and other distributions it or its custodian receives on ordinary shares or other deposited securities underlying the ADSs, after deducting its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the depositary is not required to pay such cash dividends and other distributions if it determines that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act, that are not properly registered or distributed under an applicable exemption from registration. In addition, conversion into U.S. dollars from foreign currency that was part of a dividend made in respect of deposited ordinary shares may require the approval or license of, or a filing with, a government or agency thereof, which may be unobtainable. In these cases, the depositary may determine not to distribute such property, or a portion thereof, and hold such property as “deposited securities” or it may seek to affect a substitute dividend or distribution, including of the net cash proceeds from the sale of the dividends that the depositary deems to be an equitable and practicable substitute. We have no obligation to register under U.S. securities laws any ADSs, ordinary shares, rights or other securities distributed by us. We also have no obligation to take any other action to permit the distribution of ADSs, ordinary shares, rights or any other property distributed on our ordinary shares to holders of ADSs.
 
In addition, the depositary may deduct from any dividends or distributions by us its fees and may withhold an amount on account of taxes or other governmental charges to the extent the depositary believes it is required to make such withholding. This means that you may not receive the same distributions or dividends as those we make to the holders of our ordinary shares, and, in certain limited circumstances, you may not receive any value for such distributions or dividends if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline in the value of the ADSs.
 
14

Holders or beneficial owners of our ADSs have limited recourse if we or the depositary fail to meet our respective obligations under the deposit agreement or if they wish us or the depositary to participate in legal proceedings.
 
The deposit agreement expressly limits our obligations and liability and those of the depositary. We and the depositary:
 

are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith;
 

are not liable if we are, or it is, prevented or delayed by law or circumstances beyond our, or its, control from performing our or its obligations under the deposit agreement;
 

are not liable if we exercise or it exercises discretion permitted under the deposit agreement;
 

are not liable for the inability of any holder of the ADSs to benefit from any distribution on deposited securities that is not made available to holders of the ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;
 

have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on behalf of the holders of the ADSs or any other person;
 

are not liable for the acts or omissions of any securities depositary, clearing agency or settlement system; and
 

may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person.
 
These provisions of the deposit agreement limit the ability of holders of the ADSs to obtain recourse if we or the depositary fail to meet our respective obligations under the deposit agreement or if they wish us or the depositary to participate in a legal proceeding.
 
ADS holders have limited choice of forum, which could increase your cost and limit your ability to bring a claim in a judicial forum that you find favorable for disputes against the depositary, us or the depositary’s or our respective directors, officers or employees, and may discourage such lawsuits.
 
The deposit agreement governing our ADSs provides that by holding or owning an ADS or an interest therein, holders and owners of ADSs irrevocably agree that any legal suit, action or proceeding against or involving the depositary and/or us brought by holders or owners of ADSs, arising out of or based upon the deposit agreement or the ADSs or the transactions contemplated thereby, including, without limitation, claims under the Securities Act of 1933, may be only instituted in the United States District Court for the Southern District of New York (or in the state courts of New York County in New York if either (i) the United States District Court for the Southern District of New York lacks subject matter jurisdiction over a particular dispute or (ii) the designation of the United States District Court for the Southern District of New York as the exclusive forum for any particular dispute is, or becomes, invalid, illegal or unenforceable). Any person or entity purchasing or otherwise acquiring any of our ADSs, whether by transfer, sale, operation of law or otherwise, shall be deemed to have notice of and have irrevocably agreed and consented to this choice of forum provision.
 
This forum provision may increase your cost and limit your ability to bring a claim in a judicial forum that you find favorable for disputes with the depositary or us, or the depositary’s or our respective directors, officers or employees, which may discourage such lawsuits against the depositary, us and the depositary’s and our respective directors, officers or employees. However, it is possible that a court could find this choice of forum provision to be inapplicable or unenforceable. The enforceability of similar choice of forum provisions has been challenged in legal proceedings. It is possible that a court could find this type of provisions to be inapplicable or unenforceable.
 
To the extent that any such claims may be based upon federal law claims, Section 27 of the Securities Exchange Act of 1934 creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Securities Exchange Act of 1934 or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act of 1933 creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act of 1933 or the rules and regulations thereunder. Actions by owners and holders of our ADSs to enforce any duty or liability created by the Securities Exchange Act of 1934, the Securities Act of 1933 or the respective rules and regulations thereunder must be brought in the United States District Court for the Southern District of New York. Holders of our ADSs will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.
 
15

ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable results to the plaintiff(s) in any such action.
 
The deposit agreement governing our ADSs provides that holders and beneficial owners of ADSs irrevocably waive the right to a trial by jury in any legal proceeding arising out of or relating to the deposit agreement or the ADSs, including claims under federal securities laws, against us or the depositary to the fullest extent permitted by applicable law. If this jury trial waiver provision is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with a jury trial. To our knowledge, the enforceability of a jury trial waiver under the federal securities laws has not been finally adjudicated by a federal court, and holders of the ADSs are not able to waive our or the depositary’s compliance with U.S. federal securities laws or the rules and regulations promulgated thereunder. However, we believe that a jury trial waiver provision is generally enforceable under the laws of the State of New York, which govern the deposit agreement, by a court of the State of New York or a federal court, which have non-exclusive jurisdiction over matters arising under the deposit agreement, applying such law. In determining whether to enforce a jury trial waiver provision, New York courts and federal courts will consider whether the visibility of the jury trial waiver provision within the agreement is sufficiently prominent such that a party has knowingly waived any right to trial by jury. We believe that this is the case with respect to the deposit agreement and the ADSs. In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or counterclaim sounding in fraud or one that is based upon a creditor’s negligence in failing to liquidate collateral upon a guarantor’s demand, or in the case of an intentional tort claim (as opposed to a contract dispute), none of which we believe are applicable in the case of the deposit agreement or the ADSs. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any provision of the federal securities laws. If you or any other holder or beneficial owner of ADSs brings a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may augur different results than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.
 
ITEM 4.
INFORMATION ON THE COMPANY

A.
HISTORY AND DEVELOPMENT OF THE COMPANY

General
 
SHL Telemedicine Ltd. was incorporated in Israel on November 7, 1986, and is a limited liability company for unlimited duration under the laws of the State of Israel. The address of our registered office and principal executive office is Ashdar Building, 90 Yigal Alon St., Tel Aviv 6789130, Israel. SHL’s legal name is “SHL Telemedicine Ltd.”
 
History
 
SHL was founded in Israel by Mr. Yoram Alroy in 1986 and went public in 2000 by listing on the SIX under the ticker symbol “SHLTN.” On April 3, 2023, SHL commenced trading on the Nasdaq under the ticker symbol “SHLT”. Since its founding, SHL has expanded its operations and is now an international group specializing in telemedicine services, including the provision and development of advanced personal telemedicine solutions, with operations in Israel, Germany and the United States. Since its inception, SHL’s business has been dedicated to emergency medical services and telemedicine. For more than a quarter of a century, and with tens of thousands of subscribers, SHL has been providing monitoring services to cardiac patients and taking care of people in need of home-based medical support. SHL’s ethos is to provide its subscribers professional medical care digitally when its subscribers need it. SHL monitors its subscribers’ health and wellbeing to reduce the need for emergency intervention and hospitalization. SHL’s aim is to increase its users’ chances of survival if a heart attack strikes and generally improve users’ quality of life following such medical events.
 
16

SHL expanded into Europe in 2001 by establishing a joint venture with Philips Medical Systems International B.V., providing telemedicine services based on SHL’s proprietary technology. In 2004, SHL acquired Philips’ equity interest in the joint venture. Over the years, SHL has strategically acquired local private companies in Germany such as Almeda GmbH, Gesellschaft für Patientenhilfe DGP mbH, and Jumedi GmbH, and is currently one of the leading companies in providing telehealth services and remote patient monitoring services of chronic patients for health insurance funds in Germany.
 
SHL introduced its unique and patented mobile 12 lead electrocardiogram (ECG) SmartHeart® platform in the U.S. in 2020, and since then has entered into commercial agreements with leading U.S. healthcare providers, including the Mayo Clinic, CVS and Henry Schein.
 
During January and February 2021, SHL issued 3,588,889 ordinary shares (and sold 300,000 Treasury shares) to certain investors in a private placement for approximately CHF 35 million to support the growth of its business operations in Germany, expand its business in the U.S., enhance SHL’s supply chain and accelerate research and development activities.
 
On August 31, 2021, a subsidiary of SHL acquired 70% of the share capital of Mediton Group, a leading B2B healthcare services provider in Israel for NIS 84 million. The Mediton Group is comprised of the following entities, all of which provide medical services to the institutional and payer markets:
 

Mediton Medical Centers Chain Ltd., which provides private medical services, and project management in various medical fields, including the performance of surveys, medical examinations for organizations, occupational examinations, and the operation of specialist clinics; and
 

Medishur Ltd. which primarily provides medical examinations for insurance companies.
 
We believe the Mediton acquisition provides SHL the ability to leverage synergies and cross sell its technology and services to Meriton’s customers.
 
Principal Capital Expenditures and Divestitures
 
   
2023
   
2022
   
2021
 
Property and Equipment
                 
Property and Equipment
   
1,289
     
1,661
*
   
1,434
 
Intangible assets
                       
Development Costs
   
4,203
     
5,243
     
2,633
 
Mediton’s Customer Relations
   
     
     
14,886
 
Jumedi’s Information Technology
   
     
     
705
 
     
5,492
     
6,904
     
19,658
 
*
Includes property and equipment of Mediton.
 
Public Information
 
The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us, at http://www.sec.gov. SHL is subject to the periodic reporting requirements of the Securities Exchange Act of 1934, and accordingly files certain reports with the SEC. These reports can be inspected and retrieved through the SEC’s EDGAR system on the SEC’s Internet website referred to above. See Item 10.H, “Additional Information—Documents on Display.”
 
Our website is http://www.shl-telemedicine.com. No information contained on our website is intended to be included as part of, or incorporated by reference in, this Annual Report.
 
17

B.
BUSINESS OVERVIEW
 
Overview
 
SHL is an international group specializing in telemedicine services, including the provision and development of advanced personal telemedicine solutions, with operations in Israel, Germany and the United States. Personal telemedicine is the transmission of medical data by an individual from a remote location to a telemedicine center or healthcare provider via telecommunication networks and the subsequent data reading and provision of medical assessment or services to the individual via electronic and telecommunication technologies. Our personal telemedicine systems are designed to improve quality of care and life for people suffering from various health conditions ranging from the high-risk and chronically ill to ordinary users of healthcare products and services who wish to take a more active role in managing their own health.
 
We are a leader with a long history in the telemedicine markets in Israel and Germany, providing remote medical services and patient management with telemedicine centers available 24/7, and global service of cloud-based technology, all of which results in approximately three million interactions and data readings annually.
 
SHL’s primary focus is the development of technologies, solutions, and advanced telemedicine services to assess and monitor acute and chronic heart health and cardiac diseases, such as congestive heart failure, among others. In the U.S., SHL’s primary offering is its SmartHeart® platform, the only 12 lead ECG that enables a full, hospital-quality ECG to be performed by a lay-person without the assistance of a healthcare professional. SHL’s SmartHeart® technology is patented and U.S. Food and Drug Administration, or FDA-, cleared.
 
We believe SHL’s personal telemedicine systems have strategically positioned the company to meet the increasing demand for virtual healthcare, which is more efficient and less expensive than healthcare provided in traditional clinical environments. As patients, healthcare providers and third-party payers seek new ways to deliver cost effective healthcare services without adversely affecting quality, we believe they will increasingly turn to those products that enable quality care to be delivered primarily outside the costly hospital and outpatient clinical environments.
 
Telemedicine Market Overview
 
Telemedicine is one of several segments in the healthcare market. Telemedicine is the distribution and provision of health-related services and information via electronic and telecommunication technologies for the purpose of improving health care. The goals of telemedicine are to improve interaction between patients and healthcare service providers, ensure a speedy and secure transmission of data, and provide better processing and storage of large amounts of data. Telemedicine also improves cost-efficiencies by delivering patient data and medical care virtually outside the traditional more expensive clinical environment.
 
Sub-segments of telemedicine include electronic patient records, remote telemonitoring, expert systems, ambient assisted living and virtual reality (VR) in medicine. We believe telemedicine is a particularly interesting segment of the healthcare market, due to its growth potential. Telemedicine offers diagnostic, ongoing monitoring and assessment and therapy measures that make use of telecommunications to bridge the distance and time intervals between doctors and their patients, or between consulting doctors.
 
Telemedicine goes beyond the saving and processing of data extending to testing, the secure transfer of vital signs and electronic monitoring of the state of a patient’s condition. Other applications of telemedicine include medical care services that are supplied independently of the location of service providers, patients and records of care or medical devices.
 
18

SHL’s Geographic Operations
 
We operate in three geographic segments for financial reporting purposes: Israel, Europe and the Rest of the World. Israel is our largest segment with revenues of approximately $42.1 million in the fiscal year ended December 31, 2023. Our European segment is our second largest segment and consists of our German operations with revenues of approximately $14.1 million in the fiscal year ended December 31, 2023. Our rest of the world segment consists of our U.S. operations with revenue of approximately $0.9 million in the fiscal year ended December 31, 2023.
 
Israel
 
Our primary and largest operation is in Israel where SHL has developed a successful telemedicine service offering for individuals and communities. In Israel, SHL provides personal telemedicine services and telemedicine center services to its private pay subscribers based on its proprietary medical technology which enables the users to remotely perform and transmit a full 12 lead ECG at home. SHL’s 24/7 telemedicine center is staffed with an experienced medical team that handles subscriber’s calls. SHL also provides and facilitates immediate assistance to its subscribers in emergency cases, offering home visits by professional medical staff and mobile intensive care ambulance services in certain coverage areas.
 
We have conducted several clinical studies that indicate that our 12 lead ECG product and cardiac telemedicine services offer a higher quality of care to cardiac patients as measured by post myocardial infraction hospitalization mortality and readmission rates. Specifically, a clinical study published in the Telemedicine and e-HEALTH Journal (tmj) in 2009 found the one-year post-acute myocardial infraction (“AMI”) mortality rate of SHL Telemedicine subscribers in Israel to be 4.4% compared to 9.7% for patients in the Acute Coronary Syndrome in Israel Survey (ACSIS) 2004, a biannual survey of all 26 intensive cardiac care units operating in Israel. Similarly, in a clinical study published in the Telemedicine and e-HEALTH Journal (tmj) in 2014, SHL Telemedicine subscribers hospitalized for AMI in Israel experienced 30‑day post-hospitalization readmission rates of 5.8% compared to 30‑day post-AMI readmission rates ranging from 11.3% to 28.1% in a number of previous studies published in leading medical journals.
 
Subscribers to SHL’s cardiac telemedicine services purchase our user friendly personal 12 lead ECG technology pay monthly fee for the use of these services, generating recurring revenues. SHL’s dual position both as an experienced operator of telemedicine services and as a technology developer enables it to offer solutions to healthcare payers and providers seeking a cost effective and innovative alternative to traditional healthcare delivery methods. To date, SHL has developed its expertise in the design and provision of personal telemedicine services through its extensive experience in operating the largest telemedicine center in Israel in terms of number of patient–subscribers.
 
Mediton Group
 
On August 31, 2021, SHL expanded its presence in Israel by acquiring 70% of Mediton Group for approximately $26 million. Mediton is a healthcare service provider working with institutions and payers, governmental entities, and large employer customers.
 
Mediton was established in 1993, and specializes in diagnostics, preventative healthcare and expert witness services for medical opinions, with medical centers in several of Israel’s most populated cities, and we expect Mediton to commence also offering mobile hybrid services to such customers in 2024. Mediton has long standing relationships with Israel’s blue-chip companies, government institutions, payers and health insurance funds. Mediton provides its services through a wide array of healthcare professionals, with whom it employs or contracts with, including physicians, physical therapists, occupational therapists, psychologists, nurses, paramedics, and technicians. Most of Mediton’s contracts are multi-year evergreen contracts, with governmental contracts being subject to Israeli mandatory tender law requirements.
 
19

Mediton’s main service lines include the following:
 

Preventative healthcare, including annual medical check-ups that include comprehensive laboratory tests, stress ECG tests, eye exams, and more;
 

Expert witness services for medical experts’ and medical committees, including for disability and workers comp, serving a wide range of institutions, such as pension funds, the Israeli Institute of Social Security, and the Israeli Ministry of Defense;
 

Occupational healthcare, including occupational safety and health regulated medical exams, exposure to hazardous materials, and occupational disability claims, as well as assisting organizations in promoting early detection of diseases and medical conditions within the workforce by offering periodical check-ups and specialized examinations;
 

Medical examinations, including at home, for the underwriting of insurance policies for health, disability, life, or nursing home policyholders; and
 

Medical and psychological evaluations, including for truck drivers, public transportation drivers and drivers of hazardous cargos.
 
Germany
 
SHL is a leader with a long history in the German telemedicine market having entered into agreements with the largest German health insurance funds. These agreements are typically multi-year contracts for the provision of telehealth services to insured patients of the health insurance funds. SHL provides its services in Germany primarily from its telemedicine center in Munich.
 
SHL primarily provides the following services to health insurance funds in Germany:
 

Remote monitoring of chronic patients: Our remote patient monitoring programs monitor and stabilize patients with chronic conditions, including congestive heart failure, and geriatric patients at home, reducing hospitalizations and saving costs for its health insurance fund customers.
 

Telehealth hot-line services: Remote real-time medical consultations, scheduling of doctor appointments, second opinion services, and structured health coaching programs for cardiac conditions.
 

Doctors’ Virtual Visits: A service that allows health insurance fund patients to connect on-demand with doctors for virtual video appointments.
 
Recent legislative initiations in Germany have promoted the increasing use of telemedicine. In the fall of 2020, German legislation introduced so-called digital health applications (DiGAs) to statutory health insurance (“SHI”) care. Other initiatives supporting the promotion of telemedicine include e-prescription as well as electronic health record initiatives.
 
In January 2022, the Federal Joint Committee (Gemeinsamer Bundesausschuss), or G-B-A, a German regulatory governmental body, introduced reimbursement for remote monitoring of patients with heart failure (RPM-HF) by German statutory health insurance funds. These services are provided in cooperation with a telemedicine center and physicians qualified as specialists in internal medicine and cardiology. G-B-A reimbursement for remote patient monitoring RPM-HF provides SHL another channel to offer its remote monitoring services for chronic congestive heart failure patients in addition to its traditional agreements with German health insurance funds.
 
Main Growth Drivers in Germany:
 

1.
At the end of 2020, SHL entered into an agreement with BARMER GEK, one of the largest health insurance funds in Germany (“BARMER”), to provide Doctors’ Virtual Visits in Germany. In July 2021 BARMER announced the availability of this new service to all its insured patients on a nationwide basis. Subsequently, in September 2022, SHL won a long-term contract with BARMER to provide these services for a seven year period and in 2023 BARMER launched marketing and communication activities for the new BARMER Teledoktor digital App which provides SHL’s Doctors’ Virtual Visits and Telehealth Services to all of BARMER’s insureds in Germany. In November 2022 SHL entered a contract with AOK Plus, another large German health insurance fund, to provide these services to its insured patients.
 
20


2.
New customer wins: We believe that SHL has a strong competitive advantage and position in terms of quality, know-how and long-term customer relationships. We invested significantly in the development of our platform, and we believe we are well positioned to gain more market share. In November 2021, SHL was awarded a multi-year telehealth contract to provide services to geriatric patients of AOK Rheinland-Pfalz/Saarland – Die Gesundheitskasse, a large German health insurance fund.
 

3.
Telemonitoring for congestive heart failure patients: Telemonitoring for congestive heart failure patients has become the standard of care since early 2022 following the introduction of remote monitoring reimbursement by G-BA.
 
United States
 
SHL introduced its unique and patented FDA-cleared SmartHeart® platform to the U.S. market in 2020, providing U.S. customers the high-quality technology and benefits of its mobile 12 lead ECG technology developed and sold in Israel. The SmartHeart® platform is SHL’s latest generation ECG solution which is a cloud-based technology that is the only 12 lead personal ECG enabling a full, hospital-quality ECG to be performed anywhere at any time by a lay-person without assistance from a medical professional. SHL’s SmartHeart® solution enables patients to conduct a 12 lead ECG procedure in various remote settings, including from their home. The connectivity of SHL’s SmartHeart® cloud-based platform to certified healthcare professionals allows for a prompt virtual review and interpretation of data collected on its 12 lead ECG.
 
SHL’s SmartHeart® platform is currently approved by the FDA, for use only with a prescription. SHL is in the process of seeking the FDA over-the-counter, or OTC, clearance for SmartHeart® through the 510(k) pathway. Although we believe that given the FDA’s feedback to a pre-submission that we filed regarding the OTC clearance for SmartHeart®, the materials and documentation we prepared and are contemplating to prepare will ultimately enable us to obtain OTC clearance from the FDA, the FDA approval process is highly stringent and there can be no assurance that SHL will ultimately be successful in obtaining OTC clearance from the FDA, or the length of time required to obtain any such approval. See “D. Risk Factors – We operate in a highly regulated industry and failure to comply with the complex regulations applicable to us could result in investigations, legal judgments or penalties, which could materially adversely affect our business” and “ - We depend on evolving governmental regulation in and around the health care industry and failure to comply with these and other laws and regulations could have a material adverse effect on our business, financial condition and results of operations.” in Item 3. Key Information.
 
Final results of the Imperial College London TELE-ACS clinical trial, which focused on the application of SmartHeart’s 12-lead ECG technology for monitoring of post-MI (heart attack) patients at home, were presented in April 2024 at the American College of Cardiology's 24th Annual Scientific Session & Expo Late-Breaking Clinical Trials Sessions (ACC 24 LBCT) in Atlanta. Key findings from the study included the following:
 

a 76% reduction in the likelihood of hospital readmission within six months for patients using telemedicine;

a 41% decrease in the likelihood of attending the emergency department compared to standard care recipients;

significant reductions in unplanned coronary revascularizations; and

notable decreases in patient-reported symptoms, including chest pain, breathlessness, and dizziness.

Moreover, the study was also published in the Journal of the American College of Cardiology.
 
In September 2023 we also received initial results from the HELP-MI trial conducted by the Mayo Clinic, which also focused on the application of SmartHeart’s 12-lead ECG technology for monitoring of post-MI (heart attack) patients at home. The initial results were presented at the Vulnerable Plaque and Patient Meeting (VPM) in September, 2023, and included the following:
 

the number of cardiovascular-driven emergency department visits for patients using the SmartHeart® device in the HELP-ME trial was zero (0); and

the number of cardiovascular-driven rehospitalization visits for patients using the device in the HELP-ME trial was also zero (0).

21

Growth Strategy
 
We have been at the forefront of providing and developing telemedicine services and technology for over 30 years. We have vast experience in remotely monitoring and managing acute and chronic heart patients. Our telemedicine centers review ECG transmissions and other data received directly from our customers and transmitted from a variety of devices, including the personal mobile ECG devices developed by us and provided to our customers.
 
Our telemedicine services for chronic heart failure patients and other chronic patients reduce hospital readmissions and the duration of hospitalizations of patients, decrease mortality and improves patients’ quality of life.
 
For both our acute and chronic telemedicine services, we provide cardiac and other home-use medical monitoring technology that transmit data to our telemedicine centers. We analyze the data received and interact with our clients to monitor their wellbeing and levels of compliance with their set treatment. Clinical data is maintained in our data base in compliance with data protection rules and made securely accessible online to patients and their approved physicians.
 
Virtual medical services are gaining momentum, offering growth potential in both existing and new markets.
 
The COVID‑19 pandemic illustrated the importance and many benefits of telemedicine and the need to be able to implement comprehensive technological solutions to track, diagnose, offer treatment, and maintain ongoing care for patients remotely, as our services and products offer.
 
We continue to focus our efforts on driving the growth of our operations in the German and Israeli markets by addressing current customer needs and new opportunities while promoting the SmartHeart® platform technology in the U.S. and elsewhere. In November 2023, we announced the soft launch of the SmartHeart® membership program in the U.S. as part of our direct-to-consumer initiative, offering a comprehensive private-pay subscription service that delivers at-home professional cardiac care directly to the consumer.
 
We intend to continue to seek to enhance our growth by selectively acquiring cross-selling businesses that offer synergistic product lines and complementary technologies and services, such as the Mediton acquisition. We are continuously examining potential acquisition targets, including competitors, businesses with related technologies and certain operators of telemedicine centers.
 
Regulations
 
General
 
In many countries and regions, most notably the U.S., Western Europe and Japan, medical device products and software such as our products are subject to legislation adopted by regulatory agencies and governments at all levels. In the U.S., medical products are subject to FDA approval. In Europe, many products require the CE Marking before they can be sold in the European Union, or the EU. The regulatory approval process is lengthy (usually approximately six to 12 months in all of the developed markets), expensive and uncertain, and any approvals or clearances that we seek may be denied. Product approvals and clearances, if issued, can be withdrawn for failure to comply with regulatory standards or the occurrence of unforeseen problems following initial marketing. The FDA, and similar regulatory authorities in other countries, also require us and any manufacturing contractors we employ to adhere to regulations setting forth requirements for Good Manufacturing Practices, or GMP, which include extensive testing, control and documentation requirements to ensure quality control. Failure to comply with applicable regulations could result in sanctions being imposed on us.
 
In various countries a special authorization is needed to process and store personal data, such as patient medical data. The transmission of personal medical data via telecommunications, especially cross border transfer via internet, is a relatively new development, and patient and health care industry concerns regarding the confidentiality of such information could lead to further legislation and regulations that govern the methods of transmitting and storing patient medical data. Failure to comply with these and other laws and regulations could have a material adverse effect on our business, financial condition and results of operations.
 
Israel
 
In Israel, we operate under legislations and regulations that apply to the provision of the telemedicine services provided by us and the healthcare services provided by the Mediton Group. In addition, medical equipment laws apply to the medical devices being used by our private pay subscribers and by the Mediton Group in providing its healthcare services. These laws provide that medical equipment may only be manufactured and marketed in Israel, if it is registered as medical equipment in the “AMR register,” in accordance with the Israeli registration conditions. In addition, certain regulations and Ministry of Health procedures apply to the provision of our telemedicine services and the use, operation, calibration and maintenance of certain medical devices or equipment and pharmaceutical products being used or operated by us or by the Mediton Group. The marketing and sale of our telemedicine services to our private pay consumers in Israel are also subject to Consumer Protection laws and regulations, the goal of which is to protect individual customers from misleading sales methods.
 
22

We and our business customers are subject to various laws governing privacy protection, confidentiality information and security laws. Because we and the Mediton Group retain personal and medical information of patients or other persons, we are also subject to data privacy protection and security laws, which require that owners of databases containing such information to meet certain obligations such as registration with authorities and the appointment of a database administrator to supervise the use of stored information only for its original purposes.
 
In Germany and the United States, SHL is also subject to laws prohibiting the corporate practice of medicine and laws that govern financial and other arrangements between health care providers and payers which are designed to regulate the referral of a patient to a particular provider for medical products and services.
 
Germany
 
In Germany, we utilize a business-to-business, or B2B, model, where we work with health insurance funds to remotely monitor and stabilize patients and save costs for health insurers.
 
Healthcare in Germany is primarily organized by the SHI funds. Approximately 90% of the population in Germany is insured within the SHI, while around 10% of the population are covered by private health insurance. Through the SHI funds, citizens have equal access to healthcare benefits from healthcare professionals who are licensed and provide healthcare services within the statutory healthcare system. Membership in the SHI system is mandatory for employees unless their income rises above an annually determined threshold.
 
In connection with the SHI system, the legislature creates the legal framework for the provision of medical services, and the medical self-governing bodies, such as the associations (at a federal and regional level) of SHI accredited physicians, SHI funds and the German Hospital Federation, formulate and implement in detail which healthcare services will be provided and under what conditions. The highest decision-making body in the SHI system is the G-B-A, a German association representing all relevant parties of the healthcare sector such as physicians, hospitals, health insurance funds and patients. The G-BA issues directives and determines the benefit package of the SHI system. The organization of the SHI system, the responsibilities of the G-BA and the other self-governing bodies, as well as the provisions for medical care, are laid down in the Social Code Book V (SGB V).
 
In addition, as a main principle, SGB V sets out that patient entitlement to medical service within the system of the SHI is restricted by the “efficiency principle”, namely that the respective healthcare must be sufficient, appropriate and economically efficient, and must not exceed the extent of what is necessary. Recently, SGB V has been subject to numerous legislative changes and amendments primarily to improve, enhance, and take advantage of the opportunity provided by the digitalization of medical services with the ultimate goal of improving the quality of healthcare.
 
Digitalization of medicine and the pandemic have accelerated the introduction and application of telemedicine services in Germany in recent years. Since 2018, with the exception of the State of Brandenburg, the general prohibition for physicians to diagnose and treat patients solely by means of telecommunication was lifted. These prior professional rules of conduct prohibited physicians from taking on new patients without direct, physical interactions. With the exception of the State of Brandenburg, patients in all states may now be diagnosed and treated solely by means of telecommunication, provided that – in each individual case – such provision of medical care is reasonable from a physician’s perspective and it is ensured that the necessary level of care is applied. Since then, the use of video and phone consultations of physicians is allowed and is increasing. In the wake of such change, the general prohibition to advertise such remote medical services has been abolished as well. Advertisement for remote medical services is now permitted, provided that – according to the recognized medical state of art – a personal and direct contact between the physician and patient is not necessary.
 
New legislation was introduced in Germany in 2020 that made the use of telemedicine services permissible and contained provisions designed to support and encourage their increasing usage. We believe that these favorable legislative trends will result in a significant part of the market shifting to remote medical services in the coming years, with virtual visit services and patient care becoming new standards of care. In January 2022, the G-B-A introduced reimbursement for remote monitoring of patients with heart failure (RPM-HF) by German SHI funds. These services are provided in cooperation with a telemedicine center and physicians qualified as specialists in internal medicine and cardiology. G-B-A reimbursement for remote patient monitoring RPM-HF provides SHL with another channel to offer its remote monitoring services for chronic congestive heart failure patients in addition to its traditional agreements with German SHI funds.
 
23

In the fall of 2020, German legislation introduced so-called digital health applications (DiGAs) to SHI care. DiGAs are class I or II medical devices, such as medical applications. Currently, 62 DiGAs are listed in a catalogue pursuant to Section 139e SGB V and may be prescribed by a treating physician. SHI patients are entitled to receive such DiGAs.
 
Since July 2021, SHI patients may request the use of an electronic patient file to store patient’s data.  In December 2023, the German legislator resolved that starting in 2025 use of the electronic patient file will become mandatory, unless a patient opts out of its use.
 
European Union
 
In Europe, the requirements for medical devices are established in two European regulations applicable since May 26, 2021, in all current and future member states of the EU. The two regulations are (1) the European Union Medical Device Regulation (the “MDR”) and (2) Regulation (EU) 2017/746 of April 5, 2017, relating to in vitro diagnostic medical devices. Although the MDR is self-binding in all member states of the EU, numerous acts of the EU and of national legislation in each member state are necessary to fully implement the legal provisions. These provisions essentially include higher safety standards to be met by medical devices and, therefore, require a new conformity assessment procedure and re-certification of all medical devices regardless of whether they have already been placed on the market. During the EU EPSCO (Employment, Social Policy Health and Consumer Affairs) Council Meeting in December 2022, the council identified risks relating to the shortage of medical devices in the EU market due to the MDR. It was determined that a legislative change would be required to address this, and accordingly, on March 20, 2023, the European Commission adopted amendments to the MDR, to allow for extension of the transitional provisions contained in the MDR until the end of 2027 or 2028 depending on the classification of the device.
 
United States
 
Manufacturers of medical devices are required to register with the FDA as device manufacturers and submit listing information for devices in commercial distribution. As a manufacturer of medical devices, we are subject to requirements governing premarket approval and clearance, labelling, promotion, clinical research, medical device adverse event reporting, manufacturing practices, reporting of corrections and removals, and recordkeeping. Further, we are subject to periodic inspection by the FDA for compliance with these requirements. With respect to manufacturing, we are subject to the FDA’s Quality System Regulation (21 C.F.R. Part 820) and related FDA guidance, which requires us to manufacture products in accordance with GMP, including standards governing product design. The medical device reporting regulations and guidance require that we report to the FDA whenever we receive or become aware of information that reasonably suggests a device may have caused or contributed to a death or serious injury, or that a device has malfunctioned, and a device or similar device would be likely to cause or contribute to a death or serious injury if the malfunction were to recur. FDA regulations also may require us to conduct product recalls and take certain other corrective actions in response to potential quality issues. In addition, the FDA prohibits our products division from promoting our manufactured products for unapproved or uncleared indications or in a false or misleading manner. We are also prohibited from promoting unapproved or uncleared drugs or devices more generally. Finally, as with our pharmaceutical products, states impose additional requirements on our drug and device manufacturing and distribution activities, including requiring additional state licenses. We are subject to periodic inspections by the FDA and other authorities for compliance with these requirements.
 
Sales and Marketing
 
Sales and marketing activities are managed in each of our local territories in accordance with its main business model. In Israel, the business model is focused on marketing and selling SHL cardiac monitoring services directly to individual consumers. Our marketing and sales activity therefore is focused on the acquisition of individual customers. Mediton’s marketing and sales are focused on providing its services to institutions and payers. In Germany, the business model is based on the B2B model, where we have agreements with German health insurance funds to provide services to insured patients of such healthcare insurance funds as well as other services such as Telehealth and Doctors’ Virtual Visits, and therefore marketing and sales activity in Germany is focused on the German health insurance funds’ customers. In the U.S., SHL is focused on marketing and selling its unique and patented FDA-cleared mobile 12 lead ECG SmartHeart® platform to direct consumers, health systems, healthcare providers, payers and other healthcare business customers, including leading healthcare providers such as the Mayo Clinic, CVS and Henry Schein.
 
24

Customer Relationships
 
A key part of our business is establishing and maintaining strong collaborations with leading providers and consumers in the health industry, including top health insurers, health organizations and medical centers.
 
In Germany, we have various multi-year agreements, known as Section 140 agreements, for the provision of our telemedicine services, with a number of leading German SHI funds that collectively provide health insurance coverage to approximately 30% of the German population in the aggregate (amounting to approximately 25 million persons). These agreements generally contain terms ranging from four to seven years, with some containing evergreen renewal provisions.
 
Pursuant to these agreements, the SHI funds refer their chronic patients, including those with cardiac congestive heart failure conditions, to us for remote monitoring services. We provide these patients at-home monitoring systems that enable them to transmit data to telemedicine centers on a daily basis or as needed upon presentation of symptoms. In the event of change or deviation in a patient’s data, the telemedicine center contacts the patient and provides guidance to stabilize the patient’s condition, in order to prevent further deterioration and avoid hospitalization. Payment for these services by the SHUI funds is based on a fixed amount per period for each insured patient enrolled in our service.
 
In addition, we also provide telehealth and virtual physician visit services to the insured patients of German SHI funds pursuant to other Section 140 agreements. Payment for these services by the SHI funds is transactional and is based on the number and type of service used by the insured.
 
In the U.S., our business is primarily focused on the marketing and sale of our SmartHeart® platform to consumers and healthcare business customers. We engage both directly with consumers and with healthcare facilities and providers with the goal of providing them with our SmartHeart® platform to be incorporated into their different platforms in multiple use cases and settings. In November 2023, we announced the soft launch of the SmartHeart® membership program in the U.S. as part of our direct-to-consumer initiative, offering a comprehensive private-pay subscription service that delivers at-home professional cardiac care directly to the consumer. In October 2020, we entered into a collaboration with the Mayo Clinic to evaluate the incidence of emergency department visits, rehospitalizations and major adverse cardiovascular events (MACE), and cost-effectiveness over a period of 90 days after the first hospitalization for a heart attack for patients using our SmartHeart® 12 lead ECG.
 
Competition
 
In the last few years, we have experienced rapidly growing competition within the field of telemedicine services and products. Our main competitors include small companies providing focused solutions for a limited number of specific healthcare conditions, as well as larger companies providing comprehensive healthcare services. These companies, which may offer their services at lower prices, are continuing to develop additional products and are becoming more sophisticated and effective. In addition, large, well-financed healthcare providers and insurance carriers have in some cases developed their own platform or tools and may provide these solutions to their clients at discounted prices. Competition from specialized software providers or device manufacturers, which may facilitate the collection of data but offer limited interpretation, feedback or guidance, and from other parties will result in continued pricing pressures, which are likely to lead to price declines in certain product segments, which could negatively impact our sales, profitability and market share.
 
Competition in Israel
 
In Israel, our main competitor is Natali (a company for emergency medical services in Israel) Ltd., which provides telehealth and home care services, and Monitor - emergency medical services Ltd., a cardiac monitoring company.
 
Mediton competes primarily with companies providing medical services such as LMS (lotem medical services), MPT, Cardiomedix, Femi connecting healthcare, Shemer Medical Institute, and in certain cases units operated by hospitals.
 
25

Competition in Germany
 
We operate in a highly competitive environment in Germany. We compete with large companies with global reach and significant experience in this market such as Philips Medical Systems and Teladoc, companies with significant national presence such as Otto Group – Medgate and Vitaphone, as well as smaller players such as Teleclinic, 4 sigma, and MD-Medicus. We expect there will be consolidation in this market as companies seek to acquire know-how and technologies and leverage the synergies of complementary products and services and efficiencies of scale.
 
Competition in the U.S.
 
We operate in a highly competitive and fragmented industry, subject to rapid change and significantly affected by new product introductions, results of clinical research, corporate combinations and other factors. Large competitors in the ambulatory cardiac market including GE Healthcare, Medtronic Inc., Boston Scientific Corporation, and Philips Medical Systems. Recently, there has been an increase in acquisition activity and consolidation in our industry. Many of our competitors have substantially greater financial, manufacturing, marketing and technical resources than we do. Furthermore, many of our competitors have well-established brands, widespread distribution channels, broader product offerings and an established customer base.
 
These competitors have also developed patch-based cardiac monitors that have received FDA and foreign regulatory clearances. We are also aware of small start-up companies entering the 12 lead ECG cardiac monitoring market, such as Heartbeam Inc. Large medical device companies may continue to acquire or form alliances with these smaller companies in order to diversify their product offering and participate in the digital health space. We believe the principal competitive factors in our market include:
 

ease of use, comfort and unobtrusiveness of the device for the patient;
 

quality and clinical validation of the deep-learned algorithms used to detect arrhythmias;
 

concise and comprehensive reports supporting efficient physician interpretation;
 

ease of use of service workflow for physicians and supporting clinicians;
 

contracted rates with third-party payors;
 

government reimbursement rates associated with our products and services;
 

quality of clinical data and publications in peer-reviewed journals;
 

size, experience, knowledge and training of sales and marketing teams;
 

reputation of existing device manufacturers and service providers; and
 

relationships with physicians, hospitals, administrators, and other third-party payors.
 
26

C.
ORGANIZATIONAL STRUCTURE

SHL Telemedicine Ltd. is the parent company of a group of direct and indirect subsidiaries worldwide. The following table lists our subsidiaries, their countries of incorporation and our direct or indirect ownership interests in them.
 
Subsidiary
Country of
Incorporation
Direct/Indirect Ownership Interest
Shahal Haifa Medical Services Ltd.
Israel
Authorized Share Capital: NIS 13,000 divided into 13,000 ordinary shares, par value NIS 1.00 each
 
Issued Share Capital: 200 ordinary shares—100% held by SHL
Shahal Rashlatz- Rehovot Medical Services Ltd. (“Shahal Rashlatz”, or “SHLR”)
Israel
Authorized Share Capital: NIS 16,600 divided into 16,600 ordinary shares, par value NIS 1.00 each
 
Issued Share Capital: 100 ordinary shares—100% held by SHL
Mediton Medical Centers Chain Ltd. (“Mediton Medical”)
Israel
Authorized Share Capital: NIS 22,900 divided into 22,900 ordinary shares, par value NIS 1.00 each
 
Issued Share Capital: 100 ordinary shares
 
70% (held by Shahal Rashlatz)
Medishur Ltd.
Israel
Authorized Share Capital: NIS 2,640 divided into 2,600 ordinary shares, par value NIS 1.00 each and 40 management shares, par value NIS 1.00 each
 
Issued Share Capital: 100 ordinary shares
 
70% (held by Shahal Rashlatz)
Mediton - Adam Ltd.
Israel
Authorized Share Capital: NIS 200 divided into 100 management shares, par value NIS 2.00 each, and NIS 22,800 divided into 22,800 ordinary shares, par value NIS 1.00 each
 
Issued Share Capital: 100 ordinary shares, four management shares
 
70% (100% held by Mediton Medical)
SHL Telemedicine International Ltd. (“SHL INT”)
Israel
Authorized Share Capital: NIS 101,000 divided into 101,000 ordinary shares, par value NIS1.00 each
 
Issued Share Capital: 10,000 ordinary shares—100% held by SHL
SHL Telemedicine B.V (“SHL BV”)
The Netherlands
Authorized Share Capital: EUR 75,000 divided into 300,000 ordinary shares, par value EUR 0.25 each
 
Issued Share Capital: 74,043 ordinary shares—100% held by SHL INT

27

Personal Healthcare Telemedicine Services Europe B.V. (“PHTS”)
The Netherlands
Authorized Share Capital: EUR 4,000,000 divided into 400,000 ordinary shares, par value EUR 10.00 each
 
Issued Share Capital: 811,500 ordinary shares—100% held by SHL BV
 
SHL Telemedizin GmbH (“SHL Telemedizin”)
Germany
Authorized Share Capital: EUR 300,000 divided into 2 ordinary shares, par value EUR 25,000 and EUR 275,000
 
Issued Share Capital: 2 ordinary shares—100% held by PHTS
Almeda GmbH
Germany
Authorized Share Capital: EUR 25,000
 
Issued Share Capital: 25,000 shares, par value EUR 1.00 each—100% held by SHL Telemedizin
Jumedi GmbH
Germany
Authorized Share Capital: EUR 25,000
 
Issued Share Capital: 4 shares, par value EUR 6,250 each —100% held by SHL Telemedizin
Gesellschaft für Patientenhilfe DGP mbH
Germany
Authorized Share Capital: EUR 25,000 divided into 2 ordinary shares, par value EUR 24,750 and EUR 250
 
Issued Share Capital: 2 ordinary shares—100% held by SHL Telemedizin
SHL Telemedicine USA, Inc.
USA (Delaware)
Authorized Share Capital: $1.00 divided into 100 shares of common stock, par value $0.01 each
 
Issued Share Capital: 100 shares of common stock—100% held by SHL INT
SHL Telemedicine India Private Limited
India
Authorized Share Capital: Rs 7,000,000 divided into 700,000 equity shares of Rs 10 each
 
Issued Share Capital: 625,126 equity shares—99.9% held by SHL INT and 0.01% held by SHL BV

D.
PROPERTY, PLANTS AND EQUIPMENT

The following table identifies our principal office and telemedicine center facilities, all of which are rented by us:
 
Location
    
Address
    
Description
    
Approximate Size
Munich - Germany
 
Balanstraße 69 Munich
 
SHL’s German head office and telemedicine center in Germany
 
3,208 sqm
             
Israel
 
90 Yigal Alon St.
Tel Aviv
 
SHL’s Israeli head office and telemedicine center
 
5,389 sqm
             
Israel
 
18 Hahashmal St. Tel Aviv*
 
Mediton – Medical services
 
2,752 sqm

*
We lease this property from an affiliate of the 30% minority shareholder of Mediton from whom we acquired our 70% interest in Mediton.
 
28

ITEM 4.A.
UNRESOLVED STAFF COMMENTS

Not applicable.
 
ITEM 5.
OPERATING AND FINANCIAL REVIEW AND PROSPECTS

A.           OPERATING RESULTS
 
The following discussion of our financial condition and results of operations is based upon and should be read in conjunction with the consolidated financial statements and related notes thereto of us beginning on page F‑1 of this Annual Report. The discussion should also be read in conjunction with the information included and referenced in Item 3.D. “Key Information – Risk Factors,” Item 5. “Operating and Financial Review and Prospects” Results, Item 8. “Financial Information” and Item 18. “Financial Statements.”
 
Certain information included in this discussion and analysis includes forward-looking statements that are subject to risks and uncertainties, and which may cause actual results to differ materially from those expressed or implied by such forward-looking statements. For further information on important factors that could cause our actual results to differ materially from the results described in the forward-looking statements contained in this discussion and analysis, see “Cautionary Note Regarding Forward-Looking Statements,” Item 3.D, “Key Information—Risk Factors” and information elsewhere in this Annual Report.
 
Overview
 
SHL is an international group specializing in telemedicine services, including the provision and development of advanced personal telemedicine solutions, with operations in Israel, Germany and the United States. Personal telemedicine is the transmission of medical data by an individual, from a remote location to a telemedicine center or healthcare provider via telecommunication networks and the subsequent data reading and provision of medical assessment or services to the individual via electronic telecommunication technologies. Our personal telemedicine systems are designed to improve quality of care and life for people suffering from various health conditions ranging from the high-risk and chronically ill to ordinary users of healthcare products and services who wish to take a more active role in managing their own health.
 
We are a leader with a long history in the telemedicine market in Israel and Germany, providing remote medical services and patient management, with telemedicine centers in Israel and Germany that are available 24/7, and global service of cloud-based technology, all of which results in about 3 million interactions and data readings annually.
 
Today, our primary focus is developing technologies, solutions, and advanced telemedicine services to diagnose and monitor the heart and other cardiac diseases, such as congestive heart failure. Our key product is the SmartHeart® platform, a unique advanced technology that is the only full ECG 12 lead ECG that enables a hospital-quality full ECG to be performed by a lay-person without the assistance of a healthcare professional. The SmartHeart® platform’s technology is FDA-cleared and patented, and SmartHeart® is registered as a trademark.
 
Basis of Presentation
 
We prepare our financial statements in accordance with IFRS as issued by the International Accounting Standards Board. The presentation currency of our financial statements is the U.S. dollar.
 
Our material accounting policies are described in Note 2 of our audited consolidated financial statements for the years ended December 31, 2023, 2022 and 2021 included elsewhere in this Annual Report.
 
29

Components of Operating Results
 
General
 
Most of our revenues and expenses are generated in NIS. Accordingly, we consider the NIS to be our functional currency in Israel and our consolidated financial statements are prepared in NIS.
 
Our reporting currency is in U.S. Dollars. The translation of our financial statement to U.S. dollars is based on the following methods:
 

a)
Assets and liabilities of foreign operations, including goodwill and any fair value adjustments to the carrying amounts of assets and liabilities arising from the acquisition of said foreign operation, are translated at the closing rate at the end of the reporting period.
 

b)
Income and expenses for each period presented in the statement of income are translated at average exchange rates for the presented periods.
 

c)
Share capital, capital reserves and other changes in capital are translated at the exchange rate prevailing at the date of incurrence.
 

d)
Retained earnings are translated based on the opening balance translated at the exchange rate at that date and other relevant transactions (such as issuing a dividend) during the period are translated as described in b) and c) above.
 

e)
All resulting translation differences are recognized as a separate component of other comprehensive income (loss) in equity “foreign currency translation reserve”.
 
As we evaluate our growth prospects and manage our operations for the future, we believe that we can further expand healthcare services in Israel and Germany and increase the worldwide distribution of SmartHeart® platform solutions (mainly in the United States).
 
We followed the below sales strategy in fiscal year 2023 in order to expand our revenues:
 

Leverage synergies and cross-sell our products and services with Mediton;
 

Commercial agreements with leading U.S. healthcare providers such as the Mayo clinics and CVS;
 

Commercial agreements with BARMER and other health insurance funds in Germany for doctor’s virtual visits and telehealth services;
 

Increased sales and marketing activities mainly in the U.S.;
 

Increased research and development investments related to the SmartHeart® platform; and
 

Continued pursuit of strategic relationships with customers, mainly in the U.S., including the soft launch of the SmartHeart® membership program in the U.S. as part of our direct-to-consumer initiative.
 
Revenues
 
In general, our revenues derive from healthcare services contracts (B2C and B2B), which is recognized over time, and the sale of telemedicine devices, which is recognized at the point of time when the control of the goods is transferred to customers.
 
Cost of revenues
 
The cost of revenues consists of salaries and related expenses, external services fees, cost of devices, and allocation of overhead expenses. Overhead expenses consist of a variety of costs, including rent, office IT and associated expenses.
 
30

Research and Development Expenses
 
Research and development expenses consist primarily of salaries and related expense payments for subcontractors and overhead expenses.
 
Sales and Marketing Expenses
 
Sales and marketing expenses consist primarily of salaries and related expenses, commissions and fees to third party representatives, marketing & advertising, promotional expenses, domestic and international travels, web site maintenance, and overhead expenses.
 
General and Administrative Expenses
 
General and administrative expenses consist primarily of salaries and related expenses, including share-based compensation, professional fees (which include legal, audit and other consulting fees) and other general corporate expenses.
 
Financial Income (loss), Net
 
Financial income, net, consists primarily of share option liability adjustments, earning or loss from marketable securities, interest earned on bank deposits, bank charges, and gains or losses from the exchange rate differences in respect of balances and transactions in other than functional currencies.
 
Results of Operations
 
   
Year ended December 31,
 
   
2023
   
2022
   
2021
 
   
(in thousands)
 
Revenue
 
$
57,075
   
$
58,998
     
49,582
 
Cost of revenue
   
31,814
     
31,809
     
24,989
 
Gross profit
   
25,261
     
27,189
     
24,593
 
Operating Expenses:
                       
Research and development
   
5,260
     
3,788
     
2,985
 
Sales and marketing
   
10,581
     
11,403
     
9,454
 
General and administrative
   
16,228
     
16,748
     
12,103
 
Other expenses
   
2,198
     
416
     
548
 
Total operating expenses
   
34,267
     
32,355
     
25,090
 
Operating (loss)
   
(9,006
)
   
(5,166
)
   
(497
)
Financial income (expense), net
   
3,042
     
6,478
     
(12,972
)
Profit (loss) before income taxes
   
(5,964
)
   
1,312
     
(13,469
)
Tax expenses
   
891
     
1,097
     
455
 
Net profit (loss)
 
$
(6,855
)
 
$
215
   
$
(13,924
)

31

   
Year ended
       
   
December 31,
       
   
2023
   
2022
   
2021
 
Revenue
   
100
%
   
100
%
   
100
%
Cost of revenue
   
56
     
54
     
50
 
Gross profit
   
44
     
46
     
50
 
Operating Expenses:
                       
Research and development
   
9
     
6
     
6
 
Sales and marketing
   
19
     
19
     
19
 
General and administrative
   
28
     
28
     
24
 
Other expenses
   
4
     
1
     
1
 
Total operating expenses
   
60
     
55
     
51
 
Operating (loss)
   
(16
)
   
(9
)
   
(1
)
Financial income (expense), net
   
5
     
11
     
(26
)
Profit (loss) before income taxes
   
(11
)
   
2
     
(27
)
Tax expenses
   
1
     
2
     
1
 
Net profit (loss)
   
(12
)%
   
0
%
   
(28
)%

Year Ended December 31, 2023 Compared to Year Ended December 31, 2022
 
Revenue:
 
   
Individuals
   
Institutions
             
   
and
   
and
             
   
communities
   
payers
   
Others
   
Total
 
   
(in thousands)
 
Year ended December 31, 2023:
                       
                         
Europe
 
$
-
   
$
14,067
   
$
-
   
$
14,067
 
Israel
   
20,913
     
21,179
     
-
     
42,092
 
USA
   
-
     
-
     
916
     
916
 
                                 
Total revenues
 
$
20,913
   
$
35,246
   
$
916
   
$
57,075
 
 
   
Individuals
   
Institutions
             
   
and
   
and
             
   
communities
   
payers
   
Others
   
Total
 
   
(in thousands)
 
Year ended December 31, 2022:
                       
                         
Europe
 
$
     
13,374
     
     
13,374
 
Israel
 
$
22,161
     
22,975
     
2
     
45,138
 
USA
 
$
     
     
486
     
486
 
                                 
Total revenues
 
$
22,161
     
36,349
     
488
     
58,998
 

Revenues
 
In 2023, our revenues decreased by approximately $1.9 million, compared to 2022. In Israel revenues decreased by approximately $3.0 million mainly due to a negative exchange rate of $4.0 million between the NIS and the U.S. dollar. In Germany revenues slightly increased by approximately $0.7 million and in the U.S. revenues increased by $0.4 million.
 
32

Cost of Revenues
 
Cost of revenues for each of 2023 and 2022 was $31.8 million.
 
In fiscal year 2023, gross margin was 44% compared to 46% in fiscal year 2022. The decrease was mainly due to our B2B operation in Israel due to the decrease in revenues during the last quarter of 2023 as a result of armed conflict between Israel and Hamas that began during the last quarter of 2023.
 
The following table provides our operating costs and expenses in 2023 and 2022:
 
   
Year ended
 
   
December 31,
 
   
2023
   
2022
 
   
(in thousands)
 
Research and development costs, net
 
$
5,260
   
$
3,788
 
Selling and marketing expenses
   
10,581
     
11,403
 
General and administrative expenses
   
16,228
     
16,748
 
Other expenses
   
2,198
     
416
 
                 
Total operating expenses
 
$
34,267
   
$
32,355
 

Research and Development costs, net
 
Research and development costs increased by approximately $1.5 million in 2023 compared to 2022. The increase was mainly due to the continued development of our SmartHeartTM technology platform and the development of our platform in Germany. R&D gross expenses in 2023 were $6.7 million, of which $4.2 million was capitalized, compared to $7.2 million, of which $5.2 million was capitalized, in 2022. Amortization of development costs was $2.8 million in 2023 compared to $1.8 million in 2022.
 
Selling and Marketing Expenses
 
Selling and marketing expenses for fiscal year 2023 were $10.6 million, compared to $11.4 million in fiscal year 2022. The decrease was primarily related to a slight decrease in such expenses for our German and Israeli operations while in the U.S. our sales and marketing expenses increased by $0.4 million mainly to the launch of our direct-to-consumer initiative.
 
General and Administrative Expenses
 
General and administrative expenses for the 2023 fiscal year were $16.2 million, compared to $16.7 million in the 2022 fiscal year. The decrease was mainly related to a decrease in consulting expenses.
 
Other Expenses
 
Other expenses for fiscal year 2023 were $2.2 million, compared to $0.4 million in fiscal year 2022. Other expenses mainly include restructuring expenses of USD $1.3 million, other non-recurring expenses of $0.3 million in Germany, and $0.6 million related to NASDAQ listing expenses.
 
Financial income (expenses), net

   
Year ended
 
   
December 31,
 
   
2023
   
2022
 
   
(in thousands)
 
Share options
 
$
1,712
   
$
7,504
 
Exchange rate differences
   
991
     
608
 
Gain (loss) from marketable securities, net
   
848
     
(769
)
Interest, net
   
(241
)
   
(604
)
                 
Others
   
(268
)
   
(261
)
                 
Financial expenses, net
 
$
3,042
   
$
6,478
 

33

Financial income, net for the 2023 fiscal year was $3.0 million compared to financial income, net of $6.5 million in the 2022 fiscal year. The decrease was mainly related to the revaluation of options that had been issued to investors, which were exercised during the first quarter of 2023
 
Financial income relating to share options arise from changes in fair value based on the valuation of these options at the end of each reporting period. SHL uses the Black Scholes option pricing model when estimating the fair value of its share options. The factors that significantly affected the valuation of share options were (a) the market price of SHL’s ordinary shares, (b) expected volatility and (c) the expected average life of the share options.
 
For the twelve months ended December 31, 2022, SHL’s share price decreased and the expected volatility increased from CHF 19.10 to CHF 14.80 per share, and 34.81% ‑ 35.16% to 32.59% ‑ 38.24%, respectively, while the expected average life of share options decreased from 1.06 ‑ 1.13 years to 0.06 ‑ 0.13 years.
 
In 2023, income from exchange rate differences mainly related to strengthening of the U.S. dollar versus the NIS by 3.1%. This resulted in an exchange rate difference of $1.0 million in respect of $14.0 million held by the Company in U.S. dollar deposits, since the functional currency of our financial statements is the NIS.
 
The strengthening of the U.S. dollar versus the NIS by 3.1% resulted in other comprehensive loss/ of approximately $2.1 million in the twelve months ended December 31, 2023 due mainly to the translation of the financial statements of entities of our consolidated group from their functional currency in NIS to the presentation currency in US dollar.
 
In 2022, income from exchange rate differences mainly related to the effect of the strengthening of the U.S. dollar versus the Israeli Shekel by 13.2%. This resulted in exchange rate income of $0.6 million in respect of $6.2 million held in U.S. dollar deposits (as the functional currency of the financial statements of SHL is the New Israeli Shekel).
 
Taxes on Income
 
For fiscal year 2023, tax expenses were $0.9 million, compared to tax expenses of $1.1 million in fiscal year 2022. The decrease was mainly related to a decrease in taxes from the B2B operation in Israel.
 
Year Ended December 31, 2022 Compared to Year Ended December 31, 2021
 
For a comparison of our results for the years ended December 31, 2022, and 2021, please refer to Item 5 in our Annual Report on Form 20-F/A for the year ended December 31, 2022, filed with the SEC on May 15, 2023.
 
Impact of Inflation and Foreign Currency Fluctuations
 
Our Israeli business is the most significant of our operations. As a result, the majority of our revenues and expenses are generated in NIS. Investment activities and financing activities (excluding capital raise) were made in NIS. Our business in Germany is the second largest component of our operations, the revenues and expenses of which are generated in Euros. We believe our U.S. business will be the main growth driver going forward, however, we consider the NIS to be our functional currency. Accordingly, future additional revenues may be denominated priority in currencies other than NIS and Euros.
 
Because exchange rates between the NIS, Euro and U.S. dollar fluctuate continuously, exchange rate fluctuations will have an impact on our profitability and period-to-period comparisons of our results. The effects of foreign currency re-measurements of financial assets and liabilities are reported in our financial statements as financial income or expense.
 
We currently do not have any mechanisms in place to hedge our exposure to foreign currency and interest rate fluctuations. However, we may in the future undertake hedging or other similar transactions or invest in market risk-sensitive instruments if our management determines that it is necessary to offset risks such as foreign currency and interest rate fluctuations.
 
34

Effective Corporate Tax Rate
 
As of January 1, 2018, Israeli resident companies are generally subject to corporate tax at the rate of 23%. Israeli resident companies are generally subject to capital gains tax at the corporate tax rate. We have historically incurred operating losses resulting in carry forward losses for tax purposes totaling approximately $109.8 million ($62 million in Israel, $32.5 million in Europe, and $15.3 million in the U.S.) as of December 31, 2023, and $101.5 million ($67.1 million in Israel, $23.7 million in Europe, and $10.7 million in the U.S.) as of December 31, 2022. We will be able to carry forward these tax losses to future tax years. Except for our Mediton operation, we do not expect to pay taxes in Israel on our income from operations until we utilize our carry forward tax losses. We may, however, be required to pay taxes on our passive income, if any. For more information on taxation, see “Item 10.E.— Taxation.”
 
Our effective corporate tax rate may exceed the Israeli tax rate. Our German and U.S. subsidiaries will generally be subject to applicable federal, state, local and foreign taxation, and we may also be subject to taxation in the other foreign jurisdictions in which we own assets, have employees or conduct business activities.
 
B.           LIQUIDITY AND CAPITAL RESOURCES
 
We have financed our operations through cash generated from operations, and the proceeds from our private equity offerings, including the exercise of options issued in the private equity offerings. Cash and cash equivalents and short-term bank deposits on December 31, 2023, and December 31, 2022, were approximately USD $26.0 million and USD $18.7 million, respectively.
 
For our material cash requirements, including commitments for capital expenditures, as of December 31, 2023, please see “Item 4.A. – Principal Capital Expenditures and Divestitures.” In addition, we received cash in the amount of approximately $20.3 million with respect to the exercise requests received from the exercise of the investors’ options in January and February of 2023. The sources of funds for such capital expenditure requirements have been cash generated from operations, the proceeds from our private equity offering, including the exercise of options issued in the private equity offerings, and in the case of the Mediton acquisition, our long-term credit facility.
 
35

We believe that our existing capital resources and cash flows from operations will be adequate to satisfy our expected capital expenditures and liquidity requirements through the next twelve months. Without derogating from the foregoing estimate regarding our existing capital resources and cash flows from operations, we may decide to raise additional funds in the future. We believe that, if required, we will be able to raise additional capital or reduce discretionary spending to provide the required liquidity beyond the next twelve months. There can be no guarantee that financing will be available on commercially acceptable terms or at all. Debt financing, if available, could impose additional cash payment obligations, additional covenants and operating restrictions. Future equity financings could result in the dilution of our existing shareholders. In addition, any of the items discussed in detail under “Risk Factors” elsewhere in this Annual Report may also significantly impact our liquidity.

Cash Flow Discussions
 
Fiscal Year Ended December 31, 2023 Compared to Fiscal Year Ended December 31, 2022 and Fiscal Year Ended December 31, 2021
 
The following tables reflect the changes in cash flows for the comparative periods:
 
   
For fiscal year ended December 31,
 
   
2023
   
2022
   
Change
 
   
US$
   
US$
   
US$
 
   
(In millions)
 
Cash flow data
                 
Net cash (used in) operating activities
   
(1.5
)
   
(0.1
)
   
(1.7
)
Net cash (used in) investing activities
   
(9.3
)
   
(6.4
)
   
(2.9
)
Net cash provided by (used in) financing activities
   
13.7
     
(2.3
)
   
16.0
 
 
   
For fiscal year ended December 31,
 
   
2022
   
2021
   
Change
 
   
US$
   
US$
   
US$
 
   
(In millions)
 
Cash flow data
                 
Net cash provided by (used in) operating activities
   
(0.1
)
   
0.2
     
(0.3
)
Net cash (used in) investing activities
   
(6.4
)
   
(41
)
   
34.6
 
Net cash provided by (used in) financing activities
   
(2.3
)
   
51.1
     
(53.4
)

Cash Flows Provided By/Used In Operating Activities
 
Cash used in operating activities for the year ended December 31, 2023, was $1.5 million, and primarily related to our operating loss in 2023.
 
Cash used in operating activities for the year ended December 31, 2022, was $0.1 million, and primarily related to non-cash adjustments of $3.5 million, including depreciation and amortization expenses of $7.1 million, partially offset by financing income of $6.7 million.
 
Cash provided by operating activities for the year ended December 31, 2021, was $0.2 million and primarily related to net loss of $13.0 million, partially offset by non-cash adjustments of $20.3 million, including of financial expenses of $13.0 million as a result of increase in investors options valuation and depreciation and amortization expenses of $5.4 million and cost of share expenses of $1.3 million while interest and tax payments were $1.3 million and negative change of $4.9 million in our operating assets and liabilities (including inventory increase of $3.1 million).
 
36

Cash Flows Used In Investing Activities
 
Cash used in investing activities during the year ended December 31, 2023, was $9.3 million, primarily related to the capitalization of development costs of $4.2 million, $1.3 million for the purchase of property and equipment and  $3.8 million from investment in short-term deposit.
 
Cash used in investing activities during year ended December 31, 2022, was $6.4 million, primarily related to the capitalization of development cost of $5.2 million, and $5.7 million from investment in short-term deposit, $5.6 million from investment in short-term investment and $ 1.6 million for the purchase of property and equipment, offset in part by $11.7 million from the net proceeds from short term investments.
 
Cash used in investing activities during year ended December 31, 2021, was $41.0 million and primarily related to subsidiary acquisition of $27.3 million, the purchase of short-term investments of $13.6 million, and the capitalization of development cost of $2.6 million.
 
Cash Flows Provided By/Used In Financing Activities
 
Cash provided by financing activities during the year ended December 31, 2023, was $13.7 million, primarily related to the exercise of options by investors in a net amount of $19.2 million, offset by lease payments of $2.7 million and repayment of long-term loan of $2.1 million.
 
Cash used in financing activities during the year ended December 31, 2022, was $2.3 million and primarily related to lease payments of $2.4 million, and repayment of long-term loan of $1.7 million partially offset by exercise of options of $2.0 million.
 
Cash provided from financing activities during the year ended December 31, 2021, was $51.1 million and primarily related to the net proceeds from the issuance of share capital of $36.9 million, $0.5 million from the exercise of options, and $18.3 million in proceeds from long-term loans, offset in part by lease payments of $1.9 million and short-term bank credit repayment of $2.7 million.
 
Financial Arrangements
 
On January 7, 2021, a special general meeting of the company approved the increase of the authorized share capital of the company to 25,000,000 ordinary shares of NIS 0.01 par value each.
 
On January 21, 2021, the company closed the first of two placements by selling 1,600,000 ordinary shares. In addition, the company issued options to purchase 800,000 ordinary shares at an exercise price of CHF 11.00 per share exercisable for a 24-month period.
 
On February 17, 2021, the company closed a second private placement by issuing 2,288,889 new ordinary shares. In addition, the company issued options to purchase 1,144,444 further ordinary shares at an exercise price of CHF 11.00, exercisable for a 24-month period.
 
The expiration dates for the options were January 20, 2023, and February 16, 2023. Upon expiration, the proceeds from the exercise of 1,914,478 options were recorded in equity.
 
The placement agents in these two private placements received a cash payment based on the amount of cash received in the private placements and from the exercise of the options issued in the placements. In addition, the placement agents were granted options for units at an exercise price of CHF 9.00 per unit. Each unit entitles the placement agents to receive one ordinary share together with an option to acquire 0.5 ordinary share at an exercise price of CHF 11.00 per share. The exercise period for these placement agents’ units is until March 17, 2025. As of December 31, 2023, the number of units granted to the placement agents was  155,720. These units, if fully exercised, entitle the placement agent to 233,580 shares.

37

Long-term loan
 
On August 29, 2021, the company signed an agreement with a bank in Israel to obtain a long-term loan in the amount of NIS 59 million (approximately $18 million) for a period of seven years and nine months. The loan is denominated in NIS and bears interest at prime plus 1.05% (2.65% as of the signing date). The loan is required to be repaid in 28 quarterly installments following an initial moratorium period of nine months.
 
The loan agreement includes certain financial covenants related to the company’s Israeli operations, including with respect to minimum tangible equity, minimum tangible equity to total tangible assets, and net debt to EBITDA. As of December 31, 2023, the company was in compliance with these covenants.
 
Mediton Group Acquisition
 
On August 31, 2021, the company consummated an agreement, dated August 25, 2021, to acquire 70% of the Mediton Group companies, a leading provider of healthcare services in Israel in the field of diagnostics, preventative healthcare, and medical opinions to institutional customers, including Israeli blue-chip companies, government institutions such as the Israeli Social Security and the Israeli Ministry of Defense, all four healthcare funds and insurance companies.
 
The purchase price for the acquisition of approximately NIS 84 million (approximately $26 million) was financed from cash on hand and the NIS 59 million Israeli bank long-term loan referred to above. The transaction included the grant of a put and call option over the remaining 30% interest in the Mediton Group.
 
Sellers Put Option
 
Pursuant to the Mediton SPA, the sellers have an option for one year from the day following the end of the third anniversary of the closing (“Put Option Period”), to obligate SHLR to purchase all (but not part) of the sellers’ remaining 30% holdings in both Mediton and Medishur (but not one of them), at a price based on a multiple of EBITDA of Mediton Group as defined and set out in the Mediton SPA.
 
The put option price may be paid in SHL ordinary shares so long as the ordinary shares remain listed on the SIX or another major exchange, with each ordinary shares valued at 90% of SHL’s share closing price on the date the put option is exercised.
 
As of December 31, 2023, and December 31, 2022, the estimated gross amount of cash outflow assuming the put option will be exercised at the earliest possible date was $9.9 million and $11.3 million, respectively. As discussed above, this amount may be settled in cash or through the issuance of SHL ordinary shares. The principal factor that could have a material impact on the gross amount would be a significant change in the EBITDA of the Mediton Group in the period prior to the Put Option Period.
 
For financial reporting purposes, SHL has selected as an accounting policy to record the sellers’ remaining 30% holdings in both Mediton and Medishur as non-controlling interest in the equity of SHL. The put and call options, which are financial derivatives, are measured at fair value through profit or loss and are presented net in the consolidated balance sheet.
 
The fair value of the put option to sell the remaining 30% holdings in both Mediton and Medishur represents the difference between estimated fair value of the remaining 30% holdings in both Mediton and Medishur and the exercise price discounted to its present value. As the exercise price gets closer to the fair value of the remaining 30% holdings in both Mediton and Medishur, the effect is to reduce the fair value of the put option. The same would apply in the opposite direction to the fair value of the call option of SHL to acquire the remaining 30% holdings in both Mediton and Medishur, as described under the heading “Company Call Option” below.

38

As of December 31, 2023, and December 31, 2022, the net fair value of the put and call options were $206 (liability) and $245 (asset), respectively. See Note 17h to the consolidated balance sheet as of December 31, 2023, and December 31, 2022, respectively, included elsewhere in this Annual Report for an explanation of the methodology and significant inputs used in order to determine the fair value.

In order to provide information as to its liquidity position, SHL discloses in Note 17f to the consolidated balance sheet included elsewhere in this Annual Report as of December 31, 2023, the estimated gross cash outflow of $8.2 million assuming the put option will be exercised at the earliest possible date.
 
Company Call Option
 
The Mediton SPA also provides SHLR the right for one year from the end of the Put Option Period to oblige the sellers to sell to SHLR all (but not part) of the sellers’ remaining 30% holdings in both Mediton and Medishur (but not one of them) for the higher of the same price as the put option price, or a consideration that reflects a value of NIS 120 million for the companies as of the closing date with such amount being linked to the Israeli Consumer Price Index, minus all dividends paid from the August 31, 2021, closing date until the date the Call Option is exercised, all as set forth in the Mediton SPA.
 
Long-Term Lease
 
The Company has long-term lease liabilities repayable in monthly equal installments until March 2029. The total aggregate contractual undiscounted payments for these long-term lease liabilities, including interest, amounts to approximately $10,775
 
Off-Balance Sheet Arrangements
 
We do not have any material off-balance sheet arrangements, that are reasonably likely to have a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.
 
C.           RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES, ETC.
 
Research & Development
 
We are a leading developer of advanced telemedicine technologies that is highly focused on research and development, including predicting artificial intelligence technologies. Our research and development efforts are carried out with the Hadassah Medical Center and the Hebrew University of Jerusalem.
 
Our gross research and development costs (excluding amortization and capitalization) were $6.7 million in 2023, $7.2 million in 2022 and $4.4 million in 2021.
 
Intellectual Property
 
We seek to protect our proprietary technology and intellectual property through a combination of patents, patent designs, and trademark applications, as well as trade secrets, know-how, and other contractual rights, (including confidentiality and invention assignment agreements). We hold a number of design patents and trademarks, including one of our key products and technologies, the SmartHeart®.
 
The following table sets forth certain information related to the primary patents and trademarks material to our business:
 
Owned Patent
Jurisdiction
Expiration Date
Patent #229482 – An Electrocardiographic Monitoring System and Method (Utility Patent)
Israel; China; Europe
In Israel, patent in force until May 21, 2026, and set to expire on May 21, 2032.
Device for Obtaining a Standard 12‑Lead Electrocardiogram and a Rhythm Strip – Grant Number 09215998 (Utility Patent)
United States
June 1, 2032
Status of Trademarks filed through WIPO in various countries
 
39

Trademark Number/Status
Trademark Name
Type of Trademark
Validity of Trademark (until the following dates)
Owner
Country of Registration
7478308
 ramified heart symbol
10, 38, 44
12/18/2028
SHL Intern.
Europe
(Community
Trademark)
77638118
ramified heart symbol
35, 38, 44
12/22/2028
SHL Intern.
U.S.A.
234343
CCM
(Logo CCM – Hebrew)
9, 10, 38, 44
12/13/2030
SHL Intern.
Israel
234810
HEART SMART
9, 10, 38, 44
01/02/2031
SHL Intern.
Israel
1096059
HEART SMART
9, 10, 38, 44
06/27/2031
SHL Intern.
WIPO

Trademark Number
Trademark Name
Type of Trademark
Validity of Trademark (until the following dates)
Company
Country of Registration
T1116147A
Registered after rejection and appeal
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Singapore
4204156
SMART HEART
9, 10, 38, 44
09/11/2032
SHL Intern.
U.S.A.
8‑8‑2012‑001246089
Registered after rejection and appeal
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
South Korea
2011‑360491
Registered after rejection and appeal
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Japan
1459720
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Australia
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Norway
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Switzerland
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Island
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
China
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Turkey
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Croatia
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Russia
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Ukraine
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Moldova
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Serbia
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Georgia
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Montenegro
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Belarus
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Monaco
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
Lichtenstein
1096059
Registered
SMART HEART
9, 10, 38, 44
06/21/2031
SHL Intern.
European Union

40

Status of Trademarks filed in Germany
 
Trademark Number*
Trademark Name
Type of Trademark
Validity of Trademark (until the following dates)
Company
Country of Registration
 
302021116844
TELECOR
44
Pending final approval
SHL Telemedizin GmbH
Germany

*
Where an international registration number is listed, such number serves as the only registration number in the indicated country.
 
D.           TREND INFORMATION
 
See Item 4. “Information on the company.”
 
E.           CRITICAL ACCOUNTING ESTIMATES
 
Not applicable.

41

ITEM 6.
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

A.           DIRECTORS AND SENIOR MANAGEMENT
 
The following table sets forth certain information about our directors and executive officers as of the date of this Annual Report. Unless otherwise stated, the address of each of our executive officers and directors is Yigal Alon 90, Tel Aviv 67891, Israel.
 
Name
   
Yariv Alroy 63
Chairman of the Board of Directors
Prof. Amir Lerman(1)(2)(3)
66
Director
Yehoshua (Shuky) Abramovich(1)(2)(3)
63
External Director
Dvorah Kimhi(1)(2)(3)
74
External Director
Ido Nouberger
59
Director
Nir Rotenberg
61
Director
Erez Nachtomy
63
Chief Executive Officer(4)
Amir Hai
58
Chief Financial Officer
Jason Bottiglieri
51
General Manager SHL USA
Bernd Altpeter
59
Managing Director, SHL Telemedizin, Germany

(1)
Member of Audit Committee and Financial Statements Committee.
(2)
Member of Compensation Committee.
(3)
Independent director under Nasdaq and SEC independence standards.
(4)
On March 14, 2024, Mr. Nachtomy announced that he would be resigning as Chief Executive Officer of the Company effective mid-June 2024.

Yariv Alroy joined our Board of Directors in December 2018, was elected as Chairman of the Board of Directors in December 2018, served as Co-Chairman from August 11, 2022, until February 2024, and has served as Chairman since February 2024. He served as our Co-CEO from 2000 to January 15, 2016. He previously served as managing director of SHL Telemedicine International Ltd. from 1997 to 2000 and as our Chief Operating Officer from 1993 to 1997. He also previously served as a member of the Board from 2001 to 2006 and 2010 to 2014. Before joining SHL, Mr. Alroy worked for a leading Israeli law firm from 1989 to 1993, with his last position as senior partner. Since 2016, he has been an investor and a businessman and serves as a Chairman of UAS Drone Corp. (OTCQB: USDR). He holds an LL.B. from Tel Aviv University, Israel.
 
Prof. Amir Lerman joined our Board of Directors in 2016. He has served as the Vice-Chair, Cardiovascular Department and the Director of the Cardiovascular Research Center at the Mayo Clinic in Rochester (USA) since 2010. He has also served as the Program Director for vascular and valve, Center for Regenerative Medicine at the Mayo Clinic since 2012. In addition, Prof. Lerman serves as the Director of the Mayo-Israeli startup company initiative as well as a faculty member at the Mirage Institute: US-Israel innovation bridge business leadership program, since 2009, in addition to various other positions held at the Mayo Clinic. Since 2001, he has also held an appointment as Professor of Medicine at the Mayo Medical School. Prof. Lerman graduated from the Technion School of Medicine in Haifa, Israel in 1985 and completed his training in internal medicine, cardiovascular diseases and invasive cardiology at the Mayo Clinic in 1994. Prof. Lerman has published more than 500 manuscripts, book chapters and reviews; the NIH, AHA and several foundations support his research.

42

Yehoshua (Shuky) Abramovich joined our Board of Directors in June 2017. Mr. Abramovich has held key positions in the Israeli capital market for over 25 years. He serves as the chairman of the board of Imed Infinity Medical, chairman of Atrade, member of the board of directors and chairman of the investment committee of I.D.I. Insurance Company, a member of the board of directors of each of the public companies Brimag Digital, Modiin Energy and GoTo and as a director in other high-tech, real estate and energy companies. Mr. Abramovich was the CEO of Clal Finance, one of Israel’s largest financial institutions, which provided a broad array of financial services ranging from portfolio management to brokerage and underwriting services. Clal Finance owned and managed mutual funds, an in-house hedge fund, and offered individually tailored structured products to clients. Prior to that, he served in various positions in Clal Group, including Deputy CEO of Clal Insurance Enterprises Holdings. He served on the board of directors of the Tel Aviv Stock Exchange until September 2008, and he is a member of the board of trustees of the Academic Track of the College of Management. He has a B.A. in Economics & Business Management and an M.B.A. from Tel Aviv University.
 
Dvorah Kimhi joined our Board of Directors in December 2018, after previously serving on the Board from 2010 to 2014 and 2001 to 2007. Since 2002, she has served as Vice President for regulatory and legal affairs with Channel 10. She currently serves as Vice President for regulatory and legal affairs with Reshet Media Ltd. (Channel 13), one of the two existing Israeli commercial television channels. Prior to this, Ms. Kimhi served as Chief Legal Advisor to Ananey Communications Ltd., Noga Communications and the Israeli Educational Television. She also serves on the board of directors of Kol Hayyam Hadrom Ltd., an Israel radio station. Ms. Kimhi is a member of the Israeli Bar, holds an LL.B. from Tel Aviv University and has specialized in contract law, corporate law, communication law and regulation.
 
Ido Nouberger has served on our Board of Directors since February 2024. Mr. Nouberger has served as the CEO of Value Base since its inception in 2013. He also holds the position of chairman of the board or board member of Value Base’s various subsidiaries. Prior to that, he served as CEO and a director or various Israeli companies. Mr. Nouberger holds a M.A. and B.A, both in economics, from Tel Aviv University.
 
Nir Rotenberg has served on our Board of Directors since February 2024. Mr. Rotenberg is the Chairman of the Board of Danbar Finance Ltd., a private investment group, and has served there as a director and partner since 2000. Prior to that, he served as a manager and director of certain public companies in the Danbar group of companies from 1994 until 2000 and from 1990-1993 served as chief investment officer in Migdal Insurance Company. Mr. Rotenberg holds a M.B.A. in business management and B.A in economics from Tel Aviv University.
 
Erez Nachtomy has served as our Chief Executive Officer since May 2020 and served as a member of our Board of Directors from December 2018 until February 2024. On March 14, 2024, Mr. Nachtomy announced that he would be resigning as Chief Executive Officer of the Company effective mid-June 2024. From 1989 until 2001, Mr. Nachtomy practiced law at a leading Israeli law firm – Weksler, Bregman & Co., becoming a partner in the firm in 1994 and later on promoted to a senior partner. In March 2001, he joined our executive team as Vice President, and from January 2005 to December 2016 he served as our Executive Vice President. Since 2017, he is an investor and a businessman specializing in strategic planning, M&A transactions, and capital raising and business development. He serves as Vice Chairman and a member of the Board of UAS Drone Corp. (OTCQB:USDR). Mr. Nachtomy holds an LL.B. from Tel Aviv University and he is a member of the Israeli Bar.

Amir Hai has served as our Chief Financial Officer since January 2022. Mr. Hai. Prior to joining SHL, Mr. Hai was Chief Financial Officer of RADCOM (NASDAQ: RDCM) from 2018 to December 2021. Prior to that Mr. Hai served as Chief Financial Officer for several other companies including two publicly traded companies (Valor Computerized Systems and Shamir Optical Industry) and served as High-tech Senior Manager for Ernst & Young Israel. Since 2012 to 2021, Mr. Hai also served as external director and chairman of the audit committee of Matrix IT Ltd. Mr. Hai holds a B.A. in Economics from the College of Management Academic Studies in Israel and is certified in Israel as a CPA.
 
Jason Bottiglieri has served as our General Manager in the United States since June 2022. Mr. Jason Bottiglieri has over 25 years of commercial and executive-level management experience within the cardiovascular device field. He has extensive experience establishing and leading sales, marketing and operations teams, successfully commercializing innovative technologies in the global market. In his most recent position, Mr. Bottiglieri held the role of Chief Commercial Officer at Elucid Bioimaging, a developer of a non-invasive artificial intelligence medical software used for cardiovascular disease diagnosis. Prior to that he served as President and CEO of InnovHeart S.r.L., and as President and CEO of Infraredx, which was acquired by Nipro Corporation of Japan. Mr. Bottiglieri holds a B.A. in Chemistry from Florida Atlantic University and an M.B.A. from James Madison University.
 
43

Bernd Altpeter serves as Managing Director of SHL Telemedizin, Germany and served as Co-Managing Director from April 4, 2023, until September 2023. Mr. Altpeter has significant experience in the German healthcare and telemedicine market. Prior to joining SHL Telemedizin, Germany, Mr. Altpeter was Global Head of Digital Products and Projects with Boehringer Ingelheim Vetmedica GmbH from July 2021 to April 2023. Before that, Mr. Alpeter founded the Digital Health Group in 2013 serving as its Chief Executive Officer. The Digital Health Group consisted of several companies focusing on digital chronic care management programs and health contract management, providing solutions and services to health insurance companies, physicians and pharma companies. The group was acquired in 2020 by Fresenius SE. Previously, Mr. Altpeter held executive level positions in international organizations in the field of sales and marketing consulting. Mr. Altpeter is a Business Administration graduate from the Technische Universität Berlin, and management training from INSEAD and Duke University.
 
B.           COMPENSATION
 
Aggregate Compensation of Office Holders
 
The aggregate compensation expenses to our directors and executive officers for the year ended December 31, 2023, was approximately $2,184,028. This amount includes social benefits and car leasing costs. The amount does not include the expense of share-based compensation.
 
As of April 15, 2024, we have issued outstanding options to purchase 1,205,244 ordinary shares granted to our executive officers and directors under our 2021 Executive and Key Employee Israeli Share Incentive Plan (the “Share Option Plan”) at a weighted average exercise price of CHF 12.22 per ordinary share.
 
44

Individual Compensation of Office Holders
 
The table and summary below outline the compensation granted to our directors and executive officers with respect to the year ended December 31, 2023. Our Compensation Policy, Share Option Plan and the terms of the share options granted to our directors and executive officers are described below.
 
Year-end December 31, 2023
 
               
Share
   
Weighted
       
   
Base
         
Options
   
Average
       
   
Compensation
         
Granted
   
exercise price
       
   
and Fringe
   
Cash
   
or
   
of Options
       
Name and Offices Held
 
Benefits
   
Bonus
   
exercised (1)
   
Granted
   
Total
 
Yariv Alroy
                             
Active Co-Chairman of the Board of Directors
 
$
255,362
     
     
     
   
$
255,362
 
Ehud Barak(2)
                                       
Active Co-Chairman of the Board of Directors
   
167,377
     
     
     
     
167,377
 
David Salton(3)
                                       
Director
 
$
34,195
     
     
     
     
34,195
 
Prof. Amir Lerman
                                       
Director
 
$
44,854
     
     
     
     
44,854
 
Yehoshua (Shuky) Abramovich
                                       
External Director
 
$
64,800
     
     
20,708
     
     
85,508
 
Dvorah Kimhi
                                       
External Director
 
$
46,128
     
     
     
     
46,128
 
Erez Alroy(3)
                                       
Director
 
$
46,666
     
     
     
     
46,666
 
Erez Nachtomy(3)
                                       
Chief Executive Officer and Director
 
$
330,516
     
63,742
     
     
     
394,258
 
Other Senior Management
 
$
912,862
   
$
215,725
   
$
495,444
   
CHF 9.36 – CHF 9.88
   
$
1,625,831
 

(1)
The options are exercisable on a net exercise basis method. The expiration dates of the options granted are as follows:
 
45

Weighted Average
 
Expiration date of the 
   
exercise price of Options Granted
 
options
 
Number of Options
CHF 7.70
 
10/12/2024
 
 18,000
CHF 6.51
 
21/02/2025
 
 18,000
CHF 5.61
 
30/06/2026
 
 50,000
CHF 5.73
 
10/12/2026
 
 120,000
CHF 10.73
 
01/03/2027
 
 250,000
CHF 17.02
 
08/12/2027
 
54,000
CHF 19.33
 
02/01/2028
 
 80,000
CHF 17.39
 
20/06/2028
 
 100,000
CHF 9.36
 
15/05/2029
 
 100,000
CHF 9.88
 
18/06/2029
 
 30,000

(2)
Mr. Barak served as the Co-Chairman of the Board during the year ended December 31, 2023, and ceased to serve in such capacity and as a member of our Board of Directors in February 2024.
(3)
Each of Messrs. David Salton, Erez Alroy and Erez Nachtomy served as a member of our Board of Directors during the year ended December 31, 2023, and ceased to serve in such capacities in February 2024. On March 14, 2024, Mr. Nachtomy announced that he would be resigning as Chief Executive Officer of the Company effective mid-June 2024.

Compensation Policy for Executive Officers and Directors
 
Israeli Companies Law
 
Pursuant to the Israeli Companies Law, an Israeli public company is required to adopt a compensation policy with respect to the terms of engagement of its office holders (as such term is defined under the Israeli Companies Law) (a “Compensation Policy”), including directors and controlling shareholders engaged as company officers, subject to limited exceptions which do not apply to us. The adoption of a Compensation Policy requires shareholder approval, further to approval by the Board of Directors, which must consider the recommendations of the Compensation Committee. The shareholder approval must consist of a simple majority of all votes cast, and either (i) the approval of a majority of the shareholders’ voting power represented at the meeting in person or by proxy and voting thereon who are neither controlling shareholders nor have a personal interest in approving the Compensation Policy (disregarding abstentions), or (ii) the total vote against adoption of the Compensation Policy by shareholders who do not have a personal interest in approving the Compensation Policy does not represent more than 2% of the voting rights in the company.
 
Any shareholder participating in the vote on the adoption of the Compensation Policy must inform the company prior to the relevant vote as to whether the shareholder has a personal interest in the matter. Votes of shareholders who did not notify the company as to whether or not they have a personal interest are not counted.
 
As a general rule, pursuant to the Israeli Companies Law, remuneration to office holders which is inconsistent with the Compensation Policy requires, in addition to the approval of the Compensation Committee and of the Board of Directors, the approval of a special majority in the general meeting of shareholders, as described above.
 
The Board is required to examine from time to time whether any amendments to the Compensation Policy are necessary in light of changing circumstances or for any other reason. Similarly, the Compensation Committee issues recommendations to the Board in this respect from time to time. At least once every three years, the Compensation Policy must be submitted to shareholders for renewed approval, incorporating any amendments that the Compensation Committee and Board deem appropriate.
 
Our prior Compensation Policy was adopted by the Special General Meeting of the shareholders of the Company held in September 2020 following the recommendation and earlier approval of the Compensation Committee and of the Board. The Compensation Policy expired in 2023, and we are in the process of seeking approval of a new Compensation Policy.
 
Board of Directors Compensation
 
Israeli Companies Law
 
Pursuant to the Israeli Companies Law, except under limited circumstances, the compensation to be paid to the directors in their capacity as such, as well as the terms of employment (including the terms and conditions of the directors’ and officers’ insurance and indemnification) of any of the directors in any other position, require the approval of the Compensation Committee, the Board and the shareholders (by a simple majority), and the approvals of the Compensation Committee and the Board must be made in accordance with the Compensation Policy in effect (subject to a limited exception). Further, pursuant to the Israeli Companies Law, approval by the shareholders of the terms of engagement of a controlling shareholder, which for this purpose also includes any shareholder or group of shareholders that holds at least 25% of the company’s voting power, provided that there is no other shareholder that holds more than 50% of the company’s voting rights as an office holder (including as a director) or employee generally requires either (i) that the majority vote in favor of the resolution shall include the approval of a majority of the voting power represented at the shareholders meeting in person or by proxy and voting thereon of shareholders who have no personal interest in approving the resolution (disregarding abstentions), or (ii) that the total vote against the resolution by shareholders who have no personal interest in approving the resolution do not represent more than 2% of the voting rights in the company.
 
46

Pursuant to the provisions of the Israeli Companies Law, as a general rule, any person that has a personal interest in a transaction (including approval of the terms of office of a director) may not participate or vote at the relevant Board, Audit Committee or (with respect to the approval of engagement terms) Compensation Committee meeting where the transaction is discussed; provided that office holders who have a personal interest in a transaction may be present for the purpose of presenting such transaction, if the Chairman of the Audit Committee, the Chairman of the Board or the Chairman of the Compensation Committee, as the case may be, determined that such presence is required. In addition, if the majority of the members of the Board of Directors, the Audit Committee or the Compensation Committee, as applicable, have a personal interest in the terms of office of such a director, then the relevant director may be present during the deliberations and may vote on his terms of office, and in such event, shareholder approval is also required.
 
As noted above, our Compensation Policy stipulates that with respect to our directors, compensation shall be subject to the limitations set forth in the Compensation Policy and shall be in accordance with the Director Compensation Regulations. The Director Compensation Regulations specify the annual fee and the participation fee to be paid to external directors, depending on the company’s shareholders’ equity. The Director Compensation Regulations also allow for an alternative payment method, according to which the remuneration paid to external directors will be the same as the remuneration received by the other directors of the company who are not employed by the company and are not controlling shareholders thereof (proportionate remuneration). Further, we are also entitled to pay to our directors share-based compensation (subject to applicable law and the restrictions applicable thereto in general under our Compensation Policy), but in any event the aggregate fair value of the share-based compensation, measured at the time of a new grant, for all of our directors, as a group, shall not exceed a fair value of $800,000 per year of vesting.
 
Currently, all Board members receive the same compensation per meeting, in the amount of NIS 3,600 (whether such meeting is held physically or by electronic means) as well as annual compensation in the amount of NIS 68,000. The Chairman of the Board, Mr. Yariv Alroy, is entitled to said participation fee and annual fee, in addition to his current compensation from the company. With the exception of Mr. Yariv, none of our directors have service contracts with the company relating to their service as a director, and none of the directors will receive benefits upon termination of their position as a director.
 
Share Option Plan
 
Our Share Option Plan will be in effect until terminated by the Board, pursuant to an amendment to the Share Option Plan which was approved by the Board on October 31, 2021. Pursuant to the Share Option Plan, options may be granted to executives, directors and key employees of SHL or its subsidiaries. The Board of Directors has full discretion to determine the specific grantees from time to time.
 
The maximum number of ordinary shares which may be issued under the Share Option Plan and under any other SHL share incentive option plan is 4,077,346, subject to adjustments as provided in the Share Option Plan. As of April 15, 2024, 1,920,500 share options remain available for grant.
 
Pursuant to the Share Option Plan, the exercise price shall be the closing price for an ordinary share on the last trading day prior to the grant, unless determined otherwise by our Board of Directors in its discretion. However, with respect to all option grants since May 2010, the Board of Directors determined in each case that the exercise price for such option grants shall be the average share price in the thirty (30) trading days preceding the date of grant. The foregoing has also been stipulated as the exercise price applicable to any grants of share-based compensation to our officers pursuant to our amended Compensation Policy adopted on September 21, 2020, which was in effect until September 21, 2023. Further, pursuant to a resolution of the Board as of November 7, 2010, all options issued under the Share Option Plan are exercised by way of the net exercise method.
 
Options granted under the Share Option Plan shall vest, unless determined otherwise by the Board, one-third (1/3) on each of the first, second and third anniversary of the date of grant, so that all options shall be fully vested and exercisable on the first business day following the lapse of thirty six (36) months from the date of grant, contingent upon the achievement of certain market and performance conditions which, unless determined otherwise by the Board, shall be based on the rate of the increase in the market price of the shares and of our earnings per share. The Board may in its discretion reduce the relevant performance targets to zero, and has done so in all instances since June 2011.
 
The options shall expire six (6) years from the date of grant (unless expired earlier under the terms of the Share Option Plan or the relevant award agreement). With respect to option grants to our officers, our Compensation Policy provides a minimum vesting period, as follows: (i) first cliff after one (1) year from the date of grant; and (ii) full vesting shall occur no earlier than 36 months from the date of such grant.
 
47

The grant of share options to our employees, directors and consultants is in the sole discretion of the Board, which may determine from time to time and subject to the provisions of the Share Option Plan, additional grantees of options under and any matter related to the administration of the Share Option Plan.
 
Option grant is done pursuant to the Board’s full discretion pursuant to the general rules set forth under our Compensation Policy. Option grants to vice presidents are usually based on the CEO’s recommendations, and to the CEO based on the Board’s recommendations, and are sometimes the outcome of negotiations with the relevant employee.
 
Notwithstanding the aforesaid, pursuant to the provisions of the Israeli Companies Law, should such options be granted to the directors or a controlling shareholder as part of their compensation, such grant shall require the approval of the Compensation Committee, the Board and the shareholders, and with respect to office holders who are not directors, the CEO or our controlling shareholders or their relatives, such grant shall require approval by the Compensation Committee, followed by approval by the Board, all of the foregoing approvals of the Compensation Committee and the Board to be made in accordance with the Compensation Policy.
 
C.           BOARD PRACTICES
 
Our Articles of Association provide that our Board of Directors consists of not less than three (3) and not more than nine (9) directors, including two (2) external directors, until otherwise determined by ordinary resolution of our shareholders. Our Board currently consists of six directors, each of whom was elected at our annual general meeting of shareholders held on February 4, 2024, to serve until our next annual general meeting of shareholders, except that Yehoshua (Shuky) Abramovich, one of our external directors, was reelected for a second three-year term commencing on June 28, 2023, at our special general meeting of shareholders held on June 22, 2023, and Dvorah Kimhi, our other external director, was reelected for a second three-year term at our annual general meeting of shareholders held on December 9, 2021. See Item 6.A, “Directors, Senior Management and Employees—Directors and Senior Management” for further details regarding the periods of service of each of our current directors.
 
Under the Israeli Companies Law and the company’s Articles of Association, directors are elected by the general meeting of shareholders. Pursuant to our articles of association, our directors, except the two (2) external directors, who are elected as described below under “—Director Service Contracts – Board Independence – External Directors”, pursuant to the provisions of the Israeli Companies Law, are elected individually at the annual general meeting by the vote of the holders of a simple majority of the voting power represented at such meeting in person or by proxy and voting on the election of directors. The directors so elected hold office until the next annual general meeting. The holders of a simple majority of the voting power represented at a general meeting and voting thereon are entitled to remove any director(s) from office, to elect directors in place of director(s) so removed or to fill any vacancy, however created, on the board of directors. A shareholder desiring to propose a candidate for election to the board of directors or to remove a director from his position, as a condition to such proposal being considered, is required to advise the company of the identity of such candidate or serving director at least two (2) weeks prior to the date of the general meeting at which such resolution is to be considered (or such shorter period as may be determined by the board of directors). Prior to his or her election, each nominee is required to provide the Company with an executed declaration that he or she possesses the requisite skills and has the availability to carry out his or her duties. Additionally, the nominee must provide details of such skills, and demonstrate an absence of any limitation under the Israeli Companies Law that may prevent his or her election and affirm that all of the required election-information is provided to us.
 
Terms of Office
 
Our current Board of Directors is comprised of Mr. Yariv Alroy (Chairman), Prof. Amir Lerman, Mr. Ido Nouberger, Mr. Nir Rotenberg, Mr. Yehoshua (Shuky) Abramovich (external director) and Ms. Dvorah Kimhi (external director). The terms of office of Yariv Alroy, Prof. Amir Lerman, Ido Nouberger and Nir Rotenberg will expire at our 2024 annual general meeting. The term of office of Dvorah Kimhi will expire on December 9, 2024, and the term of office of Mr. Yehoshua (Shuky) Abramovich will expire on June 27, 2026. None of our directors have service contracts with the company relating to their service as a director, and none of the directors will receive benefits upon termination of their position as a director. For a description of our compensation of directors see Item 6.B, “Directors, Senior Management and Employees—Compensation.”
 
48

Board Independence
 
External Directors
 
Israeli companies that have offered securities to the public in or outside of Israel are required to elect at least two external directors under the provisions of the Israeli Companies Law, who must meet rigid standards of independence to ensure that they are unaffiliated with us and our controlling shareholder. An external director must also have either financial and accounting expertise or professional qualifications, as defined in the regulations promulgated under the Israeli Companies Law, and at least one of the external directors is required to have financial and accounting expertise. An external director is entitled to reimbursement of expenses and compensation as provided in the regulations promulgated under the Israeli Companies Law but is otherwise prohibited from receiving any other compensation from us, directly or indirectly, during his or her term and for two years thereafter.
 
Under the Israeli Companies Law, external directors must be elected at a shareholders’ meeting by a simple majority of all votes cast, and either (i) the approval of a majority of the shareholders’ voting power represented at the meeting in person or by proxy and voting thereon who are neither controlling shareholders nor have a personal interest in the election of the director (other than a personal interest that does not result from the voting shareholder’s relationship with the controlling shareholder, and disregarding abstentions), or (ii) the total vote against the election of the director by shareholders who are neither controlling shareholders nor have a personal interest in the election of the director (other than a personal interest that does not result from the voting shareholder’s relationship with the controlling shareholder) does not represent more than 2% of the voting rights in the company
 
External directors serve for up to three terms of three years each, and our shareholders may nominate them for additional terms. A term of an external director may be terminated prior to expiration only by a shareholder vote, by the same threshold required for election, or by a court, but in each case only if the external director ceases to meet the statutory qualifications for election or if the external director violates his or her duty of loyalty to us. If at the time of election of an external director all of the members of the board of directors (excluding controlling shareholders or relatives of controlling shareholders) are of the same gender, the external director to be elected must be of the other gender.
 
Under the Israeli Companies Law, each committee of a company’s board of directors that is authorized to exercise powers of the board of directors is required to include at least one external director, and all external directors must be members of the company’s audit committee and compensation committee.
 
Pursuant to regulations promulgated under the Israeli Companies Law, a company whose shares are traded on specified stock exchanges (including Nasdaq) and which satisfies certain conditions – principally that it does not have a controlling shareholder as defined for this purpose in the Israeli Companies Law – can elect not to comply with the above external director rules, and to comply instead with the requirements of the SEC and Nasdaq applicable to U.S. domestic public companies with respect to the independence of board members and with respect to the composition of the audit committee and the compensation committee. We have not elected to opt out of the external director rules, although we may do so in the future. The relevant regulations provide transition rules for directors elected as external directors if the company opts out of the external director rules.
 
Independence under Nasdaq and SEC Standards
 
Each of our two external directors, Mr. Yehoshua (Shuky) Abramovich and Ms. Dvorah Kimhi, is considered “independent” under Nasdaq and SEC independence standards in addition to the Israeli Companies Law. Prof. Amir Lerman is also considered “independent” under Nasdaq and SEC independence standards.
 
As a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of those otherwise required under Nasdaq’s rules for domestic U.S. issuers, provided that we disclose which requirements we are not following and describe the equivalent home country requirement. Because three of the six directors on our Board are independent under Nasdaq’s independence standard, we do not currently comply with Nasdaq’s requirement that an issuer maintain a majority of independent directors.
 
49

Board Committees and Internal Auditor
 
Under the Israeli Companies Law, with respect to Companies that have offered securities to the public in or outside of Israel, each committee of the Board of Directors authorized to exercise the powers of the Board of Directors is required to include at least one external independent director, and the Board of Directors of a public company is required to appoint an Audit Committee and a Compensation Committee, which must be comprised of at least three (3) directors, including all of the external directors.
 
Our Board of Directors has established an Audit Committee, Compensation Committee, Investment Committee, M&A Committee, Cyber Committee, and Executive Committee.
 
We previously also had a Financial Statements Committee under Israeli law from March 18, 2015, until its functions were transferred to our Audit Committee and it was dissolved in January 2023. The task of the Financial Statements Committee was to examine our financial statements prior to their approval by the Board of Directors.
 
Audit Committee
 
Pursuant to the Israeli Companies Law, the Audit Committee must be comprised of at least three (3) directors, including all of the external directors, and a majority of its members must be independent directors within the meaning of the Israeli Companies Law (i.e., including the external directors).
 
The following persons may not be members of the Audit Committee:
 

the Chairman of the Board;
 

any director employed by us;
 

any director employed by a controlling shareholder of us or an entity under the control of such controlling shareholder;
 

any director who provides services, on a regular basis, to us, a controlling shareholder or an entity under the control of a controlling shareholder;
 

a director whose main livelihood is based on a controlling shareholder; and
 

a controlling shareholder or any of its relatives.
 
Subject to limited exceptions, any person who could not be a member of the Audit Committee may not be present at its meetings. The Chairman of the Audit Committee shall be an independent (external) director not serving for more than nine (9) years.
 
The legal quorum for any meeting of the Audit Committee shall be a majority of its members, provided that the majority of those present shall be independent directors, and provided further that at least one (1) independent (external) director shall be present.
 
The Audit Committee currently consists of Mr. Yehoshua (Shuky) Abramovich, Ms. Dvorah Kimhi and Prof. Amir Lerman. The Audit Committee consists exclusively of members of our board of directors who are financially literate. Our Board of Directors has determined that Mr. Abramovich is the financial expert under the SEC definition and all members of the Audit Committee satisfy the “independence” requirements set forth in Rule 10A‑3 under the Exchange Act and under Nasdaq’s corporate governance standards. The members of the Audit Committee are appointed by our Board of Directors.
 
The role of the Audit Committee is, among other things, to:
 

examine flaws in our business management, in consultation with our internal auditor and the external auditors, and to propose remedial measures to the Board;
 

determine whether an interested party transaction is an ordinary or extraordinary transaction (where extraordinary transactions are subject to special approval requirements);
 

approve interested party transactions, where so required under the Israeli Companies Law; and
 
50


examine our existing internal control measures and the functioning of our internal auditor.
 
The Audit Committee is also charged with:
 

prescribing with respect to transactions with controlling shareholders or another person in which a controlling shareholder has a personal interest (even if they are determined by the Audit Committee not to be extraordinary transactions), as well as with respect to the engagement terms of controlling shareholders and their relatives, the obligation to conduct either (i) a competitive process under the supervision of either the Audit Committee or who else the Audit Committee may determine in respect thereof pursuant to the criteria set by it; or (ii) other processes as determined by the Audit Committee, prior to the relevant transaction, and all in accordance with the type of transaction in question, and the Audit Committee may set the relevant criteria therefore once a year in advance;
 

determining the manner of approval of transactions with controlling shareholders or another person in which a controlling shareholder has a personal interest and to determine kinds of such transactions which require the approval of the Audit Committee, all with respect to such transactions which pursuant to the determination of the Audit Committee are not extraordinary transactions but also not negligible – the Audit Committee may so determine with respect to types of transactions according to criteria it may set one a year in advance; and
 

determining whether a director or candidate for director fulfills the requirements for being classified as an independent director within the meaning of the Israeli Companies Law.
 
Neither the Israeli Companies Law nor our Articles of Association prescribe a certain frequency at which meetings of the Audit Committee are to take place. Accordingly, the Audit Committee meets from time to time when deemed necessary. Pursuant to the Israeli Companies Law, our internal auditor may request the chairperson of the Audit Committee to convene a meeting and the chairperson shall then convene such meeting if it deems it fit. In addition, should the Audit Committee find that there is a material flaw in our business management, it shall hold at least one meeting with respect to such material flaw in the presence of the internal or external auditor, as the case may be, without any office holders that are not members of the committee present; provided that an office holder may be present for the purpose of presenting an opinion with respect to a matter which is in his/her field of responsibility. The duration of the meetings varies in accordance with the topics discussed.
 
Compensation Committee
 
Pursuant to the Israeli Companies Law, an Israeli public company is obligated to appoint a Compensation Committee, which shall be comprised of at least three (3) members, including all of the external directors, and a majority of its members must be external directors. The remaining members of the Compensation Committee shall be such whose engagement terms correspond to the rules of compensation set forth under applicable regulations under the Israeli Companies Law with respect to external directors.
 
Persons who may not be members of the Audit Committee (as described above) may also not be members of the Compensation Committee. The Chairman of the Compensation Committee shall be an external director not serving for more than nine (9) years. The Audit Committee and the Compensation Committee may have identical members and an Audit Committee fulfilling the above requirements may at the same time also serve as the Compensation Committee.
 
The Compensation Committee currently consists of Mr. Yehoshua (Shuky) Abramovich, Ms. Dvorah Kimhi and Prof. Amir Lerman. Our Board of Directors has determined that all members of the Compensation Committee satisfy the “independence” requirements under Nasdaq’s corporate governance standards and SEC’s standards. The members of the Compensation Committee are appointed by our Board of Directors.
 
The role and authority of the Compensation Committee shall include:
 

the issuance of a recommendation to the Board of Directors regarding the Compensation Policy;
 

issuance of a recommendation to the Board of Directors once every three (3) years regarding the extension of the Compensation Policy;
 

recommendation to the Board of Directors from time to time regarding any amendments to the Compensation Policy, as well as examination regarding its implementation;
 
51


approval of transactions with office holders (including controlling shareholders) regarding the terms of their engagement with the company as required under the Israeli Companies Law; and
 

exemption of certain transactions from the shareholder approval requirement which may otherwise apply pursuant to the Israeli Companies Law.
 
Neither the Israeli Companies Law nor our Articles of Association prescribe a certain frequency at which meetings of the Compensation Committee are to take place. Accordingly, the Compensation Committee meets from time to time when deemed necessary. The duration of the meetings varies in accordance with the topics discussed.
 
Investment Committee
 
Although not mandatory under the provisions of the Israeli Companies Law, the Board of Directors has voluntarily appointed an investment committee as of February 21, 2019 (the “Investment Committee”). The task of the Investment Committee is to determine the investment policy of the company’s cash proceeds that are not required for its ongoing operations as will be from time to time. The members of the Investment Committee as of the date of this Annual Report are Mr. Yehoshua (Shuky) Abramovich (chairman), Mr. Nouberger and Mr. Rotenberg.
 
M&A Committee
 
Although not mandatory under the provisions of the Israeli Companies Law, the Board of Directors voluntarily appointed a mergers and acquisitions committee as of June 16, 2019 (the “M&A Committee”). The task of the M&A Committee is to facilitate the execution, performance and delivery of prospective M&A transactions. The members of the M&A Committee as of the date of this Annual Report are Mr. Yariv Alroy (chairman), Mr. Yehoshua (Shuky) Abramovich, Mr. Nouberger and Mr. Rotenberg.
 
Cyber Committee
 
Although not mandatory under the provisions of the Israeli Companies Law, the Board of Directors voluntarily appointed a cyber committee as of February 10, 2020 (the “Cyber Committee”). The task of the Cyber Committee is to recommend to the Board as to actions and/or measures to be taken in connection with the company’s information technology, including, inter alia, for the purpose of developing, maintaining and promoting the security of the company’s systems, networks and data, as well as supervising and monitoring the implementations of all such actions and/ or measures. The members of the Cyber Committee as of the date of this Annual Report are Mr. Yariv Alroy (chairman) and Mr. Yehoshua (Shuky) Abramovich.
 
Executive Committee
 
Although not mandatory under the provisions of the Israeli Companies Law, the Board voluntarily appointed an advisory executive committee as of May 17, 2020 (“Executive Committee”). The task of the Executive Committee is to assist the CEO and the company in operating its ongoing business. The members of the Executive Committee as of the date of this Annual Report are Mr. Yariv Alroy, Mr. Yehoshua (Shuky) Abramovich, Mr. Nouberger and Mr. Rotenberg.
 
Internal Auditor
 
Pursuant to the Israeli Companies Law, the Board of a public company shall appoint an internal auditor. Such appointment is made upon recommendation of the Audit Committee. Neither an interested party nor an officer of the company, any relatives of the foregoing or the external auditor or anyone on its behalf may serve in such position.
 
The role of the internal auditor is to examine, among other things, whether our activities comply with the law and orderly business procedure. Pursuant to the Israeli Internal Audit Law, 5752‑1992, together with the Israeli Companies Law, the internal auditor is authorized to demand and receive any kind of document and/or information that is in our or our employees’ possession, which he deems necessary for the performance of his role, and he is to have access to all of our databases or data processing programs. Pursuant to the Israeli Companies Law, the Chairman of the Board or the Chairman of the Audit Committee may order the internal auditor to conduct an internal audit on matters where an urgent need for examination arose. In addition, the internal auditor shall receive notices of the meetings of the Audit Committee and may participate in such meetings.
 
52

The internal auditor has no decision-making powers. Pursuant to the Israeli Companies Law and our Articles of Association, the internal auditor has to submit a work program to the Audit Committee for approval. Mr. Michael Gilinsky was appointed as our internal auditor in May 2021.
 
Board Diversity Matrix
 
Board Diversity Matrix (As of April 15, 2024)
Country of Principal Executive Offices:
Israel
Foreign Private Issuer
Yes
Disclosure Prohibited under Home Country Law
No
Total Number of Directors
6
 
Female
Male
Non-Binary
Did Not Disclose Gender
Part I: Gender Identity
 
Directors
1
3
0
2
Part II: Demographic Background
 
Underrepresented Individual in Home Country Jurisdiction
0
LGBTQ+
0
Did not disclose demographic background
0
Directors who are Jewish people
6
Directors with disabilities
0
 
D.           EMPLOYEES
 
As of December 31, 2023, we had approximately 583 full-time employees. The total number of full-time employees as of the end of financial years 2022 and 2021 was approximately 402 and 419. A breakdown of such employees by country and division as of December 31, 2023, is below
 
   
Israel
   
Germany
   
U.S.A.
   
Total
 
Operation
   
335
     
86
     
0
     
421
 
Research & Development
   
15
     
22
     
0
     
37
 
Sales & Marketing
   
51
     
7
     
2
     
60
 
General & Administrative
   
46
     
17
     
2
     
65
 

In addition to the applicable laws and regulations, including jurisdiction-specific labor legislation, our employees in Germany are members of a “work council” that regulates different employment aspects, including operational, compensation, and benefit structure, while some of our employees in Israel are parties to collective bargaining agreements and are represented by a union.
 
In addition to the above, we engage, from time to time, with independent contractors and external professional consultants for certain services to perform our operations and business. Such contractors and consultants are subject to confidentiality and non-compete undertakings towards us.
 
53

E.           SHARE OWNERSHIP
 
The following table sets forth the share ownership of our directors and officers as of April 15, 2024 (except as indicated):
 
Name
 
Total
Shares
Beneficially
Total Shares Owned
   
Number of Options
   
Percentage of Ordinary Shares
 
Yariv Alroy
   
801,456
     
250,000
     
6.3
%
Ido Nouberger
   
1,406,236
**
           
8.6
%
Nir Rotenberg
   
802,426
***
           
4.0
%
Prof. Amir Lerman
   
5,694
     
18,000
     
*
 
Yehoshua (Shuky) Abramovich
   
16,961
     
18,000
     
*
 
Dvorah Kimhi
   
     
36,000
     
*
 
Erez Nachtomy
   
     
188,000
     
*
 
Amir Hai
   
     
110,000
     
*
 
Jason Bottiglieri
   
     
100,000
     
*
 
Bernd Altpeter
   
     
100,000
     
*
 

*
Represents less than one percent.
**
Represents ownership of our ordinary shares by Value Base Ltd., a private investment group located in Israel (“Value Base”), together with its subsidiaries and its controlling shareholders Ido Nouberger and Victor Shamrich. Mr. Nouberger has served as the CEO of Value Base since its inception in 2013, and he also holds the position of chairman of the board or board member of Value Base’s various subsidiaries. Mr. Nouberger disclaims beneficial ownership of the securities beneficially owned by Value Base except to the extent of his pecuniary interest therein.
***
Represents ownership of our ordinary shares by Danbar Finance Ltd., a private investment group located in Israel (“Danbar”), of which Mr. Rotenberg is the Chairman of the Board and has served there as a director and partner since 2000. Mr. Rotenberg disclaims beneficial ownership of the securities beneficially owned by Danbar except to the extent of his pecuniary interest therein.

The options in the above table are exercisable according to the “Net Exercise” method to our ordinary shares. The aggregate number of ordinary shares underlying such options is up to 820,000. The exercise price of the options range from CHF 5.61 to CHF 19.33 and the weighted average exercise price of the options are CHF 11.35. The expiration dates of the options range from February 21, 2025 to June 18, 2029.
 
Our officers and directors have the same voting rights with respect to their shares as our other shareholders.
 
F.          DISCLOSURE OF A REGISTRANT’S ACTION TO ERRONEOUSLY AWARDED COMPENSATION
 
Not applicable.
 
54

ITEM 7.
MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
 
A.           MAJOR SHAREHOLDERS
 
The following table sets forth certain information regarding the beneficial ownership of our outstanding ordinary shares as of April 15, 2024 by each person or entity who we know beneficially owns 3% or more of our outstanding ordinary shares (including ordinary shares represented by ADSs), in line with Article 120 of the Swiss Financial Market Infrastructure Act (the “FMIA”), or otherwise known to us to beneficially own more than 5% of the outstanding ordinary shares. The FMIA requires us and other persons who directly, indirectly (as beneficial owners) or in concert with other parties, acquire or dispose of our ordinary shares or purchase or sale rights or obligations relating to our ordinary shares, and thereby exceed or fall below a threshold of 3%, 5%, 10%, 15%, 20%, 25%, 33⅓%, 50% or 66⅔% of our voting rights (whether exercisable or not), to notify us and the Disclosure Office of the SIX of such acquisition or disposal using appropriate forms available on the website of the SIX Disclosure Office. The table below has been prepared based on the disclosure notices published on the platform of the SIX Disclosure Office pursuant to the FMIA. Market transactions of shareholders which have not triggered a disclosure notification are not reflected in the numbers.

Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include shares issuable upon the exercise of options that are immediately exercisable or exercisable within 60 days. Accordingly, for purposes of the table below, we deem ordinary shares issuable pursuant to share options that are currently exercisable or exercisable within 60 days of April 15, 2024 to be outstanding and to be beneficially owned by the person holding the share options for the purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. Percentage ownership calculations are based on 16,392,754 ordinary shares issued and outstanding as of April 15, 2024. Unlike the disclosure notices published on the platform of the SIX Disclosure Office pursuant to the FMIA, the table below does not separately indicate other purchase or sale positions (in terms of derivatives such as call or put options).
 
 
       
Share Options
   
Percent of
 
Identity of Person or Group
 
Amount Owned
   
Current
   
Class
 
Mrs. Mengke Cai (Zhuhai, China) and Kun Shen (Hong Kong, China) (1)
   
5,969,413
           
36.4
%
More Provident Funds (Ramat Gan, Israel)
   
1,812,525
           
11.1
%
Value Base Group (Tel Aviv, Israel) (2)
   
1,406,236
(3) 
         
8.6
%
Yariv Alroy (Herzliya, Israel)
   
801,456
     
250,000
     
6.3
%
Danbar Finance Ltd. (Tel Aviv, Israel) (4)
   
791,405
(5) 
           
4.8
%
Sphera Funds Management (Tel Aviv, Israel)
   
632,456
(6) 
           
3.9
%

(1)
Shareholder group consisting of Mrs. Mengke Cai and Mrs. Kun Shen. Pursuant to a decision of the Swiss Takeover Board, Mengke Cai, Kun Shen and their related entities have been prohibited from acquiring further shares or acquisition or disposal rights relating to SHL, including suspension of the voting rights attached to their current shares.
 
 
(2)
Shareholder group consisting of the following beneficial owners (as defined by the FMIA): Value Base (23 Yehuda Halevy St., Tel Aviv, Israel), Harmony Base LP (23 Yehuda Halevy St., Tel Aviv, Israel), Ido Nouberger (Tel Aviv, Israel), one of our directors, and Victor Shamrich (Tel Aviv, Israel). Messrs. Nouberger and Shamrich serve as the controlling shareholders of Value Base. Mr. Nouberger has served as the CEO of Value Base since its inception in 2013, and he also holds the position of chairman of the board or board member of Value Base’s various subsidiaries. Each of Messrs. Nouberger and Shamrich disclaims beneficial ownership of the securities beneficially owned by Value Base except to the extent of his respective pecuniary interest therein


(3)
Based on the Schedule 13D/A filed by Value Base with the SEC on February 12, 2024.


(4)
Shareholder group consisting of the following beneficial owners (as defined by the FMIA): Danbar (94 Yigal Alon Street, Tel Aviv, Israel), Matan Wulkan (94 Yigal Alon Street, Tel Aviv, Israel) and Nir Rotenberg (94 Yigal Alon Street, Tel Aviv, Israel), one of our directors. Mr. Rotenberg is the Chairman of the Board of Danbar and has served there as a director and partner since 2000. Mr. Rotenberg disclaims beneficial ownership of the securities beneficially owned by Danbar except to the extent of his pecuniary interest therein


(5)
Based on the Schedule 13D/A filed by Danbar with the SEC on February 14, 2024.


(6)
Based on the Form 13F-HR filed by Sphera Funds Management with the SEC on February 14, 2024.

There have been no significant changes in the percentage ownership held by any major shareholder during the past three years other than those resulting from our capital raises described in Section 5.B. “Liquidity and Capital Resources – Financial Arrangement.”

55

Except for Mrs. Mengke Cai and Kun Shen, as disclosed in footnote (1) to the table above, none of our shareholders have different voting rights from other shareholders.
 
As of April 15, 2024, ADRs evidencing 4,179,748 ADSs were outstanding. The 4,179,748 ordinary shares represented by those ADRs (approximately 25.5% of SHL’s outstanding ordinary shares) were registered in the name of UBS Switzerland AG, the custodian for the Depositary. We believe that most or all of these ADRs were held of record by persons outside the United States. As of April 15, 2024, based on the list of the registered holders of our ordinary shares, there were no registered holders of our ordinary shares showing as residing in the United States. Since certain of SHL’s ADRs and ordinary shares are held by brokers or other nominees, the number of ADRs and ordinary shares held of record may not be representative of the number of beneficial holders resident in the United States.
 
Under an agreement between us and SIX SIS AG (“SIS”), SIS acts as a nominee on behalf of any person registered in the share register maintained by Computershare Schweiz AG, and SIS is registered as the shareholder of record of the issued and outstanding ordinary shares. As a result, the number of record holders is not representative of the number of beneficial holders of our ordinary shares.
 
We are not aware of any arrangement that may, at a subsequent date, result in a change of control of SHL.
 
B.           RELATED PARTY TRANSACTIONS
 
In June 2022, our shareholders, following the approval of the Compensation Committee and the Board, approved Mr. Erez Nachtomy’s amended terms of office as Acting Chief Executive Officer. Pursuant to the amended employment terms, Mr. Nachtomy is entitled, inter alia, to a service fee in the sum of NIS 93,600 commencing on June 29, 2022, and upon meeting the terms set forth in Section 9 to the company’s Compensation Policy (Special Cash Bonus) shall be entitled to a bonus equivalent to three monthly fees, provided, however, that said bonus shall be received only once in one given year and further provided that the accumulated amount of the annual cash bonus for the CEO and the special cash bonus will not exceed twelve (12) times the CEO monthly fee in one given year.
 
In June 2020, our shareholders, following the approval of the Compensation Committee and the Board, approved Mr. Erez Nachtomy’s terms of office as Acting Chief Executive Officer. Pursuant to such terms, Mr. Nachtomy was granted options to purchase 50,000 ordinary shares, in accordance with our Share Option Plan and Compensation Policy, which vested over a period of three years (25% vested after a year of employment, and the remainder vested in equal quarterly installments thereafter). Either Mr. Nachtomy or the Company may terminate the engagement subject to a prior notice of three months. In December 2020, our shareholders, following the approval of the Compensation Committee and the Board, approved the grant of options to Mr. Erez Nachtomy to purchase 120,000 ordinary shares, in accordance with our Share Option Plan and Compensation Policy, which vested over a period of three years (25% vested after one year, and the remainder vested in equal quarterly installments thereafter).
 
On March 1, 2021, a special general meeting of our shareholders approved the grant of 250,000 options to Mr. Yariv Alroy, and an amendment to the company’s Compensation Policy with respect to the terms of office of the Active Co-Chairman of the Board – who shall be entitled to a monthly compensation of NIS 65,000 plus VAT (employer’s cost) instead of the directors’ annual and participation compensation, effective as of January 1, 2021, as approved by the Compensation Committee and the Board. Pursuant to the amendment, the Chairman of the Board shall receive this compensation in recognition of his increased duties in lieu of the remuneration to which directors are entitled as long as he is an active chairman and provided that such compensation shall not exceed the sum of NIS 780,000 per annum (employer’s cost). Said compensation shall be paid to the chairman either as an employee of the company or against an invoice, at the chairman’s sole discretion. For additional details about the approved terms of the compensation, please see Item 6.B., “Compensation – Compensation Policy for Executive Officers and Directors – SHL Compensation Policy.”
 
On December 9, 2021, our shareholders, following the approval of the Compensation Committee and the Board, approved (i) the grant of indemnification letters to the company’s current and future directors and officers, including the CEO and officers and directors who may be deemed controlling shareholders; (ii) the grant of options to purchase 18,000 ordinary shares of the company at an exercise price of CHF 17.02 per share and with vesting over a three-year period, to each of Mr. Yehoshua (Shuky) Abramovich, Ms. Dvorah Kimhi, Prof. Amir Lerman, Mr. Erez Alroy and Mr. David Salton, who then served as members of the Board; and (iii) an amendment to the company’s directors’ compensation, as further described above under Item 6(B).
 
On August 11, 2022, our shareholders, following the approval of the Compensation Committee and the Board, approved (i) a consulting agreement with Mr. Ehud Barak, the Company’s then-Active Co-Chairman of the Board of Directors, pursuant to which Mr. Barak could be actively involved in a strategic agreement on behalf of the company outside of Israel, and would be entitled to a monthly management fee of $13,800. In the event of Mr. Barak’s involvement, he would be entitled, subject to the closing of said transaction, to a transaction bonus in an amount equal to twice the monthly management fee (i.e., $27,600), which special bonus would not exceed in any calendar year a sum equal to eight times the monthly management fee; (ii) exculpation agreements with the company’s current and future directors and officers, including the CEO and other officers and directors who may be deemed controlling shareholders; and (iii) amendments to the CEO terms of office, as described above.
 
56

As noted above, the office space leased by our Mediton business in Israel is owned by an affiliate of a shareholder in Mediton. The monthly rent amount under the lease is approximately $43,000. The term of the lease runs until 2035.
 
C.
INTERESTS OF EXPERTS AND COUNSEL

Not applicable.
 
ITEM 8.
FINANCIAL INFORMATION

A.
CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION

Consolidated Financial Statements
 
See Item 18, “Financial Statements” for a list of the financial statements filed as part of this Annual Report.
 
Legal Proceedings
 
We are, from time to time, party to various claims and disputes associated with our ongoing business operations. We are not currently involved in pending or contemplated claims or disputes that we expect, either individually or in the aggregate, to have significant effects on our financial position or profitability. We may become involved in material legal proceedings in the future. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
 
Dividend Policy
 
We declared a dividend of $1.00 per ordinary share on March 18, 2019, which was paid on April 16, 2019. The aggregate amount paid was approximately $10.5 million. We did not pay a dividend in 2020, 2021, 2022 or 2023.
 
We do not have a dividend policy. All decisions related to dividend distribution (including specific dividend total aggregate amount and dividend amount per share) are made by the Board in accordance with applicable law and are based on a number of findings, including, among others, our fiscal condition, results of operations, capital instrument needs and plans and prospects. Please see Item 10.B., “Additional Information—Memorandum and Articles of Association—Liquidation and Dividend Rights.”
 
B.
SIGNIFICANT CHANGES
 
No significant change has occurred since December 31, 2023, except as otherwise disclosed in this Annual Report.
 
ITEM 9.
THE OFFER AND LISTING
 
A.
OFFER AND LISTING DETAILS
 
Our ordinary shares have been traded on the SIX under the symbol “SHLTN” since November 15, 2000. Our ADSs have been listed for trading on the Nasdaq Capital Market under the symbol “SHLT” since April 3, 2023.
 
B.
PLAN OF DISTRIBUTION
 
Not applicable.
 
C.
MARKETS
 
See Item 9.A. above.
 
57

D.
SELLING SHAREHOLDERS
 
Not applicable.
 
E.
DILUTION
 
Not applicable.
 
F.
EXPENSES OF THE ISSUE
 
Not applicable.
 
ITEM 10.
ADDITIONAL INFORMATION
 
A.
SHARE CAPITAL
 
Not applicable.
 
B.
MEMORANDUM AND ARTICLES OF ASSOCIATION
 
The information set forth under Item 10.B “Additional Information – Memorandum and Articles of Association” contained in Amendment No. 2 to our Registration Statement on Form 20‑F (File No. 001‑41641), as amended, filed with the SEC on March 8, 2023, is incorporated herein by this reference.
 
C.
MATERIAL CONTRACTS
 
Not applicable.
 
D.
EXCHANGE CONTROLS

Non-residents of Israel who purchase our ordinary shares outside of Israel with U.S. dollars or other foreign currency will be able to convert dividends (if any) thereon, and any amounts payable upon the dissolution, liquidation or winding up of our affairs, into freely repatriable dollars, at a rate of exchange prevailing at the time of conversion, provided that Israeli income tax has been withheld by us with respect to such amounts. In addition, the statutory framework for the potential imposition of currency exchange controls has not been eliminated, and these controls may be restored at any time by administrative action.
 
58

E.
TAXATION

The following is a summary of the material Israeli and United States federal tax consequences, Israeli foreign exchange regulations and certain Israeli government programs affecting us. To the extent that the discussion is based on new tax or other legislation that has not been subject to judicial or administrative interpretation, there can be no assurance that the views expressed in the discussion will be accepted by the tax or other authorities in question. The discussion is not intended, and should not be construed, as legal or professional tax advice, is not exhaustive of all possible tax considerations and should not be relied upon for tax planning purposes. POTENTIAL INVESTORS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS AS TO THE ISRAELI TAX, UNITED STATES FEDERAL INCOME TAX AND OTHER TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ADSS OR ORDINARY SHARES, INCLUDING, IN PARTICULAR, THE EFFECT OF ANY FOREIGN, STATE OR LOCAL TAXES.
 
Israeli Tax Considerations and Government Programs
 
The following is a brief summary of the material Israeli income tax laws applicable to us. This section also contains a discussion of material Israeli income tax consequences concerning the ownership and disposition of our ADSs and ordinary shares. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of such investors include residents of Israel or traders in securities who are subject to special tax regimes not covered in this discussion.
 
General corporate tax structure in Israel
 
Israeli resident companies are generally subject to corporate tax on both ordinary income and capital gains, currently at the rate of 23% of a company’s taxable income.

Taxation of our shareholders
 
Israeli law generally imposes a capital gains tax on the sale of any capital asset by Israeli residents, as defined for Israeli tax purposes. Israeli law also generally imposes a capital gains tax on the sale of capital assets located in Israel, including shares in Israeli companies, by both Israeli residents and non-residents of Israel, unless a specific exemption is available or unless a tax treaty between Israel and the shareholder’s country of residence provides otherwise. The Israeli Income Tax Ordinance (New Version), 5721‑1961 (the “Ordinance”) distinguishes between real gain and inflationary surplus. The inflationary surplus is a portion of the total capital gain equivalent to the increase of the relevant asset’s purchase price attributable to an increase in the Israeli consumer price index, or, under certain conditions, a foreign currency exchange rate, between the date of purchase and the date of sale. Inflationary surplus is currently not subject to tax in Israel. The real gain is the excess of the total capital gain over the inflationary surplus.
 
Capital Gains Taxes Applicable to Non-Israeli Resident Shareholders. A non-Israeli resident who derives capital gains from the sale of shares in an Israeli resident company that were purchased after the company was listed for trading on a stock exchange outside of Israel will be exempt from Israeli tax if, among other conditions, the shares were not held through a permanent establishment that the non-resident maintains in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemption if Israeli residents: (i) alone, or together with such Israeli residents’ related party or another person who collaborates with such Israeli resident on a permanent basis, hold, directly or indirectly, more than 25% of the means of control in such non-Israeli corporation, or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly. Additionally, such exemption is not applicable to a person whose gains from selling or otherwise disposing of the shares are deemed to be business income.
 
59

Additionally, a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example, under the United States-Israel Tax Treaty, the sale, exchange or other disposition of shares by a shareholder who is a United States resident (for purposes of the treaty) holding the shares as a capital asset and who is entitled to claim the benefits afforded to such a resident by the United States-Israel Tax Treaty (a “U.S. Resident”) is generally exempt from Israeli capital gains tax unless, among other things, (i) the capital gain arising from such sale, exchange or disposition is attributed to real estate located in Israel; (ii) the capital gain arising from such sale, exchange or other disposition is attributed to royalties; (iii) the capital gain arising from such sale, exchange or disposition is attributed to a permanent establishment in Israel, under certain conditions; (iv) such U.S. Resident holds, directly or indirectly, shares representing 10% or more of the voting capital during any part of the 12‑month period preceding the disposition, subject to certain conditions; or (v) such U.S. Resident is an individual and was present in Israel for 183 days or more in the aggregate during the relevant taxable year. In any such case, the sale, exchange or disposition by the U.S. Resident would be subject to Israeli tax, unless exempt under Israeli domestic law as described above. However, under the United States-Israel Tax Treaty, such U.S. Resident should be permitted to claim a credit for such taxes against U.S. federal income tax imposed on any gain from such sale, exchange or disposition, under the circumstances and subject to the limitations specified in the United States-Israel Tax Treaty or in the United States federal income tax laws applicable to foreign credits.
 
In some instances where our shareholders may be liable for Israeli tax on the sale of their ordinary shares, the payment of the consideration may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale (i.e., provide resident certificate and other documentation).
 
A detailed return, including a computation of the tax due, must be filed and an advance payment must be paid by January 31 and July 31 of each tax year for sales of securities traded on a stock exchange made during the last six months of the preceding year or during the first six months of the current year, respectively. However, if all tax due was withheld at source according to applicable provisions of the Ordinance and the regulations promulgated thereunder, the return does not need to be filed provided that (i) such income was not generated from business conducted in Israel by the taxpayer, (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed and an advance payment does not need to be made, and (iii) the taxpayer is not obligated to pay surtax (as further explained below). Capital gains are also reportable on an annual income tax return.
 
Taxation of Non-Israeli Shareholders on Receipt of Dividends. Non-Israeli residents (whether individuals or corporations) generally will be subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, or 30% if the recipient of the dividends is a “substantial shareholder” at the time of distribution or at any time during the preceding 12‑month period, which tax will be withheld at source, unless relief is provided in a treaty between Israel and the shareholder’s country of residence (subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax rate). Such dividends are generally subject to Israeli withholding tax at a rate of 25% if the shares are registered with a nominee company (whether or not the recipient is a substantial shareholder).
 
A different rate may be provided in a treaty between Israel and the shareholder’s country of residence. In this regard, under the United States-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ADSs or ordinary shares who is a United States resident (for purposes of the United States-Israel Tax Treaty) is 25%. However, generally, the maximum rate of withholding tax on dividends that are paid to a United States corporation holding 10% or more of the outstanding voting capital throughout the tax year in which the dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more than 25% of the gross income for such preceding year consists of certain types of dividends and interest. We cannot assure you that we will designate the profits that we may distribute in a way that will reduce shareholders’ tax liability.
 
A foreign resident who had income from a dividend that was accrued from Israeli source, from which the full tax was deducted, will generally be exempt from filing a tax return in Israel, provided that (1) such income was not generated from business conducted in Israel by the foreign resident, (ii) the foreign resident has no other taxable sources of income in Israel with respect to which a tax return is required to be filed and (iii) the foreign resident is not liable to surtax (see below) in accordance with Section 121B of the Ordinance.
 
Capital Gains Taxes Applicable to Israeli Resident Shareholders. An Israeli resident corporation that derives capital gains from the sale of shares in an Israeli resident company will generally be subject to tax on the real capital gains generated on such sale at the corporate tax rate of 23% (in 2024). An Israeli resident individual will generally be subject to capital gains tax at the rate of 25%. However, if the individual shareholder claims deduction of interest expense and linkage differences in connection with the purchase and holding of such shares or is a “substantial shareholder” at the time of the sale or at any time during the preceding 12‑month period, such gain will be taxed at the rate of 30%. A “substantial shareholder” is generally a person who alone, or together with such person’s related party or another person who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the “means of control” of the corporation. “Means of control” generally include the right to vote, receive profits, nominate a director or an executive officer, receive assets upon liquidation, or order someone who holds any of the aforesaid rights how to exercise these rights, regardless of the source of such right. Individual holders dealing in securities in Israel for whom the income from the sale of securities is considered “business income” as defined in Section 2(1) of the Ordinance are taxed at the marginal tax rates applicable to business income (up to 47% in 2023) plus an additional surtax of 3% as described below. Certain Israeli institutions that are exempt from tax under Section 9(2) or Section 129C(a)(1) of the Ordinance (such as exempt trust funds and pension funds) may be exempt from capital gains tax from the sale of the shares.
 
60

Taxation of Israeli Shareholders on Receipt of Dividends. An Israeli resident individual is generally subject to Israeli income tax on the receipt of dividends that may be paid on our ordinary shares at the rate of 25%. With respect to a person who is a “substantial shareholder” at the time of receiving the dividend or at any time during the preceding 12‑month period, the applicable tax rate is 30%. Individuals may also be required to pay surtax with respect to dividends received, as further explained below. Such dividends are generally subject to Israeli withholding tax at a rate of 25% if the shares are registered with a nominee company (whether the recipient is a substantial shareholder or not). If the recipient of the dividend is an Israeli resident corporation, such dividend income will be exempt from tax provided the income from which such dividend is distributed was derived or accrued within Israel and was received directly or indirectly from another corporation that is subject to Israeli corporate tax. An exempt trust fund, pension fund or other entity that is exempt from tax under Section 9(2) or Section 129(C)(a)(1) of the Ordinance is exempt from tax on dividends.
 
Surtax. Subject to the provisions of an applicable tax treaty, individuals who are subject to tax in Israel (whether or not Israeli residents) are subject to a surtax at a rate of 3% of annual taxable income (including, but not limited to, dividends, interest and capital gain) in excess of NIS 721,560 (for the 2024 tax year, which amount is linked to the annual change in the Israeli consumer price index).
 
Estate and Gift Tax
 
Israeli law presently does not impose estate or gift taxes.
 
Material United States Federal Income Tax Considerations
 
The following summary describes the material U.S. federal income tax consequences to “U.S. Holders” (as defined below) relating to the acquisition, ownership and disposition of our ADSs or ordinary shares. This discussion applies to U.S. Holders who acquire and hold the ordinary shares or ADSs as “capital assets” (generally, assets held for investment purposes).
 
This summary is based on the Internal Revenue Code of 1986, as amended (the “Code”), U.S. Treasury Regulations promulgated thereunder, administrative pronouncements and rulings of the United States Internal Revenue Service (the “IRS”) and judicial decisions, all as of May 5, 2023, and all of which are subject to change (possibly with retroactive effect) or different interpretations. Except as specifically set forth below, this summary does not discuss applicable income tax reporting requirements. This summary does not describe any state, local or foreign tax law considerations, or any aspect of U.S. federal tax law other than income taxation (e.g., estate or gift tax). U.S. Holders should consult their own tax advisers regarding such matters.
 
As used herein, the term “U.S. Holder” means a beneficial owner of ADSs or ordinary shares that is for U.S. federal income tax purposes:
 

an individual who is either a U.S. citizen or a resident of the United States for U.S. federal income tax purposes;
 

a corporation or other entity taxable as a corporation for U.S. federal income tax purposes created or organized in or under the laws of the United States or any political subdivision thereof;
 

an estate the income of which is subject to U.S. federal income tax regardless of the source of its income; and
 

a trust, if (a) a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (b) the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person.
 
61

This summary does not consider all aspects of U.S. federal income taxation that may be relevant to particular U.S. Holders by reason of their particular circumstances. In addition, this summary does not address the considerations that may be applicable to U.S. Holders that may be subject to special tax rules including, without limitation, the following:
 

U.S. expatriates;
 

banks, thrifts and other financial institutions;
 

regulated investment companies and real estate investment trusts;
 

pension funds and retirement plans;
 

insurance companies;
 

broker-dealers or traders in securities, commodities or currencies;
 

tax-exempt entities or organizations;
 

grantor trusts;
 

partnerships (including entities classified as partnerships for U.S. federal income tax purposes) or other pass-through entities, and holders that will hold our ADSs or ordinary shares in partnerships or other pass-through entities;
 

holders whose functional currency is not the dollar;
 

persons that generally mark their securities to market for U.S. federal income tax purposes;
 

persons liable for alternative minimum tax;
 

holders who hold our ADSs or ordinary shares as part of a “straddle,” “hedge,” “conversion transaction,” “synthetic security” or integrated investment;
 

holders selling our ADSs or ordinary shares short;
 

holders deemed to have sold our ADSs or ordinary shares in a “constructive sale;”
 

holders required to accelerate the recognition of any item of gross income with respect to our ADSs or ordinary shares as a result of such income being recognized on an applicable financial statement;
 

corporations that accumulate earnings to avoid U.S. federal income tax;
 

holders that are resident or ordinarily resident in or have a permanent establishment in a jurisdiction outside the United States or hold our shares in connection with a trade or business conducted outside the United States; and
 

holders, directly, indirectly or through attribution, of 10% or more (by vote or value) of our outstanding stock.
 
If a partnership (or any other entity treated as a partnership for U.S. federal income tax purposes) holds our ADSs or ordinary shares, the U.S. federal income tax consequences relating to an investment in our ADSs or ordinary shares will depend in part upon the status of the partner and the activities of the partnership. Such a partner or partnership should consult its tax advisor regarding the U.S. federal income tax consequences of acquiring, owning and disposing of our ADSs or ordinary shares in its particular circumstances.
 
No ruling from the IRS has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the ownership or disposition of our ADSs or ordinary shares. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to different interpretations, the IRS and U.S. courts could disagree with one or more of the positions taken in this summary.
 
62

In general, for U.S. federal income tax purposes, U.S. Holders of our ADSs will be treated as owning the underlying ordinary shares represented by those ADSs. Accordingly, exchanges of ordinary shares for ADSs, and ADSs for ordinary shares will not be subject to U.S. federal income tax.
 
This summary is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our ADSs or ordinary shares and should not be considered as income tax advice or relied upon for tax planning purposes. Each prospective U.S. Holder should consult with its own tax advisor as to the particular tax consequences to it of the ownership and disposition of our ADSs, including the effects of applicable tax treaties, state, local, foreign or other tax laws and possible changes in the tax laws.
 
Distributions With Respect to Our ADSs
 
Subject to the discussion below under “Passive Foreign Investment Company Status,” a U.S. Holder that receives a distribution with respect to ADSs or ordinary shares generally will be required to include the gross amount, including the amount of any Israeli taxes withheld on such distribution, in gross income as a dividend when actually or constructively received to the extent of the U.S. Holder’s pro rata share of our current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder’s pro rata share of our current and accumulated earnings and profits, it will be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder’s ADSs or ordinary shares. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder’s ADSs or ordinary shares, the remainder will be taxed as capital gain recognized on a sale or exchange of the ADSs or ordinary shares (as discussed below under “Sale, Exchange or Other Taxable Disposition of ADSs or ordinary shares”). However, because we do not account for our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should expect all distributions to be reported to them as dividends. Dividends on our ADSs or ordinary shares will not be eligible for the “dividends received” deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations. U.S. Holders are urged to consult their own tax advisors regarding the U.S. federal income tax consequences of their receipt of any distributions with respect to our ADSs or ordinary shares.
 
Dividends paid by a “qualified foreign corporation” to individuals and certain non-corporate U.S. Holders are treated as “qualified dividend income” and are eligible for taxation at a reduced capital gains rate rather than the marginal tax rates generally applicable to ordinary income provided that certain requirements are met. A non-United States corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (a) if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information provision, or (b) with respect to any dividend it pays on ADSs or ordinary shares that are readily tradable on an established securities market in the United States. We believe that we qualify as a resident of Israel for purposes of, and are eligible for the benefits of, the income tax treaty between the United States and Israel, which the IRS has determined is satisfactory for purposes of the qualified dividend rules. Further, our ADSs will generally be considered to be readily tradable on an established securities market in the United States if they are listed on Nasdaq Capital Market. Therefore, subject to the discussion below under “Passive Foreign Investment Company Status,” we expect that dividends paid on ADSs or ordinary shares will generally be “qualified dividend income” in the hands of individuals and certain other non-corporate U.S. Holders, provided that certain conditions are met, including conditions relating to holding period and the absence of certain risk reduction transactions.
 
Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends with regard to its particular circumstances.
 
The amount of a distribution paid to a U.S. Holder in a foreign currency will be the dollar value of the foreign currency calculated by reference to the spot exchange rate on the day the U.S. Holder receives the distribution, regardless of whether the foreign currency is converted into U.S. dollars at that time. Any foreign currency gain or loss a U.S. Holder realizes on a subsequent conversion of foreign currency into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in foreign currency are converted into U.S. dollars on the day they are received, a U.S. Holder generally should not be required to recognize foreign currency gain or loss in respect of the dividend.
 
Distributions on ADSs or ordinary shares that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes and generally will constitute passive category income. Subject to certain conditions and limitations, Israeli tax withheld on dividends may be credited against the U.S. Holder’s U.S. federal income tax liability, or deducted from taxable income, but only if the U.S. Holder elects to deduct all foreign income taxes in such year. However, Israeli income taxes that are withheld in excess of the rate applicable under the Israel-U.S. income tax treaty or that are refundable under Israeli law will not be eligible for credit against a U.S. Holder’s federal income tax liability (and will not be eligible for the deduction against U.S. federal taxable income). In addition, special rules may apply to the computation of foreign tax credits relating to qualified dividend income.
 
63

The rules governing the treatment of foreign taxes imposed on a U.S. Holder and foreign tax credits are complex, and U.S. Holders should consult their tax advisors about the impact of these rules in their particular situations.
 
Sale, Exchange or Other Taxable Disposition of ADSs or ordinary shares
 
Subject to the discussion below under “Passive Foreign Investment Company Status,” a U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of ADSs or ordinary shares in an amount equal to the difference, if any, between the amount realized (i.e., the amount of cash plus the fair market value of any property received) on the sale, exchange or other disposition (without reduction for any Israeli taxes withheld) and such U.S. Holder’s adjusted tax basis in the ADSs or ordinary shares. A U.S. Holder’s initial tax basis in shares generally will equal the cost of such shares. Such capital gain or loss generally will be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the date of sale, exchange or other disposition, the ADSs or ordinary shares were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized from the sale or other disposition of ADSs or ordinary shares will generally be gain or loss from sources within the United States for U.S. foreign tax credit purposes. Because gain on the sale or other disposition of our ADSs or ordinary shares generally will be treated as United States source income, and U.S. Holders may use foreign tax credits against only the portion of United States federal income tax liability that is attributed to foreign source income in the same category, a U.S. Holder’s ability to utilize a foreign tax credit with respect to the Israeli tax imposed on any such sale or other disposition, if any, may be significantly limited. In addition, if a U.S. Holder is eligible for the benefit of the income tax convention between the United States and the State of Israel (the “U.S. – Israel Income Tax Treaty”) and the U.S. Holder pays Israeli tax in excess of the amount applicable to such U.S. Holder under such convention or if the Israeli tax paid is refundable, the U.S. Holder will not be able to claim any foreign tax credit or deduction with respect to such Israeli tax. U.S. Holders should consult their tax advisors as to whether the Israeli tax on gains may be creditable or deductible in light of their particular circumstances, including the new “attribution requirement” under final Treasury Regulations issued on January 4, 2022, and their ability to apply the provisions of the U.S. – Israel Income Tax Treaty to treat any gain recognized from the sale or other disposition of ADSs or ordinary shares as foreign source income for foreign tax credit purposes.
 
If the consideration (or a distribution) received by a U.S. Holder is not paid in U.S. dollars, the amount realized generally will be the U.S. dollar value of the payment received. If the ADSs or ordinary shares are considered to be traded on an established securities market when the U.S. Holder sells or otherwise disposes of the ADSs or ordinary shares, the amount realized will be, in the case of cash basis and electing accrual basis taxpayers, determined by reference to the spot rate of exchange on the settlement date. An accrual basis U.S. Holder that is not eligible to or does not elect to determine the amount realized using the spot rate on the settlement date will recognize U.S. source foreign currency gain or loss to the extent of any difference between the U.S. dollar amount realized on the date of sale or disposition and the U.S. dollar value of the currency received at the spot rate on the settlement date. A U.S. Holder will have a tax basis in the currency received equal to the U.S. dollar value of the currency received at the spot rate on the settlement date. Any currency gain or loss realized on the settlement date or the subsequent sale, conversion, or other disposition of the non-U.S. currency received for a different U.S. dollar amount generally will be U.S.-source ordinary income or loss, and will not be eligible for the reduced tax rate applicable to long-term capital gains. If an accrual basis U.S. Holder makes the election described in the second sentence of this paragraph, it must be applied consistently from year to year and cannot be revoked without the consent of the IRS. A U.S. Holder should consult its own tax advisors regarding the treatment of any foreign currency gain or loss realized with respect to any currency received in a sale or other disposition of the Offered Shares.
 
Medicare Tax
 
Certain U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition of ADSs or ordinary shares. If you are a United States person that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding the applicability of this Medicare tax to your income and gains in respect of your investment in our ADSs or ordinary shares.
 
64

Passive Foreign Investment Company Status
 
In general, a corporation organized outside the United States will be treated as a passive foreign investment company (a “PFIC”) for any taxable year in which either (1) at least 75% of its gross income is “passive income” (the “income test”) or (2) on average at least 50% of the value of its assets, determined on a quarterly basis, are assets that produce passive income or are held for the production of passive income (the “asset test”). Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange of property that gives rise to passive income. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.
 
We do not believe we were a PFIC for our 2023 taxable year. While we also do not believe we will be a PFIC for the current taxable year, because PFIC status is determined on an annual basis and generally cannot be determined until the end of the taxable year, there can be no assurance that we will not be a PFIC for the current taxable year or in future taxable years. Because we may hold a substantial amount of cash and cash equivalents, and because the calculation of the value of our assets may be based in part on the value of ordinary shares and ADSs, which may fluctuate considerably, we may be a PFIC in the current or future taxable years under the PFIC asset test. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS will agree with our conclusion and that the IRS would not successfully challenge our position. Our status as a PFIC is a fact-intensive determination made on an annual basis, and our status in future years will depend on our income, assets, market capitalization and activities in those years. There can be no assurance that we will not be considered a PFIC for any taxable year.
 
If we are a PFIC in any taxable year during which a U.S. Holder owns ADSs or ordinary shares, the U.S. Holder could be liable for additional taxes and interest charges under the PFIC rules upon (1) a distribution paid during a taxable year that is greater than 125% of the average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder’s holding period for the ADSs or ordinary shares, and (2) any gain recognized on a sale, exchange or other disposition, including a pledge, of the ADSs or ordinary shares, whether or not we continue to be a PFIC. Under the PFIC rules, the tax on such excess distribution or gain would be determined by allocating the excess distribution or gain ratably over the U.S. Holder’s holding period for ADSs or ordinary shares. The amount allocated to the current taxable year (i.e., the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to the tax. In addition, our dividends on ADSs or ordinary shares will not be treated as qualified dividend income subject to preferential tax rates for non-corporate U.S. Holders, as described above, if we are classified as a PFIC in the last year prior to the year in which such dividend is paid or the year in which such dividend is paid.
 
If we are a PFIC for any year during which a U.S. Holder holds ADSs or ordinary shares, we must generally continue to be treated as a PFIC by that holder for all succeeding years during which the U.S. Holder holds the ADSs or ordinary shares, unless we cease to meet the requirements for PFIC status and the U.S. Holder makes a “deemed sale” election with respect to the ADSs or ordinary shares. If the election is made, the U.S. Holder will be deemed to sell the ADSs or ordinary shares it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain recognized from such deemed sale would be taxed under the PFIC rules described above. After the deemed sale election, the U.S. Holder’s ADSs or ordinary shares would not be treated as shares of a PFIC unless we subsequently become a PFIC.
 
If we are a PFIC for any taxable year during which a U.S. Holder holds ADSs or ordinary shares and any of the non-U.S. corporate entities in which we own equity is also a PFIC (i.e., a lower-tier PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC and would be taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain from the disposition of shares of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. Each U.S. Holder is advised to consult its tax advisors regarding the application of the PFIC rules to our non-U.S. subsidiaries.
 
If we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC rules on distributions or gain recognized on ADSs or ordinary shares if such U.S. Holder makes a valid “mark-to-market” election for our ADSs or ordinary shares. A mark-to-market election is available to a U.S. Holder only for “marketable stock.” Our ADSs or ordinary shares will be marketable stock if our ADSs or ordinary shares are “regularly traded” on a “qualified exchange.” The Nasdaq Capital Market is a qualified exchange for this purpose. Our ADSs or ordinary shares will be treated as regularly traded if they are traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. There can be no assurance that trading volumes will be sufficient to permit a mark-to-market election.
 
65

If a mark-to-market election is in effect, a U.S. Holder generally would take into account, as ordinary income each year, the excess of the fair market value of ADSs or ordinary shares held at the end of such taxable year over the adjusted tax basis of such ADSs or ordinary shares. The U.S. Holder would also take into account, as an ordinary loss each year, the excess of the adjusted tax basis of such ADSs or ordinary shares over their fair market value at the end of the taxable year, but only to the extent of the excess of amounts previously included in income over ordinary losses deducted as a result of the mark-to-market election. The U.S. Holder’s tax basis in ADSs or ordinary shares would be adjusted to reflect any income or loss recognized as a result of the mark-to-market election. Any gain from a sale, exchange or other disposition of ADSs or ordinary shares in any taxable year in which we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously included in income) and thereafter as capital loss.
 
A mark-to-market election will not apply to ADSs or ordinary shares for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become a PFIC. Such election, however, will not apply to any non-U.S. subsidiaries that we currently own, may organize or acquire in the future. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC rules with respect to any lower-tier PFICs that we currently own, may organize or acquire in the future notwithstanding the U.S. Holder’s mark-to-market election for the ADSs or ordinary shares.
 
In some cases, a shareholder of a PFIC can avoid the interest charge and the other adverse PFIC consequences described above by making a “qualified electing fund” (“QEF”) election to be taxed currently on its share of the PFIC’s undistributed income. In order for a U.S. Holder to be able to make a QEF election, the company would be required to provide the U.S. Holder with certain information. However, the company has no current plans to provide to U.S. Holders the required information. Therefore, prospective investors should assume that a QEF election will not be available.
 
U.S. Holders should consult their tax advisors as to the availability and desirability of a mark-to-market election, as well as the impact of such election on interests in any lower-tier PFICs.
 
Each U.S. person that is an investor of a PFIC is generally required to file an annual information return on IRS Form 8621 containing such information as the U.S. Treasury Department may require. The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax.
 
The U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. Holders are strongly urged to consult their own tax advisors with respect to the impact of PFIC status on the purchase, ownership and disposition of ADSs or ordinary shares, the consequences to them of an investment in a PFIC, any elections available with respect to the ADSs or ordinary shares and the IRS information reporting obligations with respect to the purchase, ownership and disposition of ADSs or ordinary shares of a PFIC.
 
Information Reporting and Backup Withholding
 
U.S. backup withholding tax and information reporting requirements may apply to certain payments to certain U.S. Holders of ADSs or ordinary shares. Information reporting generally will apply to payments of dividends on, and to proceeds from the sale or redemption of, our ADSs or ordinary shares made within the United States, or by a U.S. payor or U.S. middleman, to a U.S. Holder of our ADSs or ordinary shares, other than an exempt recipient. A payor will be required to withhold backup withholding tax from any payments of dividends on, or the proceeds from the sale or redemption of, ADSs or ordinary shares within the United States, or by a U.S. payor or U.S. middleman, to a U.S. Holder, other than an exempt recipient, if such holder fails to furnish its correct taxpayer identification number or otherwise fails to comply with, or establish an exemption from, such backup withholding tax requirements. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a credit against the beneficial owner’s U.S. federal income tax liability, if any, and any excess amounts withheld under the backup withholding rules may be refunded, provided that the required information is timely furnished to the IRS.
 
U.S. Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules.
 
Foreign Asset Reporting
 
U.S. Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in ADSs or ordinary shares, including, among others, IRS Form 8938 (Statement of Specified Foreign Financial Assets). As described above under “Passive Foreign Investment Company Status,” each U.S. Holder who is a shareholder of a PFIC must file an Annual Report containing certain information. In addition, U.S. Holders paying more than $100,000 for ADSs or ordinary shares may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties may be imposed upon a U.S. Holder that fails to comply with the required information reporting.
 
66

EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO THE INVESTOR OF AN INVESTMENT IN OUR ADSS OR ORDINARY SHARES IN LIGHT OF THE INVESTOR’S OWN CIRCUMSTANCES.
 
F.
DIVIDENDS AND PAYING AGENTS
 
Not applicable.
 
G.
STATEMENT BY EXPERTS
 
Not applicable.
 
H.
DOCUMENTS ON DISPLAY
 
Our website is http://www.shl-telemedicine.com. We are subject to the periodic reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we are required to file reports and other information with the SEC. Specifically, we are required to file annually a Form 20‑F within 120 days of the end of each fiscal year. The SEC maintains a website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that make electronic filings with the SEC using its EDGAR system. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of quarterly reports and proxy statements, and officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. We will make available, free of charge, on our website (under the heading “Investor Relations”) our Annual Reports on Form 20‑F, Reports on Form 6‑K and amendments to those reports as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. No information contained on our website is intended to be included as part of, or incorporated by reference into, this Annual Report.
 
I.
SUBSIDIARY INFORMATION
 
Not applicable.
 
J.
ANNUAL REPORT TO SECURITY HOLDERS
 
We will submit our Annual Report to our security holders when required in response to the requirements of Form 6‑K, in electronic format in accordance with the EDGAR Filer Manual.
 
ITEM 11.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The main risks arising from our financial instruments are credit risk, foreign currency risk, interest rate risk, market risk and liquidity risk. The Board of Directors reviews and agrees on policies for managing each of these risks, which are summarized below.
 

a.
Concentration of credit risks:

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash, cash equivalents, and trade receivables. Cash and cash equivalents are deposited with major banks. We believe that the financial institutions that hold the company’s investments are financially sound, and, accordingly, minimal credit risk exists with respect to these investments.
 
Our trade receivables are mainly derived from sales to customers in Germany and Israel. We have adopted credit policies and standards intended to accommodate industry growth and inherent risk. We believe that credit risks are moderated by the diversity of our end customers. We perform ongoing credit evaluations of our customers’ financial condition and require collateral as deemed necessary. An estimate for doubtful accounts is made when collection of the full amount is no longer probable.
 
67


b.
Foreign currency risk:

We are subject to foreign exchange risk as we hold cash and cash equivalents and short-term investments in foreign currency as we purchase our devices in foreign currency. We regularly monitor our foreign exchange risk and attempt to limit such risks by making adequate decisions regarding cash and credit positions.
 
Foreign currency sensitivity analysis:
 
The following table demonstrates the sensitivity test to a reasonably possible change in U.S. Dollars and EUR exchange rates, with all other variables held constant. The impact on our profit before tax is due to changes in the fair value of monetary assets discussed above. Our exposure to foreign currency changes related to all other currencies is not material to the company’s financial results.
 
   
Change in
       
   
U.S.
       
   
Dollars
   
Effect on
 
   
rate
   
profit tax
 
2023
   
+5
%
   
(721
)
     
-5
%
   
721
 
                 
2022
   
+5
%
   
(320
)
     
-5
%
   
320
 
                 
2021
   
+5
%
   
(347
)
     
-5
%
   
347
 

         
Effect on
 
   
Change in
   
profit
 
   
EUR rate
   
before tax
 
2023
   
+5
%
   
(66
)
     
-5
%
   
66
 
                 
2022
   
+5
%
   
(38
)
     
-5
%
   
38
 
                 
2021
   
+5
%
   
(252
)
     
-5
%
   
252
 

68

As of December 31, 2023, we had bank deposits of $14 million and $1.5 million in U.S. Dollars and EUR, respectively. As of December 31, 2022, we had bank deposits of $6.2 million and $0.8 million in U.S. Dollars and EUR, respectively. As of December 31, 2021, we had bank deposits of $6.9 million and $2.4 million in U.S. Dollars and EUR, respectively. The amounts presented in the above table represent the effect on profit before tax of a potential increase/decrease of 5% in the exchange rates between NIS and U.S. Dollars and EUR.
 
We closely monitor our foreign currency risk. Pursuant to the tables above, the Company does not believe that our foreign currency risk could have a material impact on the results of our business at this time. However, to the extent we believe that our foreign currency risk would materially impact our business, the company would consider entering into foreign currency hedging transactions, such as currency swaps or forwards, in order to mitigate that risk.
 

c.
Market risk:

We have investments in marketable financial instruments that are classified as financial assets at fair value through profit or loss in respect of which we are exposed to risk of fluctuations in the security price that is determined by reference to the quoted market price (level 1 of the fair value hierarchy). As of December 31, 2023, 2022 and 2021, the balance of these investments is USD 8,978, USD 8,517 and USD 17,217, respectively).

The following table demonstrates the sensitivity to a reasonably possible change in the market price with all other variables held constant, of our profit before tax (due to changes in the carrying amount of marketable securities).
 
   
Increase/
   
Effect on
 
   
decrease in
   
profit
 
   
price
   
before tax
 
2023
   
+5
%
   
449
 
     
-5
%
   
(449
)
                 
2022
   
+5
%
   
426
 
     
-5
%
   
(426
)
                 
2021
   
+5
%
   
861
 
     
-5
%
   
(861
)


d.
Fair value of financial instruments not measured at fair value:

The carrying amounts of cash and cash equivalents, trade and other receivables, short-term credit from banks, trade payables and other accounts payable approximate their fair value due to the short-term maturity of such instruments. The carrying amount of long-term bank loan approximates the fair value as the interest rate is variable.
 
We believe that the carrying amount of long-term deposits approximate their fair value.
 

e.
Interest rate risk:

Our exposure to the risk of changes in market interest rates relates primarily to our floating rate debt obligation. Specifically, during August 2021, we signed an agreement with a bank in Israel to obtain a long-term loan in the amount of approximately $18.3 million for a period of seven years and nine months. The loan is denominated in NIS and bears an annual interest rate of prime + 1.05% (2.65% as of the signing date). The loan is being repaid in 28 quarterly installments following an initial moratorium period of nine months.

69

As it relates to the loan, we do not believe that the effect of a reasonably possible increase of 5% on the interest rate would have a material impact on our profit before tax. While we do not currently have any type of hedging instrument in place related to the loan, the company would consider entering into an interest rate swap in order to mitigate the interest rate risk related to the floating rate debt obligation if it believed an increase in interest rates would materially impact its business. Furthermore, in accordance with the terms of the loan, the company has the right to prepay the loan (without penalty) if needed.
 
In addition to our floating rate debt obligation, we also had cash and cash equivalents and short-term investments of approximately $26.0 million and $18.7 million as of December 31, 2023, and December 31, 2022, respectively. Our cash and cash equivalents and short-term investments are held primarily for short term operating capital purposes. Further, our cash and cash equivalents are held primarily in bank deposits and marketable securities. Due to the short-term nature of these instruments, we do not believe that the effect of a reasonably possible increase of 5% of the interest rate would have a material impact on our profit before tax.
 
f. Liquidity risk:

 

We monitor our risk to a shortage of funds using a recurring liquidity planning tool. This tool considers the maturity of both its financial investments and financial assets and projected cash flows from operations.
 
ITEM 12.
DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
 
A.          DEBT SECURITIES
 
Not applicable.
 
B.          WARRANTS AND RIGHTS
 
Not applicable.
 
C.          OTHER SECURITIES
 
Not applicable.
 
D.          AMERICAN DEPOSITARY SHARES
 
Below we provide the information required by Item 12.D.3 and Item 12.D.4 Form 20‑F. The remainder of the information required by this Item is incorporated by reference as Exhibit 2.3 to this Annual Report on Form 20‑F and is incorporated hereunder by reference. The form of the deposit agreement and the Form of the ADR are incorporated by reference as Exhibits 2.1 and 2.2 to this Annual Report on Form 20‑F and are incorporated herein by reference
 
70

Fees and Expenses
 
Persons depositing or withdrawing shares or ADS holders must pay:
For:
 
 
$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)
Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property
Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates
 
 
$.05 (or less) per ADS
Any cash distribution to ADS holders
 
 
A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs
Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders
 
 
 
$.05 (or less) per ADS per calendar year
Depositary services
 
 
Registration or transfer fees
Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares
 
 
 
Expenses of the depositary
Cable (including SWIFT) and facsimile transmissions (when expressly provided in the deposit agreement)
Converting foreign currency to U.S. dollars
 
 
Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes
As necessary
 
 
 
Any charges incurred by the depositary or its agents for servicing the deposited securities
As necessary

The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.
 
From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.
 
The depositary may convert currency itself or through any of its affiliates, or the custodian or we may convert currency and pay U.S. dollars to the depositary. Where the depositary converts currency itself or through any of its affiliates, the depositary acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary’s obligation to act without negligence or bad faith. The methodology used to determine exchange rates used in currency conversions made by the depositary is available upon request. Where the custodian converts currency, the custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate will be determined will be the most favorable to ADS holders, and the depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate. In certain instances, the depositary may receive dividends or other distributions from us in U.S. dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by us and, in such cases, the depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor we make any representation that the rate obtained or determined by us is the most favorable rate and neither it nor we will be liable for any direct or indirect losses associated with the rate.
 
71

PART II
 
ITEM 13.
DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

None.
 
ITEM 14.
MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

Material modifications to the rights of the security holders.
 
There have been no material modifications to the rights of securities holders.
 
Use of Proceeds.
 
Not applicable.
 
ITEM 15.
CONTROLS AND PROCEDURES

(a) Disclosure Controls and Procedures.
 
Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding our required disclosure.
 
As required by Rules 13a‑15 and 15d‑15 promulgated under the Exchange Act, our management, including our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act, as of the end of the period covered by this Annual Report. Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that, as of December 31, 2023, our disclosure controls and procedures were not effective due to the material weaknesses in our internal control over financial reporting described in Item 15(b) below.
 
(b) Management’s annual report on internal control over financial reporting.
 
 Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. Our management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2023, based on the criteria set forth in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that assessment, our management concluded that our internal control over financial reporting was not effective as of December 31, 2023, due to material weaknesses in our Information Technology General Controls ("ITGC") described below.  As defined in Rule 12b-2 promulgated under the Exchange Act, a “material weakness” is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the registrant’s annual or interim financial statements will not be prevented or detected on a timely basis.

The material weaknesses we identified in our ITGC include a lack of documentation of the performance of controls related to management of access, segregation of duties and management of program changes.  We did not fully design, implement and monitor general information technology (“IT”) controls in the areas of user access and program change-management for systems supporting all of our internal control processes. Specifically, management did not design and maintain (1) sufficient user access controls to ensure appropriate segregation of duties and adequately restrict user and privileged access to financial applications, programs and data to appropriate Company personnel and (2) program change management controls to ensure that IT program and data changes affecting financial information technology applications and underlying accounting records were authorized, tested and implemented appropriately. As a result, business process controls (automated and IT-dependent manual controls) that were dependent on our ITGCs, or that used data produced from systems impacted by our ITGCs, were deemed not effective as of December 31, 2023.

72

In light of these material weaknesses, we are required to perform additional procedures to ensure that our financial statements are prepared in accordance with IFRS, including, among other things, reviewing operating systems that are interfaces to the financial systems, monitoring new accounts, and reviewing key performance indicators, all on a monthly basis, and to control manual general entries. Accordingly, management believes that the financial statements included in this Annual Report on Form 20-F present fairly in all material respects our financial position, results of operations and cash flows for the periods presented.

Remediation Activities

We currently are implementing or have implemented several items, as described below, to remediate the material weaknesses described above. Management is committed to ensuring that our internal control over financial reporting is designed and operating effectively. For example, we are replacing important elements of our ITGCs as they relate to financial reporting and are incorporating them into the design of our processes and controls within a new enterprise resource planning system, which is expected to be effective during 2025.

Our remediation plan includes, but is not limited to, the following:


implementing new IT systems related to our financial reporting;

reviewing our financial statements on a monthly basis to evaluate results, observe adherence to policies and agree on remedial actions (if necessary);

implementing improved IT-change management policies and procedures, control activities, and tools impacting financial reporting to ensure changes affecting financial IT applications are identified, authorized, tested and implemented appropriately;

implementing improved processes for requesting, authorizing and reviewing user access to key systems that impact our financial reporting, including identifying access to roles where manual business process controls may be required;

implementing appropriate segregation of duties in relevant systems that impact internal control over financial reporting;

increasing resources dedicated to monitoring ITGCs related to financial reporting to ensure compliance with policies and procedures; and

implementing additional training to ensure a clear understanding of risk assessment and monitoring activities related to automated processes and IT systems and ITGCs related to financial reporting.
 
(c) Attestation report of the registered public accounting firm.
 
This Annual Report does not include an attestation report of our Registered Public Accounting firm because we are an emerging growth company under the JOBS Act and accordingly are exempt from the requirement to provide such report.
 
73

(d) Changes in internal control over financial reporting.
 
During the period covered by this Annual Report, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, except for the material weaknesses and remediation activities described in Item 15(b) above.
 
ITEM 16.
[RESERVED]

ITEM 16.A.
AUDIT COMMITTEE FINANCIAL EXPERT

Our board has determined that Mr. Yehoshua (Shuky) Abramovich is an “audit committee financial expert” serving on our audit committee, as such term is defined in Item 16A(b) of Form 20‑F by the Securities and Exchange Commission’s rules and “independent” as that term is defined in the Nasdaq listing standards.
 
ITEM 16.B.
CODE OF ETHICS

On March 6, 2023, we adopted a Code of Ethics for all directors, officers and employees that complies with the Nasdaq rules and the definition of a “code of ethics” set forth in Section 406(c) of the Sarbanes-Oxley Act of 2002, as amended. Our Code of Ethics is incorporated by reference as Exhibit 11.1 to this Annual Report. A copy of our Code of Ethics is posted on the “Corporate Governance” page of our website at https://www.shl-telemedicine.com/corporate-governance/. We expect that any amendment to our Code of Ethics, or any waivers of its requirements, will be disclosed on our website. We will also provide to any person a copy of our Code of Ethics without charge, upon request. Such request can be submitted to SHL Telemedicine, 90 Yigal Alon Street, Tel Aviv 67891, Israel, Attention: Amir Hai, Chief Financial Officer.
 
ITEM 16.C.
PRINCIPAL ACCOUNTANT FEES AND SERVICES

Ernst and Young Or Kost Forer Gabbay & Kasierer, a Member of Ernst & Young Global has served as our independent registered public accountant for each of last two fiscal years for which audited statements appear in this Annual Report.
 
The following table shows the aggregate fees for professional services and other services rendered by Ernst and Young and the various member firms of Ernst and Young to us, including some of our subsidiaries, in fiscal years 2023 and 2022.
 
   
2023
   
2022
 
Particulars
 
(US$)
   
(US$)
 
Audit fees (audit and review of financial statements and offerings)
   
460
     
419
 
Audit-related fees
   
     
 
Tax fees
   
     
 
All other fees
   
     
 
Total
   
460
     
419
 

The policy of our audit committee is to pre-approve all audit and non-audit services provided by Ernst and Young, including audit services, audit-related services and tax services. We have a written policy on the engagement of an external auditor.

74

ITEM 16.D.
EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

Not applicable.
 
ITEM 16.E.
PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

Not applicable.
 
ITEM 16.F.
CHANGE IN REGISTRANT’S CERTIFIED ACCOUNTANT

Not applicable.
 
ITEM 16.G.
CORPORATE GOVERNANCE

We are a “foreign private issuer” (as such term is defined in Rule 3b‑4 under the Exchange Act) and our equity shares are listed on the Nasdaq Capital Market. Under Nasdaq rules, Nasdaq listed companies that are foreign private issuers are permitted to follow home country practice in lieu of the corporate governance provisions specified by the Nasdaq, with limited exceptions. As required by the Nasdaq rules, we note the following significant differences between our corporate governance practices and the corporate governance practices required to be followed by U.S. domestic companies.
 
Under the Nasdaq rules, the board of directors of U.S. domestic listed companies are required to have a majority of independent directors. We are not subject to this requirement under the Israeli law and have decided to follow home country practice on this matter. Because three of the six directors on our Board are independent under Nasdaq’s independence standard, we do not currently comply with Nasdaq’s requirement that an issuer maintain a majority of independent directors.
 
The Nasdaq rule also requires U.S. domestic listed companies to have a nominations committee comprised solely of independent directors along with a nominations committee charter. We do not have a nomination committee or a nominations committee charter and have decided to follow home country practice on this matter.
 
ITEM 16.H.
MINE SAFETY DISCLOSURE
 
Not applicable.
 
ITEM 16.I.
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
 
None.
 
ITEM 16J.
INSIDER TRADING POLICIES
 
Not applicable.
 
ITEM 16K.
CYBERSECURITY
 
As a global leader in telemedicine technologies and services, cyber security is a top priority in all our business activities. Our solutions are designed to protect patient data from unauthorized access, use, or disclosure. We have appointed an external dedicated Chief Information Security Officer reporting to our Chief Information Officer. We also developed and implemented policies, procedures and infrastructures that support our data security for sensitive information, disaster recovery and business continuity for different systems and system durability. Our information security policy is based on the standards and regulations in the healthcare industry (ISO 27001, ISO 27799, and HIPAA compliance).
 
We follow and implement the Israel Cyber Defense Doctrine 2.0 (ICDM 2.0), a methodology for managing cyber risks in organizations. In accordance with these guidelines, we have adopted several ISO standards, including the above-mentioned ISO 27001 and ISO 27799, to provide a foundation for our cybersecurity governance and risk management strategy. We also have a comprehensive privacy policy that addresses the protection of personal data that includes general guidelines for data protection, a policy for customers regarding personal data collection, retention and sharing information with third parties, and an approval form for usage of medical devices using or transmitting customer data.
 
75

In 2023, we conducted a comprehensive risk assessment to identify the cybersecurity risks that are most relevant to our organization. All risks are managed in the cybersecurity workplan for 2024. In general, we use a variety of tools and techniques to identify, assess, and analyze our cybersecurity risks on a constant basis. These tools and techniques include technical assessments, formal risk assessments, and threat modeling. We have also a comprehensive cybersecurity strategy and action plan in place that fully addresses the risks identified in our risk assessment. This plan is regularly reviewed and updated to ensure tit remains effective.
 
Finally, we have implemented a continuous monitoring and review program to ensure that our cybersecurity program is effective and up to date, managed by our Chief Information Security Officer and his team. This program includes regular penetration tests, vulnerability assessments and incident response drills, weekly reporting to the CIO and annual reporting to the CEO. No cyber incidents and/or data breaches occurred in 2023 and 2022.
 
Although not required under the Israeli Companies Law, on February 10, 2020, our Board established a cyber committee (the “Cyber Committee”). The task of the Cyber Committee is to recommend to the Board actions and measures to be taken in connection with the Company’s information technology, including, among other things, developing, maintaining and promoting the security of the Company’s systems, networks and data, as well as supervising and monitoring the implementations of all such actions and measures.  The Cyber Committee meets from time to time when necessary.
 
PART III
 
ITEM 17.
FINANCIAL STATEMENTS
 
We have furnished the financial statements and related information specified in Item 18.
 
ITEM 18.
FINANCIAL STATEMENTS
 
The consolidated financial statements and related notes required by this Item 18 are included in this Annual Report beginning on page F‑1.

76

ITEM 19.
EXHIBITS
 
The following exhibits are filed as part of this Annual Report:
 
Exhibit

 
No.

Document
 
 

 

 

 

 

 

 

 
 

 

 

 

 

 

 

 

 

 

 

 

 

 
 

 
 

 

 

 

 

 

 
 
101.INS#

Inline XBRL Instance Document-this instance document does not appear on the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
 
 
101.SCH#

Inline XBRL Taxonomy Extension Schema Document
 
 
101.CAL#

Inline XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.DEF#

Inline XBRL Taxonomy Extension Definition Linkbase Document
 
 
101.LAB#

Inline XBRL Taxonomy Extension Label Linkbase Document
 
 
101.PRE#

Inline XBRL Taxonomy Extension Presentation Linkbase Document
 
 
104#

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)


*
Incorporated by reference to the Company’s Registration Statement on Form 20‑F (File No. 001‑41641).
 
**
English translation from the original Hebrew language. Certain identified information has been excluded from this exhibit because the Company does not believe it is material and is the type that the Company customarily treats as private and confidential. Redacted information is indicated by [***].
 
Incorporated by reference to the Company’s Annual Report on Form 20‑F for the fiscal year ended December 31, 2022, originally filed with the SEC on May 11, 2023.

#
Filed with this Annual Report on Form 20‑F.

##
Furnished with this Annual Report on Form 20‑F.
 
77

SIGNATURES
 
The registrant hereby certifies that it meets all of the requirements for filing on Form 20‑F and that it has duly caused and authorized the undersigned to sign this Amendment No. 1 to Annual Report on Form 20‑F/A on its behalf.
 
 
SHL TELEMEDICINE LTD.
 
 
 
 
By:
/s/ Erez Nachtomy
 
 
Name: Erez Nachtomy
 
 
Title: Chief Executive Officer
 
 
 
Date: July 24, 2024
 
 

78


 
SHL TELEMEDICINE LTD.
 
CONSOLIDATED FINANCIAL STATEMENTS
 
AS OF DECEMBER 31, 2023
 
U.S. DOLLARS IN THOUSANDS
 
INDEX
 
 
Page
   
Independent Auditors' Report (Kost Forer Gabbay & Kasierer - Tel-Aviv, Israel) (PCAOB 1281)
F-2
   
F-3 - F-4
   
F-5
   
F-6
   
F-7 - F-8
   
F-9 - F-68
 

image0.jpg
Kost Forer Gabbay & Kasierer
144 Menachem Begin Road, Building A,
Tel-Aviv 6492102, Israel
Tel: +972-3-6232525
Fax: +972-3-5622555
ey.com
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
To the Shareholders and the Board of Directors of
 
SHL TELEMEDICINE LTD.
 
Opinion on the Financial Statements
 
We have audited the accompanying consolidated balance sheets of SHL Telemedicine Ltd. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of comprehensive income, changes in equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.
 
Basis for Opinion
 
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
 
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
 
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
 
KOST FORER GABBAY & KASIERER
 
A Member of EY Global
 
We have served as the Company’s auditor since 1997
 
Tel-Aviv, Israel
 
April 17, 2024
 
 
F - 2

SHL TELEMEDICINE LTD.
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
 
         
December 31,
 
   
Note
   
2023
   
2022
 
ASSETS
                 
                   
CURRENT ASSETS:
                 
Cash and cash equivalents
 
5
     
6,693
     
4,483
 
Short-term investments
 
6
     
19,557
     
14,217
 
Trade receivables
 
7
     
8,557
     
7,797
 
Inventory
 
2e
 
   
3,459
     
3,879
 
Other accounts receivable
 
9
     
1,792
     
1,912
 
                       
           
40,058
     
32,288
 
NON-CURRENT ASSETS:
                     
Inventory
 
2e
 
   
1,913
     
1,731
 
Prepaid expenses
 
8
     
3,220
     
3,364
 
Call option to non-controlling interests, net
 
17
     
147
     
245
 
Long-term deposits
         
328
     
423
 
Right-of-use assets
 
12
     
7,214
     
11,038
 
Deferred taxes
 
19d
 
   
2,055
     
2,872
 
                       
           
14,877
     
19,673
 
                       
PROPERTY AND EQUIPMENT, NET
 
10
     
4,892
     
4,652
 
                       
GOODWILL
 
11
     
32,965
     
33,745
 
                       
INTANGIBLE ASSETS, NET
 
11
     
20,257
     
20,425
 
                       
Total assets
         
113,049
     
110,783
 
 
The accompanying notes are an integral part of the consolidated financial statements.

 

F - 3


SHL TELEMEDICINE LTD.
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
 
         
December 31,
 
   
Note
   
2023
   
2022
 
LIABILITIES AND EQUITY
                 
                   
CURRENT LIABILITIES:
                 
Credit from banks and others
 
13
     
2,160
     
2,169
 
Current maturities of lease liabilities
 
12
     
2,435
     
2,263
 
Deferred revenues
 
15
     
304
     
260
 
Income taxes payable
 
19
     
119
     
138
 
Trade payables
         
3,884
     
3,757
 
Other payables
 
16
     
8,536
     
9,238
 
                       
           
17,438
     
17,825
 
NON-CURRENT LIABILITIES:
                     
Liability for share options
 
17
     
-
     
7,164
 
Loans from banks
 
14
     
10,460
     
13,008
 
Deferred taxes
 
19d
 
   
2,313
     
2,700
 
Lease liabilities
 
12
     
4,804
     
9,302
 
Employee benefit liabilities
 
18
     
1,573
     
1,495
 
                       
           
19,150
     
33,669
 
                       
Total liabilities
         
36,588
     
51,494
 
                       
EQUITY:
 
22
                 
Attributable to equity holders of the Company:
                     
Issued capital
         
48
     
43
 
Additional paid-in capital
         
156,334
     
130,009
 
Treasury shares
         
(2
)
   
(2
)
Foreign currency translation reserve
         
(5,294
)
   
(3,291
)
Capital reserve for options
         
1,514
     
1,002
 
Capital reserve for remeasurement gains on defined benefit plans
         
1,058
     
1,000
 
Accumulated deficit
         
(80,130
)
   
(73,074
)
                       
           
73,528
     
55,687
 
                       
Non-controlling interests
         
2,933
     
3,602
 
                       
Total equity
         
76,461
     
59,289
 
                       
Total liabilities and equity
         
113,049
     
110,783
 
 
The accompanying notes are an integral part of the consolidated financial statements.
 
April 17, 2024
 

/s/ Yariv Alroy

 

/s/ Erez Nachtomy

Date of approval of the
 
Yariv Alroy
 
Erez Nachtomy
financial statements
 
Chairman of the Board
 
CEO

 

F - 4


SHL TELEMEDICINE LTD.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
U.S. dollars in thousands (except per share data)
 
         
Year ended
December 31,
 
   
Note
   
2023
   
2022
   
2021
 
                         
Revenues
 
23a
     
57,075
     
58,998
     
49,582
 
Cost of revenues
 
23b
     
31,814
     
31,809
     
24,989
 
                               
Gross profit
         
25,261
     
27,189
     
24,593
 
                               
Research and development costs
 
23c
     
5,260
     
3,788
     
2,985
 
Selling and marketing expenses
 
23d
     
10,581
     
11,403
     
9,454
 
General and administrative expenses
 
23e
     
16,228
     
16,748
     
12,103
 
Other expenses
 
23g
     
2,198
     
416
     
548
 
                               
Operating loss
         
(9,006
)
   
(5,166
)
   
(497
)
Financial income
 
23f(1)
     
4,833
     
8,833
     
381
 
Financial expenses
 
23f(2)
     
(1,791
)
   
(2,355
)
   
(13,353
)
                               
Profit (loss) before taxes on income
         
(5,964
)
   
1,312
     
(13,469
)
Tax expenses
 
19b
     
891
     
1,097
     
455
 
                               
Net profit (loss)
         
(6,855
)
   
215
     
(13,924
)
                               
Other comprehensive income:
                             
                               
Other comprehensive income (loss) not to be reclassified to profit or loss in subsequent periods:
                             
Re-measurement gain on defined benefit plans
 
18
     
52
     
581
     
280
 
Other comprehensive income (loss) to be reclassified to profit or loss in subsequent periods:
                             
Foreign currency translation reserve
         
(2,119
)
   
(6,699
)
   
859
 
                               
Total other comprehensive income
         
(2,067
)
   
(6,118
)
   
1,139
 
                               
Total comprehensive loss
         
(8,922
)
   
(5,903
)
   
(12,785
)
                               
Net profit (loss) attributable to:
                             
Equity holders of the Company
         
(7,056
)
   
(76
)
   
(14,110
)
Non-controlling interests
         
201
     
291
     
186
 
                               
           
(6,855
)
   
215
     
(13,924
)
                               
Comprehensive income (loss) attributable to:
                             
Equity holders of the Company
         
(9,001
)
   
(5,775
)
   
(12,971
)
Non-controlling interests
         
79
     
(128
)
   
186
 
                               
           
(8,922
)
   
(5,903
)
   
(12,785
)
Earnings per share:
                             
Basic loss
 
24
     
(0.43
)
   
(0.01
)
   
(1.00
)
Diluted loss
 
24
     
(0.54
)
   
(0.49
)
   
(1.00
)
 
The accompanying notes are an integral part of the consolidated financial statements.

 

F - 5


SHL TELEMEDICINE LTD.
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
U.S. dollars in thousands
 
   
Issued
capital
   
Additional paid-in capital
   
Treasury shares
   
Foreign currency translation reserve
   
Capital reserve for options
   
Capital
reserve for remeasurement gains on defined benefit plans
   
Accumulated deficit
   
Total
   
Non-controlling interests
   
Total
equity
 
                                                             
Balance as of January 1, 2022
   
42
     
125,484
     
(86
)
   
2,966
     
1,002
     
442
     
(72,998
)
   
56,852
     
3,911
     
60,763
 
                                                                                 
Exercise of share options
   
1
     
2,975
     
-
     
-
     
-
     
-
     
-
     
2,976
     
-
     
2,976
 
Exercise of Employee options
   
*
)
   
(84
)
   
84
     
-
     
-
     
-
     
-
     
-
     
-
     
-
 
Share-based payments
   
-
     
1,347
     
-
     
-
             
-
     
-
     
1,347
     
410
     
1,757
 
Equity component of transaction with non-controlling interest
   
-
     
287
     
-
     
-
     
-
     
-
     
-
     
287
     
(287
)
   
-
 
Dividend paid to non-controlling interests
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
-
     
(130
)
   
(130
)
PPA Adjustments
                                                           
-
     
(174
)
   
(174
)
Net profit (loss)
   
-
     
-
     
-
     
-
     
-
     
-
     
(76
)
   
(76
)
   
291
     
215
 
Total other comprehensive income (loss)
   
-
     
-
     
-
     
(6,257
)
   
-
     
558
     
-
     
(5,699
)
   
(419
)
   
(6,118
)
                                                                                 
Balance as of December 31, 2022
   
43
     
130,009
     
(2
)
   
(3,291
)
   
1,002
     
1,000
     
(73,074
)
   
55,687
     
3,602
     
59,289
 
                                                                                 
Exercise of share options
   
5
     
25,114
     
-
     
-
     
512
     
-
     
-
     
25,631
     
-
     
25,631
 
Exercise of Employee options
   
*
)
   
*
)
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
-
 
Share-based payments
   
-
     
1,116
     
-
     
-
     
-
     
-
     
-
     
1,116
     
136
     
1,252
 
Equity component of transaction with non-controlling interest
   
-
     
95
     
-
     
-
     
-
     
-
     
-
     
95
     
(95
)
   
-
 
Dividend paid to non-controlling interests
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
-
     
(789
)
   
(789
)
Net profit (loss)
   
-
     
-
     
-
     
-
     
-
     
-
     
(7,056
)
   
(7,056
)
   
201
     
(6,855
)
Total other comprehensive income (loss)
   
-
     
-
     
-
     
(2,003
)
   
-
     
58
     
-
     
(1,945
)
   
(122
)
   
(2,067
)
                                                                                 
Balance as of December 31, 2023
   
48
     
156,334
     
(2
)
   
(5,294
)
   
1,514
     
1,058
     
(80,130
)
   
73,528
     
2,933
     
76,461
 
 
*)          Represents an amount lower than $1.
 
The accompanying notes are an integral part of the consolidated financial statements.

 

F - 6


SHL TELEMEDICINE LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
Cash flows from operating activities:
                 
                   
Net profit (loss)
   
(6,855
)
   
215
     
(13,924
)
                         
Adjustments required to reconcile net profit (loss) to net cash provided by (used) in operating activities:
                       
                         
Income and expenses not involving operating cash flows:
                       
                         
Depreciation and amortization
   
7,692
     
7,134
     
5,382
 
Capital loss from disposals of property and equipment
   
278
     
51
     
63
 
Impairment of property, and equipment
   
-
     
-
     
118
 
Capital gain from amendment of lease liabilities
   
(399
)
   
-
     
-
 
Change in employee benefit liabilities, net
   
180
     
90
     
21
 
Financial Expenses (income), net
   
(2,446
)
   
(7,443
)
   
12,857
 
Valuation loss (gain) from short-term investments
   
(848
)
   
769
     
114
 
Cost of share-based payments
   
1,252
     
1,757
     
1,291
 
Tax expenses
   
891
     
1,097
     
455
 
                         
     
6,600
     
3,455
     
20,301
 
Changes in operating assets and liabilities:
                       
                         
Decrease (increase) in trade receivables, net
   
(975
)
   
(641
)
   
611
 
Increase in inventory
   
(156
)
   
(2,544
)
   
(3,097
)
Decrease (increase) in prepaid expenses
   
44
     
(21
)
   
202
 
Decrease (increase) in other accounts receivable
   
62
     
(471
)
   
289
 
Increase in trade payables
   
235
     
1,264
     
494
 
Increase (decrease) in deferred revenues
   
51
     
(246
)
   
(970
)
Increase (decrease) in other accounts payable
   
965
     
845
     
(2,459
)
                         
     
226
     
(1,814
)
   
(4,930
)
Cash paid and received:
                       
                         
Interest received
   
621
     
429
     
318
 
Interest paid
   
(1,296
)
   
(1,010
)
   
(440
)
Income tax received
   
8
     
87
     
7
 
Income taxes paid
   
(800
)
   
(1,435
)
   
(1,147
)
                         
     
(1,467
)
   
(1,929
)
   
(1,262
)
                         
Net cash provided by (used) in operating activities
   
(1,496
)
   
(73
)
   
185
 
 
The accompanying notes are an integral part of the consolidated financial statements.

 

F - 7


SHL TELEMEDICINE LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
Cash flows from investing activities:
                 
                   
Purchase of property and equipment
   
(1,289
)
   
(1,661
)
   
(625
)
Acquisition of subsidiaries (a)
   
-
     
-
     
(27,323
)
Investment in intangible assets
   
(4,203
)
   
(5,243
)
   
(2,633
)
Investment in short-term deposits
   
(9,840
)
   
(5,705
)
   
(4,860
)
Proceeds from short-term deposits
   
5,855
     
-
     
4,733
 
Purchase of short-term investments
   
(2,291
)
   
(5,588
)
   
(13,622
)
Proceeds from sale of short-term investments
   
2,422
     
11,764
     
3,356
 
                         
Net cash used in investing activities
   
(9,346
)
   
(6,433
)
   
(40,974
)
                         
Cash flows from financing activities:
                       
                         
Proceeds from issue of share options liability
   
-
     
-
     
6,859
 
Dividend paid to non-controlling interests
   
(789
)
   
(130
)
   
-
 
Payment of lease liabilities
   
(2,648
)
   
(2,447
)
   
(1,933
)
Proceeds from issue of share capital, net
   
-
     
-
     
30,140
 
Exercise of share options
   
20,298
     
1,961
     
463
 
Payment of long-term loans
   
(2,070
)
   
(1,665
)
   
18,265
 
Payment of liability to underwriters
   
(1,124
)
   
-
     
(2,716
)
                         
Net cash provided by (used in) financing activities
   
13,667
     
(2,281
)
   
51,078
 
                         
Effect of exchange rate changes on cash and cash equivalents
   
(615
)
   
(1,575
)
   
414
 
                         
Increase (decrease) in cash and cash equivalents
   
2,210
     
(10,362
)
   
10,703
 
Cash and cash equivalents at the beginning of the year
   
4,483
     
14,845
     
4,142
 
                         
Cash and cash equivalents at the end of the year
   
6,693
     
4,483
     
14,845
 
                         
Non-cash transactions:
                       
                         
Right-of-use asset recognized with corresponding lease liability
   
(1,265
)
   
1,658
     
131
 
                         
Liability derecognized and recorded in equity upon exercise of share options
   
5,333
     
1,015
     
319
 
 
The accompanying notes are an integral part of the consolidated financial statements.

 

F - 8


SHL TELEMEDICINE LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
 
     
Year ended
December 31,
 
     
2023
   
2022
   
2021
 
(a)
Acquisition of subsidiaries
                 
 
 
                 
 
The subsidiaries' assets and liabilities at date of acquisition (excluding cash and cash equivalents):
                 
 
 
                 
 
Trade receivables
   
-
     
-
     
3,424
 
 
Other receivables
   
-
     
-
     
685
 
 
Property and equipment
   
-
     
-
     
807
 
 
Deferred taxes
   
-
     
-
     
(3,356
)
 
Right-of-use-assets
   
-
     
-
     
3,509
 
 
Intangible assets
   
-
     
-
     
34,157
 
 
Trade payables
   
-
     
-
     
(668
)
 
Other payables
   
-
     
-
     
(2,492
)
 
Put option, net
   
-
     
-
     
(185
)
 
Loans from banks
   
-
     
-
     
(390
)
 
Employee benefit liabilities
   
-
     
-
     
(985
)
 
Lease liabilities
   
-
     
-
     
(3,510
)
 
Non-controlling interests
   
-
     
-
     
(3,673
)
                           
       
-
     
-
     
27,323
 
 
The accompanying notes are an integral part of the consolidated financial statements.

 

F - 9


SHL TELEMEDICINE LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

 

NOTE 1:-
GENERAL
 
  a.
SHL Telemedicine Ltd. ("SHL" and/or "the Company") was incorporated in Israel. The registered office is located at Ashdar Building, Yigal Alon St. in Tel Aviv. Its shares are publicly traded on the SIX Swiss Exchange under the symbol SHLTN. In April 2023 the Company started trading its American Depositary Shares (“ADRs”) on The NASDAQ Capital Market (the “Nasdaq”), under the ticker symbol “SHLT”.
 
SHL and its subsidiaries ("the Group") develop and market advanced personal telemedicine solutions. Personal telemedicine is the transmission of medical data by an individual, from a remote location to a medical call center via telecommunication networks. SHL's personal telemedicine systems are designed to improve quality of care and life for people suffering from various health conditions ranging from the high-risk and chronically ill to ordinary users of healthcare products and services who wish to take a more active role in managing their own health. In addition, the Group provides B2B healthcare services in Israel in the field of diagnostics, preventive medicine, and medical opinions to institutional customers.
 
  b.
The effects of the Swords of Iron War:
 
In October 2023, the Swords of Iron war broke out in Israel ("the war"). The ongoing war has led to a slowdown in business activity throughout the Israeli economy, as a result, among others, of the shutdown of enterprises in the south and north of Israel, the damage to local infrastructures, the nationwide military reserve draft for an indefinite period and the disruption of economic activity in the entire country. The prolongation of the war is likely to have extensive nationwide effects on numerous business and geographic segments.
 
The potential fluctuations in commodity prices, foreign currency exchange rates, availability of materials and manpower, local services and access to local resources are all liable to affect entities whose main operations are conducted in or with Israel.
 
Mediton's operations which provide services that are based on a fee-for-service model were affected by the war in Gaza during the last quarter of 2023. In the beginning of 2024 Mediton's activity is back on track.

 

NOTE 2:-
ACCOUNTING POLICIES
 
  a.
Basis of presentation of the financial statements:
 
  1.
These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").
 
The Group's financial statements have been prepared on a cost basis, except for marketable securities, liability to underwriters and derivatives (put option, and liability for share options) which are measured at fair value through profit or loss and employee benefit assets and liabilities.
 
The Group has elected to present the statement of comprehensive income using the function of expense method.
 
  2.
Consistent accounting policies:
 
The accounting policies adopted in the financial statements have been applied consistently for all periods presented, unless otherwise stated.

 

F - 10

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
  b.
Consolidated financial statements:
 
The consolidated financial statements comprise the financial statements of companies that are controlled by the Company (subsidiaries). Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.
 
The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group.
 
Non-controlling interests in subsidiaries represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statement of financial position.
 
A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as a change in equity by adjusting the carrying amount of the non-controlling interests with a corresponding adjustment of the equity attributable to equity holders of the Company less/plus the consideration paid or received.
 
  c.
Functional currency and presentation currency:
 
  1.
Functional currency and presentation currency:
 
The presentation currency of the financial statements is the U.S. dollar.
 
The functional currency, which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions, is separately determined for each Group entity and is used to measure its financial position and operating results. The functional currency of the Company and it's subsidiaries in Israel is the NIS.
 
F - 11

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
When a Group entity's functional currency differs from the presentation currency, that entity's financial statements are translated so that they can be included in the consolidated financial statements as follows:
 
  a)
Assets and liabilities of foreign operations, including goodwill and any fair value adjustments to the carrying amounts of assets and liabilities arising from the acquisition of said foreign operation, are translated at the closing rate at the end of the reporting period.
 
  b)
Income and expenses for each period presented in the statement of income are translated at average exchange rates for the presented periods.
 
  c)
Share capital, capital reserves and other changes in capital are translated at the exchange rate prevailing at the date of incurrence.
 
  d)
Retained earnings are translated based on the opening balance translated at the exchange rate at that date and other relevant transactions (such as dividend) during the period are translated as described in b) and c) above.
 
  e)
All resulting translation differences are recognized as a separate component of other comprehensive income (loss) in equity "foreign currency translation reserve".
 
  2.
Index-linked monetary items:
 
Monetary assets and liabilities linked to the changes in the Israeli Consumer Price Index ("Israeli CPI") are adjusted at the relevant index at the end of each reporting period according to the terms of the agreement. Linkage differences arising from the adjustment, as above, other than those capitalized to qualifying assets or carried to equity in hedge transactions, are recognized in profit or loss.

 

F - 12

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
  d.
Short-term deposits:
 
Short-term bank deposits are deposits with an original maturity of more than three months from the date of investment and which do not meet the definition of cash equivalents. The deposits are presented according to their terms of deposit.
 
  e.
Inventory:
 
Inventory of telemedicine devices for sale is presented at the lower of cost or net realizable value. Cost is determined using the "first-in, first-out" method.
 
Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.
 
  f.
Financial instruments:
 
  1.
Financial assets:
 
Financial assets are measured upon initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.
 
F - 13

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
Equity instruments and other financial assets held for trading:
 
Investments in equity instruments do not meet the above criteria and accordingly are measured at fair value through profit or loss.
 
Other financial assets held for trading, including derivatives, are measured at fair value through profit or loss unless they are designated as effective hedging instruments.
 
  2.
Impairment of financial assets:
 
The Company evaluates at the end of each reporting period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss. The Company has short-term financial assets such as trade receivables in respect of which the Company applies a simplified approach and measures the loss allowance in an amount equal to the lifetime expected credit loss.
 
  3.
Financial liabilities:
 
  a)
Financial liabilities measured at amortized cost:
 
Financial liabilities are initially recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.
 
After initial recognition, the Company measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair value through profit or loss.
 
F - 14

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
  b)
Financial liabilities measured at fair value through profit or loss:
 
Financial liabilities measured at fair value through profit or loss include liabilities held for trading, including derivatives, and financial liabilities that meet certain criteria which are designated upon initial recognition to fair value through profit or loss.
 
At initial recognition, the Company measures these financial liabilities at fair value. Transaction costs are recognized in profit or loss.
 
After initial recognition, changes in fair value are recognized in profit or loss.
 
  4.
Issue of a unit of securities:
 
The issue of a unit of securities involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.
 
  g.
Leases:
 
The Group accounts for a contract as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.
 
  1.
The Group as a lessee:
 
For leases in which the Group is the lessee, the Group recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Group has elected to recognize the lease payments as an expense in profit or loss on a straight-line basis over the lease term. In measuring the lease liability, the Group has elected to apply the practical expedient in the Standard and does not separate the lease components from the non-lease components (such as management and maintenance services, etc.) included in a single contract.
 
F - 15

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
Leases which entitle employees to a company car as part of their employment terms are accounted for as employee benefits in accordance with the provisions of IAS 19 and not as subleases.
 
On the commencement date, the lease liability includes all unpaid lease payments (excluding variable lease payments) discounted at the interest rate implicit in the lease, if that rate can be readily determined, or otherwise using the Group 's incremental borrowing rate. After the commencement date, the Group measures the lease liability using the effective interest rate method.
 
On the commencement date, the right-of-use asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful life and the lease term.
 
Following are the periods of depreciation of the right-of-use assets by class of underlying asset:
 
   
Years
 
Mainly
         
Motor vehicles
 
1.5 - 3.5
 
3
Buildings
 
4 - 11
 
10
 
The Group tests for impairment of the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36.
 
  2.
Variable lease payments that depend on an index:
 
On the commencement date, the Group uses the index rate prevailing on the commencement date to calculate the future lease payments.
 
For leases in which the Group is the lessee, the aggregate changes in future lease payments resulting from a change in the index are discounted (without a change in the discount rate applicable to the lease liability) and recorded as an adjustment of the lease liability and the right-of-use asset, only when there is a change in the cash flows resulting from the change in the index (that is, when the adjustment to the lease payments takes effect).
 
F - 16

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
 
3.
Lease extension and termination options:
 
A non-cancellable lease term includes both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.
 
In the event of any change in the expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Group remeasures the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized in profit or loss.
 
  4.
Lease modifications:
 
If a lease modification does not reduce the scope of the lease and does not result in a separate lease, the Group remeasures the lease liability based on the modified lease terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset.
 
If a lease modification reduces the scope of the lease, the Group recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use asset and the lease liability. The Group subsequently remeasures the carrying amount of the lease liability according to the revised lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset.
 
  h.
Business combinations and goodwill:
 
Business combinations are accounted for by applying the acquisition method. The cost of the acquisition is measured at the fair value of the consideration transferred on the date of acquisition with the addition of non-controlling interests in the acquiree.
 
Direct acquisition costs are carried to the income statement as incurred.
 
A put option granted by the Group to non-controlling interests and concurrently a call option received by the Group from the non-controlling interests that can be settled in cash or by the delivery of a variable number of shares are accounted for as a derivative financial liability or asset presented on a net basis and measured at fair value. The non-controlling interests continue to be recognized in equity until the put or call options are exercised.
 
Goodwill is initially measured at cost which represents the excess of the acquisition consideration and the amount of non-controlling interests over the net identifiable assets acquired and liabilities assumed.
 
F - 17

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For purposes of evaluation of impairment of goodwill, goodwill purchased in a business combination is evaluated and attributed to the cash-generating units to which it had been allocated.
 
  i.
Property and equipment:
 
Property and equipment are measured at cost, including directly attributable costs, less accumulated depreciation and accumulated impairment losses.
 
Depreciation is calculated at constant annual rates on a straight-line basis over the useful life of the assets at annual rates as follows:
 
   
%
   
         
Medical equipment
 
10 - 15
 
(mainly 15%)
Motor vehicles and ambulances
 
15 - 20
 
(mainly 20%)
Office furniture and equipment
 
6 - 7
 
(mainly 6%)
Computers and peripheral equipment
 
15 - 33
 
(mainly 20%)
Leasehold improvements
 
see below
   
Telemedicine devices on loan to customers
 
10
   
 
Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including any extension option held by the Group and intended to be exercised) and the expected life of the improvement.
 
  j.
Intangible assets:
 
Intangible assets acquired in a business combination are included at fair value at the acquisition date. After initial recognition, intangible assets are carried at their cost less any accumulated amortization and any accumulated impairment losses. Expenditures relating to internally generated intangible assets, excluding capitalized development costs, are recognized in profit or loss when incurred.
 
F - 18

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
According to management's assessment, intangible assets have a finite useful life. The assets are amortized over their useful life using the straight-line method and reviewed for impairment whenever there is an indication that the asset may be impaired.
 
The useful life of intangible assets is as follows:
 
   
Years
     
Developments costs
 
5 - 10
Computer software
 
5
Contracts
 
6.75
Customer relations
 
10
Information technology
 
6
 
Research and development expenditures:
 
Research expenditures are recognized in profit or loss when incurred. An intangible asset arising from development or from the development phase of an internal project is recognized if the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale; the Company's intention to complete the intangible asset and use or sell it; the Company's ability to use or sell the intangible asset; how the intangible asset will generate future economic benefits; the availability of adequate technical, financial and other resources to complete the intangible asset; and the Company's ability to measure reliably the expenditure attributable to the intangible asset during its development.
 
The asset is measured at cost less any accumulated amortization and any accumulated impairment losses. Costs recognized as intangible assets include directly attributable costs of preparing the asset for its intended use such as cost of materials, direct labor costs and overhead.
 
Amortization of the asset begins when development is complete and the asset is available for use. As for the testing of impairment, see l below.

 

F - 19

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
  k.
Impairment of non-financial assets:
 
The Group evaluates the need to record an impairment of the carrying amount of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable. If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognized in profit or loss.
 
An impairment loss of an asset, other than goodwill, is reversed only if there have been changes in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognized. Reversal of an impairment loss, as above, shall not be increased above the lower of the carrying amount that would have been determined (net of depreciation or amortization) had no impairment loss been recognized for the asset in prior years and its recoverable amount. The reversal of impairment loss of an asset presented at cost is recognized in profit or loss.
 
The following criteria are applied in assessing impairment of these specific assets:
 
 
1.
Goodwill related to subsidiaries:
 
For the purpose of impairment testing, goodwill acquired in a business combination is allocated, at the acquisition date, to each of the Group's cash-generating units that is expected to benefit from the synergies of the combination.
 
The Company reviews goodwill for impairment once a year or more frequently if events or changes in circumstances indicate that there is impairment.
 
Goodwill is tested for impairment by assessing the recoverable amount of the cash-generating unit (or group of cash-generating units) to which the goodwill has been allocated. An impairment loss is recognized if the recoverable amount of the cash-generating unit (or group of cash-generating units) to which goodwill has been allocated is less than the carrying amount of the cash-generating unit (or group of cash-generating units). Any impairment loss is allocated first to goodwill. Impairment losses recognized for goodwill cannot be reversed in subsequent periods.
 
  2.
Development costs capitalized during the development period:
 
The impairment test is performed annually, on December 31, or more frequently if events or changes in circumstances indicate that there is impairment.

 

F - 20

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
  l.
Taxes on income:
 
Taxes on income in the statement of comprehensive income comprise current and deferred taxes. Current or deferred taxes are recognized in the statement of income except to the extent that the tax arises from items which are recognized directly in other comprehensive income or in equity. In such cases, the tax effect is also recognized in the relevant item.
 
  1.
Current taxes:
 
The current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period as well as adjustments required in connection with the tax liability in respect of previous years.
 
  2.
Deferred taxes:
 
Deferred taxes are computed in respect of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.
 
Deferred taxes are measured at the tax rates that are expected to apply to the period when the taxes are reversed in profit or loss, comprehensive income or equity, based on tax laws that have been enacted or substantively enacted by the end of the reporting period. Deferred taxes in profit or loss represent the changes in the carrying amount of deferred tax balances during the reporting period, excluding changes attributable to items recognized outside of profit or loss.
 
Deferred tax assets are reviewed at the end of each reporting period and reduced to the extent that it is not probable that they will be utilized. Also, temporary differences (such as carry forward losses) for which deferred tax assets have not been recognized are reassessed and deferred tax assets are recognized to the extent that their recoverability has become probable. Any resulting reduction or reversal is recognized in the line item, "taxes on income". Taxes that would apply in the event of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends does not involve an additional tax liability or since it is the Group's policy not to initiate distribution of dividends that triggers an additional tax liability.

 

F - 21

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
 
m.
Share-based payment transactions:
 
The Company's employees are entitled to remuneration in the form of equity-settled share-based payment transactions (see details in Note 22).
 
Equity-settled transactions:
 
The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using a standard option pricing model, additional details are given in Note 22d
 
No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.
 
If the Group modifies the conditions on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.

 

F - 22

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
  n.
Employee benefit liabilities:
 
The Group has several employee benefit plans:
 
  1.
Short-term employee benefits:
 
Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized when the Group has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made. The short-term employee benefit liability in the statement of financial position is measured on an undiscounted basis.
 
  2.
Post-employment benefits:
 
The plans are normally financed by contributions to insurance companies or funds and classified as defined contribution plans or as defined benefit plans.
 
  a)
Defined contribution plans:
 
The Group has defined contribution plans pursuant to section 14 to the Severance Pay Law under which the Group pays fixed contributions and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods.
 
Contributions to a defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed concurrently with performance of the employee's services.
 
  b)
Defined benefit plans:
 
The Group operates a defined benefit plan in respect of severance pay pursuant to the Severance Pay Law in Israel. According to the Law, employees are entitled to severance pay upon dismissal or retirement. The liability for termination of employee-employer relation is measured using the projected unit credit method. The actuarial assumptions include rates of employee turnover and future salary increases based on the estimated timing of payment. The amounts are presented based on discounted expected future cash flows using a discount rate determined by reference to market yields at the reporting date on high quality corporate bonds that are linked to the Consumer Price Index with term of the benefit obligation.
 
F - 23

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
In respect of its severance pay obligation to certain of its employees, the Group makes current deposits in pension funds and insurance companies ("the plan assets"). Plan assets comprise assets held by a long-term employee benefit fund or qualifying insurance policies. Plan assets are not available to the Group's own creditors and cannot be returned directly to the Group.
 
The liability for employee benefits presented in the balance sheet reflects the present value of the defined benefit obligation less the fair value of the plan assets (see details in Note 18).
 
Remeasurements of the net liability are recognized as other comprehensive income (loss) in the period in which they occur.
 
  o.
Revenue recognition:
 
Revenue recognition:
 
Revenue from contracts with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf of third parties (such as taxes).
 
F - 24

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
Revenue from rendering of services:
 
Revenue from rendering of services is recognized over time, during the period the customer simultaneously receives and consumes the benefits provided by the Company's performance. Revenue is recognized in the reporting periods in which the services are rendered. Revenues from the installation fees are recognized as the installation is performed.
 
The Company charges its customers based on payment terms agreed upon in specific agreements. When payments are made before or after the service is performed, the Company recognizes the resulting contract asset (income receivable) or liability (deferred revenues) and recognizes revenue in profit or loss when the work is performed. The Company has elected to apply the practical expedient allowed by the Standard and does not separate the financing component in transactions in which the period between receipt of the advance payment and the performance of the service is expected to be less than one year.
 
Revenue from the sale of telemedicine devices:
 
Revenue from sale of telemedicine devices is recognized in profit or loss at the point in time when the control of the goods is transferred to the customer, generally upon delivery of the goods to the customer.
 
Costs of obtaining a contract:
 
Costs incurred in obtaining subscription contracts which would not have been incurred if the contract had not been obtained (incremental costs) and which the Company expects to recover are recognized as an asset (prepaid expenses). The asset is amortized over the estimated average service period of subscriber contracts, adjusted for cancellations.
 
  p.
Interest income:
 
Interest income on financial assets is recognized as it accrues using the effective interest method.
 
  q.
Earnings per share:
 
Basic earnings per share are calculated by dividing the net income attributable to equity holders of the Company by the weighted number of Ordinary shares outstanding during the period.
 
For diluted earnings per share, the weighted average of shares outstanding is adjusted, assuming conversion of potential dilutive shares (employee options), except when such conversion has an anti-dilutive effect.

 

F - 25

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
 
r.
Fair value measurement:
 
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
 
Fair value measurement is based on the assumption that the transaction will take place in the asset's or the liability's principal market, or in the absence of a principal market, in the most advantageous market.
 
The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.
 
F - 26

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
Fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.
 
The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.
 
All assets and liabilities measured at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level input that is significant to the entire fair value measurement:
 
Level 1
-
quoted prices (unadjusted) in active markets for identical assets or liabilities.
     
Level 2
-
inputs other than quoted prices included within Level 1 that are observable directly or indirectly.
     
Level 3
-
inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).
 
  s.
Exchange rates and linkage basis:
 
Data regarding Israeli CPI and exchange rates of the U.S. dollar, the Euro and the Swiss Franc in relation to the NIS is as follows:
 
   
Israeli
   
Exchange rate of
 
For the year ended
 
CPI
   
   
U.S. $
   
CHF
 
   
Points *)
   
NIS
 
                           
December 31, 2023
   
248.6
     
4.01
     
3.63
     
4.31
 
December 31, 2022
   
241.4
     
3.75
     
3.52
     
3.82
 
December 31, 2021
   
229.4
     
3.52
     
3.11
     
3.40
 
                                 
Change during the year
 
%
 
                                 
2023
   
3
     
6. 9
     
3.1
     
12.8
 
2022
   
5.2
     
6.5
     
13.2
     
12.4
 
2021     2.8       (10.7 )     (3.1 )     (6.8 )
 
  *)
The index on an average basis of 1993 = 100.

 

F - 27

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
  t.
Changes in accounting policies - initial application of new financial reporting and accounting standards and amendments to existing financial reporting and accounting standards:
 
  1.
Amendment to IAS 8, "Accounting Policies, Changes to Accounting Estimates and Errors":
 
In February 2021, the IASB issued an amendment to IAS 8, "Accounting Policies, Changes to Accounting Estimates and Errors" ("the Amendment"), in which it introduces a new definition of "accounting estimates".
 
Accounting estimates are defined as "monetary amounts in financial statements that are subject to measurement uncertainty". The Amendment clarifies the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors.
 
The Amendment is applied prospectively for annual reporting periods beginning on January 1, 2023 and is applicable to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period.
 
The application of the Amendment did not have a material impact on the Company's consolidated financial statements.
 
  2.
Amendment to IAS 12, "Income Taxes":
 
In May 2021, the IASB issued an amendment to IAS 12, "Income Taxes" ("IAS 12"), which narrows the scope of the initial recognition exception under IAS 12.15 and IAS 12.24 ("the Amendment").
 
According to the recognition guidelines of deferred tax assets and liabilities, IAS 12 excludes recognition of deferred tax assets and liabilities in respect of certain temporary differences arising from the initial recognition of certain transactions. This exception is referred to as the "initial recognition exception". The Amendment narrows the scope of the initial recognition exception and clarifies that it does not apply to the recognition of deferred tax assets and liabilities arising from transactions that are not a business combination and that give rise to equal taxable and deductible temporary differences, even if they meet the other criteria of the initial recognition exception.
 
The Amendment applies for annual reporting periods beginning on January 1, 2023. In relation to leases and decommissioning obligations, the Amendment is applied commencing from the earliest reporting period presented in the financial statements in which the Amendment is initially applied. The cumulative effect of the initial application of the Amendment is recognized as an adjustment to the opening balance of retained earnings (or another component of equity, as appropriate) at that date.
 
The application of the Amendment did not have a material impact on the Company's consolidated financial statements.
 
F - 28

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 2:-
ACCOUNTING POLICIES (Cont.)
   
  3.
Amendment to IAS 1, "Disclosure of Accounting Policies":
 
In February 2021, the IASB issued an amendment to IAS 1, "Presentation of Financial Statements" ("the Amendment"), which replaces the requirement to disclose 'significant' accounting policies with a requirement to disclose 'material' accounting policies. One of the main reasons for the Amendment is the absence of a definition of the term 'significant' in IFRS whereas the term 'material' is defined in several standards and particularly in IAS 1.
 
The Amendment is applicable for annual periods beginning on January 1, 2023.
 
The application of the above Amendment had an effect on the disclosures of the Company's accounting policies, but did not affect the measurement, recognition or presentation of any items in the Company's consolidated financial statements.
 
  4.
Amendment to IAS 12, "Income Taxes":
 
In May 2023, the IASB issued "International Tax Reform—Pillar Two Model Rules – Amendment to IAS 12" ("the Amendment") to clarify the application of IAS 12, "Income Taxes", to income taxes arising from tax law enacted or substantively enacted to implement the Organisation for Economic Co-operation and Development (OECD)/G20 Inclusive Framework on Base Erosion and Profit Shifting (BEPS) Pillar Two model rules (Pillar Two income taxes).
 
The Amendment introduces:
 
  (a)
A mandatory temporary exception from the application of IAS 12 regarding recognition and disclosure of deferred tax assets and liabilities arising from the implementation of the Pillar Two model rules; and
 
  (b)
Disclosure requirements for international entities affected by the international tax reform.
 
The mandatory temporary exception in (a) above – the use of which is required to be disclosed – applies immediately. The remaining disclosure requirements apply for annual reporting periods beginning on January 1, 2023.
 
The application of the Amendment did not have any impact on the Company's consolidated financial statements since the International Tax Reform does not apply to the Group whose annual revenues are less than € 750 million.

 

NOTE 3:-
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS
 
Significant accounting judgments, estimates and assumptions used in the preparation of the financial statements:
 
  a.
Judgments:
 
In the process of applying the significant accounting policies, the Group has made the following judgments which have the most significant effect on the amounts recognized in the financial statements:
 
  -
Capitalization of development costs
 
Development costs are capitalized in accordance with the accounting policy described in Note 2k, which is based on the criteria set forth in IAS 38. The assessment of whether development costs meet the criteria for recognition as an intangible asset requires significant management judgment, in particular with respect to technical feasibility, generation of future economic benefits, and ability to measure reliably the costs attributable to the intangible asset.
 
F - 29

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 3:-
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS (Cont.)
   
  b.
Estimates and assumptions:
 
The preparation of these financial statements requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported amounts of assets, liabilities, revenues and expenses. In determining its accounting estimates, management relies on past experience, various underlying facts, external factors and reasonable assumptions, based on the relevant circumstances. These estimates and underlying assumptions are reviewed regularly. Changes in accounting estimates are reported in the period of the change in estimate.
 
The key assumptions made in the financial statements concerning uncertainties at the end of the reporting period and the critical estimates computed by the Group that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.
 
  -
Impairment of goodwill:
 
The Group reviews goodwill for impairment at least once a year. This requires management to make an estimate of the projected future cash flows from the continuing use of the cash-generating unit to which the goodwill is allocated and also to choose a suitable discount rate for those cash flows. Further details are given in Note 11.
 
  -
Deferred tax assets:
 
Deferred tax assets are recognized for unused carry forward tax losses and temporary differences to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and level of future taxable profits together with future tax planning strategies. Further details are given in Notes 2m and 19c.

 

F - 30

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 4:-
DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION
 
Amendment to IAS 1, "Presentation of Financial Statements":
 
In January 2020, the IASB issued an amendment to IAS 1, "Presentation of Financial Statements" regarding the criteria for determining the classification of liabilities as current or non-current ("the Original Amendment"). In October 2022, the IASB issued a subsequent amendment ("the Subsequent Amendment").
 
According to the Subsequent Amendment:
 
 
Only financial covenants with which an entity must comply on or before the reporting date will affect a liability's classification as current or non-current.
 
 
In respect of a liability for which compliance with financial covenants is to be evaluated within twelve months from the reporting date, disclosure is required to enable users of the financial statements to assess the risks related to that liability. The Subsequent Amendment requires disclosure of the carrying amount of the liability, information about the financial covenants, and the facts and circumstances at the end of the reporting period that could result in the conclusion that the entity may have difficulty in complying with the financial covenants.
 
According to the Original Amendment, the conversion option of a liability affects the classification of the entire liability as current or non-current unless the conversion component is an equity instrument.
 
The Original Amendment and Subsequent Amendment are both effective for annual periods beginning on or after January 1, 2024 and must be applied retrospectively. Early adoption is permitted.
 
The above Amendments are not expected to have a material impact on the Company's consolidated financial statements.

 

F - 31

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 5:-
CASH AND CASH EQUIVALENTS
 
   
December 31,
 
   
2023
   
2022
 
             
Cash in banks (mainly in USD, 2022 – in NIS)
   
6,271
     
4,377
 
Short-term deposits (in NIS)
   
422
     
106
 
                 
     
6,693
     
4,483
 
 
NOTE 6:-
SHORT-TERM INVESTMENTS
 
   
December 31,
 
   
2023
   
2022
 
Marketable securities:
           
             
Financial assets at fair value through profit or loss (mainly in USD)
           
Corporate bonds
   
4,181
     
4,033
 
Government bonds and loans
   
784
     
392
 
Shares
   
638
     
784
 
Exchange Traded Funds
   
3,375
     
3,308
 
                 
     
8,978
     
8,517
 
                 
Short-term deposits
   
10,579
     
5,700
 
                 
     
19,557
     
14,217
 

 

F - 32

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 7:-
TRADE RECEIVABLES
   
December 31,
 
   
2023
   
2022
 
             
Accounts receivable (1)
   
8,419
     
7,596
 
Other
   
138
     
201
 
Allowance for doubtful accounts
   
-
     
-
 
                 
     
8,557
     
7,797
 
 
  (1)
The terms of billed accounts receivable are generally 30-60 days. As of December 31, 2023 and 2022, there were no material billed receivables that were past due.

 

NOTE 8:-
PREPAID EXPENSES
 
Amortization of prepaid expenses (costs of obtaining contracts – see Note 2o) amounted to $731 in the year ended December 31, 2023 (2022- $788).

 

NOTE 9:-
OTHER ACCOUNTS RECEIVABLE
 
   
December 31,
 
   
2023
   
2022
 
             
Interest receivable
   
53
     
190
 
Government authorities
   
298
     
616
 
Advances to supplies
   
328
     
54
 
Prepaid expenses
   
552
     
469
 
Others
   
561
     
583
 
                 
     
1,792
     
1,912
 

 

F - 33

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 10:-
PROPERTY AND EQUIPMENT
 
   
Computers and
peripheral equipment
   
Medical equipment
   
Office
furniture and equipment
   
Motor
vehicles and ambulances
   
Leasehold improvements
   
Devices
on loan
   
Total
 
Cost:
                                         
                                           
Balance as of January 1, 2022
   
18,334
     
6,150
     
2,350
     
2,498
     
3,777
     
46,570
     
79,679
 
Additions during the year
   
479
     
31
     
153
     
4
     
598
     
395
     
1,660
 
Disposals during the year
   
(4
)
   
-
     
(64
)
   
(2
)
   
-
     
(1,106
)
   
(1,176
)
Transfer from inventory, net
   
-
     
-
     
-
     
-
     
-
     
564
     
564
 
Currency translation differences
   
(1,953
)
   
(715
)
   
(241
)
   
(290
)
   
(445
)
   
(5,232
)
   
(8,876
)
                                                         
Balance as of December 31, 2022
   
16,856
     
5,466
     
2,198
     
2,210
     
3,930
     
41,191
     
71,851
 
Additions during the year
   
699
     
7
     
66
     
181
     
127
     
209
     
1,289
 
Disposals during the year
   
(3,275
)
   
-
     
(366
)
   
(46
)
   
-
     
(4,497
)
   
(8,184
)
Transfer from inventory, net
   
-
     
-
     
-
     
-
     
-
     
226
     
226
 
Currency translation differences
   
(348
)
   
(165
)
   
(33
)
   
(60
)
   
(106
)
   
(1,126
)
   
(1,838
)
                                                         
Balance as of December 31, 2023
   
13,932
     
5,308
     
1,865
     
2,285
     
3,951
     
36,003
     
63,344
 
                                                         
Accumulated depreciation:
                                                       
                                                         
Balance as of January 1, 2022
   
17,292
     
6,018
     
1,756
     
2,139
     
3,152
     
45,297
     
75,654
 
Additions during the year
   
385
     
42
     
100
     
36
     
158
     
388
     
1,109
 
Disposals during the year
   
(4
)
   
-
     
(64
)
   
(2
)
   
-
     
(1,054
)
   
(1,124
)
Transfer from inventory, net
   
-
     
-
     
-
     
-
     
-
     
7
     
7
 
Currency translation differences
   
(1,852
)
   
(701
)
   
(181
)
   
(250
)
   
(364
)
   
(5,099
)
   
(8,447
)
                                                         
Balance as of December 31, 2022
   
15,821
     
5,359
     
1,611
     
1,923
     
2,946
     
39,539
     
67,199
 
Additions during the year
   
329
     
26
     
104
     
60
     
139
     
300
     
958
 
Disposals during the year
   
(3,113
)
   
-
     
(325
)
   
(46
)
   
-
     
(4,422
)
   
(7,906
)
Currency translation differences
   
(344
)
   
(160
)
   
(27
)
   
(59
)
   
(84
)
   
(1,125
)
   
(1,799
)
                                                         
Balance as of December 31, 2023
   
12,693
     
5,225
     
1,363
     
1,878
     
3,001
     
34,292
     
58,452
 
                                                         
Depreciated cost as of December 31, 2023
   
1,239
     
83
     
502
     
407
     
950
     
1,711
     
4,892
 
                                                         
Depreciated cost as of December 31, 2022
   
1,035
     
107
     
587
     
287
     
984
     
1,652
     
4,652
 

 

F - 34

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 11:-
GOODWILL AND INTANGIBLE ASSETS, NET
 
   
Development costs
   
Contracts and
others
   
Customer relations
   
Information Technology
   
Total
other intangible assets
   
Goodwill
(1)
 
                                     
As of January 1, 2023, net of accumulated amortization
   
8,274
     
-
     
11,737
     
414
     
20,425
     
33,745
 
Additions during the year
   
4,203
     
-
     
-
     
-
     
4,203
     
-
 
Amortization during the year
   
(2,770
)
   
-
     
(1,309
)
   
(104
)
   
(4,183
)
   
-
 
Currency translation differences
   
171
     
-
     
(372
)
   
13
     
(188
)
   
(780
)
                                                 
As of December 31, 2023, net of accumulated amortization
   
9,878
     
-
     
10,056
     
323
     
20,257
     
32,965
 
                                                 
As of December 31, 2023:
                                               
                                                 
Cost
   
44,131
     
7,766
     
16,215
     
644
     
68,756
     
32,965
 
Accumulated amortization
   
(34,253
)
   
(7,766
)
   
(6,159
)
   
(321
)
   
(48,499
)
   
-
 
                                                 
Net carrying amount
   
9,878
     
-
     
10,056
     
323
     
20,257
     
32,965
 
 
   
Development costs
   
Contracts and
others
   
Customer relations
   
Information Technology
   
Total
other intangible assets
   
Goodwill
(1)
 
                                     
As of January 1, 2022, net of accumulated amortization
   
5,309
     
-
     
14,929
     
549
     
20,787
     
37,508
 
Additions during the year
   
5,243
     
-
     
-
     
-
     
5,243
     
-
 
Amortization during the year
   
(1,829
)
   
-
     
(1,526
)
   
(102
)
   
(3,457
)
   
-
 
PPA adjustment (see Note 5)
   
-
     
-
     
-
     
-
     
-
     
407
 
Currency translation differences
   
(449
)
   
-
     
(1,666
)
   
(33
)
   
(2,148
)
   
(4,170
)
                                                 
As of December 31, 2022, net of accumulated amortization
   
8,274
     
-
     
11,737
     
414
     
20,425
     
33,745
 
                                                 
As of December 31, 2022:
                                               
                                                 
Cost
   
46,961
     
7,488
     
16,510
     
621
     
71,580
     
33,745
 
Accumulated amortization
   
(38,687
)
   
(7,488
)
   
(4,773
)
   
(207
)
   
(51,155
)
   
-
 
                                                 
Net carrying amount
   
8,274
     
-
     
11,737
     
414
     
20,425
     
33,745
 
 
  (1)
The recoverable amount of the cash generating units to which the goodwill mainly relates has been determined based on a value in use calculation using cash flow projections from financial budgets approved by senior management covering a five-year period.

 

F - 35

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 11:-
GOODWILL AND INTANGIBLE ASSETS, NET (Cont.)
   
The carrying amount of the goodwill has been allocated to the following cash generating units:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
2,954
     
3,044
 
Israel – Mediton
   
16,111
     
16,606
 
Germany
   
13,900
     
14,095
 
                 
     
32,965
     
33,745
 
 
The recoverable amount of each of the cash generating units has been determined based on a value in use calculation using cash flow projections from financial budgets and forecasts approved by senior management covering a five-year period. The key assumptions used in the value in use calculations are the (i) discount rate (ii) growth rate of revenues in the 5 year forecast period subsequent to end of the reporting period, and (iii) growth rates used to extrapolate cash flows beyond the forecast period.
 
The pre-tax discount rate applied to cash flow projections are as follows:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
20.7
%
   
19.1
%
Israel – Mediton
   
19.4
%
   
18.3
%
Germany
   
20.5
%
   
16.8
%
 
The average growth rate of revenues in the 5 year forecast period subsequent to the end of the reporting period, are as follows:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
3.2
%
   
4
%
Israel – Mediton
   
4.9
%
   
5.4
%
Germany
   
11.3
%
   
13.8
%

 

F - 36

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 11:-
GOODWILL AND INTANGIBLE ASSETS, NET (Cont.)
   
The cash flows beyond the 5-year period are extrapolated using the following growth rates:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
3.2
%
   
3.2
%
Israel – Mediton
   
3.2
%
   
3.2
%
Germany
   
3
%
   
3
%
 
The recoverable amounts, based on value in use, of each of the cash generating units exceeds their carrying amounts.
 
As of December 31, 2023,, management of the Group believes that no reasonably possible changes in any of the above key assumptions would cause the carrying amount of the CGU Telemedicine to materially exceed its recoverable amount.
 
As of December 31, 2023, the estimated recoverable amount of the CGU Germany exceeds its carrying amount by $0.8 million. The changes in the following assumptions used in the value in use calculations would result in the carrying amount to equal the recoverable amount:
 
 
Pre-tax discount rate of 21.0%.
 
Long term growth rate of 2.2 % or lower
 
Reduction in the annual growth rate in fiscal years 2025-2028 of -1.9%.
 
As of December 31, 2023, the estimated recoverable amount of the CGU Mediton exceeds its carrying amount by $3.0 million. The change in the following assumption used in the value in use calculations would result in the carrying amount to equal the recoverable amount:
 
 
Pre-tax discount rate of 20.9%.
 
Long term growth rate of 1.4 % or lower

 

F - 37

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 12:-
LEASES
 
Disclosures for leases in which the Company acts as lessee:
 
The Company has entered into leases of buildings and motor vehicles which are used for the Company's operations.
 
Leases of buildings have lease terms of between 4 and 11 years whereas leases of vehicles have lease terms of 3 years.
 
Some of the leases entered into by the Company include extension and/or termination options and variable lease payments.
 
During 2023, the Group reduced the scope of the lease in Germany. In addition modified the term of the lease in Germany such that the contract will end in 2027 instead of 2029 and the monthly rent decreased. As a result of this the Group recognized a capital gain of $399.
 
  a.
Information on leases:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Interest expense on lease liabilities
   
343
     
361
     
378
 
Expenses relating to short-term leases
   
-
     
25
     
25
 
Total cash outflow for leases
   
2,992
     
2,808
     
2,546
 
 
  b
Lease extension and termination options:
 
The Company has leases that include extension and termination options. These options provide flexibility in managing the leased assets and align with the Company's business needs.
 
The Company exercises significant judgement in deciding whether it is reasonably certain that the extension and termination options will be exercised.
 
The Company generally includes in the lease term the exercise of extension options existing in the lease agreements when it is reasonably certain that the extension option will be exercised. In these leases, the Company usually exercises the extension option to avoid a significant adverse impact to its operating activities in the event that an alternative asset is not available immediately upon termination of the noncancelable lease period.
 
In leases of motor vehicles, the Company does not include in the lease term the exercise of extension options since the Company does not ordinarily exercise options that extend the lease period beyond 5 years.
 
Lease terms that include termination options will include the period covered by the termination option when it is reasonably certain that the termination option will not be exercised.
 
F - 38

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 12:-
LEASES (Cont.)
   
Following are details of potential future undiscounted lease payments for periods covered by extension or termination options that were not included in the measurement of the Company's lease liabilities:
 
   
More than 5 years
 
   
December 31,
 
   
2023
   
2022
 
Lease payments applicable in extension option periods which as of the end of the reporting period are not reasonably certain to be exercised
   
2,479
     
2,472
 
 
 
c.
Disclosures in respect of right-of-use assets:
 
   
Buildings
   
Motor vehicles
   
Total
 
Cost:
                 
                   
Balance as of January 1, 2023
   
15,844
     
1,449
     
17,293
 
Additions during the year:
                       
New leases
   
663
     
634
     
1,297
 
Adjustments for indexation
   
145
     
23
     
168
 
Disposals
   
(6,198
)
   
(52
)
   
(6,250
)
Currency translation differences
   
(22
)
   
(18
)
   
(40
)
                         
Balance as of December 31, 2023
   
10,432
     
2,036
     
12,468
 
                         
Accumulated depreciation:
                       
                         
Balance as of January 1, 2023
   
5,258
     
997
     
6,255
 
Additions during the year:
                       
Depreciation and amortization
   
2,214
     
337
     
2,551
 
Disposals
   
(3,520
)
   
-
     
(3,520
)
Currency translation differences
   
(19
)
   
(13
)
   
(32
)
                         
Balance as of December 31, 2023
   
3,933
     
1,321
     
5,254
 
                         
Depreciated cost at December 31, 2023
   
6,499
     
715
     
7,214
 

 

F - 39

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 12:-
LEASES (Cont.)
   
   
Buildings
   
Motor vehicles
   
Total
 
Cost:
                 
                   
Balance as of January 1, 2022
   
16,089
     
1,078
     
17,167
 
Additions during the year:
                       
New leases
   
950
     
475
     
1,425
 
Adjustments for indexation
   
266
     
30
     
296
 
Disposals
   
(55
)
   
-
     
(55
)
Currency translation differences
   
(1,406
)
   
(134
)
   
(1,540
)
                         
Balance as of December 31, 2022
   
15,844
     
1,449
     
17,293
 
                         
Accumulated depreciation:
                       
                         
Balance as of January 1, 2022
   
3,384
     
770
     
4,154
 
Additions during the year:
                       
Depreciation and amortization
   
2,248
     
321
     
2,569
 
Disposals
   
(29
)
   
-
     
(29
)
Currency translation differences
   
(345
)
   
(94
)
   
(439
)
                         
Balance as of December 31, 2022
   
5,258
     
997
     
6,255
 
                         
Depreciated cost at December 31, 2022
   
10,586
     
452
     
11,038
 

 

NOTE 13:-
CREDIT FROM BANKS
 
 
Interest
           
 
rate (1)
 
December 31,
 
 
%
 
2023
   
2022
 
               
Current maturities of long-term loans (see Note 14)
Prime (1)+1.05
   
2,160
     
2,169
 
                   
       
2,160
     
2,169
 
 
  (1)
The Prime rate as of December 31, 2023 – 6.25% (December 31, 2022 – 4.75%).

 

F - 40

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 14:-
LONG-TERM LOANS
 
  a.
On August 29, 2021, the Company signed an agreement with a bank in Israel to obtain a long-term loan in the amount of NIS 59 million (approximately $18,000) for a period of 7 years and 9 months. The loan is denominated in NIS and bears an annual interest rate of prime + 1.05% (2.65% as of the signing date). The loan will be repaid in 28 quarterly installments following an initial moratorium period of 9 months.
 
The loan agreement includes certain financial covenants related to the Company's Israeli operations, as follows: (i) tangible equity of at least NIS 40 million; (ii) tangible equity to total tangible assets of at least 40%; and (iii) net debt to EBITDA of 3.5 at the maximum. As of December 31, 2023 the Company is in compliance with these covenants.
 
  b.
Composition:
 
   
December 31,
 
   
2023
   
2022
 
             
Long-term loan
   
12,620
     
15,177
 
Less – current maturities
   
2,160
     
2,169
 
                 
Balance
   
10,460
     
13,008
 

 

NOTE 15:-
DEFERRED REVENUES
 
Deferred revenues are in respect of contracts in which the period between receipt of the advance payment and the performance of the service is expected to be less than one year.

 

NOTE 16:-
OTHER PAYABLES
 
   
December 31,
 
   
2023
   
2022
 
             
Employees and payroll accruals
   
4,376
     
4,562
 
Accrued expenses
   
2,304
     
2,090
 
Liability for underwriter – see Note 17
   
-
     
1,131
 
VAT to customers and suppliers
   
-
     
399
 
Government authorities
   
754
     
640
 
Accruals restructuring
   
686
     
-
 
Other
   
416
     
416
 
                 
     
8,536
     
9,238
 

 

F - 41

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 17:-
FINANCIAL INSTRUMENTS
 
Financial assets and liabilities:
 
   
Carrying amount
 
   
December 31,
 
   
2023
   
2022
 
Financial assets at amortized cost:
           
             
Cash and cash equivalents
   
6,693
     
4,483
 
Short term deposits
   
10,579
     
5,700
 
Trade receivables
   
8,557
     
7,797
 
Other accounts receivable
   
1,792
     
1,912
 
Long term deposits
   
328
     
423
 
                 
Total
   
27,949
     
20,315
 
                 
Financial assets at fair value through profit or loss:
               
                 
Call option from non-controlling interests
   
147
     
245
 
Short term investments
   
8,978
     
8,517
 
                 
Total
   
9,125
     
8,762
 
                 
Financial liabilities at amortized cost:
               
                 
Credit from banks and others
   
2,160
     
2,169
 
Trade payables
   
3,884
     
3,757
 
Other payables
   
8,536
     
8,110
 
Loans from banks
   
10,460
     
13,008
 
Lease liabilities
   
7,239
     
11,565
 
                 
Total
   
32,279
     
38,609
 
                 
Financial liabilities at fair value through profit or loss:
               
                 
Liability for share options
   
-
     
7,164
 
Other payables - liability to underwriters
   
-
     
1,131
 
                 
Total
   
-
     
8,295
 
 
The main risks arising from the Group's financial instruments are credit risk, foreign currency risk, interest rate risk, market risk and liquidity risk. The Board of Directors reviews and agrees on policies for managing each of these risks, which are summarized below.
 
F - 42

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 17:-
FINANCIAL INSTRUMENTS (Cont.)
   
  a.
Concentration of credit risks:
 
Financial instruments that potentially subject the Group to concentrations of credit risk consist principally of cash, cash equivalents, and trade receivables. Cash and cash equivalents are deposited with major banks. Management believes that the financial institutions that hold the Group's investments are financially sound, and, accordingly, minimal credit risk exists with respect to these investments.
 
The Group's trade receivables mainly derived from sales to customers in Germany and Israel. The Group has adopted credit policies and standards intended to accommodate industry growth and inherent risk. Management believes that credit risks are moderated by the diversity of its end customers. The Group performs ongoing credit evaluations of its customers' financial condition and requires collateral as deemed necessary. An estimate for doubtful accounts is made when collection of the full amount is no longer probable.
 
  b.
Foreign currency risk:
 
The Group is subject to foreign exchange risk as it holds cash and cash equivalents and short-term investments in foreign currency as the Group purchases its devices in foreign currency. Group management regularly monitors its foreign exchange risk and attempts to limit such risks by making adequate decisions regarding cash and credit positions.
 
Foreign currency sensitivity analysis:
 
The following table demonstrates the sensitivity test to a reasonably possible change in USD and EUR exchange rates, with all other variables held constant. The impact on the Company's profit before tax is due to changes in the fair value of monetary assets. The Company's exposure to foreign currency changes for all other currencies is immaterial.
 
   
Change in USD rate
   
Effect on profit tax
 
             
2023
   
+5
%
   
(721
)
     
-5
%
   
721
 
                 
2022
   
+5
%
   
(320
)
     
-5
%
   
320
 
 
   
Change in EUR rate
   
Effect on profit tax
 
             
2023
   
+5
%
   
(66
)
     
-5
%
   
66
 
                 
2022
   
+5
%
   
(38
)
     
-5
%
   
38
 

 

F - 43

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 17:-
FINANCIAL INSTRUMENTS (Cont.)
   
  c.
Market risk:
 
The Group has investments in marketable financial instruments that commencing from March 31, 2020 are classified as Financial assets at fair value through profit or loss in respect of which the Group is exposed to risk of fluctuations in the security price that is determined by reference to the quoted market price (level 1 of the fair value hierarchy). As of December 31, 2023, the balance of these investments is $8,978.
 
The following table demonstrates the sensitivity to a reasonably possible change in the market price with all other variables held constant, of the Group's profit before tax (due to changes in the carrying amount of marketable securities).
 
   
Increase/
decrease in price
   
Effect on
profit
before tax
 
             
2023
   
+5
%
   
449
 
     
-5
%
   
(449
)
                 
2022
   
+5
%
   
426
 
     
-5
%
   
(426
)
 
  d.
Fair value of financial instruments not measured at fair value:
 
The carrying amounts of cash and cash equivalents, trade and other receivables, short-term credit from banks, trade payables and other accounts payable approximate their fair value due to the short-term maturity of such instruments. The carrying amount of long-term bank loan approximates the fair value as the interest rate is variable.
 
Management believes that the carrying amount of long-term deposits approximates their fair value.
 
  e.
Interest rate risk:
 
The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's debt obligations with floating interest rates.
 
The effect of reasonably possible increase of 5% of the interest rate on the Group's profit before tax is not material.
 
F - 44

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 17:-
FINANCIAL INSTRUMENTS (Cont.)
   
  f.
Liquidity risk:
 
The Group monitors its risk to a shortage of funds using a recurring liquidity planning tool. This tool considers the maturity of both its financial investments and financial assets and projected cash flows from operations.
 
The Group has long-term lease liabilities repayable in monthly equal installments until June 2032.
 
Total aggregate contractual undiscounted payments including interest amounts to approximately $10,776.
 
The table below summarizes the maturity profile of the Group's financial liabilities based on contractual undiscounted payments (including interest payments):
 
December 31, 2023:
 
   
Less than one year
   
1 to 2 years
   
2 to 3
years
   
3 to 4 years
   
4 to 5 years
   
> 5
years
   
Total
 
                                           
Trade payables
   
3,884
     
-
     
-
     
-
     
-
     
-
     
3,884
 
Accrued expenses
   
2,990
     
-
     
-
     
-
     
-
     
-
     
2,990
 
PUT option (*)
   
-
     
8,225
     
-
     
-
     
-
     
-
     
8,225
 
Lease liabilities
   
2,542
     
2,280
     
1,814
     
1,615
     
1,571
     
953
     
10,775
 
Loans from bank
   
3,023
     
2,920
     
2,816
     
2,710
     
2,600
     
1,258
     
15,327
 
                                                         
     
12,439
     
13,425
     
4,630
     
4,325
     
4,171
     
2,211
     
41,201
 
 
December 31, 2022:
 
   
Less than one year
   
1 to 2 years
   
2 to 3
years
   
3 to 4 years
   
4 to 5 years
   
> 5
years
   
Total
 
                                           
Trade payables
   
3,757
     
-
     
-
     
-
     
-
     
-
     
3,757
 
Accrued expenses
   
2,090
     
-
     
-
     
-
     
-
     
-
     
2,090
 
PUT option (*)
   
-
     
-
     
11,289
     
-
     
-
     
-
     
11,289
 
Liability for underwriter
   
1,131
     
-
     
-
     
-
     
-
     
-
     
1,131
 
Lease liabilities
   
2,478
     
2,294
     
1,932
     
1,726
     
3,608
     
274
     
12,312
 
Loans from bank
   
3,002
     
2,933
     
2,861
     
2,788
     
2,714
     
3,927
     
18,225
 
                                                         
     
12,458
     
5,227
     
16,082
     
4,514
     
6,322
     
4,201
     
48,804
 
 
  (*)
Estimated gross cash outflow assuming that option will be exercised at earliest possible date.

 

F - 45

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 17:-
FINANCIAL INSTRUMENTS (Cont.)
   
  g.
Changes in liabilities arising from financing activities:
 
   
January 1,
2023
   
Cash
flows
   
Foreign
exchange
movement
   
Other
   
December 31, 2023
 
                               
Lease liabilities (including current maturities)
   
11,564
     
(3,048
)
   
(12
)
   
(1,265
)
   
7,239
 
Liability for underwriters
   
1,131
     
(1,124
)
   
(22
)
   
15
     
-
 
Long term bank loan
   
15,176
     
(2,070
)
   
(486
)
   
-
     
12,620
 
                                         
Total liabilities from financing activities
   
27,871
     
(6,241
)
   
(520
)
   
(1,250
)
   
19,859
 
 
   
January 1,
2022
   
Cash
flows
   
Foreign
exchange
movement
   
Other
   
December 31, 2022
 
                               
Lease liabilities (including current maturities)
   
13,530
     
(2,447
)
   
(1,176
)
   
1,657
     
11,564
 
Liability for underwriters
   
1,021
     
-
     
(129
)
   
239
     
1,131
 
Long term bank loan
   
18,971
     
(1,665
)
   
(2,130
)
   
-
     
15,176
 
                                         
Total liabilities from financing activities
   
33,522
     
(4,112
)
   
(3,435
)
   
1,896
     
27,871
 

 

F - 46

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 17:-
FINANCIAL INSTRUMENTS (Cont.)
   
  h.
Fair value:
 
The table below is a comparison between the carrying amount and fair value of the Company's financial instruments that are presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):
 
Reconciliation of fair value measurements that are categorized within Level 3 of the fair value hierarchy in financial instruments:
 
   
Financial instruments
 
   
Liability for share options (*)
   
Liability to underwriters
   
Call (Put) option to non-controlling interests, net
   
Total
 
                         
Balance as of January 1, 2023
   
(7,164
)
   
(1,131
)
   
245
     
(8,050
)
                                 
Issuance of Share Options
                               
Remeasurement recognized in:
                               
Profit (loss)
   
1,801
     
(15
)
   
(89
)
   
1,697
 
Other comprehensive income (loss)
   
30
     
22
     
(9
)
   
43
 
Exercise of Share Options into shares
   
5,333
     
-
     
-
     
5,333
 
Payment
   
-
     
1,124
     
-
     
1,124
 
                                 
As of December 31, 2023
   
-
     
-
     
147
     
147
 
                                 
Presented in balance sheet:
                               
                                 
Put option
   
-
     
-
     
147
     
147
 
 
   
Financial instruments
 
   
Liability for share options (*)
   
Liability to underwriters
   
Call (Put) option to non-controlling interests, net
   
Total
 
                         
Balance as of January 1, 2022
   
(17,220
)
   
(1,021
)
   
(67
)
   
(18,308
)
                                 
Issuance of Share Options
                               
Remeasurement recognized in:
                               
Profit (loss)
   
7,423
     
(240
)
   
320
     
7,503
 
Other comprehensive income (loss)
   
1,618
     
130
     
(8
)
   
1,740
 
Exercise of Share Options into shares
   
1,015
     
-
     
-
     
1,015
 
                                 
As of December 31, 2022
   
(7,164
)
   
(1,131
)
   
245
     
(8,050
)
                                 
Presented in balance sheet:
                               
                                 
Call option
   
-
     
-
     
245
     
245
 
Other payables (short-term)
   
-
     
(1,131
)
   
-
     
(1,131
)
                                 
Liability for share options
   
(7,164
)
   
-
     
-
     
(7,164
)
 
  (*)
See Note 22b for information on fair value measurement.

 

F - 47

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 17:-
FINANCIAL INSTRUMENTS (Cont.)
   
The Company used the Monte Carlo option pricing model when estimating the fair value of the Put and Call Options granted in the acquisition of Mediton Group – in 2021.
 
The following table lists the significant inputs to the Monte Carlo model used to determine the fair value of the Put Option net of the Call option:
 
   
December 31, 2023
   
December 31, 2022
 
             
Underlying asset value
   
35,732
     
35,541
 
Expected volatility of the share price
   
34.7%
 
   
36.7%-39.2%
 
Discount rate
   
14.9%
 
   
15%
 
Risk-free interest rate
   
3.64%
 
   
3.68%
 
Term of option
 
2.67 years
   
3.67 years
 
 
The following table demonstrates the effect on fair value of a reasonably possible change in the underlying asset value with all other variables held constant:
 
2023:
 
   
Increase/
decrease in underlying asset value
   
Effect on
Fair value, net
 
             
     
+5%
 
   
433
 
     
-5%
 
   
(430)
 
 
2022:
 
   
Increase/
decrease in underlying asset value
   
Effect on
Fair value, net
 
             
     
+5%
 
   
463
 
     
-5%
 
   
(453)
 

 

F - 48

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 18:-
EMPLOYEE BENEFIT LIABILITIES
 
  a.
Changes in the defined benefit obligation and fair value of plan assets:
 
2023:
 
         
Expenses recognized in profit or loss
               
Gain (loss) from remeasurement in other comprehensive income
                   
   
Balance at January 1, 2023
   
Current service cost
   
Net interest expense
   
 
Past service cost and effect of settlements
   
Total expense recognized in profit or loss for the period
   
Payments from the plan
   
Actuarial gain (loss) arising from changes in financial assumptions
   
Actuarial gain (loss) arising from experience adjustments
   
Total effect
on other comprehensive income for the period
   
Effect of changes in foreign exchange rates
   
Contributions by employer
   
Balance at December 31, 2023
 
                                                                         
Defined benefit obligation
   
(8,153
)
   
(340
)
   
(409
)
   
(35
)
   
(784
)
   
148
     
81
     
(7
)
   
74
     
223
     
-
     
(8,492
)
Fair value of plan assets
   
6,658
     
-
     
351
     
-
     
351
     
(134
)
   
-
     
(4
)
   
(4
)
   
(191
)
   
239
     
6,919
 
                                                                                                 
Net defined benefit liability (asset)
   
(1,495
)
   
(340
)
   
(58
)
   
(35
)
   
(433
)
   
14
     
81
     
(11
)
   
70
     
32
     
239
     
(1,573
)
 
2022:
 
   
Expenses recognized in profit or loss
               
Gain (loss) from remeasurement in other comprehensive income
                   
   
Balance at January 1, 2022
   
Current service cost
   
Net interest expense
   
Total expense recognized in profit or loss for the period
   
Payments from the plan
   
Actuarial gain (loss) arising from changes in financial assumptions
   
Actuarial gain (loss) arising from experience adjustments
   
Total effect
on other comprehensive income for the period
   
Effect of changes in foreign exchange rates
   
Contributions by employer
   
Balance at December 31, 2022
 
                                                                   
Defined benefit obligation
   
(9,848
)
   
(405
)
   
(245
)
   
(650
)
   
374
     
775
     
87
     
862
     
1,109
     
-
     
(8,153
)
Fair value of plan assets
   
7,466
     
-
     
198
     
198
     
(349
)
   
-
     
(123
)
   
(123
)
   
(870
)
   
336
     
6,658
 
                                                                                         
Net defined benefit liability (asset)
   
(2,382
)
   
(405
)
   
(47
)
   
(452
)
   
25
     
775
     
(36
)
   
739
     
239
     
336
     
(1,495
)

 

F - 49

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 18:-
EMPLOYEE BENEFIT LIABILITIES (Cont.)
   
  b.
Disaggregation of the fair value of the plan assets:
 
   
Year ended
December 31,
 
   
2023
   
2022
 
             
Insurance contracts
   
6,919
     
6,658
 
 
  c.
The principal assumptions underlying the defined benefit plan:
 
   
2023
   
2022
 
   
%
 
             
Discount rate
   
5.55
     
5.57
 
Expected rate of salary increase
   
2.0-5.48
     
2.0-5.92
 
 
  d.
Amount, timing and uncertainty of future cash flows:
 
Below are reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions are constant:
 
   
Change in defined
benefit obligation
 
   
Year ended
December 31,
 
   
2023
   
2022
 
Sensitivity test for changes in the expected rate of salary increase:
           
             
The change as a result of:
           
             
Salary increase of  6.1% (instead of 5.5%) (2022- 6.51% instead of 5.9%)
   
(45
)
   
(49
)
                 
Sensitivity test for changes in the discount rate of the plan assets and liability:
               
                 
The change as a result of:
               
                 
Increase of 1% in discount rate
           
(13
)
Decrease of 1% in discount rate
   
45
     
45
 

 

F - 50

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 19:-
TAXES ON INCOME
 
  a.
Tax rates applicable to the income of the Group companies:
 
  1.
Companies in Israel:
 
The Israeli corporate income tax rate was 23% in 2023 and 2022.
 
The deferred taxes are computed at the average tax rate of 23% (2022 – 23%), based on the tax rates that are expected to apply upon realization.
 
  2.
Foreign subsidiaries:
 
The principal tax rates applicable to the major subsidiaries whose place of incorporation is outside Israel are:
 
The U.S. - tax at the rate of 21%.
Germany - tax at the rate of 31.4%.
 
  b.
Taxes on income included in the statements of comprehensive income:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Current taxes
   
552
     
749
     
236
 
Deferred taxes
   
409
     
341
     
259
 
Taxes in respect of prior yearsa
   
(70
)
   
7
     
(40
)
                         
     
891
     
1,097
     
455
 
 
F - 51

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 19:-
TAXES ON INCOME (Cont.)
   
  c.
Deferred tax assets (liabilities):
 
Composition and changes in deferred taxes, as presented in the consolidated balance sheet, are as follows:
 
   
Fixed
and
intangible
assets
   
Employee benefit liabilities
   
 
 
Short term investments
   
Carry-
forward tax losses
   
Total
 
                               
Balance at January 1, 2022
   
(4,006
)
   
824
     
-
     
3,916
     
734
 
                                         
Amount included in statement of comprehensive income
   
498
     
(122
)
   
-
     
(875
)
   
(*)(499
)
Currency translation differences
   
443
     
(90
)
   
-
     
(416
)
   
(63
)
                                         
Balance at December 31, 2022
   
(3,065
)
   
612
     
-
     
2,625
     
172
 
                                         
Amount included in statement of comprehensive income
   
55
     
39
     
(192
)
   
(320
)
   
(418
)
Currency translation differences
   
91
     
(19
)
   
(3
)
   
(81
)
   
(12
)
                                         
Balance at December 31, 2023
   
(2,919
)
   
632
     
(195
)
   
2,224
     
(258
)
 
  (*)
$159 presented in other comprehensive income.
 
  d.
The deferred taxes are reflected in the balance sheet as follows:
 
   
December 31,
 
   
2023
   
2022
 
             
Non-current assets
   
2,055
     
2,872
 
Non-current liabilities
   
2,313
     
2,700
 
                 
     
(258
)
   
172
 
 
F - 52

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 19:-
TAXES ON INCOME (Cont.)
   
  e.
A reconciliation of the theoretical tax expense assuming all income is taxed at the statutory rate applicable to the income of companies in Israel, and the actual tax expense is as follows:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Income (loss) before taxes on income
   
(5,964
)
   
1,312
     
(13,469
)
                         
Statutory tax rate in Israel
   
23
%
   
23
%
   
23
%
                         
Tax computed at the statutory tax rate
   
(1,372
)
   
302
     
(3,098
)
                         
Increase (decrease) in taxes resulting from:
                       
Taxes in respect of previous years
   
(70
)
   
7
     
(40
)
Tax adjustment in respect of inflation in Israel
   
-
     
-
     
(2
)
Non-deductible expenses (non-taxable income)
   
406
     
(1,699
)
   
2,613
 
Different tax rates
   
63
     
60
     
24
 
Loss for which deferred taxes were not recognized
   
1,864
     
2,234
     
926
 
Utilization of previously unrecognized capital gain
   
-
     
-
     
32
 
Capital losses for which deferred taxes were not recognized
   
-
     
193
     
-
 
                         
Total tax expenses reported in the consolidated statements of comprehensive income
   
891
     
1,097
     
455
 
 
  f.
Carry forward tax losses:
 
The carry forward losses for tax purposes as of December 31, 2023 amount to NIS 227,833,000 ($62,816) (2022 – NIS 236,130,000 ($67,102), 2021 – NIS 249,552,000 ($80,242)) in Israel (which may be carried forward indefinitely) and EUR 29,387,000 ($32,503) (2022 – EUR 22,212,000 ($23,689), 2021 – EUR 17,026,000 ($19,270)) in Europe. In the U.S., SHL USA has federal and state net operating losses and credits of $15,337 (2022 - $10,716, 2021 - $8,866), which expire at various times.
 
Deferred tax assets in the amount of $23,938 (2022 - $21,113) relating to carry forward tax losses as described above, and deductible temporary differences, are not included in the consolidated financial statements as management presently believes that it is not probable that these deferred taxes will be realized in the foreseeable future.
 
F - 53

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 19:-
TAXES ON INCOME (Cont.)
   
  g.
The expiry dates for carry forward tax losses which are not recognized are as follows:
 
   
Year ended
December 31,
 
   
2023
   
2022
 
             
First year
   
37
     
24
 
Second year
   
762
     
229
 
Third year
   
413
     
126
 
Fourth year
   
153
     
52
 
Fifth year
   
959
     
281
 
Sixth - Fifteen
   
4,891
     
1,280
 
Unlimited
   
93,771
     
87,278
 
                 
     
100,986
     
89,270
 

 

NOTE 20:-
COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS)
 
     
December 31,
 
     
2023
   
2022
   
2021
 
a.
Balances:
                 
                     
 
Other accounts payable
   
182
     
181
     
170
 
 
     
Year ended
December 31,
 
     
2023
   
2022
   
2021
 
b.
Transactions:
                 
                     
 
Short-term employee benefits
   
2,639
     
2,531
     
2,108
 
 
Share-based payment benefits
   
638
     
1,179
     
883
 
                           
 
Total
   
3,277
     
3,710
     
2,991
 

 

F - 54

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 21:-
COMMITMENTS AND CONTINGENT LIABILITIES
 
  a.
Charges:
 
As collateral for the Group's liabilities, fixed charges have been placed on specific accounts receivable.
 
  b.
Contingent liabilities:
 
The Group, from time to time, is party to various claims and disputes associated with its ongoing business operations. In management's opinion, based on the opinion of its legal counsels, none of these claims or disputes is expected, either individually or in the aggregate, to have a material adverse effect on the Group's financial position, results of operations or cash flows.

 

F - 55

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 22:-
EQUITY
 
  a.
Composition of share capital:

?

   
December 31, 2023
   
December 31, 2022
 
   
Authorized
   
Issued and outstanding*)
   
Authorized
   
Issued and outstanding*)
 
   
Number of shares
 
                         
Ordinary shares of NIS 0.01 par value each
   
25,000,000
     
16,391,382
     
25,000,000
     
14,682,272
 
 
  *)
Net of treasury shares – see (c).

 

  b.
Movement in share capital:

 

On January 7, 2021, the Special General Meeting of the Company approved the increase of the authorized share capital of the Company to 25,000,000 Ordinary shares of NIS 0.01 par value each.
 
On January 21, 2021 the Company closed the first of the two Capital Increases by issuing 1,300,000 new Ordinary shares from authorized capital (the "New Shares") and selling 300,000 treasury shares. The New Shares were listed on SIX Swiss Exchange on January 22, 2021. In addition, 800,000 Share Options to purchase Ordinary shares were granted on January 21, 2021, to be newly issued from the authorized capital upon exercise (“Share Options”, ratio 1:1, exercise price CHF 11.00, exercise period 24 months).
 
On February 17, 2021 the Company closed the second Capital Increase by issuing 2,288,889 new Ordinary shares from its authorized capital (the "New Shares"). The New Shares were listed on SIX Swiss Exchange on February 18, 2021. In addition, 1,144,444 Share Options to purchase further Ordinary shares were granted on February 17, 2021, to be newly issued from the authorized capital upon exercise (ratio 1:1, exercise price CHF 11.00, exercise period 24 months).
 
In both Capital Increases the New Shares have been placed by way of a private placement. No subscription rights of the existing shareholders apply and no public offering takes place. Pursuant to the Swiss Financial Services Act, a listing prospectus has been issued by SHL and approved by SIX Exchange Regulation for the purpose of the listing of the New Shares.

?

F - 56

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 22:-

EQUITY (Cont.)

Since the exercise price of the Share Options issued to the investors is denominated in CHF which is not the functional currency (NIS) of the Company, these Share Options are accounted for upon initial recognition as a financial liability at fair value through profit or loss. After initial recognition, increase (decrease) in fair value in each reporting period are recognized in profit or loss as non-cash financial expenses (income).
 
The Company uses the Black and Scholes option pricing model when estimating the fair value of the Share Options.
 
The following table lists the significant inputs to the Black and Scholes model used for the fair value measurement of the Share Options :
 
     
December 31, 2022
       
Expected dividend
   
0%
Expected volatility of the share price
   
32.59%-38.24%
Risk-free interest rate
   
0.82%
Expected average life of options
   
0.06-0.13 years
Share price
   
CHF 14.80 ($16.05)

 

F - 57

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 22:-

EQUITY (Cont.)

The expected volatility of the share price reflects the assumption that the historical volatility of the share price is reasonably indicative of expected future trends.
 
Based on the above inputs, the total fair value of the Share Option liability was $7,164 at December 31, 2022. During the reporting period $1,801 (2022 - $7,423) was recorded in financial income in respect of the revaluation of the liability (this amount is a non cash income). The fair value measurement of the liability is categorized in Level 3 of the fair value hierarchy.
 
During January 2023 and February 2023, the Company received proceeds of approximately CHF 18.7 million (USD 20.3 million) from exercises of 1,703,908 share options granted in the private placements in January 2021 and February 2021 and 29,967 options were not exercised and expired
 
The following table lists the movements in Share Options:
 
Balance on January 1, 2022
   
1,905,820
 
Exercise of share options
   
(171,945
)
         
Balance on December 31, 2022
   
1,733,875
 
Exercise of share options
   
(1,703,908
)
Expiration of share options
   
(29,967
)
         
Balance on December 31, 2023
   
-
 

 

In respect of the Capital Increases, the underwriters were also granted options to acquire 97,222 Units of securities. Each Unit comprises 1 Ordinary share and 0.5 option to acquire 1 Ordinary share at an exercise price of CHF 11 ($11.93). As of December 31, 2022, no options had been exercised. See below for details of the changes made to the terms of these options in March 2023.
 
The underwriters were also entitled to receive a cash payment derived from future cash received by the Company from the exercise of the Share Options in 2023. In addition, the underwriters were granted options to acquire a certain number of Units of securities based on a formula derived from the future cash payments received from the exercise of the Share Options. See below for the terms of these Units.
 
The Company used the Monte Carlo option pricing model when estimating the fair value of the liability for future payment to the underwriter as described above.

?

F - 58

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 22:-

EQUITY (Cont.)

The following table lists the significant inputs to the Monte Carlo model used for the fair value measurement of the liability:

 

   
December 31, 2022
 
       
Expected volatility of the share price
 
43.15%
 
Risk-free interest rate
 
0.82%
 
Expected average life of options
 
0.21 years
 
Share price
 
CHF 14.80 ($16.05)
 

 

Based on the above inputs, the total fair value of the options to acquire Units and the future payment liability at the date of issuance were $1,002 and $416, respectively. The fair value of the liability at December 31, 2022 was $1,131. The increase in fair value of the liability during 2022 in the amount of $239 was recorded in financial expenses (this amount is a non cash expense).
 
In 2023, the underwriters received a cash payment of approximately CHF 1.1 million (USD 1.1 million) derived from cash received by the Company from the exercise of the Share Options. The cash payment was offset from the liability to the underwriters recorded in the balance sheet. In addition, the underwriters received options to acquire 58,498 Units of securities. Each Unit comprises 1 Ordinary share and 0.5 option to acquire 1 Ordinary share at an exercise price of CHF 11 ($11.93)
 
In March, 2023, in connection with services provided in respect of the exercise of options described above, the Company signed an agreement with the underwriter for the extension of the exercise period of the 97,222 Units of securities previously granted in 2021 for an additional 2 years until 2025 and for change of the exercise price to NIS 35.64 ($ 9.83) for each Unit of securities (which comprises 1 Ordinary share and 0.5 option to acquire 1 Ordinary share of the Company) and NIS 43.56 ($ 12.01) for each option included in the Unit.
 
The Company used the Black and Scholes option pricing model when estimating the incremental fair value of the options to acquire Units after the modifications described above.
 
The following table lists the significant inputs to the Black and Scholes model used for the fair value measurement of the options to acquire Units:
 
Expected dividend
 
0%
 
Expected volatility of the share price
 
41.18%
 
Risk-free interest rate
 
4.11%
 
Expected average life of options
 
2.01 years
 
Share price
 
CHF 11.55 ($12.53)
 
 
Based on the above inputs, the total incremental fair value of the options to acquire Units as of the date of the modifications was $ 512 and was recorded as a deduction from Additional paid-in capital arising from the exercise of the  share options in January and February 2023, as described above with a corresponding increase in the Capital reserve for options.
 
F - 59

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 22:-
EQUITY (Cont.)
   
Issued and outstanding share capital (net of treasury shares):
 
   
Number of
shares
 
       
Balance at January 1, 2022
   
14,491,171
 
         
Exercise of share options
   
171,945
 
Exercise of employees share options
   
5,694
 
Treasury shares sold upon exercise of employee options
   
13,462
 
         
Balance at December 31, 2022
   
14,682,272
 
         
Exercise of share options
   
1,703,908
 
Exercise of employees share options
   
5,202
 
         
Balance at December 31, 2023
   
16,391,382
 

 

  c.
Treasury shares:
 
The Company holds 1,372 shares at a total cost of $2 as of December 31, 2023 and 2022.
 
  d.
Share option plans:
 
On January 2, 2022, the Company's Board of Directors approved the grant of 97,500 options to Senior Managers, under the 2021 Executive and Key Employee Israeli Share Incentive Plan. The options shall vest over a period of 3 years (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 5.893 ($6.451). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 19.10; exercise price – CHF 19.33; expected volatility – 42.33%; risk free interest rate – 0%; expected dividend – 0%; and expected average life of options – 3.71 years.
 
On February 15, 2022, the Company's Board of Directors approved the grant of 12,500 options to a Senior Manager, under the 2021 Executive and Key E,ployee Israeli Share Incentive Plan. The options shall vest over a period of 3 years (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 5.387 ($5.822). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 17.40; exercise price – CHF 17.69; expected volatility – 42.61%; risk free interest rate – 0.13%; expected dividend – 0%; and expected average life of options – 3.68 years.
 
F - 60

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 22:-
EQUITY (Cont.)
   
On June 20, 2022, the Company's Board of Directors approved the grant of 100,000 options to a Senior Manager, under the 2021 Executive and Key E,ployee Israeli Share Incentive Plan. The options shall vest over a period of 3 years (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 5.550 ($5.753). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 17.40; exercise price – CHF 17.39; expected volatility – 41.75%; risk free interest rate – 1.15%; expected dividend – 0%; and expected average life of options – 3.6 years.
 
On January 2, 2023, the Company's Board of Directors approved the grant of 248,500 options to Managers and employees, under the Executive and Key Employee Israeli Share Incentive Plan. The options shall vest over a period of 3 years after appointment (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 4.655 ($5.047). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 14.80; exercise price – CHF 15.56; expected volatility – 43.87%; risk free interest rate – 0%; expected dividend – 0%; and expected average life of options – 3.49 years.
 
On May 15, 2023, the Company's Board of Directors approved the grant of 145,000 options to Managers, under the Executive and Key Employee Israeli Share Incentive Plan. The options shall vest over a period of 3 years after appointment (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 3.374 ($3.76). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 9.70; exercise price – CHF 9.36; expected volatility – 46.03%; risk free interest rate – 0%; expected dividend – 0%; and expected average life of options – 3.43 years.
 
On June 18, 2023, the Company's Board of Directors approved the grant of 30,000 options to a Senior Managers, under the Executive and Key Employee Israeli Share Incentive Plan. The options shall vest over a period of 3 years after appointment (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 3.663 ($4.113). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 10.30; exercise price – CHF 9.88; expected volatility – 46.57%; risk free interest rate – 0%; expected dividend – 0%; and expected average life of options – 3.43 years.
 
All options are exercisable for a period of 6 years from grant date.
 
On October 31, 2021, the Board of Directors approved to increase the maximum number of shares which may be issued under the Plan by 2,000,000.
 
On October 31, 2021, the Board of Directors approved to amend and rename the share options plan as "The SHL Telemedicine LTD. 2021 Executive and Key Employee Israeli Share Incentive Plan", and to extend the term of the Plan until the Board decides otherwise.
 
F - 61

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 22:-
EQUITY (Cont.)
   
In the years ended December 31, 2023, 2022 and 2021, the Group recorded share-based compensation in the statements of comprehensive income in the amount of $1,252, $1,757 and $1,116, respectively.
 
 

e.

The following table illustrates the number and weighted average exercise prices ("WAEP") of, and movements in, share options during the year.

 

   
2023
   
2022
 
   
No. of options
   
WAEP (CHF)
   
No. of options
   
WAEP (CHF)
 
                         
Outstanding at the beginning of the year
   
1,001,430
     
11.85
     
835,055
     
10.12
 
Granted during the year
   
423,500
     
13.03
     
210,000
     
18.31
 
Forfeited during the year
   
(165,881
)
   
12.89
     
(7,500
)
   
19.33
 
Exercised during the year *)
   
(38,808
)
   
7.04
     
(36,125
)
   
7.94
 
                                 
Outstanding at the end of the year
   
1,220,241
     
12.27
     
1,001,430
     
11.85
 
                                 
Exercisable at the end of the year
   
720,758
     
11.02
     
454,480
     
9.42
 
 
  *)
The weighted average share price at the date of exercise of these options was CHF 8.13 (2022 – CHF 16.85). Exercise was cashless.
 
The weighted average remaining contractual life for the share options outstanding as of December 31, 2023 was 3.83 years (as of December 31, 2022 – 4.18 years).
 
  f.
Restricted Shares of Mediton Group:
 
On December 20, 2021, a Mediton executive was granted 256 restricted share units (“RSU”) of Mediton Group. The fair value of the RSUs in the amount of $822 was determined based on the price that the Company paid for the acquisition of the Mediton Group shares in 2021, The RSUs shall vest over a period of 3 years (33% after 1 year, and 16.5% each half year thereafter). The purchase agreement of Mediton Group includes a provision for anti-dilution protection to the Company in respect of the grant of the RSUs.

 

F - 62

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 23:-
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME
 
  a.
Revenues:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Revenues for services performed during the period
   
55,678
     
57,869
     
48,343
 
Revenues from sale of devices
   
1,397
     
1,129
     
1,239
 
                         
     
57,075
     
58,998
     
49,582
 
 
  b.
Cost of revenues:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Salaries and related benefits
   
16,212
     
16,480
     
14,955
 
Medical services
   
8,355
     
8,712
     
4,682
 
Rental fees and maintenance
   
1,246
     
1,013
     
1,072
 
Depreciation and amortization
   
1,978
     
1,789
     
1,736
 
Cost of devices
   
1,025
     
1,013
     
1,249
 
Others
   
2,998
     
2,802
     
1,295
 
                         
     
31,814
     
31,809
     
24,989
 
 
  c.
Research and development costs:
 
Salaries and related benefits
   
3,917
     
3,468
     
2,173
 
Amortization of development costs
   
2,772
     
1,829
     
1,243
 
Others
   
2,774
     
3,734
     
2,202
 
                         
     
9,463
     
9,031
     
5,618
 
Less - capitalization of development costs
   
4,203
     
5,243
     
2,633
 
                         
     
5,260
     
3,788
     
2,985
 

 

F - 63

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 23:-
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME (Cont.)
   
  d.
Selling and marketing expenses:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Salaries and related benefits
   
5,285
     
5,409
     
4,803
 
Marketing and related expenses
   
1,943
     
2,190
     
1,802
 
Depreciation and amortization
   
1,633
     
1,918
     
1,453
 
Rental fees and maintenance
   
160
     
271
     
205
 
Maintenance of vehicles
   
313
     
240
     
182
 
Others
   
1,247
     
1,375
     
1,009
 
                         
     
10,581
     
11,403
     
9,454
 
 
  e.
General and administrative expenses:
 
Salaries and related benefits
   
8,881
     
8,492
     
5,837
 
Office expenses
   
2,634
     
2,349
     
1,366
 
Professional fees
   
3,156
     
3,897
     
3,245
 
Depreciation and amortization
   
1,309
     
1,599
     
950
 
Others
   
248
     
411
     
705
 
                         
     
16,228
     
16,748
     
12,103
 
 
  f.
Financial income (expenses):
 
1.       Financial income:
 
Exchange rate differences
   
1,129
     
661
     
5
 
Gain on marketable securities, net
   
848
     
-
     
-
 
Share options
   
1,801
     
7,423
     
-
 
Call+Put options
   
-
     
320
     
-
 
Interest
   
1,055
     
429
     
376
 
                         
     
4,833
     
8,833
     
381
 
 
2.       Financial expenses:
 
Share options
   
-
     
(239
)
   
(10,126
)
Exchange rate differences
   
(138
)
   
(53
)
   
(1,595
)
Loss from marketable securities, net
   
-
     
(769
)
   
(114
)
Interest
   
(1,296
)
   
(1,033
)
   
(529
)
Call+Put options
   
(89
)
   
-
     
(677
)
Others
   
(268
)
   
(261
)
   
(312
)
                         
     
(1,791
)
   
(2,355
)
   
(13,353
)

 

F - 64

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 23:-
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME (Cont.)
   
  g.
Other expenses:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Impairment of property and equipment – see Note 10
   
-
     
-
     
118
 
Expenses related to acquisitions
   
-
     
-
     
590
 
Restructuring expenses*
   
1,235
     
-
     
-
 
Other expenses
   
963
     
416
     
(160
)
                         
     
2,198
     
416
     
548
 
 
 
Including expenses related to employee benefits and other direct expenditures arising from the restructuring.

 

NOTE 24:-    NET EARNINGS PER SHARE
 
  a.
Details of the number of shares and net loss used in the computation of net earnings per share:
 
   
Year ended December 31,
 
   
2023
   
2022
 
   
Weighted average number of shares
   
Net
loss
   
Weighted average\ number of shares
   
Net
loss
 
   
In
thousands
         
In
thousands
       
                         
For the computation of basic net earnings
   
16,269
     
(7,055
)
   
14,542
     
(76
)
Effect of dilution - share options
   
26
     
(1,801
)
   
656
     
(7,423
)
                                 
For the computation of diluted net earnings
   
16,295
     
(8,856
)
   
15,198
     
(7,499
)
 
  b.
To compute diluted net earnings per share, the following options (dilutive potential Ordinary shares), have not been taken into account since their conversion has an anti-dilutive effect: 1,453,824 (2022 – 1,236,824) options to employees under share-based payment plans and options to investors and others.

 

F - 65

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 25:-
SEGMENT INFORMATION
 
The Group operates in three geographical segments: Israel, Europe (principally Germany) and Rest of the world ("ROW").
 
Management monitors the operating results of its geographical units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on segment profit. SG&A Group expenses and some research and development expenses are mostly allocated to the separate geographic units. Some corporate expenses, some research and development expenses, finance costs and finance income and income taxes are managed on a group basis and are not allocated to the geographic segments.
 
Revenues are allocated based on the location of the end customer. The Group presents disaggregated revenue information based on types of customers: Individual customers and communities, Institutions and payers (income from service agreements with institutions, insurance companies and HMOs), and others.
 
  a.
Segment revenues:
 
   
Individuals and communities
   
Institutions and payers
   
Others
   
Total
 
Year ended December 31, 2023:
                       
                         
Europe
   
-
     
14,067
     
-
     
14,067
 
Israel
   
20,913
     
21,179
     
-
     
42,092
 
ROW
   
-
     
-
     
916
     
916
 
                                 
Total revenues
   
20,913
     
35,246
     
916
     
57,075
 
                                 
Year ended December 31, 2022:
                               
                                 
Europe
   
-
     
13,374
     
-
     
13,374
 
Israel
   
22,161
     
22,975
     
2
     
45,138
 
ROW
   
-
     
-
     
486
     
486
 
                                 
Total revenues
   
22,161
     
36,349
     
488
     
58,998
 
                                 
Year ended December 31, 2021:
                               
                                 
Europe
   
-
     
17,942
     
-
     
17,942
 
Israel
   
22,331
     
8,832
     
27
     
31,190
 
ROW
   
-
     
-
     
450
     
450
 
                                 
Total revenues
   
22,331
     
26,774
     
477
     
49,582
 
 
F - 66

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 25:-
SEGMENT INFORMATION (cont.)
   
  b.
Reporting on geographic segments:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
Segment profit (loss):
                 
                   
Europe
   
(5,347
)
   
(3,044
)
   
(477
)
Israel
   
8,424
     
8,641
     
8,266
 
ROW
   
(3,622
)
   
(2,972
)
   
(1,132
)
                         
     
(545
)
   
2,625
     
6,617
 
Unallocated income and expenses:
                       
                         
Corporate, R&D and other expenses
   
(6,263
)
   
(7,375
)
   
(6,798
)
Other expenses
   
(2,198
)
   
(416
)
   
(316
)
                         
Operating loss
   
(9,006
)
   
(5,166
)
   
(497
)
Financial income, net
   
3,042
     
6,478
     
(12,972
)
                         
Profit (loss) before taxes on income
   
(5,964
)
   
1,312
     
(13,469
)
 
 
c.
Additional information:
 
   
Europe
   
Israel
   
Others
   
Total
 
                         
Year ended December 31, 2023
                       
                         
Depreciation and amortization
   
3,637
     
4,049
     
6
     
7,692
 
 
   
Europe
   
Israel
   
ROW
   
Unallocated assets
   
Total
 
                               
Non-current assets
   
23,588
     
36,803
     
1,940
     
4,910
     
67,241
 
 
   
Europe
   
Israel
   
Others
   
Total
 
                         
Year ended December 31, 2022
                       
                         
Depreciation and amortization
   
2,654
     
4,470
     
10
     
7,134
 
 
   
Europe
   
Israel
   
ROW
   
Unallocated assets
   
Total
 
                               
Non-current assets
   
27,132
     
40,056
     
1,767
     
2,636
     
71,591
 
 
   
Europe
   
Israel
   
Others
   
Total
 
                         
Year ended December 31, 2021
                       
                         
Depreciation and amortization
   
2,765
     
2,735
     
-
     
5,500
 
 
   
Europe
   
Israel
   
ROW
   
Unallocated assets
   
Total
 
                               
Non-current assets
   
11,539
     
61,534
     
-
     
2,260
     
75,333
 

 

F - 67

SHL TELEMEDICINE LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


U.S. dollars in thousands

NOTE 26:-
SUBSEQUENT EVENTS
 
  a.
On March 14, 2024 the Company announced that Mr. Erez Nachtomy, the Company's CEO, will be stepping down as CEO in mid June 2024.
F - 68
EX-12.1 2 exhibit_12-1.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

Exhibit 12.1
 
Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
I, Erez Nachtomy, certify that:
 
1.          I have reviewed this Annual Report on Form 20-F/A of SHL Telemedicine Ltd. (the “registrant”);
 
2.          Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.          Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.          The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a)          Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b)          Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c)          Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d)          Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.          The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a)          All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b)          Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: July 24, 2024

 
/s/ Erez Nachtomy
 
Name:
Erez Nachtomy
 
Title:
Chief Executive Officer
   
(Principal Executive Officer)


EX-12.2 3 exhibit_12-2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Exhibit 12.2
 
Certification of Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
I, Amir Hai, certify that:
 
1.          I have reviewed this Annual Report on Form 20-F/A of SHL Telemedicine Ltd. (the “registrant”);
 
2.          Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.          Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.         The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedure (as defined in Exchange Act Rules 13a-15(e) and 15d – 15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a)          Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b)          Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c)         Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d)          Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.          The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a)          All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b)          Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: July 24, 2024
 
 
/s/ Amir Hai
 
Name:
Amir Hai
 
Title:
Chief Financial Officer
   
(Principal Financial Officer)


EX-13.1 4 exhibit_13-1.htm CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

Exhibit 13.1
 
Certification Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
 
In connection with the Annual Report of SHL Telemedicine, Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Erez Nachtomy, Chief Executive Officer of the Company and Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
 
1.          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
2.          The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: July 24, 2024
 
 
/s/ Erez Nachtomy
 
Name:
Erez Nachtomy
 
Title:
Chief Executive Officer
   
(Principal Executive Officer)


EX-13.2 5 exhibit_13-2.htm CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

Exhibit 13.2
 
Certification Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
 
In connection with the Annual Report of SHL Telemedicine, Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Amir Hai, Chief Financial Officer of the Company and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
 
1.          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
2.          The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: July 24, 2024
 
 
/s/ Amir Hai
 
Name:
Amir Hai
 
Title:
Chief Financial Officer
   
(Principal Financial Officer)


EX-15.1 6 exhibit_15-1.htm EXHIBIT 15.1

Exhibit 15.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-272546) of SHL Telemedicine Ltd. of our report dated April 17, 2024, with respect to the consolidated financial statements of SHL Telemedicine Ltd. and its subsidiaries included in this Annual Report on Form 20-F/A for the year ended December 31, 2023, filed with the Securities and Exchange Commission.
 
/s/ Kost Forer Gabbay & Kasierer
KOST FORER GABBAY & KASIERER
A Member of Ernst & Young Global
 
Tel Aviv, Israel
July 24, 2024



 

EX-101.SCH 7 shlt-20231231.xsd XBRL SCHEMA FILE 0001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 0002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 0003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:definitionLink link:calculationLink 0004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY link:presentationLink link:definitionLink link:calculationLink 0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 0007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 0008 - Disclosure - GENERAL link:presentationLink link:definitionLink link:calculationLink 0009 - Disclosure - ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 0010 - Disclosure - SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS link:presentationLink link:definitionLink link:calculationLink 0011 - Disclosure - DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION link:presentationLink link:definitionLink link:calculationLink 0012 - Disclosure - CASH AND CASH EQUIVALENTS link:presentationLink link:definitionLink link:calculationLink 0013 - Disclosure - SHORT-TERM INVESTMENTS link:presentationLink link:definitionLink link:calculationLink 0014 - Disclosure - TRADE RECEIVABLES link:presentationLink link:definitionLink link:calculationLink 0015 - Disclosure - PREPAID EXPENSES link:presentationLink link:definitionLink link:calculationLink 0016 - Disclosure - OTHER ACCOUNTS RECEIVABLE link:presentationLink link:definitionLink link:calculationLink 0017 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:definitionLink link:calculationLink 0018 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET link:presentationLink link:definitionLink link:calculationLink 0019 - Disclosure - LEASES link:presentationLink link:definitionLink link:calculationLink 0020 - Disclosure - CREDIT FROM BANKS link:presentationLink link:definitionLink link:calculationLink 0021 - Disclosure - LONG-TERM LOANS link:presentationLink link:definitionLink link:calculationLink 0022 - Disclosure - DEFERRED REVENUES link:presentationLink link:definitionLink link:calculationLink 0023 - Disclosure - OTHER PAYABLES link:presentationLink link:definitionLink link:calculationLink 0024 - Disclosure - FINANCIAL INSTRUMENTS link:presentationLink link:definitionLink link:calculationLink 0025 - Disclosure - EMPLOYEE BENEFIT LIABILITIES link:presentationLink link:definitionLink link:calculationLink 0026 - Disclosure - TAXES ON INCOME link:presentationLink link:definitionLink link:calculationLink 0027 - Disclosure - COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) link:presentationLink link:definitionLink link:calculationLink 0028 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES link:presentationLink link:definitionLink link:calculationLink 0029 - Disclosure - EQUITY link:presentationLink link:definitionLink link:calculationLink 0030 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:definitionLink link:calculationLink 0031 - Disclosure - NET EARNINGS PER SHARE link:presentationLink link:definitionLink link:calculationLink 0032 - Disclosure - SEGMENT INFORMATION link:presentationLink link:definitionLink link:calculationLink 0033 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 0034 - Disclosure - ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 0035 - Disclosure - ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 0036 - Disclosure - CASH AND CASH EQUIVALENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 0037 - Disclosure - SHORT-TERM INVESTMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 0038 - Disclosure - TRADE RECEIVABLES (Tables) link:presentationLink link:definitionLink link:calculationLink 0039 - Disclosure - OTHER ACCOUNTS RECEIVABLE (Tables) link:presentationLink link:definitionLink link:calculationLink 0040 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 0041 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET (Tables) link:presentationLink link:definitionLink link:calculationLink 0042 - Disclosure - LEASES (Tables) link:presentationLink link:definitionLink link:calculationLink 0043 - Disclosure - CREDIT FROM BANKS (Tables) link:presentationLink link:definitionLink link:calculationLink 0044 - Disclosure - LONG-TERM LOANS (Tables) link:presentationLink link:definitionLink link:calculationLink 0045 - Disclosure - OTHER PAYABLES (Tables) link:presentationLink link:definitionLink link:calculationLink 0046 - Disclosure - FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 0047 - Disclosure - EMPLOYEE BENEFIT LIABILITIES (Tables) link:presentationLink link:definitionLink link:calculationLink 0048 - Disclosure - TAXES ON INCOME (Tables) link:presentationLink link:definitionLink link:calculationLink 0049 - Disclosure - COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Tables) link:presentationLink link:definitionLink link:calculationLink 0050 - Disclosure - EQUITY (Tables) link:presentationLink link:definitionLink link:calculationLink 0051 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME (Tables) link:presentationLink link:definitionLink link:calculationLink 0052 - Disclosure - NET EARNINGS PER SHARE (Tables) link:presentationLink link:definitionLink link:calculationLink 0053 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:definitionLink link:calculationLink 0054 - Disclosure - GENERAL (Details) link:presentationLink link:definitionLink link:calculationLink 0055 - Disclosure - ACCOUNTING POLICIES - (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0056 - Disclosure - ACCOUNTING POLICIES - Disclosure of depreciation of the right-of-use assets by class of underlying asset (Details) link:presentationLink link:definitionLink link:calculationLink 0057 - Disclosure - ACCOUNTING POLICIES - Disclosure of depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates (Details) link:presentationLink link:definitionLink link:calculationLink 0058 - Disclosure - ACCOUNTING POLICIES - Disclosure of useful life of intangible assets (Details) link:presentationLink link:definitionLink link:calculationLink 0059 - Disclosure - ACCOUNTING POLICIES - Disclosure of exchange rates and linkage basis (Details) link:presentationLink link:definitionLink link:calculationLink 0060 - Disclosure - CASH AND CASH EQUIVALENTS (Details) link:presentationLink link:definitionLink link:calculationLink 0061 - Disclosure - SHORT-TERM INVESTMENTS (Details) link:presentationLink link:definitionLink link:calculationLink 0062 - Disclosure - TRADE RECEIVABLES (Details) link:presentationLink link:definitionLink link:calculationLink 0063 - Disclosure - PREPAID EXPENSES (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0064 - Disclosure - OTHER ACCOUNTS RECEIVABLE (Details) link:presentationLink link:definitionLink link:calculationLink 0065 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:definitionLink link:calculationLink 0066 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET (Details) link:presentationLink link:definitionLink link:calculationLink 0067 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill (Details) link:presentationLink link:definitionLink link:calculationLink 0068 - Disclosure - LEASES (Details) link:presentationLink link:definitionLink link:calculationLink 0069 - Disclosure - LEASES - Right-of-use assets (Details) link:presentationLink link:definitionLink link:calculationLink 0070 - Disclosure - CREDIT FROM BANKS (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0071 - Disclosure - CREDIT FROM BANKS - Disclosure of credit from banks (Details) link:presentationLink link:definitionLink link:calculationLink 0072 - Disclosure - LONG-TERM LOANS (Details) link:presentationLink link:definitionLink link:calculationLink 0073 - Disclosure - DEFERRED REVENUES (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0074 - Disclosure - OTHER PAYABLES - Disclosure of other current payables (Details) link:presentationLink link:definitionLink link:calculationLink 0075 - Disclosure - FINANCIAL INSTRUMENTS (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0076 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Financial assets and liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 0077 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Foreign currency sensitivity analysis (Details) link:presentationLink link:definitionLink link:calculationLink 0078 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Market risk profit before tax due to changes in carrying amount of marketable securities (Details) link:presentationLink link:definitionLink link:calculationLink 0079 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Liquidity of summarizes maturity profile of financial liabilities based on contractual undiscounted payments (Details) link:presentationLink link:definitionLink link:calculationLink 0080 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of liabilities arising from financing activities (Details) link:presentationLink link:definitionLink link:calculationLink 0081 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Reconciliation of fair value measurements within Level 3 of fair value hierarchy in financial instruments (Details) link:presentationLink link:definitionLink link:calculationLink 0082 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of lists the significant inputs fair value of Put Option net of Call option (Details) link:presentationLink link:definitionLink link:calculationLink 0083 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of demonstrates effect on fair value of reasonably possible change in underlying asset value with all other variables (Details) link:presentationLink link:definitionLink link:calculationLink 0084 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of changes in the defined benefit obligation and fair value of plan assets (Details) link:presentationLink link:definitionLink link:calculationLink 0085 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of disaggregation of the fair value of the plan assets (Details) link:presentationLink link:definitionLink link:calculationLink 0086 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of principal assumptions underlying the defined benefit plan (Details) link:presentationLink link:definitionLink link:calculationLink 0087 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions are constant (Details) link:presentationLink link:definitionLink link:calculationLink 0088 - Disclosure - TAXES ON INCOME - Disclosure of general (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0089 - Disclosure - TAXES ON INCOME - Disclosure of taxes on income included in the statements of comprehensive income (Details) link:presentationLink link:definitionLink link:calculationLink 0090 - Disclosure - TAXES ON INCOME - Disclosure of deferred tax assets (liabilities) (Details) link:presentationLink link:definitionLink link:calculationLink 0091 - Disclosure - TAXES ON INCOME - Disclosure of reconciliation of theoretical tax expense assuming all income is taxed at statutory rate applicable to income of companies in Israel, and actual tax expense (Details) link:presentationLink link:definitionLink link:calculationLink 0092 - Disclosure - TAXES ON INCOME - Disclosure of carry forward tax losses (Details) link:presentationLink link:definitionLink link:calculationLink 0093 - Disclosure - TAXES ON INCOME - Disclosure of expiry dates for carry forward tax losses which are not recognized (Details) link:presentationLink link:definitionLink link:calculationLink 0094 - Disclosure - COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Details) link:presentationLink link:definitionLink link:calculationLink 0095 - Disclosure - Equity (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0096 - Disclosure - EQUITY - Disclosure of composition of share capital (Details) link:presentationLink link:definitionLink link:calculationLink 0097 - Disclosure - Equity - Disclosure of significant inputs to Black and Scholes model used for fair value measurement of Share Options (Details) link:presentationLink link:definitionLink link:calculationLink 0098 - Disclosure - EQUITY - Disclosure of movement in share capital (Details) link:presentationLink link:definitionLink link:calculationLink 0099 - Disclosure - EQUITY - Disclosure of issued and outstanding share capital (net of treasury shares) (Details) link:presentationLink link:definitionLink link:calculationLink 0100 - Disclosure - EQUITY - Disclosure of number and weighted average exercise prices ("WAEP") of, and movements in, share options (Details) link:presentationLink link:definitionLink link:calculationLink 0101 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of revenues (Details) link:presentationLink link:definitionLink link:calculationLink 0102 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of cost of revenues (Details) link:presentationLink link:definitionLink link:calculationLink 0103 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of research and development costs (Details) link:presentationLink link:definitionLink link:calculationLink 0104 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of selling and marketing expenses (Details) link:presentationLink link:definitionLink link:calculationLink 0105 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of general and administrative expenses (Details) link:presentationLink link:definitionLink link:calculationLink 0106 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial income (Details) link:presentationLink link:definitionLink link:calculationLink 0107 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial expenses (Details) link:presentationLink link:definitionLink link:calculationLink 0108 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of other expenses (Details) link:presentationLink link:definitionLink link:calculationLink 0109 - Disclosure - NET EARNINGS PER SHARE (Details) link:presentationLink link:definitionLink link:calculationLink 0110 - Disclosure - NET EARNINGS PER SHARE (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 0111 - Disclosure - SEGMENT INFORMATION - Disclosure of disaggregated revenue information (Details) link:presentationLink link:definitionLink link:calculationLink 0112 - Disclosure - SEGMENT INFORMATION - Disclosure of revenue from geographic segments (Details) link:presentationLink link:definitionLink link:calculationLink 0113 - Disclosure - SEGMENT INFORMATION - Disclosure of additional information of segments (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 shlt-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 shlt-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 shlt-20231231_lab.xml XBRL LABEL FILE EX-101.PRE 11 shlt-20231231_pre.xml XBRL PRESENTATION FILE GRAPHIC 12 image00001.jpg GRAPHIC begin 644 image00001.jpg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image0.jpg GRAPHIC begin 644 image0.jpg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end GRAPHIC 14 image2.jpg GRAPHIC begin 644 image2.jpg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end GRAPHIC 15 image3.jpg GRAPHIC begin 644 image3.jpg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end GRAPHIC 16 image00004.jpg GRAPHIC begin 644 image00004.jpg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htm IDEA: XBRL DOCUMENT v3.24.2
Document and Entity Information
12 Months Ended
Dec. 31, 2023
shares
Document Information  
Document Type 20-F/A
Document Registration Statement false
Document Annual Report true
Document Transition Report false
Document Shell Company Report false
Document Period End Date Dec. 31, 2023
Entity File Number 001-41641
Entity Registrant Name SHL TELEMEDICINE LTD
Entity Incorporation, State or Country Code IL
Entity Address, Address Line One 90 Yigal Alon Street
Entity Address, City or Town Tel Aviv
Entity Address, Postal Zip Code 67891
Entity Address, Country IL
Entity Well-known Seasoned Issuer No
Entity Voluntary Filers No
Entity Current Reporting Status No
Entity Interactive Data Current Yes
Entity Filer Category Non-accelerated Filer
Entity Emerging Growth Company true
Entity Ex Transition Period false
ICFR Auditor Attestation Flag false
Document Accounting Standard International Financial Reporting Standards
Entity Shell Company false
Entity Common Stock, Shares Outstanding 16,392,754
Entity Central Index Key 0001166834
Current Fiscal Year End Date --12-31
Document Fiscal Year Focus 2023
Document Fiscal Period Focus FY
Amendment Description Amendment No. 1
Amendment Flag true
Auditor Name EY Global
Auditor Location Tel-Aviv, Israel
Auditor Firm ID 1281
Document Financial Statement Error Correction [Flag] false
ADS  
Document Information  
Title of 12(b) Security American Depositary Shares, each repres
Trading Symbol SHLT
Security Exchange Name NASDAQ
Ordinary shares  
Document Information  
Title of 12(b) Security Ordinary shares, nominal value NIS 0.01 per share
Business Contact Person  
Document Information  
Contact Personnel Name Erez Nachtomy
Entity Address, Address Line One 90 Yigal Alon Street
Entity Address, City or Town Tel Aviv
Entity Address, Postal Zip Code 67891
City Area Code 3
Local Phone Number 561‑2212
Entity Address, Country IL
XML 19 R2.htm IDEA: XBRL DOCUMENT v3.24.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
CURRENT ASSETS:    
Cash and cash equivalents $ 6,693 $ 4,483
Short-term investments 19,557 14,217
Trade receivables 8,557 7,797
Inventory 3,459 3,879
Other accounts receivable 1,792 1,912
Total current assets 40,058 32,288
NON-CURRENT ASSETS:    
Inventory 1,913 1,731
Prepaid expenses 3,220 3,364
Call option to non-controlling interests, net 147 245
Long-term deposits 328 423
Right-of-use assets 7,214 11,038
Deferred taxes 2,055 2,872
Total non-current assets other than long-lived assets 14,877 19,673
PROPERTY AND EQUIPMENT, NET 4,892 4,652
GOODWILL 32,965 33,745
INTANGIBLE ASSETS, NET 20,257 20,425
Total assets 113,049 110,783
CURRENT LIABILITIES:    
Credit from banks and others 2,160 2,169
Current maturities of lease liabilities 2,435 2,263
Deferred revenues 304 260
Income taxes payable 119 138
Trade payables 3,884 3,757
Other payables 8,536 9,238
Total current liabilities 17,438 17,825
NON-CURRENT LIABILITIES:    
Liability for share options 0 7,164
Loans from banks 10,460 13,008
Deferred taxes 2,313 2,700
Lease liabilities 4,804 9,302
Employee benefit liabilities 1,573 1,495
Total non-current liabilities 19,150 33,669
Total liabilities 36,588 51,494
Attributable to equity holders of the Company:    
Issued capital 48 43
Additional paid-in capital 156,334 130,009
Treasury shares (2) (2)
Foreign currency translation reserve (5,294) (3,291)
Capital reserve for options 1,514 1,002
Capital reserve for remeasurement gains on defined benefit plans 1,058 1,000
Accumulated deficit (80,130) (73,074)
Total 73,528 55,687
Non-controlling interests 2,933 3,602
Total equity 76,461 59,289
Total liabilities and equity $ 113,049 $ 110,783
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.24.2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Profit or loss [abstract]      
Revenues $ 57,075 $ 58,998 $ 49,582
Cost of revenues 31,814 31,809 24,989
Gross profit 25,261 27,189 24,593
Research and development costs 5,260 3,788 2,985
Selling and marketing expenses 10,581 11,403 9,454
General and administrative expenses 16,228 16,748 12,103
Other expenses 2,198 416 548
Operating loss (9,006) (5,166) (497)
Financial income 4,833 8,833 381
Financial expenses (1,791) (2,355) (13,353)
Profit (loss) before taxes on income (5,964) 1,312 (13,469)
Tax expenses 891 1,097 455
Net profit (loss) (6,855) 215 (13,924)
Other comprehensive income:      
Re-measurement gain on defined benefit plans 52 581 280
Other comprehensive income (loss) to be reclassified to profit or loss in subsequent periods:      
Foreign currency translation reserve (2,119) (6,699) 859
Total other comprehensive income (2,067) (6,118) 1,139
Total comprehensive loss (8,922) (5,903) (12,785)
Net profit (loss) attributable to:      
Equity holders of the Company (7,056) (76) (14,110)
Non-controlling interests 201 291 186
Net profit (loss) (6,855) 215 (13,924)
Comprehensive income (loss) attributable to:      
Equity holders of the Company (9,001) (5,775) (12,971)
Non-controlling interests 79 (128) 186
Total comprehensive loss $ (8,922) $ (5,903) $ (12,785)
Earnings per share:      
Basic loss $ (0.43) $ (0.01) $ (1)
Diluted loss $ (0.54) $ (0.49) $ (1)
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.24.2
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
$ in Thousands
Equity attributable to owners of parent
Issued capital
Additional paid-in capital
Treasury shares
Foreign currency translation reserve
Capital reserve for options
Capital reserve for remeasurement gains on defined benefit plans
Accumulated deficit
Non- controlling interests
Total
Balance as of beginning at Dec. 31, 2021 $ 56,852 $ 42 $ 125,484 $ (86) $ 2,966 $ 1,002 $ 442 $ (72,998) $ 3,911 $ 60,763
Exercise of share options 2,976 1 2,975 0 0 0 0 0 0 2,976
Exercise of Employee options 0 [1] (84) 84 0 0 0 0 0 0
Share-based payments 1,347 0 1,347 0 0   0 0 410 1,757
Equity component of transaction with non-controlling interest 287 0 287 0 0 0 0 0 (287) 0
Dividend paid to non-controlling interests 0 0 0 0 0 0 0 0 (130) (130)
PPA Adjustments 0               (174) (174)
Net profit (loss) (76) 0 0 0 0 0   (76) 291 215
Total other comprehensive income (loss) (5,699) 0 0 0 (6,257) 0 558 0 (419) (6,118)
Balance as of ending at Dec. 31, 2022 55,687 43 130,009 (2) (3,291) 1,002 1,000 (73,074) 3,602 59,289
Exercise of share options 25,631 5 25,114 0 0 512 0 0 0 25,631
Exercise of Employee options 0 [1] [1] 0 0 0 0 0 0 0
Share-based payments 1,116 0 1,116 0 0 0 0 0 136 1,252
Equity component of transaction with non-controlling interest 95 0 95 0 0 0 0 0 (95) 0
Dividend paid to non-controlling interests 0 0 0 0 0 0 0 0 (789) (789)
Net profit (loss) (7,056) 0 0 0 0 0   (7,056) 201 (6,855)
Total other comprehensive income (loss) (1,945) 0 0 0 (2,003) 0 58 0 (122) (2,067)
Balance as of ending at Dec. 31, 2023 $ 73,528 $ 48 $ 156,334 $ (2) $ (5,294) $ 1,514 $ 1,058 $ (80,130) $ 2,933 $ 76,461
[1] Represents an amount lower than $1.
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.24.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:      
Net profit (loss) $ (6,855) $ 215 $ (13,924)
Income and expenses not involving operating cash flows:      
Depreciation and amortization 7,692 7,134 5,382
Capital loss from disposals of property and equipment 278 51 63
Impairment of property, and equipment 0 0 118
Capital gain from amendment of lease liabilities (399) 0 0
Change in employee benefit liabilities, net 180 90 21
Financial Expenses (income), net (2,446) (7,443) 12,857
Valuation loss (gain) from short-term investments (848) 769 114
Cost of share-based payments 1,252 1,757 1,291
Tax expenses 891 1,097 455
Income and expenses not involving operating cash flows 6,600 3,455 20,301
Changes in operating assets and liabilities:      
Decrease (increase) in trade receivables, net (975) (641) 611
Increase in inventory (156) (2,544) (3,097)
Decrease (increase) in prepaid expenses 44 (21) 202
Decrease (increase) in other accounts receivable 62 (471) 289
Increase in trade payables 235 1,264 494
Increase (decrease) in deferred revenues 51 (246) (970)
Increase (decrease) in other accounts payable 965 845 (2,459)
Changes in operating assets and liabilities 226 (1,814) (4,930)
Cash paid and received:      
Interest received 621 429 318
Interest paid (1,296) (1,010) (440)
Income tax received 8 87 7
Income taxes paid (800) (1,435) (1,147)
Cash paid and received (1,467) (1,929) (1,262)
Net cash provided by (used) in operating activities (1,496) (73) 185
Cash flows from investing activities:      
Purchase of property and equipment (1,289) (1,661) (625)
Acquisition of subsidiaries 0 0 (27,323)
Investment in intangible assets (4,203) (5,243) (2,633)
Investment in short-term deposits (9,840) (5,705) (4,860)
Proceeds from short-term deposits 5,855 0 4,733
Purchase of short-term investments (2,291) (5,588) (13,622)
Proceeds from sale of short-term investments 2,422 11,764 3,356
Net cash used in investing activities (9,346) (6,433) (40,974)
Cash flows from financing activities:      
Proceeds from issue of share options liability 0 0 6,859
Dividend paid to non-controlling interests (789) (130) 0
Payment of lease liabilities (2,648) (2,447) (1,933)
Proceeds from issue of share capital, net 0 0 30,140
Exercise of share options 20,298 1,961 463
Payment of long-term loans (2,070) (1,665) 18,265
Payment of liability to underwriters (1,124) 0 (2,716)
Net cash provided by (used in) financing activities 13,667 (2,281) 51,078
Effect of exchange rate changes on cash and cash equivalents (615) (1,575) 414
Increase (decrease) in cash and cash equivalents 2,210 (10,362) 10,703
Cash and cash equivalents at the beginning of the year 4,483 14,845 4,142
Cash and cash equivalents at the end of the year 6,693 4,483 14,845
Non-cash transactions:      
Right-of-use asset recognized with corresponding lease liability (1,265) 1,658 131
Liability derecognized and recorded in equity upon exercise of share options $ 5,333 $ 1,015 $ 319
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.24.2
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
CONSOLIDATED STATEMENTS OF CASH FLOWS      
Trade receivables $ 0 $ 0 $ 3,424
Other receivables 0 0 685
Property and equipment 0 0 807
Deferred taxes 0 0 (3,356)
Right-of-use-assets 0 0 3,509
Intangible assets 0 0 34,157
Trade payables 0 0 (668)
Other payables 0 0 (2,492)
Put option, net 0 0 (185)
Loans from banks 0 0 (390)
Employee benefit liabilities 0 0 (985)
Lease liabilities 0 0 (3,510)
Non-controlling interests 0 0 (3,673)
Total $ 0 $ 0 $ 27,323
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.24.2
GENERAL
12 Months Ended
Dec. 31, 2023
Disclosure Of General Information About Financial Statements Abstract  
GENERAL
NOTE 1:-
GENERAL
 
  a.
SHL Telemedicine Ltd. ("SHL" and/or "the Company") was incorporated in Israel. The registered office is located at Ashdar Building, Yigal Alon St. in Tel Aviv. Its shares are publicly traded on the SIX Swiss Exchange under the symbol SHLTN. In April 2023 the Company started trading its American Depositary Shares (“ADRs”) on The NASDAQ Capital Market (the “Nasdaq”), under the ticker symbol “SHLT”.
 
SHL and its subsidiaries ("the Group") develop and market advanced personal telemedicine solutions. Personal telemedicine is the transmission of medical data by an individual, from a remote location to a medical call center via telecommunication networks. SHL's personal telemedicine systems are designed to improve quality of care and life for people suffering from various health conditions ranging from the high-risk and chronically ill to ordinary users of healthcare products and services who wish to take a more active role in managing their own health. In addition, the Group provides B2B healthcare services in Israel in the field of diagnostics, preventive medicine, and medical opinions to institutional customers.
 
  b.
The effects of the Swords of Iron War:
 
In October 2023, the Swords of Iron war broke out in Israel ("the war"). The ongoing war has led to a slowdown in business activity throughout the Israeli economy, as a result, among others, of the shutdown of enterprises in the south and north of Israel, the damage to local infrastructures, the nationwide military reserve draft for an indefinite period and the disruption of economic activity in the entire country. The prolongation of the war is likely to have extensive nationwide effects on numerous business and geographic segments.
 
The potential fluctuations in commodity prices, foreign currency exchange rates, availability of materials and manpower, local services and access to local resources are all liable to affect entities whose main operations are conducted in or with Israel.
 
Mediton's operations which provide services that are based on a fee-for-service model were affected by the war in Gaza during the last quarter of 2023. In the beginning of 2024 Mediton's activity is back on track.
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.24.2
ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2023
Disclosure Of Summary Of Significant Accounting Policies Abstract  
ACCOUNTING POLICIES
NOTE 2:-
ACCOUNTING POLICIES
 
  a.
Basis of presentation of the financial statements:
 
  1.
These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").
 
The Group's financial statements have been prepared on a cost basis, except for marketable securities, liability to underwriters and derivatives (put option, and liability for share options) which are measured at fair value through profit or loss and employee benefit assets and liabilities.
 
The Group has elected to present the statement of comprehensive income using the function of expense method.
 
  2.
Consistent accounting policies:
 
The accounting policies adopted in the financial statements have been applied consistently for all periods presented, unless otherwise stated.

 

  b.
Consolidated financial statements:
 
The consolidated financial statements comprise the financial statements of companies that are controlled by the Company (subsidiaries). Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.
 
The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group.
 
Non-controlling interests in subsidiaries represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statement of financial position.
 
A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as a change in equity by adjusting the carrying amount of the non-controlling interests with a corresponding adjustment of the equity attributable to equity holders of the Company less/plus the consideration paid or received.
 
  c.
Functional currency and presentation currency:
 
  1.
Functional currency and presentation currency:
 
The presentation currency of the financial statements is the U.S. dollar.
 
The functional currency, which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions, is separately determined for each Group entity and is used to measure its financial position and operating results. The functional currency of the Company and it's subsidiaries in Israel is the NIS.
 
When a Group entity's functional currency differs from the presentation currency, that entity's financial statements are translated so that they can be included in the consolidated financial statements as follows:
 
  a)
Assets and liabilities of foreign operations, including goodwill and any fair value adjustments to the carrying amounts of assets and liabilities arising from the acquisition of said foreign operation, are translated at the closing rate at the end of the reporting period.
 
  b)
Income and expenses for each period presented in the statement of income are translated at average exchange rates for the presented periods.
 
  c)
Share capital, capital reserves and other changes in capital are translated at the exchange rate prevailing at the date of incurrence.
 
  d)
Retained earnings are translated based on the opening balance translated at the exchange rate at that date and other relevant transactions (such as dividend) during the period are translated as described in b) and c) above.
 
  e)
All resulting translation differences are recognized as a separate component of other comprehensive income (loss) in equity "foreign currency translation reserve".
 
  2.
Index-linked monetary items:
 
Monetary assets and liabilities linked to the changes in the Israeli Consumer Price Index ("Israeli CPI") are adjusted at the relevant index at the end of each reporting period according to the terms of the agreement. Linkage differences arising from the adjustment, as above, other than those capitalized to qualifying assets or carried to equity in hedge transactions, are recognized in profit or loss.

 

  d.
Short-term deposits:
 
Short-term bank deposits are deposits with an original maturity of more than three months from the date of investment and which do not meet the definition of cash equivalents. The deposits are presented according to their terms of deposit.
 
  e.
Inventory:
 
Inventory of telemedicine devices for sale is presented at the lower of cost or net realizable value. Cost is determined using the "first-in, first-out" method.
 
Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.
 
  f.
Financial instruments:
 
  1.
Financial assets:
 
Financial assets are measured upon initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.
 
Equity instruments and other financial assets held for trading:
 
Investments in equity instruments do not meet the above criteria and accordingly are measured at fair value through profit or loss.
 
Other financial assets held for trading, including derivatives, are measured at fair value through profit or loss unless they are designated as effective hedging instruments.
 
  2.
Impairment of financial assets:
 
The Company evaluates at the end of each reporting period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss. The Company has short-term financial assets such as trade receivables in respect of which the Company applies a simplified approach and measures the loss allowance in an amount equal to the lifetime expected credit loss.
 
  3.
Financial liabilities:
 
  a)
Financial liabilities measured at amortized cost:
 
Financial liabilities are initially recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.
 
After initial recognition, the Company measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair value through profit or loss.
 
  b)
Financial liabilities measured at fair value through profit or loss:
 
Financial liabilities measured at fair value through profit or loss include liabilities held for trading, including derivatives, and financial liabilities that meet certain criteria which are designated upon initial recognition to fair value through profit or loss.
 
At initial recognition, the Company measures these financial liabilities at fair value. Transaction costs are recognized in profit or loss.
 
After initial recognition, changes in fair value are recognized in profit or loss.
 
  4.
Issue of a unit of securities:
 
The issue of a unit of securities involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.
 
  g.
Leases:
 
The Group accounts for a contract as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.
 
  1.
The Group as a lessee:
 
For leases in which the Group is the lessee, the Group recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Group has elected to recognize the lease payments as an expense in profit or loss on a straight-line basis over the lease term. In measuring the lease liability, the Group has elected to apply the practical expedient in the Standard and does not separate the lease components from the non-lease components (such as management and maintenance services, etc.) included in a single contract.
 
Leases which entitle employees to a company car as part of their employment terms are accounted for as employee benefits in accordance with the provisions of IAS 19 and not as subleases.
 
On the commencement date, the lease liability includes all unpaid lease payments (excluding variable lease payments) discounted at the interest rate implicit in the lease, if that rate can be readily determined, or otherwise using the Group 's incremental borrowing rate. After the commencement date, the Group measures the lease liability using the effective interest rate method.
 
On the commencement date, the right-of-use asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful life and the lease term.
 
Following are the periods of depreciation of the right-of-use assets by class of underlying asset:
 
   
Years
 
Mainly
         
Motor vehicles
 
1.5 - 3.5
 
3
Buildings
 
4 - 11
 
10
 
The Group tests for impairment of the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36.
 
  2.
Variable lease payments that depend on an index:
 
On the commencement date, the Group uses the index rate prevailing on the commencement date to calculate the future lease payments.
 
For leases in which the Group is the lessee, the aggregate changes in future lease payments resulting from a change in the index are discounted (without a change in the discount rate applicable to the lease liability) and recorded as an adjustment of the lease liability and the right-of-use asset, only when there is a change in the cash flows resulting from the change in the index (that is, when the adjustment to the lease payments takes effect).
 
 
3.
Lease extension and termination options:
 
A non-cancellable lease term includes both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.
 
In the event of any change in the expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Group remeasures the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized in profit or loss.
 
  4.
Lease modifications:
 
If a lease modification does not reduce the scope of the lease and does not result in a separate lease, the Group remeasures the lease liability based on the modified lease terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset.
 
If a lease modification reduces the scope of the lease, the Group recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use asset and the lease liability. The Group subsequently remeasures the carrying amount of the lease liability according to the revised lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset.
 
  h.
Business combinations and goodwill:
 
Business combinations are accounted for by applying the acquisition method. The cost of the acquisition is measured at the fair value of the consideration transferred on the date of acquisition with the addition of non-controlling interests in the acquiree.
 
Direct acquisition costs are carried to the income statement as incurred.
 
A put option granted by the Group to non-controlling interests and concurrently a call option received by the Group from the non-controlling interests that can be settled in cash or by the delivery of a variable number of shares are accounted for as a derivative financial liability or asset presented on a net basis and measured at fair value. The non-controlling interests continue to be recognized in equity until the put or call options are exercised.
 
Goodwill is initially measured at cost which represents the excess of the acquisition consideration and the amount of non-controlling interests over the net identifiable assets acquired and liabilities assumed.
 
After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For purposes of evaluation of impairment of goodwill, goodwill purchased in a business combination is evaluated and attributed to the cash-generating units to which it had been allocated.
 
  i.
Property and equipment:
 
Property and equipment are measured at cost, including directly attributable costs, less accumulated depreciation and accumulated impairment losses.
 
Depreciation is calculated at constant annual rates on a straight-line basis over the useful life of the assets at annual rates as follows:
 
   
%
   
         
Medical equipment
 
10 - 15
 
(mainly 15%)
Motor vehicles and ambulances
 
15 - 20
 
(mainly 20%)
Office furniture and equipment
 
6 - 7
 
(mainly 6%)
Computers and peripheral equipment
 
15 - 33
 
(mainly 20%)
Leasehold improvements
 
see below
   
Telemedicine devices on loan to customers
 
10
   
 
Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including any extension option held by the Group and intended to be exercised) and the expected life of the improvement.
 
  j.
Intangible assets:
 
Intangible assets acquired in a business combination are included at fair value at the acquisition date. After initial recognition, intangible assets are carried at their cost less any accumulated amortization and any accumulated impairment losses. Expenditures relating to internally generated intangible assets, excluding capitalized development costs, are recognized in profit or loss when incurred.
 
According to management's assessment, intangible assets have a finite useful life. The assets are amortized over their useful life using the straight-line method and reviewed for impairment whenever there is an indication that the asset may be impaired.
 
The useful life of intangible assets is as follows:
 
   
Years
     
Developments costs
 
5 - 10
Computer software
 
5
Contracts
 
6.75
Customer relations
 
10
Information technology
 
6
 
Research and development expenditures:
 
Research expenditures are recognized in profit or loss when incurred. An intangible asset arising from development or from the development phase of an internal project is recognized if the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale; the Company's intention to complete the intangible asset and use or sell it; the Company's ability to use or sell the intangible asset; how the intangible asset will generate future economic benefits; the availability of adequate technical, financial and other resources to complete the intangible asset; and the Company's ability to measure reliably the expenditure attributable to the intangible asset during its development.
 
The asset is measured at cost less any accumulated amortization and any accumulated impairment losses. Costs recognized as intangible assets include directly attributable costs of preparing the asset for its intended use such as cost of materials, direct labor costs and overhead.
 
Amortization of the asset begins when development is complete and the asset is available for use. As for the testing of impairment, see l below.

 

  k.
Impairment of non-financial assets:
 
The Group evaluates the need to record an impairment of the carrying amount of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable. If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognized in profit or loss.
 
An impairment loss of an asset, other than goodwill, is reversed only if there have been changes in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognized. Reversal of an impairment loss, as above, shall not be increased above the lower of the carrying amount that would have been determined (net of depreciation or amortization) had no impairment loss been recognized for the asset in prior years and its recoverable amount. The reversal of impairment loss of an asset presented at cost is recognized in profit or loss.
 
The following criteria are applied in assessing impairment of these specific assets:
 
 
1.
Goodwill related to subsidiaries:
 
For the purpose of impairment testing, goodwill acquired in a business combination is allocated, at the acquisition date, to each of the Group's cash-generating units that is expected to benefit from the synergies of the combination.
 
The Company reviews goodwill for impairment once a year or more frequently if events or changes in circumstances indicate that there is impairment.
 
Goodwill is tested for impairment by assessing the recoverable amount of the cash-generating unit (or group of cash-generating units) to which the goodwill has been allocated. An impairment loss is recognized if the recoverable amount of the cash-generating unit (or group of cash-generating units) to which goodwill has been allocated is less than the carrying amount of the cash-generating unit (or group of cash-generating units). Any impairment loss is allocated first to goodwill. Impairment losses recognized for goodwill cannot be reversed in subsequent periods.
 
  2.
Development costs capitalized during the development period:
 
The impairment test is performed annually, on December 31, or more frequently if events or changes in circumstances indicate that there is impairment.

 

  l.
Taxes on income:
 
Taxes on income in the statement of comprehensive income comprise current and deferred taxes. Current or deferred taxes are recognized in the statement of income except to the extent that the tax arises from items which are recognized directly in other comprehensive income or in equity. In such cases, the tax effect is also recognized in the relevant item.
 
  1.
Current taxes:
 
The current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period as well as adjustments required in connection with the tax liability in respect of previous years.
 
  2.
Deferred taxes:
 
Deferred taxes are computed in respect of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.
 
Deferred taxes are measured at the tax rates that are expected to apply to the period when the taxes are reversed in profit or loss, comprehensive income or equity, based on tax laws that have been enacted or substantively enacted by the end of the reporting period. Deferred taxes in profit or loss represent the changes in the carrying amount of deferred tax balances during the reporting period, excluding changes attributable to items recognized outside of profit or loss.
 
Deferred tax assets are reviewed at the end of each reporting period and reduced to the extent that it is not probable that they will be utilized. Also, temporary differences (such as carry forward losses) for which deferred tax assets have not been recognized are reassessed and deferred tax assets are recognized to the extent that their recoverability has become probable. Any resulting reduction or reversal is recognized in the line item, "taxes on income". Taxes that would apply in the event of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends does not involve an additional tax liability or since it is the Group's policy not to initiate distribution of dividends that triggers an additional tax liability.

 

 
m.
Share-based payment transactions:
 
The Company's employees are entitled to remuneration in the form of equity-settled share-based payment transactions (see details in Note 22).
 
Equity-settled transactions:
 
The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using a standard option pricing model, additional details are given in Note 22d
 
No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.
 
If the Group modifies the conditions on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.

 

  n.
Employee benefit liabilities:
 
The Group has several employee benefit plans:
 
  1.
Short-term employee benefits:
 
Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized when the Group has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made. The short-term employee benefit liability in the statement of financial position is measured on an undiscounted basis.
 
  2.
Post-employment benefits:
 
The plans are normally financed by contributions to insurance companies or funds and classified as defined contribution plans or as defined benefit plans.
 
  a)
Defined contribution plans:
 
The Group has defined contribution plans pursuant to section 14 to the Severance Pay Law under which the Group pays fixed contributions and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods.
 
Contributions to a defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed concurrently with performance of the employee's services.
 
  b)
Defined benefit plans:
 
The Group operates a defined benefit plan in respect of severance pay pursuant to the Severance Pay Law in Israel. According to the Law, employees are entitled to severance pay upon dismissal or retirement. The liability for termination of employee-employer relation is measured using the projected unit credit method. The actuarial assumptions include rates of employee turnover and future salary increases based on the estimated timing of payment. The amounts are presented based on discounted expected future cash flows using a discount rate determined by reference to market yields at the reporting date on high quality corporate bonds that are linked to the Consumer Price Index with term of the benefit obligation.
 
In respect of its severance pay obligation to certain of its employees, the Group makes current deposits in pension funds and insurance companies ("the plan assets"). Plan assets comprise assets held by a long-term employee benefit fund or qualifying insurance policies. Plan assets are not available to the Group's own creditors and cannot be returned directly to the Group.
 
The liability for employee benefits presented in the balance sheet reflects the present value of the defined benefit obligation less the fair value of the plan assets (see details in Note 18).
 
Remeasurements of the net liability are recognized as other comprehensive income (loss) in the period in which they occur.
 
  o.
Revenue recognition:
 
Revenue recognition:
 
Revenue from contracts with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf of third parties (such as taxes).
 
Revenue from rendering of services:
 
Revenue from rendering of services is recognized over time, during the period the customer simultaneously receives and consumes the benefits provided by the Company's performance. Revenue is recognized in the reporting periods in which the services are rendered. Revenues from the installation fees are recognized as the installation is performed.
 
The Company charges its customers based on payment terms agreed upon in specific agreements. When payments are made before or after the service is performed, the Company recognizes the resulting contract asset (income receivable) or liability (deferred revenues) and recognizes revenue in profit or loss when the work is performed. The Company has elected to apply the practical expedient allowed by the Standard and does not separate the financing component in transactions in which the period between receipt of the advance payment and the performance of the service is expected to be less than one year.
 
Revenue from the sale of telemedicine devices:
 
Revenue from sale of telemedicine devices is recognized in profit or loss at the point in time when the control of the goods is transferred to the customer, generally upon delivery of the goods to the customer.
 
Costs of obtaining a contract:
 
Costs incurred in obtaining subscription contracts which would not have been incurred if the contract had not been obtained (incremental costs) and which the Company expects to recover are recognized as an asset (prepaid expenses). The asset is amortized over the estimated average service period of subscriber contracts, adjusted for cancellations.
 
  p.
Interest income:
 
Interest income on financial assets is recognized as it accrues using the effective interest method.
 
  q.
Earnings per share:
 
Basic earnings per share are calculated by dividing the net income attributable to equity holders of the Company by the weighted number of Ordinary shares outstanding during the period.
 
For diluted earnings per share, the weighted average of shares outstanding is adjusted, assuming conversion of potential dilutive shares (employee options), except when such conversion has an anti-dilutive effect.

 

 
r.
Fair value measurement:
 
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
 
Fair value measurement is based on the assumption that the transaction will take place in the asset's or the liability's principal market, or in the absence of a principal market, in the most advantageous market.
 
The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.
 
Fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.
 
The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.
 
All assets and liabilities measured at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level input that is significant to the entire fair value measurement:
 
Level 1
-
quoted prices (unadjusted) in active markets for identical assets or liabilities.
     
Level 2
-
inputs other than quoted prices included within Level 1 that are observable directly or indirectly.
     
Level 3
-
inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).
 
  s.
Exchange rates and linkage basis:
 
Data regarding Israeli CPI and exchange rates of the U.S. dollar, the Euro and the Swiss Franc in relation to the NIS is as follows:
 
   
Israeli
   
Exchange rate of
 
For the year ended
 
CPI
   
   
U.S. $
   
CHF
 
   
Points *)
   
NIS
 
                           
December 31, 2023
   
248.6
     
4.01
     
3.63
     
4.31
 
December 31, 2022
   
241.4
     
3.75
     
3.52
     
3.82
 
December 31, 2021
   
229.4
     
3.52
     
3.11
     
3.40
 
                                 
Change during the year
 
%
 
                                 
2023
   
3
     
6. 9
     
3.1
     
12.8
 
2022
   
5.2
     
6.5
     
13.2
     
12.4
 
2021     2.8       (10.7 )     (3.1 )     (6.8 )
 
  *)
The index on an average basis of 1993 = 100.

 

  t.
Changes in accounting policies - initial application of new financial reporting and accounting standards and amendments to existing financial reporting and accounting standards:
 
  1.
Amendment to IAS 8, "Accounting Policies, Changes to Accounting Estimates and Errors":
 
In February 2021, the IASB issued an amendment to IAS 8, "Accounting Policies, Changes to Accounting Estimates and Errors" ("the Amendment"), in which it introduces a new definition of "accounting estimates".
 
Accounting estimates are defined as "monetary amounts in financial statements that are subject to measurement uncertainty". The Amendment clarifies the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors.
 
The Amendment is applied prospectively for annual reporting periods beginning on January 1, 2023 and is applicable to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period.
 
The application of the Amendment did not have a material impact on the Company's consolidated financial statements.
 
  2.
Amendment to IAS 12, "Income Taxes":
 
In May 2021, the IASB issued an amendment to IAS 12, "Income Taxes" ("IAS 12"), which narrows the scope of the initial recognition exception under IAS 12.15 and IAS 12.24 ("the Amendment").
 
According to the recognition guidelines of deferred tax assets and liabilities, IAS 12 excludes recognition of deferred tax assets and liabilities in respect of certain temporary differences arising from the initial recognition of certain transactions. This exception is referred to as the "initial recognition exception". The Amendment narrows the scope of the initial recognition exception and clarifies that it does not apply to the recognition of deferred tax assets and liabilities arising from transactions that are not a business combination and that give rise to equal taxable and deductible temporary differences, even if they meet the other criteria of the initial recognition exception.
 
The Amendment applies for annual reporting periods beginning on January 1, 2023. In relation to leases and decommissioning obligations, the Amendment is applied commencing from the earliest reporting period presented in the financial statements in which the Amendment is initially applied. The cumulative effect of the initial application of the Amendment is recognized as an adjustment to the opening balance of retained earnings (or another component of equity, as appropriate) at that date.
 
The application of the Amendment did not have a material impact on the Company's consolidated financial statements.
 
  3.
Amendment to IAS 1, "Disclosure of Accounting Policies":
 
In February 2021, the IASB issued an amendment to IAS 1, "Presentation of Financial Statements" ("the Amendment"), which replaces the requirement to disclose 'significant' accounting policies with a requirement to disclose 'material' accounting policies. One of the main reasons for the Amendment is the absence of a definition of the term 'significant' in IFRS whereas the term 'material' is defined in several standards and particularly in IAS 1.
 
The Amendment is applicable for annual periods beginning on January 1, 2023.
 
The application of the above Amendment had an effect on the disclosures of the Company's accounting policies, but did not affect the measurement, recognition or presentation of any items in the Company's consolidated financial statements.
 
  4.
Amendment to IAS 12, "Income Taxes":
 
In May 2023, the IASB issued "International Tax Reform—Pillar Two Model Rules – Amendment to IAS 12" ("the Amendment") to clarify the application of IAS 12, "Income Taxes", to income taxes arising from tax law enacted or substantively enacted to implement the Organisation for Economic Co-operation and Development (OECD)/G20 Inclusive Framework on Base Erosion and Profit Shifting (BEPS) Pillar Two model rules (Pillar Two income taxes).
 
The Amendment introduces:
 
  (a)
A mandatory temporary exception from the application of IAS 12 regarding recognition and disclosure of deferred tax assets and liabilities arising from the implementation of the Pillar Two model rules; and
 
  (b)
Disclosure requirements for international entities affected by the international tax reform.
 
The mandatory temporary exception in (a) above – the use of which is required to be disclosed – applies immediately. The remaining disclosure requirements apply for annual reporting periods beginning on January 1, 2023.
 
The application of the Amendment did not have any impact on the Company's consolidated financial statements since the International Tax Reform does not apply to the Group whose annual revenues are less than € 750 million.
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.24.2
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS
12 Months Ended
Dec. 31, 2023
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS  
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS
NOTE 3:-
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS
 
Significant accounting judgments, estimates and assumptions used in the preparation of the financial statements:
 
  a.
Judgments:
 
In the process of applying the significant accounting policies, the Group has made the following judgments which have the most significant effect on the amounts recognized in the financial statements:
 
  -
Capitalization of development costs
 
Development costs are capitalized in accordance with the accounting policy described in Note 2k, which is based on the criteria set forth in IAS 38. The assessment of whether development costs meet the criteria for recognition as an intangible asset requires significant management judgment, in particular with respect to technical feasibility, generation of future economic benefits, and ability to measure reliably the costs attributable to the intangible asset.
 
  b.
Estimates and assumptions:
 
The preparation of these financial statements requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported amounts of assets, liabilities, revenues and expenses. In determining its accounting estimates, management relies on past experience, various underlying facts, external factors and reasonable assumptions, based on the relevant circumstances. These estimates and underlying assumptions are reviewed regularly. Changes in accounting estimates are reported in the period of the change in estimate.
 
The key assumptions made in the financial statements concerning uncertainties at the end of the reporting period and the critical estimates computed by the Group that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.
 
  -
Impairment of goodwill:
 
The Group reviews goodwill for impairment at least once a year. This requires management to make an estimate of the projected future cash flows from the continuing use of the cash-generating unit to which the goodwill is allocated and also to choose a suitable discount rate for those cash flows. Further details are given in Note 11.
 
  -
Deferred tax assets:
 
Deferred tax assets are recognized for unused carry forward tax losses and temporary differences to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and level of future taxable profits together with future tax planning strategies. Further details are given in Notes 2m and 19c.
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.24.2
DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION
12 Months Ended
Dec. 31, 2023
DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION  
DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION
NOTE 4:-
DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION
 
Amendment to IAS 1, "Presentation of Financial Statements":
 
In January 2020, the IASB issued an amendment to IAS 1, "Presentation of Financial Statements" regarding the criteria for determining the classification of liabilities as current or non-current ("the Original Amendment"). In October 2022, the IASB issued a subsequent amendment ("the Subsequent Amendment").
 
According to the Subsequent Amendment:
 
 
Only financial covenants with which an entity must comply on or before the reporting date will affect a liability's classification as current or non-current.
 
 
In respect of a liability for which compliance with financial covenants is to be evaluated within twelve months from the reporting date, disclosure is required to enable users of the financial statements to assess the risks related to that liability. The Subsequent Amendment requires disclosure of the carrying amount of the liability, information about the financial covenants, and the facts and circumstances at the end of the reporting period that could result in the conclusion that the entity may have difficulty in complying with the financial covenants.
 
According to the Original Amendment, the conversion option of a liability affects the classification of the entire liability as current or non-current unless the conversion component is an equity instrument.
 
The Original Amendment and Subsequent Amendment are both effective for annual periods beginning on or after January 1, 2024 and must be applied retrospectively. Early adoption is permitted.
 
The above Amendments are not expected to have a material impact on the Company's consolidated financial statements.
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.24.2
CASH AND CASH EQUIVALENTS
12 Months Ended
Dec. 31, 2023
Cash and cash equivalents [abstract]  
CASH AND CASH EQUIVALENTS
NOTE 5:-
CASH AND CASH EQUIVALENTS
 
   
December 31,
 
   
2023
   
2022
 
             
Cash in banks (mainly in USD, 2022 – in NIS)
   
6,271
     
4,377
 
Short-term deposits (in NIS)
   
422
     
106
 
                 
     
6,693
     
4,483
 
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.24.2
SHORT-TERM INVESTMENTS
12 Months Ended
Dec. 31, 2023
Short Term Investment Abstract  
SHORT-TERM INVESTMENTS
NOTE 6:-
SHORT-TERM INVESTMENTS
 
   
December 31,
 
   
2023
   
2022
 
Marketable securities:
           
             
Financial assets at fair value through profit or loss (mainly in USD)
           
Corporate bonds
   
4,181
     
4,033
 
Government bonds and loans
   
784
     
392
 
Shares
   
638
     
784
 
Exchange Traded Funds
   
3,375
     
3,308
 
                 
     
8,978
     
8,517
 
                 
Short-term deposits
   
10,579
     
5,700
 
                 
     
19,557
     
14,217
 
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.24.2
TRADE RECEIVABLES
12 Months Ended
Dec. 31, 2023
Trade Receivables Abstract  
TRADE RECEIVABLES
NOTE 7:-
TRADE RECEIVABLES
   
December 31,
 
   
2023
   
2022
 
             
Accounts receivable (1)
   
8,419
     
7,596
 
Other
   
138
     
201
 
Allowance for doubtful accounts
   
-
     
-
 
                 
     
8,557
     
7,797
 
 
  (1)
The terms of billed accounts receivable are generally 30-60 days. As of December 31, 2023 and 2022, there were no material billed receivables that were past due.
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.24.2
PREPAID EXPENSES
12 Months Ended
Dec. 31, 2023
Prepaid Expenses Abstract  
PREPAID EXPENSES
NOTE 8:-
PREPAID EXPENSES
 
Amortization of prepaid expenses (costs of obtaining contracts – see Note 2o) amounted to $731 in the year ended December 31, 2023 (2022- $788).
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.24.2
OTHER ACCOUNTS RECEIVABLE
12 Months Ended
Dec. 31, 2023
Other Accounts Receivable Abstract  
OTHER ACCOUNTS RECEIVABLE
NOTE 9:-
OTHER ACCOUNTS RECEIVABLE
 
   
December 31,
 
   
2023
   
2022
 
             
Interest receivable
   
53
     
190
 
Government authorities
   
298
     
616
 
Advances to supplies
   
328
     
54
 
Prepaid expenses
   
552
     
469
 
Others
   
561
     
583
 
                 
     
1,792
     
1,912
 
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.24.2
PROPERTY AND EQUIPMENT
12 Months Ended
Dec. 31, 2023
PROPERTY AND EQUIPMENT  
PROPERTY AND EQUIPMENT
NOTE 10:-
PROPERTY AND EQUIPMENT
 
   
Computers and
peripheral equipment
   
Medical equipment
   
Office
furniture and equipment
   
Motor
vehicles and ambulances
   
Leasehold improvements
   
Devices
on loan
   
Total
 
Cost:
                                         
                                           
Balance as of January 1, 2022
   
18,334
     
6,150
     
2,350
     
2,498
     
3,777
     
46,570
     
79,679
 
Additions during the year
   
479
     
31
     
153
     
4
     
598
     
395
     
1,660
 
Disposals during the year
   
(4
)
   
-
     
(64
)
   
(2
)
   
-
     
(1,106
)
   
(1,176
)
Transfer from inventory, net
   
-
     
-
     
-
     
-
     
-
     
564
     
564
 
Currency translation differences
   
(1,953
)
   
(715
)
   
(241
)
   
(290
)
   
(445
)
   
(5,232
)
   
(8,876
)
                                                         
Balance as of December 31, 2022
   
16,856
     
5,466
     
2,198
     
2,210
     
3,930
     
41,191
     
71,851
 
Additions during the year
   
699
     
7
     
66
     
181
     
127
     
209
     
1,289
 
Disposals during the year
   
(3,275
)
   
-
     
(366
)
   
(46
)
   
-
     
(4,497
)
   
(8,184
)
Transfer from inventory, net
   
-
     
-
     
-
     
-
     
-
     
226
     
226
 
Currency translation differences
   
(348
)
   
(165
)
   
(33
)
   
(60
)
   
(106
)
   
(1,126
)
   
(1,838
)
                                                         
Balance as of December 31, 2023
   
13,932
     
5,308
     
1,865
     
2,285
     
3,951
     
36,003
     
63,344
 
                                                         
Accumulated depreciation:
                                                       
                                                         
Balance as of January 1, 2022
   
17,292
     
6,018
     
1,756
     
2,139
     
3,152
     
45,297
     
75,654
 
Additions during the year
   
385
     
42
     
100
     
36
     
158
     
388
     
1,109
 
Disposals during the year
   
(4
)
   
-
     
(64
)
   
(2
)
   
-
     
(1,054
)
   
(1,124
)
Transfer from inventory, net
   
-
     
-
     
-
     
-
     
-
     
7
     
7
 
Currency translation differences
   
(1,852
)
   
(701
)
   
(181
)
   
(250
)
   
(364
)
   
(5,099
)
   
(8,447
)
                                                         
Balance as of December 31, 2022
   
15,821
     
5,359
     
1,611
     
1,923
     
2,946
     
39,539
     
67,199
 
Additions during the year
   
329
     
26
     
104
     
60
     
139
     
300
     
958
 
Disposals during the year
   
(3,113
)
   
-
     
(325
)
   
(46
)
   
-
     
(4,422
)
   
(7,906
)
Currency translation differences
   
(344
)
   
(160
)
   
(27
)
   
(59
)
   
(84
)
   
(1,125
)
   
(1,799
)
                                                         
Balance as of December 31, 2023
   
12,693
     
5,225
     
1,363
     
1,878
     
3,001
     
34,292
     
58,452
 
                                                         
Depreciated cost as of December 31, 2023
   
1,239
     
83
     
502
     
407
     
950
     
1,711
     
4,892
 
                                                         
Depreciated cost as of December 31, 2022
   
1,035
     
107
     
587
     
287
     
984
     
1,652
     
4,652
 
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.24.2
GOODWILL AND INTANGIBLE ASSETS, NET
12 Months Ended
Dec. 31, 2023
GOODWILL AND INTANGIBLE ASSETS, NET  
GOODWILL AND INTANGIBLE ASSETS, NET
NOTE 11:-
GOODWILL AND INTANGIBLE ASSETS, NET
 
   
Development costs
   
Contracts and
others
   
Customer relations
   
Information Technology
   
Total
other intangible assets
   
Goodwill
(1)
 
                                     
As of January 1, 2023, net of accumulated amortization
   
8,274
     
-
     
11,737
     
414
     
20,425
     
33,745
 
Additions during the year
   
4,203
     
-
     
-
     
-
     
4,203
     
-
 
Amortization during the year
   
(2,770
)
   
-
     
(1,309
)
   
(104
)
   
(4,183
)
   
-
 
Currency translation differences
   
171
     
-
     
(372
)
   
13
     
(188
)
   
(780
)
                                                 
As of December 31, 2023, net of accumulated amortization
   
9,878
     
-
     
10,056
     
323
     
20,257
     
32,965
 
                                                 
As of December 31, 2023:
                                               
                                                 
Cost
   
44,131
     
7,766
     
16,215
     
644
     
68,756
     
32,965
 
Accumulated amortization
   
(34,253
)
   
(7,766
)
   
(6,159
)
   
(321
)
   
(48,499
)
   
-
 
                                                 
Net carrying amount
   
9,878
     
-
     
10,056
     
323
     
20,257
     
32,965
 
 
   
Development costs
   
Contracts and
others
   
Customer relations
   
Information Technology
   
Total
other intangible assets
   
Goodwill
(1)
 
                                     
As of January 1, 2022, net of accumulated amortization
   
5,309
     
-
     
14,929
     
549
     
20,787
     
37,508
 
Additions during the year
   
5,243
     
-
     
-
     
-
     
5,243
     
-
 
Amortization during the year
   
(1,829
)
   
-
     
(1,526
)
   
(102
)
   
(3,457
)
   
-
 
PPA adjustment (see Note 5)
   
-
     
-
     
-
     
-
     
-
     
407
 
Currency translation differences
   
(449
)
   
-
     
(1,666
)
   
(33
)
   
(2,148
)
   
(4,170
)
                                                 
As of December 31, 2022, net of accumulated amortization
   
8,274
     
-
     
11,737
     
414
     
20,425
     
33,745
 
                                                 
As of December 31, 2022:
                                               
                                                 
Cost
   
46,961
     
7,488
     
16,510
     
621
     
71,580
     
33,745
 
Accumulated amortization
   
(38,687
)
   
(7,488
)
   
(4,773
)
   
(207
)
   
(51,155
)
   
-
 
                                                 
Net carrying amount
   
8,274
     
-
     
11,737
     
414
     
20,425
     
33,745
 
 
  (1)
The recoverable amount of the cash generating units to which the goodwill mainly relates has been determined based on a value in use calculation using cash flow projections from financial budgets approved by senior management covering a five-year period.

 

The carrying amount of the goodwill has been allocated to the following cash generating units:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
2,954
     
3,044
 
Israel – Mediton
   
16,111
     
16,606
 
Germany
   
13,900
     
14,095
 
                 
     
32,965
     
33,745
 
 
The recoverable amount of each of the cash generating units has been determined based on a value in use calculation using cash flow projections from financial budgets and forecasts approved by senior management covering a five-year period. The key assumptions used in the value in use calculations are the (i) discount rate (ii) growth rate of revenues in the 5 year forecast period subsequent to end of the reporting period, and (iii) growth rates used to extrapolate cash flows beyond the forecast period.
 
The pre-tax discount rate applied to cash flow projections are as follows:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
20.7
%
   
19.1
%
Israel – Mediton
   
19.4
%
   
18.3
%
Germany
   
20.5
%
   
16.8
%
 
The average growth rate of revenues in the 5 year forecast period subsequent to the end of the reporting period, are as follows:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
3.2
%
   
4
%
Israel – Mediton
   
4.9
%
   
5.4
%
Germany
   
11.3
%
   
13.8
%

 

The cash flows beyond the 5-year period are extrapolated using the following growth rates:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
3.2
%
   
3.2
%
Israel – Mediton
   
3.2
%
   
3.2
%
Germany
   
3
%
   
3
%
 
The recoverable amounts, based on value in use, of each of the cash generating units exceeds their carrying amounts.
 
As of December 31, 2023,, management of the Group believes that no reasonably possible changes in any of the above key assumptions would cause the carrying amount of the CGU Telemedicine to materially exceed its recoverable amount.
 
As of December 31, 2023, the estimated recoverable amount of the CGU Germany exceeds its carrying amount by $0.8 million. The changes in the following assumptions used in the value in use calculations would result in the carrying amount to equal the recoverable amount:
 
 
Pre-tax discount rate of 21.0%.
 
Long term growth rate of 2.2 % or lower
 
Reduction in the annual growth rate in fiscal years 2025-2028 of -1.9%.
 
As of December 31, 2023, the estimated recoverable amount of the CGU Mediton exceeds its carrying amount by $3.0 million. The change in the following assumption used in the value in use calculations would result in the carrying amount to equal the recoverable amount:
 
 
Pre-tax discount rate of 20.9%.
 
Long term growth rate of 1.4 % or lower
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.24.2
LEASES
12 Months Ended
Dec. 31, 2023
LEASES  
LEASES
NOTE 12:-
LEASES
 
Disclosures for leases in which the Company acts as lessee:
 
The Company has entered into leases of buildings and motor vehicles which are used for the Company's operations.
 
Leases of buildings have lease terms of between 4 and 11 years whereas leases of vehicles have lease terms of 3 years.
 
Some of the leases entered into by the Company include extension and/or termination options and variable lease payments.
 
During 2023, the Group reduced the scope of the lease in Germany. In addition modified the term of the lease in Germany such that the contract will end in 2027 instead of 2029 and the monthly rent decreased. As a result of this the Group recognized a capital gain of $399.
 
  a.
Information on leases:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Interest expense on lease liabilities
   
343
     
361
     
378
 
Expenses relating to short-term leases
   
-
     
25
     
25
 
Total cash outflow for leases
   
2,992
     
2,808
     
2,546
 
 
  b
Lease extension and termination options:
 
The Company has leases that include extension and termination options. These options provide flexibility in managing the leased assets and align with the Company's business needs.
 
The Company exercises significant judgement in deciding whether it is reasonably certain that the extension and termination options will be exercised.
 
The Company generally includes in the lease term the exercise of extension options existing in the lease agreements when it is reasonably certain that the extension option will be exercised. In these leases, the Company usually exercises the extension option to avoid a significant adverse impact to its operating activities in the event that an alternative asset is not available immediately upon termination of the noncancelable lease period.
 
In leases of motor vehicles, the Company does not include in the lease term the exercise of extension options since the Company does not ordinarily exercise options that extend the lease period beyond 5 years.
 
Lease terms that include termination options will include the period covered by the termination option when it is reasonably certain that the termination option will not be exercised.
 
Following are details of potential future undiscounted lease payments for periods covered by extension or termination options that were not included in the measurement of the Company's lease liabilities:
 
   
More than 5 years
 
   
December 31,
 
   
2023
   
2022
 
Lease payments applicable in extension option periods which as of the end of the reporting period are not reasonably certain to be exercised
   
2,479
     
2,472
 
 
 
c.
Disclosures in respect of right-of-use assets:
 
   
Buildings
   
Motor vehicles
   
Total
 
Cost:
                 
                   
Balance as of January 1, 2023
   
15,844
     
1,449
     
17,293
 
Additions during the year:
                       
New leases
   
663
     
634
     
1,297
 
Adjustments for indexation
   
145
     
23
     
168
 
Disposals
   
(6,198
)
   
(52
)
   
(6,250
)
Currency translation differences
   
(22
)
   
(18
)
   
(40
)
                         
Balance as of December 31, 2023
   
10,432
     
2,036
     
12,468
 
                         
Accumulated depreciation:
                       
                         
Balance as of January 1, 2023
   
5,258
     
997
     
6,255
 
Additions during the year:
                       
Depreciation and amortization
   
2,214
     
337
     
2,551
 
Disposals
   
(3,520
)
   
-
     
(3,520
)
Currency translation differences
   
(19
)
   
(13
)
   
(32
)
                         
Balance as of December 31, 2023
   
3,933
     
1,321
     
5,254
 
                         
Depreciated cost at December 31, 2023
   
6,499
     
715
     
7,214
 

 

   
Buildings
   
Motor vehicles
   
Total
 
Cost:
                 
                   
Balance as of January 1, 2022
   
16,089
     
1,078
     
17,167
 
Additions during the year:
                       
New leases
   
950
     
475
     
1,425
 
Adjustments for indexation
   
266
     
30
     
296
 
Disposals
   
(55
)
   
-
     
(55
)
Currency translation differences
   
(1,406
)
   
(134
)
   
(1,540
)
                         
Balance as of December 31, 2022
   
15,844
     
1,449
     
17,293
 
                         
Accumulated depreciation:
                       
                         
Balance as of January 1, 2022
   
3,384
     
770
     
4,154
 
Additions during the year:
                       
Depreciation and amortization
   
2,248
     
321
     
2,569
 
Disposals
   
(29
)
   
-
     
(29
)
Currency translation differences
   
(345
)
   
(94
)
   
(439
)
                         
Balance as of December 31, 2022
   
5,258
     
997
     
6,255
 
                         
Depreciated cost at December 31, 2022
   
10,586
     
452
     
11,038
 
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.24.2
CREDIT FROM BANKS
12 Months Ended
Dec. 31, 2023
Disclosure Of Credit From Banks Abstract  
CREDIT FROM BANKS
NOTE 13:-
CREDIT FROM BANKS
 
 
Interest
           
 
rate (1)
 
December 31,
 
 
%
 
2023
   
2022
 
               
Current maturities of long-term loans (see Note 14)
Prime (1)+1.05
   
2,160
     
2,169
 
                   
       
2,160
     
2,169
 
 
  (1)
The Prime rate as of December 31, 2023 – 6.25% (December 31, 2022 – 4.75%).
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.24.2
LONG-TERM LOANS
12 Months Ended
Dec. 31, 2023
Long Term Loans Abstract  
LONG-TERM LOANS
NOTE 14:-
LONG-TERM LOANS
 
  a.
On August 29, 2021, the Company signed an agreement with a bank in Israel to obtain a long-term loan in the amount of NIS 59 million (approximately $18,000) for a period of 7 years and 9 months. The loan is denominated in NIS and bears an annual interest rate of prime + 1.05% (2.65% as of the signing date). The loan will be repaid in 28 quarterly installments following an initial moratorium period of 9 months.
 
The loan agreement includes certain financial covenants related to the Company's Israeli operations, as follows: (i) tangible equity of at least NIS 40 million; (ii) tangible equity to total tangible assets of at least 40%; and (iii) net debt to EBITDA of 3.5 at the maximum. As of December 31, 2023 the Company is in compliance with these covenants.
 
  b.
Composition:
 
   
December 31,
 
   
2023
   
2022
 
             
Long-term loan
   
12,620
     
15,177
 
Less – current maturities
   
2,160
     
2,169
 
                 
Balance
   
10,460
     
13,008
 
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.24.2
DEFERRED REVENUES
12 Months Ended
Dec. 31, 2023
DEFERRED REVENUES  
DEFERRED REVENUES
NOTE 15:-
DEFERRED REVENUES
 
Deferred revenues are in respect of contracts in which the period between receipt of the advance payment and the performance of the service is expected to be less than one year.
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.24.2
OTHER PAYABLES
12 Months Ended
Dec. 31, 2023
Other Payables Abstract  
OTHER PAYABLES
NOTE 16:-
OTHER PAYABLES
 
   
December 31,
 
   
2023
   
2022
 
             
Employees and payroll accruals
   
4,376
     
4,562
 
Accrued expenses
   
2,304
     
2,090
 
Liability for underwriter – see Note 17
   
-
     
1,131
 
VAT to customers and suppliers
   
-
     
399
 
Government authorities
   
754
     
640
 
Accruals restructuring
   
686
     
-
 
Other
   
416
     
416
 
                 
     
8,536
     
9,238
 
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.24.2
FINANCIAL INSTRUMENTS
12 Months Ended
Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]  
FINANCIAL INSTRUMENTS
NOTE 17:-
FINANCIAL INSTRUMENTS
 
Financial assets and liabilities:
 
   
Carrying amount
 
   
December 31,
 
   
2023
   
2022
 
Financial assets at amortized cost:
           
             
Cash and cash equivalents
   
6,693
     
4,483
 
Short term deposits
   
10,579
     
5,700
 
Trade receivables
   
8,557
     
7,797
 
Other accounts receivable
   
1,792
     
1,912
 
Long term deposits
   
328
     
423
 
                 
Total
   
27,949
     
20,315
 
                 
Financial assets at fair value through profit or loss:
               
                 
Call option from non-controlling interests
   
147
     
245
 
Short term investments
   
8,978
     
8,517
 
                 
Total
   
9,125
     
8,762
 
                 
Financial liabilities at amortized cost:
               
                 
Credit from banks and others
   
2,160
     
2,169
 
Trade payables
   
3,884
     
3,757
 
Other payables
   
8,536
     
8,110
 
Loans from banks
   
10,460
     
13,008
 
Lease liabilities
   
7,239
     
11,565
 
                 
Total
   
32,279
     
38,609
 
                 
Financial liabilities at fair value through profit or loss:
               
                 
Liability for share options
   
-
     
7,164
 
Other payables - liability to underwriters
   
-
     
1,131
 
                 
Total
   
-
     
8,295
 
 
The main risks arising from the Group's financial instruments are credit risk, foreign currency risk, interest rate risk, market risk and liquidity risk. The Board of Directors reviews and agrees on policies for managing each of these risks, which are summarized below.
 
  a.
Concentration of credit risks:
 
Financial instruments that potentially subject the Group to concentrations of credit risk consist principally of cash, cash equivalents, and trade receivables. Cash and cash equivalents are deposited with major banks. Management believes that the financial institutions that hold the Group's investments are financially sound, and, accordingly, minimal credit risk exists with respect to these investments.
 
The Group's trade receivables mainly derived from sales to customers in Germany and Israel. The Group has adopted credit policies and standards intended to accommodate industry growth and inherent risk. Management believes that credit risks are moderated by the diversity of its end customers. The Group performs ongoing credit evaluations of its customers' financial condition and requires collateral as deemed necessary. An estimate for doubtful accounts is made when collection of the full amount is no longer probable.
 
  b.
Foreign currency risk:
 
The Group is subject to foreign exchange risk as it holds cash and cash equivalents and short-term investments in foreign currency as the Group purchases its devices in foreign currency. Group management regularly monitors its foreign exchange risk and attempts to limit such risks by making adequate decisions regarding cash and credit positions.
 
Foreign currency sensitivity analysis:
 
The following table demonstrates the sensitivity test to a reasonably possible change in USD and EUR exchange rates, with all other variables held constant. The impact on the Company's profit before tax is due to changes in the fair value of monetary assets. The Company's exposure to foreign currency changes for all other currencies is immaterial.
 
   
Change in USD rate
   
Effect on profit tax
 
             
2023
   
+5
%
   
(721
)
     
-5
%
   
721
 
                 
2022
   
+5
%
   
(320
)
     
-5
%
   
320
 
 
   
Change in EUR rate
   
Effect on profit tax
 
             
2023
   
+5
%
   
(66
)
     
-5
%
   
66
 
                 
2022
   
+5
%
   
(38
)
     
-5
%
   
38
 

 

  c.
Market risk:
 
The Group has investments in marketable financial instruments that commencing from March 31, 2020 are classified as Financial assets at fair value through profit or loss in respect of which the Group is exposed to risk of fluctuations in the security price that is determined by reference to the quoted market price (level 1 of the fair value hierarchy). As of December 31, 2023, the balance of these investments is $8,978.
 
The following table demonstrates the sensitivity to a reasonably possible change in the market price with all other variables held constant, of the Group's profit before tax (due to changes in the carrying amount of marketable securities).
 
   
Increase/
decrease in price
   
Effect on
profit
before tax
 
             
2023
   
+5
%
   
449
 
     
-5
%
   
(449
)
                 
2022
   
+5
%
   
426
 
     
-5
%
   
(426
)
 
  d.
Fair value of financial instruments not measured at fair value:
 
The carrying amounts of cash and cash equivalents, trade and other receivables, short-term credit from banks, trade payables and other accounts payable approximate their fair value due to the short-term maturity of such instruments. The carrying amount of long-term bank loan approximates the fair value as the interest rate is variable.
 
Management believes that the carrying amount of long-term deposits approximates their fair value.
 
  e.
Interest rate risk:
 
The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's debt obligations with floating interest rates.
 
The effect of reasonably possible increase of 5% of the interest rate on the Group's profit before tax is not material.
 
  f.
Liquidity risk:
 
The Group monitors its risk to a shortage of funds using a recurring liquidity planning tool. This tool considers the maturity of both its financial investments and financial assets and projected cash flows from operations.
 
The Group has long-term lease liabilities repayable in monthly equal installments until June 2032.
 
Total aggregate contractual undiscounted payments including interest amounts to approximately $10,776.
 
The table below summarizes the maturity profile of the Group's financial liabilities based on contractual undiscounted payments (including interest payments):
 
December 31, 2023:
 
   
Less than one year
   
1 to 2 years
   
2 to 3
years
   
3 to 4 years
   
4 to 5 years
   
> 5
years
   
Total
 
                                           
Trade payables
   
3,884
     
-
     
-
     
-
     
-
     
-
     
3,884
 
Accrued expenses
   
2,990
     
-
     
-
     
-
     
-
     
-
     
2,990
 
PUT option (*)
   
-
     
8,225
     
-
     
-
     
-
     
-
     
8,225
 
Lease liabilities
   
2,542
     
2,280
     
1,814
     
1,615
     
1,571
     
953
     
10,775
 
Loans from bank
   
3,023
     
2,920
     
2,816
     
2,710
     
2,600
     
1,258
     
15,327
 
                                                         
     
12,439
     
13,425
     
4,630
     
4,325
     
4,171
     
2,211
     
41,201
 
 
December 31, 2022:
 
   
Less than one year
   
1 to 2 years
   
2 to 3
years
   
3 to 4 years
   
4 to 5 years
   
> 5
years
   
Total
 
                                           
Trade payables
   
3,757
     
-
     
-
     
-
     
-
     
-
     
3,757
 
Accrued expenses
   
2,090
     
-
     
-
     
-
     
-
     
-
     
2,090
 
PUT option (*)
   
-
     
-
     
11,289
     
-
     
-
     
-
     
11,289
 
Liability for underwriter
   
1,131
     
-
     
-
     
-
     
-
     
-
     
1,131
 
Lease liabilities
   
2,478
     
2,294
     
1,932
     
1,726
     
3,608
     
274
     
12,312
 
Loans from bank
   
3,002
     
2,933
     
2,861
     
2,788
     
2,714
     
3,927
     
18,225
 
                                                         
     
12,458
     
5,227
     
16,082
     
4,514
     
6,322
     
4,201
     
48,804
 
 
  (*)
Estimated gross cash outflow assuming that option will be exercised at earliest possible date.

 

  g.
Changes in liabilities arising from financing activities:
 
   
January 1,
2023
   
Cash
flows
   
Foreign
exchange
movement
   
Other
   
December 31, 2023
 
                               
Lease liabilities (including current maturities)
   
11,564
     
(3,048
)
   
(12
)
   
(1,265
)
   
7,239
 
Liability for underwriters
   
1,131
     
(1,124
)
   
(22
)
   
15
     
-
 
Long term bank loan
   
15,176
     
(2,070
)
   
(486
)
   
-
     
12,620
 
                                         
Total liabilities from financing activities
   
27,871
     
(6,241
)
   
(520
)
   
(1,250
)
   
19,859
 
 
   
January 1,
2022
   
Cash
flows
   
Foreign
exchange
movement
   
Other
   
December 31, 2022
 
                               
Lease liabilities (including current maturities)
   
13,530
     
(2,447
)
   
(1,176
)
   
1,657
     
11,564
 
Liability for underwriters
   
1,021
     
-
     
(129
)
   
239
     
1,131
 
Long term bank loan
   
18,971
     
(1,665
)
   
(2,130
)
   
-
     
15,176
 
                                         
Total liabilities from financing activities
   
33,522
     
(4,112
)
   
(3,435
)
   
1,896
     
27,871
 

 

  h.
Fair value:
 
The table below is a comparison between the carrying amount and fair value of the Company's financial instruments that are presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):
 
Reconciliation of fair value measurements that are categorized within Level 3 of the fair value hierarchy in financial instruments:
 
   
Financial instruments
 
   
Liability for share options (*)
   
Liability to underwriters
   
Call (Put) option to non-controlling interests, net
   
Total
 
                         
Balance as of January 1, 2023
   
(7,164
)
   
(1,131
)
   
245
     
(8,050
)
                                 
Issuance of Share Options
                               
Remeasurement recognized in:
                               
Profit (loss)
   
1,801
     
(15
)
   
(89
)
   
1,697
 
Other comprehensive income (loss)
   
30
     
22
     
(9
)
   
43
 
Exercise of Share Options into shares
   
5,333
     
-
     
-
     
5,333
 
Payment
   
-
     
1,124
     
-
     
1,124
 
                                 
As of December 31, 2023
   
-
     
-
     
147
     
147
 
                                 
Presented in balance sheet:
                               
                                 
Put option
   
-
     
-
     
147
     
147
 
 
   
Financial instruments
 
   
Liability for share options (*)
   
Liability to underwriters
   
Call (Put) option to non-controlling interests, net
   
Total
 
                         
Balance as of January 1, 2022
   
(17,220
)
   
(1,021
)
   
(67
)
   
(18,308
)
                                 
Issuance of Share Options
                               
Remeasurement recognized in:
                               
Profit (loss)
   
7,423
     
(240
)
   
320
     
7,503
 
Other comprehensive income (loss)
   
1,618
     
130
     
(8
)
   
1,740
 
Exercise of Share Options into shares
   
1,015
     
-
     
-
     
1,015
 
                                 
As of December 31, 2022
   
(7,164
)
   
(1,131
)
   
245
     
(8,050
)
                                 
Presented in balance sheet:
                               
                                 
Call option
   
-
     
-
     
245
     
245
 
Other payables (short-term)
   
-
     
(1,131
)
   
-
     
(1,131
)
                                 
Liability for share options
   
(7,164
)
   
-
     
-
     
(7,164
)
 
  (*)
See Note 22b for information on fair value measurement.

 

The Company used the Monte Carlo option pricing model when estimating the fair value of the Put and Call Options granted in the acquisition of Mediton Group – in 2021.
 
The following table lists the significant inputs to the Monte Carlo model used to determine the fair value of the Put Option net of the Call option:
 
   
December 31, 2023
   
December 31, 2022
 
             
Underlying asset value
   
35,732
     
35,541
 
Expected volatility of the share price
   
34.7%
 
   
36.7%-39.2%
 
Discount rate
   
14.9%
 
   
15%
 
Risk-free interest rate
   
3.64%
 
   
3.68%
 
Term of option
 
2.67 years
   
3.67 years
 
 
The following table demonstrates the effect on fair value of a reasonably possible change in the underlying asset value with all other variables held constant:
 
2023:
 
   
Increase/
decrease in underlying asset value
   
Effect on
Fair value, net
 
             
     
+5%
 
   
433
 
     
-5%
 
   
(430)
 
 
2022:
 
   
Increase/
decrease in underlying asset value
   
Effect on
Fair value, net
 
             
     
+5%
 
   
463
 
     
-5%
 
   
(453)
 
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.24.2
EMPLOYEE BENEFIT LIABILITIES
12 Months Ended
Dec. 31, 2023
EMPLOYEE BENEFIT LIABILITIES  
EMPLOYEE BENEFIT LIABILITIES
NOTE 18:-
EMPLOYEE BENEFIT LIABILITIES
 
  a.
Changes in the defined benefit obligation and fair value of plan assets:
 
2023:
 
         
Expenses recognized in profit or loss
               
Gain (loss) from remeasurement in other comprehensive income
                   
   
Balance at January 1, 2023
   
Current service cost
   
Net interest expense
   
 
Past service cost and effect of settlements
   
Total expense recognized in profit or loss for the period
   
Payments from the plan
   
Actuarial gain (loss) arising from changes in financial assumptions
   
Actuarial gain (loss) arising from experience adjustments
   
Total effect
on other comprehensive income for the period
   
Effect of changes in foreign exchange rates
   
Contributions by employer
   
Balance at December 31, 2023
 
                                                                         
Defined benefit obligation
   
(8,153
)
   
(340
)
   
(409
)
   
(35
)
   
(784
)
   
148
     
81
     
(7
)
   
74
     
223
     
-
     
(8,492
)
Fair value of plan assets
   
6,658
     
-
     
351
     
-
     
351
     
(134
)
   
-
     
(4
)
   
(4
)
   
(191
)
   
239
     
6,919
 
                                                                                                 
Net defined benefit liability (asset)
   
(1,495
)
   
(340
)
   
(58
)
   
(35
)
   
(433
)
   
14
     
81
     
(11
)
   
70
     
32
     
239
     
(1,573
)
 
2022:
 
   
Expenses recognized in profit or loss
               
Gain (loss) from remeasurement in other comprehensive income
                   
   
Balance at January 1, 2022
   
Current service cost
   
Net interest expense
   
Total expense recognized in profit or loss for the period
   
Payments from the plan
   
Actuarial gain (loss) arising from changes in financial assumptions
   
Actuarial gain (loss) arising from experience adjustments
   
Total effect
on other comprehensive income for the period
   
Effect of changes in foreign exchange rates
   
Contributions by employer
   
Balance at December 31, 2022
 
                                                                   
Defined benefit obligation
   
(9,848
)
   
(405
)
   
(245
)
   
(650
)
   
374
     
775
     
87
     
862
     
1,109
     
-
     
(8,153
)
Fair value of plan assets
   
7,466
     
-
     
198
     
198
     
(349
)
   
-
     
(123
)
   
(123
)
   
(870
)
   
336
     
6,658
 
                                                                                         
Net defined benefit liability (asset)
   
(2,382
)
   
(405
)
   
(47
)
   
(452
)
   
25
     
775
     
(36
)
   
739
     
239
     
336
     
(1,495
)

 

  b.
Disaggregation of the fair value of the plan assets:
 
   
Year ended
December 31,
 
   
2023
   
2022
 
             
Insurance contracts
   
6,919
     
6,658
 
 
  c.
The principal assumptions underlying the defined benefit plan:
 
   
2023
   
2022
 
   
%
 
             
Discount rate
   
5.55
     
5.57
 
Expected rate of salary increase
   
2.0-5.48
     
2.0-5.92
 
 
  d.
Amount, timing and uncertainty of future cash flows:
 
Below are reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions are constant:
 
   
Change in defined
benefit obligation
 
   
Year ended
December 31,
 
   
2023
   
2022
 
Sensitivity test for changes in the expected rate of salary increase:
           
             
The change as a result of:
           
             
Salary increase of  6.1% (instead of 5.5%) (2022- 6.51% instead of 5.9%)
   
(45
)
   
(49
)
                 
Sensitivity test for changes in the discount rate of the plan assets and liability:
               
                 
The change as a result of:
               
                 
Increase of 1% in discount rate
           
(13
)
Decrease of 1% in discount rate
   
45
     
45
 
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.24.2
TAXES ON INCOME
12 Months Ended
Dec. 31, 2023
Major components of tax expense (income) [abstract]  
TAXES ON INCOME
NOTE 19:-
TAXES ON INCOME
 
  a.
Tax rates applicable to the income of the Group companies:
 
  1.
Companies in Israel:
 
The Israeli corporate income tax rate was 23% in 2023 and 2022.
 
The deferred taxes are computed at the average tax rate of 23% (2022 – 23%), based on the tax rates that are expected to apply upon realization.
 
  2.
Foreign subsidiaries:
 
The principal tax rates applicable to the major subsidiaries whose place of incorporation is outside Israel are:
 
The U.S. - tax at the rate of 21%.
Germany - tax at the rate of 31.4%.
 
  b.
Taxes on income included in the statements of comprehensive income:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Current taxes
   
552
     
749
     
236
 
Deferred taxes
   
409
     
341
     
259
 
Taxes in respect of prior yearsa
   
(70
)
   
7
     
(40
)
                         
     
891
     
1,097
     
455
 
 
  c.
Deferred tax assets (liabilities):
 
Composition and changes in deferred taxes, as presented in the consolidated balance sheet, are as follows:
 
   
Fixed
and
intangible
assets
   
Employee benefit liabilities
   
 
 
Short term investments
   
Carry-
forward tax losses
   
Total
 
                               
Balance at January 1, 2022
   
(4,006
)
   
824
     
-
     
3,916
     
734
 
                                         
Amount included in statement of comprehensive income
   
498
     
(122
)
   
-
     
(875
)
   
(*)(499
)
Currency translation differences
   
443
     
(90
)
   
-
     
(416
)
   
(63
)
                                         
Balance at December 31, 2022
   
(3,065
)
   
612
     
-
     
2,625
     
172
 
                                         
Amount included in statement of comprehensive income
   
55
     
39
     
(192
)
   
(320
)
   
(418
)
Currency translation differences
   
91
     
(19
)
   
(3
)
   
(81
)
   
(12
)
                                         
Balance at December 31, 2023
   
(2,919
)
   
632
     
(195
)
   
2,224
     
(258
)
 
  (*)
$159 presented in other comprehensive income.
 
  d.
The deferred taxes are reflected in the balance sheet as follows:
 
   
December 31,
 
   
2023
   
2022
 
             
Non-current assets
   
2,055
     
2,872
 
Non-current liabilities
   
2,313
     
2,700
 
                 
     
(258
)
   
172
 
 
  e.
A reconciliation of the theoretical tax expense assuming all income is taxed at the statutory rate applicable to the income of companies in Israel, and the actual tax expense is as follows:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Income (loss) before taxes on income
   
(5,964
)
   
1,312
     
(13,469
)
                         
Statutory tax rate in Israel
   
23
%
   
23
%
   
23
%
                         
Tax computed at the statutory tax rate
   
(1,372
)
   
302
     
(3,098
)
                         
Increase (decrease) in taxes resulting from:
                       
Taxes in respect of previous years
   
(70
)
   
7
     
(40
)
Tax adjustment in respect of inflation in Israel
   
-
     
-
     
(2
)
Non-deductible expenses (non-taxable income)
   
406
     
(1,699
)
   
2,613
 
Different tax rates
   
63
     
60
     
24
 
Loss for which deferred taxes were not recognized
   
1,864
     
2,234
     
926
 
Utilization of previously unrecognized capital gain
   
-
     
-
     
32
 
Capital losses for which deferred taxes were not recognized
   
-
     
193
     
-
 
                         
Total tax expenses reported in the consolidated statements of comprehensive income
   
891
     
1,097
     
455
 
 
  f.
Carry forward tax losses:
 
The carry forward losses for tax purposes as of December 31, 2023 amount to NIS 227,833,000 ($62,816) (2022 – NIS 236,130,000 ($67,102), 2021 – NIS 249,552,000 ($80,242)) in Israel (which may be carried forward indefinitely) and EUR 29,387,000 ($32,503) (2022 – EUR 22,212,000 ($23,689), 2021 – EUR 17,026,000 ($19,270)) in Europe. In the U.S., SHL USA has federal and state net operating losses and credits of $15,337 (2022 - $10,716, 2021 - $8,866), which expire at various times.
 
Deferred tax assets in the amount of $23,938 (2022 - $21,113) relating to carry forward tax losses as described above, and deductible temporary differences, are not included in the consolidated financial statements as management presently believes that it is not probable that these deferred taxes will be realized in the foreseeable future.
 
  g.
The expiry dates for carry forward tax losses which are not recognized are as follows:
 
   
Year ended
December 31,
 
   
2023
   
2022
 
             
First year
   
37
     
24
 
Second year
   
762
     
229
 
Third year
   
413
     
126
 
Fourth year
   
153
     
52
 
Fifth year
   
959
     
281
 
Sixth - Fifteen
   
4,891
     
1,280
 
Unlimited
   
93,771
     
87,278
 
                 
     
100,986
     
89,270
 
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.24.2
COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS)
12 Months Ended
Dec. 31, 2023
COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS)  
COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS)
NOTE 20:-
COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS)
 
     
December 31,
 
     
2023
   
2022
   
2021
 
a.
Balances:
                 
                     
 
Other accounts payable
   
182
     
181
     
170
 
 
     
Year ended
December 31,
 
     
2023
   
2022
   
2021
 
b.
Transactions:
                 
                     
 
Short-term employee benefits
   
2,639
     
2,531
     
2,108
 
 
Share-based payment benefits
   
638
     
1,179
     
883
 
                           
 
Total
   
3,277
     
3,710
     
2,991
 
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.24.2
COMMITMENTS AND CONTINGENT LIABILITIES
12 Months Ended
Dec. 31, 2023
Disclosure Of Commitments And Contingent Liabilities Abstract  
COMMITMENTS AND CONTINGENT LIABILITIES
NOTE 21:-
COMMITMENTS AND CONTINGENT LIABILITIES
 
  a.
Charges:
 
As collateral for the Group's liabilities, fixed charges have been placed on specific accounts receivable.
 
  b.
Contingent liabilities:
 
The Group, from time to time, is party to various claims and disputes associated with its ongoing business operations. In management's opinion, based on the opinion of its legal counsels, none of these claims or disputes is expected, either individually or in the aggregate, to have a material adverse effect on the Group's financial position, results of operations or cash flows.
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.24.2
EQUITY
12 Months Ended
Dec. 31, 2023
Disclosure of classes of share capital [abstract]  
EQUITY
NOTE 22:-
EQUITY
 
  a.
Composition of share capital:

?

   
December 31, 2023
   
December 31, 2022
 
   
Authorized
   
Issued and outstanding*)
   
Authorized
   
Issued and outstanding*)
 
   
Number of shares
 
                         
Ordinary shares of NIS 0.01 par value each
   
25,000,000
     
16,391,382
     
25,000,000
     
14,682,272
 
 
  *)
Net of treasury shares – see (c).

 

  b.
Movement in share capital:

 

On January 7, 2021, the Special General Meeting of the Company approved the increase of the authorized share capital of the Company to 25,000,000 Ordinary shares of NIS 0.01 par value each.
 
On January 21, 2021 the Company closed the first of the two Capital Increases by issuing 1,300,000 new Ordinary shares from authorized capital (the "New Shares") and selling 300,000 treasury shares. The New Shares were listed on SIX Swiss Exchange on January 22, 2021. In addition, 800,000 Share Options to purchase Ordinary shares were granted on January 21, 2021, to be newly issued from the authorized capital upon exercise (“Share Options”, ratio 1:1, exercise price CHF 11.00, exercise period 24 months).
 
On February 17, 2021 the Company closed the second Capital Increase by issuing 2,288,889 new Ordinary shares from its authorized capital (the "New Shares"). The New Shares were listed on SIX Swiss Exchange on February 18, 2021. In addition, 1,144,444 Share Options to purchase further Ordinary shares were granted on February 17, 2021, to be newly issued from the authorized capital upon exercise (ratio 1:1, exercise price CHF 11.00, exercise period 24 months).
 
In both Capital Increases the New Shares have been placed by way of a private placement. No subscription rights of the existing shareholders apply and no public offering takes place. Pursuant to the Swiss Financial Services Act, a listing prospectus has been issued by SHL and approved by SIX Exchange Regulation for the purpose of the listing of the New Shares.

?

Since the exercise price of the Share Options issued to the investors is denominated in CHF which is not the functional currency (NIS) of the Company, these Share Options are accounted for upon initial recognition as a financial liability at fair value through profit or loss. After initial recognition, increase (decrease) in fair value in each reporting period are recognized in profit or loss as non-cash financial expenses (income).
 
The Company uses the Black and Scholes option pricing model when estimating the fair value of the Share Options.
 
The following table lists the significant inputs to the Black and Scholes model used for the fair value measurement of the Share Options :
 
     
December 31, 2022
       
Expected dividend
   
0%
Expected volatility of the share price
   
32.59%-38.24%
Risk-free interest rate
   
0.82%
Expected average life of options
   
0.06-0.13 years
Share price
   
CHF 14.80 ($16.05)

 

The expected volatility of the share price reflects the assumption that the historical volatility of the share price is reasonably indicative of expected future trends.
 
Based on the above inputs, the total fair value of the Share Option liability was $7,164 at December 31, 2022. During the reporting period $1,801 (2022 - $7,423) was recorded in financial income in respect of the revaluation of the liability (this amount is a non cash income). The fair value measurement of the liability is categorized in Level 3 of the fair value hierarchy.
 
During January 2023 and February 2023, the Company received proceeds of approximately CHF 18.7 million (USD 20.3 million) from exercises of 1,703,908 share options granted in the private placements in January 2021 and February 2021 and 29,967 options were not exercised and expired
 
The following table lists the movements in Share Options:
 
Balance on January 1, 2022
   
1,905,820
 
Exercise of share options
   
(171,945
)
         
Balance on December 31, 2022
   
1,733,875
 
Exercise of share options
   
(1,703,908
)
Expiration of share options
   
(29,967
)
         
Balance on December 31, 2023
   
-
 

 

In respect of the Capital Increases, the underwriters were also granted options to acquire 97,222 Units of securities. Each Unit comprises 1 Ordinary share and 0.5 option to acquire 1 Ordinary share at an exercise price of CHF 11 ($11.93). As of December 31, 2022, no options had been exercised. See below for details of the changes made to the terms of these options in March 2023.
 
The underwriters were also entitled to receive a cash payment derived from future cash received by the Company from the exercise of the Share Options in 2023. In addition, the underwriters were granted options to acquire a certain number of Units of securities based on a formula derived from the future cash payments received from the exercise of the Share Options. See below for the terms of these Units.
 
The Company used the Monte Carlo option pricing model when estimating the fair value of the liability for future payment to the underwriter as described above.

?

The following table lists the significant inputs to the Monte Carlo model used for the fair value measurement of the liability:

 

   
December 31, 2022
 
       
Expected volatility of the share price
 
43.15%
 
Risk-free interest rate
 
0.82%
 
Expected average life of options
 
0.21 years
 
Share price
 
CHF 14.80 ($16.05)
 

 

Based on the above inputs, the total fair value of the options to acquire Units and the future payment liability at the date of issuance were $1,002 and $416, respectively. The fair value of the liability at December 31, 2022 was $1,131. The increase in fair value of the liability during 2022 in the amount of $239 was recorded in financial expenses (this amount is a non cash expense).
 
In 2023, the underwriters received a cash payment of approximately CHF 1.1 million (USD 1.1 million) derived from cash received by the Company from the exercise of the Share Options. The cash payment was offset from the liability to the underwriters recorded in the balance sheet. In addition, the underwriters received options to acquire 58,498 Units of securities. Each Unit comprises 1 Ordinary share and 0.5 option to acquire 1 Ordinary share at an exercise price of CHF 11 ($11.93)
 
In March, 2023, in connection with services provided in respect of the exercise of options described above, the Company signed an agreement with the underwriter for the extension of the exercise period of the 97,222 Units of securities previously granted in 2021 for an additional 2 years until 2025 and for change of the exercise price to NIS 35.64 ($ 9.83) for each Unit of securities (which comprises 1 Ordinary share and 0.5 option to acquire 1 Ordinary share of the Company) and NIS 43.56 ($ 12.01) for each option included in the Unit.
 
The Company used the Black and Scholes option pricing model when estimating the incremental fair value of the options to acquire Units after the modifications described above.
 
The following table lists the significant inputs to the Black and Scholes model used for the fair value measurement of the options to acquire Units:
 
Expected dividend
 
0%
 
Expected volatility of the share price
 
41.18%
 
Risk-free interest rate
 
4.11%
 
Expected average life of options
 
2.01 years
 
Share price
 
CHF 11.55 ($12.53)
 
 
Based on the above inputs, the total incremental fair value of the options to acquire Units as of the date of the modifications was $ 512 and was recorded as a deduction from Additional paid-in capital arising from the exercise of the  share options in January and February 2023, as described above with a corresponding increase in the Capital reserve for options.
 
Issued and outstanding share capital (net of treasury shares):
 
   
Number of
shares
 
       
Balance at January 1, 2022
   
14,491,171
 
         
Exercise of share options
   
171,945
 
Exercise of employees share options
   
5,694
 
Treasury shares sold upon exercise of employee options
   
13,462
 
         
Balance at December 31, 2022
   
14,682,272
 
         
Exercise of share options
   
1,703,908
 
Exercise of employees share options
   
5,202
 
         
Balance at December 31, 2023
   
16,391,382
 

 

  c.
Treasury shares:
 
The Company holds 1,372 shares at a total cost of $2 as of December 31, 2023 and 2022.
 
  d.
Share option plans:
 
On January 2, 2022, the Company's Board of Directors approved the grant of 97,500 options to Senior Managers, under the 2021 Executive and Key Employee Israeli Share Incentive Plan. The options shall vest over a period of 3 years (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 5.893 ($6.451). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 19.10; exercise price – CHF 19.33; expected volatility – 42.33%; risk free interest rate – 0%; expected dividend – 0%; and expected average life of options – 3.71 years.
 
On February 15, 2022, the Company's Board of Directors approved the grant of 12,500 options to a Senior Manager, under the 2021 Executive and Key E,ployee Israeli Share Incentive Plan. The options shall vest over a period of 3 years (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 5.387 ($5.822). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 17.40; exercise price – CHF 17.69; expected volatility – 42.61%; risk free interest rate – 0.13%; expected dividend – 0%; and expected average life of options – 3.68 years.
 
On June 20, 2022, the Company's Board of Directors approved the grant of 100,000 options to a Senior Manager, under the 2021 Executive and Key E,ployee Israeli Share Incentive Plan. The options shall vest over a period of 3 years (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 5.550 ($5.753). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 17.40; exercise price – CHF 17.39; expected volatility – 41.75%; risk free interest rate – 1.15%; expected dividend – 0%; and expected average life of options – 3.6 years.
 
On January 2, 2023, the Company's Board of Directors approved the grant of 248,500 options to Managers and employees, under the Executive and Key Employee Israeli Share Incentive Plan. The options shall vest over a period of 3 years after appointment (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 4.655 ($5.047). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 14.80; exercise price – CHF 15.56; expected volatility – 43.87%; risk free interest rate – 0%; expected dividend – 0%; and expected average life of options – 3.49 years.
 
On May 15, 2023, the Company's Board of Directors approved the grant of 145,000 options to Managers, under the Executive and Key Employee Israeli Share Incentive Plan. The options shall vest over a period of 3 years after appointment (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 3.374 ($3.76). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 9.70; exercise price – CHF 9.36; expected volatility – 46.03%; risk free interest rate – 0%; expected dividend – 0%; and expected average life of options – 3.43 years.
 
On June 18, 2023, the Company's Board of Directors approved the grant of 30,000 options to a Senior Managers, under the Executive and Key Employee Israeli Share Incentive Plan. The options shall vest over a period of 3 years after appointment (25% after 1 year, and 9.375% each quarter thereafter). The weighted average fair value of options granted is CHF 3.663 ($4.113). The weighted average fair value was estimated based on the binomial model using the following data and assumptions: share price - CHF 10.30; exercise price – CHF 9.88; expected volatility – 46.57%; risk free interest rate – 0%; expected dividend – 0%; and expected average life of options – 3.43 years.
 
All options are exercisable for a period of 6 years from grant date.
 
On October 31, 2021, the Board of Directors approved to increase the maximum number of shares which may be issued under the Plan by 2,000,000.
 
On October 31, 2021, the Board of Directors approved to amend and rename the share options plan as "The SHL Telemedicine LTD. 2021 Executive and Key Employee Israeli Share Incentive Plan", and to extend the term of the Plan until the Board decides otherwise.
 
In the years ended December 31, 2023, 2022 and 2021, the Group recorded share-based compensation in the statements of comprehensive income in the amount of $1,252, $1,757 and $1,116, respectively.
 
 

e.

The following table illustrates the number and weighted average exercise prices ("WAEP") of, and movements in, share options during the year.

 

   
2023
   
2022
 
   
No. of options
   
WAEP (CHF)
   
No. of options
   
WAEP (CHF)
 
                         
Outstanding at the beginning of the year
   
1,001,430
     
11.85
     
835,055
     
10.12
 
Granted during the year
   
423,500
     
13.03
     
210,000
     
18.31
 
Forfeited during the year
   
(165,881
)
   
12.89
     
(7,500
)
   
19.33
 
Exercised during the year *)
   
(38,808
)
   
7.04
     
(36,125
)
   
7.94
 
                                 
Outstanding at the end of the year
   
1,220,241
     
12.27
     
1,001,430
     
11.85
 
                                 
Exercisable at the end of the year
   
720,758
     
11.02
     
454,480
     
9.42
 
 
  *)
The weighted average share price at the date of exercise of these options was CHF 8.13 (2022 – CHF 16.85). Exercise was cashless.
 
The weighted average remaining contractual life for the share options outstanding as of December 31, 2023 was 3.83 years (as of December 31, 2022 – 4.18 years).
 
  f.
Restricted Shares of Mediton Group:
 
On December 20, 2021, a Mediton executive was granted 256 restricted share units (“RSU”) of Mediton Group. The fair value of the RSUs in the amount of $822 was determined based on the price that the Company paid for the acquisition of the Mediton Group shares in 2021, The RSUs shall vest over a period of 3 years (33% after 1 year, and 16.5% each half year thereafter). The purchase agreement of Mediton Group includes a provision for anti-dilution protection to the Company in respect of the grant of the RSUs.
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.24.2
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME
12 Months Ended
Dec. 31, 2023
Supplementary Information To Statements Of Comprehensive Income Abstract  
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME
NOTE 23:-
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME
 
  a.
Revenues:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Revenues for services performed during the period
   
55,678
     
57,869
     
48,343
 
Revenues from sale of devices
   
1,397
     
1,129
     
1,239
 
                         
     
57,075
     
58,998
     
49,582
 
 
  b.
Cost of revenues:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Salaries and related benefits
   
16,212
     
16,480
     
14,955
 
Medical services
   
8,355
     
8,712
     
4,682
 
Rental fees and maintenance
   
1,246
     
1,013
     
1,072
 
Depreciation and amortization
   
1,978
     
1,789
     
1,736
 
Cost of devices
   
1,025
     
1,013
     
1,249
 
Others
   
2,998
     
2,802
     
1,295
 
                         
     
31,814
     
31,809
     
24,989
 
 
  c.
Research and development costs:
 
Salaries and related benefits
   
3,917
     
3,468
     
2,173
 
Amortization of development costs
   
2,772
     
1,829
     
1,243
 
Others
   
2,774
     
3,734
     
2,202
 
                         
     
9,463
     
9,031
     
5,618
 
Less - capitalization of development costs
   
4,203
     
5,243
     
2,633
 
                         
     
5,260
     
3,788
     
2,985
 

 

  d.
Selling and marketing expenses:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Salaries and related benefits
   
5,285
     
5,409
     
4,803
 
Marketing and related expenses
   
1,943
     
2,190
     
1,802
 
Depreciation and amortization
   
1,633
     
1,918
     
1,453
 
Rental fees and maintenance
   
160
     
271
     
205
 
Maintenance of vehicles
   
313
     
240
     
182
 
Others
   
1,247
     
1,375
     
1,009
 
                         
     
10,581
     
11,403
     
9,454
 
 
  e.
General and administrative expenses:
 
Salaries and related benefits
   
8,881
     
8,492
     
5,837
 
Office expenses
   
2,634
     
2,349
     
1,366
 
Professional fees
   
3,156
     
3,897
     
3,245
 
Depreciation and amortization
   
1,309
     
1,599
     
950
 
Others
   
248
     
411
     
705
 
                         
     
16,228
     
16,748
     
12,103
 
 
  f.
Financial income (expenses):
 
1.       Financial income:
 
Exchange rate differences
   
1,129
     
661
     
5
 
Gain on marketable securities, net
   
848
     
-
     
-
 
Share options
   
1,801
     
7,423
     
-
 
Call+Put options
   
-
     
320
     
-
 
Interest
   
1,055
     
429
     
376
 
                         
     
4,833
     
8,833
     
381
 
 
2.       Financial expenses:
 
Share options
   
-
     
(239
)
   
(10,126
)
Exchange rate differences
   
(138
)
   
(53
)
   
(1,595
)
Loss from marketable securities, net
   
-
     
(769
)
   
(114
)
Interest
   
(1,296
)
   
(1,033
)
   
(529
)
Call+Put options
   
(89
)
   
-
     
(677
)
Others
   
(268
)
   
(261
)
   
(312
)
                         
     
(1,791
)
   
(2,355
)
   
(13,353
)

 

  g.
Other expenses:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Impairment of property and equipment – see Note 10
   
-
     
-
     
118
 
Expenses related to acquisitions
   
-
     
-
     
590
 
Restructuring expenses*
   
1,235
     
-
     
-
 
Other expenses
   
963
     
416
     
(160
)
                         
     
2,198
     
416
     
548
 
 
 
Including expenses related to employee benefits and other direct expenditures arising from the restructuring.
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.24.2
NET EARNINGS PER SHARE
12 Months Ended
Dec. 31, 2023
NET EARNINGS PER SHARE  
NET EARNINGS PER SHARE
NOTE 24:-    NET EARNINGS PER SHARE
 
  a.
Details of the number of shares and net loss used in the computation of net earnings per share:
 
   
Year ended December 31,
 
   
2023
   
2022
 
   
Weighted average number of shares
   
Net
loss
   
Weighted average\ number of shares
   
Net
loss
 
   
In
thousands
         
In
thousands
       
                         
For the computation of basic net earnings
   
16,269
     
(7,055
)
   
14,542
     
(76
)
Effect of dilution - share options
   
26
     
(1,801
)
   
656
     
(7,423
)
                                 
For the computation of diluted net earnings
   
16,295
     
(8,856
)
   
15,198
     
(7,499
)
 
  b.
To compute diluted net earnings per share, the following options (dilutive potential Ordinary shares), have not been taken into account since their conversion has an anti-dilutive effect: 1,453,824 (2022 – 1,236,824) options to employees under share-based payment plans and options to investors and others.
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.24.2
SEGMENT INFORMATION
12 Months Ended
Dec. 31, 2023
SEGMENT INFORMATION  
SEGMENT INFORMATION
NOTE 25:-
SEGMENT INFORMATION
 
The Group operates in three geographical segments: Israel, Europe (principally Germany) and Rest of the world ("ROW").
 
Management monitors the operating results of its geographical units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on segment profit. SG&A Group expenses and some research and development expenses are mostly allocated to the separate geographic units. Some corporate expenses, some research and development expenses, finance costs and finance income and income taxes are managed on a group basis and are not allocated to the geographic segments.
 
Revenues are allocated based on the location of the end customer. The Group presents disaggregated revenue information based on types of customers: Individual customers and communities, Institutions and payers (income from service agreements with institutions, insurance companies and HMOs), and others.
 
  a.
Segment revenues:
 
   
Individuals and communities
   
Institutions and payers
   
Others
   
Total
 
Year ended December 31, 2023:
                       
                         
Europe
   
-
     
14,067
     
-
     
14,067
 
Israel
   
20,913
     
21,179
     
-
     
42,092
 
ROW
   
-
     
-
     
916
     
916
 
                                 
Total revenues
   
20,913
     
35,246
     
916
     
57,075
 
                                 
Year ended December 31, 2022:
                               
                                 
Europe
   
-
     
13,374
     
-
     
13,374
 
Israel
   
22,161
     
22,975
     
2
     
45,138
 
ROW
   
-
     
-
     
486
     
486
 
                                 
Total revenues
   
22,161
     
36,349
     
488
     
58,998
 
                                 
Year ended December 31, 2021:
                               
                                 
Europe
   
-
     
17,942
     
-
     
17,942
 
Israel
   
22,331
     
8,832
     
27
     
31,190
 
ROW
   
-
     
-
     
450
     
450
 
                                 
Total revenues
   
22,331
     
26,774
     
477
     
49,582
 
 
  b.
Reporting on geographic segments:
 
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
Segment profit (loss):
                 
                   
Europe
   
(5,347
)
   
(3,044
)
   
(477
)
Israel
   
8,424
     
8,641
     
8,266
 
ROW
   
(3,622
)
   
(2,972
)
   
(1,132
)
                         
     
(545
)
   
2,625
     
6,617
 
Unallocated income and expenses:
                       
                         
Corporate, R&D and other expenses
   
(6,263
)
   
(7,375
)
   
(6,798
)
Other expenses
   
(2,198
)
   
(416
)
   
(316
)
                         
Operating loss
   
(9,006
)
   
(5,166
)
   
(497
)
Financial income, net
   
3,042
     
6,478
     
(12,972
)
                         
Profit (loss) before taxes on income
   
(5,964
)
   
1,312
     
(13,469
)
 
 
c.
Additional information:
 
   
Europe
   
Israel
   
Others
   
Total
 
                         
Year ended December 31, 2023
                       
                         
Depreciation and amortization
   
3,637
     
4,049
     
6
     
7,692
 
 
   
Europe
   
Israel
   
ROW
   
Unallocated assets
   
Total
 
                               
Non-current assets
   
23,588
     
36,803
     
1,940
     
4,910
     
67,241
 
 
   
Europe
   
Israel
   
Others
   
Total
 
                         
Year ended December 31, 2022
                       
                         
Depreciation and amortization
   
2,654
     
4,470
     
10
     
7,134
 
 
   
Europe
   
Israel
   
ROW
   
Unallocated assets
   
Total
 
                               
Non-current assets
   
27,132
     
40,056
     
1,767
     
2,636
     
71,591
 
 
   
Europe
   
Israel
   
Others
   
Total
 
                         
Year ended December 31, 2021
                       
                         
Depreciation and amortization
   
2,765
     
2,735
     
-
     
5,500
 
 
   
Europe
   
Israel
   
ROW
   
Unallocated assets
   
Total
 
                               
Non-current assets
   
11,539
     
61,534
     
-
     
2,260
     
75,333
 
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.24.2
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2023
SUBSEQUENT EVENTS  
SUBSEQUENT EVENTS
NOTE 26:-
SUBSEQUENT EVENTS
 
  a.
On March 14, 2024 the Company announced that Mr. Erez Nachtomy, the Company's CEO, will be stepping down as CEO in mid June 2024.
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.24.2
ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2023
Disclosure Of Summary Of Significant Accounting Policies Abstract  
Basis of presentation of the financial statements
  a.
Basis of presentation of the financial statements:
 
  1.
These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").
 
The Group's financial statements have been prepared on a cost basis, except for marketable securities, liability to underwriters and derivatives (put option, and liability for share options) which are measured at fair value through profit or loss and employee benefit assets and liabilities.
 
The Group has elected to present the statement of comprehensive income using the function of expense method.
 
  2.
Consistent accounting policies:
 
The accounting policies adopted in the financial statements have been applied consistently for all periods presented, unless otherwise stated.
Consolidated financial statements
  b.
Consolidated financial statements:
 
The consolidated financial statements comprise the financial statements of companies that are controlled by the Company (subsidiaries). Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.
 
The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group.
 
Non-controlling interests in subsidiaries represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statement of financial position.
 
A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as a change in equity by adjusting the carrying amount of the non-controlling interests with a corresponding adjustment of the equity attributable to equity holders of the Company less/plus the consideration paid or received.
Functional currency and presentation currency
  c.
Functional currency and presentation currency:
 
  1.
Functional currency and presentation currency:
 
The presentation currency of the financial statements is the U.S. dollar.
 
The functional currency, which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions, is separately determined for each Group entity and is used to measure its financial position and operating results. The functional currency of the Company and it's subsidiaries in Israel is the NIS.
 
When a Group entity's functional currency differs from the presentation currency, that entity's financial statements are translated so that they can be included in the consolidated financial statements as follows:
 
  a)
Assets and liabilities of foreign operations, including goodwill and any fair value adjustments to the carrying amounts of assets and liabilities arising from the acquisition of said foreign operation, are translated at the closing rate at the end of the reporting period.
 
  b)
Income and expenses for each period presented in the statement of income are translated at average exchange rates for the presented periods.
 
  c)
Share capital, capital reserves and other changes in capital are translated at the exchange rate prevailing at the date of incurrence.
 
  d)
Retained earnings are translated based on the opening balance translated at the exchange rate at that date and other relevant transactions (such as dividend) during the period are translated as described in b) and c) above.
 
  e)
All resulting translation differences are recognized as a separate component of other comprehensive income (loss) in equity "foreign currency translation reserve".
 
  2.
Index-linked monetary items:
 
Monetary assets and liabilities linked to the changes in the Israeli Consumer Price Index ("Israeli CPI") are adjusted at the relevant index at the end of each reporting period according to the terms of the agreement. Linkage differences arising from the adjustment, as above, other than those capitalized to qualifying assets or carried to equity in hedge transactions, are recognized in profit or loss.
Short-term deposits
  d.
Short-term deposits:
 
Short-term bank deposits are deposits with an original maturity of more than three months from the date of investment and which do not meet the definition of cash equivalents. The deposits are presented according to their terms of deposit.
Inventory
  e.
Inventory:
 
Inventory of telemedicine devices for sale is presented at the lower of cost or net realizable value. Cost is determined using the "first-in, first-out" method.
 
Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.
Financial instruments
  f.
Financial instruments:
 
  1.
Financial assets:
 
Financial assets are measured upon initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.
 
Equity instruments and other financial assets held for trading:
 
Investments in equity instruments do not meet the above criteria and accordingly are measured at fair value through profit or loss.
 
Other financial assets held for trading, including derivatives, are measured at fair value through profit or loss unless they are designated as effective hedging instruments.
 
  2.
Impairment of financial assets:
 
The Company evaluates at the end of each reporting period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss. The Company has short-term financial assets such as trade receivables in respect of which the Company applies a simplified approach and measures the loss allowance in an amount equal to the lifetime expected credit loss.
 
  3.
Financial liabilities:
 
  a)
Financial liabilities measured at amortized cost:
 
Financial liabilities are initially recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.
 
After initial recognition, the Company measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair value through profit or loss.
 
  b)
Financial liabilities measured at fair value through profit or loss:
 
Financial liabilities measured at fair value through profit or loss include liabilities held for trading, including derivatives, and financial liabilities that meet certain criteria which are designated upon initial recognition to fair value through profit or loss.
 
At initial recognition, the Company measures these financial liabilities at fair value. Transaction costs are recognized in profit or loss.
 
After initial recognition, changes in fair value are recognized in profit or loss.
 
  4.
Issue of a unit of securities:
 
The issue of a unit of securities involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.
Leases
  g.
Leases:
 
The Group accounts for a contract as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.
 
  1.
The Group as a lessee:
 
For leases in which the Group is the lessee, the Group recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Group has elected to recognize the lease payments as an expense in profit or loss on a straight-line basis over the lease term. In measuring the lease liability, the Group has elected to apply the practical expedient in the Standard and does not separate the lease components from the non-lease components (such as management and maintenance services, etc.) included in a single contract.
 
Leases which entitle employees to a company car as part of their employment terms are accounted for as employee benefits in accordance with the provisions of IAS 19 and not as subleases.
 
On the commencement date, the lease liability includes all unpaid lease payments (excluding variable lease payments) discounted at the interest rate implicit in the lease, if that rate can be readily determined, or otherwise using the Group 's incremental borrowing rate. After the commencement date, the Group measures the lease liability using the effective interest rate method.
 
On the commencement date, the right-of-use asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful life and the lease term.
 
Following are the periods of depreciation of the right-of-use assets by class of underlying asset:
 
   
Years
 
Mainly
         
Motor vehicles
 
1.5 - 3.5
 
3
Buildings
 
4 - 11
 
10
 
The Group tests for impairment of the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36.
 
  2.
Variable lease payments that depend on an index:
 
On the commencement date, the Group uses the index rate prevailing on the commencement date to calculate the future lease payments.
 
For leases in which the Group is the lessee, the aggregate changes in future lease payments resulting from a change in the index are discounted (without a change in the discount rate applicable to the lease liability) and recorded as an adjustment of the lease liability and the right-of-use asset, only when there is a change in the cash flows resulting from the change in the index (that is, when the adjustment to the lease payments takes effect).
 
 
3.
Lease extension and termination options:
 
A non-cancellable lease term includes both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.
 
In the event of any change in the expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Group remeasures the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized in profit or loss.
 
  4.
Lease modifications:
 
If a lease modification does not reduce the scope of the lease and does not result in a separate lease, the Group remeasures the lease liability based on the modified lease terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset.
 
If a lease modification reduces the scope of the lease, the Group recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use asset and the lease liability. The Group subsequently remeasures the carrying amount of the lease liability according to the revised lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset.
Business combinations and goodwill
  h.
Business combinations and goodwill:
 
Business combinations are accounted for by applying the acquisition method. The cost of the acquisition is measured at the fair value of the consideration transferred on the date of acquisition with the addition of non-controlling interests in the acquiree.
 
Direct acquisition costs are carried to the income statement as incurred.
 
A put option granted by the Group to non-controlling interests and concurrently a call option received by the Group from the non-controlling interests that can be settled in cash or by the delivery of a variable number of shares are accounted for as a derivative financial liability or asset presented on a net basis and measured at fair value. The non-controlling interests continue to be recognized in equity until the put or call options are exercised.
 
Goodwill is initially measured at cost which represents the excess of the acquisition consideration and the amount of non-controlling interests over the net identifiable assets acquired and liabilities assumed.
 
After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For purposes of evaluation of impairment of goodwill, goodwill purchased in a business combination is evaluated and attributed to the cash-generating units to which it had been allocated.
Property and equipment
  i.
Property and equipment:
 
Property and equipment are measured at cost, including directly attributable costs, less accumulated depreciation and accumulated impairment losses.
 
Depreciation is calculated at constant annual rates on a straight-line basis over the useful life of the assets at annual rates as follows:
 
   
%
   
         
Medical equipment
 
10 - 15
 
(mainly 15%)
Motor vehicles and ambulances
 
15 - 20
 
(mainly 20%)
Office furniture and equipment
 
6 - 7
 
(mainly 6%)
Computers and peripheral equipment
 
15 - 33
 
(mainly 20%)
Leasehold improvements
 
see below
   
Telemedicine devices on loan to customers
 
10
   
 
Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including any extension option held by the Group and intended to be exercised) and the expected life of the improvement.
Intangible assets
  j.
Intangible assets:
 
Intangible assets acquired in a business combination are included at fair value at the acquisition date. After initial recognition, intangible assets are carried at their cost less any accumulated amortization and any accumulated impairment losses. Expenditures relating to internally generated intangible assets, excluding capitalized development costs, are recognized in profit or loss when incurred.
 
According to management's assessment, intangible assets have a finite useful life. The assets are amortized over their useful life using the straight-line method and reviewed for impairment whenever there is an indication that the asset may be impaired.
 
The useful life of intangible assets is as follows:
 
   
Years
     
Developments costs
 
5 - 10
Computer software
 
5
Contracts
 
6.75
Customer relations
 
10
Information technology
 
6
 
Research and development expenditures:
 
Research expenditures are recognized in profit or loss when incurred. An intangible asset arising from development or from the development phase of an internal project is recognized if the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale; the Company's intention to complete the intangible asset and use or sell it; the Company's ability to use or sell the intangible asset; how the intangible asset will generate future economic benefits; the availability of adequate technical, financial and other resources to complete the intangible asset; and the Company's ability to measure reliably the expenditure attributable to the intangible asset during its development.
 
The asset is measured at cost less any accumulated amortization and any accumulated impairment losses. Costs recognized as intangible assets include directly attributable costs of preparing the asset for its intended use such as cost of materials, direct labor costs and overhead.
 
Amortization of the asset begins when development is complete and the asset is available for use. As for the testing of impairment, see l below.
Impairment of non-financial assets
  k.
Impairment of non-financial assets:
 
The Group evaluates the need to record an impairment of the carrying amount of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable. If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognized in profit or loss.
 
An impairment loss of an asset, other than goodwill, is reversed only if there have been changes in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognized. Reversal of an impairment loss, as above, shall not be increased above the lower of the carrying amount that would have been determined (net of depreciation or amortization) had no impairment loss been recognized for the asset in prior years and its recoverable amount. The reversal of impairment loss of an asset presented at cost is recognized in profit or loss.
 
The following criteria are applied in assessing impairment of these specific assets:
 
 
1.
Goodwill related to subsidiaries:
 
For the purpose of impairment testing, goodwill acquired in a business combination is allocated, at the acquisition date, to each of the Group's cash-generating units that is expected to benefit from the synergies of the combination.
 
The Company reviews goodwill for impairment once a year or more frequently if events or changes in circumstances indicate that there is impairment.
 
Goodwill is tested for impairment by assessing the recoverable amount of the cash-generating unit (or group of cash-generating units) to which the goodwill has been allocated. An impairment loss is recognized if the recoverable amount of the cash-generating unit (or group of cash-generating units) to which goodwill has been allocated is less than the carrying amount of the cash-generating unit (or group of cash-generating units). Any impairment loss is allocated first to goodwill. Impairment losses recognized for goodwill cannot be reversed in subsequent periods.
 
  2.
Development costs capitalized during the development period:
 
The impairment test is performed annually, on December 31, or more frequently if events or changes in circumstances indicate that there is impairment.
Taxes on income
  l.
Taxes on income:
 
Taxes on income in the statement of comprehensive income comprise current and deferred taxes. Current or deferred taxes are recognized in the statement of income except to the extent that the tax arises from items which are recognized directly in other comprehensive income or in equity. In such cases, the tax effect is also recognized in the relevant item.
 
  1.
Current taxes:
 
The current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period as well as adjustments required in connection with the tax liability in respect of previous years.
 
  2.
Deferred taxes:
 
Deferred taxes are computed in respect of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.
 
Deferred taxes are measured at the tax rates that are expected to apply to the period when the taxes are reversed in profit or loss, comprehensive income or equity, based on tax laws that have been enacted or substantively enacted by the end of the reporting period. Deferred taxes in profit or loss represent the changes in the carrying amount of deferred tax balances during the reporting period, excluding changes attributable to items recognized outside of profit or loss.
 
Deferred tax assets are reviewed at the end of each reporting period and reduced to the extent that it is not probable that they will be utilized. Also, temporary differences (such as carry forward losses) for which deferred tax assets have not been recognized are reassessed and deferred tax assets are recognized to the extent that their recoverability has become probable. Any resulting reduction or reversal is recognized in the line item, "taxes on income". Taxes that would apply in the event of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends does not involve an additional tax liability or since it is the Group's policy not to initiate distribution of dividends that triggers an additional tax liability.
Share-based payment transactions
 
m.
Share-based payment transactions:
 
The Company's employees are entitled to remuneration in the form of equity-settled share-based payment transactions (see details in Note 22).
 
Equity-settled transactions:
 
The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using a standard option pricing model, additional details are given in Note 22d
 
No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.
 
If the Group modifies the conditions on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.
Employee benefit liabilities
  n.
Employee benefit liabilities:
 
The Group has several employee benefit plans:
 
  1.
Short-term employee benefits:
 
Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized when the Group has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made. The short-term employee benefit liability in the statement of financial position is measured on an undiscounted basis.
 
  2.
Post-employment benefits:
 
The plans are normally financed by contributions to insurance companies or funds and classified as defined contribution plans or as defined benefit plans.
 
  a)
Defined contribution plans:
 
The Group has defined contribution plans pursuant to section 14 to the Severance Pay Law under which the Group pays fixed contributions and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods.
 
Contributions to a defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed concurrently with performance of the employee's services.
 
  b)
Defined benefit plans:
 
The Group operates a defined benefit plan in respect of severance pay pursuant to the Severance Pay Law in Israel. According to the Law, employees are entitled to severance pay upon dismissal or retirement. The liability for termination of employee-employer relation is measured using the projected unit credit method. The actuarial assumptions include rates of employee turnover and future salary increases based on the estimated timing of payment. The amounts are presented based on discounted expected future cash flows using a discount rate determined by reference to market yields at the reporting date on high quality corporate bonds that are linked to the Consumer Price Index with term of the benefit obligation.
 
In respect of its severance pay obligation to certain of its employees, the Group makes current deposits in pension funds and insurance companies ("the plan assets"). Plan assets comprise assets held by a long-term employee benefit fund or qualifying insurance policies. Plan assets are not available to the Group's own creditors and cannot be returned directly to the Group.
 
The liability for employee benefits presented in the balance sheet reflects the present value of the defined benefit obligation less the fair value of the plan assets (see details in Note 18).
 
Remeasurements of the net liability are recognized as other comprehensive income (loss) in the period in which they occur.
Revenue recognition
  o.
Revenue recognition:
 
Revenue recognition:
 
Revenue from contracts with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf of third parties (such as taxes).
 
Revenue from rendering of services:
 
Revenue from rendering of services is recognized over time, during the period the customer simultaneously receives and consumes the benefits provided by the Company's performance. Revenue is recognized in the reporting periods in which the services are rendered. Revenues from the installation fees are recognized as the installation is performed.
 
The Company charges its customers based on payment terms agreed upon in specific agreements. When payments are made before or after the service is performed, the Company recognizes the resulting contract asset (income receivable) or liability (deferred revenues) and recognizes revenue in profit or loss when the work is performed. The Company has elected to apply the practical expedient allowed by the Standard and does not separate the financing component in transactions in which the period between receipt of the advance payment and the performance of the service is expected to be less than one year.
 
Revenue from the sale of telemedicine devices:
 
Revenue from sale of telemedicine devices is recognized in profit or loss at the point in time when the control of the goods is transferred to the customer, generally upon delivery of the goods to the customer.
 
Costs of obtaining a contract:
 
Costs incurred in obtaining subscription contracts which would not have been incurred if the contract had not been obtained (incremental costs) and which the Company expects to recover are recognized as an asset (prepaid expenses). The asset is amortized over the estimated average service period of subscriber contracts, adjusted for cancellations.
Interest income
  p.
Interest income:
 
Interest income on financial assets is recognized as it accrues using the effective interest method.
Earnings per share
  q.
Earnings per share:
 
Basic earnings per share are calculated by dividing the net income attributable to equity holders of the Company by the weighted number of Ordinary shares outstanding during the period.
 
For diluted earnings per share, the weighted average of shares outstanding is adjusted, assuming conversion of potential dilutive shares (employee options), except when such conversion has an anti-dilutive effect.
Fair value measurement
 
r.
Fair value measurement:
 
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
 
Fair value measurement is based on the assumption that the transaction will take place in the asset's or the liability's principal market, or in the absence of a principal market, in the most advantageous market.
 
The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.
 
Fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.
 
The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.
 
All assets and liabilities measured at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level input that is significant to the entire fair value measurement:
 
Level 1
-
quoted prices (unadjusted) in active markets for identical assets or liabilities.
     
Level 2
-
inputs other than quoted prices included within Level 1 that are observable directly or indirectly.
     
Level 3
-
inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).
Exchange rates and linkage basis
  s.
Exchange rates and linkage basis:
 
Data regarding Israeli CPI and exchange rates of the U.S. dollar, the Euro and the Swiss Franc in relation to the NIS is as follows:
 
   
Israeli
   
Exchange rate of
 
For the year ended
 
CPI
   
   
U.S. $
   
CHF
 
   
Points *)
   
NIS
 
                           
December 31, 2023
   
248.6
     
4.01
     
3.63
     
4.31
 
December 31, 2022
   
241.4
     
3.75
     
3.52
     
3.82
 
December 31, 2021
   
229.4
     
3.52
     
3.11
     
3.40
 
                                 
Change during the year
 
%
 
                                 
2023
   
3
     
6. 9
     
3.1
     
12.8
 
2022
   
5.2
     
6.5
     
13.2
     
12.4
 
2021     2.8       (10.7 )     (3.1 )     (6.8 )
 
  *)
The index on an average basis of 1993 = 100.
Changes in accounting policies
  t.
Changes in accounting policies - initial application of new financial reporting and accounting standards and amendments to existing financial reporting and accounting standards:
 
  1.
Amendment to IAS 8, "Accounting Policies, Changes to Accounting Estimates and Errors":
 
In February 2021, the IASB issued an amendment to IAS 8, "Accounting Policies, Changes to Accounting Estimates and Errors" ("the Amendment"), in which it introduces a new definition of "accounting estimates".
 
Accounting estimates are defined as "monetary amounts in financial statements that are subject to measurement uncertainty". The Amendment clarifies the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors.
 
The Amendment is applied prospectively for annual reporting periods beginning on January 1, 2023 and is applicable to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period.
 
The application of the Amendment did not have a material impact on the Company's consolidated financial statements.
 
  2.
Amendment to IAS 12, "Income Taxes":
 
In May 2021, the IASB issued an amendment to IAS 12, "Income Taxes" ("IAS 12"), which narrows the scope of the initial recognition exception under IAS 12.15 and IAS 12.24 ("the Amendment").
 
According to the recognition guidelines of deferred tax assets and liabilities, IAS 12 excludes recognition of deferred tax assets and liabilities in respect of certain temporary differences arising from the initial recognition of certain transactions. This exception is referred to as the "initial recognition exception". The Amendment narrows the scope of the initial recognition exception and clarifies that it does not apply to the recognition of deferred tax assets and liabilities arising from transactions that are not a business combination and that give rise to equal taxable and deductible temporary differences, even if they meet the other criteria of the initial recognition exception.
 
The Amendment applies for annual reporting periods beginning on January 1, 2023. In relation to leases and decommissioning obligations, the Amendment is applied commencing from the earliest reporting period presented in the financial statements in which the Amendment is initially applied. The cumulative effect of the initial application of the Amendment is recognized as an adjustment to the opening balance of retained earnings (or another component of equity, as appropriate) at that date.
 
The application of the Amendment did not have a material impact on the Company's consolidated financial statements.
 
  3.
Amendment to IAS 1, "Disclosure of Accounting Policies":
 
In February 2021, the IASB issued an amendment to IAS 1, "Presentation of Financial Statements" ("the Amendment"), which replaces the requirement to disclose 'significant' accounting policies with a requirement to disclose 'material' accounting policies. One of the main reasons for the Amendment is the absence of a definition of the term 'significant' in IFRS whereas the term 'material' is defined in several standards and particularly in IAS 1.
 
The Amendment is applicable for annual periods beginning on January 1, 2023.
 
The application of the above Amendment had an effect on the disclosures of the Company's accounting policies, but did not affect the measurement, recognition or presentation of any items in the Company's consolidated financial statements.
 
  4.
Amendment to IAS 12, "Income Taxes":
 
In May 2023, the IASB issued "International Tax Reform—Pillar Two Model Rules – Amendment to IAS 12" ("the Amendment") to clarify the application of IAS 12, "Income Taxes", to income taxes arising from tax law enacted or substantively enacted to implement the Organisation for Economic Co-operation and Development (OECD)/G20 Inclusive Framework on Base Erosion and Profit Shifting (BEPS) Pillar Two model rules (Pillar Two income taxes).
 
The Amendment introduces:
 
  (a)
A mandatory temporary exception from the application of IAS 12 regarding recognition and disclosure of deferred tax assets and liabilities arising from the implementation of the Pillar Two model rules; and
 
  (b)
Disclosure requirements for international entities affected by the international tax reform.
 
The mandatory temporary exception in (a) above – the use of which is required to be disclosed – applies immediately. The remaining disclosure requirements apply for annual reporting periods beginning on January 1, 2023.
 
The application of the Amendment did not have any impact on the Company's consolidated financial statements since the International Tax Reform does not apply to the Group whose annual revenues are less than € 750 million.
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.24.2
ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2023
Disclosure Of Summary Of Significant Accounting Policies Abstract  
Schedule of depreciation of the right-of-use assets by class of underlying asset
   
Years
 
Mainly
         
Motor vehicles
 
1.5 - 3.5
 
3
Buildings
 
4 - 11
 
10
Schedule of useful life of the assets at annual rates
   
%
   
         
Medical equipment
 
10 - 15
 
(mainly 15%)
Motor vehicles and ambulances
 
15 - 20
 
(mainly 20%)
Office furniture and equipment
 
6 - 7
 
(mainly 6%)
Computers and peripheral equipment
 
15 - 33
 
(mainly 20%)
Leasehold improvements
 
see below
   
Telemedicine devices on loan to customers
 
10
   
Schedule of useful life of intangible assets
   
Years
     
Developments costs
 
5 - 10
Computer software
 
5
Contracts
 
6.75
Customer relations
 
10
Information technology
 
6
Schedule of data regarding Israeli CPI and exchange rates of U.S. dollar, Euro and Swiss Franc
   
Israeli
   
Exchange rate of
 
For the year ended
 
CPI
   
   
U.S. $
   
CHF
 
   
Points *)
   
NIS
 
                           
December 31, 2023
   
248.6
     
4.01
     
3.63
     
4.31
 
December 31, 2022
   
241.4
     
3.75
     
3.52
     
3.82
 
December 31, 2021
   
229.4
     
3.52
     
3.11
     
3.40
 
                                 
Change during the year
 
%
 
                                 
2023
   
3
     
6. 9
     
3.1
     
12.8
 
2022
   
5.2
     
6.5
     
13.2
     
12.4
 
2021     2.8       (10.7 )     (3.1 )     (6.8 )
 
  *)
The index on an average basis of 1993 = 100.
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.24.2
CASH AND CASH EQUIVALENTS (Tables)
12 Months Ended
Dec. 31, 2023
Cash and cash equivalents [abstract]  
Schedule of cash and cash equivalents
   
December 31,
 
   
2023
   
2022
 
             
Cash in banks (mainly in USD, 2022 – in NIS)
   
6,271
     
4,377
 
Short-term deposits (in NIS)
   
422
     
106
 
                 
     
6,693
     
4,483
 
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.24.2
SHORT-TERM INVESTMENTS (Tables)
12 Months Ended
Dec. 31, 2023
Short Term Investment Abstract  
Schedule of cash and cash equivalents
 
   
December 31,
 
   
2023
   
2022
 
Marketable securities:
           
             
Financial assets at fair value through profit or loss (mainly in USD)
           
Corporate bonds
   
4,181
     
4,033
 
Government bonds and loans
   
784
     
392
 
Shares
   
638
     
784
 
Exchange Traded Funds
   
3,375
     
3,308
 
                 
     
8,978
     
8,517
 
                 
Short-term deposits
   
10,579
     
5,700
 
                 
     
19,557
     
14,217
 
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.24.2
TRADE RECEIVABLES (Tables)
12 Months Ended
Dec. 31, 2023
Trade Receivables Abstract  
Schedule of trade receivables
   
December 31,
 
   
2023
   
2022
 
             
Accounts receivable (1)
   
8,419
     
7,596
 
Other
   
138
     
201
 
Allowance for doubtful accounts
   
-
     
-
 
                 
     
8,557
     
7,797
 
 
  (1)
The terms of billed accounts receivable are generally 30-60 days. As of December 31, 2023 and 2022, there were no material billed receivables that were past due.
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.24.2
OTHER ACCOUNTS RECEIVABLE (Tables)
12 Months Ended
Dec. 31, 2023
Other Accounts Receivable Abstract  
Schedule of other accounts receivable
 
   
December 31,
 
   
2023
   
2022
 
             
Interest receivable
   
53
     
190
 
Government authorities
   
298
     
616
 
Advances to supplies
   
328
     
54
 
Prepaid expenses
   
552
     
469
 
Others
   
561
     
583
 
                 
     
1,792
     
1,912
 
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.24.2
PROPERTY AND EQUIPMENT (Tables)
12 Months Ended
Dec. 31, 2023
PROPERTY AND EQUIPMENT  
Schedule of property, plant and equipment
   
Computers and
peripheral equipment
   
Medical equipment
   
Office
furniture and equipment
   
Motor
vehicles and ambulances
   
Leasehold improvements
   
Devices
on loan
   
Total
 
Cost:
                                         
                                           
Balance as of January 1, 2022
   
18,334
     
6,150
     
2,350
     
2,498
     
3,777
     
46,570
     
79,679
 
Additions during the year
   
479
     
31
     
153
     
4
     
598
     
395
     
1,660
 
Disposals during the year
   
(4
)
   
-
     
(64
)
   
(2
)
   
-
     
(1,106
)
   
(1,176
)
Transfer from inventory, net
   
-
     
-
     
-
     
-
     
-
     
564
     
564
 
Currency translation differences
   
(1,953
)
   
(715
)
   
(241
)
   
(290
)
   
(445
)
   
(5,232
)
   
(8,876
)
                                                         
Balance as of December 31, 2022
   
16,856
     
5,466
     
2,198
     
2,210
     
3,930
     
41,191
     
71,851
 
Additions during the year
   
699
     
7
     
66
     
181
     
127
     
209
     
1,289
 
Disposals during the year
   
(3,275
)
   
-
     
(366
)
   
(46
)
   
-
     
(4,497
)
   
(8,184
)
Transfer from inventory, net
   
-
     
-
     
-
     
-
     
-
     
226
     
226
 
Currency translation differences
   
(348
)
   
(165
)
   
(33
)
   
(60
)
   
(106
)
   
(1,126
)
   
(1,838
)
                                                         
Balance as of December 31, 2023
   
13,932
     
5,308
     
1,865
     
2,285
     
3,951
     
36,003
     
63,344
 
                                                         
Accumulated depreciation:
                                                       
                                                         
Balance as of January 1, 2022
   
17,292
     
6,018
     
1,756
     
2,139
     
3,152
     
45,297
     
75,654
 
Additions during the year
   
385
     
42
     
100
     
36
     
158
     
388
     
1,109
 
Disposals during the year
   
(4
)
   
-
     
(64
)
   
(2
)
   
-
     
(1,054
)
   
(1,124
)
Transfer from inventory, net
   
-
     
-
     
-
     
-
     
-
     
7
     
7
 
Currency translation differences
   
(1,852
)
   
(701
)
   
(181
)
   
(250
)
   
(364
)
   
(5,099
)
   
(8,447
)
                                                         
Balance as of December 31, 2022
   
15,821
     
5,359
     
1,611
     
1,923
     
2,946
     
39,539
     
67,199
 
Additions during the year
   
329
     
26
     
104
     
60
     
139
     
300
     
958
 
Disposals during the year
   
(3,113
)
   
-
     
(325
)
   
(46
)
   
-
     
(4,422
)
   
(7,906
)
Currency translation differences
   
(344
)
   
(160
)
   
(27
)
   
(59
)
   
(84
)
   
(1,125
)
   
(1,799
)
                                                         
Balance as of December 31, 2023
   
12,693
     
5,225
     
1,363
     
1,878
     
3,001
     
34,292
     
58,452
 
                                                         
Depreciated cost as of December 31, 2023
   
1,239
     
83
     
502
     
407
     
950
     
1,711
     
4,892
 
                                                         
Depreciated cost as of December 31, 2022
   
1,035
     
107
     
587
     
287
     
984
     
1,652
     
4,652
 
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.24.2
GOODWILL AND INTANGIBLE ASSETS, NET (Tables)
12 Months Ended
Dec. 31, 2023
GOODWILL AND INTANGIBLE ASSETS, NET  
Schedule of changes in intangible assets and goodwill
 
   
Development costs
   
Contracts and
others
   
Customer relations
   
Information Technology
   
Total
other intangible assets
   
Goodwill
(1)
 
                                     
As of January 1, 2023, net of accumulated amortization
   
8,274
     
-
     
11,737
     
414
     
20,425
     
33,745
 
Additions during the year
   
4,203
     
-
     
-
     
-
     
4,203
     
-
 
Amortization during the year
   
(2,770
)
   
-
     
(1,309
)
   
(104
)
   
(4,183
)
   
-
 
Currency translation differences
   
171
     
-
     
(372
)
   
13
     
(188
)
   
(780
)
                                                 
As of December 31, 2023, net of accumulated amortization
   
9,878
     
-
     
10,056
     
323
     
20,257
     
32,965
 
                                                 
As of December 31, 2023:
                                               
                                                 
Cost
   
44,131
     
7,766
     
16,215
     
644
     
68,756
     
32,965
 
Accumulated amortization
   
(34,253
)
   
(7,766
)
   
(6,159
)
   
(321
)
   
(48,499
)
   
-
 
                                                 
Net carrying amount
   
9,878
     
-
     
10,056
     
323
     
20,257
     
32,965
 
 
   
Development costs
   
Contracts and
others
   
Customer relations
   
Information Technology
   
Total
other intangible assets
   
Goodwill
(1)
 
                                     
As of January 1, 2022, net of accumulated amortization
   
5,309
     
-
     
14,929
     
549
     
20,787
     
37,508
 
Additions during the year
   
5,243
     
-
     
-
     
-
     
5,243
     
-
 
Amortization during the year
   
(1,829
)
   
-
     
(1,526
)
   
(102
)
   
(3,457
)
   
-
 
PPA adjustment (see Note 5)
   
-
     
-
     
-
     
-
     
-
     
407
 
Currency translation differences
   
(449
)
   
-
     
(1,666
)
   
(33
)
   
(2,148
)
   
(4,170
)
                                                 
As of December 31, 2022, net of accumulated amortization
   
8,274
     
-
     
11,737
     
414
     
20,425
     
33,745
 
                                                 
As of December 31, 2022:
                                               
                                                 
Cost
   
46,961
     
7,488
     
16,510
     
621
     
71,580
     
33,745
 
Accumulated amortization
   
(38,687
)
   
(7,488
)
   
(4,773
)
   
(207
)
   
(51,155
)
   
-
 
                                                 
Net carrying amount
   
8,274
     
-
     
11,737
     
414
     
20,425
     
33,745
 
 
  (1)
The recoverable amount of the cash generating units to which the goodwill mainly relates has been determined based on a value in use calculation using cash flow projections from financial budgets approved by senior management covering a five-year period.
Schedule of information for cash-generating units
The carrying amount of the goodwill has been allocated to the following cash generating units:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
2,954
     
3,044
 
Israel – Mediton
   
16,111
     
16,606
 
Germany
   
13,900
     
14,095
 
                 
     
32,965
     
33,745
 
The pre-tax discount rate applied to cash flow projections are as follows:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
20.7
%
   
19.1
%
Israel – Mediton
   
19.4
%
   
18.3
%
Germany
   
20.5
%
   
16.8
%
 
The average growth rate of revenues in the 5 year forecast period subsequent to the end of the reporting period, are as follows:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
3.2
%
   
4
%
Israel – Mediton
   
4.9
%
   
5.4
%
Germany
   
11.3
%
   
13.8
%

 

The cash flows beyond the 5-year period are extrapolated using the following growth rates:
 
   
December 31,
 
   
2023
   
2022
 
             
Israel - Telemedicine
   
3.2
%
   
3.2
%
Israel – Mediton
   
3.2
%
   
3.2
%
Germany
   
3
%
   
3
%
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.24.2
LEASES (Tables)
12 Months Ended
Dec. 31, 2023
LEASES  
Schedule of information on leases
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Interest expense on lease liabilities
   
343
     
361
     
378
 
Expenses relating to short-term leases
   
-
     
25
     
25
 
Total cash outflow for leases
   
2,992
     
2,808
     
2,546
 
Schedule of potential future undiscounted lease payments for periods covered by extension or termination options that were not included in measurement of lease liabilities
   
More than 5 years
 
   
December 31,
 
   
2023
   
2022
 
Lease payments applicable in extension option periods which as of the end of the reporting period are not reasonably certain to be exercised
   
2,479
     
2,472
 
Schedule of information about right-of-use assets
 
   
Buildings
   
Motor vehicles
   
Total
 
Cost:
                 
                   
Balance as of January 1, 2023
   
15,844
     
1,449
     
17,293
 
Additions during the year:
                       
New leases
   
663
     
634
     
1,297
 
Adjustments for indexation
   
145
     
23
     
168
 
Disposals
   
(6,198
)
   
(52
)
   
(6,250
)
Currency translation differences
   
(22
)
   
(18
)
   
(40
)
                         
Balance as of December 31, 2023
   
10,432
     
2,036
     
12,468
 
                         
Accumulated depreciation:
                       
                         
Balance as of January 1, 2023
   
5,258
     
997
     
6,255
 
Additions during the year:
                       
Depreciation and amortization
   
2,214
     
337
     
2,551
 
Disposals
   
(3,520
)
   
-
     
(3,520
)
Currency translation differences
   
(19
)
   
(13
)
   
(32
)
                         
Balance as of December 31, 2023
   
3,933
     
1,321
     
5,254
 
                         
Depreciated cost at December 31, 2023
   
6,499
     
715
     
7,214
 

 

   
Buildings
   
Motor vehicles
   
Total
 
Cost:
                 
                   
Balance as of January 1, 2022
   
16,089
     
1,078
     
17,167
 
Additions during the year:
                       
New leases
   
950
     
475
     
1,425
 
Adjustments for indexation
   
266
     
30
     
296
 
Disposals
   
(55
)
   
-
     
(55
)
Currency translation differences
   
(1,406
)
   
(134
)
   
(1,540
)
                         
Balance as of December 31, 2022
   
15,844
     
1,449
     
17,293
 
                         
Accumulated depreciation:
                       
                         
Balance as of January 1, 2022
   
3,384
     
770
     
4,154
 
Additions during the year:
                       
Depreciation and amortization
   
2,248
     
321
     
2,569
 
Disposals
   
(29
)
   
-
     
(29
)
Currency translation differences
   
(345
)
   
(94
)
   
(439
)
                         
Balance as of December 31, 2022
   
5,258
     
997
     
6,255
 
                         
Depreciated cost at December 31, 2022
   
10,586
     
452
     
11,038
 
XML 59 R42.htm IDEA: XBRL DOCUMENT v3.24.2
CREDIT FROM BANKS (Tables)
12 Months Ended
Dec. 31, 2023
Disclosure Of Credit From Banks Abstract  
Schedule of credit from banks
 
 
Interest
           
 
rate (1)
 
December 31,
 
 
%
 
2023
   
2022
 
               
Current maturities of long-term loans (see Note 14)
Prime (1)+1.05
   
2,160
     
2,169
 
                   
       
2,160
     
2,169
 
 
  (1)
The Prime rate as of December 31, 2023 – 6.25% (December 31, 2022 – 4.75%).
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.24.2
LONG-TERM LOANS (Tables)
12 Months Ended
Dec. 31, 2023
Long Term Loans Abstract  
Schedule of long-term loans
 
   
December 31,
 
   
2023
   
2022
 
             
Long-term loan
   
12,620
     
15,177
 
Less – current maturities
   
2,160
     
2,169
 
                 
Balance
   
10,460
     
13,008
 
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.24.2
OTHER PAYABLES (Tables)
12 Months Ended
Dec. 31, 2023
Other Payables Abstract  
Schedule of other payables
   
December 31,
 
   
2023
   
2022
 
             
Employees and payroll accruals
   
4,376
     
4,562
 
Accrued expenses
   
2,304
     
2,090
 
Liability for underwriter – see Note 17
   
-
     
1,131
 
VAT to customers and suppliers
   
-
     
399
 
Government authorities
   
754
     
640
 
Accruals restructuring
   
686
     
-
 
Other
   
416
     
416
 
                 
     
8,536
     
9,238
 
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.24.2
FINANCIAL INSTRUMENTS (Tables)
12 Months Ended
Dec. 31, 2023
Financial instruments  
Schedule of financial assets and liabilities
   
Carrying amount
 
   
December 31,
 
   
2023
   
2022
 
Financial assets at amortized cost:
           
             
Cash and cash equivalents
   
6,693
     
4,483
 
Short term deposits
   
10,579
     
5,700
 
Trade receivables
   
8,557
     
7,797
 
Other accounts receivable
   
1,792
     
1,912
 
Long term deposits
   
328
     
423
 
                 
Total
   
27,949
     
20,315
 
                 
Financial assets at fair value through profit or loss:
               
                 
Call option from non-controlling interests
   
147
     
245
 
Short term investments
   
8,978
     
8,517
 
                 
Total
   
9,125
     
8,762
 
                 
Financial liabilities at amortized cost:
               
                 
Credit from banks and others
   
2,160
     
2,169
 
Trade payables
   
3,884
     
3,757
 
Other payables
   
8,536
     
8,110
 
Loans from banks
   
10,460
     
13,008
 
Lease liabilities
   
7,239
     
11,565
 
                 
Total
   
32,279
     
38,609
 
                 
Financial liabilities at fair value through profit or loss:
               
                 
Liability for share options
   
-
     
7,164
 
Other payables - liability to underwriters
   
-
     
1,131
 
                 
Total
   
-
     
8,295
 
Schedule of maturity profile of financial liabilities based on contractual undiscounted payments
 
December 31, 2023:
 
   
Less than one year
   
1 to 2 years
   
2 to 3
years
   
3 to 4 years
   
4 to 5 years
   
> 5
years
   
Total
 
                                           
Trade payables
   
3,884
     
-
     
-
     
-
     
-
     
-
     
3,884
 
Accrued expenses
   
2,990
     
-
     
-
     
-
     
-
     
-
     
2,990
 
PUT option (*)
   
-
     
8,225
     
-
     
-
     
-
     
-
     
8,225
 
Lease liabilities
   
2,542
     
2,280
     
1,814
     
1,615
     
1,571
     
953
     
10,775
 
Loans from bank
   
3,023
     
2,920
     
2,816
     
2,710
     
2,600
     
1,258
     
15,327
 
                                                         
     
12,439
     
13,425
     
4,630
     
4,325
     
4,171
     
2,211
     
41,201
 
 
December 31, 2022:
 
   
Less than one year
   
1 to 2 years
   
2 to 3
years
   
3 to 4 years
   
4 to 5 years
   
> 5
years
   
Total
 
                                           
Trade payables
   
3,757
     
-
     
-
     
-
     
-
     
-
     
3,757
 
Accrued expenses
   
2,090
     
-
     
-
     
-
     
-
     
-
     
2,090
 
PUT option (*)
   
-
     
-
     
11,289
     
-
     
-
     
-
     
11,289
 
Liability for underwriter
   
1,131
     
-
     
-
     
-
     
-
     
-
     
1,131
 
Lease liabilities
   
2,478
     
2,294
     
1,932
     
1,726
     
3,608
     
274
     
12,312
 
Loans from bank
   
3,002
     
2,933
     
2,861
     
2,788
     
2,714
     
3,927
     
18,225
 
                                                         
     
12,458
     
5,227
     
16,082
     
4,514
     
6,322
     
4,201
     
48,804
 
 
  (*)
Estimated gross cash outflow assuming that option will be exercised at earliest possible date.
Schedule of changes in liabilities arising from financing activities
 
   
January 1,
2023
   
Cash
flows
   
Foreign
exchange
movement
   
Other
   
December 31, 2023
 
                               
Lease liabilities (including current maturities)
   
11,564
     
(3,048
)
   
(12
)
   
(1,265
)
   
7,239
 
Liability for underwriters
   
1,131
     
(1,124
)
   
(22
)
   
15
     
-
 
Long term bank loan
   
15,176
     
(2,070
)
   
(486
)
   
-
     
12,620
 
                                         
Total liabilities from financing activities
   
27,871
     
(6,241
)
   
(520
)
   
(1,250
)
   
19,859
 
 
   
January 1,
2022
   
Cash
flows
   
Foreign
exchange
movement
   
Other
   
December 31, 2022
 
                               
Lease liabilities (including current maturities)
   
13,530
     
(2,447
)
   
(1,176
)
   
1,657
     
11,564
 
Liability for underwriters
   
1,021
     
-
     
(129
)
   
239
     
1,131
 
Long term bank loan
   
18,971
     
(1,665
)
   
(2,130
)
   
-
     
15,176
 
                                         
Total liabilities from financing activities
   
33,522
     
(4,112
)
   
(3,435
)
   
1,896
     
27,871
 
Schedule of reconciliation of fair value measurements that are categorized within Level 3 of fair value hierarchy
 
   
Financial instruments
 
   
Liability for share options (*)
   
Liability to underwriters
   
Call (Put) option to non-controlling interests, net
   
Total
 
                         
Balance as of January 1, 2023
   
(7,164
)
   
(1,131
)
   
245
     
(8,050
)
                                 
Issuance of Share Options
                               
Remeasurement recognized in:
                               
Profit (loss)
   
1,801
     
(15
)
   
(89
)
   
1,697
 
Other comprehensive income (loss)
   
30
     
22
     
(9
)
   
43
 
Exercise of Share Options into shares
   
5,333
     
-
     
-
     
5,333
 
Payment
   
-
     
1,124
     
-
     
1,124
 
                                 
As of December 31, 2023
   
-
     
-
     
147
     
147
 
                                 
Presented in balance sheet:
                               
                                 
Put option
   
-
     
-
     
147
     
147
 
 
   
Financial instruments
 
   
Liability for share options (*)
   
Liability to underwriters
   
Call (Put) option to non-controlling interests, net
   
Total
 
                         
Balance as of January 1, 2022
   
(17,220
)
   
(1,021
)
   
(67
)
   
(18,308
)
                                 
Issuance of Share Options
                               
Remeasurement recognized in:
                               
Profit (loss)
   
7,423
     
(240
)
   
320
     
7,503
 
Other comprehensive income (loss)
   
1,618
     
130
     
(8
)
   
1,740
 
Exercise of Share Options into shares
   
1,015
     
-
     
-
     
1,015
 
                                 
As of December 31, 2022
   
(7,164
)
   
(1,131
)
   
245
     
(8,050
)
                                 
Presented in balance sheet:
                               
                                 
Call option
   
-
     
-
     
245
     
245
 
Other payables (short-term)
   
-
     
(1,131
)
   
-
     
(1,131
)
                                 
Liability for share options
   
(7,164
)
   
-
     
-
     
(7,164
)
 
  (*)
See Note 22b for information on fair value measurement.
Schedule of significant inputs to model used to determine fair value
   
December 31, 2023
   
December 31, 2022
 
             
Underlying asset value
   
35,732
     
35,541
 
Expected volatility of the share price
   
34.7%
 
   
36.7%-39.2%
 
Discount rate
   
14.9%
 
   
15%
 
Risk-free interest rate
   
3.64%
 
   
3.68%
 
Term of option
 
2.67 years
   
3.67 years
 
Schedule of sensitivity analysis of reasonably possible change in underlying asset value
 
2023:
 
   
Increase/
decrease in underlying asset value
   
Effect on
Fair value, net
 
             
     
+5%
 
   
433
 
     
-5%
 
   
(430)
 
 
2022:
 
   
Increase/
decrease in underlying asset value
   
Effect on
Fair value, net
 
             
     
+5%
 
   
463
 
     
-5%
 
   
(453)
 
Foreign currency risk  
Financial instruments  
Schedule of sensitivity analysis
 
   
Change in USD rate
   
Effect on profit tax
 
             
2023
   
+5
%
   
(721
)
     
-5
%
   
721
 
                 
2022
   
+5
%
   
(320
)
     
-5
%
   
320
 
 
   
Change in EUR rate
   
Effect on profit tax
 
             
2023
   
+5
%
   
(66
)
     
-5
%
   
66
 
                 
2022
   
+5
%
   
(38
)
     
-5
%
   
38
 
Market risk  
Financial instruments  
Schedule of sensitivity analysis
   
Increase/
decrease in price
   
Effect on
profit
before tax
 
             
2023
   
+5
%
   
449
 
     
-5
%
   
(449
)
                 
2022
   
+5
%
   
426
 
     
-5
%
   
(426
)
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.24.2
EMPLOYEE BENEFIT LIABILITIES (Tables)
12 Months Ended
Dec. 31, 2023
EMPLOYEE BENEFIT LIABILITIES  
Schedule of changes in the defined benefit obligation and fair value of plan assets
2023:
 
         
Expenses recognized in profit or loss
               
Gain (loss) from remeasurement in other comprehensive income
                   
   
Balance at January 1, 2023
   
Current service cost
   
Net interest expense
   
 
Past service cost and effect of settlements
   
Total expense recognized in profit or loss for the period
   
Payments from the plan
   
Actuarial gain (loss) arising from changes in financial assumptions
   
Actuarial gain (loss) arising from experience adjustments
   
Total effect
on other comprehensive income for the period
   
Effect of changes in foreign exchange rates
   
Contributions by employer
   
Balance at December 31, 2023
 
                                                                         
Defined benefit obligation
   
(8,153
)
   
(340
)
   
(409
)
   
(35
)
   
(784
)
   
148
     
81
     
(7
)
   
74
     
223
     
-
     
(8,492
)
Fair value of plan assets
   
6,658
     
-
     
351
     
-
     
351
     
(134
)
   
-
     
(4
)
   
(4
)
   
(191
)
   
239
     
6,919
 
                                                                                                 
Net defined benefit liability (asset)
   
(1,495
)
   
(340
)
   
(58
)
   
(35
)
   
(433
)
   
14
     
81
     
(11
)
   
70
     
32
     
239
     
(1,573
)
 
2022:
 
   
Expenses recognized in profit or loss
               
Gain (loss) from remeasurement in other comprehensive income
                   
   
Balance at January 1, 2022
   
Current service cost
   
Net interest expense
   
Total expense recognized in profit or loss for the period
   
Payments from the plan
   
Actuarial gain (loss) arising from changes in financial assumptions
   
Actuarial gain (loss) arising from experience adjustments
   
Total effect
on other comprehensive income for the period
   
Effect of changes in foreign exchange rates
   
Contributions by employer
   
Balance at December 31, 2022
 
                                                                   
Defined benefit obligation
   
(9,848
)
   
(405
)
   
(245
)
   
(650
)
   
374
     
775
     
87
     
862
     
1,109
     
-
     
(8,153
)
Fair value of plan assets
   
7,466
     
-
     
198
     
198
     
(349
)
   
-
     
(123
)
   
(123
)
   
(870
)
   
336
     
6,658
 
                                                                                         
Net defined benefit liability (asset)
   
(2,382
)
   
(405
)
   
(47
)
   
(452
)
   
25
     
775
     
(36
)
   
739
     
239
     
336
     
(1,495
)
Schedule of disaggregation of the fair value of the plan assets
   
Year ended
December 31,
 
   
2023
   
2022
 
             
Insurance contracts
   
6,919
     
6,658
 
Schedule of principal assumptions underlying the defined benefit plan
   
2023
   
2022
 
   
%
 
             
Discount rate
   
5.55
     
5.57
 
Expected rate of salary increase
   
2.0-5.48
     
2.0-5.92
 
Schedule of reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions are constant
   
Change in defined
benefit obligation
 
   
Year ended
December 31,
 
   
2023
   
2022
 
Sensitivity test for changes in the expected rate of salary increase:
           
             
The change as a result of:
           
             
Salary increase of  6.1% (instead of 5.5%) (2022- 6.51% instead of 5.9%)
   
(45
)
   
(49
)
                 
Sensitivity test for changes in the discount rate of the plan assets and liability:
               
                 
The change as a result of:
               
                 
Increase of 1% in discount rate
           
(13
)
Decrease of 1% in discount rate
   
45
     
45
 
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.24.2
TAXES ON INCOME (Tables)
12 Months Ended
Dec. 31, 2023
Major components of tax expense (income) [abstract]  
Schedule of taxes on income included in the statements of comprehensive income
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Current taxes
   
552
     
749
     
236
 
Deferred taxes
   
409
     
341
     
259
 
Taxes in respect of prior yearsa
   
(70
)
   
7
     
(40
)
                         
     
891
     
1,097
     
455
 
Schedule of composition and changes in deferred taxes, as presented in the consolidated balance sheet
 
   
Fixed
and
intangible
assets
   
Employee benefit liabilities
   
 
 
Short term investments
   
Carry-
forward tax losses
   
Total
 
                               
Balance at January 1, 2022
   
(4,006
)
   
824
     
-
     
3,916
     
734
 
                                         
Amount included in statement of comprehensive income
   
498
     
(122
)
   
-
     
(875
)
   
(*)(499
)
Currency translation differences
   
443
     
(90
)
   
-
     
(416
)
   
(63
)
                                         
Balance at December 31, 2022
   
(3,065
)
   
612
     
-
     
2,625
     
172
 
                                         
Amount included in statement of comprehensive income
   
55
     
39
     
(192
)
   
(320
)
   
(418
)
Currency translation differences
   
91
     
(19
)
   
(3
)
   
(81
)
   
(12
)
                                         
Balance at December 31, 2023
   
(2,919
)
   
632
     
(195
)
   
2,224
     
(258
)
 
  (*)
$159 presented in other comprehensive income.
   
December 31,
 
   
2023
   
2022
 
             
Non-current assets
   
2,055
     
2,872
 
Non-current liabilities
   
2,313
     
2,700
 
                 
     
(258
)
   
172
 
Schedule of reconciliation of the theoretical tax expense assuming all income is taxed at the statutory rate applicable to the income of companies in Israel, and the actual tax expense
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Income (loss) before taxes on income
   
(5,964
)
   
1,312
     
(13,469
)
                         
Statutory tax rate in Israel
   
23
%
   
23
%
   
23
%
                         
Tax computed at the statutory tax rate
   
(1,372
)
   
302
     
(3,098
)
                         
Increase (decrease) in taxes resulting from:
                       
Taxes in respect of previous years
   
(70
)
   
7
     
(40
)
Tax adjustment in respect of inflation in Israel
   
-
     
-
     
(2
)
Non-deductible expenses (non-taxable income)
   
406
     
(1,699
)
   
2,613
 
Different tax rates
   
63
     
60
     
24
 
Loss for which deferred taxes were not recognized
   
1,864
     
2,234
     
926
 
Utilization of previously unrecognized capital gain
   
-
     
-
     
32
 
Capital losses for which deferred taxes were not recognized
   
-
     
193
     
-
 
                         
Total tax expenses reported in the consolidated statements of comprehensive income
   
891
     
1,097
     
455
 
Schedule of expiry dates for carry forward tax losses not recognized
   
Year ended
December 31,
 
   
2023
   
2022
 
             
First year
   
37
     
24
 
Second year
   
762
     
229
 
Third year
   
413
     
126
 
Fourth year
   
153
     
52
 
Fifth year
   
959
     
281
 
Sixth - Fifteen
   
4,891
     
1,280
 
Unlimited
   
93,771
     
87,278
 
                 
     
100,986
     
89,270
 
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.24.2
COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Tables)
12 Months Ended
Dec. 31, 2023
COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS)  
Schedule of compensation of key management personnel (including directors)
     
December 31,
 
     
2023
   
2022
   
2021
 
a.
Balances:
                 
                     
 
Other accounts payable
   
182
     
181
     
170
 
 
     
Year ended
December 31,
 
     
2023
   
2022
   
2021
 
b.
Transactions:
                 
                     
 
Short-term employee benefits
   
2,639
     
2,531
     
2,108
 
 
Share-based payment benefits
   
638
     
1,179
     
883
 
                           
 
Total
   
3,277
     
3,710
     
2,991
 
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.24.2
EQUITY (Tables)
12 Months Ended
Dec. 31, 2023
EQUITY  
Schedule of composition of share capital

?

   
December 31, 2023
   
December 31, 2022
 
   
Authorized
   
Issued and outstanding*)
   
Authorized
   
Issued and outstanding*)
 
   
Number of shares
 
                         
Ordinary shares of NIS 0.01 par value each
   
25,000,000
     
16,391,382
     
25,000,000
     
14,682,272
 
 
  *)
Net of treasury shares – see (c).
Schedule of movements in Share Options
Balance on January 1, 2022
   
1,905,820
 
Exercise of share options
   
(171,945
)
         
Balance on December 31, 2022
   
1,733,875
 
Exercise of share options
   
(1,703,908
)
Expiration of share options
   
(29,967
)
         
Balance on December 31, 2023
   
-
 
Schedule of issued and outstanding share capital
   
Number of
shares
 
       
Balance at January 1, 2022
   
14,491,171
 
         
Exercise of share options
   
171,945
 
Exercise of employees share options
   
5,694
 
Treasury shares sold upon exercise of employee options
   
13,462
 
         
Balance at December 31, 2022
   
14,682,272
 
         
Exercise of share options
   
1,703,908
 
Exercise of employees share options
   
5,202
 
         
Balance at December 31, 2023
   
16,391,382
 
Schedule of number and weighted average exercise prices ("WAEP") of, and movements in, share options
   
2023
   
2022
 
   
No. of options
   
WAEP (CHF)
   
No. of options
   
WAEP (CHF)
 
                         
Outstanding at the beginning of the year
   
1,001,430
     
11.85
     
835,055
     
10.12
 
Granted during the year
   
423,500
     
13.03
     
210,000
     
18.31
 
Forfeited during the year
   
(165,881
)
   
12.89
     
(7,500
)
   
19.33
 
Exercised during the year *)
   
(38,808
)
   
7.04
     
(36,125
)
   
7.94
 
                                 
Outstanding at the end of the year
   
1,220,241
     
12.27
     
1,001,430
     
11.85
 
                                 
Exercisable at the end of the year
   
720,758
     
11.02
     
454,480
     
9.42
 
 
  *)
The weighted average share price at the date of exercise of these options was CHF 8.13 (2022 – CHF 16.85). Exercise was cashless.
Black and Scholes model  
EQUITY  
Schedule of significant inputs used for the fair value measurement
     
December 31, 2022
       
Expected dividend
   
0%
Expected volatility of the share price
   
32.59%-38.24%
Risk-free interest rate
   
0.82%
Expected average life of options
   
0.06-0.13 years
Share price
   
CHF 14.80 ($16.05)
Black and Scholes model | Underwriters  
EQUITY  
Schedule of significant inputs used for the fair value measurement
Expected dividend
 
0%
 
Expected volatility of the share price
 
41.18%
 
Risk-free interest rate
 
4.11%
 
Expected average life of options
 
2.01 years
 
Share price
 
CHF 11.55 ($12.53)
 
Monte Carlo model  
EQUITY  
Schedule of significant inputs used for the fair value measurement
   
December 31, 2022
 
       
Expected volatility of the share price
 
43.15%
 
Risk-free interest rate
 
0.82%
 
Expected average life of options
 
0.21 years
 
Share price
 
CHF 14.80 ($16.05)
 
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.24.2
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME (Tables)
12 Months Ended
Dec. 31, 2023
Supplementary Information To Statements Of Comprehensive Income Abstract  
Schedule of revenue
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Revenues for services performed during the period
   
55,678
     
57,869
     
48,343
 
Revenues from sale of devices
   
1,397
     
1,129
     
1,239
 
                         
     
57,075
     
58,998
     
49,582
 
Schedule of cost of revenues
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Salaries and related benefits
   
16,212
     
16,480
     
14,955
 
Medical services
   
8,355
     
8,712
     
4,682
 
Rental fees and maintenance
   
1,246
     
1,013
     
1,072
 
Depreciation and amortization
   
1,978
     
1,789
     
1,736
 
Cost of devices
   
1,025
     
1,013
     
1,249
 
Others
   
2,998
     
2,802
     
1,295
 
                         
     
31,814
     
31,809
     
24,989
 
Schedule of research and development costs
Salaries and related benefits
   
3,917
     
3,468
     
2,173
 
Amortization of development costs
   
2,772
     
1,829
     
1,243
 
Others
   
2,774
     
3,734
     
2,202
 
                         
     
9,463
     
9,031
     
5,618
 
Less - capitalization of development costs
   
4,203
     
5,243
     
2,633
 
                         
     
5,260
     
3,788
     
2,985
 
Schedule of selling and marketing expenses
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Salaries and related benefits
   
5,285
     
5,409
     
4,803
 
Marketing and related expenses
   
1,943
     
2,190
     
1,802
 
Depreciation and amortization
   
1,633
     
1,918
     
1,453
 
Rental fees and maintenance
   
160
     
271
     
205
 
Maintenance of vehicles
   
313
     
240
     
182
 
Others
   
1,247
     
1,375
     
1,009
 
                         
     
10,581
     
11,403
     
9,454
 
Schedule of general and administrative expenses
Salaries and related benefits
   
8,881
     
8,492
     
5,837
 
Office expenses
   
2,634
     
2,349
     
1,366
 
Professional fees
   
3,156
     
3,897
     
3,245
 
Depreciation and amortization
   
1,309
     
1,599
     
950
 
Others
   
248
     
411
     
705
 
                         
     
16,228
     
16,748
     
12,103
 
Schedule of financial income
Exchange rate differences
   
1,129
     
661
     
5
 
Gain on marketable securities, net
   
848
     
-
     
-
 
Share options
   
1,801
     
7,423
     
-
 
Call+Put options
   
-
     
320
     
-
 
Interest
   
1,055
     
429
     
376
 
                         
     
4,833
     
8,833
     
381
 
Schedule of financial expenses
Share options
   
-
     
(239
)
   
(10,126
)
Exchange rate differences
   
(138
)
   
(53
)
   
(1,595
)
Loss from marketable securities, net
   
-
     
(769
)
   
(114
)
Interest
   
(1,296
)
   
(1,033
)
   
(529
)
Call+Put options
   
(89
)
   
-
     
(677
)
Others
   
(268
)
   
(261
)
   
(312
)
                         
     
(1,791
)
   
(2,355
)
   
(13,353
)
Schedule of other expenses
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
                   
Impairment of property and equipment – see Note 10
   
-
     
-
     
118
 
Expenses related to acquisitions
   
-
     
-
     
590
 
Restructuring expenses*
   
1,235
     
-
     
-
 
Other expenses
   
963
     
416
     
(160
)
                         
     
2,198
     
416
     
548
 
 
 
Including expenses related to employee benefits and other direct expenditures arising from the restructuring.
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.24.2
NET EARNINGS PER SHARE (Tables)
12 Months Ended
Dec. 31, 2023
NET EARNINGS PER SHARE  
Schedule of details of the number of shares and net profit (loss) used in the computation of net earnings per share
 
   
Year ended December 31,
 
   
2023
   
2022
 
   
Weighted average number of shares
   
Net
loss
   
Weighted average\ number of shares
   
Net
loss
 
   
In
thousands
         
In
thousands
       
                         
For the computation of basic net earnings
   
16,269
     
(7,055
)
   
14,542
     
(76
)
Effect of dilution - share options
   
26
     
(1,801
)
   
656
     
(7,423
)
                                 
For the computation of diluted net earnings
   
16,295
     
(8,856
)
   
15,198
     
(7,499
)
XML 69 R52.htm IDEA: XBRL DOCUMENT v3.24.2
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2023
SEGMENT INFORMATION  
Schedule of disaggregated revenue information
   
Individuals and communities
   
Institutions and payers
   
Others
   
Total
 
Year ended December 31, 2023:
                       
                         
Europe
   
-
     
14,067
     
-
     
14,067
 
Israel
   
20,913
     
21,179
     
-
     
42,092
 
ROW
   
-
     
-
     
916
     
916
 
                                 
Total revenues
   
20,913
     
35,246
     
916
     
57,075
 
                                 
Year ended December 31, 2022:
                               
                                 
Europe
   
-
     
13,374
     
-
     
13,374
 
Israel
   
22,161
     
22,975
     
2
     
45,138
 
ROW
   
-
     
-
     
486
     
486
 
                                 
Total revenues
   
22,161
     
36,349
     
488
     
58,998
 
                                 
Year ended December 31, 2021:
                               
                                 
Europe
   
-
     
17,942
     
-
     
17,942
 
Israel
   
22,331
     
8,832
     
27
     
31,190
 
ROW
   
-
     
-
     
450
     
450
 
                                 
Total revenues
   
22,331
     
26,774
     
477
     
49,582
 
Schedule of revenue from geographic segments
   
Year ended
December 31,
 
   
2023
   
2022
   
2021
 
Segment profit (loss):
                 
                   
Europe
   
(5,347
)
   
(3,044
)
   
(477
)
Israel
   
8,424
     
8,641
     
8,266
 
ROW
   
(3,622
)
   
(2,972
)
   
(1,132
)
                         
     
(545
)
   
2,625
     
6,617
 
Unallocated income and expenses:
                       
                         
Corporate, R&D and other expenses
   
(6,263
)
   
(7,375
)
   
(6,798
)
Other expenses
   
(2,198
)
   
(416
)
   
(316
)
                         
Operating loss
   
(9,006
)
   
(5,166
)
   
(497
)
Financial income, net
   
3,042
     
6,478
     
(12,972
)
                         
Profit (loss) before taxes on income
   
(5,964
)
   
1,312
     
(13,469
)
Schedule of additional information of segments
 
   
Europe
   
Israel
   
Others
   
Total
 
                         
Year ended December 31, 2023
                       
                         
Depreciation and amortization
   
3,637
     
4,049
     
6
     
7,692
 
 
   
Europe
   
Israel
   
ROW
   
Unallocated assets
   
Total
 
                               
Non-current assets
   
23,588
     
36,803
     
1,940
     
4,910
     
67,241
 
 
   
Europe
   
Israel
   
Others
   
Total
 
                         
Year ended December 31, 2022
                       
                         
Depreciation and amortization
   
2,654
     
4,470
     
10
     
7,134
 
 
   
Europe
   
Israel
   
ROW
   
Unallocated assets
   
Total
 
                               
Non-current assets
   
27,132
     
40,056
     
1,767
     
2,636
     
71,591
 
 
   
Europe
   
Israel
   
Others
   
Total
 
                         
Year ended December 31, 2021
                       
                         
Depreciation and amortization
   
2,765
     
2,735
     
-
     
5,500
 
 
   
Europe
   
Israel
   
ROW
   
Unallocated assets
   
Total
 
                               
Non-current assets
   
11,539
     
61,534
     
-
     
2,260
     
75,333
 
XML 70 R53.htm IDEA: XBRL DOCUMENT v3.24.2
ACCOUNTING POLICIES - (Narrative) (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Disclosure Of Summary Of Significant Accounting Policies Abstract  
Impairment loss $ 0
Expense recognized $ 0
XML 71 R54.htm IDEA: XBRL DOCUMENT v3.24.2
ACCOUNTING POLICIES - Disclosure of depreciation of the right-of-use assets by class of underlying asset (Details)
12 Months Ended
Dec. 31, 2023
Motor vehicles | Minimum  
Leases  
Period of depreciation (in years) 1 year 6 months
Motor vehicles | Maximum  
Leases  
Period of depreciation (in years) 3 years 6 months
Motor vehicles | Mainly  
Leases  
Period of depreciation (in years) 3 years
Buildings | Minimum  
Leases  
Period of depreciation (in years) 4 years
Buildings | Maximum  
Leases  
Period of depreciation (in years) 11 years
Buildings | Mainly  
Leases  
Period of depreciation (in years) 10 years
XML 72 R55.htm IDEA: XBRL DOCUMENT v3.24.2
ACCOUNTING POLICIES - Disclosure of depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates (Details)
12 Months Ended
Dec. 31, 2023
Medical equipment | Minimum  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 10.00%
Medical equipment | Maximum  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 15.00%
Medical equipment | Mainly  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 15.00%
Motor vehicles and ambulances | Minimum  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 15.00%
Motor vehicles and ambulances | Maximum  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 20.00%
Motor vehicles and ambulances | Mainly  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 20.00%
Office furniture and equipment | Minimum  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 6.00%
Office furniture and equipment | Maximum  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 7.00%
Office furniture and equipment | Mainly  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 6.00%
Computers and peripheral equipment | Minimum  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 15.00%
Computers and peripheral equipment | Maximum  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 33.00%
Computers and peripheral equipment | Mainly  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 20.00%
Telemedicine devices on loan to customers  
Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates  
Annual rate (in percent) 10.00%
XML 73 R56.htm IDEA: XBRL DOCUMENT v3.24.2
ACCOUNTING POLICIES - Disclosure of useful life of intangible assets (Details)
12 Months Ended
Dec. 31, 2023
Developments costs | Minimum  
Useful life of intangible assets  
Useful life of intangible assets (in years) 5 years
Developments costs | Maximum  
Useful life of intangible assets  
Useful life of intangible assets (in years) 10 years
Computer software  
Useful life of intangible assets  
Useful life of intangible assets (in years) 5 years
Contracts  
Useful life of intangible assets  
Useful life of intangible assets (in years) 6 years 9 months
Customer relations  
Useful life of intangible assets  
Useful life of intangible assets (in years) 10 years
Information technology  
Useful life of intangible assets  
Useful life of intangible assets (in years) 6 years
XML 74 R57.htm IDEA: XBRL DOCUMENT v3.24.2
ACCOUNTING POLICIES - Disclosure of exchange rates and linkage basis (Details)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Israeli      
Exchange rates and linkage basis      
CPI Points [1] 248.6 241.4 229.4
Change [1] 3.00% 5.20% 2.80%
EUR      
Exchange rates and linkage basis      
Exchange rate 4.01 3.75 3.52
Change 6.90% 6.50% (10.70%)
USD      
Exchange rates and linkage basis      
Exchange rate 3.63 3.52 3.11
Change 3.10% 13.20% (3.10%)
CHF      
Exchange rates and linkage basis      
Exchange rate 4.31 3.82 3.4
Change 12.80% 12.40% (6.80%)
[1] The index on an average basis of 1993 = 100.
XML 75 R58.htm IDEA: XBRL DOCUMENT v3.24.2
CASH AND CASH EQUIVALENTS (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash and cash equivalents [abstract]        
Cash in banks (mainly in EUR) $ 6,271 $ 4,377    
Short-term deposits (in NIS) 422 106    
Cash and cash equivalents $ 6,693 $ 4,483 $ 14,845 $ 4,142
XML 76 R59.htm IDEA: XBRL DOCUMENT v3.24.2
SHORT-TERM INVESTMENTS (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Short Term Investment Abstract    
Corporate bonds $ 4,181 $ 4,033
Government bonds and loans 784 392
Shares 638 784
Exchange Traded Funds 3,375 3,308
Short-term investments, Gross 8,978 8,517
Short-term deposits 10,579 5,700
Short-term investments $ 19,557 $ 14,217
XML 77 R60.htm IDEA: XBRL DOCUMENT v3.24.2
TRADE RECEIVABLES (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Trade receivables    
Trade receivables $ 8,557 $ 7,797
Minimum    
Trade receivables    
Terms of billed accounts receivable 30 months  
Maximum    
Trade receivables    
Terms of billed accounts receivable 60 days  
Gross carrying amount    
Trade receivables    
Accounts receivable [1] $ 8,419 7,596
Other 138 201
Allowance for doubtful accounts    
Trade receivables    
Trade receivables $ 0 $ 0
[1] The terms of billed accounts receivable are generally 30-60 days. As of December 31, 2023 and 2022, there were no material billed receivables that were past due.
XML 78 R61.htm IDEA: XBRL DOCUMENT v3.24.2
PREPAID EXPENSES (Narrative) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Prepaid Expenses Abstract    
Amortization of prepaid expenses $ 731 $ 788
XML 79 R62.htm IDEA: XBRL DOCUMENT v3.24.2
OTHER ACCOUNTS RECEIVABLE (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Other Accounts Receivable Abstract    
Interest receivable $ 53 $ 190
Government authorities 298 616
Advances to supplies 328 54
Prepaid expenses 552 469
Others 561 583
Other accounts receivable $ 1,792 $ 1,912
XML 80 R63.htm IDEA: XBRL DOCUMENT v3.24.2
PROPERTY AND EQUIPMENT (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Property and equipment      
Balance at beginning of period $ 4,652    
Impairment 0 $ 0 $ (118)
Balance at end of period 4,892 4,652  
Cost      
Property and equipment      
Balance at beginning of period 71,851 79,679  
Additions during the year 1,289 1,660  
Disposals during the year (8,184) (1,176)  
Transfer from inventory, net 226 564  
Currency translation differences (1,838) (8,876)  
Balance at end of period 63,344 71,851 79,679
Accumulated depreciation      
Property and equipment      
Balance at beginning of period (67,199) (75,654)  
Additions during the year 958 1,109  
Disposals during the year 7,906 1,124  
Transfer from inventory, net   7  
Currency translation differences (1,799) (8,447)  
Balance at end of period (58,452) (67,199) (75,654)
Computers and peripheral equipment      
Property and equipment      
Balance at beginning of period 1,035    
Balance at end of period 1,239 1,035  
Computers and peripheral equipment | Cost      
Property and equipment      
Balance at beginning of period 16,856 18,334  
Additions during the year 699 479  
Disposals during the year (3,275) (4)  
Transfer from inventory, net 0 0  
Currency translation differences (348) (1,953)  
Balance at end of period 13,932 16,856 18,334
Computers and peripheral equipment | Accumulated depreciation      
Property and equipment      
Balance at beginning of period (15,821) (17,292)  
Additions during the year 329 385  
Disposals during the year 3,113 4  
Transfer from inventory, net   0  
Currency translation differences (344) (1,852)  
Balance at end of period (12,693) (15,821) (17,292)
Medical equipment      
Property and equipment      
Balance at beginning of period 107    
Balance at end of period 83 107  
Medical equipment | Cost      
Property and equipment      
Balance at beginning of period 5,466 6,150  
Additions during the year 7 31  
Disposals during the year 0 0  
Transfer from inventory, net 0 0  
Currency translation differences (165) (715)  
Balance at end of period 5,308 5,466 6,150
Medical equipment | Accumulated depreciation      
Property and equipment      
Balance at beginning of period (5,359) (6,018)  
Additions during the year 26 42  
Disposals during the year 0 0  
Transfer from inventory, net   0  
Currency translation differences (160) (701)  
Balance at end of period (5,225) (5,359) (6,018)
Office furniture and equipment      
Property and equipment      
Balance at beginning of period 587    
Balance at end of period 502 587  
Office furniture and equipment | Cost      
Property and equipment      
Balance at beginning of period 2,198 2,350  
Additions during the year 66 153  
Disposals during the year (366) (64)  
Transfer from inventory, net 0 0  
Currency translation differences (33) (241)  
Balance at end of period 1,865 2,198 2,350
Office furniture and equipment | Accumulated depreciation      
Property and equipment      
Balance at beginning of period (1,611) (1,756)  
Additions during the year 104 100  
Disposals during the year 325 64  
Transfer from inventory, net   0  
Currency translation differences (27) (181)  
Balance at end of period (1,363) (1,611) (1,756)
Motor vehicles and ambulances      
Property and equipment      
Balance at beginning of period 287    
Balance at end of period 407 287  
Motor vehicles and ambulances | Cost      
Property and equipment      
Balance at beginning of period 2,210 2,498  
Additions during the year 181 4  
Disposals during the year (46) (2)  
Transfer from inventory, net 0 0  
Currency translation differences (60) (290)  
Balance at end of period 2,285 2,210 2,498
Motor vehicles and ambulances | Accumulated depreciation      
Property and equipment      
Balance at beginning of period (1,923) (2,139)  
Additions during the year 60 36  
Disposals during the year 46 2  
Transfer from inventory, net   0  
Currency translation differences (59) (250)  
Balance at end of period (1,878) (1,923) (2,139)
Leasehold improvements      
Property and equipment      
Balance at beginning of period 984    
Balance at end of period 950 984  
Leasehold improvements | Cost      
Property and equipment      
Balance at beginning of period 3,930 3,777  
Additions during the year 127 598  
Disposals during the year 0 0  
Transfer from inventory, net 0 0  
Currency translation differences (106) (445)  
Balance at end of period 3,951 3,930 3,777
Leasehold improvements | Accumulated depreciation      
Property and equipment      
Balance at beginning of period (2,946) (3,152)  
Additions during the year 139 158  
Disposals during the year 0 0  
Transfer from inventory, net   0  
Currency translation differences (84) (364)  
Balance at end of period (3,001) (2,946) (3,152)
Devices on loan      
Property and equipment      
Balance at beginning of period 1,652    
Balance at end of period 1,711 1,652  
Devices on loan | Cost      
Property and equipment      
Balance at beginning of period 41,191 46,570  
Additions during the year 209 395  
Disposals during the year (4,497) (1,106)  
Transfer from inventory, net 226 564  
Currency translation differences (1,126) (5,232)  
Balance at end of period 36,003 41,191 46,570
Devices on loan | Accumulated depreciation      
Property and equipment      
Balance at beginning of period (39,539) (45,297)  
Additions during the year 300 388  
Disposals during the year 4,422 1,054  
Transfer from inventory, net   7  
Currency translation differences (1,125) (5,099)  
Balance at end of period $ (34,292) $ (39,539) $ (45,297)
XML 81 R64.htm IDEA: XBRL DOCUMENT v3.24.2
GOODWILL AND INTANGIBLE ASSETS, NET (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Goodwill and intangible assets, net    
Balance at beginning of period $ 20,425 $ 20,787
Additions during the year 4,203 5,243
Amortization during the year (4,183) (3,457)
Currency translation differences (188) (2,148)
Balance at end of period 20,257 20,425
Cost    
Goodwill and intangible assets, net    
Balance at beginning of period 71,580  
Balance at end of period 68,756 71,580
Accumulated depreciation    
Goodwill and intangible assets, net    
Balance at beginning of period (51,155)  
Balance at end of period (48,499) (51,155)
Development costs    
Goodwill and intangible assets, net    
Balance at beginning of period 8,274 5,309
Additions during the year 4,203 5,243
Amortization during the year (2,770) (1,829)
Currency translation differences 171 (449)
Balance at end of period 9,878 8,274
Development costs | Cost    
Goodwill and intangible assets, net    
Balance at beginning of period 46,961  
Balance at end of period 44,131 46,961
Development costs | Accumulated depreciation    
Goodwill and intangible assets, net    
Balance at beginning of period (38,687)  
Balance at end of period (34,253) (38,687)
Contracts and others    
Goodwill and intangible assets, net    
Currency translation differences   0
Contracts and others | Cost    
Goodwill and intangible assets, net    
Balance at beginning of period 7,488  
Balance at end of period 7,766 7,488
Contracts and others | Accumulated depreciation    
Goodwill and intangible assets, net    
Balance at beginning of period (7,488)  
Balance at end of period (7,766) (7,488)
Customer relations    
Goodwill and intangible assets, net    
Balance at beginning of period 11,737 14,929
Amortization during the year (1,309) (1,526)
Currency translation differences (372) (1,666)
Balance at end of period 10,056 11,737
Customer relations | Cost    
Goodwill and intangible assets, net    
Balance at beginning of period 16,510  
Balance at end of period 16,215 16,510
Customer relations | Accumulated depreciation    
Goodwill and intangible assets, net    
Balance at beginning of period (4,773)  
Balance at end of period (6,159) (4,773)
Information Technology    
Goodwill and intangible assets, net    
Balance at beginning of period 414 549
Amortization during the year (104) (102)
Currency translation differences 13 (33)
Balance at end of period 323 414
Information Technology | Cost    
Goodwill and intangible assets, net    
Balance at beginning of period 621  
Balance at end of period 644 621
Information Technology | Accumulated depreciation    
Goodwill and intangible assets, net    
Balance at beginning of period (207)  
Balance at end of period (321) (207)
Goodwill    
Goodwill and intangible assets, net    
Balance at beginning of period [1] 33,745 37,508
PPA adjustment [1]   407
Currency translation differences [1] (780) (4,170)
Balance at end of period [1] 32,965 33,745
Goodwill | Cost    
Goodwill and intangible assets, net    
Balance at beginning of period [1] 33,745  
Balance at end of period [1] $ 32,965 $ 33,745
[1] The recoverable amount of the cash generating units to which the goodwill mainly relates has been determined based on a value in use calculation using cash flow projections from financial budgets approved by senior management covering a five-year period.
XML 82 R65.htm IDEA: XBRL DOCUMENT v3.24.2
GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash-generating units    
Goodwill $ 32,965 $ 33,745
Period covered by financial budgets used in cash flow projections 5 years  
Israel telemedicine    
Cash-generating units    
Goodwill $ 2,954 $ 3,044
Pre-tax discount rate applied to cash flow projections 20.70% 19.10%
Growth rate used to extrapolate cash flow projections 3.20% 3.20%
Israel telemedicine | 5 year forecast    
Cash-generating units    
Growth rate used to extrapolate cash flow projections 3.20% 4.00%
Israel Mediton    
Cash-generating units    
Goodwill $ 16,111 $ 16,606
Pre-tax discount rate applied to cash flow projections 19.40% 18.30%
Growth rate used to extrapolate cash flow projections 3.20% 3.20%
Recoverable amount of the CGU exceeding its carrying amount $ 3,000  
Pre-tax discount rate 20.90%  
Long term growth rate 1.40%  
Israel Mediton | 5 year forecast    
Cash-generating units    
Growth rate used to extrapolate cash flow projections 4.90% 5.40%
Germany    
Cash-generating units    
Goodwill $ 13,900 $ 14,095
Pre-tax discount rate applied to cash flow projections 20.50% 16.80%
Growth rate used to extrapolate cash flow projections 3.00% 3.00%
Recoverable amount of the CGU exceeding its carrying amount $ 800  
Pre-tax discount rate 21.00%  
Long term growth rate 2.20%  
Reduction in annual growth rate (1.90%)  
Germany | 5 year forecast    
Cash-generating units    
Growth rate used to extrapolate cash flow projections 11.30% 13.80%
XML 83 R66.htm IDEA: XBRL DOCUMENT v3.24.2
LEASES (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Leases      
Interest expense on lease liabilities $ 343 $ 361 $ 378
Expenses relating to short-term leases 0 25 25
Capital gain 399    
Total cash outflow for leases 2,992 2,808 $ 2,546
Lease payments applicable in extension option periods which are not reasonably certain to be exercised $ 2,479 $ 2,472  
Buildings | Minimum      
Leases      
Lease term 4 years    
Buildings | Maximum      
Leases      
Lease term 11 years    
Vehicles      
Leases      
Lease term 3 years    
XML 84 R67.htm IDEA: XBRL DOCUMENT v3.24.2
LEASES - Right-of-use assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Leases    
Balance at beginning of period $ 11,038  
Balance at end of period 7,214 $ 11,038
Cost    
Leases    
Balance at beginning of period 17,293 17,167
New leases 1,297 1,425
Adjustments for indexation 168 296
Disposals (6,250) (55)
Currency translation differences (40) (1,540)
Balance at end of period 12,468 17,293
Accumulated depreciation    
Leases    
Balance at beginning of period (6,255) (4,154)
Depreciation and amortization (2,551) (2,569)
Disposals (3,520) (29)
Currency translation differences (32) (439)
Balance at end of period (5,254) (6,255)
Buildings    
Leases    
Balance at beginning of period 10,586  
Balance at end of period 6,499 10,586
Buildings | Cost    
Leases    
Balance at beginning of period 15,844 16,089
New leases 663 950
Adjustments for indexation 145 266
Disposals (6,198) (55)
Currency translation differences (22) (1,406)
Balance at end of period 10,432 15,844
Buildings | Accumulated depreciation    
Leases    
Balance at beginning of period (5,258) (3,384)
Depreciation and amortization (2,214) (2,248)
Disposals (3,520) (29)
Currency translation differences (19) (345)
Balance at end of period (3,933) (5,258)
Motor vehicles    
Leases    
Balance at beginning of period 452  
Balance at end of period 715 452
Motor vehicles | Cost    
Leases    
Balance at beginning of period 1,449 1,078
New leases 634 475
Adjustments for indexation 23 30
Disposals (52) 0
Currency translation differences (18) (134)
Balance at end of period 2,036 1,449
Motor vehicles | Accumulated depreciation    
Leases    
Balance at beginning of period (997) (770)
Depreciation and amortization (337) (321)
Disposals 0 0
Currency translation differences (13) (94)
Balance at end of period $ (1,321) $ (997)
XML 85 R68.htm IDEA: XBRL DOCUMENT v3.24.2
CREDIT FROM BANKS (Narrative) (Details)
Dec. 31, 2023
Dec. 31, 2022
Disclosure Of Credit From Banks Abstract    
Prime rate 6.25% 4.75%
XML 86 R69.htm IDEA: XBRL DOCUMENT v3.24.2
CREDIT FROM BANKS - Disclosure of credit from banks (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Disclosure Of Credit From Banks Abstract    
Current maturities of long-term loans $ 2,160 $ 2,169
Total credit from banks $ 2,160 $ 2,169
Borrowings, interest rate basis [1] Prime (1)+1.05  
Borrowings, adjustment to interest rate basis 1.05%  
[1] The Prime rate as of December 31, 2023 – 6.25% (December 31, 2022 – 4.75%).
XML 87 R70.htm IDEA: XBRL DOCUMENT v3.24.2
LONG-TERM LOANS (Details)
$ in Thousands, ₪ in Millions
12 Months Ended
Aug. 29, 2021
ILS (₪)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Aug. 29, 2021
USD ($)
Long-term loans        
Borrowings, interest rate basis [1]   Prime (1)+1.05    
Borrowings, adjustment to interest rate basis   1.05%    
Long-term loan   $ 12,620 $ 15,177  
Less - current maturities   2,160 2,169  
Long-term loans   $ 10,460 $ 13,008  
Agreement With Bank In Israel        
Long-term loans        
Long-term loan amount ₪ 59     $ 18,000
Loan term 7 years 9 months      
Borrowings, interest rate basis prime + 1.05%      
Borrowings, adjustment to interest rate basis 1.05%     1.05%
Borrowings, interest rate 2.65%     2.65%
Initial moratorium period for repayment of loan 9 months      
Tangible equity financial covenant | ₪ ₪ 40      
Tangible equity to total tangible assets financial covenant 40.00%     40.00%
Net debt to EBITDA financial covenant 3.5     3.5
[1] The Prime rate as of December 31, 2023 – 6.25% (December 31, 2022 – 4.75%).
XML 88 R71.htm IDEA: XBRL DOCUMENT v3.24.2
DEFERRED REVENUES (Narrative) (Details)
12 Months Ended
Dec. 31, 2023
DEFERRED REVENUES  
Maximum expected period between receipt of advance payment and performance of service 1 year
XML 89 R72.htm IDEA: XBRL DOCUMENT v3.24.2
OTHER PAYABLES - Disclosure of other current payables (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Other Payables Abstract    
Employees and payroll accruals $ 4,376 $ 4,562
Accrued expenses 2,304 2,090
Liability for underwriter 0 1,131
VAT to customers and suppliers 0 399
Government authorities 754 640
Accruals restructuring 686 0
Other 416 416
Total other payables $ 8,536 $ 9,238
XML 90 R73.htm IDEA: XBRL DOCUMENT v3.24.2
FINANCIAL INSTRUMENTS (Narrative) (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Disclosure of detailed information about financial instruments [abstract]    
Short-term investments $ 8,978 $ 8,517
Aggregate contractual undiscounted payments $ 10,776  
XML 91 R74.htm IDEA: XBRL DOCUMENT v3.24.2
FINANCIAL INSTRUMENTS - Disclosure of Financial assets and liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Financial liabilities at amortized cost    
Financial instruments    
Financial liabilities $ 32,279 $ 38,609
Financial liabilities at amortized cost | Credit from banks and others    
Financial instruments    
Financial liabilities 2,160 2,169
Financial liabilities at amortized cost | Trade payables    
Financial instruments    
Financial liabilities 3,884 3,757
Financial liabilities at amortized cost | Other payables    
Financial instruments    
Financial liabilities 8,536 8,110
Financial liabilities at amortized cost | Loans from banks    
Financial instruments    
Financial liabilities 10,460 13,008
Financial liabilities at amortized cost | Lease liabilities    
Financial instruments    
Financial liabilities 7,239 11,565
Financial liabilities at fair value through profit or loss    
Financial instruments    
Financial liabilities 0 8,295
Financial liabilities at fair value through profit or loss | Liability for share options    
Financial instruments    
Financial liabilities 0 7,164
Financial liabilities at fair value through profit or loss | Other payables - liability to underwriters    
Financial instruments    
Financial liabilities 0 1,131
Financial assets at amortized cost    
Financial instruments    
Financial assets 27,949 20,315
Financial assets at amortized cost | Cash and cash equivalents    
Financial instruments    
Financial assets 6,693 4,483
Financial assets at amortized cost | Short term deposits    
Financial instruments    
Financial assets 10,579 5,700
Financial assets at amortized cost | Trade receivables    
Financial instruments    
Financial assets 8,557 7,797
Financial assets at amortized cost | Other accounts receivable    
Financial instruments    
Financial assets 1,792 1,912
Financial assets at amortized cost | Long term deposits    
Financial instruments    
Financial assets 328 423
Financial assets at fair value through profit or loss    
Financial instruments    
Financial assets 9,125 8,762
Financial assets at fair value through profit or loss | Call option from non-controlling interests    
Financial instruments    
Financial assets 147 245
Financial assets at fair value through profit or loss | Short-term investments    
Financial instruments    
Financial assets $ 8,978 $ 8,517
XML 92 R75.htm IDEA: XBRL DOCUMENT v3.24.2
FINANCIAL INSTRUMENTS - Disclosure of Foreign currency sensitivity analysis (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Financial instruments    
Short-term investments $ 19,557 $ 14,217
Foreign currency risk | USD    
Financial instruments    
Reasonably possible increase in risk component 5.00% 5.00%
Increase (decrease) in profit before tax due to reasonably possible decrease in risk component $ (721) $ (320)
Reasonably possible decrease in risk component (5.00%) (5.00%)
Increase (decrease) in profit before tax due to reasonably possible increase in risk component $ 721 $ 320
Foreign currency risk | EUR    
Financial instruments    
Reasonably possible increase in risk component 5.00% 5.00%
Increase (decrease) in profit before tax due to reasonably possible decrease in risk component $ (66) $ (38)
Reasonably possible decrease in risk component (5.00%) (5.00%)
Increase (decrease) in profit before tax due to reasonably possible increase in risk component $ 66 $ 38
XML 93 R76.htm IDEA: XBRL DOCUMENT v3.24.2
FINANCIAL INSTRUMENTS - Disclosure of Market risk profit before tax due to changes in carrying amount of marketable securities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]    
Percentage of reasonably possible increase in unobservable input profit loss before tax 5.00% 5.00%
Effect on fair value measurement due to reasonably possible increase in unobservable input profit loss before tax $ 449 $ 426
Percentage of reasonably possible decrease in unobservable input profit loss before tax (5.00%) (5.00%)
Effect on fair value measurement due to reasonably possible decrease in unobservable input profit before tax $ (449) $ (426)
XML 94 R77.htm IDEA: XBRL DOCUMENT v3.24.2
FINANCIAL INSTRUMENTS - Disclosure of Liquidity of summarizes maturity profile of financial liabilities based on contractual undiscounted payments (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Financial instruments    
Financial liabilities, undiscounted cash flows $ 41,201 $ 48,804
Less than one year    
Financial instruments    
Financial liabilities, undiscounted cash flows 12,439 12,458
1 to 2 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 13,425 5,227
2 to 3 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 4,630 16,082
3 to 4 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 4,325 4,514
4 to 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 4,171 6,322
More than 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 2,211 4,201
Trade payables    
Financial instruments    
Financial liabilities, undiscounted cash flows 3,884 3,757
Trade payables | Less than one year    
Financial instruments    
Financial liabilities, undiscounted cash flows 3,884 3,757
Trade payables | 1 to 2 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 0 0
Trade payables | 2 to 3 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 0 0
Trade payables | 3 to 4 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 0 0
Trade payables | 4 to 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 0 0
Trade payables | More than 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 0 0
Accrued expenses    
Financial instruments    
Financial liabilities, undiscounted cash flows 2,990 2,090
Accrued expenses | Less than one year    
Financial instruments    
Financial liabilities, undiscounted cash flows 2,990 2,090
Accrued expenses | 1 to 2 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 0 0
Accrued expenses | 2 to 3 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 0 0
Accrued expenses | 3 to 4 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 0 0
Accrued expenses | 4 to 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 0 0
Accrued expenses | More than 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 0 0
PUT option    
Financial instruments    
Financial liabilities, undiscounted cash flows [1] 8,225 11,289
PUT option | Less than one year    
Financial instruments    
Financial liabilities, undiscounted cash flows [1] 0 0
PUT option | 1 to 2 years    
Financial instruments    
Financial liabilities, undiscounted cash flows [1] 8,225 0
PUT option | 2 to 3 years    
Financial instruments    
Financial liabilities, undiscounted cash flows [1] 0 11,289
PUT option | 3 to 4 years    
Financial instruments    
Financial liabilities, undiscounted cash flows [1] 0 0
PUT option | 4 to 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows [1] 0 0
PUT option | More than 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows [1] 0 0
Liability for underwriter    
Financial instruments    
Financial liabilities, undiscounted cash flows   1,131
Liability for underwriter | Less than one year    
Financial instruments    
Financial liabilities, undiscounted cash flows   1,131
Liability for underwriter | 1 to 2 years    
Financial instruments    
Financial liabilities, undiscounted cash flows   0
Liability for underwriter | 2 to 3 years    
Financial instruments    
Financial liabilities, undiscounted cash flows   0
Liability for underwriter | 3 to 4 years    
Financial instruments    
Financial liabilities, undiscounted cash flows   0
Liability for underwriter | 4 to 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows   0
Liability for underwriter | More than 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows   0
Lease liabilities    
Financial instruments    
Financial liabilities, undiscounted cash flows 10,775 12,312
Lease liabilities | Less than one year    
Financial instruments    
Financial liabilities, undiscounted cash flows 2,542 2,478
Lease liabilities | 1 to 2 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 2,280 2,294
Lease liabilities | 2 to 3 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 1,814 1,932
Lease liabilities | 3 to 4 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 1,615 1,726
Lease liabilities | 4 to 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 1,571 3,608
Lease liabilities | More than 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 953 274
Loans from bank    
Financial instruments    
Financial liabilities, undiscounted cash flows 15,327 18,225
Loans from bank | Less than one year    
Financial instruments    
Financial liabilities, undiscounted cash flows 3,023 3,002
Loans from bank | 1 to 2 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 2,920 2,933
Loans from bank | 2 to 3 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 2,816 2,861
Loans from bank | 3 to 4 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 2,710 2,788
Loans from bank | 4 to 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows 2,600 2,714
Loans from bank | More than 5 years    
Financial instruments    
Financial liabilities, undiscounted cash flows $ 1,258 $ 3,927
[1] Estimated gross cash outflow assuming that option will be exercised at earliest possible date.
XML 95 R78.htm IDEA: XBRL DOCUMENT v3.24.2
FINANCIAL INSTRUMENTS - Disclosure of liabilities arising from financing activities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Financial instruments    
Liabilities arising from financing activities at beginning of period $ 27,871 $ 33,522
Cash flows (6,241) (4,112)
Foreign exchange movement (520) (3,435)
Other (1,250) 1,896
Liabilities arising from financing activities at end of period 19,859 27,871
Lease liabilities (including current maturities)    
Financial instruments    
Liabilities arising from financing activities at beginning of period 11,564 13,530
Cash flows (3,048) (2,447)
Foreign exchange movement (12) (1,176)
Other (1,265) 1,657
Liabilities arising from financing activities at end of period 7,239 11,564
Liability for underwriter    
Financial instruments    
Liabilities arising from financing activities at beginning of period 1,131 1,021
Cash flows (1,124) 0
Foreign exchange movement (22) (129)
Other 15 239
Liabilities arising from financing activities at end of period 0 1,131
Long term bank loan    
Financial instruments    
Liabilities arising from financing activities at beginning of period 15,176 18,971
Cash flows (2,070) (1,665)
Foreign exchange movement (486) (2,130)
Other 0 0
Liabilities arising from financing activities at end of period $ 12,620 $ 15,176
XML 96 R79.htm IDEA: XBRL DOCUMENT v3.24.2
FINANCIAL INSTRUMENTS - Disclosure of Reconciliation of fair value measurements within Level 3 of fair value hierarchy in financial instruments (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Financial instruments    
Liabilities at beginning of period $ (51,494)  
Liabilities at end of period (36,588) $ (51,494)
Other payables (short term) (8,536) (9,238)
Liability for share options 0 (7,164)
Level 3    
Financial instruments    
Liabilities at beginning of period (8,050) (18,308)
Profit (loss) 1,697 7,503
Other comprehensive income (loss) 43 1,740
Exercise of Share Options into shares 5,333 1,015
Payment 1,124  
Liabilities at end of period 147 (8,050)
Call option   245
Put option 147  
Other payables (short term)   (1,131)
Liability for share options   (7,164)
Level 3 | Liability for share options    
Financial instruments    
Liabilities at beginning of period [1] (7,164) (17,220)
Profit (loss) [1] 1,801 7,423
Other comprehensive income (loss) [1] 30 1,618
Exercise of Share Options into shares [1] 5,333 1,015
Payment [1] 0  
Liabilities at end of period [1] 0 (7,164)
Liability for share options [1]   (7,164)
Level 3 | Liability for underwriter    
Financial instruments    
Liabilities at beginning of period (1,131) (1,021)
Profit (loss) (15) (240)
Other comprehensive income (loss) 22 130
Exercise of Share Options into shares 0  
Payment 1,124  
Liabilities at end of period 0 (1,131)
Other payables (short term)   (1,131)
Level 3 | Put option to non-controlling interests    
Financial instruments    
Liabilities at beginning of period 245 (67)
Profit (loss) (89) 320
Other comprehensive income (loss) (9) (8)
Exercise of Share Options into shares 0  
Payment 0  
Liabilities at end of period 147 245
Call option   $ 245
Put option $ 147  
[1] See Note 22b for information on fair value measurement.
XML 97 R80.htm IDEA: XBRL DOCUMENT v3.24.2
FINANCIAL INSTRUMENTS - Disclosure of lists the significant inputs fair value of Put Option net of Call option (Details) - Put option to non-controlling interests - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Financial instruments    
Underlying asset value $ 35,732 $ 35,541
Expected volatility of the share price 34.70%  
Discount rate 14.90% 15.00%
Risk-free interest rate 3.64% 3.68%
Term of option 2 years 8 months 1 day 3 years 8 months 1 day
Minimum    
Financial instruments    
Expected volatility of the share price   36.70%
Maximum    
Financial instruments    
Expected volatility of the share price   39.20%
XML 98 R81.htm IDEA: XBRL DOCUMENT v3.24.2
FINANCIAL INSTRUMENTS - Disclosure of demonstrates effect on fair value of reasonably possible change in underlying asset value with all other variables (Details) - Put option to non-controlling interests - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Financial instruments    
Percentage of reasonably possible increase in unobservable input 5.00% 5.00%
Effect on fair value measurement due to reasonably possible increase in unobservable input $ 433 $ 463
Percentage of reasonably possible decrease in unobservable input (5.00%) (5.00%)
Effect on fair value measurement due to reasonably possible decrease in unobservable input $ (430) $ (453)
XML 99 R82.htm IDEA: XBRL DOCUMENT v3.24.2
EMPLOYEE BENEFIT LIABILITIES - Disclosure of changes in the defined benefit obligation and fair value of plan assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Changes in the defined benefit obligation and fair value of plan assets    
Balance at beginning $ (1,495) $ (2,382)
Expenses recognized in profit or loss    
Current service cost (340) (405)
Net interest expense (58) (47)
Past service cost and effect of settlements (35)  
Total expense recognized in profit or loss for the period (433) (452)
Payments from the plan 14 25
Actuarial gain (loss) arising from changes in financial assumptions 81 775
Gain (loss) from remeasurement in other comprehensive income    
Actuarial gain (loss) arising from experience adjustments (11) (36)
Total effect on other comprehensive income for the Period 70 739
Effect of changes in foreign exchange rates 32 239
Contributions by employer 239 336
Balance at ending (1,573) (1,495)
Defined benefit obligation    
Changes in the defined benefit obligation and fair value of plan assets    
Balance at beginning (8,153) (9,848)
Expenses recognized in profit or loss    
Current service cost (340) (405)
Net interest expense (409) (245)
Past service cost and effect of settlements (35)  
Total expense recognized in profit or loss for the period (784) (650)
Payments from the plan 148 374
Actuarial gain (loss) arising from changes in financial assumptions 81 775
Gain (loss) from remeasurement in other comprehensive income    
Actuarial gain (loss) arising from experience adjustments (7) 87
Total effect on other comprehensive income for the Period 74 862
Effect of changes in foreign exchange rates 223 1,109
Contributions by employer 0 0
Balance at ending (8,492) (8,153)
Fair value of plan assets    
Changes in the defined benefit obligation and fair value of plan assets    
Balance at beginning 6,658 7,466
Expenses recognized in profit or loss    
Current service cost 0 0
Net interest expense 351 198
Past service cost and effect of settlements 0  
Total expense recognized in profit or loss for the period 351 198
Payments from the plan (134) (349)
Actuarial gain (loss) arising from changes in financial assumptions 0 0
Gain (loss) from remeasurement in other comprehensive income    
Actuarial gain (loss) arising from experience adjustments (4) (123)
Total effect on other comprehensive income for the Period (4) (123)
Effect of changes in foreign exchange rates (191) (870)
Contributions by employer 239 336
Balance at ending $ 6,919 $ 6,658
XML 100 R83.htm IDEA: XBRL DOCUMENT v3.24.2
EMPLOYEE BENEFIT LIABILITIES - Disclosure of disaggregation of the fair value of the plan assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Fair value of plan assets    
Disaggregation of the fair value of the plan assets    
Insurance contracts $ 6,919 $ 6,658
XML 101 R84.htm IDEA: XBRL DOCUMENT v3.24.2
EMPLOYEE BENEFIT LIABILITIES - Disclosure of principal assumptions underlying the defined benefit plan (Details)
Dec. 31, 2023
Dec. 31, 2022
Principal assumptions underlying the defined benefit plan    
Discount rate 5.55% 5.57%
Minimum    
Principal assumptions underlying the defined benefit plan    
Expected rate of salary increase 2.00% 2.00%
Maximum    
Principal assumptions underlying the defined benefit plan    
Expected rate of salary increase 5.48% 5.92%
XML 102 R85.htm IDEA: XBRL DOCUMENT v3.24.2
EMPLOYEE BENEFIT LIABILITIES - Disclosure of reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions are constant (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Expected rate of salary increase    
Reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions    
Increase in assumption 6.10% 6.51%
Change in defined benefit obligation if increase in assumption $ (45) $ (49)
Increase in previous assumption 5.50% 5.90%
Discount rate of the plan assets and liability    
Reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions    
Increase in assumption   1.00%
Change in defined benefit obligation if increase in assumption   $ (13)
Decrease in assumption 1.00% 1.00%
Change in defined benefit obligation if decrease in assumption $ 45 $ 45
XML 103 R86.htm IDEA: XBRL DOCUMENT v3.24.2
TAXES ON INCOME - Disclosure of general (Narrative) (Details)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
TAXES ON INCOME      
Corporate income tax rate 23.00% 23.00% 23.00%
Companies in Israel      
TAXES ON INCOME      
Corporate income tax rate 23.00% 23.00%  
Average tax rate 23.00% 23.00%  
Foreign subsidiaries | U.S.      
TAXES ON INCOME      
Corporate income tax rate 21.00%    
Foreign subsidiaries | Germany      
TAXES ON INCOME      
Corporate income tax rate 31.40%    
XML 104 R87.htm IDEA: XBRL DOCUMENT v3.24.2
TAXES ON INCOME - Disclosure of taxes on income included in the statements of comprehensive income (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Major components of tax expense (income) [abstract]      
Current taxes $ 552 $ 749 $ 236
Deferred taxes 409 341 259
Taxes in respect of prior years (70) 7 (40)
Total $ 891 $ 1,097 $ 455
XML 105 R88.htm IDEA: XBRL DOCUMENT v3.24.2
TAXES ON INCOME - Disclosure of deferred tax assets (liabilities) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Composition and changes in deferred taxes, as presented in the consolidated balance sheet,    
Balance at beginning $ 172 $ 734
Amount included in statement of comprehensive income (418) (499) [1]
Currency translation differences (12) (63)
Balance at ending (258) 172
Amount presented in other comprehensive income 159  
Deferred taxes are reflected in the balance sheet    
Non-current assets 2,055 2,872
Non-current liabilities 2,313 2,700
Total (258) 172
Fixed and intangible assets    
Composition and changes in deferred taxes, as presented in the consolidated balance sheet,    
Balance at beginning (3,065) (4,006)
Amount included in statement of comprehensive income 55 498
Currency translation differences 91 443
Balance at ending (2,919) (3,065)
Deferred taxes are reflected in the balance sheet    
Total (2,919) (3,065)
Employee benefit liabilities    
Composition and changes in deferred taxes, as presented in the consolidated balance sheet,    
Balance at beginning 612 824
Amount included in statement of comprehensive income 39 (122)
Currency translation differences (19) (90)
Balance at ending 632 612
Deferred taxes are reflected in the balance sheet    
Total 632 612
Short term investments [Member]    
Composition and changes in deferred taxes, as presented in the consolidated balance sheet,    
Balance at beginning 0 0
Amount included in statement of comprehensive income (192) 0
Currency translation differences (3) 0
Balance at ending (195) 0
Deferred taxes are reflected in the balance sheet    
Total (195) 0
Carry- forward tax losses    
Composition and changes in deferred taxes, as presented in the consolidated balance sheet,    
Balance at beginning 2,625 3,916
Amount included in statement of comprehensive income (320) (875)
Currency translation differences (81) (416)
Balance at ending 2,224 2,625
Deferred taxes are reflected in the balance sheet    
Total $ 2,224 $ 2,625
[1] $159 presented in other comprehensive income.
XML 106 R89.htm IDEA: XBRL DOCUMENT v3.24.2
TAXES ON INCOME - Disclosure of reconciliation of theoretical tax expense assuming all income is taxed at statutory rate applicable to income of companies in Israel, and actual tax expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Major components of tax expense (income) [abstract]      
Income (loss) before taxes on income $ (5,964) $ 1,312 $ (13,469)
Statutory tax rate in Israel 23.00% 23.00% 23.00%
Tax computed at the statutory tax rate $ (1,372) $ 302 $ (3,098)
Increase (decrease) in taxes resulting from:      
Taxes in respect of previous years (70) 7 (40)
Tax adjustment in respect of inflation in Israel 0 0 (2)
Non-deductible expenses (non-taxable income) 406 (1,699) 2,613
Different tax rates 63 60 24
Loss for which deferred taxes were not recognized 1,864 2,234 926
Utilization of previously unrecognized capital gain 0 0 32
Capital losses for which deferred taxes were not recognized 0 193 0
Total $ 891 $ 1,097 $ 455
XML 107 R90.htm IDEA: XBRL DOCUMENT v3.24.2
TAXES ON INCOME - Disclosure of carry forward tax losses (Details)
$ in Thousands
Dec. 31, 2023
EUR (€)
Dec. 31, 2023
ILS (₪)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2022
ILS (₪)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
EUR (€)
Dec. 31, 2021
ILS (₪)
Dec. 31, 2021
USD ($)
TAXES ON INCOME                  
Deferred tax assets relating to carry forward tax losses as described above, and deductible temporary differences, are not included     $ 23,938     $ 21,113      
Israel                  
TAXES ON INCOME                  
Carry forward losses for tax purposes   ₪ 227,833,000 62,816   ₪ 236,130,000 67,102   ₪ 249,552,000 $ 80,242
Europe                  
TAXES ON INCOME                  
Carry forward losses for tax purposes € 29,387,000   32,503 € 22,212,000   23,689 € 17,026,000   19,270
U.S.                  
TAXES ON INCOME                  
Carry forward losses for tax purposes     $ 15,337     $ 10,716     $ 8,866
XML 108 R91.htm IDEA: XBRL DOCUMENT v3.24.2
TAXES ON INCOME - Disclosure of expiry dates for carry forward tax losses which are not recognized (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Expiry dates for carry forward tax losses not recognized    
First year $ 37 $ 24
Second year 762 229
Third year 413 126
Fourth year 153 52
Fifth year 959 281
Sixth - Fifteen 4,891 1,280
Unlimited 93,771 87,278
Carry forward tax losses not recognized $ 100,986 $ 89,270
XML 109 R92.htm IDEA: XBRL DOCUMENT v3.24.2
COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Details) - Key management personnel - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Balance      
Other accounts payables $ 182 $ 181 $ 170
Transactions:      
Short-term employee benefits 2,639 2,531 2,108
Share-based payment benefits 638 1,179 883
Total $ 3,277 $ 3,710 $ 2,991
XML 110 R93.htm IDEA: XBRL DOCUMENT v3.24.2
Equity (Narrative) (Details)
₪ / shares in Units, SFr / shares in Units, $ / shares in Units, SFr in Millions
1 Months Ended 12 Months Ended
May 15, 2023
USD ($)
yr
SFr / shares
May 15, 2023
USD ($)
yr
$ / shares
Jan. 02, 2023
USD ($)
yr
SFr / shares
Jan. 02, 2023
USD ($)
yr
$ / shares
Jun. 20, 2022
USD ($)
yr
SFr / shares
Jun. 20, 2022
USD ($)
yr
$ / shares
Feb. 15, 2022
USD ($)
yr
SFr / shares
Feb. 15, 2022
USD ($)
yr
$ / shares
Jan. 02, 2022
USD ($)
yr
SFr / shares
Jan. 02, 2022
USD ($)
yr
$ / shares
Dec. 20, 2021
USD ($)
Feb. 17, 2021
SFr / shares
shares
Jan. 21, 2021
Capital_Increases
SFr / shares
shares
Jun. 18, 2023
USD ($)
yr
SFr / shares
Jun. 18, 2023
USD ($)
yr
$ / shares
Mar. 31, 2023
ILS (₪)
₪ / shares
shares
Mar. 31, 2023
USD ($)
$ / shares
shares
Feb. 28, 2023
CHF (SFr)
shares
Feb. 28, 2023
USD ($)
shares
Feb. 28, 2021
shares
Dec. 31, 2023
CHF (SFr)
Share
Years
SFr / shares
shares
Dec. 31, 2023
USD ($)
Share
Years
$ / shares
shares
Dec. 31, 2022
USD ($)
SFr / shares
$ / shares
shares
Dec. 31, 2022
USD ($)
yr
Unit_Standard_item_uchMkKGtLkOnxpJzjI5Eyg
$ / shares
shares
Dec. 31, 2021
USD ($)
shares
Oct. 31, 2021
shares
Jan. 07, 2021
$ / shares
shares
EQUITY                                                      
Ordinary shares of NIS 0.01 par value each, Authorized                                           25,000,000 25,000,000 25,000,000     25,000,000
Ordinary shares, par value | $ / shares                                           $ 0.01 $ 0.01 $ 0.01     $ 0.01
Number of Capital Increases | Capital_Increases                         2                            
Number of treasury shares sold                                         1,372 1,372   1,372      
Movements in Share Options:                                                      
Exercise of share options                                         1,703,908 1,703,908   171,945      
Fair value of the options to acquire Units | $                                             $ 1,131,000 $ 1,131,000      
Increase in fair value of liability | $                                           $ 239,000          
Treasury shares held at cost | $                                           $ 2,000 $ 2,000 $ 2,000      
Number of options granted                                         423,500 423,500   210,000      
Proceeds from exercises share options | $                                           $ 20,298,000   $ 1,961,000 $ 463,000    
Exercise of share options                                         1,703,908 1,703,908   171,945      
Exercise of share options | $                                           $ 25,631,000   $ 2,976,000      
Weighted average remaining contractual life for the share options outstanding                                         3 years 9 months 29 days 3 years 9 months 29 days   4 years 2 months 4 days      
Restricted share units ("RSU")                                                      
Movements in Share Options:                                                      
Vesting period                     3 years                                
Percentage of vesting after one year                     33.00%                                
Percentage of vesting in each half year thereafter                     16.50%                                
Number of restricted share units ("RSU") | $                     256                                
Fair value of the RSUs | $                     $ 822,000                                
2015 Executive and Key Employee Israeli Share Option Plan                                                      
Movements in Share Options:                                                      
Number of options granted | $ 145,000 145,000 248,500 248,500 100,000 100,000 12,500 12,500 97,500 97,500       30,000 30,000                        
Vesting period 3 years 3 years 3 years 3 years 3 years 3 years 3 years 3 years 3 years 3 years       3 years 3 years                        
Percentage of vesting after one year 25.00% 25.00% 25.00% 25.00% 25.00% 25.00% 25.00% 25.00% 25.00% 25.00%       25.00% 25.00%                        
Percentage of vesting in each year thereafter 9.375% 9.375% 9.375% 9.375% 9.375% 9.375% 9.375% 9.375% 9.375% 9.375%       9.375% 9.375%                        
Weighted average fair value of options granted | (per share) SFr 3.374 $ 3.76 SFr 4.655 $ 5.047 SFr 5.55 $ 5.753 SFr 5.387 $ 5.822 SFr 5.893 $ 6.451       SFr 3.663 $ 4.113                        
Share price | SFr / shares 9.7   14.8   17.4   17.4   19.1         10.3                          
Exercise price | SFr / shares SFr 9.36   SFr 15.56   SFr 17.39   SFr 17.69   SFr 19.33         SFr 9.88                          
Expected volatility 46.03% 46.03% 43.87% 43.87% 41.75% 41.75% 42.61% 42.61% 42.33% 42.33%       46.57% 46.57%                        
Risk free interest rate 0.00% 0.00% 0.00% 0.00% 1.15% 1.15% 0.13% 0.13% 0.00% 0.00%       0.00% 0.00%                        
Expected dividend (In percentage) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%       0.00% 0.00%                        
Expected average life of options | yr 3.43 3.43 3.49 3.49 3.6 3.6 3.68 3.68 3.71 3.71       3.43 3.43                        
Maximum number of shares which may be issued under the Plan                                                   2,000,000  
2021 Executive and Key Employee Israeli Share Option Plan                                                      
Movements in Share Options:                                                      
Share-based compensation | $                                           $ 1,252,000   $ 1,757,000 $ 1,116,000    
Share options                                                      
EQUITY                                                      
Number of Share Options to purchase Ordinary shares granted                       1,144,444 800,000                            
Ratio                       100.00% 100.00%                            
Exercise price | SFr / shares                       SFr 11 SFr 11                            
Exercise period                       24 months 24 months                            
Movements in Share Options:                                                      
Exercise of share options                                       1,703,908 1,703,908 1,703,908   171,945      
Ending balance                                           0 1,733,875 1,733,875 1,905,820    
Number of Ordinary Shares in an Unit                                         1 1          
Number of options in an Unit                                         0.5 0.5          
Exercise price of option | (per share)                                         SFr 11 $ 11.93          
Proceeds from exercises share options                                   SFr 18.7 $ 20,300,000                
Exercise of share options                                       1,703,908 1,703,908 1,703,908   171,945      
Expiration of share options                                   29,967 29,967   29,967 29,967          
Share options | Underwriters                                                      
Issue costs:                                                      
Payment to underwriter in cash                                         SFr 1.1 $ 1,100,000          
Share options granted to underwriter                                         58,498 58,498          
Share options | Black and Scholes model                                                      
Movements in Share Options:                                                      
Exercise price | (per share)                                         SFr 11.55 $ 12.53 $ 14.8 $ 16.05      
Expected volatility                                         41.18% 41.18%          
Risk free interest rate                                         4.11% 4.11%   0.82%      
Expected dividend (In percentage)                                         0.00% 0.00%   0.00%      
Expected average life of options | Years                                         2.01 2.01          
Share options | Black and Scholes model | Minimum                                                      
Movements in Share Options:                                                      
Expected volatility                                               32.59%      
Expected average life of options | yr                                               0.06      
Share options | Black and Scholes model | Maximum                                                      
Movements in Share Options:                                                      
Expected volatility                                               38.24%      
Expected average life of options | yr                                               0.13      
Share options | Monte Carlo model | Share price                                                      
Movements in Share Options:                                                      
Exercise price | (per share)                                             $ 14.8 $ 16.05      
Issued capital                                                      
EQUITY                                                      
Number of Ordinary shares issued                       2,288,889 1,300,000                            
Number of treasury shares sold                         300,000                            
Issue costs:                                                      
Fair Value of Liabilities | $                                             $ 7,164,000 $ 7,164,000      
Financial expense recorded expenses in respect of the revaluation of the liability | $                                           $ 1,801,000   7,423,000      
Movements in Share Options:                                                      
Exercise of share options | $                                           $ 5,000   $ 1,000      
Issued capital | Underwriters                                                      
Movements in Share Options:                                                      
Number of Options Granted to Acquire Units                               97,222 97,222       97,222 97,222          
Number of Ordinary Shares in an Unit                               1 1       1 1          
Number of options in an Unit                               0.5 0.5       0.5 0.5          
Number of ordinary shares toa acquire each option                               1 1       1 1          
Exercise price of option | (per share)                               ₪ 43.56 $ 12.01       SFr 11 $ 11.93          
Fair value of the options to acquire Units | $                                           $ 1,002,000          
Future Payment Liability | $                                           416,000          
Exercise of share options                               ₪ 35.64 $ 9.83                    
Issued capital | Monte Carlo model | Expected dividend                                                      
Movements in Share Options:                                                      
Expected volatility                                               43.15%      
Issued capital | Monte Carlo model | Risk-free interest rate                                                      
Movements in Share Options:                                                      
Risk free interest rate                                               0.82%      
Issued capital | Monte Carlo model | Expected average life of options                                                      
Movements in Share Options:                                                      
Expected average life of options | yr                                               0.21      
Capital reserve for options                                                      
Movements in Share Options:                                                      
Exercise of share options | $                                           $ 512,000   $ 0      
XML 111 R94.htm IDEA: XBRL DOCUMENT v3.24.2
EQUITY - Disclosure of composition of share capital (Details) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jan. 07, 2021
Disclosure of classes of share capital [abstract]        
Ordinary shares of NIS 0.01 par value each, Authorized 25,000,000 25,000,000   25,000,000
Ordinary shares of NIS 0.01 par value each, Issued 16,391,382 14,682,272    
Ordinary shares of NIS 0.01 par value each, Outstanding 16,391,382 14,682,272 14,491,171  
Ordinary shares, par value $ 0.01 $ 0.01   $ 0.01
XML 112 R95.htm IDEA: XBRL DOCUMENT v3.24.2
Equity - Disclosure of significant inputs to Black and Scholes model used for fair value measurement of Share Options (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Mar. 31, 2023
₪ / shares
shares
Mar. 31, 2023
$ / shares
shares
Feb. 28, 2021
shares
Dec. 31, 2023
USD ($)
SFr / shares
shares
Dec. 31, 2023
USD ($)
Years
$ / shares
shares
Dec. 31, 2022
USD ($)
yr
SFr / shares
shares
Dec. 31, 2022
USD ($)
yr
$ / shares
shares
Dec. 31, 2021
shares
Movements in Share Options:                
Exercise of share options         (1,703,908) (171,945) (171,945)  
Fair value of the options to acquire Units | $           $ 1,131 $ 1,131  
Increase in fair value of liability | $         $ 239      
Issued capital                
EQUITY                
Fair Value of Liabilities | $           $ 7,164 $ 7,164  
Share options                
Movements in Share Options:                
Exercise of share options     (1,703,908)   (1,703,908) (171,945) (171,945)  
Ending balance       0 0 1,733,875 1,733,875 1,905,820
Number of Ordinary Shares in an Unit         1      
Number of options in an Unit         0.5      
Exercise price of option | (per share)       SFr (11) $ (11.93)      
Underwriters | Issued capital                
Movements in Share Options:                
Number of Options Granted to Acquire Units 97,222 97,222     97,222      
Number of Ordinary Shares in an Unit 1 1     1      
Number of options in an Unit 0.5 0.5     0.5      
Number of ordinary shares toa acquire each option 1 1     1      
Exercise price of option | (per share) ₪ (43.56) $ (12.01)   SFr (11) $ (11.93)      
Fair value of the options to acquire Units | $       SFr 1,002 $ 1,002      
Future Payment Liability | $       SFr 416 $ 416      
Black and Scholes model | Share options                
EQUITY                
Expected dividend         0.00% 0.00% 0.00%  
Expected volatility of the share price         41.18%      
Risk-free interest rate         4.11% 0.82% 0.82%  
Expected average life of options | Years         2.01      
Exercise price, share options granted | (per share)       SFr 11.55 $ 12.53 $ 14.8 $ 16.05  
Black and Scholes model | Minimum | Share options                
EQUITY                
Expected volatility of the share price           32.59% 32.59%  
Expected average life of options | yr           0.06 0.06  
Black and Scholes model | Maximum | Share options                
EQUITY                
Expected volatility of the share price           38.24% 38.24%  
Expected average life of options | yr           0.13 0.13  
Monte Carlo model | Expected dividend | Issued capital                
EQUITY                
Expected volatility of the share price           43.15% 43.15%  
Monte Carlo model | Risk-free interest rate | Issued capital                
EQUITY                
Risk-free interest rate           0.82% 0.82%  
Monte Carlo model | Expected average life of options | Issued capital                
EQUITY                
Expected average life of options | yr           0.21 0.21  
Monte Carlo model | Share price | Share options                
EQUITY                
Exercise price, share options granted | (per share)           $ 14.8 $ 16.05  
XML 113 R96.htm IDEA: XBRL DOCUMENT v3.24.2
EQUITY - Disclosure of movement in share capital (Details) - shares
1 Months Ended 12 Months Ended
Feb. 28, 2023
Feb. 28, 2021
Dec. 31, 2023
Dec. 31, 2022
Movements in Share Options:        
Exercise of share options     (1,703,908) (171,945)
Share options        
Movements in Share Options:        
Opening balance     1,733,875 1,905,820
Exercise of share options   (1,703,908) (1,703,908) (171,945)
Expiration of share options (29,967)   (29,967)  
Ending balance     0 1,733,875
XML 114 R97.htm IDEA: XBRL DOCUMENT v3.24.2
EQUITY - Disclosure of issued and outstanding share capital (net of treasury shares) (Details) - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Reconciliation of number of shares outstanding [abstract]    
Balance at beginning 14,682,272 14,491,171
Exercise of share options 1,703,908 171,945
Treasury shares sold 1,372 1,372
Exercise of employees share options 5,202 5,694
Treasury shares sold upon exercise of employee options   13,462
Balance at ending 16,391,382 14,682,272
XML 115 R98.htm IDEA: XBRL DOCUMENT v3.24.2
EQUITY - Disclosure of number and weighted average exercise prices ("WAEP") of, and movements in, share options (Details)
12 Months Ended
Dec. 31, 2023
Share
SFr / shares
Dec. 31, 2023
Share
SFr / shares
Dec. 31, 2023
Share
SFr / shares
Dec. 31, 2023
Share
Unit_Standard_item_uchMkKGtLkOnxpJzjI5Eyg
SFr / shares
Dec. 31, 2022
Unit_Standard_item_uchMkKGtLkOnxpJzjI5Eyg
SFr / shares
Dec. 31, 2022
Share
Unit_Standard_item_uchMkKGtLkOnxpJzjI5Eyg
SFr / shares
Dec. 31, 2022
Unit_Standard_item_uchMkKGtLkOnxpJzjI5Eyg
SFr / shares
Dec. 31, 2022
Unit_Standard_item_uchMkKGtLkOnxpJzjI5Eyg
SFr / shares
No. of options                
Outstanding at the beginning of the year   1,001,430   1,001,430       835,055
Granted during the year   423,500           210,000
Forfeited during the year   (165,881)           (7,500)
Exercised during the year   (38,808)           (36,125)
Outstanding at the end of the year   1,220,241       1,001,430   1,001,430
Exercisable at the end of the year 720,758 720,758 720,758 720,758 454,480 454,480 454,480 454,480
WAEP                
Outstanding at the beginning of the year     SFr 11.85       SFr 10.12  
Granted during the year     13.03       18.31  
Forfeited during the year     12.89       19.33  
Exercised during the year     7.04       7.94  
Outstanding at the end of the year     12.27       11.85  
Exercisable at the end of the year SFr 11.02 SFr 11.02 11.02 SFr 11.02 SFr 9.42 SFr 9.42 9.42 SFr 9.42
Weighted average share price at the date of exercise of options     SFr 8.13       SFr 16.85  
Weighted average remaining contractual life for the share options outstanding 3 years 9 months 29 days       4 years 2 months 4 days      
XML 116 R99.htm IDEA: XBRL DOCUMENT v3.24.2
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of revenues (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Supplementary Information To Statements Of Comprehensive Income Abstract      
Revenues for services performed during the period $ 55,678 $ 57,869 $ 48,343
Revenues from sale of devices 1,397 1,129 1,239
Revenues $ 57,075 $ 58,998 $ 49,582
XML 117 R100.htm IDEA: XBRL DOCUMENT v3.24.2
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of cost of revenues (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Cost of revenues $ 31,814 $ 31,809 $ 24,989
Salaries and related benefits      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Cost of revenues 16,212 16,480 14,955
Medical services      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Cost of revenues 8,355 8,712 4,682
Rental fees and maintenance      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Cost of revenues 1,246 1,013 1,072
Depreciation and amortization      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Cost of revenues 1,978 1,789 1,736
Cost of devices      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Cost of revenues 1,025 1,013 1,249
Others      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Cost of revenues $ 2,998 $ 2,802 $ 1,295
XML 118 R101.htm IDEA: XBRL DOCUMENT v3.24.2
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of research and development costs (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Research and development costs, Gross $ 9,463 $ 9,031 $ 5,618
Less - capitalization of development costs 4,203 5,243 2,633
Research and development costs 5,260 3,788 2,985
Salaries and related benefits      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Research and development costs, Gross 3,917 3,468 2,173
Amortization of development costs      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Research and development costs, Gross 2,772 1,829 1,243
Others      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Research and development costs, Gross $ 2,774 $ 3,734 $ 2,202
XML 119 R102.htm IDEA: XBRL DOCUMENT v3.24.2
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of selling and marketing expenses (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Selling and marketing expenses $ 10,581 $ 11,403 $ 9,454
Salaries and related benefits      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Selling and marketing expenses 5,285 5,409 4,803
Marketing and related expenses      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Selling and marketing expenses 1,943 2,190 1,802
Depreciation and amortization      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Selling and marketing expenses 1,633 1,918 1,453
Rental fees and maintenance      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Selling and marketing expenses 160 271 205
Maintenance of vehicles      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Selling and marketing expenses 313 240 182
Others      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
Selling and marketing expenses $ 1,247 $ 1,375 $ 1,009
XML 120 R103.htm IDEA: XBRL DOCUMENT v3.24.2
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of general and administrative expenses (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
General and administrative expenses $ 16,228 $ 16,748 $ 12,103
Salaries and related benefits      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
General and administrative expenses 8,881 8,492 5,837
Office expenses      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
General and administrative expenses 2,634 2,349 1,366
Professional fees      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
General and administrative expenses 3,156 3,897 3,245
Depreciation and amortization      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
General and administrative expenses 1,309 1,599 950
Others      
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME      
General and administrative expenses $ 248 $ 411 $ 705
XML 121 R104.htm IDEA: XBRL DOCUMENT v3.24.2
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial income (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Supplementary Information To Statements Of Comprehensive Income Abstract      
Exchange rate differences $ 1,129 $ 661 $ 5
Gain on marketable securities, net 848 0 0
Share options 1,801 7,423 0
Call+Put options 0 320 0
Interest 1,055 429 376
Financial income $ 4,833 $ 8,833 $ 381
XML 122 R105.htm IDEA: XBRL DOCUMENT v3.24.2
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial expenses (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Supplementary Information To Statements Of Comprehensive Income Abstract      
Share options $ 0 $ (239) $ (10,126)
Exchange rate differences (138) (53) (1,595)
Loss from marketable securities, net 0 (769) (114)
Interest (1,296) (1,033) (529)
Call+Put options (89) 0 (677)
Others (268) (261) (312)
Financial expenses $ (1,791) $ (2,355) $ (13,353)
XML 123 R106.htm IDEA: XBRL DOCUMENT v3.24.2
SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of other expenses (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Supplementary Information To Statements Of Comprehensive Income Abstract      
Impairment of property and equipment $ 0 $ 0 $ 118
Expenses related to acquisitions 0 0 590
Restructuring expenses [1] 1,235 0 0
Other expenses 963 416 (160)
Total other expenses $ 2,198 $ 416 $ 548
[1] Including expenses related to employee benefits and other direct expenditures arising from the restructuring.
XML 124 R107.htm IDEA: XBRL DOCUMENT v3.24.2
NET EARNINGS PER SHARE (Details) - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Weighted average number of shares    
For the computation of basic net earnings 16,269 14,542
Effect of dilution - share options 26 656
For the computation of diluted net earnings 16,295 15,198
Net loss    
For the computation of basic net earnings $ (7,055) $ (76)
Effect of dilution - share options (1,801) (7,423)
For the computation of diluted net earnings $ (8,856) $ (7,499)
XML 125 R108.htm IDEA: XBRL DOCUMENT v3.24.2
NET EARNINGS PER SHARE (Narrative) (Details) - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Employee Stock Option    
NET EARNINGS PER SHARE    
Anti-dilutive effect excluded from computation of diluted net earnings per share 1,453,824 1,236,824
XML 126 R109.htm IDEA: XBRL DOCUMENT v3.24.2
SEGMENT INFORMATION - Disclosure of disaggregated revenue information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
SEGMENT INFORMATION      
Revenues $ 57,075 $ 58,998 $ 49,582
Individuals and communities      
SEGMENT INFORMATION      
Revenues 20,913 22,161 22,331
Institutions and payers      
SEGMENT INFORMATION      
Revenues 35,246 36,349 26,774
Others      
SEGMENT INFORMATION      
Revenues 916 488 477
Europe      
SEGMENT INFORMATION      
Revenues 14,067 13,374 17,942
Europe | Individuals and communities      
SEGMENT INFORMATION      
Revenues 0 0 0
Europe | Institutions and payers      
SEGMENT INFORMATION      
Revenues 14,067 13,374 17,942
Europe | Others      
SEGMENT INFORMATION      
Revenues 0 0 0
Israel      
SEGMENT INFORMATION      
Revenues 42,092 45,138 31,190
Israel | Individuals and communities      
SEGMENT INFORMATION      
Revenues 20,913 22,161 22,331
Israel | Institutions and payers      
SEGMENT INFORMATION      
Revenues 21,179 22,975 8,832
Israel | Others      
SEGMENT INFORMATION      
Revenues 0 2 27
ROW      
SEGMENT INFORMATION      
Revenues 916 486 450
ROW | Individuals and communities      
SEGMENT INFORMATION      
Revenues 0 0 0
ROW | Institutions and payers      
SEGMENT INFORMATION      
Revenues 0 0 0
ROW | Others      
SEGMENT INFORMATION      
Revenues $ 916 $ 486 $ 450
XML 127 R110.htm IDEA: XBRL DOCUMENT v3.24.2
SEGMENT INFORMATION - Disclosure of revenue from geographic segments (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
SEGMENT INFORMATION      
Segment profit (loss) $ 57,075 $ 58,998 $ 49,582
Other expenses (2,198) (416) (548)
Operating loss (9,006) (5,166) (497)
Financial income, net 3,042 6,478 (12,972)
Profit (loss) before taxes on income (5,964) 1,312 (13,469)
Operating segments      
SEGMENT INFORMATION      
Segment profit (loss) (545) 2,625 6,617
Unallocated income and expenses      
SEGMENT INFORMATION      
Corporate, R&D and other expenses (6,263) (7,375) (6,798)
Other expenses (2,198) (416) (316)
Europe      
SEGMENT INFORMATION      
Segment profit (loss) 14,067 13,374 17,942
Europe | Operating segments      
SEGMENT INFORMATION      
Segment profit (loss) (5,347) (3,044) (477)
Israel      
SEGMENT INFORMATION      
Segment profit (loss) 42,092 45,138 31,190
Israel | Operating segments      
SEGMENT INFORMATION      
Segment profit (loss) 8,424 8,641 8,266
ROW      
SEGMENT INFORMATION      
Segment profit (loss) 916 486 450
ROW | Operating segments      
SEGMENT INFORMATION      
Segment profit (loss) $ (3,622) $ (2,972) $ (1,132)
XML 128 R111.htm IDEA: XBRL DOCUMENT v3.24.2
SEGMENT INFORMATION - Disclosure of additional information of segments (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
SEGMENT INFORMATION      
Depreciation and amortization $ 7,692 $ 7,134 $ 5,500
Non-current assets 67,241 71,591 75,333
Others      
SEGMENT INFORMATION      
Depreciation and amortization 6 10 0
Unallocated      
SEGMENT INFORMATION      
Non-current assets 4,910 2,636 2,260
Europe      
SEGMENT INFORMATION      
Depreciation and amortization 3,637 2,654 2,765
Non-current assets 23,588 27,132 11,539
Israel      
SEGMENT INFORMATION      
Depreciation and amortization 4,049 4,470 2,735
Non-current assets 36,803 40,056 61,534
ROW      
SEGMENT INFORMATION      
Non-current assets $ 1,940 $ 1,767 $ 0
EXCEL 129 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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¹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end XML 130 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 131 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 133 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 653 506 1 true 124 0 false 14 false false R1.htm 0001 - Document - Document and Entity Information Sheet http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 0002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 0004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Sheet http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Statements 4 false false R5.htm 0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 0007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 6 false false R7.htm 0008 - Disclosure - GENERAL Sheet http://www.shl-telemedicine.com/role/DisclosureGeneral GENERAL Notes 7 false false R8.htm 0009 - Disclosure - ACCOUNTING POLICIES Sheet http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPolicies ACCOUNTING POLICIES Notes 8 false false R9.htm 0010 - Disclosure - SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS Sheet http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatements SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS Notes 9 false false R10.htm 0011 - Disclosure - DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION Sheet http://www.shl-telemedicine.com/role/DisclosureDisclosureOfNewStandardsInPeriodPriorToTheirAdoption DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION Notes 10 false false R11.htm 0012 - Disclosure - CASH AND CASH EQUIVALENTS Sheet http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalents CASH AND CASH EQUIVALENTS Notes 11 false false R12.htm 0013 - Disclosure - SHORT-TERM INVESTMENTS Sheet http://www.shl-telemedicine.com/role/DisclosureShortTermInvestments SHORT-TERM INVESTMENTS Notes 12 false false R13.htm 0014 - Disclosure - TRADE RECEIVABLES Sheet http://www.shl-telemedicine.com/role/DisclosureTradeReceivables TRADE RECEIVABLES Notes 13 false false R14.htm 0015 - Disclosure - PREPAID EXPENSES Sheet http://www.shl-telemedicine.com/role/DisclosurePrepaidExpenses PREPAID EXPENSES Notes 14 false false R15.htm 0016 - Disclosure - OTHER ACCOUNTS RECEIVABLE Sheet http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivable OTHER ACCOUNTS RECEIVABLE Notes 15 false false R16.htm 0017 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipment PROPERTY AND EQUIPMENT Notes 16 false false R17.htm 0018 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET Sheet http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNet GOODWILL AND INTANGIBLE ASSETS, NET Notes 17 false false R18.htm 0019 - Disclosure - LEASES Sheet http://www.shl-telemedicine.com/role/DisclosureLeases LEASES Notes 18 false false R19.htm 0020 - Disclosure - CREDIT FROM BANKS Sheet http://www.shl-telemedicine.com/role/DisclosureCreditFromBanks CREDIT FROM BANKS Notes 19 false false R20.htm 0021 - Disclosure - LONG-TERM LOANS Sheet http://www.shl-telemedicine.com/role/DisclosureLongTermLoans LONG-TERM LOANS Notes 20 false false R21.htm 0022 - Disclosure - DEFERRED REVENUES Sheet http://www.shl-telemedicine.com/role/DisclosureDeferredRevenues DEFERRED REVENUES Notes 21 false false R22.htm 0023 - Disclosure - OTHER PAYABLES Sheet http://www.shl-telemedicine.com/role/DisclosureOtherPayables OTHER PAYABLES Notes 22 false false R23.htm 0024 - Disclosure - FINANCIAL INSTRUMENTS Sheet http://www.shl-telemedicine.com/role/DisclosureFinancialInstruments FINANCIAL INSTRUMENTS Notes 23 false false R24.htm 0025 - Disclosure - EMPLOYEE BENEFIT LIABILITIES Sheet http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilities EMPLOYEE BENEFIT LIABILITIES Notes 24 false false R25.htm 0026 - Disclosure - TAXES ON INCOME Sheet http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncome TAXES ON INCOME Notes 25 false false R26.htm 0027 - Disclosure - COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) Sheet http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectors COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) Notes 26 false false R27.htm 0028 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES Sheet http://www.shl-telemedicine.com/role/DisclosureCommitmentsAndContingentLiabilities COMMITMENTS AND CONTINGENT LIABILITIES Notes 27 false false R28.htm 0029 - Disclosure - EQUITY Sheet http://www.shl-telemedicine.com/role/DisclosureEquity EQUITY Notes 28 false false R29.htm 0030 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncome SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME Notes 29 false false R30.htm 0031 - Disclosure - NET EARNINGS PER SHARE Sheet http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShare NET EARNINGS PER SHARE Notes 30 false false R31.htm 0032 - Disclosure - SEGMENT INFORMATION Sheet http://www.shl-telemedicine.com/role/DisclosureSegmentInformation SEGMENT INFORMATION Notes 31 false false R32.htm 0033 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.shl-telemedicine.com/role/DisclosureSubsequentEvents SUBSEQUENT EVENTS Notes 32 false false R33.htm 0034 - Disclosure - ACCOUNTING POLICIES (Policies) Sheet http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies ACCOUNTING POLICIES (Policies) Policies 33 false false R34.htm 0035 - Disclosure - ACCOUNTING POLICIES (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesTables ACCOUNTING POLICIES (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPolicies 34 false false R35.htm 0036 - Disclosure - CASH AND CASH EQUIVALENTS (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsTables CASH AND CASH EQUIVALENTS (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalents 35 false false R36.htm 0037 - Disclosure - SHORT-TERM INVESTMENTS (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsTables SHORT-TERM INVESTMENTS (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureShortTermInvestments 36 false false R37.htm 0038 - Disclosure - TRADE RECEIVABLES (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesTables TRADE RECEIVABLES (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureTradeReceivables 37 false false R38.htm 0039 - Disclosure - OTHER ACCOUNTS RECEIVABLE (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableTables OTHER ACCOUNTS RECEIVABLE (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivable 38 false false R39.htm 0040 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipment 39 false false R40.htm 0041 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetTables GOODWILL AND INTANGIBLE ASSETS, NET (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNet 40 false false R41.htm 0042 - Disclosure - LEASES (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureLeasesTables LEASES (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureLeases 41 false false R42.htm 0043 - Disclosure - CREDIT FROM BANKS (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksTables CREDIT FROM BANKS (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureCreditFromBanks 42 false false R43.htm 0044 - Disclosure - LONG-TERM LOANS (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureLongTermLoansTables LONG-TERM LOANS (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureLongTermLoans 43 false false R44.htm 0045 - Disclosure - OTHER PAYABLES (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureOtherPayablesTables OTHER PAYABLES (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureOtherPayables 44 false false R45.htm 0046 - Disclosure - FINANCIAL INSTRUMENTS (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables FINANCIAL INSTRUMENTS (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureFinancialInstruments 45 false false R46.htm 0047 - Disclosure - EMPLOYEE BENEFIT LIABILITIES (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesTables EMPLOYEE BENEFIT LIABILITIES (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilities 46 false false R47.htm 0048 - Disclosure - TAXES ON INCOME (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTables TAXES ON INCOME (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncome 47 false false R48.htm 0049 - Disclosure - COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsTables COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectors 48 false false R49.htm 0050 - Disclosure - EQUITY (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables EQUITY (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureEquity 49 false false R50.htm 0051 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeTables SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncome 50 false false R51.htm 0052 - Disclosure - NET EARNINGS PER SHARE (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareTables NET EARNINGS PER SHARE (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShare 51 false false R52.htm 0053 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.shl-telemedicine.com/role/DisclosureSegmentInformationTables SEGMENT INFORMATION (Tables) Tables http://www.shl-telemedicine.com/role/DisclosureSegmentInformation 52 false false R53.htm 0055 - Disclosure - ACCOUNTING POLICIES - (Narrative) (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesImpairmentOfNonFinancialAssetsDetails ACCOUNTING POLICIES - (Narrative) (Details) Details http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesTables 53 false false R54.htm 0056 - Disclosure - ACCOUNTING POLICIES - Disclosure of depreciation of the right-of-use assets by class of underlying asset (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails ACCOUNTING POLICIES - Disclosure of depreciation of the right-of-use assets by class of underlying asset (Details) Details 54 false false R55.htm 0057 - Disclosure - ACCOUNTING POLICIES - Disclosure of depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails ACCOUNTING POLICIES - Disclosure of depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates (Details) Details 55 false false R56.htm 0058 - Disclosure - ACCOUNTING POLICIES - Disclosure of useful life of intangible assets (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails ACCOUNTING POLICIES - Disclosure of useful life of intangible assets (Details) Details 56 false false R57.htm 0059 - Disclosure - ACCOUNTING POLICIES - Disclosure of exchange rates and linkage basis (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails ACCOUNTING POLICIES - Disclosure of exchange rates and linkage basis (Details) Details 57 false false R58.htm 0060 - Disclosure - CASH AND CASH EQUIVALENTS (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsDetails CASH AND CASH EQUIVALENTS (Details) Details http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsTables 58 false false R59.htm 0061 - Disclosure - SHORT-TERM INVESTMENTS (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails SHORT-TERM INVESTMENTS (Details) Details http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsTables 59 false false R60.htm 0062 - Disclosure - TRADE RECEIVABLES (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails TRADE RECEIVABLES (Details) Details http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesTables 60 false false R61.htm 0063 - Disclosure - PREPAID EXPENSES (Narrative) (Details) Sheet http://www.shl-telemedicine.com/role/DisclosurePrepaidExpensesDetails PREPAID EXPENSES (Narrative) (Details) Details http://www.shl-telemedicine.com/role/DisclosurePrepaidExpenses 61 false false R62.htm 0064 - Disclosure - OTHER ACCOUNTS RECEIVABLE (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails OTHER ACCOUNTS RECEIVABLE (Details) Details http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableTables 62 false false R63.htm 0065 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentTables 63 false false R64.htm 0066 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails GOODWILL AND INTANGIBLE ASSETS, NET (Details) Details http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetTables 64 false false R65.htm 0067 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill (Details) Details 65 false false R66.htm 0068 - Disclosure - LEASES (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureLeasesDetails LEASES (Details) Details http://www.shl-telemedicine.com/role/DisclosureLeasesTables 66 false false R67.htm 0069 - Disclosure - LEASES - Right-of-use assets (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails LEASES - Right-of-use assets (Details) Details 67 false false R68.htm 0070 - Disclosure - CREDIT FROM BANKS (Narrative) (Details) Sheet http://www.shl-telemedicine.com/role/CREDITFROMBANKSNarrativeDetails CREDIT FROM BANKS (Narrative) (Details) Details http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksTables 68 false false R69.htm 0071 - Disclosure - CREDIT FROM BANKS - Disclosure of credit from banks (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksDetails CREDIT FROM BANKS - Disclosure of credit from banks (Details) Details 69 false false R70.htm 0072 - Disclosure - LONG-TERM LOANS (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails LONG-TERM LOANS (Details) Details http://www.shl-telemedicine.com/role/DisclosureLongTermLoansTables 70 false false R71.htm 0073 - Disclosure - DEFERRED REVENUES (Narrative) (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureDeferredRevenuesDetails DEFERRED REVENUES (Narrative) (Details) Details http://www.shl-telemedicine.com/role/DisclosureDeferredRevenues 71 false false R72.htm 0074 - Disclosure - OTHER PAYABLES - Disclosure of other current payables (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails OTHER PAYABLES - Disclosure of other current payables (Details) Details 72 false false R73.htm 0075 - Disclosure - FINANCIAL INSTRUMENTS (Narrative) (Details) Sheet http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSNarrativeDetails FINANCIAL INSTRUMENTS (Narrative) (Details) Details http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables 73 false false R74.htm 0076 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Financial assets and liabilities (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails FINANCIAL INSTRUMENTS - Disclosure of Financial assets and liabilities (Details) Details 74 false false R75.htm 0077 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Foreign currency sensitivity analysis (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails FINANCIAL INSTRUMENTS - Disclosure of Foreign currency sensitivity analysis (Details) Details 75 false false R76.htm 0078 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Market risk profit before tax due to changes in carrying amount of marketable securities (Details) Sheet http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSDisclosureOfProfitBeforeTaxDueToChangesInCarryingAmountOfMarketableSecurities FINANCIAL INSTRUMENTS - Disclosure of Market risk profit before tax due to changes in carrying amount of marketable securities (Details) Details 76 false false R77.htm 0079 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Liquidity of summarizes maturity profile of financial liabilities based on contractual undiscounted payments (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails FINANCIAL INSTRUMENTS - Disclosure of Liquidity of summarizes maturity profile of financial liabilities based on contractual undiscounted payments (Details) Details 77 false false R78.htm 0080 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of liabilities arising from financing activities (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails FINANCIAL INSTRUMENTS - Disclosure of liabilities arising from financing activities (Details) Details 78 false false R79.htm 0081 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Reconciliation of fair value measurements within Level 3 of fair value hierarchy in financial instruments (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details FINANCIAL INSTRUMENTS - Disclosure of Reconciliation of fair value measurements within Level 3 of fair value hierarchy in financial instruments (Details) Details 79 false false R80.htm 0082 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of lists the significant inputs fair value of Put Option net of Call option (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails FINANCIAL INSTRUMENTS - Disclosure of lists the significant inputs fair value of Put Option net of Call option (Details) Details 80 false false R81.htm 0083 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of demonstrates effect on fair value of reasonably possible change in underlying asset value with all other variables (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsFairValueSensitivityDetails FINANCIAL INSTRUMENTS - Disclosure of demonstrates effect on fair value of reasonably possible change in underlying asset value with all other variables (Details) Details 81 false false R82.htm 0084 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of changes in the defined benefit obligation and fair value of plan assets (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails EMPLOYEE BENEFIT LIABILITIES - Disclosure of changes in the defined benefit obligation and fair value of plan assets (Details) Details 82 false false R83.htm 0085 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of disaggregation of the fair value of the plan assets (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesDisaggregationOfFairValueOfPlanAssetsDetails EMPLOYEE BENEFIT LIABILITIES - Disclosure of disaggregation of the fair value of the plan assets (Details) Details 83 false false R84.htm 0086 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of principal assumptions underlying the defined benefit plan (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesPrincipalAssumptionsUnderlyingDefinedBenefitPlanDetails EMPLOYEE BENEFIT LIABILITIES - Disclosure of principal assumptions underlying the defined benefit plan (Details) Details 84 false false R85.htm 0087 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions are constant (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails EMPLOYEE BENEFIT LIABILITIES - Disclosure of reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions are constant (Details) Details 85 false false R86.htm 0088 - Disclosure - TAXES ON INCOME - Disclosure of general (Narrative) (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails TAXES ON INCOME - Disclosure of general (Narrative) (Details) Details 86 false false R87.htm 0089 - Disclosure - TAXES ON INCOME - Disclosure of taxes on income included in the statements of comprehensive income (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTaxesOnIncomeIncludedInStatementsOfComprehensiveIncomeDetails TAXES ON INCOME - Disclosure of taxes on income included in the statements of comprehensive income (Details) Details 87 false false R88.htm 0090 - Disclosure - TAXES ON INCOME - Disclosure of deferred tax assets (liabilities) (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails TAXES ON INCOME - Disclosure of deferred tax assets (liabilities) (Details) Details 88 false false R89.htm 0091 - Disclosure - TAXES ON INCOME - Disclosure of reconciliation of theoretical tax expense assuming all income is taxed at statutory rate applicable to income of companies in Israel, and actual tax expense (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails TAXES ON INCOME - Disclosure of reconciliation of theoretical tax expense assuming all income is taxed at statutory rate applicable to income of companies in Israel, and actual tax expense (Details) Details 89 false false R90.htm 0092 - Disclosure - TAXES ON INCOME - Disclosure of carry forward tax losses (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeCarryForwardTaxLossesDetails TAXES ON INCOME - Disclosure of carry forward tax losses (Details) Details 90 false false R91.htm 0093 - Disclosure - TAXES ON INCOME - Disclosure of expiry dates for carry forward tax losses which are not recognized (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails TAXES ON INCOME - Disclosure of expiry dates for carry forward tax losses which are not recognized (Details) Details 91 false false R92.htm 0094 - Disclosure - COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Details) Details http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsTables 92 false false R93.htm 0095 - Disclosure - Equity (Narrative) (Details) Sheet http://www.shl-telemedicine.com/role/EquityNarrativeDetails Equity (Narrative) (Details) Details 93 false false R94.htm 0096 - Disclosure - EQUITY - Disclosure of composition of share capital (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalDetails EQUITY - Disclosure of composition of share capital (Details) Details 94 false false R95.htm 0097 - Disclosure - Equity - Disclosure of significant inputs to Black and Scholes model used for fair value measurement of Share Options (Details) Sheet http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails Equity - Disclosure of significant inputs to Black and Scholes model used for fair value measurement of Share Options (Details) Details 95 false false R96.htm 0098 - Disclosure - EQUITY - Disclosure of movement in share capital (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails EQUITY - Disclosure of movement in share capital (Details) Details 96 false false R97.htm 0099 - Disclosure - EQUITY - Disclosure of issued and outstanding share capital (net of treasury shares) (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureEquityIssuedAndOutstandingShareCapitalNetOfTreasurySharesDetails EQUITY - Disclosure of issued and outstanding share capital (net of treasury shares) (Details) Details 97 false false R98.htm 0100 - Disclosure - EQUITY - Disclosure of number and weighted average exercise prices ("WAEP") of, and movements in, share options (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails EQUITY - Disclosure of number and weighted average exercise prices ("WAEP") of, and movements in, share options (Details) Details 98 false false R99.htm 0101 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of revenues (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeRevenuesDetails SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of revenues (Details) Details 99 false false R100.htm 0102 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of cost of revenues (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of cost of revenues (Details) Details 100 false false R101.htm 0103 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of research and development costs (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of research and development costs (Details) Details 101 false false R102.htm 0104 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of selling and marketing expenses (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of selling and marketing expenses (Details) Details 102 false false R103.htm 0105 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of general and administrative expenses (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of general and administrative expenses (Details) Details 103 false false R104.htm 0106 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial income (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialIncomeDetails SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial income (Details) Details 104 false false R105.htm 0107 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial expenses (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialExpensesDetails SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial expenses (Details) Details 105 false false R106.htm 0108 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of other expenses (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeOtherExpensesDetails SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of other expenses (Details) Details 106 false false R107.htm 0109 - Disclosure - NET EARNINGS PER SHARE (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareDetails NET EARNINGS PER SHARE (Details) Details http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareTables 107 false false R108.htm 0110 - Disclosure - NET EARNINGS PER SHARE (Narrative) (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareAdditionalInformationDetails NET EARNINGS PER SHARE (Narrative) (Details) Details http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareTables 108 false false R109.htm 0111 - Disclosure - SEGMENT INFORMATION - Disclosure of disaggregated revenue information (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails SEGMENT INFORMATION - Disclosure of disaggregated revenue information (Details) Details 109 false false R110.htm 0112 - Disclosure - SEGMENT INFORMATION - Disclosure of revenue from geographic segments (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails SEGMENT INFORMATION - Disclosure of revenue from geographic segments (Details) Details 110 false false R111.htm 0113 - Disclosure - SEGMENT INFORMATION - Disclosure of additional information of segments (Details) Sheet http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails SEGMENT INFORMATION - Disclosure of additional information of segments (Details) Details 111 false false All Reports Book All Reports shlt-20231231.xsd shlt-20231231_cal.xml shlt-20231231_def.xml shlt-20231231_lab.xml shlt-20231231_pre.xml zk2431705.htm image0.jpg image00001.jpg image00004.jpg image2.jpg image3.jpg http://xbrl.sec.gov/dei/2023 https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full true true JSON 136 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "zk2431705.htm": { "nsprefix": "shlt", "nsuri": "http://www.shl-telemedicine.com/20231231", "dts": { "schema": { "local": [ "shlt-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "shlt-20231231_cal.xml" ] }, "definitionLink": { "local": [ "shlt-20231231_def.xml" ] }, "labelLink": { "local": [ "shlt-20231231_lab.xml" ] }, "presentationLink": { "local": [ "shlt-20231231_pre.xml" ] }, "inline": { "local": [ "zk2431705.htm" ] } }, "keyStandard": 347, "keyCustom": 159, "axisStandard": 34, "axisCustom": 2, "memberStandard": 65, "memberCustom": 52, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2023": 4, "http://www.shl-telemedicine.com/20231231": 3 }, "contextCount": 653, "entityCount": 1, "segmentCount": 124, "elementCount": 859, "unitCount": 14, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 1508, "http://xbrl.sec.gov/dei/2023": 45 }, "report": { "R1": { "role": "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation", "longName": "0001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets", "longName": "0002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:Inventories", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R3": { "role": "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome", "longName": "0003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:Revenue", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:GrossProfit", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R4": { "role": "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity", "longName": "0004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_20211231_ifrsfullComponentsOfEquityAxis_ifrsfullEquityAttributableToOwnersOfParentMember", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20211231_ifrsfullComponentsOfEquityAxis_ifrsfullEquityAttributableToOwnersOfParentMember", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R6": { "role": "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical", "longName": "0007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_20231231", "name": "shlt:TradeReceivablesRecognisedAsOfAcquisitionDate", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "shlt:TradeReceivablesRecognisedAsOfAcquisitionDate", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.shl-telemedicine.com/role/DisclosureGeneral", "longName": "0008 - Disclosure - GENERAL", "shortName": "GENERAL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPolicies", "longName": "0009 - Disclosure - ACCOUNTING POLICIES", "shortName": "ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatements", "longName": "0010 - Disclosure - SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS", "shortName": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.shl-telemedicine.com/role/DisclosureDisclosureOfNewStandardsInPeriodPriorToTheirAdoption", "longName": "0011 - Disclosure - DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION", "shortName": "DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalents", "longName": "0012 - Disclosure - CASH AND CASH EQUIVALENTS", "shortName": "CASH AND CASH EQUIVALENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestments", "longName": "0013 - Disclosure - SHORT-TERM INVESTMENTS", "shortName": "SHORT-TERM INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.shl-telemedicine.com/role/DisclosureTradeReceivables", "longName": "0014 - Disclosure - TRADE RECEIVABLES", "shortName": "TRADE RECEIVABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfTradeReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfTradeReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.shl-telemedicine.com/role/DisclosurePrepaidExpenses", "longName": "0015 - Disclosure - PREPAID EXPENSES", "shortName": "PREPAID EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfPrepaidExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfPrepaidExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivable", "longName": "0016 - Disclosure - OTHER ACCOUNTS RECEIVABLE", "shortName": "OTHER ACCOUNTS RECEIVABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfOtherAccountsReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfOtherAccountsReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipment", "longName": "0017 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNet", "longName": "0018 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET", "shortName": "GOODWILL AND INTANGIBLE ASSETS, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.shl-telemedicine.com/role/DisclosureLeases", "longName": "0019 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanks", "longName": "0020 - Disclosure - CREDIT FROM BANKS", "shortName": "CREDIT FROM BANKS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfCurrentBorrowingsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfCurrentBorrowingsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.shl-telemedicine.com/role/DisclosureLongTermLoans", "longName": "0021 - Disclosure - LONG-TERM LOANS", "shortName": "LONG-TERM LOANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfNonCurrentBorrowingsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfNonCurrentBorrowingsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.shl-telemedicine.com/role/DisclosureDeferredRevenues", "longName": "0022 - Disclosure - DEFERRED REVENUES", "shortName": "DEFERRED REVENUES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfDeferredIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfDeferredIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.shl-telemedicine.com/role/DisclosureOtherPayables", "longName": "0023 - Disclosure - OTHER PAYABLES", "shortName": "OTHER PAYABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfOtherPayablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfOtherPayablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.shl-telemedicine.com/role/DisclosureFinancialInstruments", "longName": "0024 - Disclosure - FINANCIAL INSTRUMENTS", "shortName": "FINANCIAL INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilities", "longName": "0025 - Disclosure - EMPLOYEE BENEFIT LIABILITIES", "shortName": "EMPLOYEE BENEFIT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncome", "longName": "0026 - Disclosure - TAXES ON INCOME", "shortName": "TAXES ON INCOME", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectors", "longName": "0027 - Disclosure - COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS)", "shortName": "COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.shl-telemedicine.com/role/DisclosureCommitmentsAndContingentLiabilities", "longName": "0028 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.shl-telemedicine.com/role/DisclosureEquity", "longName": "0029 - Disclosure - EQUITY", "shortName": "EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncome", "longName": "0030 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShare", "longName": "0031 - Disclosure - NET EARNINGS PER SHARE", "shortName": "NET EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.shl-telemedicine.com/role/DisclosureSegmentInformation", "longName": "0032 - Disclosure - SEGMENT INFORMATION", "shortName": "SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.shl-telemedicine.com/role/DisclosureSubsequentEvents", "longName": "0033 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies", "longName": "0034 - Disclosure - ACCOUNTING POLICIES (Policies)", "shortName": "ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "33", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesTables", "longName": "0035 - Disclosure - ACCOUNTING POLICIES (Tables)", "shortName": "ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:ScheduleOfPeriodOfDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ix:continuation", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:ScheduleOfPeriodOfDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ix:continuation", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsTables", "longName": "0036 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)", "shortName": "CASH AND CASH EQUIVALENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsTables", "longName": "0037 - Disclosure - SHORT-TERM INVESTMENTS (Tables)", "shortName": "SHORT-TERM INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutShortTermInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutShortTermInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesTables", "longName": "0038 - Disclosure - TRADE RECEIVABLES (Tables)", "shortName": "TRADE RECEIVABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutTradeReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "shlt:DisclosureOfTradeReceivablesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutTradeReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "shlt:DisclosureOfTradeReceivablesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableTables", "longName": "0039 - Disclosure - OTHER ACCOUNTS RECEIVABLE (Tables)", "shortName": "OTHER ACCOUNTS RECEIVABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutOtherAccountsReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "shlt:DisclosureOfOtherAccountsReceivableTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutOtherAccountsReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "shlt:DisclosureOfOtherAccountsReceivableTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentTables", "longName": "0040 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetTables", "longName": "0041 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.shl-telemedicine.com/role/DisclosureLeasesTables", "longName": "0042 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfInformationOnLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfInformationOnLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksTables", "longName": "0043 - Disclosure - CREDIT FROM BANKS (Tables)", "shortName": "CREDIT FROM BANKS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutCurrentBorrowingsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "shlt:DisclosureOfCurrentBorrowingsTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutCurrentBorrowingsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "shlt:DisclosureOfCurrentBorrowingsTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansTables", "longName": "0044 - Disclosure - LONG-TERM LOANS (Tables)", "shortName": "LONG-TERM LOANS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutNonCurrentBorrowingsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "shlt:DisclosureOfNonCurrentBorrowingsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutNonCurrentBorrowingsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "shlt:DisclosureOfNonCurrentBorrowingsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesTables", "longName": "0045 - Disclosure - OTHER PAYABLES (Tables)", "shortName": "OTHER PAYABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutOtherPayablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "shlt:DisclosureOfOtherPayablesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:DisclosureOfDetailedInformationAboutOtherPayablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "shlt:DisclosureOfOtherPayablesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables", "longName": "0046 - Disclosure - FINANCIAL INSTRUMENTS (Tables)", "shortName": "FINANCIAL INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesTables", "longName": "0047 - Disclosure - EMPLOYEE BENEFIT LIABILITIES (Tables)", "shortName": "EMPLOYEE BENEFIT LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTables", "longName": "0048 - Disclosure - TAXES ON INCOME (Tables)", "shortName": "TAXES ON INCOME (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsTables", "longName": "0049 - Disclosure - COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Tables)", "shortName": "COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables", "longName": "0050 - Disclosure - EQUITY (Tables)", "shortName": "EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeTables", "longName": "0051 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME (Tables)", "shortName": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareTables", "longName": "0052 - Disclosure - NET EARNINGS PER SHARE (Tables)", "shortName": "NET EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationTables", "longName": "0053 - Disclosure - SEGMENT INFORMATION (Tables)", "shortName": "SEGMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesImpairmentOfNonFinancialAssetsDetails", "longName": "0055 - Disclosure - ACCOUNTING POLICIES - (Narrative) (Details)", "shortName": "ACCOUNTING POLICIES - (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:ImpairmentLossesOnFinancialAssets", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:ImpairmentLossesOnFinancialAssets", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails", "longName": "0056 - Disclosure - ACCOUNTING POLICIES - Disclosure of depreciation of the right-of-use assets by class of underlying asset (Details)", "shortName": "ACCOUNTING POLICIES - Disclosure of depreciation of the right-of-use assets by class of underlying asset (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_20230101to20231231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:ScheduleOfPeriodOfDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetTableTextBlock", "div", "div", "ix:continuation", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:ScheduleOfPeriodOfDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetTableTextBlock", "div", "div", "ix:continuation", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails", "longName": "0057 - Disclosure - ACCOUNTING POLICIES - Disclosure of depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates (Details)", "shortName": "ACCOUNTING POLICIES - Disclosure of depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_20230101to20231231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_shltMedicalEquipmentMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "name": "ifrs-full:DepreciationRatePropertyPlantAndEquipment", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:ScheduleOfUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_shltMedicalEquipmentMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "name": "ifrs-full:DepreciationRatePropertyPlantAndEquipment", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:ScheduleOfUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails", "longName": "0058 - Disclosure - ACCOUNTING POLICIES - Disclosure of useful life of intangible assets (Details)", "shortName": "ACCOUNTING POLICIES - Disclosure of useful life of intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_20230101to20231231_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullCapitalisedDevelopmentExpenditureMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:ScheduleOfUsefulLifeOfIntangibleAssetsTableTextBlock", "div", "div", "ix:continuation", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullCapitalisedDevelopmentExpenditureMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:ScheduleOfUsefulLifeOfIntangibleAssetsTableTextBlock", "div", "div", "ix:continuation", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails", "longName": "0059 - Disclosure - ACCOUNTING POLICIES - Disclosure of exchange rates and linkage basis (Details)", "shortName": "ACCOUNTING POLICIES - Disclosure of exchange rates and linkage basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_20231231_srtCurrencyAxis_currencyILS", "name": "shlt:ConsumerPriceIndexPoints", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "shlt:ScheduleOfDataRegardingForeignExchangeRatesAndLinkageBasisTableTextBlock", "div", "shlt:DescriptionOfAccountingPolicyForExchangeRatesAndLinkageBasisExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231_srtCurrencyAxis_currencyILS", "name": "shlt:ConsumerPriceIndexPoints", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "shlt:ScheduleOfDataRegardingForeignExchangeRatesAndLinkageBasisTableTextBlock", "div", "shlt:DescriptionOfAccountingPolicyForExchangeRatesAndLinkageBasisExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsDetails", "longName": "0060 - Disclosure - CASH AND CASH EQUIVALENTS (Details)", "shortName": "CASH AND CASH EQUIVALENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:BalancesWithBanks", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTextBlock", "div", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:BalancesWithBanks", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTextBlock", "div", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails", "longName": "0061 - Disclosure - SHORT-TERM INVESTMENTS (Details)", "shortName": "SHORT-TERM INVESTMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:CorporateDebtInstrumentsHeld", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "shlt:DisclosureOfDetailedInformationAboutShortTermInvestmentsTextBlock", "div", "div", "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:CorporateDebtInstrumentsHeld", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "shlt:DisclosureOfDetailedInformationAboutShortTermInvestmentsTextBlock", "div", "div", "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails", "longName": "0062 - Disclosure - TRADE RECEIVABLES (Details)", "shortName": "TRADE RECEIVABLES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "name": "shlt:TermsOfBilledAccountsReceivable", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "table", "div", "shlt:DisclosureOfDetailedInformationAboutTradeReceivablesTextBlock", "div", "div", "shlt:DisclosureOfTradeReceivablesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R61": { "role": "http://www.shl-telemedicine.com/role/DisclosurePrepaidExpensesDetails", "longName": "0063 - Disclosure - PREPAID EXPENSES (Narrative) (Details)", "shortName": "PREPAID EXPENSES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "shlt:DisclosureOfPrepaidExpensesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "shlt:DisclosureOfPrepaidExpensesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails", "longName": "0064 - Disclosure - OTHER ACCOUNTS RECEIVABLE (Details)", "shortName": "OTHER ACCOUNTS RECEIVABLE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:CurrentInterestReceivable", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "shlt:DisclosureOfDetailedInformationAboutOtherAccountsReceivableTextBlock", "div", "div", "shlt:DisclosureOfOtherAccountsReceivableTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:CurrentInterestReceivable", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "shlt:DisclosureOfDetailedInformationAboutOtherAccountsReceivableTextBlock", "div", "div", "shlt:DisclosureOfOtherAccountsReceivableTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "longName": "0065 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "shortName": "PROPERTY AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_20221231", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember", "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R64": { "role": "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails", "longName": "0066 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS, NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_20221231", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "div", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20211231", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "div", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R65": { "role": "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails", "longName": "0067 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS, NET - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:Goodwill", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:PeriodCoveredByFinancialBudgetsUsedInCashFlowProjections", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "div", "ix:continuation", "div", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R66": { "role": "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails", "longName": "0068 - Disclosure - LEASES (Details)", "shortName": "LEASES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "shlt:DisclosureOfInformationOnLeasesTextBlock", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "shlt:DisclosureOfInformationOnLeasesTextBlock", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "longName": "0069 - Disclosure - LEASES - Right-of-use assets (Details)", "shortName": "LEASES - Right-of-use assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_20221231", "name": "ifrs-full:RightofuseAssets", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20211231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember", "name": "ifrs-full:RightofuseAssets", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R68": { "role": "http://www.shl-telemedicine.com/role/CREDITFROMBANKSNarrativeDetails", "longName": "0070 - Disclosure - CREDIT FROM BANKS (Narrative) (Details)", "shortName": "CREDIT FROM BANKS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_20231231", "name": "shlt:BorrowingsInterestRateBasisValue", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "shlt:DisclosureOfDetailedInformationAboutCurrentBorrowingsTextBlock", "shlt:DisclosureOfCurrentBorrowingsTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "shlt:BorrowingsInterestRateBasisValue", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "shlt:DisclosureOfDetailedInformationAboutCurrentBorrowingsTextBlock", "shlt:DisclosureOfCurrentBorrowingsTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksDetails", "longName": "0071 - Disclosure - CREDIT FROM BANKS - Disclosure of credit from banks (Details)", "shortName": "CREDIT FROM BANKS - Disclosure of credit from banks (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:CurrentPortionOfLongtermBorrowings", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "shlt:DisclosureOfDetailedInformationAboutCurrentBorrowingsTextBlock", "shlt:DisclosureOfCurrentBorrowingsTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "shlt:DisclosureOfDetailedInformationAboutCurrentBorrowingsTextBlock", "shlt:DisclosureOfCurrentBorrowingsTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R70": { "role": "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails", "longName": "0072 - Disclosure - LONG-TERM LOANS (Details)", "shortName": "LONG-TERM LOANS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:BorrowingsInterestRateBasis", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "shlt:DisclosureOfDetailedInformationAboutCurrentBorrowingsTextBlock", "shlt:DisclosureOfCurrentBorrowingsTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:Borrowings", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "shlt:DisclosureOfDetailedInformationAboutNonCurrentBorrowingsTextBlock", "div", "div", "shlt:DisclosureOfNonCurrentBorrowingsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R71": { "role": "http://www.shl-telemedicine.com/role/DisclosureDeferredRevenuesDetails", "longName": "0073 - Disclosure - DEFERRED REVENUES (Narrative) (Details)", "shortName": "DEFERRED REVENUES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:MaximumExpectedPeriodBetweenReceiptOfAdvancePaymentAndPerformanceOfServiceRecognitionOfDeferredRevenue", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "div", "div", "div", "ifrs-full:DisclosureOfDeferredIncomeExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:MaximumExpectedPeriodBetweenReceiptOfAdvancePaymentAndPerformanceOfServiceRecognitionOfDeferredRevenue", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "div", "div", "div", "ifrs-full:DisclosureOfDeferredIncomeExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails", "longName": "0074 - Disclosure - OTHER PAYABLES - Disclosure of other current payables (Details)", "shortName": "OTHER PAYABLES - Disclosure of other current payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:DisclosureOfDetailedInformationAboutOtherPayablesTextBlock", "div", "div", "shlt:DisclosureOfOtherPayablesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:DisclosureOfDetailedInformationAboutOtherPayablesTextBlock", "div", "div", "shlt:DisclosureOfOtherPayablesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "longName": "0075 - Disclosure - FINANCIAL INSTRUMENTS (Narrative) (Details)", "shortName": "FINANCIAL INSTRUMENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:DebtInstrumentsHeld", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "shlt:DisclosureOfDetailedInformationAboutShortTermInvestmentsTextBlock", "div", "div", "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R74": { "role": "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails", "longName": "0076 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Financial assets and liabilities (Details)", "shortName": "FINANCIAL INSTRUMENTS - Disclosure of Financial assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C_20231231_ifrsfullCategoriesOfFinancialLiabilitiesAxis_ifrsfullFinancialLiabilitiesAtAmortisedCostCategoryMember", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231_ifrsfullCategoriesOfFinancialLiabilitiesAxis_ifrsfullFinancialLiabilitiesAtAmortisedCostCategoryMember", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails", "longName": "0077 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Foreign currency sensitivity analysis (Details)", "shortName": "FINANCIAL INSTRUMENTS - Disclosure of Foreign currency sensitivity analysis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:CurrentInvestments", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20231231_ifrsfullTypesOfRisksAxis_ifrsfullCurrencyRiskMember_srtCurrencyAxis_currencyUSD", "name": "shlt:ReasonablyPossibleIncreaseInRiskComponent", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R76": { "role": "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSDisclosureOfProfitBeforeTaxDueToChangesInCarryingAmountOfMarketableSecurities", "longName": "0078 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Market risk profit before tax due to changes in carrying amount of marketable securities (Details)", "shortName": "FINANCIAL INSTRUMENTS - Disclosure of Market risk profit before tax due to changes in carrying amount of marketable securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "C_20231231", "name": "shlt:PercentageOfReasonablyPossibleIncreaseInUnobservableInputProfitBeforeTax", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "shlt:PercentageOfReasonablyPossibleIncreaseInUnobservableInputProfitBeforeTax", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails", "longName": "0079 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Liquidity of summarizes maturity profile of financial liabilities based on contractual undiscounted payments (Details)", "shortName": "FINANCIAL INSTRUMENTS - Disclosure of Liquidity of summarizes maturity profile of financial liabilities based on contractual undiscounted payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "C_20231231", "name": "shlt:FinancialLiabilitiesUndiscountedCashFlows", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "shlt:DisclosureOfMaturityAnalysisForFinancialLiabilitiesTextBlock", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "shlt:FinancialLiabilitiesUndiscountedCashFlows", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "shlt:DisclosureOfMaturityAnalysisForFinancialLiabilitiesTextBlock", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails", "longName": "0080 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of liabilities arising from financing activities (Details)", "shortName": "FINANCIAL INSTRUMENTS - Disclosure of liabilities arising from financing activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "C_20221231", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20211231", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R79": { "role": "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details", "longName": "0081 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of Reconciliation of fair value measurements within Level 3 of fair value hierarchy in financial instruments (Details)", "shortName": "FINANCIAL INSTRUMENTS - Disclosure of Reconciliation of fair value measurements within Level 3 of fair value hierarchy in financial instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "C_20221231", "name": "ifrs-full:Liabilities", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20211231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember", "name": "ifrs-full:Liabilities", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R80": { "role": "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails", "longName": "0082 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of lists the significant inputs fair value of Put Option net of Call option (Details)", "shortName": "FINANCIAL INSTRUMENTS - Disclosure of lists the significant inputs fair value of Put Option net of Call option (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "C_20230101to20231231_ifrsfullClassesOfFinancialLiabilitiesAxis_shltPutOptionToNonControllingInterestsMember", "name": "shlt:UnderlyingAssetValueMeasurementInput", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullClassesOfFinancialLiabilitiesAxis_shltPutOptionToNonControllingInterestsMember", "name": "shlt:UnderlyingAssetValueMeasurementInput", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsFairValueSensitivityDetails", "longName": "0083 - Disclosure - FINANCIAL INSTRUMENTS - Disclosure of demonstrates effect on fair value of reasonably possible change in underlying asset value with all other variables (Details)", "shortName": "FINANCIAL INSTRUMENTS - Disclosure of demonstrates effect on fair value of reasonably possible change in underlying asset value with all other variables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "C_20231231_ifrsfullClassesOfFinancialLiabilitiesAxis_shltPutOptionToNonControllingInterestsMember", "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfSensitivityAnalysisOfFairValueMeasurementToChangesInUnobservableInputsLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231_ifrsfullClassesOfFinancialLiabilitiesAxis_shltPutOptionToNonControllingInterestsMember", "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfSensitivityAnalysisOfFairValueMeasurementToChangesInUnobservableInputsLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails", "longName": "0084 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of changes in the defined benefit obligation and fair value of plan assets (Details)", "shortName": "EMPLOYEE BENEFIT LIABILITIES - Disclosure of changes in the defined benefit obligation and fair value of plan assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "C_20221231", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20211231", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R83": { "role": "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesDisaggregationOfFairValueOfPlanAssetsDetails", "longName": "0085 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of disaggregation of the fair value of the plan assets (Details)", "shortName": "EMPLOYEE BENEFIT LIABILITIES - Disclosure of disaggregation of the fair value of the plan assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "C_20231231_ifrsfullNetDefinedBenefitLiabilityAssetAxis_ifrsfullPlanAssetsMember", "name": "ifrs-full:QualifyingInsurancePoliciesAmountContributedToFairValueOfPlanAssets", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory", "div", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231_ifrsfullNetDefinedBenefitLiabilityAssetAxis_ifrsfullPlanAssetsMember", "name": "ifrs-full:QualifyingInsurancePoliciesAmountContributedToFairValueOfPlanAssets", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory", "div", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesPrincipalAssumptionsUnderlyingDefinedBenefitPlanDetails", "longName": "0086 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of principal assumptions underlying the defined benefit plan (Details)", "shortName": "EMPLOYEE BENEFIT LIABILITIES - Disclosure of principal assumptions underlying the defined benefit plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:ScheduleOfPrincipalAssumptionsOfUnderlyingDefinedBenefitPlansTableTextBlock", "div", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:ScheduleOfPrincipalAssumptionsOfUnderlyingDefinedBenefitPlansTableTextBlock", "div", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails", "longName": "0087 - Disclosure - EMPLOYEE BENEFIT LIABILITIES - Disclosure of reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions are constant (Details)", "shortName": "EMPLOYEE BENEFIT LIABILITIES - Disclosure of reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions are constant (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "C_20231231_ifrsfullActuarialAssumptionsAxis_ifrsfullActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember", "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory", "div", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231_ifrsfullActuarialAssumptionsAxis_ifrsfullActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember", "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory", "div", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails", "longName": "0088 - Disclosure - TAXES ON INCOME - Disclosure of general (Narrative) (Details)", "shortName": "TAXES ON INCOME - Disclosure of general (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "shlt:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "Unit_Standard_pure_8rL2BJja9UGOW3UHHvFpOw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "ifrs-full:ApplicableTaxRate", "span", "span", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R87": { "role": "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTaxesOnIncomeIncludedInStatementsOfComprehensiveIncomeDetails", "longName": "0089 - Disclosure - TAXES ON INCOME - Disclosure of taxes on income included in the statements of comprehensive income (Details)", "shortName": "TAXES ON INCOME - Disclosure of taxes on income included in the statements of comprehensive income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:CurrentTaxExpenseIncome", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "shlt:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:CurrentTaxExpenseIncome", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "shlt:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails", "longName": "0090 - Disclosure - TAXES ON INCOME - Disclosure of deferred tax assets (liabilities) (Details)", "shortName": "TAXES ON INCOME - Disclosure of deferred tax assets (liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "C_20221231", "name": "ifrs-full:DeferredTaxLiabilityAsset", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20211231", "name": "ifrs-full:DeferredTaxLiabilityAsset", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R89": { "role": "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails", "longName": "0091 - Disclosure - TAXES ON INCOME - Disclosure of reconciliation of theoretical tax expense assuming all income is taxed at statutory rate applicable to income of companies in Israel, and actual tax expense (Details)", "shortName": "TAXES ON INCOME - Disclosure of reconciliation of theoretical tax expense assuming all income is taxed at statutory rate applicable to income of companies in Israel, and actual tax expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:AccountingProfit", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "shlt:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:AccountingProfit", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "shlt:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeCarryForwardTaxLossesDetails", "longName": "0092 - Disclosure - TAXES ON INCOME - Disclosure of carry forward tax losses (Details)", "shortName": "TAXES ON INCOME - Disclosure of carry forward tax losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "C_20231231", "name": "shlt:DeductibleTemporaryDifferencesAndCarryforwardTaxLossForWhichNoDeferredTaxAssetIsRecognised", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "shlt:DeductibleTemporaryDifferencesAndCarryforwardTaxLossForWhichNoDeferredTaxAssetIsRecognised", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails", "longName": "0093 - Disclosure - TAXES ON INCOME - Disclosure of expiry dates for carry forward tax losses which are not recognized (Details)", "shortName": "TAXES ON INCOME - Disclosure of expiry dates for carry forward tax losses which are not recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "C_20231231", "name": "shlt:CarryForwardTaxLossesToBeRecognizedYearOne", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:SummaryOfExpiryDateForCarryForwardTaxLossesTableTextBlock", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "shlt:CarryForwardTaxLossesToBeRecognizedYearOne", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "shlt:SummaryOfExpiryDateForCarryForwardTaxLossesTableTextBlock", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails", "longName": "0094 - Disclosure - COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Details)", "shortName": "COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "C_20231231_ifrsfullCategoriesOfRelatedPartiesAxis_ifrsfullKeyManagementPersonnelOfEntityOrParentMember", "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231_ifrsfullCategoriesOfRelatedPartiesAxis_ifrsfullKeyManagementPersonnelOfEntityOrParentMember", "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.shl-telemedicine.com/role/EquityNarrativeDetails", "longName": "0095 - Disclosure - Equity (Narrative) (Details)", "shortName": "Equity (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "Unit_Standard_shares_hR5gwsPBbESsGU8mNIHWvA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20210121to20210121", "name": "shlt:NumberOfCapitalIncreases", "unitRef": "Capital_Increases", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "span", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R94": { "role": "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalDetails", "longName": "0096 - Disclosure - EQUITY - Disclosure of composition of share capital (Details)", "shortName": "EQUITY - Disclosure of composition of share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "Unit_Standard_shares_hR5gwsPBbESsGU8mNIHWvA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "Unit_Standard_shares_hR5gwsPBbESsGU8mNIHWvA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "ifrs-full:NumberOfSharesOutstanding", "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R95": { "role": "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "longName": "0097 - Disclosure - Equity - Disclosure of significant inputs to Black and Scholes model used for fair value measurement of Share Options (Details)", "shortName": "Equity - Disclosure of significant inputs to Black and Scholes model used for fair value measurement of Share Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:ShareOptionsExercises", "unitRef": "Unit_Standard_shares_hR5gwsPBbESsGU8mNIHWvA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": null }, "R96": { "role": "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "longName": "0098 - Disclosure - EQUITY - Disclosure of movement in share capital (Details)", "shortName": "EQUITY - Disclosure of movement in share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:ShareOptionsExercises", "unitRef": "Unit_Standard_shares_hR5gwsPBbESsGU8mNIHWvA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": null }, "R97": { "role": "http://www.shl-telemedicine.com/role/DisclosureEquityIssuedAndOutstandingShareCapitalNetOfTreasurySharesDetails", "longName": "0099 - Disclosure - EQUITY - Disclosure of issued and outstanding share capital (net of treasury shares) (Details)", "shortName": "EQUITY - Disclosure of issued and outstanding share capital (net of treasury shares) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "C_20221231", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "Unit_Standard_shares_hR5gwsPBbESsGU8mNIHWvA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:ExerciseOfEmployeesShareOptions", "unitRef": "Unit_Standard_shares_hR5gwsPBbESsGU8mNIHWvA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R98": { "role": "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails", "longName": "0100 - Disclosure - EQUITY - Disclosure of number and weighted average exercise prices (\"WAEP\") of, and movements in, share options (Details)", "shortName": "EQUITY - Disclosure of number and weighted average exercise prices (\"WAEP\") of, and movements in, share options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "C_20221231", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20211231", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Unit_Standard_item_uchMkKGtLkOnxpJzjI5Eyg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R99": { "role": "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeRevenuesDetails", "longName": "0101 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of revenues (Details)", "shortName": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:RevenueFromRenderingOfServices", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:RevenueFromRenderingOfServices", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails", "longName": "0102 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of cost of revenues (Details)", "shortName": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of cost of revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:CostOfSales", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis_shltSalariesAndRelatedBenefitsMember", "name": "ifrs-full:CostOfSales", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfCostOfSalesExplanatory", "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R101": { "role": "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails", "longName": "0103 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of research and development costs (Details)", "shortName": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of research and development costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:ResearchAndDevelopmentExpenseGross", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "div", "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:ResearchAndDevelopmentExpenseGross", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "div", "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails", "longName": "0104 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of selling and marketing expenses (Details)", "shortName": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of selling and marketing expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:SalesAndMarketingExpense", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis_shltSalariesAndRelatedBenefitsMember", "name": "ifrs-full:SalesAndMarketingExpense", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "shlt:DisclosureOfSellingAndMarketingExpenseTableTextBlock", "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R103": { "role": "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails", "longName": "0105 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of general and administrative expenses (Details)", "shortName": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of general and administrative expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis_shltSalariesAndRelatedBenefitsMember", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R104": { "role": "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialIncomeDetails", "longName": "0106 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial income (Details)", "shortName": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:ForeignExchangeGain", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "div", "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:ForeignExchangeGain", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "div", "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R105": { "role": "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialExpensesDetails", "longName": "0107 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial expenses (Details)", "shortName": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of financial expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:ExpenseFromShareOptions", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinanceCostExplanatory", "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "shlt:ExpenseFromShareOptions", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinanceCostExplanatory", "div", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R106": { "role": "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeOtherExpensesDetails", "longName": "0108 - Disclosure - SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of other expenses (Details)", "shortName": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME - Disclosure of other expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "div", "div", "shlt:SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R107": { "role": "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareDetails", "longName": "0109 - Disclosure - NET EARNINGS PER SHARE (Details)", "shortName": "NET EARNINGS PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:WeightedAverageShares", "unitRef": "Unit_Standard_shares_hR5gwsPBbESsGU8mNIHWvA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:EarningsPerShareExplanatory", "div", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:WeightedAverageShares", "unitRef": "Unit_Standard_shares_hR5gwsPBbESsGU8mNIHWvA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:EarningsPerShareExplanatory", "div", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareAdditionalInformationDetails", "longName": "0110 - Disclosure - NET EARNINGS PER SHARE (Narrative) (Details)", "shortName": "NET EARNINGS PER SHARE (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember", "name": "ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented", "unitRef": "Unit_Standard_shares_hR5gwsPBbESsGU8mNIHWvA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember", "name": "ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented", "unitRef": "Unit_Standard_shares_hR5gwsPBbESsGU8mNIHWvA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } }, "R109": { "role": "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails", "longName": "0111 - Disclosure - SEGMENT INFORMATION - Disclosure of disaggregated revenue information (Details)", "shortName": "SEGMENT INFORMATION - Disclosure of disaggregated revenue information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:Revenue", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_ifrsfullSegmentsAxis_shltIndividualsAndCommunitiesMember", "name": "ifrs-full:Revenue", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R110": { "role": "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails", "longName": "0112 - Disclosure - SEGMENT INFORMATION - Disclosure of revenue from geographic segments (Details)", "shortName": "SEGMENT INFORMATION - Disclosure of revenue from geographic segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:Revenue", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:FinanceIncomeCost", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "unique": true } }, "R111": { "role": "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "longName": "0113 - Disclosure - SEGMENT INFORMATION - Disclosure of additional information of segments (Details)", "shortName": "SEGMENT INFORMATION - Disclosure of additional information of segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DepreciationAndAmortisationExpense", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfAdditionalInformationExplanatory", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "ifrs-full:DepreciationAndAmortisationExpense", "unitRef": "Unit_Standard_USD_vp3jRGis50i1Pt6yLzWONw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfAdditionalInformationExplanatory", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431705.htm", "first": true, "unique": true } } }, "tag": { "ifrs-full_AccountingProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccountingProfit", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Accounting profit", "terseLabel": "Income (loss) before taxes on income" } }, "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r47", "r48" ] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails": { "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Accruals classified as current", "terseLabel": "Accrued expenses" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r325" ] }, "shlt_AccrualsRestructuringCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "AccrualsRestructuringCurrent", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails": { "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Accruals Restructuring Current", "documentation": "Accruals restructuring classified as current", "terseLabel": "Accruals restructuring" } } }, "auth_ref": [] }, "shlt_AccruedExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "AccruedExpensesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued expenses", "label": "Accrued expenses [member]", "terseLabel": "Accrued expenses" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]", "terseLabel": "Accumulated depreciation" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } } }, "auth_ref": [ "r54", "r63", "r114", "r121", "r124" ] }, "ifrs-full_AccumulatedImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedImpairmentMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated impairment [member]", "terseLabel": "Allowance for doubtful accounts" } }, "en": { "role": { "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]" } } }, "auth_ref": [ "r212", "r221", "r294", "r330", "r341", "r346", "r347" ] }, "ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeOtherExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination", "terseLabel": "Expenses related to acquisitions" } }, "en": { "role": { "documentation": "The amount of acquisition-related costs recognised as an expense for transactions that are recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r210" ] }, "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Acquisitions through business combinations, intangible assets and goodwill", "terseLabel": "Initially consolidated company" } }, "en": { "role": { "documentation": "The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets and goodwill]" } } }, "auth_ref": [ "r342" ] }, "ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Acquisitions through business combinations, property, plant and equipment", "terseLabel": "Initially consolidated company" } }, "en": { "role": { "documentation": "The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r57" ] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesPrincipalAssumptionsUnderlyingDefinedBenefitPlanDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of discount rates", "terseLabel": "Discount rate" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRatesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of discount rates [member]", "terseLabel": "Discount rate of the plan assets and liability" } }, "en": { "role": { "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [member]]" } } }, "auth_ref": [ "r337" ] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesPrincipalAssumptionsUnderlyingDefinedBenefitPlanDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of expected rates of salary increases", "terseLabel": "Expected rate of salary increase" } }, "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of expected rates of salary increases [member]", "terseLabel": "Expected rate of salary increase" } }, "en": { "role": { "documentation": "This member stands for the expected rates of salary increases used as actuarial assumptions. [Refer: Actuarial assumptions [member]]" } } }, "auth_ref": [ "r337" ] }, "ifrs-full_ActuarialAssumptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionsAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumptions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r79" ] }, "ifrs-full_ActuarialAssumptionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumptions [member]" } }, "en": { "role": { "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used." } } }, "auth_ref": [ "r79" ] }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions", "terseLabel": "Actuarial gain (loss) arising from changes in financial assumptions" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r71" ] }, "ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments", "terseLabel": "Actuarial gain (loss) arising from experience adjustments" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r333" ] }, "ifrs-full_AdditionalPaidinCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionalPaidinCapital", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "terseLabel": "Additional paid-in capital" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r323" ] }, "ifrs-full_AdditionalPaidinCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionalPaidinCapitalMember", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital [member]", "terseLabel": "Additional paid-in capital" } }, "en": { "role": { "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r320" ] }, "shlt_AdditionsDueToInitiallyConsolidatedCompaniesToRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "AdditionsDueToInitiallyConsolidatedCompaniesToRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of additions to right-of-use assets due to initially consolidated companies.", "label": "Additions Due to Initially Consolidated Companies To Right of use Assets", "terseLabel": "Initially consolidated company" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "terseLabel": "Additions during the year" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r115" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment", "terseLabel": "Additions during the year" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r55" ] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions to right-of-use assets", "terseLabel": "New leases" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r177" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "For the computation of diluted net earnings" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r98" ] }, "shlt_AdjustmentForCapitalGainFromAmendmentOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "AdjustmentForCapitalGainFromAmendmentOfLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustment For Capital Gain From Amendment Of Lease Liabilities", "documentation": "The amount repesents adjustment for capital gain from amendment of lease liabilities.", "terseLabel": "Capital gain from amendment of lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInContractAssets", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 50.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in contract assets", "terseLabel": "Increase (decrease) in deferred revenues", "negatedLabel": "Decrease in deferred revenues" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in contract assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract assets; Profit (loss)]" } } }, "auth_ref": [ "r350" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "terseLabel": "Increase in inventory", "negatedLabel": "Increase in inventory" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } } }, "auth_ref": [ "r350" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 60.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in other operating receivables", "terseLabel": "Decrease (increase) in other accounts receivable", "negatedLabel": "Decrease (increase) in other accounts receivable" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r350" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in prepaid expenses", "terseLabel": "Decrease (increase) in prepaid expenses", "negatedLabel": "Increase in prepaid expenses" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade accounts receivable", "terseLabel": "Decrease (increase) in trade receivables, net", "negatedLabel": "Increase in trade receivables, net" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r350" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0, "order": 80.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for depreciation and amortisation expense", "terseLabel": "Depreciation and amortization" } }, "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } } }, "auth_ref": [ "r351" ] }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": -1.0, "order": 60.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Financial Expenses (income), net", "label": "Adjustments for finance income (cost)" } }, "en": { "role": { "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": -1.0, "order": 70.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital loss from disposals of property and equipment", "label": "Adjustments for gain (loss) on disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]" } } }, "auth_ref": [ "r352" ] }, "shlt_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssets", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for impairment loss (reversal of impairment loss) on intangible assets recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss Intangible Assets", "terseLabel": "Impairment of intangible assets" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0, "order": 90.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment", "terseLabel": "Impairment of property, and equipment" } }, "en": { "role": { "documentation": "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Tax expenses" } }, "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r130" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in employee benefit liabilities", "terseLabel": "Change in employee benefit liabilities, net" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in other operating payables", "terseLabel": "Increase (decrease) in other accounts payable", "negatedLabel": "Increase in other accounts payable" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r350" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade accounts payable", "terseLabel": "Increase in trade payables", "negatedLabel": "Increase (decrease) in trade payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r350" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "verboseLabel": "Adjustments required to reconcile net profit (loss) to net cash provided by (used) in operating activities:" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Cost of share-based payments" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r351" ] }, "shlt_AdjustmentsForValuationLossGainsOfShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "AdjustmentsForValuationLossGainsOfShortTermInvestments", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for valuation loss (gains) of short-term investments to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Valuation Loss (Gains) of Short-term Investments", "terseLabel": "Valuation loss (gain) from short-term investments" } } }, "auth_ref": [] }, "shlt_AdjustmentsOfTaxesOfPriorPeriods": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "AdjustmentsOfTaxesOfPriorPeriods", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTaxesOnIncomeIncludedInStatementsOfComprehensiveIncomeDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTaxesOnIncomeIncludedInStatementsOfComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjustments of tax expense (income) recognised in the period for current tax and deferred tax of prior periods.", "label": "Adjustments of Taxes of Prior Periods", "terseLabel": "Taxes in respect of prior years" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) other than changes in working capital", "totalLabel": "Income and expenses not involving operating cash flows" } }, "en": { "role": { "documentation": "Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_AggregatedTimeBandsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedTimeBandsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Aggregated time bands [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r21", "r169", "r182", "r183", "r186", "r187", "r188", "r194", "r215", "r271", "r296", "r298" ] }, "shlt_AgreementWithBankInIsraelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "AgreementWithBankInIsraelMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement with bank in Israel", "label": "Agreement With Bank In Israel Member", "verboseLabel": "Agreement With Bank In Israel" } } }, "auth_ref": [] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AllLevelsOfFairValueHierarchyMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "label": "All levels of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r77", "r158" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "shlt_AmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "AmericanDepositarySharesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Represent the member information pertaining to American Depositary Shares.", "label": "American Depositary Shares Member", "terseLabel": "ADS" } } }, "auth_ref": [] }, "ifrs-full_AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmortisationAssetsRecognisedFromCostsIncurredToObtainOrFulfilContractsWithCustomers", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Amortisation, assets recognised from costs incurred to obtain or fulfil contracts with customers", "terseLabel": "Amortization of prepaid expenses" } }, "en": { "role": { "documentation": "The amount of amortisation for assets recognised from the costs incurred to obtain or fulfil contracts with customers. [Refer: Assets recognised from costs to obtain or fulfil contracts with customers; Amortisation expense]" } } }, "auth_ref": [ "r170" ] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization during the year", "label": "Amortisation, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r116" ] }, "shlt_AmortizationOfDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "AmortizationOfDevelopmentCostsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for amortization of development costs.", "label": "Amortization of Development Costs [Member]", "terseLabel": "Amortization of development costs" } } }, "auth_ref": [] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Amounts payable, related party transactions", "terseLabel": "Other accounts payables" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r88", "r92" ] }, "ifrs-full_AntidilutiveInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AntidilutiveInstrumentsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive instruments [member]" } }, "en": { "role": { "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used." } } }, "auth_ref": [ "r99" ] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails", "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Applicable tax rate", "terseLabel": "Corporate income tax rate", "verboseLabel": "Statutory tax rate in Israel" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r48" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r18", "r157", "r158", "r162", "r243", "r246" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r318", "r321" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r309", "r310", "r311" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r309", "r310", "r311" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r309", "r310", "r311" ] }, "ifrs-full_AverageEffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageEffectiveTaxRate", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails" ], "lang": { "en-us": { "role": { "label": "Average effective tax rate", "terseLabel": "Average tax rate" } }, "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } } }, "auth_ref": [ "r48" ] }, "ifrs-full_BalancesWithBanks": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BalancesWithBanks", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Balances with banks", "terseLabel": "Cash in banks (mainly in EUR)" } }, "en": { "role": { "documentation": "The amount of cash balances held at banks." } } }, "auth_ref": [ "r354" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic loss" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r95", "r96" ] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings", "totalLabel": "Long-term loan" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r323" ] }, "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsAdjustmentToInterestRateBasis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksDetails", "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, adjustment to interest rate basis" } }, "en": { "role": { "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r359" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r359" ] }, "ifrs-full_BorrowingsByNameMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [member]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r359" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r359" ] }, "ifrs-full_BorrowingsInterestRateBasis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsInterestRateBasis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksDetails", "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, interest rate basis" } }, "en": { "role": { "documentation": "The basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r359" ] }, "shlt_BorrowingsInterestRateBasisValue": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "BorrowingsInterestRateBasisValue", "presentation": [ "http://www.shl-telemedicine.com/role/CREDITFROMBANKSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Borrowings, interest rate basis, value", "label": "Borrowings, interest rate basis, value", "verboseLabel": "Prime rate" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "negatedLabel": "Loans from banks", "label": "Borrowings recognised as of acquisition date" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for borrowings assumed in a business combination. [Refer: Borrowings; Business combinations [member]]" } } }, "auth_ref": [ "r358" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesPrincipalAssumptionsUnderlyingDefinedBenefitPlanDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails", "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Bottom of range [member]", "terseLabel": "Minimum", "verboseLabel": "Minimum" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r166", "r188", "r204", "r284", "r285", "r359" ] }, "ifrs-full_BuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BuildingsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails" ], "lang": { "en-us": { "role": { "label": "Buildings [member]", "terseLabel": "Buildings", "verboseLabel": "Buildings" } }, "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r329" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "terseLabel": "Business Contact Person", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r310", "r311" ] }, "currency_CHF": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "CHF", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails" ], "lang": { "en-us": { "role": { "label": "Switzerland, Francs", "verboseLabel": "CHF" } } }, "auth_ref": [] }, "shlt_CallOptionFromNonControllingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CallOptionFromNonControllingInterestsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for call option from non-controlling interests.", "label": "Call Option From Non-Controlling Interests [Member]", "terseLabel": "Call option from non-controlling interests" } } }, "auth_ref": [] }, "shlt_CallOptionToNonControllingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CallOptionToNonControllingInterests", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Call Option To Non Controlling Interests", "documentation": "Represents the amount of call Option to non controlling interests.", "terseLabel": "Call option" } } }, "auth_ref": [] }, "shlt_CallOptionToNonControllingInterestsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CallOptionToNonControllingInterestsNet", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "shlt_NonCurrentAssetsOtherThanLongLivedAssets", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "The amount of non-current call option to non-controlling interests, net.", "label": "Call Option to Non-controlling Interests, Net", "terseLabel": "Call option to non-controlling interests, net" } } }, "auth_ref": [] }, "ifrs-full_CapitalisedDevelopmentExpenditureMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalisedDevelopmentExpenditureMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Development costs", "terseLabel": "Developments costs" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets arising from development expenditure capitalised before the start of commercial production or use. An intangible asset shall only be recognised if the entity can demonstrate all of the following: (a) the technical feasibility of completing the intangible asset so that it will be available for use or sale; (b) its intention to complete the intangible asset and use or sell it; (c) its ability to use or sell the intangible asset; (d) how the intangible asset will generate probable future economic benefits. Among other things, the entity can demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset; (e) the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and (f) its ability to measure reliably the expenditure attributable to the intangible asset during its development." } } }, "auth_ref": [ "r345" ] }, "shlt_CapitalizationOfDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CapitalizationOfDevelopmentCosts", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of capitalized development costs.", "negatedLabel": "Less - capitalization of development costs", "label": "Capitalization of Development Costs" } } }, "auth_ref": [] }, "shlt_CarryForwardTaxLossesNotRecognizedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CarryForwardTaxLossesNotRecognizedAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Carry Forward Tax Losses Not Recognized [Abstract]", "terseLabel": "Expiry dates for carry forward tax losses not recognized" } } }, "auth_ref": [] }, "shlt_CarryForwardTaxLossesToBeRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CarryForwardTaxLossesToBeRecognized", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of unused tax losses for which deferred tax asset can be carried forward in the statement of financial position.", "label": "Carry Forward Tax Losses to be Recognized", "totalLabel": "Carry forward tax losses not recognized" } } }, "auth_ref": [] }, "shlt_CarryForwardTaxLossesToBeRecognizedUnlimited": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CarryForwardTaxLossesToBeRecognizedUnlimited", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails": { "parentTag": "shlt_CarryForwardTaxLossesToBeRecognized", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of unused tax losses for which deferred tax asset can be carried forward for unlimited years in the statement of financial position.", "label": "Carry Forward Tax Losses to be Recognized, Unlimited", "terseLabel": "Unlimited" } } }, "auth_ref": [] }, "shlt_CarryForwardTaxLossesToBeRecognizedYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CarryForwardTaxLossesToBeRecognizedYearFive", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails": { "parentTag": "shlt_CarryForwardTaxLossesToBeRecognized", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of unused tax losses for which deferred tax asset is recognised in year five in the statement of financial position.", "label": "Carry Forward Tax Losses to be Recognized, Year Five", "terseLabel": "2026", "verboseLabel": "Fifth year" } } }, "auth_ref": [] }, "shlt_CarryForwardTaxLossesToBeRecognizedYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CarryForwardTaxLossesToBeRecognizedYearFour", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails": { "parentTag": "shlt_CarryForwardTaxLossesToBeRecognized", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of unused tax losses for which deferred tax asset is recognised in year four in the statement of financial position.", "label": "Carry Forward Tax Losses to be Recognized, Year Four", "verboseLabel": "2025", "terseLabel": "Fourth year" } } }, "auth_ref": [] }, "shlt_CarryForwardTaxLossesToBeRecognizedYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CarryForwardTaxLossesToBeRecognizedYearOne", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails": { "parentTag": "shlt_CarryForwardTaxLossesToBeRecognized", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of unused tax losses for which deferred tax asset is recognised in year one in the statement of financial position.", "label": "Carry Forward Tax Losses to be Recognized, Year One", "terseLabel": "2022", "verboseLabel": "First year" } } }, "auth_ref": [] }, "shlt_CarryForwardTaxLossesToBeRecognizedYearSixToFifteen": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CarryForwardTaxLossesToBeRecognizedYearSixToFifteen", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails": { "parentTag": "shlt_CarryForwardTaxLossesToBeRecognized", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails" ], "lang": { "en-us": { "role": { "label": "Carry Forward Tax Losses To Be Recognized, Year Six To Fifteen", "documentation": "The amount of unused tax losses for which deferred tax asset is recognized in year six to fifteen in the statement of financial position.", "terseLabel": "Sixth - Fifteen" } } }, "auth_ref": [] }, "shlt_CarryForwardTaxLossesToBeRecognizedYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CarryForwardTaxLossesToBeRecognizedYearThree", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails": { "parentTag": "shlt_CarryForwardTaxLossesToBeRecognized", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of unused tax losses for which deferred tax asset is recognised in year three in the statement of financial position.", "label": "Carry Forward Tax Losses to be Recognized, Year Three", "terseLabel": "2024", "verboseLabel": "Third year" } } }, "auth_ref": [] }, "shlt_CarryForwardTaxLossesToBeRecognizedYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CarryForwardTaxLossesToBeRecognizedYearTwo", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails": { "parentTag": "shlt_CarryForwardTaxLossesToBeRecognized", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeExpiryDatesForCarryForwardTaxLossesWhichAreNotRecognizedDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of unused tax losses for which deferred tax asset is recognised in year two in the statement of financial position.", "label": "Carry Forward Tax Losses to be Recognized, Year Two", "terseLabel": "2023", "verboseLabel": "Second year" } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r54", "r61", "r114", "r117", "r120", "r121", "r122", "r123", "r124", "r212", "r221", "r222" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r61", "r117", "r120", "r122", "r123", "r212", "r221", "r222" ] }, "shlt_CashAndCashEquivalentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CashAndCashEquivalentMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents", "label": "Cash and cash equivalent [member]", "terseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 0.0 }, "http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and cash equivalents at the end of the year", "periodStartLabel": "Cash and cash equivalents at the beginning of the year", "label": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r13", "r135", "r153" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments", "terseLabel": "Proceeds from short-term deposits" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } } }, "auth_ref": [ "r348" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash provided by (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } } }, "auth_ref": [ "r125", "r137" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash used in investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } } }, "auth_ref": [ "r125", "r137" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash provided by (used) in operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } } }, "auth_ref": [ "r125", "r137" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 60.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of subsidiaries", "negatedTotalLabel": "Net cash", "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities", "totalLabel": "Total", "verboseLabel": "Total" } }, "en": { "role": { "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r131" ] }, "ifrs-full_CashOutflowForLeases": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashOutflowForLeases", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Cash outflow for leases", "terseLabel": "Total cash outflow for leases" } }, "en": { "role": { "documentation": "The cash outflow for leases." } } }, "auth_ref": [ "r176" ] }, "shlt_CashPaidAndReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CashPaidAndReceived", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflows (inflows), classified as operating activities.", "label": "Cash Paid and Received", "totalLabel": "Cash paid and received" } } }, "auth_ref": [] }, "shlt_CashPaidAndReceivedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CashPaidAndReceivedAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Cash Paid and Received [Abstract]", "terseLabel": "Cash paid and received:" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r236" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r236" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r91" ] }, "ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ChangesInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLossAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Changes in net defined benefit liability (asset) resulting from expense (income) in profit or loss [abstract]", "terseLabel": "Expenses recognized in profit or loss" } } }, "auth_ref": [] }, "shlt_ChangesInOperatingAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Changes in Operating Assets and Liabilities [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails" ], "lang": { "en-us": { "role": { "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r101", "r102", "r165", "r179" ] }, "ifrs-full_ClassesOfAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfAssetsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails" ], "lang": { "en-us": { "role": { "label": "Assets [member]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r101", "r165", "r179" ] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r195", "r229", "r230", "r256", "r257" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsFairValueSensitivityDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r229", "r230", "r256", "r257" ] }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets and goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r344" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r118" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r62" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r29" ] }, "ifrs-full_ClassesOfShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalMember", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Share capital [member]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r29" ] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails" ], "lang": { "en-us": { "role": { "label": "Closing foreign exchange rate", "verboseLabel": "Exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r321" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]", "terseLabel": "Other comprehensive income (loss) to be reclassified to profit or loss in subsequent periods:", "verboseLabel": "Other comprehensive income (loss) to be reclassified to profit or loss in subsequent periods:" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive loss" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r2", "r33", "r141", "r143", "r150", "r281" ] }, "ifrs-full_ComprehensiveIncomeAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive income attributable to [abstract]", "terseLabel": "Comprehensive income (loss) attributable to:" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive income, attributable to non-controlling interests", "terseLabel": "Non-controlling interests" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]" } } }, "auth_ref": [ "r2", "r36" ] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive income, attributable to owners of parent", "terseLabel": "Equity holders of the Company" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r2", "r37" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails" ], "lang": { "en-us": { "role": { "label": "Computers and peripheral equipment", "verboseLabel": "Computers and peripheral equipment" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Computer software [member]", "verboseLabel": "Computer software" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r274" ] }, "shlt_ConsumerPriceIndexPoints": { "xbrltype": "decimalItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ConsumerPriceIndexPoints", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the CPI points.", "label": "Consumer Price Index Points", "verboseLabel": "CPI Points" } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "shlt_ContractsAndOthersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ContractsAndOthersMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Contracts and others", "label": "Contracts And Others Member", "verboseLabel": "Contracts and others" } } }, "auth_ref": [] }, "shlt_ContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ContractsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for contracts.", "label": "Contracts [Member]", "verboseLabel": "Contracts" } } }, "auth_ref": [] }, "ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from resulting from contributions to plan by employer", "terseLabel": "Contributions by employer" } }, "en": { "role": { "documentation": "The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]" } } }, "auth_ref": [ "r75" ] }, "ifrs-full_CorporateDebtInstrumentsHeld": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CorporateDebtInstrumentsHeld", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails": { "parentTag": "ifrs-full_DebtInstrumentsHeld", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Corporate debt instruments held", "terseLabel": "Corporate bonds" } }, "en": { "role": { "documentation": "The amount of debt instruments held by the entity that were issued by a corporate entity. [Refer: Debt instruments held]" } } }, "auth_ref": [ "r321" ] }, "shlt_CorporateResearchAndDevelopmentAndOtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CorporateResearchAndDevelopmentAndOtherExpenses", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of expenses for corporate, R&D and other expenses.", "label": "Corporate, Research and development and other expenses", "terseLabel": "Corporate, R&D and other expenses" } } }, "auth_ref": [] }, "shlt_CostOfDevicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CostOfDevicesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for cost of devices.", "label": "Cost Of Devices [Member]", "terseLabel": "Cost of devices" } } }, "auth_ref": [] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_GrossProfit", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Cost of sales", "terseLabel": "Cost of revenues", "verboseLabel": "Cost of revenues" } }, "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } } }, "auth_ref": [ "r0", "r44" ] }, "ifrs-full_CountryOfDomicileMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CountryOfDomicileMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails" ], "lang": { "en-us": { "role": { "label": "Country of domicile [member]", "terseLabel": "Companies in Israel" } }, "en": { "role": { "documentation": "This member stands for the country in which the entity is registered and where it has its legal address or registered office." } } }, "auth_ref": [ "r251", "r252" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "shlt_CreditFromBanksAndOthersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CreditFromBanksAndOthersMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Credit from banks and others", "label": "Credit from banks and others [member]", "terseLabel": "Credit from banks and others" } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Currency risk [member]", "terseLabel": "Foreign currency risk" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r189", "r190", "r191", "r192", "r237" ] }, "shlt_CurrentAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CurrentAccountsReceivable", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Current accounts receivable", "label": "Current accounts receivable", "terseLabel": "Accounts receivable" } } }, "auth_ref": [] }, "shlt_CurrentAccountsReceivableFromGovernmentAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CurrentAccountsReceivableFromGovernmentAuthorities", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "documentation": "Current accounts receivable from government authorities", "label": "Current accounts receivable from government authorities", "terseLabel": "Government authorities" } } }, "auth_ref": [] }, "ifrs-full_CurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAdvancesToSuppliers", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Current advances to suppliers", "terseLabel": "Advances to supplies" } }, "en": { "role": { "documentation": "The amount of current advances made to suppliers before goods or services are received." } } }, "auth_ref": [ "r321" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r22", "r147", "r281" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "auth_ref": [] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksDetails" ], "lang": { "en-us": { "role": { "label": "Current borrowings and current portion of non-current borrowings", "totalLabel": "Total credit from banks" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current contract liabilities", "terseLabel": "Deferred revenues" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r167" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentInterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentInterestReceivable", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Current interest receivable", "terseLabel": "Interest receivable" } }, "en": { "role": { "documentation": "The amount of current interest receivable. [Refer: Interest receivable]" } } }, "auth_ref": [ "r321" ] }, "ifrs-full_CurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentInvestments", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 10.0 }, "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails", "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current investments", "terseLabel": "Short-term investments", "totalLabel": "Short-term investments" } }, "en": { "role": { "documentation": "The amount of current investments." } } }, "auth_ref": [ "r323" ] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current lease liabilities", "terseLabel": "Current maturities of lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r172" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r23", "r148", "r281" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "shlt_CurrentLiabilityForUnderwriter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CurrentLiabilityForUnderwriter", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails": { "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Current liability for underwriter", "label": "Current liability for underwriter", "terseLabel": "Liability for underwriter" } } }, "auth_ref": [] }, "ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current loans received and current portion of non-current loans received", "terseLabel": "Credit from banks and others" } }, "en": { "role": { "documentation": "The amount of current loans received and the current portion of non-current loans received. [Refer: Loans received]" } } }, "auth_ref": [ "r321" ] }, "shlt_CurrentPayablesToGovernmentAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CurrentPayablesToGovernmentAuthorities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails": { "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Current payables to government authorities", "label": "Current payables to government authorities", "terseLabel": "Government authorities" } } }, "auth_ref": [] }, "ifrs-full_CurrentPortionOfLongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPortionOfLongtermBorrowings", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 0.0 }, "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksDetails": { "parentTag": "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksDetails", "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Current portion of non-current borrowings", "terseLabel": "Current maturities of long-term loans", "verboseLabel": "Less - current maturities" } }, "en": { "role": { "documentation": "The current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r321" ] }, "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Current service cost", "label": "Increase in net defined benefit liability (asset) resulting from current service cost", "verboseLabel": "Current service cost" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r69" ] }, "ifrs-full_CurrentTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTaxesOnIncomeIncludedInStatementsOfComprehensiveIncomeDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTaxesOnIncomeIncludedInStatementsOfComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Current tax expense (income)", "terseLabel": "Current taxes" } }, "en": { "role": { "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } } }, "auth_ref": [ "r266" ] }, "ifrs-full_CurrentTaxLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current tax liabilities, current", "terseLabel": "Income taxes payable" } }, "en": { "role": { "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]" } } }, "auth_ref": [ "r14" ] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current trade receivables", "terseLabel": "Trade receivables", "totalLabel": "Trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r261", "r263" ] }, "ifrs-full_CurrentValueAddedTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentValueAddedTaxPayables", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails": { "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Current value added tax payables", "terseLabel": "VAT to customers and suppliers" } }, "en": { "role": { "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]" } } }, "auth_ref": [ "r325" ] }, "shlt_CustomerRelationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "CustomerRelationsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Customer relations", "label": "Customer Relations Member", "verboseLabel": "Customer relations" } } }, "auth_ref": [] }, "ifrs-full_CustomerrelatedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CustomerrelatedIntangibleAssetsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Customer-related intangible assets [member]", "verboseLabel": "Customer relations" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing assets related to customers. Such assets may include customer lists, order or production backlog, customer contracts and related customer relationships as well as non-contractual customer relationships." } } }, "auth_ref": [ "r345" ] }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "DE", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails" ], "lang": { "en-us": { "role": { "label": "GERMANY", "terseLabel": "Germany" } } }, "auth_ref": [] }, "ifrs-full_DebtInstrumentsHeld": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DebtInstrumentsHeld", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails": { "parentTag": "ifrs-full_CurrentInvestments", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails", "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt instruments held", "totalLabel": "Short-term investments, Gross", "verboseLabel": "Short-term investments" } }, "en": { "role": { "documentation": "The amount of instruments representing indebtedness held by the entity." } } }, "auth_ref": [ "r323" ] }, "shlt_DecreaseThroughDisposalsRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DecreaseThroughDisposalsRightOfUseAssets", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease through disposals, right-of-use assets", "negatedLabel": "Disposals", "label": "Decrease through disposals, right-of-use assets" } } }, "auth_ref": [] }, "shlt_DeductibleTemporaryDifferencesAndCarryforwardTaxLossForWhichNoDeferredTaxAssetIsRecognised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DeductibleTemporaryDifferencesAndCarryforwardTaxLossForWhichNoDeferredTaxAssetIsRecognised", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeCarryForwardTaxLossesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of deductible temporary differences and carryforward losses for which no deferred tax asset is recognised in the statement of financial position.", "label": "Deductible Temporary Differences and carryforward Tax Loss For which No Deferred Tax Asset Is Recognised", "terseLabel": "Deferred tax assets relating to carry forward tax losses as described above, and deductible temporary differences, are not included" } } }, "auth_ref": [] }, "ifrs-full_DeferredIncomeIncludingContractLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredIncomeIncludingContractLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "DEFERRED REVENUES" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "shlt_NonCurrentAssetsOtherThanLongLivedAssets", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets", "terseLabel": "Deferred taxes", "verboseLabel": "Non-current assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r15", "r19", "r49" ] }, "ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxAssetsAndLiabilitiesAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets and liabilities [abstract]", "terseLabel": "Deferred taxes are reflected in the balance sheet" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTaxesOnIncomeIncludedInStatementsOfComprehensiveIncomeDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTaxesOnIncomeIncludedInStatementsOfComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax expense (income)", "terseLabel": "Deferred taxes" } }, "en": { "role": { "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r50" ] }, "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax expense (income) recognised in profit or loss", "verboseLabel": "Amount included in statement of comprehensive income" } }, "en": { "role": { "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]" } } }, "auth_ref": [ "r50" ] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-current liabilities", "label": "Deferred tax liabilities", "terseLabel": "Deferred taxes", "verboseLabel": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r15", "r19", "r49" ] }, "shlt_DeferredTaxLiabilitiesAssetsRecognizedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DeferredTaxLiabilitiesAssetsRecognizedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The amount recognized as of the acquisition date for deferred tax assets or liabilities acquired in a business combination.", "negatedLabel": "Deferred taxes", "label": "Deferred Tax Liabilities (Assets) Recognized As Of Acquisition Date" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginning", "label": "Deferred tax liability (asset)", "totalLabel": "Total", "verboseLabel": "Total" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r49" ] }, "ifrs-full_DepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationAndAmortisationExpense", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortisation expense", "terseLabel": "Depreciation and amortization" } }, "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } } }, "auth_ref": [ "r1", "r44", "r154", "r241", "r248", "r258" ] }, "shlt_DepreciationAndAmortizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DepreciationAndAmortizationMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for depreciation and amortization.", "label": "Depreciation And Amortization [Member]", "terseLabel": "Depreciation and amortization" } } }, "auth_ref": [] }, "ifrs-full_DepreciationRatePropertyPlantAndEquipment": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationRatePropertyPlantAndEquipment", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation rate, property, plant and equipment", "verboseLabel": "Annual rate (in percent)" } }, "en": { "role": { "documentation": "The depreciation rate used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r53" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, right-of-use assets", "terseLabel": "Depreciation and amortization" } }, "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } } }, "auth_ref": [ "r173" ] }, "ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DerivativeFinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Derivative financial liabilities, undiscounted cash flows", "verboseLabel": "Aggregate contractual undiscounted payments" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r226" ] }, "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for business combinations and goodwill [text block]", "terseLabel": "Business combinations and goodwill" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for business combinations and goodwill. [Refer: Business combinations [member]; Goodwill]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for earnings per share [text block]", "terseLabel": "Earnings per share" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for earnings per share." } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Employee benefit liabilities" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r322" ] }, "shlt_DescriptionOfAccountingPolicyForExchangeRatesAndLinkageBasisExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DescriptionOfAccountingPolicyForExchangeRatesAndLinkageBasisExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of accounting policies for exchange rates and linkage basis.", "label": "Description Of Accounting Policy For Exchange Rates And Linkage Basis Explanatory", "terseLabel": "Exchange rates and linkage basis" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForExpensesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for expenses [text block]", "terseLabel": "Advertising expenses" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for expenses." } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for fair value measurement [text block]", "terseLabel": "Fair value measurement" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of other accounting policies relevant to understanding of financial statements [text block]", "terseLabel": "Consolidated financial statements" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for financial instruments [text block]", "terseLabel": "Financial instruments" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for functional currency [text block]", "terseLabel": "Functional currency and presentation currency" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the currency of the primary economic environment in which the entity operates." } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for impairment of non-financial assets [text block]", "terseLabel": "Impairment of non-financial assets" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Taxes on income" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for intangible assets other than goodwill [text block]", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for interest income and expense [text block]", "terseLabel": "Interest income" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income and expense arising from interest." } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Leases" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for measuring inventories [text block]", "terseLabel": "Inventory" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r81" ] }, "shlt_DescriptionOfAccountingPolicyForPresentationOfComprehensiveIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DescriptionOfAccountingPolicyForPresentationOfComprehensiveIncomeExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of accounting policies for presentation of statement of comprehensive income.", "label": "Description Of Accounting Policy For Presentation Of Comprehensive Income Explanatory", "terseLabel": "Presentation of statement of comprehensive income" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "terseLabel": "Property and equipment" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for provisions [text block]", "terseLabel": "Provisions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for recognition of revenue [text block]", "terseLabel": "Revenue recognition" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based payment transactions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } } }, "auth_ref": [ "r322" ] }, "shlt_DescriptionOfAccountingPolicyForShortTermDepositsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DescriptionOfAccountingPolicyForShortTermDepositsPolicyTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for short-term deposits.", "label": "Description of Accounting Policy for Short-term Deposits [Policy Text Block]", "terseLabel": "Short-term deposits" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTreasurySharesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for treasury shares [text block]", "terseLabel": "Treasury shares" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash equivalents" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r136" ] }, "ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfDiscountRatesAppliedToCashFlowProjections", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate applied to cash flow projections", "terseLabel": "Pre-tax discount rate applied to cash flow projections" } }, "en": { "role": { "documentation": "The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]" } } }, "auth_ref": [ "r107", "r109" ] }, "ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate used in current estimate of value in use", "terseLabel": "Pre-tax discount rate" } }, "en": { "role": { "documentation": "The discount rate used in the current estimate of the present value of the future cash flows expected to be derived from an asset or cash-generating unit." } } }, "auth_ref": [ "r104" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureDisclosureOfNewStandardsInPeriodPriorToTheirAdoption" ], "lang": { "en-us": { "role": { "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]", "terseLabel": "DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION" } }, "en": { "role": { "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have." } } }, "auth_ref": [ "r138" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract", "lang": { "en-us": { "role": { "label": "DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility", "verboseLabel": "Expected volatility of the share price" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r206" ] }, "ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Growth rate used to extrapolate cash flow projections" } }, "en": { "role": { "documentation": "The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]" } } }, "auth_ref": [ "r106", "r108" ] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Expected average life of options" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r206" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk free interest rate", "verboseLabel": "Risk-free interest rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r206" ] }, "shlt_DevicesOnLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DevicesOnLoanMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails" ], "lang": { "en-us": { "role": { "documentation": "Devices on loan", "label": "Devices On Loan Member", "verboseLabel": "Telemedicine devices on loan to customers", "terseLabel": "Devices on loan" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted loss" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r95", "r96" ] }, "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Dilutive effect of share options on number of ordinary shares", "terseLabel": "Effect of dilution - share options" } }, "en": { "role": { "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options." } } }, "auth_ref": [ "r339" ] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatements" ], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS", "verboseLabel": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of additional information about leasing activities for lessee [text block]", "terseLabel": "Schedule of potential future undiscounted lease payments for periods covered by extension or termination options that were not included in measurement of lease liabilities" } }, "en": { "role": { "documentation": "The disclosure of additional information about leasing activities of a lessee." } } }, "auth_ref": [ "r180" ] }, "ifrs-full_DisclosureOfAdditionalInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAdditionalInformationExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of additional information [text block]", "terseLabel": "Schedule of additional information of segments" } }, "en": { "role": { "documentation": "The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]", "terseLabel": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to attribution of expenses by nature to analysis of expenses by function in the statement of profit or loss." } } }, "auth_ref": [ "r318", "r321" ] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "Basis of presentation of the financial statements" } }, "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalents" ], "lang": { "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "CASH AND CASH EQUIVALENTS" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfChangesInAccountingEstimatesAbstract", "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of changes in accounting policies, accounting estimates and errors [text block]", "terseLabel": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS", "verboseLabel": "ACCOUNTING POLICIES" } }, "en": { "role": { "documentation": "The entire disclosure for changes in accounting policies, accounting estimates and errors." } } }, "auth_ref": [ "r139" ] }, "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of changes in accounting policies [text block]", "terseLabel": "Changes in accounting policies" } }, "en": { "role": { "documentation": "The disclosure of changes made to accounting policies by the entity." } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of composition of share capital" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } } }, "auth_ref": [ "r29" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables", "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "EQUITY" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables", "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r29" ] }, "shlt_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Disclosure Of Commitments And Contingent Liabilities Abstract" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCommitmentsAndContingentLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [text block]", "terseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfCostOfSalesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCostOfSalesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of cost of sales [text block]", "terseLabel": "Schedule of cost of revenues" } }, "en": { "role": { "documentation": "The disclosure of the cost of sales. [Refer: Cost of sales]" } } }, "auth_ref": [ "r317" ] }, "shlt_DisclosureOfCreditFromBanksAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfCreditFromBanksAbstract", "lang": { "en-us": { "role": { "documentation": "Credit from banks", "label": "Disclosure Of Credit From Banks Abstract", "verboseLabel": "Disclosure of credit from banks [Abstract]" } } }, "auth_ref": [] }, "shlt_DisclosureOfCurrentBorrowingsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfCurrentBorrowingsTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanks" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of current borrowings", "label": "Disclosure of current borrowings [text block]", "terseLabel": "CREDIT FROM BANKS" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDeferredIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDeferredIncomeExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureDeferredRevenues" ], "lang": { "en-us": { "role": { "label": "Disclosure of deferred income [text block]", "terseLabel": "DEFERRED REVENUES" } }, "en": { "role": { "documentation": "The disclosure of deferred income. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfDeferredTaxesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDeferredTaxesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of deferred taxes [text block]", "terseLabel": "Schedule of composition and changes in deferred taxes, as presented in the consolidated balance sheet" } }, "en": { "role": { "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesPrincipalAssumptionsUnderlyingDefinedBenefitPlanDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [line items]", "terseLabel": "Principal assumptions underlying the defined benefit plan" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesPrincipalAssumptionsUnderlyingDefinedBenefitPlanDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r65" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]", "terseLabel": "Long-term loans" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r359" ] }, "shlt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about cash and cash equivalents", "label": "Disclosure of detailed information about cash and cash equivalents [text block]", "terseLabel": "Schedule of cash and cash equivalents" } } }, "auth_ref": [] }, "shlt_DisclosureOfDetailedInformationAboutCurrentBorrowingsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfDetailedInformationAboutCurrentBorrowingsTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about current borrowings", "label": "Disclosure of detailed information about current borrowings [text block]", "terseLabel": "Schedule of credit from banks" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r217", "r223", "r231" ] }, "shlt_DisclosureOfDetailedInformationAboutNonCurrentBorrowingsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfDetailedInformationAboutNonCurrentBorrowingsTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about non-current borrowings", "label": "Disclosure of detailed information about non-current borrowings [text block]", "terseLabel": "Schedule of long-term loans" } } }, "auth_ref": [] }, "shlt_DisclosureOfDetailedInformationAboutOtherAccountsReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfDetailedInformationAboutOtherAccountsReceivableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about other accounts receivable", "label": "Disclosure of detailed information about other accounts receivable [text block]", "terseLabel": "Schedule of other accounts receivable" } } }, "auth_ref": [] }, "shlt_DisclosureOfDetailedInformationAboutOtherPayablesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfDetailedInformationAboutOtherPayablesTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about other payables", "label": "Disclosure of detailed information about other payables [text block]", "terseLabel": "Schedule of other payables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of property, plant and equipment" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r62" ] }, "shlt_DisclosureOfDetailedInformationAboutShortTermInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfDetailedInformationAboutShortTermInvestmentsTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about short-term investments", "label": "Disclosure of detailed information about short-term investments [text block]", "terseLabel": "Schedule of cash and cash equivalents" } } }, "auth_ref": [] }, "shlt_DisclosureOfDetailedInformationAboutTradeReceivablesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfDetailedInformationAboutTradeReceivablesTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about trade receivables", "label": "Disclosure of detailed information about trade receivables [text block]", "terseLabel": "Schedule of trade receivables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "NET EARNINGS PER SHARE" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r100" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "terseLabel": "EMPLOYEE BENEFIT LIABILITIES" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r80" ] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformation" ], "lang": { "en-us": { "role": { "label": "Disclosure of entity's operating segments [text block]", "terseLabel": "SEGMENT INFORMATION" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r255" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "SUBSEQUENT EVENTS" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r45" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of liabilities [text block]", "terseLabel": "Schedule of reconciliation of fair value measurements that are categorized within Level 3 of fair value hierarchy" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of liabilities." } } }, "auth_ref": [ "r165" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of liabilities [line items]", "terseLabel": "Financial instruments" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of liabilities." } } }, "auth_ref": [ "r165" ] }, "ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueOfPlanAssetsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of plan assets [text block]", "terseLabel": "Schedule of disaggregation of the fair value of the plan assets" } }, "en": { "role": { "documentation": "The disclosure of the fair value of defined benefit plan assets. [Refer: Plan assets [member]; Defined benefit plans [member]]" } } }, "auth_ref": [ "r77" ] }, "ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueOfPlanAssetsLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesDisaggregationOfFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of plan assets [line items]", "terseLabel": "Disaggregation of the fair value of the plan assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfPlanAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueOfPlanAssetsTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesDisaggregationOfFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of plan assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the fair value of defined benefit plan assets." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_DisclosureOfFinanceCostExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinanceCostExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of finance cost [text block]", "terseLabel": "Schedule of financial expenses" } }, "en": { "role": { "documentation": "The disclosure of finance cost. [Refer: Finance costs]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfFinanceIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinanceIncomeExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of finance income [text block]", "terseLabel": "Schedule of financial income" } }, "en": { "role": { "documentation": "The disclosure of finance income. [Refer: Finance income]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial instruments [text block]", "terseLabel": "FINANCIAL INSTRUMENTS" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r238" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Financial instruments" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r217", "r223", "r231" ] }, "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of general and administrative expense [text block]", "terseLabel": "Schedule of general and administrative expenses" } }, "en": { "role": { "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]" } } }, "auth_ref": [ "r317" ] }, "shlt_DisclosureOfGeneralInformationAboutFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Disclosure Of General Information About Financial Statements Abstract" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGeneral" ], "lang": { "en-us": { "role": { "label": "Disclosure of general information about financial statements [text block]", "terseLabel": "GENERAL" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r9" ] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [text block]", "terseLabel": "Schedule of revenue from geographic segments" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r253" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncome" ], "lang": { "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "TAXES ON INCOME" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r52" ] }, "ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInformationAboutDefinedBenefitPlansAbstract", "lang": { "en-us": { "role": { "label": "EMPLOYEE BENEFIT LIABILITIES" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectors" ], "lang": { "en-us": { "role": { "label": "Disclosure of information about key management personnel [text block]", "terseLabel": "COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS)" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of information for cash-generating units [text block]", "terseLabel": "Schedule of information for cash-generating units" } }, "en": { "role": { "documentation": "The disclosure of information for cash-generating units. [Refer: Cash-generating units [member]]" } } }, "auth_ref": [ "r110" ] }, "ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of information for cash-generating units [line items]", "terseLabel": "Cash-generating units" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of information for cash-generating units [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to cash-generating units." } } }, "auth_ref": [ "r110" ] }, "shlt_DisclosureOfInformationOnLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfInformationOnLeasesTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information on leases", "label": "Disclosure of information on leases [text block]", "terseLabel": "Schedule of information on leases" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNet" ], "lang": { "en-us": { "role": { "label": "Disclosure of intangible assets and goodwill [text block]", "terseLabel": "GOODWILL AND INTANGIBLE ASSETS, NET" } }, "en": { "role": { "documentation": "The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "terseLabel": "Goodwill and intangible assets, net", "verboseLabel": "Useful life of intangible assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r118" ] }, "ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestments" ], "lang": { "en-us": { "role": { "label": "Disclosure of investments other than investments accounted for using equity method [text block]", "terseLabel": "SHORT-TERM INVESTMENTS" } }, "en": { "role": { "documentation": "The disclosure of investments other than investments accounted for using the equity method. [Refer: Investments other than investments accounted for using equity method]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIssuedCapitalExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of issued capital [text block]", "terseLabel": "Schedule of issued and outstanding share capital" } }, "en": { "role": { "documentation": "The disclosure of issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Disclosure of leases [text block]", "terseLabel": "LEASES" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r184", "r185" ] }, "shlt_DisclosureOfMaturityAnalysisForFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfMaturityAnalysisForFinancialLiabilitiesLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of maturity analysis for financial liabilities", "label": "Disclosure of maturity analysis for financial liabilities [Line Items]", "terseLabel": "Financial instruments" } } }, "auth_ref": [] }, "shlt_DisclosureOfMaturityAnalysisForFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfMaturityAnalysisForFinancialLiabilitiesTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis for financial liabilities.", "label": "Disclosure of maturity analysis for financial liabilities [table]" } } }, "auth_ref": [] }, "shlt_DisclosureOfMaturityAnalysisForFinancialLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfMaturityAnalysisForFinancialLiabilitiesTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of maturity analysis for financial liabilities", "label": "Disclosure of maturity analysis for financial liabilities [text block]", "terseLabel": "Schedule of maturity profile of financial liabilities based on contractual undiscounted payments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]", "terseLabel": "Financial instruments" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments." } } }, "auth_ref": [ "r218", "r219" ] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of net defined benefit liability (asset) [text block]", "terseLabel": "Schedule of changes in the defined benefit obligation and fair value of plan assets" } }, "en": { "role": { "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r68" ] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of net defined benefit liability (asset) [line items]", "terseLabel": "Changes in the defined benefit obligation and fair value of plan assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of net defined benefit liability (asset) [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the net defined benefit liability (asset)." } } }, "auth_ref": [ "r68" ] }, "shlt_DisclosureOfNonCurrentBorrowingsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfNonCurrentBorrowingsTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoans" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of non-current borrowings", "label": "Disclosure of non-current borrowings [text block]", "terseLabel": "LONG-TERM LOANS" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Schedule of number and weighted average exercise prices (\"WAEP\") of, and movements in, share options" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r202" ] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "SEGMENT INFORMATION" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOperatingSegmentsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [text block]", "terseLabel": "Schedule of disaggregated revenue information" } }, "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } } }, "auth_ref": [ "r243" ] }, "ifrs-full_DisclosureOfOperatingSegmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOperatingSegmentsLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [line items]", "terseLabel": "SEGMENT INFORMATION" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOperatingSegmentsTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [table]", "terseLabel": "Disclosure of operating segments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } } }, "auth_ref": [ "r243" ] }, "shlt_DisclosureOfOtherAccountsReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfOtherAccountsReceivableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivable" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of other accounts receivable", "label": "Disclosure of other accounts receivable [text block]", "terseLabel": "OTHER ACCOUNTS RECEIVABLE" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other operating income (expense) [text block]", "terseLabel": "Schedule of other expenses" } }, "en": { "role": { "documentation": "The disclosure of other operating income or expense. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r317" ] }, "shlt_DisclosureOfOtherPayablesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfOtherPayablesTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherPayables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of other payables", "label": "Disclosure of other payables [text block]", "terseLabel": "OTHER PAYABLES" } } }, "auth_ref": [] }, "shlt_DisclosureOfPrepaidExpensesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfPrepaidExpensesTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePrepaidExpenses" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of prepaid expenses", "label": "Disclosure of prepaid expenses [text block]", "terseLabel": "PREPAID EXPENSES" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "PROPERTY AND EQUIPMENT" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r64" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "terseLabel": "Property and equipment", "verboseLabel": "Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r62" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [text block]", "terseLabel": "Schedule of information about right-of-use assets" } }, "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r179" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [line items]", "terseLabel": "Leases" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } } }, "auth_ref": [ "r179" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]", "terseLabel": "Schedule of changes in intangible assets and goodwill" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r344" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]", "terseLabel": "Schedule of changes in liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r279" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]", "terseLabel": "Financial instruments" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } } }, "auth_ref": [ "r279" ] }, "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of research and development expense [text block]", "terseLabel": "Schedule of research and development costs" } }, "en": { "role": { "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRevenueExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of revenue [text block]", "terseLabel": "Schedule of revenue" } }, "en": { "role": { "documentation": "The entire disclosure for revenue." } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSegmentsMajorCustomersExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of major customers [text block]", "terseLabel": "Schedule of revenues from major customers" } }, "en": { "role": { "documentation": "The disclosure of major customers." } } }, "auth_ref": [ "r254" ] }, "shlt_DisclosureOfSellingAndMarketingExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfSellingAndMarketingExpenseTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of selling and marketing expense.", "label": "Disclosure Of Selling and Marketing Expense [Table Text Block]", "terseLabel": "Schedule of selling and marketing expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]", "terseLabel": "Schedule of reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions are constant" } }, "en": { "role": { "documentation": "The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]" } } }, "auth_ref": [ "r79" ] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [line items]", "terseLabel": "Reasonably possible changes at the end of the reporting period in each actuarial assumption assuming that all other actuarial assumptions" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the sensitivity analysis for actuarial assumptions." } } }, "auth_ref": [ "r79" ] }, "ifrs-full_DisclosureOfSensitivityAnalysisOfFairValueMeasurementToChangesInUnobservableInputsAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisOfFairValueMeasurementToChangesInUnobservableInputsAssetsTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsFairValueSensitivityDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the sensitivity analysis of fair value measurement of assets to changes in unobservable inputs." } } }, "auth_ref": [ "r164" ] }, "ifrs-full_DisclosureOfSensitivityAnalysisOfFairValueMeasurementToChangesInUnobservableInputsLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisOfFairValueMeasurementToChangesInUnobservableInputsLiabilitiesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [text block]", "terseLabel": "Schedule of sensitivity analysis of reasonably possible change in underlying asset value" } }, "en": { "role": { "documentation": "The disclosure of the sensitivity analysis of the fair value measurement of liabilities to changes in unobservable inputs." } } }, "auth_ref": [ "r164" ] }, "ifrs-full_DisclosureOfSensitivityAnalysisOfFairValueMeasurementToChangesInUnobservableInputsLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisOfFairValueMeasurementToChangesInUnobservableInputsLiabilitiesLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsFairValueSensitivityDetails", "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSDisclosureOfProfitBeforeTaxDueToChangesInCarryingAmountOfMarketableSecurities" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]", "terseLabel": "Financial instruments" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSensitivityAnalysisOfFairValueMeasurementToChangesInUnobservableInputsLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisOfFairValueMeasurementToChangesInUnobservableInputsLiabilitiesTable", "presentation": [ "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSDisclosureOfProfitBeforeTaxDueToChangesInCarryingAmountOfMarketableSecurities" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the sensitivity analysis of the fair value measurement of liabilities to changes in unobservable inputs." } } }, "auth_ref": [ "r164" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquity" ], "lang": { "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "EQUITY" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r30" ] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]", "terseLabel": "Schedule of significant inputs to model used to determine fair value" } }, "en": { "role": { "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities." } } }, "auth_ref": [ "r159" ] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]", "terseLabel": "Financial instruments" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to significant unobservable inputs used in the fair value measurement of liabilities." } } }, "auth_ref": [ "r159" ] }, "shlt_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Disclosure Of Summary Of Significant Accounting Policies Abstract", "terseLabel": "ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "terseLabel": "Deferred tax assets (liabilities):" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r51" ] }, "shlt_DisclosureOfTradeReceivablesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "DisclosureOfTradeReceivablesTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTradeReceivables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of trade receivables", "label": "Disclosure of trade receivables [text block]", "terseLabel": "TRADE RECEIVABLES" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS)" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "terseLabel": "Schedule of compensation of key management personnel (including directors)" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r89" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]", "terseLabel": "COMPENSATION OF KEY MANAGEMENT PERSONNEL (INCLUDING DIRECTORS)" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r91" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Disposals during the year", "label": "Disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r56" ] }, "ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 70.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividend paid to non-controlling interests", "label": "Dividends paid to non-controlling interests, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for dividends paid to non-controlling interests, classified as financing activities. [Refer: Non-controlling interests; Dividends paid to non-controlling interests]" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DividendsRecognisedAsDistributionsToNoncontrollingInterests", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividend paid to non-controlling interests", "label": "Dividends recognised as distributions to non-controlling interests" } }, "en": { "role": { "documentation": "The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]" } } }, "auth_ref": [ "r319" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r310" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r309", "r310", "r311" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r309", "r310", "r311", "r313" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document Information", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r305" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r310" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r312" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "EUR", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails" ], "lang": { "en-us": { "role": { "label": "EUR", "terseLabel": "EUR", "verboseLabel": "\u20ac" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "NET EARNINGS PER SHARE", "terseLabel": "Earnings per share:" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of details of the number of shares and net profit (loss) used in the computation of net earnings per share" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r95" ] }, "ifrs-full_EarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Earnings per share [line items]", "terseLabel": "NET EARNINGS PER SHARE" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Earnings per share [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to earnings per share." } } }, "auth_ref": [ "r95" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r127", "r128" ] }, "shlt_EmployeeBenefitLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "EmployeeBenefitLiabilitiesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for employee benefit liabilities.", "label": "Employee Benefit Liabilities [Member]", "terseLabel": "Employee benefit liabilities" } } }, "auth_ref": [] }, "shlt_EmployeeBenefitLiabilitiesRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "EmployeeBenefitLiabilitiesRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Employee benefit liabilities recognised as of acquisition date", "negatedLabel": "Employee benefit liabilities", "label": "Employee benefit liabilities recognised as of acquisition date", "terseLabel": "Employee benefit liabilities" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r307" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r307" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r316" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r307" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r314" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r307" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r307" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r315" ] }, "ifrs-full_EntitysTotalForCashgeneratingUnitsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForCashgeneratingUnitsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for cash-generating units [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Cash-generating units' axis if no other member is used." } } }, "auth_ref": [ "r110", "r112" ] }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForRelatedPartiesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for related parties [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r91" ] }, "ifrs-full_EntitysTotalForSegmentConsolidationItemsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForSegmentConsolidationItemsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for segment consolidation items [member]", "terseLabel": "Entity's total for segment consolidation items [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Segment consolidation items' axis if no other member is used." } } }, "auth_ref": [ "r249" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance as of ending", "periodStartLabel": "Balance as of beginning", "label": "Equity", "totalLabel": "Total equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r18", "r25", "r140", "r142", "r157", "r158", "r162" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "EQUITY:" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and equity" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r18" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "auth_ref": [] }, "ifrs-full_EquityAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity attributable to owners of parent", "totalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } } }, "auth_ref": [ "r17" ] }, "shlt_EquityAttributableToOwnersOfParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "EquityAttributableToOwnersOfParentAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Equity Attributable To Owners Of Parent [Abstract]", "terseLabel": "Attributable to equity holders of the Company:" } } }, "auth_ref": [] }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAttributableToOwnersOfParentMember", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Equity attributable to owners of parent [member]", "terseLabel": "Equity attributable to owners of parent" } }, "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } } }, "auth_ref": [ "r6" ] }, "shlt_EquityComponentOfTransactionsWithNonControllingInterestAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "EquityComponentOfTransactionsWithNonControllingInterestAmount", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]", "negatedLabel": "Equity component of transaction with non-controlling interest", "label": "Equity component of transactions with non-controlling interest, Amount" } } }, "auth_ref": [] }, "ifrs-full_EquityInstrumentsHeld": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityInstrumentsHeld", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails": { "parentTag": "ifrs-full_DebtInstrumentsHeld", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Equity instruments held", "terseLabel": "Shares" } }, "en": { "role": { "documentation": "The amount of instruments held by the entity that provide evidence of a residual interest in the assets of another entity after deducting all of its liabilities." } } }, "auth_ref": [ "r323" ] }, "ifrs-full_EquityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityMember", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Equity [member]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_EquityPriceRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityPriceRiskMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Equity price risk [member]", "terseLabel": "Market risk" } }, "en": { "role": { "documentation": "This member stands for a component of other price risk that represents the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in equity prices. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r295", "r300" ] }, "shlt_EstimatedLiabilityForFutureCashPaymentToUnderwriterUponExerciseOfOptionsByInvestors": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "EstimatedLiabilityForFutureCashPaymentToUnderwriterUponExerciseOfOptionsByInvestors", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for estimated liability for future cash payment to underwriter upon exercise of options by investors.", "label": "Estimated Liability For Future Cash Payment To Underwriter Upon Exercise Of Options By Investors", "terseLabel": "Estimated liability for future cash payment to underwriter upon exercise of options by investors" } } }, "auth_ref": [] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails", "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeCarryForwardTaxLossesDetails" ], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "auth_ref": [] }, "shlt_ExchangeRateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExchangeRateLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Exchange Rate [Line Items]", "terseLabel": "Exchange rates and linkage basis" } } }, "auth_ref": [] }, "shlt_ExchangeRatePercentageOfChange": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExchangeRatePercentageOfChange", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of change during the period.", "label": "Exchange Rate, Percentage of Change", "verboseLabel": "Change" } } }, "auth_ref": [] }, "shlt_ExchangeRateTable": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExchangeRateTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to exchange rates.", "label": "Exchange Rate [Table]" } } }, "auth_ref": [] }, "shlt_ExchangeTradedFundsHeld": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExchangeTradedFundsHeld", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails": { "parentTag": "ifrs-full_DebtInstrumentsHeld", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Exchange Traded Funds held", "label": "Exchange Traded Funds held", "terseLabel": "Exchange Traded Funds" } } }, "auth_ref": [] }, "shlt_ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2015Member", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for 2015 Executive and Key Employee Israeli Share Option Plan.", "label": "Executive and Key Employee Israeli Share Option Plan 2015 [Member]", "terseLabel": "2015 Executive and Key Employee Israeli Share Option Plan" } } }, "auth_ref": [] }, "shlt_ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExecutiveAndKeyEmployeeIsraeliShareOptionPlan2021Member", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Executive And Key Employee Israeli Share Option Plan 2021 [Member]", "documentation": "This member stands for 2021 executive and key employee israeli share option plan.", "verboseLabel": "2021 Executive and Key Employee Israeli Share Option Plan" } } }, "auth_ref": [] }, "shlt_ExerciseOfEmployeesShareOptions": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExerciseOfEmployeesShareOptions", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityIssuedAndOutstandingShareCapitalNetOfTreasurySharesDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of employees share options exercised.", "label": "Exercise of Employees Share Options", "terseLabel": "Exercise of employees share options" } } }, "auth_ref": [] }, "shlt_ExerciseOfShareOptionsIntoSharesFairValueMeasurementLabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExerciseOfShareOptionsIntoSharesFairValueMeasurementLabilities", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "documentation": "The increase in fair value measurement of liabilities resulting from exercise of share options into shares.", "label": "Exercise of Share Options into Shares, Fair Value Measurement, Labilities", "terseLabel": "Exercise of Share Options into shares" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price, share options granted", "terseLabel": "Exercise price", "verboseLabel": "Share price" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r206" ] }, "shlt_ExpectedAverageLifeOfOptionsMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExpectedAverageLifeOfOptionsMeasurementInputMember", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for average life of options used as a measurement input.", "label": "Expected Average Life of Options, Measurement Input [Member]", "terseLabel": "Expected average life of options" } } }, "auth_ref": [] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Expected dividend as percentage, share options granted", "terseLabel": "Expected dividend (In percentage)", "verboseLabel": "Expected dividend" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r206" ] }, "shlt_ExpectedDividendMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExpectedDividendMeasurementInputMember", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for expected dividend used as a measurement input.", "label": "Expected Dividend, Measurement Input [Member]", "terseLabel": "Expected dividend" } } }, "auth_ref": [] }, "shlt_ExpectedVolatilityOfSharePriceMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExpectedVolatilityOfSharePriceMeasurementInputMember", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Expected volatility of share price, measurement input", "label": "Expected Volatility Of Share Price Measurement Input Member", "terseLabel": "Expected volatility of the share price" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesImpairmentOfNonFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Expense from equity-settled share-based payment transactions", "terseLabel": "Expense recognized" } }, "en": { "role": { "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]" } } }, "auth_ref": [ "r208" ] }, "shlt_ExpenseFromShareOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ExpenseFromShareOptions", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of expense from share options.", "negatedLabel": "Share options", "label": "Expense from Share Options" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions", "terseLabel": "Share-based compensation" } }, "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } } }, "auth_ref": [ "r208" ] }, "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Expense relating to short-term leases for which recognition exemption has been used", "terseLabel": "Expenses relating to short-term leases" } }, "en": { "role": { "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease." } } }, "auth_ref": [ "r175" ] }, "shlt_FairValueOfLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FairValueOfLiabilities", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of fair value of liabilities.", "label": "Fair Value of Liabilities" } } }, "auth_ref": [] }, "shlt_FairValueOfOptionsToAcquireUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FairValueOfOptionsToAcquireUnits", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of fair value of options to acquire Units.", "label": "Fair Value of Options to Acquire Units", "terseLabel": "Fair value of the options to acquire Units" } } }, "auth_ref": [] }, "shlt_FairValueOfSignificantInputOfExpectedVolatilityOfDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FairValueOfSignificantInputOfExpectedVolatilityOfDiscountRate", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Of Significant Input Of Expected Volatility Of Discount Rate", "documentation": "It represents fair value of significant input of expected volatility of discount rate.", "verboseLabel": "Discount rate" } } }, "auth_ref": [] }, "shlt_FairValueOfSignificantInputOfExpectedVolatilityOfRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FairValueOfSignificantInputOfExpectedVolatilityOfRiskFreeInterestRate", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Of Significant Input Of Expected Volatility Of Risk Free Interest Rate", "documentation": "It represents fair value of significant input of expected volatility of risk free interest rate.", "verboseLabel": "Risk-free interest rate" } } }, "auth_ref": [] }, "shlt_FairValueOfSignificantInputOfExpectedVolatilityOfSharePrice": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FairValueOfSignificantInputOfExpectedVolatilityOfSharePrice", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Of Significant Input Of Expected Volatility Of Share Price", "documentation": "It represents fair value of significant input of expected volatility of share price.", "verboseLabel": "Expected volatility of the share price" } } }, "auth_ref": [] }, "shlt_FairValueOfSignificantInputOfExpectedVolatilityOfTermOfOption": { "xbrltype": "durationItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FairValueOfSignificantInputOfExpectedVolatilityOfTermOfOption", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Of Significant Input Of Expected Volatility Of Term Of Option", "documentation": "It represents fair value of significant input of expected volatility of term of option.", "verboseLabel": "Term of option" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialExpensesDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedLabel": "Financial expenses", "negatedTotalLabel": "Financial expenses", "label": "Finance costs" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r39" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialIncomeDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Finance income", "terseLabel": "Financial income", "totalLabel": "Financial income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r327" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance income (cost)", "verboseLabel": "Financial income (expenses), net", "terseLabel": "Financial income, net" } }, "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r327" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets", "terseLabel": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } } }, "auth_ref": [ "r216", "r221", "r222", "r225", "r294" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets at amortized cost", "verboseLabel": "Financial assets at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r234" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets at fair value through profit or loss, category [member]", "terseLabel": "Financial assets at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r232" ] }, "ifrs-full_FinancialAssetsCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsCategoryMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r236" ] }, "ifrs-full_FinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r195", "r229", "r230", "r256", "r257" ] }, "shlt_FinancialExpensesCallAndPutOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FinancialExpensesCallAndPutOptions", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of financial expenses arising from share options liability.", "negatedLabel": "Call+Put options", "label": "Financial Expenses Call And Put Options" } } }, "auth_ref": [] }, "shlt_FinancialIncomeCallAndPutOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FinancialIncomeCallAndPutOptions", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income associated with interest and other financing activities related to call and put options of the entity.", "label": "Financial Income, Call and Put Options", "terseLabel": "Call+Put options" } } }, "auth_ref": [] }, "shlt_FinancialIncomeShareOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FinancialIncomeShareOptions", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income associated with interest and other financing activities related to share options of the entity.", "label": "Financial Income, Share Options", "terseLabel": "Share options" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities", "terseLabel": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r216" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortized cost", "verboseLabel": "Financial liabilities at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r235" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at fair value through profit or loss, category [member]", "terseLabel": "Financial liabilities at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r233" ] }, "ifrs-full_FinancialLiabilitiesCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesCategoryMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r236" ] }, "ifrs-full_FinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsFairValueSensitivityDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r229", "r230", "r256", "r257" ] }, "shlt_FinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Financial liabilities, undiscounted cash flows", "label": "Financial liabilities, undiscounted cash flows", "terseLabel": "Financial liabilities, undiscounted cash flows" } } }, "auth_ref": [] }, "shlt_FiveYearForecastPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FiveYearForecastPeriodMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for 5 year forecast period subsequent to the end of the reporting period.", "label": "Five Year Forecast Period [Member]", "terseLabel": "5 year forecast" } } }, "auth_ref": [] }, "shlt_FixedAndIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FixedAndIntangibleAssetsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for fixed assets and intangible assets.", "label": "Fixed and Intangible Assets [Member]", "terseLabel": "Fixed and intangible assets" } } }, "auth_ref": [] }, "ifrs-full_ForeignCountriesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForeignCountriesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails" ], "lang": { "en-us": { "role": { "label": "Foreign countries [member]", "terseLabel": "Foreign subsidiaries" } }, "en": { "role": { "documentation": "This member stands for countries outside the entity's country of domicile. [Refer: Country of domicile [member]]" } } }, "auth_ref": [ "r251", "r252" ] }, "ifrs-full_ForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForeignExchangeGain", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gain", "terseLabel": "Exchange rate differences" } }, "en": { "role": { "documentation": "The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r8", "r83" ] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialExpensesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exchange rate differences", "label": "Foreign exchange loss" } }, "en": { "role": { "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r8", "r83" ] }, "shlt_FuturePaymentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "FuturePaymentLiability", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of future payment liability.", "label": "Future Payment Liability" } } }, "auth_ref": [] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income", "terseLabel": "Total effect on other comprehensive income for the Period" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r72" ] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Changes in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income [abstract]", "terseLabel": "Gain (loss) from remeasurement in other comprehensive income" } } }, "auth_ref": [] }, "shlt_GainOnMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "GainOnMarketableSecurities", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of gain on marketable securities.", "label": "Gain on Marketable Securities", "terseLabel": "Gain on marketable securities, net" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementLiabilities", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, liabilities", "terseLabel": "Other comprehensive income (loss)" } }, "en": { "role": { "documentation": "The gains (losses) including exchange differences recognised in other comprehensive income on the fair value measurement of liabilities. [Refer: At fair value [member]; Other comprehensive income]" } } }, "auth_ref": [ "r161" ] }, "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities", "terseLabel": "Profit (loss)" } }, "en": { "role": { "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r160" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "General and administrative expense", "terseLabel": "General and administrative expenses", "verboseLabel": "General and administrative expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } } }, "auth_ref": [ "r321" ] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails", "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]", "terseLabel": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r253", "r269", "r286", "r289" ] }, "ifrs-full_GeographicalAreasMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails", "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [member]", "terseLabel": "Geographical areas [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r253", "r269", "r286", "r289" ] }, "ifrs-full_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "GOODWILL" } }, "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r11", "r105", "r111", "r212" ] }, "ifrs-full_GoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GoodwillMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill [member]", "terseLabel": "Goodwill" } }, "en": { "role": { "documentation": "This member stands for goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r273" ] }, "ifrs-full_GovernmentDebtInstrumentsHeld": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GovernmentDebtInstrumentsHeld", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails": { "parentTag": "ifrs-full_DebtInstrumentsHeld", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Government debt instruments held", "terseLabel": "Government bonds and loans" } }, "en": { "role": { "documentation": "The amount of debt instruments held by the entity that were issued by a government. [Refer: Debt instruments held; Government [member]]" } } }, "auth_ref": [ "r321" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Gross carrying amount", "terseLabel": "Cost" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r54", "r114", "r121", "r124", "r212", "r222", "r225", "r294" ] }, "ifrs-full_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Gross profit", "totalLabel": "Gross profit" } }, "en": { "role": { "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]" } } }, "auth_ref": [ "r259" ] }, "country_IL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "IL", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails", "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeCarryForwardTaxLossesDetails" ], "lang": { "en-us": { "role": { "label": "ISRAEL", "terseLabel": "Israel" } } }, "auth_ref": [] }, "currency_ILS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "ILS", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails" ], "lang": { "en-us": { "role": { "label": "Israel, New Shekels", "verboseLabel": "Israeli" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r309", "r310", "r311" ] }, "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Identifiable intangible assets recognised as of acquisition date", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]" } } }, "auth_ref": [ "r291", "r292" ] }, "shlt_IfrsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeCarryForwardTaxLossesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "IFRS Operating Loss Carryforwards", "terseLabel": "Carry forward losses for tax purposes" } } }, "auth_ref": [] }, "shlt_IfrsOverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsOverAllotmentOptionMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "IFRS Over-Allotment Option [Member]", "terseLabel": "Underwriters" } } }, "auth_ref": [] }, "shlt_IfrsPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsPlanNameAxis", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "IFRS Plan Name [Axis]" } } }, "auth_ref": [] }, "shlt_IfrsPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsPlanNameDomain", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "IFRS Plan Name [Domain]" } } }, "auth_ref": [] }, "shlt_IfrsRestrictedStockUnitsRsusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsRestrictedStockUnitsRsusMember", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "IFRS Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted share units (\"RSU\")" } } }, "auth_ref": [] }, "shlt_IfrsSaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsSaleOfStockAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock", "label": "IFRS Sale of Stock [Axis]" } } }, "auth_ref": [] }, "shlt_IfrsSaleOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsSaleOfStockDomain", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "IFRS Sale of Stock [Domain]" } } }, "auth_ref": [] }, "shlt_IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense.", "label": "IFRS Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of taxes on income included in the statements of comprehensive income" } } }, "auth_ref": [] }, "shlt_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "IFRS Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of the theoretical tax expense assuming all income is taxed at the statutory rate applicable to the income of companies in Israel, and the actual tax expense" } } }, "auth_ref": [] }, "shlt_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "IFRS Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "auth_ref": [] }, "shlt_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentageInYearOne": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentageInYearOne", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement in year one after grant date.", "label": "IFRS Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage in Year One", "terseLabel": "Percentage of vesting after one year" } } }, "auth_ref": [] }, "shlt_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "IFRS Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Additional Shares Authorized", "terseLabel": "Maximum number of shares which may be issued under the Plan" } } }, "auth_ref": [] }, "shlt_IfrsStockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsStockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityIssuedAndOutstandingShareCapitalNetOfTreasurySharesDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "IFRS Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of Ordinary shares issued", "verboseLabel": "Issue of share capital" } } }, "auth_ref": [] }, "shlt_IfrsStockIssuedDuringPeriodSharesTreasuryStockReissued": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsStockIssuedDuringPeriodSharesTreasuryStockReissued", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityIssuedAndOutstandingShareCapitalNetOfTreasurySharesDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "IFRS Stock Issued During Period, Shares, Treasury Stock Reissued", "terseLabel": "Number of treasury shares sold", "verboseLabel": "Treasury shares sold" } } }, "auth_ref": [] }, "shlt_IfrsStockIssuedDuringPeriodSharesTreasuryStockReissuedOnExerciseOfEmployeeOptions": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsStockIssuedDuringPeriodSharesTreasuryStockReissuedOnExerciseOfEmployeeOptions", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityIssuedAndOutstandingShareCapitalNetOfTreasurySharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares or units reissued on exercise of employee options. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "IFRS Stock Issued During Period, Shares, Treasury Stock Reissued on Exercise of Employee Options", "verboseLabel": "Treasury shares sold upon exercise of employee options" } } }, "auth_ref": [] }, "shlt_IfrsTreasuryStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IfrsTreasuryStockShares", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "IFRS Treasury Stock, Shares", "terseLabel": "Number of treasury shares held" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeOtherExpensesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment", "label": "Impairment loss recognised in profit or loss, property, plant and equipment", "terseLabel": "Impairment of property and equipment" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]" } } }, "auth_ref": [ "r43", "r58" ] }, "shlt_ImpairmentLossesOnFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ImpairmentLossesOnFinancialAssets", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesImpairmentOfNonFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of impairment losses on non-financial assets.", "label": "Impairment Losses On Financial Assets", "terseLabel": "Impairment loss" } } }, "auth_ref": [] }, "shlt_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Income and Expenses Not Involving Operating Cash Flows [Abstract]", "terseLabel": "Income and expenses not involving operating cash flows:" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "shlt_IncomeTaxDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncomeTaxDisclosureLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeCarryForwardTaxLossesDetails", "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Income Tax Disclosure [Line Items]", "terseLabel": "TAXES ON INCOME" } } }, "auth_ref": [] }, "shlt_IncomeTaxDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncomeTaxDisclosureTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeCarryForwardTaxLossesDetails", "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to income tax disclosures.", "label": "Income Tax Disclosure [Table]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 10.0 }, "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTaxesOnIncomeIncludedInStatementsOfComprehensiveIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails", "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTaxesOnIncomeIncludedInStatementsOfComprehensiveIncomeDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Tax expense (income)", "terseLabel": "Tax expenses", "totalLabel": "Total", "verboseLabel": "Total" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r40", "r46", "r47", "r48", "r93", "r156", "r242" ] }, "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss", "terseLabel": "Amount presented in other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will not be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]" } } }, "auth_ref": [ "r42" ] }, "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "shlt_CashPaidAndReceived", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Income taxes paid", "label": "Income taxes paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for income taxes paid, classified as operating activities." } } }, "auth_ref": [ "r353" ] }, "ifrs-full_IncomeTaxesRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxesRefundClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "shlt_CashPaidAndReceived", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes refund, classified as operating activities", "terseLabel": "Income tax received" } }, "en": { "role": { "documentation": "The cash inflow from income taxes refunded, classified as operating activities." } } }, "auth_ref": [ "r353" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "Increase (decrease) in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r135" ] }, "ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption", "terseLabel": "Change in defined benefit obligation if decrease in assumption" } }, "en": { "role": { "documentation": "The increase (decrease) in a defined benefit obligation that would have been caused by a decrease in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]" } } }, "auth_ref": [ "r78" ] }, "ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption", "terseLabel": "Change in defined benefit obligation if increase in assumption" } }, "en": { "role": { "documentation": "The increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]" } } }, "auth_ref": [ "r78" ] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsFairValueSensitivityDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities", "terseLabel": "Effect on fair value measurement due to reasonably possible decrease in unobservable input", "negatedLabel": "Effect on fair value measurement due to reasonably possible decrease in unobservable input" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible decrease in an unobservable input." } } }, "auth_ref": [ "r163" ] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities", "presentation": [ "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSDisclosureOfProfitBeforeTaxDueToChangesInCarryingAmountOfMarketableSecurities" ], "lang": { "en-us": { "role": { "negatedLabel": "Effect on fair value measurement due to reasonably possible decrease in unobservable input profit before tax", "label": "Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities", "verboseLabel": "Effect on fair value measurement due to reasonably possible decrease in unobservable input profit before tax" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible decrease in an unobservable input. [Refer: Tax income (expense)]" } } }, "auth_ref": [ "r355" ] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsFairValueSensitivityDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities", "terseLabel": "Effect on fair value measurement due to reasonably possible increase in unobservable input" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible increase in an unobservable input." } } }, "auth_ref": [ "r163" ] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities", "presentation": [ "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSDisclosureOfProfitBeforeTaxDueToChangesInCarryingAmountOfMarketableSecurities" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities", "verboseLabel": "Effect on fair value measurement due to reasonably possible increase in unobservable input profit loss before tax" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible increase in an unobservable input. [Refer: Tax income (expense)]" } } }, "auth_ref": [ "r355" ] }, "shlt_IncreaseDecreaseInFairValueOfLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncreaseDecreaseInFairValueOfLiability", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in fair value of liability/", "label": "Increase Decrease in Fair Value of Liability", "terseLabel": "Increase in fair value of liability" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss", "terseLabel": "Total expense recognized in profit or loss for the period" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from expense (income) included in profit or loss. [Refer: Net defined benefit liability (asset); Profit (loss)] [Contrast: Post-employment benefit expense in profit or loss, defined benefit plans]" } } }, "auth_ref": [ "r334" ] }, "shlt_IncreaseDecreaseInProfitAndLossBeforeTaxDueToReasonablyPossibleDecreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncreaseDecreaseInProfitAndLossBeforeTaxDueToReasonablyPossibleDecreaseInDesignatedRiskComponent", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in profit and loss as a result of an decrease in a designated risk component that was reasonably possible at the end of the reporting period. Excludes defined benefit plan obligations.", "negatedLabel": "Increase in profit and loss before tax due to increase in share price", "label": "Increase Decrease In Profit And Loss Before Tax Due To Reasonably Possible Decrease In Designated Risk Component", "terseLabel": "Decrease in profit and loss before tax due to decrease in share price" } } }, "auth_ref": [] }, "shlt_IncreaseDecreaseInProfitAndLossBeforeTaxDueToReasonablyPossibleIncreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncreaseDecreaseInProfitAndLossBeforeTaxDueToReasonablyPossibleIncreaseInDesignatedRiskComponent", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in profit and loss before tax as a result of an increase in a designated risk component that was reasonably possible at the end of the reporting period. Excludes defined benefit plan obligations.", "negatedLabel": "Decrease in profit and loss before tax due to increase in share price", "label": "Increase Decrease In Profit And Loss Before Tax Due To Reasonably Possible Increase In Designated Risk Component", "terseLabel": "Decrease in profit and loss before tax due to increase in share price" } } }, "auth_ref": [] }, "shlt_IncreaseDecreaseInProfitBeforeTaxDueToReasonablyPossibleDecreaseInRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncreaseDecreaseInProfitBeforeTaxDueToReasonablyPossibleDecreaseInRiskComponent", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in profit before tax due to reasonably possible decrease in risk component", "negatedLabel": "Increase (decrease) in profit before tax due to reasonably possible decrease in risk component", "negatedTerseLabel": "Increase (decrease) in profit before tax due to reasonably possible decrease in risk component", "label": "Increase (decrease) in profit before tax due to reasonably possible decrease in risk component", "terseLabel": "Increase (decrease) in profit before tax due to reasonably possible decrease in risk component" } } }, "auth_ref": [] }, "shlt_IncreaseDecreaseInProfitBeforeTaxDueToReasonablyPossibleIncreaseInRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncreaseDecreaseInProfitBeforeTaxDueToReasonablyPossibleIncreaseInRiskComponent", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in profit before tax due to reasonably possible increase in risk component", "label": "Increase (decrease) in profit before tax due to reasonably possible increase in risk component", "terseLabel": "Increase (decrease) in profit before tax due to reasonably possible increase in risk component" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Changes in operating assets and liabilities", "label": "Increase (decrease) in working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r352" ] }, "ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughAcquisitionOfSubsidiary", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through acquisition of subsidiary, equity", "terseLabel": "Non-controlling interests arising on acquisition of subsidiary" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the acquisition of subsidiaries. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r319" ] }, "shlt_IncreaseDecreaseThroughAdjustmentsForIndexationRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncreaseDecreaseThroughAdjustmentsForIndexationRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through adjustments for indexation, right-of-use assets", "label": "Increase (decrease) through adjustments for indexation, right-of-use assets", "terseLabel": "Adjustments for indexation" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from changes in foreign exchange rates, net defined benefit liability (asset)", "totalLabel": "Effect of changes in foreign exchange rates", "verboseLabel": "Effect of changes in foreign exchange rates" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes in foreign exchange rates. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r74" ] }, "shlt_IncreaseDecreaseThroughCurrencyTranslationDifferencesRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncreaseDecreaseThroughCurrencyTranslationDifferencesRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through currency translation differences, right-of-use assets", "label": "Increase (decrease) through currency translation differences, right-of-use assets", "terseLabel": "Currency translation differences" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities", "terseLabel": "Foreign exchange movement" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r133" ] }, "shlt_IncreaseDecreaseThroughExerciseOfEmployeeOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncreaseDecreaseThroughExerciseOfEmployeeOptions", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of employee options.", "label": "Increase Decrease Through Exercise Of Employee Options", "terseLabel": "Exercise of Employee options" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfOptions", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through exercise of options, equity", "terseLabel": "Exercise of share options" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } } }, "auth_ref": [ "r319" ] }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities", "terseLabel": "Cash flows" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } } }, "auth_ref": [ "r132" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, deferred tax liability (asset)", "terseLabel": "Currency translation differences" } }, "en": { "role": { "documentation": "The increase (decrease) in deferred tax liability (asset) resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Deferred tax liability (asset)]" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill", "terseLabel": "Currency translation differences" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r343" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, property, plant and equipment", "terseLabel": "Currency translation differences" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r60" ] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through other changes, liabilities arising from financing activities", "terseLabel": "Other" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r134" ] }, "shlt_IncreaseDecreaseThroughPurchasePriceAllocationAdjustmentsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IncreaseDecreaseThroughPurchasePriceAllocationAdjustmentsEquity", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in the entity's equity resulting from adjustment from purchase price allocation.", "label": "Increase (Decrease) Through Purchase Price Allocation Adjustments, Equity", "terseLabel": "PPA Adjustments" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based payments" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r5" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through transfers, property, plant and equipment", "terseLabel": "Transfer from inventory, net" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_IncreaseDecreaseToProfitLossToReflectDilutiveEffectResultingFromAssumedConversionOfPotentialOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseToProfitLossToReflectDilutiveEffectResultingFromAssumedConversionOfPotentialOrdinaryShares", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) to profit (loss) to reflect dilutive effect resulting from assumed conversion of potential ordinary shares", "terseLabel": "Effect of dilution - share options" } }, "en": { "role": { "documentation": "The increase (decrease) to profit (loss) to reflect the dilutive effect from assumed conversion of all potential ordinary shares." } } }, "auth_ref": [ "r97" ] }, "ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Cash-generating units [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r110" ] }, "shlt_IndividualsAndCommunitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IndividualsAndCommunitiesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for individuals and communities.", "label": "Individuals and Communities [Member]", "terseLabel": "Individuals and communities" } } }, "auth_ref": [] }, "shlt_InitialMoratoriumPeriodForRepaymentOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "InitialMoratoriumPeriodForRepaymentOfLoan", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial moratorium period for repayment of loan", "label": "Initial moratorium period for repayment of loan" } } }, "auth_ref": [] }, "shlt_InstitutionsAndPayersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "InstitutionsAndPayersMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for institutions and payers.", "label": "Institutions and Payers [Member]", "terseLabel": "Institutions and payers" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "label": "Intangible assets and goodwill" } }, "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_IntangibleAssetsAndGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsAndGoodwillAbstract", "lang": { "en-us": { "role": { "label": "GOODWILL AND INTANGIBLE ASSETS, NET" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsAndGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsAndGoodwillMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets and goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r344" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill", "terseLabel": "INTANGIBLE ASSETS, NET" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r11", "r117" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill [member]", "terseLabel": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r118", "r273", "r287" ] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialExpensesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest", "label": "Interest expense" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r155", "r240", "r248" ] }, "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)", "terseLabel": "Net interest expense" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r70" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense on lease liabilities" } }, "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r174" ] }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "shlt_CashPaidAndReceived", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest paid", "label": "Interest paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } } }, "auth_ref": [ "r129" ] }, "ifrs-full_InterestRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestRateMeasurementInputMember", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "terseLabel": "Risk-free interest rate" } }, "en": { "role": { "documentation": "This member stands for an interest rate used as a measurement input." } } }, "auth_ref": [ "r283" ] }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestReceivedClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "shlt_CashPaidAndReceived", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest received, classified as operating activities", "terseLabel": "Interest received" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } } }, "auth_ref": [ "r129" ] }, "ifrs-full_InterestRevenueExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestRevenueExpense", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Interest income (expense)", "terseLabel": "Interest" } }, "en": { "role": { "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]" } } }, "auth_ref": [ "r243", "r248", "r327" ] }, "shlt_InternationalCguMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "InternationalCguMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "International CGU", "label": "International Cgu Member", "terseLabel": "Germany" } } }, "auth_ref": [] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventory" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r12", "r82", "r261" ] }, "shlt_IsraelCguMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IsraelCguMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "Israel CGU", "label": "Israel CGU [member]", "terseLabel": "Israel" } } }, "auth_ref": [] }, "shlt_IsraelMeditonCguMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IsraelMeditonCguMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "Israel Mediton CGU", "label": "Israel Mediton Cgu Member", "verboseLabel": "Israel Mediton" } } }, "auth_ref": [] }, "shlt_IsraelTelemedicineCguMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IsraelTelemedicineCguMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "Israel telemedicine CGU", "label": "Israel Telemedicine Cgu Member", "verboseLabel": "Israel telemedicine" } } }, "auth_ref": [] }, "shlt_IssuanceOfShareOptionsFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IssuanceOfShareOptionsFairValueMeasurementLiabilities", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "documentation": "The decrease in fair value measurement of liabilities resulting from issuance of share options.", "label": "Issuance of Share Options, Fair Value Measurement, Liabilities", "terseLabel": "Issuance of Share Options" } } }, "auth_ref": [] }, "shlt_IssueCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "IssueCostsAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Issue Costs [Abstract]", "terseLabel": "Issue costs:" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issue of share capital (net of issue costs of $2,907)" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Issued capital", "terseLabel": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r264" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Issued capital" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation", "terseLabel": "Total", "totalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r87" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Share-based payment benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r86" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation, short-term employee benefits", "terseLabel": "Short-term employee benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r85" ] }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelOfEntityOrParentMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel of entity or parent [member]", "terseLabel": "Key management personnel" } }, "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } } }, "auth_ref": [ "r90" ] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "More than 5 years", "verboseLabel": "More than 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r182", "r183", "r194", "r296", "r297", "r299" ] }, "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Later than four years and not later than five years [member]", "terseLabel": "4 to 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than four years and not later than five years." } } }, "auth_ref": [ "r182", "r183", "r194", "r296", "r299", "r321" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Later than one year and not later than two years [member]", "terseLabel": "1 to 2 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r182", "r183", "r194", "r296", "r299", "r321" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Later than three years and not later than four years [member]", "terseLabel": "3 to 4 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } } }, "auth_ref": [ "r182", "r183", "r194", "r296", "r299", "r321" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Later than two years and not later than three years [member]", "terseLabel": "2 to 3 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } } }, "auth_ref": [ "r182", "r183", "r194", "r296", "r299", "r321" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities [member]", "terseLabel": "Lease liabilities", "verboseLabel": "Lease liabilities", "netLabel": "Lease liabilities (including current maturities)" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r278", "r280" ] }, "shlt_LeaseLiabilitiesRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LeaseLiabilitiesRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Lease liabilities recognised as of acquisition date", "negatedLabel": "Lease liabilities", "label": "Lease liabilities recognised as of acquisition date", "terseLabel": "Lease liabilities" } } }, "auth_ref": [] }, "shlt_LeasePaymentsApplicableInExtensionOptionPeriodsWhichAreNotReasonablyCertainToBeExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LeasePaymentsApplicableInExtensionOptionPeriodsWhichAreNotReasonablyCertainToBeExercised", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease payments applicable in extension option periods which are not reasonably certain to be exercised", "label": "Lease payments applicable in extension option periods which are not reasonably certain to be exercised" } } }, "auth_ref": [] }, "shlt_LeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LeaseTerm", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease term", "label": "Lease term" } } }, "auth_ref": [] }, "ifrs-full_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold improvements [member]", "terseLabel": "Leasehold improvements", "verboseLabel": "Leasehold improvements" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement." } } }, "auth_ref": [ "r329" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Level 3 of fair value hierarchy", "verboseLabel": "Level 3" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r158" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r77", "r158" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedPeriodEndLabel": "Liabilities at end of period", "negatedPeriodStartLabel": "Liabilities at beginning of period", "label": "Liabilities", "totalLabel": "Total liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r18", "r157", "r158", "r162", "r243", "r247" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Liabilities arising from financing activities at end of period", "periodStartLabel": "Liabilities arising from financing activities at beginning of period", "label": "Liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } } }, "auth_ref": [ "r279" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r279" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities [member]" } }, "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r279" ] }, "ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesFromSharebasedPaymentTransactions2011", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Liability for share options", "label": "Liabilities from share-based payment transactions", "terseLabel": "Liability for share options" } }, "en": { "role": { "documentation": "The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } } }, "auth_ref": [ "r209" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset)", "terseLabel": "Balance at beginning", "periodStartLabel": "Balance at beginning", "periodEndLabel": "Balance at ending" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]" } } }, "auth_ref": [ "r68" ] }, "shlt_LiabilityDerecognizedAndRecordedInEquityUponExerciseOfShareOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LiabilityDerecognizedAndRecordedInEquityUponExerciseOfShareOptions", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of liability derecognized and recorded in equity upon exercise of share options", "label": "Liability Derecognized And Recorded In Equity Upon Exercise Of Share Options", "terseLabel": "Liability derecognized and recorded in equity upon exercise of share options" } } }, "auth_ref": [] }, "shlt_LiabilityForShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LiabilityForShareOptionsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Liability for share options", "label": "Liability for share options [member]", "terseLabel": "Liability for share options", "verboseLabel": "Share options" } } }, "auth_ref": [] }, "shlt_LiabilityToUnderwritersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LiabilityToUnderwritersMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Liability to underwriters", "label": "Liability to underwriters [member]", "terseLabel": "Other payables - liability to underwriters", "verboseLabel": "Liability for underwriter" } } }, "auth_ref": [] }, "ifrs-full_LineItemsByFunctionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LineItemsByFunctionMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Line items by function [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used." } } }, "auth_ref": [ "r318", "r321" ] }, "shlt_LoanTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LoanTerm", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Loan term", "label": "Loan term" } } }, "auth_ref": [] }, "shlt_LoansAndCreditsFromBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LoansAndCreditsFromBanksMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Loans and credits from banks", "label": "Loans and credits from banks [member]", "terseLabel": "Loans from bank" } } }, "auth_ref": [] }, "shlt_LoansFromBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LoansFromBanksMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Loans from banks", "label": "Loans from banks [member]", "terseLabel": "Loans from banks" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "shlt_LongTermDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LongTermDepositsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term deposits", "label": "Long term deposits [member]", "terseLabel": "Long term deposits" } } }, "auth_ref": [] }, "shlt_LongTermGrowthRateCurrentEstimatedValueOfUse": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LongTermGrowthRateCurrentEstimatedValueOfUse", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of long term growth rate.", "label": "Long Term Growth Rate Current Estimated Value Of Use", "terseLabel": "Long term growth rate" } } }, "auth_ref": [] }, "shlt_LongTermLoansAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LongTermLoansAbstract", "lang": { "en-us": { "role": { "documentation": "Long-term loans", "label": "Long Term Loans Abstract" } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Non-current portion of non-current borrowings", "terseLabel": "Long-term loans" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_LongtermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LongtermBorrowingsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term borrowings [member]", "terseLabel": "Long term bank loan", "verboseLabel": "Long term bank loan" } }, "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r278", "r280" ] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "shlt_NonCurrentAssetsOtherThanLongLivedAssets", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term deposits", "terseLabel": "Long-term deposits" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r323" ] }, "shlt_LossOnMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "LossOnMarketableSecurities", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of gain on marketable securities.", "negatedLabel": "Loss from marketable securities, net", "label": "Loss on Marketable Securities" } } }, "auth_ref": [] }, "shlt_MaintenanceOfVehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "MaintenanceOfVehiclesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for maintenance of vehicles.", "label": "Maintenance Of Vehicles [Member]", "terseLabel": "Maintenance of vehicles" } } }, "auth_ref": [] }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "lang": { "en-us": { "role": { "label": "Major components of tax expense (income) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_MarketRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MarketRiskMember", "presentation": [ "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSDisclosureOfProfitBeforeTaxDueToChangesInCarryingAmountOfMarketableSecurities" ], "lang": { "en-us": { "role": { "label": "Market risk [member]", "verboseLabel": "Market risk" } }, "en": { "role": { "documentation": "This member stands for the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk. [Refer: Currency risk [member]; Interest rate risk [member]; Other price risk [member]; Financial instruments, class [member]]" } } }, "auth_ref": [ "r189", "r190", "r191", "r192", "r293" ] }, "shlt_MarketingAndRelatedExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "MarketingAndRelatedExpensesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for marketing and related expenses.", "label": "Marketing And Related Expenses [Member]", "terseLabel": "Marketing and related expenses" } } }, "auth_ref": [] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r21", "r169", "r182", "r183", "r186", "r187", "r188", "r194", "r215", "r228", "r271", "r296" ] }, "shlt_MaximumExpectedPeriodBetweenReceiptOfAdvancePaymentAndPerformanceOfServiceRecognitionOfDeferredRevenue": { "xbrltype": "durationItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "MaximumExpectedPeriodBetweenReceiptOfAdvancePaymentAndPerformanceOfServiceRecognitionOfDeferredRevenue", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureDeferredRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum expected period between receipt of advance payment and performance of service, recognition of deferred revenue", "label": "Maximum expected period between receipt of advance payment and performance of service, recognition of deferred revenue", "terseLabel": "Maximum expected period between receipt of advance payment and performance of service" } } }, "auth_ref": [] }, "shlt_MedicalEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "MedicalEquipmentMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails" ], "lang": { "en-us": { "role": { "documentation": "Medical equipment", "label": "Medical Equipment Member", "verboseLabel": "Medical equipment" } } }, "auth_ref": [] }, "shlt_MedicalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "MedicalServicesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for medical services.", "label": "Medical Services [Member]", "terseLabel": "Medical services" } } }, "auth_ref": [] }, "shlt_MiscellaneousCurrentAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "MiscellaneousCurrentAccountsReceivable", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "documentation": "Miscellaneous current accounts receivable", "label": "Miscellaneous current accounts receivable", "terseLabel": "Others" } } }, "auth_ref": [] }, "shlt_MiscellaneousOtherOperatingIncomeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "MiscellaneousOtherOperatingIncomeExpenses", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeOtherExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of miscellaneous other operating income (expense).", "negatedLabel": "Other (incomes) expenses", "label": "Miscellaneous Other Operating Income (Expenses)", "verboseLabel": "Other expenses" } } }, "auth_ref": [] }, "shlt_MonteCarloOptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "MonteCarloOptionPricingModelMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Monte Carlo option pricing model.", "label": "Monte Carlo Option Pricing Model [Member]", "terseLabel": "Monte Carlo model" } } }, "auth_ref": [] }, "ifrs-full_MotorVehiclesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MotorVehiclesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails" ], "lang": { "en-us": { "role": { "label": "Motor vehicles [member]", "terseLabel": "Motor vehicles", "verboseLabel": "Vehicles" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing self-propelled ground vehicles used in the entity's operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r267" ] }, "shlt_MovementsInShareOptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "MovementsInShareOptionsAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Movements in Share Options [Abstract]", "terseLabel": "Movements in Share Options:" } } }, "auth_ref": [] }, "shlt_NetDebtToEbitdaFinancialCovenant": { "xbrltype": "pureItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NetDebtToEbitdaFinancialCovenant", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Net debt to EBITDA financial covenant", "label": "Net debt to EBITDA financial covenant" } } }, "auth_ref": [] }, "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesDisaggregationOfFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset) [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r68" ] }, "ifrs-full_NetDefinedBenefitLiabilityAssetMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesDisaggregationOfFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset) [member]" } }, "en": { "role": { "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r68" ] }, "shlt_NonCashTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NonCashTransactionsAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Non-cash Transactions [Abstract]", "terseLabel": "Non-cash transactions:" } } }, "auth_ref": [] }, "shlt_NonCurrentAssetsOtherThanLongLivedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NonCurrentAssetsOtherThanLongLivedAssets", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "The amount of non-current assets other than long-lived assets.", "label": "Non-current Assets Other than Long-lived Assets", "totalLabel": "Total non-current assets other than long-lived assets" } } }, "auth_ref": [] }, "ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-controlling interests", "label": "Non-controlling interest in acquiree recognised at acquisition date" } }, "en": { "role": { "documentation": "The amount of non-controlling interest in the acquiree recognised at the acquisition date for business combinations in which the acquirer holds less than 100 per cent of the equity interests in the acquiree at the acquisition date. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r211" ] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests", "terseLabel": "Non-controlling interests" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r16", "r144", "r146" ] }, "ifrs-full_NoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncontrollingInterestsMember", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests [member]", "terseLabel": "Non- controlling interests" } }, "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "NON-CURRENT ASSETS:" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts", "terseLabel": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Financial instruments, class [member]; Non-current assets]" } } }, "auth_ref": [ "r252" ] }, "ifrs-full_NoncurrentInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentInventories", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "shlt_NonCurrentAssetsOtherThanLongLivedAssets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current inventories", "terseLabel": "Inventory" } }, "en": { "role": { "documentation": "The amount of non-current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r12" ] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r172" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r23", "r149", "r281" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "NON-CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentPortionOfNoncurrentLoansReceived", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current portion of non-current loans received", "terseLabel": "Loans from banks" } }, "en": { "role": { "documentation": "The non-current portion of non-current loans received. [Refer: Loans received]" } } }, "auth_ref": [ "r321" ] }, "ifrs-full_NoncurrentPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentPrepayments", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "shlt_NonCurrentAssetsOtherThanLongLivedAssets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current prepayments", "terseLabel": "Prepaid expenses" } }, "en": { "role": { "documentation": "The amount of non-current prepayments. [Refer: Prepayments]" } } }, "auth_ref": [ "r263" ] }, "ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentRecognisedLiabilitiesDefinedBenefitPlan", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current net defined benefit liability", "terseLabel": "Employee benefit liabilities" } }, "en": { "role": { "documentation": "The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Not later than one year [member]", "terseLabel": "Less than one year" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r20", "r182", "r183", "r194", "r296", "r299" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Notional amount", "terseLabel": "Long-term loan amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r321" ] }, "shlt_NumberOfCapitalIncreases": { "xbrltype": "integerItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfCapitalIncreases", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of capital increases.", "label": "Number of Capital Increases", "terseLabel": "Number of Capital Increases" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Number of restricted share units (\"RSU\")" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r207", "r357" ] }, "shlt_NumberOfOptionsGrantedToAcquireUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfOptionsGrantedToAcquireUnits", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of options granted to acquire Units.", "label": "Number of Options Granted to Acquire Units" } } }, "auth_ref": [] }, "shlt_NumberOfOrdinarySharesInUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfOrdinarySharesInUnit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of ordinary shares in an Unit.", "label": "Number of Ordinary Shares in an Unit" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at the end of the year", "periodStartLabel": "Outstanding at the beginning of the year", "label": "Number of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r196", "r200", "r204" ] }, "ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of potential ordinary shares that are antidilutive in period presented", "terseLabel": "Anti-dilutive effect excluded from computation of diluted net earnings per share" } }, "en": { "role": { "documentation": "Number of potential ordinary shares that are antidilutive in the period presented." } } }, "auth_ref": [ "r340" ] }, "shlt_NumberOfQuarterlyInstallmentsForRepaymentOfLoan": { "xbrltype": "decimalItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfQuarterlyInstallmentsForRepaymentOfLoan", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of quarterly installments for repayment of loan", "label": "Number of quarterly installments for repayment of loan" } } }, "auth_ref": [] }, "shlt_NumberOfShareOptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfShareOptionsAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Number of Share Options [Abstract]", "terseLabel": "No. of options" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options exercisable in share-based payment arrangement", "terseLabel": "Exercisable at the end of the year" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r201" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised during the year", "label": "Number of share options exercised in share-based payment arrangement", "verboseLabel": "Number of options exercised" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r199" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited during the year", "label": "Number of share options forfeited in share-based payment arrangement", "verboseLabel": "Number of options forfeited" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r198" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options granted in share-based payment arrangement", "terseLabel": "Number of options granted", "verboseLabel": "Granted during the year" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r197" ] }, "shlt_NumberOfShareOptionsInUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfShareOptionsInUnit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of share options in an Unit.", "label": "Number of Share Options in an Unit", "terseLabel": "Number of options in an Unit" } } }, "auth_ref": [] }, "shlt_NumberOfShareOptionsToPurchaseOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfShareOptionsToPurchaseOrdinaryShares", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares options to purchase ordinary shares granted.", "label": "Number of Share Options to Purchase Ordinary Shares", "terseLabel": "Number of Share Options to purchase Ordinary shares granted" } } }, "auth_ref": [] }, "shlt_NumberOfShareOptionsToPurchaseOrdinarySharesExercisePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfShareOptionsToPurchaseOrdinarySharesExercisePeriod", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the exercise period of shares options to purchase ordinary shares granted.", "label": "Number of Share Options to Purchase Ordinary Shares, Exercise Period", "terseLabel": "Exercise period" } } }, "auth_ref": [] }, "shlt_NumberOfShareOptionsToPurchaseOrdinarySharesExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfShareOptionsToPurchaseOrdinarySharesExercisePrice", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the exercise price of shares options to purchase ordinary shares granted.", "label": "Number of Share Options to Purchase Ordinary Shares, Exercise Price", "terseLabel": "Exercise price" } } }, "auth_ref": [] }, "shlt_NumberOfShareOptionsToPurchaseOrdinarySharesRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfShareOptionsToPurchaseOrdinarySharesRatio", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Ratio of shares options to purchase ordinary shares granted.", "label": "Number of Share Options to Purchase Ordinary Shares, Ratio", "terseLabel": "Ratio" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesAuthorised": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesAuthorised", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares authorised", "terseLabel": "Ordinary shares of NIS 0.01 par value each, Authorized" } }, "en": { "role": { "documentation": "The number of shares authorised." } } }, "auth_ref": [ "r26" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares issued", "terseLabel": "Ordinary shares of NIS 0.01 par value each, Issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r319" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalDetails", "http://www.shl-telemedicine.com/role/DisclosureEquityIssuedAndOutstandingShareCapitalNetOfTreasurySharesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginning", "label": "Number of shares outstanding", "terseLabel": "Ordinary shares of NIS 0.01 par value each, Outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r28" ] }, "shlt_NumberOfSickFundsToBeAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfSickFundsToBeAcquired", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGeneralDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of sick funds to be acquired.", "label": "Number of Sick Funds to be Acquired", "terseLabel": "Number of sick funds" } } }, "auth_ref": [] }, "shlt_NumberOfUnitsToBeIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "NumberOfUnitsToBeIssued", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the estimated number of Units to be issued.", "label": "Number of Units to be Issued", "terseLabel": "Number of estimated units to be issued" } } }, "auth_ref": [] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails" ], "lang": { "en-us": { "role": { "label": "Office furniture and equipment", "verboseLabel": "Office furniture and equipment" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r268" ] }, "ifrs-full_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating segments [member]", "terseLabel": "Operating segments" } }, "en": { "role": { "documentation": "This member stands for operating segments. An operating segment is a component of an entity: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity); (b) whose operating results are regularly reviewed by the entity\u2019s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and (c) for which discrete financial information is available. [Refer: Revenue]" } } }, "auth_ref": [ "r249" ] }, "shlt_OptionNumberOfOrdinarySharesCalledForEachOption": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OptionNumberOfOrdinarySharesCalledForEachOption", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares into which each share option may be converted.", "label": "Option, Number of Ordinary Shares called for Each Option", "terseLabel": "Number of ordinary shares toa acquire each option" } } }, "auth_ref": [] }, "ifrs-full_OptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OptionPricingModelMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Option pricing model [member]", "terseLabel": "Black and Scholes model" } }, "en": { "role": { "documentation": "This member stands for a specific valuation technique consistent with the income approach that involves analysing future amounts with option pricing models, such as the Black-Scholes-Merton formula or a binominal model (ie a lattice model), that incorporate present value techniques and reflect both the time value and intrinsic value of an option. [Refer: Income approach [member]]" } } }, "auth_ref": [ "r282", "r285" ] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Ordinary shares [member]", "terseLabel": "Ordinary shares" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } } }, "auth_ref": [ "r95", "r326" ] }, "shlt_OtherAccountsReceivableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OtherAccountsReceivableAbstract", "lang": { "en-us": { "role": { "documentation": "Other accounts receivable", "label": "Other Accounts Receivable Abstract" } } }, "auth_ref": [] }, "shlt_OtherAccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OtherAccountsReceivableMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other accounts receivable", "label": "Other accounts receivable [member]", "terseLabel": "Other accounts receivable" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Total other comprehensive income (loss)", "totalLabel": "Total other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r4", "r32", "r41", "r152" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income [abstract]", "terseLabel": "Other comprehensive income:" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Foreign currency translation reserve" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r24", "r41" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "terseLabel": "Re-measurement gain on defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r24", "r41", "r332" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 50.0 }, "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details", "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Other payables (short term)", "label": "Other current payables", "terseLabel": "Other payables", "totalLabel": "Total other payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r323" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 40.0 }, "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other accounts receivable", "totalLabel": "Other accounts receivable" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r263" ] }, "shlt_OtherCurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OtherCurrentTradeReceivables", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Other current trade receivables", "label": "Other current trade receivables", "terseLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_OtherExpenseByNature": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherExpenseByNature", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedLabel": "Other expenses", "label": "Other expenses, by nature", "terseLabel": "Other expenses" } }, "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]" } } }, "auth_ref": [ "r44", "r258" ] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeFinancialExpensesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Others", "label": "Other finance cost" } }, "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } } }, "auth_ref": [ "r321" ] }, "shlt_OtherGeographicalAreasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OtherGeographicalAreasMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other geographical areas.", "label": "Other Geographical Areas [Member]", "terseLabel": "ROW" } } }, "auth_ref": [] }, "shlt_OtherMiscellaneousCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OtherMiscellaneousCurrentPayables", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails": { "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Other miscellaneous current payables", "label": "Other miscellaneous current payables", "terseLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeOtherExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Other expenses", "label": "Other operating income (expense)", "totalLabel": "Total other expenses", "verboseLabel": "Total other expenses" } }, "en": { "role": { "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r327" ] }, "shlt_OtherPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OtherPayablesAbstract", "lang": { "en-us": { "role": { "documentation": "Other payables", "label": "Other Payables Abstract" } } }, "auth_ref": [] }, "shlt_OtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OtherPayablesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other payables", "label": "Other payables [member]", "terseLabel": "Other payables" } } }, "auth_ref": [] }, "shlt_OtherPayablesRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OtherPayablesRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Other payables recognised as of acquisition date", "negatedLabel": "Other payables", "label": "Other payables recognised as of acquisition date", "terseLabel": "Other payables" } } }, "auth_ref": [] }, "shlt_OtherReceivablesRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OtherReceivablesRecognisedAsOfAcquisitionDate", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Other receivables recognised as of acquisition date", "label": "Other receivables recognised as of acquisition date", "terseLabel": "Other receivables" } } }, "auth_ref": [] }, "shlt_OtherSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OtherSegmentMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other segments.", "label": "Other Segment [Member]", "terseLabel": "Others" } } }, "auth_ref": [] }, "shlt_OthersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "OthersMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for others.", "label": "Others [Member]", "terseLabel": "Others" } } }, "auth_ref": [] }, "ifrs-full_OutstandingBalancesForRelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OutstandingBalancesForRelatedPartyTransactionsAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Outstanding balances for related party transactions [abstract]", "terseLabel": "Balance" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Par value per share", "terseLabel": "Ordinary shares, par value" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r27" ] }, "ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements", "verboseLabel": "Past service cost and effect of settlements" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements. [Refer: Decrease (increase) in net defined benefit liability (asset) resulting from gains (losses) arising from settlements; Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r73" ] }, "shlt_PaymentInCashToOtherConsultants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PaymentInCashToOtherConsultants", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for cash to other consultants.", "label": "Payment In Cash To Other Consultants", "terseLabel": "Payment in cash to other consultants" } } }, "auth_ref": [] }, "shlt_PaymentOfShareOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PaymentOfShareOptions", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Payment Of Share Options", "documentation": "Represents the amount of payment for share options.", "terseLabel": "Payment" } } }, "auth_ref": [] }, "shlt_PaymentToUnderwriterInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PaymentToUnderwriterInCash", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for underwriter in cash.", "label": "Payment to Underwriter in Cash", "terseLabel": "Payment to underwriter in cash", "verboseLabel": "Amount paid to underwriters" } } }, "auth_ref": [] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments for share issue costs", "terseLabel": "Total Issue costs" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r349" ] }, "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan", "totalLabel": "Payments from the plan", "verboseLabel": "Payments from the plan" } }, "en": { "role": { "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r76" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 60.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of lease liabilities", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r277" ] }, "shlt_PercentageOfEquityInterestToBeAcquired": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PercentageOfEquityInterestToBeAcquired", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGeneralDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of equity interest to be acquired.", "label": "Percentage of Equity Interest to be Acquired", "terseLabel": "Percentage of equity interest to be acquired" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PercentageOfReasonablyPossibleDecreaseInActuarialAssumption", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of reasonably possible decrease in actuarial assumption", "terseLabel": "Decrease in assumption" } }, "en": { "role": { "documentation": "The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]" } } }, "auth_ref": [ "r78" ] }, "shlt_PercentageOfReasonablyPossibleDecreaseInRiskAssumption": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PercentageOfReasonablyPossibleDecreaseInRiskAssumption", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The reasonably possible percentage of the decrease in the designated risk component used to determine the value of the financial instrument. Excludes defined benefit plan obligations.", "label": "Percentage Of Reasonably Possible Decrease In Risk Assumption", "terseLabel": "Decrease in share price" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsFairValueSensitivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Percentage of reasonably possible decrease in unobservable input", "label": "Percentage of reasonably possible decrease in unobservable input, assets" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of assets." } } }, "auth_ref": [ "r355" ] }, "shlt_PercentageOfReasonablyPossibleDecreaseInUnobservableInputProfitBeforeTax": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputProfitBeforeTax", "presentation": [ "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSDisclosureOfProfitBeforeTaxDueToChangesInCarryingAmountOfMarketableSecurities" ], "lang": { "en-us": { "role": { "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of profit loss before tax.", "negatedLabel": "Percentage of reasonably possible decrease in unobservable input profit loss before tax", "label": "Percentage Of Reasonably Possible Decrease In Unobservable Input Profit Before Tax", "verboseLabel": "Percentage of reasonably possible decrease in unobservable input profit loss before tax" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PercentageOfReasonablyPossibleIncreaseInActuarialAssumption", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of reasonably possible increase in actuarial assumption", "terseLabel": "Increase in assumption" } }, "en": { "role": { "documentation": "The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]" } } }, "auth_ref": [ "r78" ] }, "shlt_PercentageOfReasonablyPossibleIncreaseInPreviousActuarialAssumption": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PercentageOfReasonablyPossibleIncreaseInPreviousActuarialAssumption", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesReasonablyPossibleChangesAtEndOfReportingPeriodInEachActuarialAssumptionAssumingThatAllOtherActuarialAssumptionsAreConstantDetails" ], "lang": { "en-us": { "role": { "documentation": "The previous reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation.", "label": "Percentage Of Reasonably Possible Increase In Previous Actuarial Assumption", "terseLabel": "Increase in previous assumption" } } }, "auth_ref": [] }, "shlt_PercentageOfReasonablyPossibleIncreaseInRiskAssumption": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PercentageOfReasonablyPossibleIncreaseInRiskAssumption", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The reasonably possible percentage of the increase in the designated risk component used to determine the value of the financial instrument. Excludes defined benefit plan obligations.", "label": "Percentage Of Reasonably Possible Increase In Risk Assumption", "terseLabel": "Increase in share price" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsFairValueSensitivityDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of reasonably possible increase in unobservable input, assets", "terseLabel": "Percentage of reasonably possible increase in unobservable input" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of assets." } } }, "auth_ref": [ "r355" ] }, "shlt_PercentageOfReasonablyPossibleIncreaseInUnobservableInputProfitBeforeTax": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputProfitBeforeTax", "presentation": [ "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSDisclosureOfProfitBeforeTaxDueToChangesInCarryingAmountOfMarketableSecurities" ], "lang": { "en-us": { "role": { "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of profit loss before tax.", "label": "Percentage Of Reasonably Possible Increase In Unobservable Input Profit Before Tax", "verboseLabel": "Percentage of reasonably possible increase in unobservable input profit loss before tax" } } }, "auth_ref": [] }, "shlt_PerformanceBasedRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PerformanceBasedRevenues", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of performance based revenue.", "label": "Performance Based Revenues", "terseLabel": "Performance-based revenues" } } }, "auth_ref": [] }, "shlt_PerformanceBasedRevenuesWithRespectOfCostSavingsArisingFrom2019": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PerformanceBasedRevenuesWithRespectOfCostSavingsArisingFrom2019", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of performance-based revenue with respect of cost savings arising from 2019.", "label": "Performance-based Revenues with Respect of Cost Savings Arising from 2019", "terseLabel": "Performance-based revenues with respect of cost savings arising from 2019" } } }, "auth_ref": [] }, "shlt_PeriodCoveredByFinancialBudgetsUsedInCashFlowProjections": { "xbrltype": "durationItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PeriodCoveredByFinancialBudgetsUsedInCashFlowProjections", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "Period covered by financial budgets used in cash flow projections", "label": "Period covered by financial budgets used in cash flow projections" } } }, "auth_ref": [] }, "ifrs-full_PlanAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PlanAssetsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesDisaggregationOfFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Plan assets [member]", "terseLabel": "Fair value of plan assets" } }, "en": { "role": { "documentation": "This member stands for defined benefit plan assets. Plan assets comprise: (a) assets held by a long-term employee benefit fund; and (b) qualifying insurance policies." } } }, "auth_ref": [ "r66" ] }, "shlt_PpaAdjustmentSeeNote5PurchasePriceAllocationAdjustmentIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PpaAdjustmentSeeNote5PurchasePriceAllocationAdjustmentIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of purchase price allocation of intangible assets other than goodwill.", "label": "PPA adjustment (see Note 5) Purchase Price Allocation Adjustment, Intangible Assets Other Than Goodwill", "terseLabel": "PPA adjustment" } } }, "auth_ref": [] }, "shlt_PrepaidExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PrepaidExpensesAbstract", "lang": { "en-us": { "role": { "documentation": "Prepaid expenses", "label": "Prepaid Expenses Abstract" } } }, "auth_ref": [] }, "ifrs-full_PresentValueOfDefinedBenefitObligationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PresentValueOfDefinedBenefitObligationMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesChangesInDefinedBenefitObligationAndFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Present value of defined benefit obligation [member]", "terseLabel": "Defined benefit obligation" } }, "en": { "role": { "documentation": "This member stands for the present value of a defined benefit obligation. The present value of a defined benefit obligation is the present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods." } } }, "auth_ref": [ "r67" ] }, "ifrs-full_PresentationOfLeasesForLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PresentationOfLeasesForLesseeAbstract", "lang": { "en-us": { "role": { "label": "LEASES" } } }, "auth_ref": [] }, "shlt_ProccedFromPaymentOfLiabilityToUnderwriters": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ProccedFromPaymentOfLiabilityToUnderwriters", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Procced From Payment Of Liability To Underwriters", "documentation": "The amount represents payment of liability to underwriters,", "terseLabel": "Payment of liability to underwriters" } } }, "auth_ref": [] }, "shlt_ProceedsFromCapitalIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ProceedsFromCapitalIncrease", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of proceeds from capital increase.", "label": "Proceeds from Capital Increase", "terseLabel": "Capital Increase" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromExerciseOfOptions", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of options", "terseLabel": "Exercise of share options", "verboseLabel": "Proceeds from exercises share options" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of options." } } }, "auth_ref": [ "r349" ] }, "shlt_ProceedsFromIssueOfShareOptionsLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ProceedsFromIssueOfShareOptionsLiability", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issue of share options liability.", "label": "Proceeds from Issue of Share Options Liability", "terseLabel": "Proceeds from issue of share options liability" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Proceeds from issue of share capital, net" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r276" ] }, "shlt_ProceedsFromPaymentOfLongTermLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ProceedsFromPaymentOfLongTermLoans", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow (outflow) from long-term loans.", "label": "Proceeds from (Payment of) Long-term Loans", "terseLabel": "Payment of long-term loans" } } }, "auth_ref": [] }, "shlt_ProceedsFromPaymentOfShortTermCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ProceedsFromPaymentOfShortTermCredit", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow (outflow) from short-term credit.", "label": "Proceeds from (Payment of) Short-term Credit", "terseLabel": "Proceeds from (payment of) short-term credit" } } }, "auth_ref": [] }, "shlt_ProceedsFromSaleOrMaturityOfShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ProceedsFromSaleOrMaturityOfShortTermInvestments", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the disposal or maturity of short-term investments.", "label": "Proceeds from Sale or Maturity of Short-term Investments", "terseLabel": "Proceeds from sale of short-term investments" } } }, "auth_ref": [] }, "shlt_ProfessionalFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ProfessionalFeesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for professional fees.", "label": "Professional Fees [Member]", "terseLabel": "Professional fees" } } }, "auth_ref": [] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 0.0 }, "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Net profit (loss)", "totalLabel": "Net profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r3", "r31", "r126", "r141", "r143", "r243", "r245", "r281", "r288" ] }, "ifrs-full_ProfitLossAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to [abstract]", "terseLabel": "Net profit (loss) attributable to:" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to non-controlling interests", "terseLabel": "Non-controlling interests" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } } }, "auth_ref": [ "r34", "r145" ] }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share", "terseLabel": "For the computation of basic net earnings" } }, "en": { "role": { "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r97" ] }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to ordinary equity holders of parent entity [abstract]", "terseLabel": "Net profit (loss)", "verboseLabel": "Net loss" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share", "terseLabel": "For the computation of diluted net earnings" } }, "en": { "role": { "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r97" ] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to owners of parent", "terseLabel": "Equity holders of the Company" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r35" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss) before tax", "terseLabel": "Profit (loss) before taxes on income", "totalLabel": "Profit (loss) before taxes on income" } }, "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r213", "r258", "r259", "r301", "r302" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "terseLabel": "Operating profit (loss)", "totalLabel": "Operating loss", "verboseLabel": "Operating loss" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r272", "r327" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "label": "Property, plant and equipment", "terseLabel": "PROPERTY AND EQUIPMENT, NET" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r10", "r61" ] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r62", "r273", "r287" ] }, "ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment recognised as of acquisition date", "terseLabel": "Property, plant and equipment", "verboseLabel": "Property and equipment" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]" } } }, "auth_ref": [ "r291", "r292" ] }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment in intangible assets", "label": "Purchase of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r275" ] }, "shlt_PurchaseOfLongTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PurchaseOfLongTermDeposits", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of long-term deposits.", "negatedLabel": "Investment in short-term deposits", "label": "Purchase of Long-term Deposits" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r275" ] }, "shlt_PurchaseOfShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PurchaseOfShortTermInvestments", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of short-term investments.", "negatedLabel": "Purchase of short-term investments", "label": "Purchase of Short-term Investments" } } }, "auth_ref": [] }, "shlt_PutOptionNetRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PutOptionNetRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The amount recognised as of the acquisition date for put option, net assumed in a business combination.", "label": "Put Option, Net Recognised As Of Acquisition Date", "terseLabel": "Put option, net" } } }, "auth_ref": [] }, "shlt_PutOptionToNonControllingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PutOptionToNonControllingInterests", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Put Option To Non Controlling Interests", "documentation": "Represents the amount of put option to non controlling interests.", "terseLabel": "Put option" } } }, "auth_ref": [] }, "shlt_PutOptionToNonControllingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PutOptionToNonControllingInterestsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsFairValueSensitivityDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLevel3Details", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Put option to non-controlling interests", "label": "Put option to non-controlling interests [member]", "terseLabel": "Put option to non-controlling interests", "verboseLabel": "PUT option" } } }, "auth_ref": [] }, "shlt_PutOptionToNonControllingInterestsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "PutOptionToNonControllingInterestsNet", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "The amount of put options to non-controlling interests.", "label": "Put Option to Non-controlling Interests, Net", "terseLabel": "Put option to non-controlling interests, net" } } }, "auth_ref": [] }, "ifrs-full_QualifyingInsurancePoliciesAmountContributedToFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "QualifyingInsurancePoliciesAmountContributedToFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesDisaggregationOfFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Qualifying insurance policies, amount contributed to fair value of plan assets", "terseLabel": "Insurance contracts" } }, "en": { "role": { "documentation": "The amount qualifying insurance policies contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [member]]" } } }, "auth_ref": [ "r335", "r338" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesPrincipalAssumptionsUnderlyingDefinedBenefitPlanDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails", "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r166", "r188", "r204", "r284", "r285", "r359" ] }, "ifrs-full_RangesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesPrincipalAssumptionsUnderlyingDefinedBenefitPlanDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails", "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Ranges [member]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r166", "r188", "r204", "r284", "r285", "r359" ] }, "shlt_ReasonablyPossibleDecreaseInRiskComponent": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ReasonablyPossibleDecreaseInRiskComponent", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Reasonably possible decrease in risk component", "negatedLabel": "Reasonably possible decrease in risk component", "label": "Reasonably possible decrease in risk component" } } }, "auth_ref": [] }, "shlt_ReasonablyPossibleIncreaseInRiskComponent": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ReasonablyPossibleIncreaseInRiskComponent", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Reasonably possible increase in risk component", "label": "Reasonably possible increase in risk component", "terseLabel": "Reasonably possible increase in risk component" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of accounting profit multiplied by applicable tax rates [abstract]", "terseLabel": "Increase (decrease) in taxes resulting from:" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in deferred tax liability (asset) [abstract]", "terseLabel": "Composition and changes in deferred taxes, as presented in the consolidated balance sheet," } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityIssuedAndOutstandingShareCapitalNetOfTreasurySharesDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of number of shares outstanding [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RecoverableAmountOfAssetOrCashgeneratingUnit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RecoverableAmountOfAssetOrCashgeneratingUnit", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Recoverable amount of asset or cash-generating unit", "terseLabel": "Recoverable amount of the CGU exceeding its carrying amount" } }, "en": { "role": { "documentation": "The higher of an asset\u2019s (or cash-generating unit\u2019s) fair value less costs of disposal and its value in use. [Refer: Cash-generating units [member]]" } } }, "auth_ref": [ "r103" ] }, "shlt_ReductionInGrowthRateUsedInCurrentEstimateOfValueInUse": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ReductionInGrowthRateUsedInCurrentEstimateOfValueInUse", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "The reduction in growth rate used in the current estimate of the present value of the future cash flows expected to be derived from an asset or cash-generating unit.", "label": "Reduction in Growth Rate Used in Current Estimate of Value in Use", "terseLabel": "Reduction in annual growth rate" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCompensationOfKeyManagementPersonnelIncludingDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Related party transactions [abstract]", "terseLabel": "Transactions:" } } }, "auth_ref": [] }, "shlt_RemeasurementOfLiabilitiesNonCashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "RemeasurementOfLiabilitiesNonCashExpense", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of non-cash expense incurred on remeasurement of liabilities.", "label": "Remeasurement of Liabilities, Non-cash Expense", "terseLabel": "Financial expense recorded expenses in respect of the revaluation of the liability" } } }, "auth_ref": [] }, "shlt_RentalFeesAndMaintenanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "RentalFeesAndMaintenanceMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for rental fees and maintenance.", "label": "Rental Fees And Maintenance [Member]", "terseLabel": "Rental fees and maintenance" } } }, "auth_ref": [] }, "shlt_RentalFeesAndOfficeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "RentalFeesAndOfficeExpensesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for rental fees and office expenses.", "label": "Rental Fees And Office Expenses [Member]", "terseLabel": "Office expenses" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "terseLabel": "Research and development costs", "totalLabel": "Research and development costs" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r119" ] }, "shlt_ResearchAndDevelopmentExpenseGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ResearchAndDevelopmentExpenseGross", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "The gross amount of research and development expenses.", "label": "Research And Development Expense, Gross", "terseLabel": "Research and development costs, Gross" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Foreign currency translation reserve" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r84" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]", "terseLabel": "Foreign currency translation reserve" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r84", "r260" ] }, "ifrs-full_ReserveOfRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Reserve of remeasurements of defined benefit plans", "terseLabel": "Capital reserve for remeasurement gains on defined benefit plans" } }, "en": { "role": { "documentation": "A component of equity representing the accumulated remeasurements of defined benefit plans. [Refer: Defined benefit plans [member]]" } } }, "auth_ref": [ "r324" ] }, "ifrs-full_ReserveOfRemeasurementsOfDefinedBenefitPlansMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfRemeasurementsOfDefinedBenefitPlansMember", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Reserve of remeasurements of defined benefit plans [member]", "terseLabel": "Capital reserve for remeasurement gains on defined benefit plans" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from remeasurements of defined benefit plans. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans]" } } }, "auth_ref": [ "r260" ] }, "ifrs-full_ReserveOfSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfSharebasedPayments", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Reserve of share-based payments", "terseLabel": "Capital reserve for options" } }, "en": { "role": { "documentation": "A component of equity resulting from share-based payments." } } }, "auth_ref": [ "r324" ] }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfSharebasedPaymentsMember", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Reserve of share-based payments [member]", "terseLabel": "Capital reserve for options" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } } }, "auth_ref": [ "r260" ] }, "shlt_RestructuringRelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "RestructuringRelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeOtherExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring -Related Costs Recognised As Expense For Transaction Recognised Separately From Acquisition Of Assets And Assumption Of Liabilities In Business Combination", "documentation": "The amount of Restructuring -related costs recognised as an expense for transactions that are recognised separately from the acquisition of assets and the assumption of liabilities in business combinations.", "terseLabel": "Restructuring expenses" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated deficit" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r264", "r265" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings [member]", "terseLabel": "Accumulated deficit" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r6", "r260" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_GrossProfit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeRevenuesDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenues", "totalLabel": "Total", "verboseLabel": "Segment profit (loss)" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r38", "r151", "r213", "r239", "r244", "r250", "r251", "r254", "r258", "r259", "r281" ] }, "ifrs-full_RevenueFromRenderingOfServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromRenderingOfServices", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from rendering of services", "terseLabel": "Revenues for services performed during the period" } }, "en": { "role": { "documentation": "The amount of revenue arising from the rendering of services. [Refer: Revenue]" } } }, "auth_ref": [ "r321" ] }, "shlt_RevenueFromSaleOfDevices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "RevenueFromSaleOfDevices", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of revenue arising from the sale of devices.", "label": "Revenue From Sale Of Devices", "terseLabel": "Revenues from sale of devices" } } }, "auth_ref": [] }, "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Reversal of impairment loss recognised in profit or loss, property, plant and equipment", "terseLabel": "Impairment - reversal" } }, "en": { "role": { "documentation": "The amount of reversal of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Reversal of impairment loss recognised in profit or loss; Property, plant and equipment]" } } }, "auth_ref": [ "r43", "r59" ] }, "shlt_RightOfUseAssetObtainedInExchangeForLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiability", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Lease Liability", "terseLabel": "Right-of-use asset recognized with corresponding lease liability" } } }, "auth_ref": [] }, "shlt_RightOfUseAssetsRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "RightOfUseAssetsRecognisedAsOfAcquisitionDate", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Right of use assets recognised as of acquisition date", "label": "Right of use assets recognised as of acquisition date", "terseLabel": "Right of use assets", "verboseLabel": "Right-of-use-assets" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "shlt_NonCurrentAssetsOtherThanLongLivedAssets", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesRightOfUseAssetsDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "label": "Right-of-use assets", "terseLabel": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r171", "r178" ] }, "shlt_SalariesAndRelatedBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "SalariesAndRelatedBenefitsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeCostOfRevenuesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeGeneralAndAdministrativeExpensesDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeResearchAndDevelopmentCostsDetails", "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for salaries and related benefits.", "label": "Salaries And Related Benefits [Member]", "terseLabel": "Salaries and related benefits" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncomeSellingAndMarketingExpensesDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Sales and marketing expense", "terseLabel": "Selling and marketing expenses", "verboseLabel": "Selling and marketing expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } } }, "auth_ref": [ "r327" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [] }, "shlt_ScheduleOfAmountsOfProceedsReceivedFromBothCapitalIncreasesAndAllocationOfProceedsToShareCapitalAndShareOptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ScheduleOfAmountsOfProceedsReceivedFromBothCapitalIncreasesAndAllocationOfProceedsToShareCapitalAndShareOptionsTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to amounts of proceeds received from both Capital Increases and the allocation of the proceeds to Share capital and Share options.", "label": "Schedule of Amounts Of Proceeds Received From Both Capital Increases And The Allocation Of The Proceeds To Share Capital And Share Options [Table Text Block]", "terseLabel": "Schedule of amounts of proceeds received from both Capital Increases and the allocation of the proceeds to Share capital and Share options" } } }, "auth_ref": [] }, "shlt_ScheduleOfDataRegardingForeignExchangeRatesAndLinkageBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ScheduleOfDataRegardingForeignExchangeRatesAndLinkageBasisTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of information pertaining to data regarding Israeli CPI and exchange rates of the U.S. dollar, the Euro and the Swiss Franc in relation to the NIS.", "label": "Schedule of Data Regarding Foreign Exchange Rates and Linkage Basis [Table Text Block]", "terseLabel": "Schedule of data regarding Israeli CPI and exchange rates of U.S. dollar, Euro and Swiss Franc" } } }, "auth_ref": [] }, "shlt_ScheduleOfMovementsOfShareOptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ScheduleOfMovementsOfShareOptionsTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to movements in share options.", "label": "Schedule of Movements of Share Options [Table Text Block]", "terseLabel": "Schedule of movements in Share Options" } } }, "auth_ref": [] }, "shlt_ScheduleOfPeriodOfDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ScheduleOfPeriodOfDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of information pertaining to depreciation of the right-of-use assets by class of underlying asset.", "label": "Schedule of Period of Depreciation Of The Right-Of-Use Assets By Class Of Underlying Asset [Table Text Block]", "terseLabel": "Schedule of depreciation of the right-of-use assets by class of underlying asset" } } }, "auth_ref": [] }, "shlt_ScheduleOfPrincipalAssumptionsOfUnderlyingDefinedBenefitPlansTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ScheduleOfPrincipalAssumptionsOfUnderlyingDefinedBenefitPlansTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for principal assumptions underlying the defined benefit plan.", "label": "Schedule of Principal Assumptions of Underlying Defined Benefit Plans [Table Text Block]", "terseLabel": "Schedule of principal assumptions underlying the defined benefit plan" } } }, "auth_ref": [] }, "shlt_ScheduleOfSignificantInputsUsedForFairValueMeasurementOfOptionLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ScheduleOfSignificantInputsUsedForFairValueMeasurementOfOptionLiabilitiesTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of information pertaining to significant inputs used for the fair value measurement of option liabilities.", "label": "Schedule of Significant Inputs Used for the Fair Value Measurement Of Option Liabilities [Table Text Block]", "terseLabel": "Schedule of significant inputs used for the fair value measurement" } } }, "auth_ref": [] }, "shlt_ScheduleOfUsefulLifeOfIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ScheduleOfUsefulLifeOfIntangibleAssetsTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of information pertaining to useful life of intangible assets.", "label": "Schedule of Useful Life of Intangible Assets [Table Text Block]", "terseLabel": "Schedule of useful life of intangible assets" } } }, "auth_ref": [] }, "shlt_ScheduleOfUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ScheduleOfUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of information pertaining to useful life of property, plant and equipment.", "label": "Schedule of Useful Life of Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of useful life of the assets at annual rates" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r306" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r308" ] }, "ifrs-full_SegmentConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SegmentConsolidationItemsAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Segment consolidation items [axis]", "terseLabel": "Segment consolidation items [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r243" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeCarryForwardTaxLossesDetails", "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "ifrs-full_SegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SegmentsAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [axis]", "terseLabel": "Segments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r102", "r168", "r243", "r270", "r290" ] }, "ifrs-full_SegmentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SegmentsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [member]", "terseLabel": "Segments [member]" } }, "en": { "role": { "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used." } } }, "auth_ref": [ "r102", "r168", "r249", "r270", "r290" ] }, "ifrs-full_SellingProfitLossOnFinanceLeases": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SellingProfitLossOnFinanceLeases", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Selling profit (loss) on finance leases", "terseLabel": "Capital gain" } }, "en": { "role": { "documentation": "The selling profit (loss) on finance leases. Finance lease is a lease that transfers substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r181" ] }, "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SensitivityAnalysisForEachTypeOfMarketRisk", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Sensitivity analysis for types of market risk [text block]", "terseLabel": "Schedule of sensitivity analysis" } }, "en": { "role": { "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]" } } }, "auth_ref": [ "r227" ] }, "shlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage1", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights Percentage 1", "documentation": "Percentage of vesting of award under share-based payment arrangement in year one after grant date.", "verboseLabel": "Percentage of vesting in each year thereafter" } } }, "auth_ref": [] }, "shlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage2": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage2", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights Percentage2", "documentation": "Percentage of vesting in each half year thereafter.", "verboseLabel": "Percentage of vesting in each half year thereafter" } } }, "auth_ref": [] }, "shlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisablePeriod", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Exercisable Period", "terseLabel": "Exercisable period (in years)" } } }, "auth_ref": [] }, "shlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExtensionTerm", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of extension of plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Extension Term", "terseLabel": "Extension term of Plan" } } }, "auth_ref": [] }, "shlt_ShareOptionExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShareOptionExercisePrice", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the exercise price of share options.", "negatedLabel": "Exercise price of option", "label": "Share Option, Exercise Price", "terseLabel": "Exercise price of option" } } }, "auth_ref": [] }, "shlt_ShareOptionsBalance": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShareOptionsBalance", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The balance of share options.", "label": "Share Options, Balance", "terseLabel": "Ending balance", "periodEndLabel": "Ending balance", "periodStartLabel": "Opening balance" } } }, "auth_ref": [] }, "shlt_ShareOptionsExercises": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShareOptionsExercises", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityIssuedAndOutstandingShareCapitalNetOfTreasurySharesDetails", "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of share options exercised.", "negatedLabel": "Exercise of share options", "label": "Share Options, Exercises", "verboseLabel": "Exercise of share options" } } }, "auth_ref": [] }, "shlt_ShareOptionsExpiration": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShareOptionsExpiration", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share Options Expiration", "documentation": "The number of share options expiration.", "negatedLabel": "Expiration of share options", "terseLabel": "Expiration of share options" } } }, "auth_ref": [] }, "shlt_ShareOptionsFirstCapitalIncrease": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShareOptionsFirstCapitalIncrease", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of share options under first capital increase.", "label": "Share Options, First Capital Increase", "terseLabel": "First Capital Increase" } } }, "auth_ref": [] }, "shlt_ShareOptionsGrantedToUnderwriter": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShareOptionsGrantedToUnderwriter", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of share options granted to underwriter.", "label": "Share Options Granted to Underwriter", "terseLabel": "Share options granted to underwriter" } } }, "auth_ref": [] }, "ifrs-full_ShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareOptionsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share options [member]", "terseLabel": "Employee Stock Option" } }, "en": { "role": { "documentation": "This member stands for a class of antidilutive instrument representing share options." } } }, "auth_ref": [ "r340" ] }, "shlt_ShareOptionsSecondCapitalIncrease": { "xbrltype": "sharesItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShareOptionsSecondCapitalIncrease", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityMovementInShareCapitalDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of share options under second capital increase.", "label": "Share Options, Second Capital Increase", "terseLabel": "Second Capital Increase" } } }, "auth_ref": [] }, "shlt_SharePriceMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "SharePriceMeasurementInputMember", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for share price used as a measurement input.", "label": "Share Price, Measurement Input [Member]", "terseLabel": "Share price" } } }, "auth_ref": [] }, "ifrs-full_SharebasedPaymentArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharebasedPaymentArrangementsMember", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-based payment arrangements [member]", "terseLabel": "Share-based payment arrangements [member]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r205" ] }, "shlt_ShortTermDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShortTermDepositsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for short term deposits.", "label": "Short Term Deposits [Member]", "terseLabel": "Short term deposits", "verboseLabel": "Short term deposits" } } }, "auth_ref": [] }, "shlt_ShortTermInvestmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShortTermInvestmentAbstract", "lang": { "en-us": { "role": { "documentation": "Short-term investments", "label": "Short Term Investment Abstract" } } }, "auth_ref": [] }, "shlt_ShortTermInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShortTermInvestmentMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Short-term investments", "label": "Short-term investment [member]", "terseLabel": "Short-term investments" } } }, "auth_ref": [] }, "shlt_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short Term Investments [Member]", "documentation": "Short term investments.", "terseLabel": "Short term investments [Member]" } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermBorrowingsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiabilitiesArisingFromFinancialActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term borrowings [member]", "terseLabel": "Credit from banks", "verboseLabel": "Credit from banks" } }, "en": { "role": { "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r278", "r280" ] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "terseLabel": "Short-term deposits (in NIS)" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r354" ] }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails": { "parentTag": "ifrs-full_CurrentInvestments", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, not classified as cash equivalents", "terseLabel": "Short-term deposits" } }, "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_ShorttermEmployeeBenefitsAccruals": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermEmployeeBenefitsAccruals", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails": { "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term employee benefits accruals", "terseLabel": "Employees and payroll accruals" } }, "en": { "role": { "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]" } } }, "auth_ref": [ "r325" ] }, "ifrs-full_SignificantUnobservableInputLiabilities": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantUnobservableInputLiabilities", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Significant unobservable input, liabilities", "terseLabel": "Significant unobservable input" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } } }, "auth_ref": [ "r159" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeCarryForwardTaxLossesDetails", "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statements [line items]", "terseLabel": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [] }, "shlt_SummaryOfExpiryDateForCarryForwardTaxLossesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "SummaryOfExpiryDateForCarryForwardTaxLossesTableTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of expiry dates for carry forward tax losses.", "label": "Summary of Expiry Date For Carry Forward Tax Losses [Table Text Block]", "terseLabel": "Schedule of expiry dates for carry forward tax losses not recognized" } } }, "auth_ref": [] }, "shlt_SupplementaryInformationToStatementsOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "SupplementaryInformationToStatementsOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Supplementary Information To Statements Of Comprehensive Income Abstract" } } }, "auth_ref": [] }, "shlt_SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "SupplementaryInformationToStatementsOfComprehensiveIncomeTextBlock", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSupplementaryInformationToStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplementary information to statements of comprehensive income.", "label": "Supplementary Information To Statements Of Comprehensive Income [Text Block]", "terseLabel": "SUPPLEMENTARY INFORMATION TO STATEMENTS OF COMPREHENSIVE INCOME" } } }, "auth_ref": [] }, "shlt_TangibleEquityFinancialCovenant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TangibleEquityFinancialCovenant", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Tangible equity financial covenant", "label": "Tangible equity financial covenant" } } }, "auth_ref": [] }, "shlt_TangibleEquityToTotalTangibleAssetsFinancialCovenant": { "xbrltype": "percentItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TangibleEquityToTotalTangibleAssetsFinancialCovenant", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureLongTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Tangible equity to total tangible assets financial covenant", "label": "Tangible equity to total tangible assets financial covenant" } } }, "auth_ref": [] }, "shlt_TaxAdjustmentInRespectOfInflationInIsrael": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TaxAdjustmentInRespectOfInflationInIsrael", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Tax Adjustment In Respect Of Inflation In Israel", "documentation": "Represent the tax adjustment in respect of inflation in Israel.", "terseLabel": "Tax adjustment in respect of inflation in Israel" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectFromChangeInTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectFromChangeInTaxRate", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Tax effect from change in tax rate", "terseLabel": "Different tax rates" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]" } } }, "auth_ref": [ "r47" ] }, "shlt_TaxEffectOfCapitalLossForWhichDeferredTaxesWereNotRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TaxEffectOfCapitalLossForWhichDeferredTaxesWereNotRecognized", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to capital loss for which deferred taxes were not recognized.", "label": "Tax Effect Of Capital Loss For Which Deferred Taxes Were Not Recognized", "terseLabel": "Capital losses for which deferred taxes were not recognized" } } }, "auth_ref": [] }, "shlt_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxIncomeLoss", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit [tax income (loss)]. [Refer: Accounting profit]", "label": "Tax Effect Of Expense Not Deductible In Determining Taxable Profit (Tax Income (Loss))", "terseLabel": "Non-deductible expenses (non-taxable income)" } } }, "auth_ref": [] }, "shlt_TaxEffectOfLossForWhichDeferredTaxesWereNotRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TaxEffectOfLossForWhichDeferredTaxesWereNotRecognized", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to loss for which deferred taxes were not recognized.", "label": "Tax Effect of Loss For Which Deferred Taxes Were Not Recognized", "terseLabel": "Loss for which deferred taxes were not recognized" } } }, "auth_ref": [] }, "shlt_TaxEffectOfTaxesInRespectOfPreviousYears": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TaxEffectOfTaxesInRespectOfPreviousYears", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to taxes in respect of previous years.", "label": "Tax Effect of Taxes in Respect of Previous Years", "terseLabel": "Taxes in respect of previous years" } } }, "auth_ref": [] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Tax expense (income) at applicable tax rate", "terseLabel": "Tax computed at the statutory tax rate" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r47" ] }, "ifrs-full_TechnologybasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TechnologybasedIntangibleAssetsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Information Technology", "verboseLabel": "Information technology" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing assets based on technology. Such assets may include patented and unpatented technology, databases as well as trade secrets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r345" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r51" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [member]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r51" ] }, "shlt_TermsOfBilledAccountsReceivable": { "xbrltype": "durationItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TermsOfBilledAccountsReceivable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Terms of billed accounts receivable", "label": "Terms of billed accounts receivable" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEmployeeBenefitLiabilitiesPrincipalAssumptionsUnderlyingDefinedBenefitPlanDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails", "http://www.shl-telemedicine.com/role/DisclosureLeasesDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails", "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Maximum", "verboseLabel": "Maximum" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r166", "r188", "r204", "r284", "r285", "r359" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r262", "r325" ] }, "ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentReceivablesDueFromRelatedParties", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureOtherAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Current receivables due from related parties", "terseLabel": "Related parties" } }, "en": { "role": { "documentation": "The amount of current receivables due from related parties. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r263" ] }, "shlt_TradePayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TradePayablesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Trade payables", "label": "Trade payables [member]", "terseLabel": "Trade payables", "verboseLabel": "Trade payables" } } }, "auth_ref": [] }, "shlt_TradePayablesRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TradePayablesRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Trade payables recognised as of acquisition date", "negatedLabel": "Trade payables", "label": "Trade payables recognised as of acquisition date", "terseLabel": "Trade payables" } } }, "auth_ref": [] }, "shlt_TradeReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TradeReceivablesAbstract", "lang": { "en-us": { "role": { "documentation": "Trade receivables", "label": "Trade Receivables Abstract" } } }, "auth_ref": [] }, "shlt_TradeReceivablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TradeReceivablesLineItems", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Trade receivables", "label": "Trade receivables [Line Items]", "terseLabel": "Trade receivables" } } }, "auth_ref": [] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Trade receivables [member]", "terseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r220", "r224", "r294", "r321" ] }, "shlt_TradeReceivablesRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TradeReceivablesRecognisedAsOfAcquisitionDate", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Trade receivables recognised as of acquisition date", "label": "Trade receivables recognised as of acquisition date", "terseLabel": "Trade receivables" } } }, "auth_ref": [] }, "shlt_TradeReceivablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "TradeReceivablesTable", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Trade receivables", "label": "Trade receivables [table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.shl-telemedicine.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ifrs-full_TreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TreasuryShares", "crdr": "debit", "calculation": { "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails", "http://www.shl-telemedicine.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury shares", "label": "Treasury shares", "verboseLabel": "Treasury shares held at cost" } }, "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r94", "r264" ] }, "ifrs-full_TreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TreasurySharesMember", "presentation": [ "http://www.shl-telemedicine.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Treasury shares [member]", "terseLabel": "Treasury shares" } }, "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfAntidilutiveInstrumentsAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Types of antidilutive instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r99" ] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables", "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSDisclosureOfProfitBeforeTaxDueToChangesInCarryingAmountOfMarketableSecurities" ], "lang": { "en-us": { "role": { "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r189", "r190", "r191", "r193", "r214", "r218", "r219" ] }, "ifrs-full_TypesOfRisksMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails", "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsTables", "http://www.shl-telemedicine.com/role/FINANCIALINSTRUMENTSDisclosureOfProfitBeforeTaxDueToChangesInCarryingAmountOfMarketableSecurities" ], "lang": { "en-us": { "role": { "label": "Risks [member]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r189", "r190", "r191", "r193", "r214", "r218", "r219" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]", "terseLabel": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r205" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeCarryForwardTaxLossesDetails", "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeGeneralDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S." } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "USD", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsSensitivityDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesExchangeRatesAndLinkageBasisDetails" ], "lang": { "en-us": { "role": { "label": "USD", "terseLabel": "USD", "verboseLabel": "U.S. $" } } }, "auth_ref": [] }, "ifrs-full_UnallocatedAmountsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnallocatedAmountsMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://www.shl-telemedicine.com/role/DisclosureSegmentInformationGeographicSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Unallocated amounts [member]", "terseLabel": "Unallocated income and expenses", "verboseLabel": "Unallocated" } }, "en": { "role": { "documentation": "This member stands for items that have not been allocated to operating segments." } } }, "auth_ref": [ "r303", "r304" ] }, "shlt_UnderlyingAssetValueMeasurementInput": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "UnderlyingAssetValueMeasurementInput", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureFinancialInstrumentsInputsToValuationModelDetails" ], "lang": { "en-us": { "role": { "documentation": "Underlying asset value, measurement input", "label": "Underlying asset value, measurement input", "terseLabel": "Underlying asset value" } } }, "auth_ref": [] }, "shlt_UnlinkedBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "UnlinkedBorrowings", "crdr": "credit", "calculation": { "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksDetails": { "parentTag": "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureCreditFromBanksDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of unlinked borrowings.", "label": "Unlinked Borrowings", "terseLabel": "NIS - unlinked" } } }, "auth_ref": [] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r159", "r356" ] }, "ifrs-full_UnobservableInputsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnobservableInputsMember", "presentation": [ "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [member]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r159", "r356" ] }, "ifrs-full_UnusedTaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedTaxLossesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Unused tax losses [member]", "terseLabel": "Carry- forward tax losses" } }, "en": { "role": { "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r51" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesUsefulLifeOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Useful life measured as period of time, intangible assets other than goodwill", "verboseLabel": "Useful life of intangible assets (in years)" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r113" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails" ], "lang": { "en-us": { "role": { "label": "Useful life measured as period of time, property, plant and equipment", "terseLabel": "Period of depreciation (in years)" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r53" ] }, "shlt_UtilizationOfPreviouslyUnrecognizedCapitalGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "UtilizationOfPreviouslyUnrecognizedCapitalGain", "crdr": "debit", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureTaxesOnIncomeReconciliationOfTheoreticalTaxExpenseAssumingAllIncomeIsTaxedAtStatutoryRateApplicableToIncomeOfCompaniesInIsraelAndActualTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Utilization Of Previously Unrecognized Capital Gain", "documentation": "Represent the amount of utilization of previously unrecognized capital gain.", "terseLabel": "Utilization of previously unrecognized capital gain" } } }, "auth_ref": [] }, "ifrs-full_ValuationTechniquesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ValuationTechniquesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Valuation techniques [member]" } }, "en": { "role": { "documentation": "This member stands for valuation techniques used by the entity to measure fair value. It also represents the standard value for the 'Valuation techniques used in fair value measurement' axis if no other member is used. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r159" ] }, "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ValuationTechniquesUsedInFairValueMeasurementAxis", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityCompositionOfShareCapitalTables", "http://www.shl-telemedicine.com/role/EquityDisclosureOfSignificantInputsToBlackAndScholesModelUsedForFairValueMeasurementOfShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Valuation techniques used in fair value measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r159" ] }, "ifrs-full_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "VehiclesMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails" ], "lang": { "en-us": { "role": { "label": "Motor vehicles and ambulances", "verboseLabel": "Motor vehicles and ambulances" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r329" ] }, "shlt_WeightedAverageExercisePriceOfShareOptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "WeightedAverageExercisePriceOfShareOptionsAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Weighted Average Exercise Price of Share Options [Abstract]", "terseLabel": "WAEP" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement", "terseLabel": "Exercisable at the end of the year" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r201" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options exercised in share-based payment arrangement", "terseLabel": "Exercised during the year" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r199" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement", "terseLabel": "Forfeited during the year" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r198" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options granted in share-based payment arrangement", "terseLabel": "Granted during the year" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r197" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise", "terseLabel": "Weighted average share price at the date of exercise of options" } }, "en": { "role": { "documentation": "The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]" } } }, "auth_ref": [ "r203" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at the end of the year", "periodStartLabel": "Outstanding at the beginning of the year", "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r196", "r200" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted", "crdr": "credit", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date, other equity instruments granted", "terseLabel": "Fair value of the RSUs" } }, "en": { "role": { "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r207" ] }, "shlt_WeightedAverageFairValueOfShareOptionsGrantedPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.shl-telemedicine.com/20231231", "localname": "WeightedAverageFairValueOfShareOptionsGrantedPerShare", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value of share options granted during the period", "label": "Weighted Average Fair Value of Share Options Granted, Per Share", "terseLabel": "Weighted average fair value of options granted" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationIsCalculatedOnStraightLineBasisOverUsefulLifeOfAssetsAtAnnualRatesDetails", "http://www.shl-telemedicine.com/role/DisclosureSignificantAccountingPoliciesDepreciationOfRightOfUseAssetsByClassOfUnderlyingAssetDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "verboseLabel": "Mainly" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureEquityNumberAndWeightedAverageExercisePriceswaepOfAndMovementsInShareOptionsDetails", "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding share options", "terseLabel": "Weighted average remaining contractual life for the share options outstanding" } }, "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r204" ] }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "presentation": [ "http://www.shl-telemedicine.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price, share options granted", "terseLabel": "Share price" } }, "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } } }, "auth_ref": [ "r206" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "For the computation of basic net earnings" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r98" ] }, "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract", "presentation": [ "http://www.shl-telemedicine.com/role/DisclosureNetEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]", "terseLabel": "Number of shares", "verboseLabel": "Weighted average number of shares" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2023-03-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2023-03-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard", "URIDate": "2023-03-23" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_51&doctype=Standard", "URIDate": "2023-03-23" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2023-03-23" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2023-03-23" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2023-03-23" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2023-03-23" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2023-03-23" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2023-03-23" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2023-03-23" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2023-03-23" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard", "URIDate": "2023-03-23" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2023-03-23" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard", "URIDate": "2023-03-23" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard", "URIDate": "2023-03-23" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2023-03-23" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2023-03-23" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2023-03-23" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2023-03-23" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2023-03-23" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2023-03-23" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2023-03-23" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "91", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91&doctype=Standard", "URIDate": "2023-03-23" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "98", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_a&doctype=Standard", "URIDate": "2023-03-23" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard", "URIDate": "2023-03-23" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2023-03-23" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2023-03-23" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2023-03-23" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2023-03-23" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_v&doctype=Standard", "URIDate": "2023-03-23" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2023-03-23" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard", "URIDate": "2023-03-23" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2023-03-23" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2023-03-23" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138&doctype=Standard", "URIDate": "2023-03-23" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "140", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "140", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2023-03-23" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_a&doctype=Standard", "URIDate": "2023-03-23" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_b&doctype=Standard", "URIDate": "2023-03-23" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "c", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2023-03-23" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_d&doctype=Standard", "URIDate": "2023-03-23" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_e&doctype=Standard", "URIDate": "2023-03-23" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_f&doctype=Standard", "URIDate": "2023-03-23" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_g&doctype=Standard", "URIDate": "2023-03-23" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard", "URIDate": "2023-03-23" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "145", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145_a&doctype=Standard", "URIDate": "2023-03-23" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145&doctype=Standard", "URIDate": "2023-03-23" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2023-03-23" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2023-03-23" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2023-03-23" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2023-03-23" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2023-03-23" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard", "URIDate": "2023-03-23" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2023-03-23" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard", "URIDate": "2023-03-23" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard", "URIDate": "2023-03-23" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2023-03-23" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2023-03-23" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2023-03-23" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "130", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_e&doctype=Standard", "URIDate": "2023-03-23" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "130", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_g&doctype=Standard", "URIDate": "2023-03-23" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2023-03-23" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "134", "Subparagraph": "d", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_d_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "134", "Subparagraph": "d", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_d_v&doctype=Standard", "URIDate": "2023-03-23" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_e_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_e_v&doctype=Standard", "URIDate": "2023-03-23" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "134", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134&doctype=Standard", "URIDate": "2023-03-23" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2023-03-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "135", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135&doctype=Standard", "URIDate": "2023-03-23" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2023-03-23" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2023-03-23" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard", "URIDate": "2023-03-23" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2023-03-23" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard", "URIDate": "2023-03-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard", "URIDate": "2023-03-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2023-03-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_e&doctype=Standard", "URIDate": "2023-03-23" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_46&doctype=Standard", "URIDate": "2023-03-23" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2023-03-23" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2023-03-23" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Section": "Accounting policies", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS08_g7-31_TI", "URIDate": "2023-03-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2023-03-23" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard", "URIDate": "2023-03-23" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2023-03-23" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2023-03-23" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2023-03-23" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2023-03-23" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2023-03-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2023-03-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2023-03-23" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard", "URIDate": "2023-03-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard", "URIDate": "2023-03-23" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_115&doctype=Standard", "URIDate": "2023-03-23" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_128_b&doctype=Standard", "URIDate": "2023-03-23" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2023-03-23" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2023-03-23" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_c&doctype=Standard", "URIDate": "2023-03-23" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2023-03-23" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2023-03-23" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2023-03-23" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "59", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_59&doctype=Standard", "URIDate": "2023-03-23" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "90", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_90_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard", "URIDate": "2023-03-23" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard", "URIDate": "2023-03-23" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2023-03-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2023-03-23" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard", "URIDate": "2023-03-23" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2023-03-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard", "URIDate": "2023-03-23" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard", "URIDate": "2023-03-23" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard", "URIDate": "2023-03-23" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2023-03-23" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2023-03-23" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2023-03-23" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2023-03-23" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2023-03-23" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2023-03-23" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2023-03-23" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "51", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "m", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "o", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_o_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2023-03-23" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2023-03-23" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2023-03-23" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2023-03-23" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2023-03-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2023-03-23" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2023-03-23" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2023-03-23" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2023-03-23" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard", "URIDate": "2023-03-23" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2023-03-23" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2023-03-23" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2023-03-23" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2023-03-23" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard", "URIDate": "2023-03-23" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2023-03-23" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2023-03-23" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2023-03-23" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2023-03-23" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2023-03-23" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2023-03-23" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2023-03-23" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2023-03-23" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2023-03-23" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2023-03-23" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2023-03-23" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2023-03-23" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2023-03-23" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2023-03-23" }, "r258": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard", "URIDate": "2023-03-23" }, "r259": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r260": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r261": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard", "URIDate": "2023-03-23" }, "r262": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard", "URIDate": "2023-03-23" }, "r263": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r264": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r265": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r266": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2023-03-23" }, "r267": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_f&doctype=Standard", "URIDate": "2023-03-23" }, "r268": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2023-03-23" }, "r269": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2023-03-23" }, "r270": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_d&doctype=Standard", "URIDate": "2023-03-23" }, "r271": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2023-03-23" }, "r272": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r273": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r274": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2023-03-23" }, "r275": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2023-03-23" }, "r276": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r277": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r278": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2023-03-23" }, "r279": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2023-03-23" }, "r280": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2023-03-23" }, "r281": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r282": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "B11", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B11_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r283": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "B36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r284": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r285": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r286": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r287": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r288": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r289": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2023-03-23" }, "r290": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "96", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_c&doctype=Standard", "URIDate": "2023-03-23" }, "r291": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r292": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "IE72", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_IE72&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r293": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r294": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2023-03-23" }, "r295": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2023-03-23" }, "r296": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r297": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r298": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r299": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r300": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG32&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r301": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r302": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r303": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r304": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "IG4", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_IG4&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2023-03-23" }, "r318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23" }, "r322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard", "URIDate": "2023-03-23" }, "r326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard", "URIDate": "2023-03-23" }, "r328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81&doctype=Standard", "URIDate": "2023-03-23" }, "r329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2023-03-23" }, "r332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2023-03-23" }, "r333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2023-03-23" }, "r334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141&doctype=Standard", "URIDate": "2023-03-23" }, "r335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard", "URIDate": "2023-03-23" }, "r336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_144&doctype=Standard", "URIDate": "2023-03-23" }, "r337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145&doctype=Standard", "URIDate": "2023-03-23" }, "r338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard", "URIDate": "2023-03-23" }, "r339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2023-03-23" }, "r341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard", "URIDate": "2023-03-23" }, "r346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard", "URIDate": "2023-03-23" }, "r349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2023-03-23" }, "r351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2023-03-23" }, "r352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2023-03-23" }, "r357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" } } } ZIP 137 0001178913-24-002281-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001178913-24-002281-xbrl.zip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

- JE-M*C^!JW$@+U%WE4P.=_['B[?_+" QZ?GV ML^.?'?(VK_O^&J['WYP2K_O^;C4CY*7@J[Y_%^+QJ]]7$4!GS]OU8X&4_JH3 M?_I%0>]NB2C'B]_TY!4X-!@H5GEL63LIY.AL&5$*I\$]MJ7OBBL-4T7IG X_ M)-1W[3U=_7Y#"R.S,BQ^W+HT\_U&L?_C+B:E7?D2E]+]((NUD^&@D@.5N?VE MZ04_D%'>6]IT*Y^ B[;4UT\@:VV3Q!1_B<96QE/[/^JE9CY_//#E_U3&?>Q$ M]!R;E2\KL4W3J!F]*Y1$VSQ^Q,AM2UK6;%C6@@KMZI/_(,3 ;/S^[6#:W?)$ M2NO/XFTSZ<^C1BYFB?)E1<[[K4/GR38V^3[2!X#/"KLVQJ[IYP^!/J8AT4((ANXTRLTX64Y_5*]-N*^)5J MSZ[R3!<[(#FHG)6]0EVZKS_4;A1F[/CN2K[*'TPP'DUR(]-0S9\ T+!21ZZ# M_&.3:F45=#&.Z^,EW?O\W< T$BC3*#2'YF\,:,DM2'7*,X[:^)6Q=G[CBG?G MT'#^PN <;V8A]WZ$"4$ZY.!"A7BH1@4:3>(QE9XN7P4K%)^H'(N=],8FTKOU M1K$PN78S)/(T184_,5;ID>ZG\\&N%V\HL@8OSPL0/>QK@5N'E4=/)AXDJJ[L MY*+V]4<8J@S]!WY*L-8O2"@EBG6^SN'EMK+3SI*T?V!X(&L/?+&Y-[6^$!OB MKU=LV!U0<&+1)8M(.#U+'V"F!3?7IO?'X>+[&^KKD+R QCPD]_2&9<2G::M' MOM2Q[UTBO;VUC.9MC],LP2Y+ 0$EFTC#]BHISP-MC<9Q%\VT_L>:7,..:FST M@(809.%2S?7(7<_(KZ)+)1,K+@_]U?']APK5]CIY2,5P:47^'DCGHD&F (2A MU:#K:X(K?<(XNW(8A4R'1=690FU!-0#"YD'TD->F7P'YZ:6^?H.IODOOIY/I M'=FC&V)EI=:C51**VN7E;U3WL 'E-T*K0K2C6Q7&@JPU#/69:V.I-X]IV:QU MPC7&G#UM&%U5 MRLEWF%Q9!O*8SQ..[X'%]Z3,H6UT70E.M63,9$*TR*TAO@3;GF83O:=V#2W: M+P\6?I!9KJ]\5XG=-:\<OKH0&W-:"[_>OH(V=K%N.KM M-2#VT/EJ9E"!_$QNF<\U[_W\S79_6O5,DA-#CP;-T"IYID)-4GBW@#,W^1W+ M$R8F"T5*1+2;YZ=N/L]*+7UX7*).@7^!L-A@]:VUV$&1ZNG. MF1Z-2;3D&IU?7-(6RY;71YY<^*EBR#^O-_@W_LM1(4BDZ'$);V51)B_O+IV/ MR$V34Z"X.9%EF>3^DVY+Z)0JW#:X#U#WQ3 1L_WS;?V9@GJU5K^_0\U]O]&S M*'(N'QB51>)GS!6 5_X%WA!,Q3\93@I[@W;+&%\1>T'Z$:OJ89W>+0O7$.=B%!8= 2%V M-^"\#":&^(6\)%X+N]7J!NSND:K02SJ[1V&VSHQXA(/II+]* !>JW%[/%[63 MWIOIS:^VIGP =#OVLST)PXYR9MF$#4]*.[T^H'\=)B'GP'5-R3FJ1/H_8^KE M)6C^+@JE>$>-'N\TDRZ!V]P3Q,\ZS [K5 /NZ>T0SO@3\ O"5G=?BP&XZ98W M:TU.???*N,.OC)UM!#I/^6;6S: B:!H4@(L2P$+^J4(=931 :TB['HA-(&@' M?FYFE'=Q)K+V+C%O!WK(>DQF,5;%[U;>.6QXD3SBX!D2RCU> ?B*W,,^@O#O M\CWETI15$Z)F-W.NNQ#^(0Y/[ZO;532, *POM?8T[.;+)\X]"S60%FFJ7%H*5%_C=SZQ[V._C\!64_'93]P>/5T,A9W M[@ZIB[&N]T-(J;6U_LZM$Z,;O\.J'2)CN-!2N,K? O 62R_-,[@;_X YN;X(LK*C5C;/&!I]N[ MT)?(2?*XYHJT-*?A/%__22T2'TEW<[7[?6M='(ER <+'UE-6!]]OU&$T\S=/ M_2NJ@ZQF%NTOO/Q'Y$9.#3Y>C*SAA?D'3O4R6S4N-!-:O0][[Y[?#DQFL@-3 M507=\%=L[T?YGMBV"O2C"=02VA2A^DW(3&>9+MVVST3\3SZH"J(S]N:P@_(F)^ED]8"K'[-6*%85.=C M(1X(4A^OA>\L+9<$5:H%H&'A6DD4U4]7@^PJ:RI;D8((UZR7DN1^3G9O^K?7 ME-",168!D?[66FY707A1N-9XN7G#$TW-))7(/_G1:CYE_Z+,DB'E+*]T#W!B M:L][57^79+C($F%).<#7=J1RY^(#-'_/CT]7.EZ6T!O\I!4+[QH;E(X2'Z[6 M!Z.!6?F$!A#KAVJRZH?@D%UEE.S7]5NB:0E%$R5JROFMFO0KM*2OFCI?#8F, M5:]Y$,:+M)SD.'GQ;E1;W6KV&;::&@R:B@=IS7ZL86WW)1B+2G?/F/%T:^F! MO:UC0A[-6FL]^_7I 6@5.ZM;NG%U.+I,RFQ#@ETOAQAT=BJ?9V>6%]0PY35IB.C)^7[#A*VN)1MX ML;H_';#M^ZWC6@\Q SU\BDL9O1C#7>XEQ>-VHUI=;MZ,-@EKLN/VI]#2R4Y7 MA.G#]Q TN#_3GOK)F_<@Y-JWM#<)J/V4$>J3$>JAGTN@F9W:YWQ M.SI8*9^YJ:%3S5F1-975KP;)0[L[@0PGOX!JX<-+[8LL2#KO';]=T3F=)GG+ M6'Z?^MD$;^]J7&:PS]0#'ZV0L*=Q*@S"+E?9;]FC>9\.WH_C[E$15#KFLTIY M]#HP 2QW<%M?NQV%V*DJ$UVG2S_3_M9E?=)/\9!$&\%D*ELK:Q_&D"G=D<1( M01+$'86/8>^M(_KL.1C(* <.K52*Y-%W .(2>)[GVW:H2X%>A1B]24B_?%X> MXN<80O _/M_R;_SWHFL* ,1]OT'^KRL[-DULGNVU'5LNW"^_6NDO.[;TS3P# M]BL[-I^9-;@X(C])PH64J+++C!N@VW,ZXS?S+C>-YFPY6G4IM%W"U-H8_8&D MGG .'/(8591(2/)UF:5V)I,B\G4*+(7!:@^3"=SO=^2Y KE.TCOF96([M745 M)D9V27R2:::T.P$FK"6$ KVCQ4=HDL. ],+(BY$8Y59@*VLA";I?24RG@;49@W('YUK[96%3+RB[3+KVA13Z^I3'6 MP7$2VZ5 W_H8%CHMV2R)<+2&V^Z< 1C55$UYR&Y"CFF=3/51 @<#+IYHXW^- M-7@B((P>X0/\9Z7$V..^-3I-AV08.2Z)7;+K>8MOT+9"Y%C2;8%,6:E"]7** M4)B[F$^2:)BHRQRV H$'Q%,K4H"HMM>REJBEEQ7T^_QIRN1T\&18@;,.].Q;8H'%]BEK3Q"X-OO-P"+?FT/ M8K_M5-P!@ZSTVZKW+<'IV,=?-<)3N/NPCFPZ^2G57D@5VI5\J&BJXPDBE MI10DEOWJ'^?6_A^;JBX6A"G\K3Q/ZLRVMQA%IFJ7Z2^S5L/)]H"&1M_Z^WF3R4#G.VK:['(6NJ?[P.[N9 M*R)O=FNR@\O&=L(4QTU!%9JC/ZC)O>?_^-#BVPNW'=0%^H03[^6B3,VOA8X- MO[61\K_8>\^H)M/VW9L9'0NHB/0^@-10I <,,,( TB7T+IW00PW29I . >DU M,-00JI30I B!(%VJTDEHTH2@(-UMXO-\>-=ZU[O^SKOW?O9_KW%Y?F>M._=] MG==Y'L?QTRQ/YXP0D-S".6\PG+/1"Y3$P5F4R2MNZC&R:&Y.(_G R;EF^]!< M/4Q <$=+GKV/W:1I*:&!UP2KA177AXSXFC/'9\A&<4(6*MCHE8.MK<]$OY+U MI68CX[Z2; M.NG:VJ(97>BBTDVF1O3#V0^GED0M!K6Y7$>./4F+P>(FCG&A(6HQ:KD>Z_\: MP 6>0SRZ8*@]=EF^+3L->!AZ'?;LL?52[5[#H!OXPTDRJ&I]R5EW87$TTN_; MT_MVQ[K'<*3,XM3>3N)T6> %Q@O,>G18ZLP;J9!A>;S"RQW4?8[@&D.?O+X1UO-(#\(W69;C\BE?ZUB9P&7XYT>A(-ZR7B;-M[23 MQ?5CCL(HEHCD=\8MM2W)G'5\9N$1?SG>4ZECY$S3>]N0/]/4^T['Z;2QJA B M-?'[_59CRSV]25?$7\*-N\Z-1R1*^:_-3K[>/U.*.?&TZBOG[#H30XL5[%3' MGDSY1WPSA6Z92]YZ+P? MI!1=0P[.W6^NE.?H;I#785ZAI[717XDH2;&>FLV<@^PLS3CY_=,-251?.33Y;3O M:$- 5MS P>7@FFM**&*])FUQ4^&*//,FQ,ENS&&JVG6=.F[8[$D;XJ,%KSBV MR<_P8!9"3_7KW$]-;A*/0#?N;EBWO%="/B?_)>M..[8KG+\Z9 MIKXV&B6$ M81VDE;OL%8VA2N@934]GIS2LQ-WT?RHV MCY&L?CGC3D&;4+U[UB;$E%9",YLHI_T8K9WML8C2Q>8:S!_:'POI7\ MO\,P@TFUX*WNPM*AT!H7IH0*SF%O"4" K^!+T_:5BGFA-)1'O7$OERK#F5SN M@]]0-+K%+BRZY5_)LBQ%+]^%7@$*5XL#]HNB@'&].],1LL[I[B?'(F%KIEY/ M*FXX,'904/4TEV<"]!'*.A%\R] $"=1R/62L1M"!_?!61M?\&5.!D70/[N 9 MV/VS3Y]M +C5'<'81_&+W+T.80.."@3-2K\(NDV5\.5U-B_B#D)R*4;$]LQ5 M44Z8FC76PA3'H78(&.7D;7B5F19[IIYHF-B?H!&A1C-7U3<:PG5\MM+N,1*E MG3V!\0,'-W*P9=Q(/MEU?_FB^#1M(U_,8O9W\M[@$M7B_@TU[NYB5Z'II1ZG MFH- K,[LP\^EA*AMH,CAW"5'$Z6-".4..\5*/"YP[&)@M0=*^0Z::Q1]5)YX M9B&R.V#,HM/4"SY- [&&EBL=#F5@+&GZ6QP/V7=!FKZG6)?^V/IWQKCVW =) M3=+-%\]1;,8*3AML_NZGEU_)]%O3S\#MKR8]'&G/D=.!4]^5_DJ;I6&(9*0P!K;,\*M#G[>,A=K-W54(0^MDJ/*K;7 MII:6VXPJI@KBZK=3U8S_G8I??U7X7]7YO0C6CI&0Z)RQJR4(0KU'G'5>6.';F:_C[N51JOY MO&Q?1);-//S-PFUVRNT[#O&1Y]NM]:ML=F^U?,KBI -^5"!%I-#.8#YC5[@5 MT>PWH$$R?U2!2_A7COL4<'G,,!.EZRQVK$'YK#G5W#[;@>K&SKZ>)ZS/=+': M^@#MN.X5^\AO?6",.7W8>GQ]M(VS,@]J^>5QI8Z8]VH0&C5V6K7B*%5B*9)D M*6#^%GR\'GMQ93SD6I#T^/C;_L+A"O.9(5[Z[,:"@(?SK=J.=JK6&<6'. M1XU7W&>=PF!WN2>]ZX<.GM'EX/)O?ZAO)\Y3J=5:DGE(\]27M8AEQ^_SU%B5 MF.)87J=!&A$65R,O?O;)<\8SIC;[(5Q$55\(_W% M\3VA66)J[S2\]'C4=$N MW8I'^C4:5!I4D3A01ZD"A*P987[YU;^2;+2*&MC(])=>34=L^ M'KJNF\X)"Z*5Z50-#7" =C 0>])4%ITOV=Y(N M3NLN_LT3/CEG'^[Y/EYULG0Q"[ U29>Q\8M_Z9FLTNO7FO+A2.&G#NZ%!64/ M:-$L)$FM,_CPJ*94S>7:FX5WPUI2&[KM\BY\$: 3Y39I8'"HB@]+?7B? 0F\\0IX[IM/$%F61=ZK)36 MRJK7\Y[69AJK4@G -J=J5$JIUT0[)#;2S-.O" QZ>B9GZU ):DM5RB0_2>5E MRI0U_[PD42-+'3X7ZS,>GWHI0[)A^UF1;-C:^4W?;=CK-1N._[)A4^Y<6G(> MM'6B ^96EU9/-#:>T?[XH-9*4==J\ISY3"8D*HA>.[]V__E//;#W9K/K('L$ ME)):O^< CXPIV17;P4BD/]*8X5>Z=8E,P8741I20PT8K!PR01JN$CON$/,D. MU_52)DIGF !#D$!B:^$N&,$=[5^?T6EJ7N>&23,1 1+U%-+CCD0]Q>;!&P)1 M3R$B6?:S>!])3^%1590IX4R'XS"9NI54&29C;[3W8T&&Q)@\)8S([3;Y^(+7 MEFS["E<5?;;!N3"E\ ,VIGB4C+#>'L^Y)A4.CR"1M?*T_,_ MO]GXI_[S9:B-KG&Z9*E- ;^3!&@)#\BMC+Q*L_UD]]B^^4RN(6C0WV^_2QSC MZ,+R3N_$]:42UVUT5[9#BX-JAJUXT+;H:WM&;0O%4L"#H4^:#NPB@R^!IAK9 MU;R,\-[)DDC,DU(TRK3=6"]L&OQX/$T O:4()S< &**XR7U0B@8"^BFS#\*I M4XM/^4J7;$UC3^9Z%!I"(WR^. 4IE#K+?@RRZJ4\DIS9[L!,ZT*T^?EFSUE4 M3X?L?D8XJ(1 UP)!:BBDVZ![OO@/LW3 -!)WSABJ/0S'LF=AE^^G\9.:>6J9 MFF_@R_(<%Z6_WAB#&6'J07 :S8Q%CC3.QXZ?1O.9(<]<)R2'5&9^B[6N-)4= MY1=Q'YO;;3GAB27:@9]>5+$_[I!+!US!35-&M3&_<=&K4F&?H>&'&M&U F.? M( T9$GA&]S5^(D^== ;QB-S'Q<>Q1O@BP4#4.V1DE=)A94XW&_/@B8"#7L^& M<71S_QD$Q$.9+=2P$H$9G97XO!$19/#,6U<-DS8@MM.F1+B.S>-7B3(GT!4% MN-W751**]V!-0,@^DFF)J998D'VH01&3'%PGU#.])V\;SBC5=2,17OCM[Y2$ M%<4UU\,_F69]88(JW"7X!9CF0@Q&8$6R0_7GTU5\(R6/)U"9Z\VYEF(^*V"T M:5)X!1 UA;K?@N3Y2J;5O;R?R02@#.O&O?2A;BV(*-"@5)9*=M,K8GCT4$5@ M2[I.PRXLEJ\F3U;Q/S9#!WAK[8_&2):Q;:ON7[94F*F*F[5C_WCO]*QLC2R3G@#=IF%_"N8+FC]T>O M [ ?7)R" @-=606F$+(0I$R95Y?$ZM10A5%15%1#C6D:N;_N45JY8J[PD?D$ M%+ZD'-@1R4J[/:OS>C2&J6B6?LQFW*V&DS1*J?]3*&GY^RAE8>OHDPQIE#)Z M]>.]+2 M#^QL^(>7MLCKP3UD+=6XO"5/*K7WH*J=^UWNWCY M<,YM06D;.R*0[3'4IUY82=I(>>^;UXZ$:U5^TCI7WE]00Q*D: M#%439!K+.HISM:%+)KU\R"H:9\U*NFD2:Q* 4_8K B*!/5QBUU/6= MIXJ+P%;<\82XB#(+ZS*'S,V9@U:8LSY?(R(YE0",];4I1FM+\);">0M.ABW: M$S%6T4SP24._RSN$6U[#G;9+D Q9B[*#E0"SX8[)HH:ZYP+AO @H>P['8]LE MB:2BD,0?]N*RG]$#;:*FM@A?$EJ.7$8O7*Z> '-_AXSY/PV)0VON? /YV]GOT\0*T?:#K&GCO& MKA\9#_'\+.85U RZ?=T)[?YXD*'6ES.=D)S?H&,9?,_RAW./CXX4;@?]A#3M M=?18WJ-4N_7P2.XHRZW<@EU,-:UM;E?]X:N9_9$NT'8,J*Q;B>U-$9R^J;"S M'*CS8>QSP+*S9Q0YC OGKF-( \!9RB=>]3P,PC?24\4:#S2[&OK'O;81#[*_ M'A/!CTT0835%2"K=ULZUUK@=%:&0TDM0I5J9@[5]D:S,+5)P(+S/'(O'L3T> MH.$ 2UAS,R/Y%(5:U+6^_4_550Y9A#U2IGGRTS_U3_T_*J OMD,0QMZMQKFX M3>5,3]"2? 5A F!0SOQR#81'OK<'[O>[(8?=Q]-AAP\K>%\\@K*V#H.$;L.N M1W][ >4<-D::]CMB("7=(7/DSDS%\+(E"8_PVK:P:9'Z&>.%[E>EZ8MKZ K# MK*+X+.N(X=$#G?A0;9TBWC\/H5G^]+",=(<@C>=(;3TQDO66\^HU\ZN_^.-3&JB00G2]/_P3S%3V>!A898$C1QW.,?0%3 M@@X&RU%168Y7K3? N7Q01T8\/T'Z+D@V%J'>;,F&T1'>T8G$'Q^PN*#X[G,;[^(8Q2>_1X!8?PNG9Z';$_^[+$.W<^W/) MXS_+%I2)7_>[?8)SQ*^[=\ELHK#T]Z^[!I]8F6+ .ZJ3.II(N4]J3-(>Q .$ MRI>2>'YH1ZT%D,X/FB7G3R#2^>%\%H2(^W9^[)Q\LCT(FM=8"\%UAZHD%DNS M3(8#];K8:>IC]7J^:WCP3(QR+(;LY/_6\&&2W;\N2-#QP]80.)@1PI)J7 MDCR/3B06Z$V6T[O18D!7Q'@FG8!1;RB0\5)Y4D">7 5LL9!1O*>F G93$7/I M<:JI_"_KI(@I+!NXW?@]R?'M["$W:I(1V"9,6N2[$5BM15R@2*7\"^5/:G9" M%(\Y85_)4,>J1T87#YJS]4,;CE4CFNG@SJGZ4!8+[ SKXVZXL^6[;-M&KL1=,_?#K7;(507L3EZEAM'<+.^LRC!%8OAU%QKSU#KSNP M/#I,T=PWN= [8@M^Z^+/N3 M.YSHB_((30>I//8,>Q6O(L4$0-YI:T,:S&M&1=)^>)1])%@:1]\#-[W>C-[/ M*Z*!B/]F!$X>5N/XY]4^!^C^[/7#6F-W:Q!MK$+#E"51^I M[95#*BF0VMXEBR7C/F%2V_M+7GQG?CJ"-069"Z8R2U_0JM&ODU'">N0I)]B=Y3 B8*5S=]].03]%U M?MT*]0KXXV^/!BO,7^,;69"V;.T_L(DK?U>98JBNUX,7 *?$30'?1K9*3$<- MM5KM#!Y)!U8M]R](8#0WCJH\2@>W:3E_V.CJF#H$?D4MHTOG-::4!0V.]_OHH M46RDCICM_9H='Z-#!:(N-/J<7IND"P5A51#D)%UH.7175>=;W_1=%PIE-4U; M,10@ZD(%#>DIB+I0%IJ2J%#^N)6.!]C&;>@=^VMK1%VHR;,V:Y(NU*[(S?YJ M*K?"HKIP""&F]-@1\TQPS[?H./3W<7>[F*K%%:UQ5T%'&.-*4D% E1L^J1#" M&3,KUDO1QTP['ZNR0&/T&:N7O'IR[0Y18[N6)?RS)"])8QLQ^!):88 D:6SU MG^;CTGM;(5,.-#SE?8 M+O[K?WRG\4_]GUOUAT)6ZF-/-:IL]28^YT!XS'R:)VO<*I\&S-Q/LE:K+HF5 MRBJ*-3+&T/.SQ-,[B[+1XZUF1;I-'=/8H]R$SW4!)QZ"6?F_UT9*?9J:&.FH M2S[2:)X%,@]82)BV23/W?D%0S^5CSPU/%8]YER-OX\_U"2(1S?(AH[/C X3, MC7@\R/[^)K_^8+.1 #(1;SZ"4/!0-$!FK $SQ^#.>N4X\B2/V0&8-VC4L3]U M#=9FTXXPUEO%/-JVUZ,WF>@>]T@W- H-V8;0?(5C<3Q[(S'1MUEP_C;_CH3 M=L:%S73)6NM;8ET2Z[,R59]?0:6*O*FR+$PU DUTK^H]K.N[.I1/=1RUDM@C M%,Q$.\7YMJHXEF_U.>:M9%Q]KTRNN7"!Q+MG[6TC?LH"LUMW']VGBLYFK9L/ M6%2R6G.,#VU4C3C8WA4[G4U6$VM@S!-FT8C1N=I_P &AS M'($W^55*("OBBW2]6/V-J$@F712+.4F*USN%-O]*)HZ,2)0(G1%[?_9L/#)W M %9.@#-)2JLI4<9%EFL_ RI4M2F=:?Y&5;A?$^40P,27)=*F)/#[B]&-?'FI M\<\SI2Z9\+H_:3#&#;YY8,N%HJ8Y[V4VOF/X"CM]O_=%;=5"#B 7X'3D)9<7 M_[)DPM*LV^>8U:;E3&(H3VOX*]GL7BS&8\-BZ*W*8(^NU>J7>"O-SN*,A-1: MACORA(>R*,QQK%>17@3P&3"$#I>="<$V\$9AUP)N"]X2C_6*Y&S@!AV50J(1 M,N5Z50+Z91/(TW6-+G/Q%\V3@P>M%%1TQ;6P/%=+?C4@FL^@1Z95"*A<$J5? MF+VN"_9R+8P%G 2=_O6_Y1=>]?Z]U5:&KO%FH]$S^,X9<E#T? 3U"SLF%-*GIEK9^TN-EYH^.^\UNYWIKP0X8BM>R?6U/3GPFN37&]J#/= MII>2%OO=4)G"\T7#+?SC::7[X/+@OALP>[Q.M%@JD *S"%P)Z"YQUDN\X9D7 MW%,'-Y<3D"30K+'D_ 2'HA03.".7VY-8+RM'?^UWTH(-9IMQA#W6_B.FM@*1Z(LGTH9>P%7SPD&3Z0-B!2NPC0#E ;Q8GNT\\8NJ723]XBJH2HSZP MG4SU:D]0?7E\,&@W@^GDOH&]SJ\%/2!(CC7M,P/>> Q^/S.7\J9]OMGKT?>Z MNEV.F?-L EX]ZGFR-&6ZJ#AB:)P,-S=WQII)GAC46PW/'=D%S@>HWPM?T6,T M2BY<3]M0I [3U<[Q2HY:;_Q1&TU$\?FMXZ1RN8)@.B&>V0,.8-L4F@)X;X;M M"LC%W]Y#:+'&0QSQDMEO0G-?&R=<]"?8,?$S.5&0-OI^:GG:!"3D_I"@TR,O MC%+:.@18'["P*75E^4FA!;9*GAG'&L=+TSE([#.4 [8^%80/>[[?4M=#J8I' M:*L2<1^2C@;Z*W\,>.TP98C%UU+WV#HK"DO%Q<6_]%EXK+$(1O#K/>-5JUA: M0?SHT#:P^'*X@PJMH3IUZ.9MV!)IS3W>?93M@'@6)^/;Y&+0]*JS*69YYA>, M4D7,_$G*(\D*D OE& F6$3+"7C!ZK96V[%@I' \*9O+EUV''RGPEHX9R]JK MWJS\NKUZO+.P/XY2G1G'Z%5$O?E@D'[G7H&I;SJ 65"G?R5(?4730\(^5^>V MMI:DSB]1W;@6TRBNM2KMQ.DJ0 M:X,#\(T%W+2PQ%_+MS6;>%&__]F9_/K&# M$=_LC.S)GQA72&^V]/38$)/DMS>['T ]!.$HE2KW&^L4Q[S^N5/ZG_IN492!>(3;O MZGXG@JVH9E8GD'+NR6:KB2QBO_5E][ MR"_$U=1W3E.Y3:U\V)I9\[YA&AU% M5-QJ\V BC O35EAS%_J%?O_=-;O4ACR77L9%BZ1E\Y."&^/(Z*%:AF>^%9,H M<)J \3-AWVW#"G6X@'>%82[W3-@@X23-/FIP'U;IYH\6%")';[A9S$-4M$75 MI-8 *OQ2LVKH#P:TO3UT+[1\?24,IZ?'U*#?_G$J_=)VMTA-8D*+2Q"J3.,\ M>C]9K)"S7OR7J^_Z%KDNB@]S\F67ND^Y2S-NGKGRESDG2Q4%C77, MVMOZDW_,-@M,GZXR=4@0LX^DEY:_C1>A@R7V9F@$X(4L]_3302+R=5A,5=.M170(+GY9B>V0"LXYF_41$_OZ*" M.ZQH)>-/D!SKD)__5[+]I"U/'%?=6+U013]WA;GB@ZD" M7[?[Q<&11F%XX/GU'H4&';@DK]W;Y8ES25>>V,?90-LI-&O<3VIN'X71#-G= MQB6(;%\GGSB3E9NW.!T,LJI!/\=^)1,(LKDH^4JFGDB[A7_0XL$PL5\1A02[ M)VCATF1/[LCIQ5>H4H)TZ UZ;([K8,VX;0%8EOU,AT$ZWD41F&D/#.B.=[JL M3SZV[@Y0C"]?SG.+4?,V'&:!TNQ];.%[.FD=_L0+OK++-UW!T'3=5&TP>^'P MXA+E*W14$DB_MG[2DL16M-2+MK87AL!]48NZI@>@]2M=S66E1N&:.?Z M-'4T-_\(.#4G]*]N*N2-"21#]]UXZQN* @_".5-M&;#\?%A^;H;B9+7[E=_> MA:=/=)5IR/[GE_N/ZJ@VUV2$H?DK7$2QMB/"=DW[NUB[LH]10#_YNUC;M!ZI M);$A><>8)S>[)8PO9 M6-& M I=^H.*IH*D6>E41&E#A3.?)70>Z!IO^.+!H1H(9/Y7:+"PAU_M34W]E_D#%RF4K4OH^/ M)DP1M>_0"R98>1I)^]X 8[ZMJ]?5]R_MNUR4L7IS0!]1^VX,J"#]W=$;9Y_BK??8Q<:L7#85 MZCW"W;NW6LZC3)@/ MIA[=(I&GFGM$9HB\"1L/D1FRCB93@7UGAAPV>%^#*\[?!\@6)$N^4!4L_THV MQ<)XQBF?AK*X.#&L?+1D#.\Z2QPG08F3X*#?&A^RVIO*JWM2-N @?Z M6VPJ=&L8A@/'0@U3D^M2;0$E?VL9&[_9JI)6^)I(6$-N2HUKD@AK9L:O/]6I MD@AK-&[BJC2/QVF%P<#)QLDG$H#3_+"O9#9[=\;@Y(N.]S-A2BM$A:E M\/;#+$T M"R6B92>EX,229-E1EIYM&_UNV>E8XK4A6G;D@]Z?YTO?.[&,^*_;@:9IOK6! MURX'1@N^DI%/%->[T^&7[HK2M'_ 'P_"O9\9L"K'YG'2"N":A?;]S,R2[T52 MOY]^/4IA1*%.WDZ.7C-MMTK%'M=BC1LO$D2N9RCOW:*[%F>XJ@O18#ZU=5I2 M3D&M,=F^20.N?C2+O8Y(5J.CR=XR+H)D TM\XT6]DMYT^151]2<./9"QI*3* M=(#-\UC\T:WG"S7>">%)H+X>69RM7NEYB=K9=,8_7$<=12S;YD=G\W"E!CCKJFK1JUZ*UL; MT8[D%VKOG2ZXM]0K\02@774GR?=J!"YV!I^5^VJ#4^4:Q.;_[YT?&C#X(=ZG *Z MR[[-*)I@I: /&$DWP\4_"/AH0C[6]J 6"[4/NQ:>9CHY0&O3.C*=<9=&C6&-#VA@@F M[Y0G!@:EN*.-Z"!'G!5Y$1$0JZ"59$,"Q.:4#5Z=R"$!8GMFX4,J]D1 K/WO M5)H?!UFHQ6#2L9T0(=F%^TW[?BF2%P/#$K;@Z1=SD#F./ [67C2\#7]Y 'CS M2Y=R:XYJWMN< .Y(!W$SWC<9]-0+HY)3DQ/F\_/#W+V]O3V)$E^HAW;O3VA) MQ(]K2-2)@Y(?BK^J%Q>UT5*R6A.)ST>_ZEN42;!-@]FG>NZ%!]P10)C+W0JA M2\&'2$8+Z 2+6:JV']Q!S!J)B2+" *(+-TE=!D<#>J\-Z M7#22J/ONXW)=SFZ9SX(@7*QG=@GG4)OW4$' 367,YN?%^U,.G4G68@#U73G, MX$:#KM5Z!B-TCP46DS.%OR./O^1> 7VL3AF&%3T<\A[RBA+D8-(G,"9P48'A MY#Z;XR4:E,K=$4P2*-T2;1J47GBH=I?],4MC+&;M&"1,'C:;3A[>C^J-$ M$2V_U)Q7VAK/G%OCW+?OY0G7R_^I0435@VK'@2MPMUUZK?WJ%D%_ D6<1DLE M3^U$Z9]_28L.M98WAG>U;O"%()A&T+/3=XZH:Q_&O9"V@1O9GBZ\6I(\"C@-M'P[[ MM*[7,_\^%F>AH6?\%WP0VXUC5D6/NVL.E(V5MV->@TTH%,=OY"EL=5!=I'TE MTQ3F26/?E:?"N?]29%I"RZ)*#VU4!3\H,LU GPZ[2M^8P@\%,_E\1$T7Z%UG M"1+HL$*A&=45N.,)5L\]VQ8'&>/Z!@1T,J[_65US?[>?T9;N7F[.HIC>D9O+ M:+D.3J#)UCJTW$+9MG3&8DNZ?N_ =<>M]%5KS@!\/66@J4F-.V4P5H8[.-I/ M)6$W JSZX?!;IT8&F:XUF3M^B!E7NG.1&%QJYIRA.I2TYB%U!D[X>!0D_E)' M%J\C\.!%7QW?BO+N]FG^\V^=UP;UN]-V2WG".XZ!%H5Z9YM]%O:NF:B[P;;9 M!R,/8$%+LB- EZV\@8%(L\S)?M&.I5F0(4 $T@;7G.0.(74NHG5V_E.G\3IT]8N,@9F>+Z2?;NA )IJCV_OCX]/ M$Y$O>WK9BQ>M:IU7RGK4HF*UDY9N6QD'C3_@:E,)U_E?6WOML#A/0291+%)WTI@$ M2E12]W/L&IVNLJ!0@EFC30T%B@!)";<:UI70-(!Q[9/'M+*_1?/,? MCV/[I_Y[U]\CBX7\A$^IQ!G8Q[NO7$H%:BHU9I-MA!HXM% M)S]0().ENLT3#4Z%-J,/-9E+9RVG$:;S-517E\Z[L6T+)8/T@X!@?TME/'N" M J7/=2;A M0MV2[N@'X%@J;.M$3W4V?@I2N;U@ M71*."TJAC1CP<@TRMP4W$++V:'#<3"D8S&U&O03AT"J[#@IKB&EU:-9DKT:Z MPDZ6:W $PZBV/<@ -H!V#BPNB.K64>:5,Z?O)#;0A-+BG6\-=&AD5?@8L8%^ MUEA4^Y340!=1&VO0U-<3&V@7D#5'N.9 O61?])9I1U65=H8I%DF"MS=N0E&6 M\T1X>S]G=XJ%!@G>7ET;>8--C4%XP\:[K.8 V3 D/D;0IB2&H]HP(K3"Y MMYMK"=:(#FWIXG98GQUR&58>+#(,3E-&>74$3)3 UEHLZ<@E/#]/&LC2V%). M>U6SOCD EJV96%)>/=%G-?5)K16/-TBNB$6-QE38+:*=AQ?!'B9J==\^8GV) M=O^_?\45?E+TIR63AK)N:8M%@?)?R7A&L+,NKU!M98L04$6@3[()J+DHV>A] ME)W3Q_<&]_U.K;H3HUO[\H]T;FR]O<@?^*2 YHI36M@(R $E[J)\OK5DM@,> MTCN+'BF9YWLB(W&ALY[YD9>1@10,L0[KXF88;K,4 MB&3D4P\9$7-'/^9FU)F/;_3^HM<1E3=FI6@<,GPIV7Q&DS&;$=7PP?%,?%'U M*&?[U3;#VOMW-U9W3ST-,N;G;6\Z31?)SMBSUD M/K.E%E JW6R2';2XVZ\>M4--'QF49J>O+;!ZRN9OF?BSH=3 M6V@X2N/V\J)CTM,-<#S MOG50UPU0P*=)"K0::HBPZ&E]]9!%1 [5OG2Q%"X MBKSF_322/%8WL7\%I+;<1CM97VX<4SP;>2<20#OJZ)"F+F'_2+XBKX$F'=40 M%*PT$#0YX>ZSS;$&$.1?G<%D MKBCQ9HDF&WT&L-\XUM-HC3W3VN^+:MA^+WTBG2XKG /QIG7 4,$KT0BMM65E7] BH1M M+>\8J2!B6VGY^]+.^/N;^S[]J $G[P"S'-7SZBM9K<(YUY)-4_N9>'#A5S+= M":'+_MM8S(;ES$7M(1 4'OQ%:LDZ\$,CR,K.)>) YX,RL8U1J,WO&KKJ-)@ M,B:PQVSK(94GS67"<"-WNM[U*-9(&LDRG-,SVA2$5ZD)6!F5)")C2N?+5=G] M:=E3L; IA/ZZ,4N14'=OBPG>,08[(NH\,(X$T;#@#]=]YBUC)A8Z$WPZ9W(L M,D@:@13D[G>-0$#%R3HL8L^3=C$NAR MD+(3Z5R,(-5^_+GFBJ:9_PAW9)2$'0KWH%E3-BX^P ?%1$G%-VBB3ET%E'E8 M5L+ =X+]T3A%C])-)L.X*\2\G_SB.35Q4MZ/F^V5D?[O>3^Z#<,LNER/]5L> MKX#G='][6]A9?JS3O70+1I%RH;*_\2=09"8PU/$2M1]%N;]7?SK54=]_D9BQ M?")?.\CN,>CA9K\K4YF8TKL^4VH=6K-N$BEU3H1/4\5TBA#AT_YK9W*MO]#H M6OD%X/[C"OY_ZO^>TN_HK!W?M>^8K'&3V.:3"GB7\>XN*8SS1=_ZO#F(%,8) MY?G"O.JC/"CV')?'<5$81%]:Q!-UK0AOED(#_GT,PY."]( ,:'A ?POSYIGOL623_3!")]L[VV5(>2QDX:+,]^DASS[=<#REBRX\[WY/+B=1+ MMR&TU<-EIDJT*N7X!^9KJV)1_9&%LT%+[164?@?'>BY+%7D$^CB0#.ZA01N! MK@92@N$)2LW*TZBH2GY$DV];VZ16XP%*;_EC/CA]T:.^[]?L4.%?1^2Y"*I] M(JS'D1J9.WM?R7 L$SS=JO9%-H#BA(>ES1&KTXRA#9?OZ@>:6M('W.2GUX'1 M9[?4Y'J\ FA[>[YX#_OZ2KR3EA8G[:BYAN5Z/CTD[:@EDH<%XT?O)PQ]W!D: M,DZQ6HN*SV]\&':0N2YC]&<(JT.02:8*0IU!6&AEH.97W!N;(D-GAED6\?2I MJA[&13-P*F2 !MJ"O+9^Q]>A7#$,4Q)S8<6];\5J-F,P6B]@+.N&TN]:(YQB MN;L']M,%"A/8(O3GV@HTF+7N5ZX-G82\_CN0XI.]GE!:D#\^459.U>I5V(!' M8\&$3YW$(+5+:$0V%K9SCD(S*T=3P%(,LB^5P]]4 1J^4(I\:T/6I./SM2F+ M1Q.L3+JAH3%9C2:8YIS>_=!?FKI!$A\4;'DCL3BOF/$^QTG:9U2]>HGWUF4F M/]BP2['Y%) _09XN:KQN$TGR&KV>-E81D]!ICOU*UFC3@C;?3[,7@ 5X-='M M-WS@5\5K--+U.\\W,4V&=/VVJ6>Q0X'5OE^_ MG4<0$A/?KM]/L[VWN7WX%-L8M?O@.;-)O.[DLSDX!-?9/+!U1?B,"FO<+WA."D:OI^^8@? MWL4F+2\52(_W)0J D2]@%'A6ANGI!*Y8,=_7S4PO828K7(9YUGVTS?Y79&GY M'IVQ_ Z]$^$\7A)9 H9E3T)TUJ%MT&Z99QY4/8P^N2%\.)?@D,*@K=NRL!MX M9WY^.=O!H<+?#+]@POT MW7AP.BOS7*7 _1XMXDD_TQNN=(/0K1"*BR0K=3:.-/)U"'#*F*1 M.5 > &@8)6@@D"9*\^"]-MW IZ!ZZKA!Y(TG6)7J@.==DPCC09$^6XA*R6-B M AX;+<9;4 @T*(I8+_R *U",6X6H@/.$JYAJ(WZ?BRC3ABB7IVXVIIRO_ZTA M[5(SM$\KB%=R]4F3>7Z;)/ M;<(2=XM"9L@ONV1MN%YPPNP73DB#GP9D_KF'/\NCTM-I4O3=C-[G1SA'Q8": MVX0H=@/,1%F:MNB*YD!RA:GQ&SS*Q@5W+)9_?7EK$J.7. EYF\Z\1?O2*^.= M)ZQ-[W3\1-,C#F0;MZY?"P2UJU4],&;2'EM=A<;7UC!*%'\E@ZV6['(IA'E& M-<-^="'K0800!A:_)D((Q[CAZT0(H4N5-FLR"4+H46T;+>ALN,!C3#N4+&BC M9N^XQU>S%4)]*A+,TLR>;"ZT[!_18LF3W_1D*'2R,HHYE\]&:!<5ZN8 %+1T M_:"E+%+1YE) 4T4.-?K6=1Y7Q$"_&+=]D:R@'SSKK+'A4-D_MM_A'Z$)R/CD MY2U=X1;QK75[E?>_0&'R3_U3Q((2I?S+>S=4B5+^68HY5Z*4GWN];D*N@B3E MMRAM/--4)TGY9P25M#PV++KKL<.?S,VP0=RO381YHX_G8NK8[KUYD&$Q,@[3T*3-$"(*X!0X-9,X$O*%.6UW+M5D1,-Q+H+F* M.)5"9 (37'V*J15^PH_54E;7U=8>,S)RWO!0#DK[41A8WM\8JIU/$1*/&B[8 M8!2SRR"IUXZ+XHX^%>\*P";F@/U$&N M6DQ)*?&L#S\=!&/P5G!+LOVEU/S9SKDO]T[ M[[LFS^UB3X(^<)]Q-*6,L!&): J]IF$2\NP3$E_)[F )OY?B52YG)VT0O&)J MW&WO'I@13Y;P)B=WB1SD;PYIPE>3%=TN?8F86P8%R-)X1B^CS4L3=FIK$"]N M1UEV,K0>!,($JTJF"304J&G7T*_DB<EF6O MLENDVR_5+P"IT 5T\ B+';7$MWQ8D-IYZ7/RH.[Y&/ =T@+-[&T*!H]-HH/- M3!'":+B.[E2U;8S;^ JXO:4#\:M1LG($3VNZ"1UWLHF%[:V[H.0'%B,]&[K* MH?FP&ZA:D2;T(=WL2%D9E?=W[(1!<9,5ID6J?'*IJ16 M)G=$?4C=G"BY,4%+,,EEL)->;6:MU8\.!:$#"G3P RJ7'# MK=I^^#CL=%W>*_(8I^CY11%Y'2:$]PL.[YE$J:>[A"]77C(R5>A<9PE"38\2 M@$R,PDS%+]/XIDMN:;364P.(%_I67 M']M+%!RR,=CBBG[OTARX5-$@+X!/K8:JL*-B/-1!;4:(^QW(B 8TBVJ!% MQ!5(QMZ8;_N.*^!9'2J',U7,@W[A?M$@]&O,RB5R>70&\ODU_HVUBP,+!\;\ M9F3OA:7/-B&?8>TN B3/$U;#H@(0P<5 5=R>'ZGKED1WX>M.91#DN^.H/^(+ M]%)6"1T 3W>J$0E"9F50P3!L^:5!ME=\2X"U'LW+!F2PN2-30FI1.:J\L]O M'=M--'7']FG5$4W=2ZLS[^=(IF[F8=XT#_=DHJG;2_WL[@Z<=8Z\.'$,(8T+ MQ2SP7&]"[T?&"'J(:YN!ZRV2L ;"Z.?!WBR/;,&-FV*OJ^V2;.]I !0" M2.EQ]+!Z:B;:MM\)@U%UD.Y2*#26 M3%Q.)?*W+=4'=&C;?FKKE!6ZC+ ^DSZ>7MD!6SE;LDT4Y.^,!K#/>E3O5=IF MV)KSIMP.FS%?F /(GN@Z*TY#4FRL;F2:&\VEDK1M;W2*Y)6T$=H"HR#UE4KW M?.,$<;E!KUN%YIFHJ:BIES)W="*&^0(U1>J[\<$=P?%'"9)0!@_40#&'ZK?G M(TI0X4"'%Z0_Y3@R?W (I47'ZF3#8B=* -H'B<)L=%HJYD=NYUVEET/9^GJO M7-@ DQZ[\9JH.SFE\A?FV;INBJ$ #Y[2T(VS>7 [-KAH?'[M M& )QH6W')OJCAMDNOKR;[4"R3IZM^EM)2LPA9-\$J ^2!TAYK@/?]J]KVJ5= M)!!Y%Y1_]8W1AW'QK2[^Y'E-4AWA[$8(L8HF7%.7W!JKDF8D?!2)<21/0MP0 MD+3FF\*,ISDS!(P71==H(P=L@9_B18=ESQ]E=@\K',DF#6:T9AN9!#U 54C[ M?$YI*,XMHFO9_M$1\&<)7:L)&:E'29[K=*44477F2,XN@QI! W,>K?3E@S8A M3?W-\2*0EJ;\-3BY7HVL!!\X#?)H,DU6XJ_5%>V;0>VN*ES4DB#E9^]CRLKX MIU&R]4^TT+3\ UK*,FIEB_V-NQ5$"ZWMW<+_M$WSG_J_O%#!H;8ELX/!*,M9 MR/03UT\U(M4<#>BHX22.Q.'F9A@N<2C[,5[KH_2;#W'I]M=O&0)N_]F-AS;/ M:]UBH[BNV B@C^LU1$9UXSR;GWE51??@H;0EY/I\3TIN3E695JYHIP$'O%-M MZ:84J5' "22CMG>J]0U%8;W-7ZI5)L4MX;D%O?8_5':H-!]R\AD MI2*)1?Y),*3@P4Q ^C,?#P^0[N/QK7=TNRRU&LPZW ALAD?Y(Z^G&+6KXDJ> MBS_A%1(['DZ??_#9K ))V_/.V5!M>L:(Y$UOWR3705D&?.)>*/ZMTFA6_YEF MGD^RN8!*]X+;5[((D.U%L8)RZ/6M%;$I+!KT&*_)+>N5KHR#D[-HJ>E7<-^8 MJ.BEI U;GO7ETT"L[#<EF5T:91$%GSI44D,M) H0*-,&@NB[ 2?7UE-#WOT=_@C9WYFZ'5_B\8$MZZVM MV2XY.5G?1XAY:@5MHWM-!EL MXWM3QWY#+#8#J?.@D1T.[-#_2N95(K(KN"%<],):KC4BU)\2H]=KS1&S6I Y M2!U9DI"QG27R?.;.]?12C^@>1\GTZOSV/[N0->>M18;&,0>+LH/W"J29!Y+C M>=^ M\)3_2@;I#F$^CNE#! M_>H=[+_PX;?'8GWY<':UM%Q,6IKXWO4 /\OK75'L%+[&9T07M4[9 Y>";?Z.;"/S10_Y"MUNAOF@3CKU7(BC]/"!/^3E" M_4%5 GYG+[+9!F@\7;);9%AMD;U!(S[0L,*L4M=E;]S:(-!I:YHKP*]"5'7Q MANT;@4=0-CPIS@RR#)5&@DU+QPB'M%]V$U][1*:GUYK- M.WUYECNV1R2V;D$7=#I42<36B0:][0W>JNO*]Y/D^YA7_%4&ZJ],^>?.VU/98"U9O]+3Y]?C5X\?M2#9-/]]"*2J>A?B^F+&^].@:"Z@4S3H3<\J'=C91 M]D#7$_S#!OK):?538]V97@8_9JAY'+U%E4T4:VN/*ELO,0( M+)-R_7FH@/C\^K[!1=H,\H.I(H\HSB\WIR7-LB?WVIJ@!R;^K_>>VN#_;Z1: MD.$,B?L\U;F=50PUH_9QW9=A+ON&+>=,MZ9MOKWG,JP:%1C(9AG(77.)+.S> M8?[]:=\T2:4.S&%^MI+Z>J/@8@6XYI=&P6-!ORQ*K#<*]N\L+&L8NQMUI< U MXYRDAF_)99\*@3LK;BIN^293A4I_+00T\L+20BSJ4 JOP>'>X*C718D:$ECX M^9/O3G\_RM(]^,+;/O9H!+;D9H"*?6YXF.*EB&HSRJ=:F<8J?E;2V*7P<+]' MO6=V)^[YGJX"N3C#,'P!GR2/D4)@.>5*\DZW9R"+M%V\ZYP0^J>?J;.0ME^C M3F24,IFNSN/FGB>E7/I=_2.R(U3CUZ]0;,--5K+"8U M0L:&,W;(.T?U[8)<*G@<1%<'EK2B!E[L\'^6ZNZ1DB'U6=-_]4D-I_0 % ML,+>H*E5*@DI1 M3SVB&6Y'WC(4)RWJM]AE.4E$\N&*3,A#7>6)SP4SYF>KKIS^E:ML-./3?.F# MB8YCIF)!9GHHR5HE)3&+^A03]:_<4RR0*813.R(6,BGE;18+%^OBD4M%8S"# MG&&8KU&'#W 7%:)0^H$Y0&T1+Y!W5]W5C/>YU@4= T<) 1<6#O#\\K(8^,B/ M]DW]ERBAWD':1_?OJ GSNGKB?69Z%.EFMJ69&KU 72W$N64&B1M&-[M9("?7;3Y64L9UYXF"UFE=\KM.K6%05\* M_!H[;OZQ:*^\K&ZK:Y^!$##K*N/8(V@=0^.Y&M:U%*..B: T,(Y]P6.Q=D$9 MJO)A<#S([D9[:]>F'.\QVO>X.E&+CC?X_-U".7R//L,"^WQ]9-)U@;=MG&: MXQ0GS>2HFEZK8_FF5E(STL!OC8[1^)%" %V>*U6W,) R)[,6^QS!ON"K#=1C M=\S%Y;[]='2AJH(K1C,I9G"/7M9X$C*DP_9D*916S\@?Z5)5>_C3.^T4*4&A M/KC^9'%='45/%2;YZ'W;R>K'/=V:TK,EFH^Q%YAQG80I://BRQ*-309F6=M7 MCC>(7H1%Y1\>WZ@9^AM3JW(\U(^!MD$/8ZI:FKG9.Q/V7\Z?IM]P$&ZG*AIV^LJC6Y M+SXS:2C?/M NMCFJT3K!0-K314+Y=37PQ"-6>.A)7JOXCHZ320L7CYW?METS M);0NY6EQ '/EBG4I9C9A/^7AQ1=3II>+DR8\ A+E-[.*F@71T[,]CN MG@'\QVBI1UU#L]JK0.J>\P>?WGFB&JDT>.RUY<6'GSM.-XK%=5OI7.@NNR3? M9]:]S%>DFB?3YY8'5>#[Y.]<&(6ER5UZ&9/MQ8B4-R:1HE M]R>;.J[+L(.\Q&*C+ ;7TI),;*\L[LJF^+@WQAY=)*AKB:L[5S8>#:2Y;TTZ M:F YGK!Q5157[#.WC#529(!/FWBE#=?2APZ8"VF86V;I+YG MDRGLV$ZG+2M"0%&],VC8O&*B(]-C7TAX&(Q8VD$:W#\,S^K3>D957._1G-ST MK:_;;SV:XV]==S"-<9B7_^;)KQ#IO_W(8J\A&H2 \.J?)!!PNOCN2\/77U1D M7:^FT >./LISA7^W-G[V?G.63[?'OK7:WW/A]K&-Z* M=$E@P+@!.UKX%K_Z536$'1FF)K%[W>\WC;<_I-BMU3172UITXJ7\48D:4:^3 M@ '1';7VNX_1;YO$WKVW/$&28M34;91Y@I(=6NK]U;O[7S>6U4, M^LY5K/C4N017B-2?UZ&_/LVTP?^7Y$&A_5-W2FC>3A7KG=X-9EIG(KYT>K_@ MON2K+O^ET_O9^)"81;TC8\_/L3HD>6BF8N3$>;Q5(,.R7S"X*\[R8B/>/W&1&)T4&:C8QO&>79L&0>7N0HXEUP.U:VNJKO!>W:HDR9YMCCV2^S*7/6.#R M$Z\%-0> /!,\7G^X/7[SZ:3MBQSR$PO'_ B8348&I"=WRX*)VV(49NA2\D0D M"D3/V=)<5P!;N^@C]:&S<(QB"_9/]"+C->$*[K/LFQWZ!L6FC\N> M-!>RS"($1IP%EZ5T^"6L'[A( ;3N%!:JK774;"-WE>1B0;9^E=/)OT2 @8W4]W MD)%RS-802[B2?_5LDG9V60/?Z>!.J;Q\BZ+#CKEF$A9I^BNHI+>/WM>$7EX] MF7XODWR+]#.16AQ8]U3)T396.GKX\O*PFO/Q1;SB%#^&$4?5)R6>^CC(<6Q8 MN%RWSS)DYE>:=1V*WYY6UJV. M,R@%=Y?'-AU+!=33[+/!";HSG:$>:^WK.=?MG[Q/D\:>%B,C,NLKGQ\?A5<\ M17/R_G;Q>-MK6HJ$/_K9_]0_N'J$W^7!\] 1_1QPXQE2 M#O_9P!#V&M3$73,P1+RNA?VPL\7C8&;T$7/V.]_=/8>-;G\H_F9TO>_=*D,] M?8)?-&C>R2.HM HH/4=2YMP\GQ-_%31901'QQ2A:&1]G= ,#3HE$$:AG=2;' M1A:;#?VX)/3 MT\)]%;6F46N)+6QWXI->)4HM% 8+#OSZPW?*UF%[+]\U(M=;?7N MN8.LEM-KY';+PUZ00ZW"4DWRS$G.DXZG'P<+55M?%7NH.-?%__G/3J2\!5 M5MX7NW"XO/S^>N_UC$K13\R7WNON8?NNQ#BN]UZ_&'NVQU;2P<'XKLI:Q@/0 MU=5]#*70? 8PAJ<53X[KF7:_>7E_PV?\;NOR?$+A"+,J.RB&?HE>Q7QO*?&L MY_TI3'OMT[PQ!]C;9OQ[=Y3/6Q,KCP%IY=+5ITHQ37:D8_/<^%3EO2Q4;U*3 MN6,HHZP@A;R48LFQ9KX]@%05;C M_)2VQ=O U+'/78@%?]Q 1XM,+DP[*^"E5W';29>:H*+Q.LJ-D3W//CV^4ER1 M8EWUK('H51FJ=5>F2_=]";W9!*;R#W$.8&-T]Z1&,M",L_5@_43"S M[X6VAL'[6SMBR]).:^4Z9#SXM<1 .R \=\>QLR-YN2Q%Q00'%ZF(4#TIS] U MG&@FKS%09IHWG]T@;/J._(AN7'&D%MWNK*2W,F9LWE:5?^7EJ%=3U3$ET#-- MVD"\152@CWM3< R_.#+A,-E_T$LSQ(:1Y=D$N.O02 M53<$K3,B00K9)R]7J&_;>PV6?"X@U[OO,5AV;XQ)M7KLFE5QI+.LB6=E4&OK M(5CRJ=UF\>-&@-^X&^(JQX0 EY//A@V)O6ISND) WXM M2:Z;F\.L(1[4$[!663R>(+"7::EUCR%6,'8TR(A^W?_%:9& A*.-TV1IP^55 M]3WMP2T-1GN[YU_6DU&GZ'-Z;'&!U5AL=#;5]?QX,_/=V&6703--S#4[\SVS M?O4Z_C?R3QJ*[W5:'K?ZV[7+NJ&Y]^FS22=^?>4 ;Y5RVB:**@T(8O92>OXY M'7OL)>YE&#^=:8_9OC<+8A-PS#KFN.Y9\GVHFHMD1&,;6-*MXHBW\O: /.L" MRAX?$XM;\;;6=MXZ)3XUW@VB>/=2XU]^JG.##5Y6@79S9AK<=GW)>&6GJ@J< MH_KV#-$T;WW^+>-55>=B"H>M9[RB;4\'*5XYG _J=7D0\>G8T[ M3/_IP99W*Q^6(F^CB$?>GTSKOEPF*'U^_=DC]>WA!G7](9#.\<2HV.$Q)0?[*/\1(M G.(0VXZ MWCF3=H2"4,N,.NY1'#-:3,9?4-(YI=6<@C>#7?$[#:XP>9T\-/'AY@/%_L.2 M0D!*_2E!KT1&>'A:WZ8WNSIJKW/5L:WP M]C09"26I]T55I\X^TOSXQ,* D(HF,>*BA[]E9B9I5R97LL/P\'N*"1D_!HBE M'ZJ&FQ=^2H48GNZ=[QE-F+^Q$"#FDI,1@5.HK9C2Z< 96[N-J0Z55!_'X]=+GG38VJ_!> MLG#L=+22P<6U<5=24/OFAIURA#F8W1OFMW[[,(<3I3'#)]/.Z8\2 =]!M7N$/UZ6./[G[T.F]]3(B8D4L\I![??KBAD;[^GN\T4Q M(S33'.JJS=<5\SN5V?,EFH$WE)_HHS7H9HVN[AUV/_[3L;E&OHO;^U?(O+T[T$$+?=.&M PY<'=WV_NGA;0Z^)S(SE&.R M@N1#3$($\5Q=#F-%39%25&8EK9LM%HC0^MA7'?/BF]L'GJAJ:Y-A?6?V.Z[;"KQMF#PT!L&IF#BT:C! M8/AK4Z0%,D],TCI;Y7C'FW##]*AA'C<@CUFK2[ M(/'9GY&^97-FSH^S85MZL_+=3 R\[+2D)ZOUI[2;CUV#2:4-36BHWLOV:C0' M9O1SS!J272E.5$28@2'>[2WQ76UQE_^@90ZJ?WB_07YTB-=XW()V&YP=H6KE_?R".?#3[?F3;:]>!R=XFYU$OM!_ MR0-LHX)A%!4CC8H\S+TV_^5%4G.;-_=<]8IY>G%/N MD'B0H:M0AU.MRU8D* P^>8$W/IW]Q ]OQX8F4]T>%,VD8=GJT?G>0H#'8CV9 MGX1W\P9Z+M5V*'5P%4Y_=@M,T$@8]UDRR-7V='?O+##Z'F5)Y.X1 AH,V2HA MM%(=JL;*P=.TV;]]O&$4,(<;!-H_^-6,=MN'+5,?[=[$-GT-51 \_.T6V/VU MAUMSNU%H!BT"Y12)7P#SG5I?A]R_J84_<'':5.OD0"(P]I3WPU=I'>*0O;>5 M'<8@6GX7BS6E+ER9Y&7K-->.9V '/ANY/HSN0GMG*QVT4WFLDFN?^,V!]X%/ M;F4R7E(.'/,\@8)E"SX(%!(#7=T;(<="7T4^5R1?)?;@8:O-TCJ5U>$F,4=. M/7?.EK'3JS:]/Y1H^D1]\<^F?2?7UIN^@*[W=4X\/'K"K"$*9?DH58_B&HIYF%B2ZR2(AN%,D,0U^&OW) M(XE=T_#V;/D.>3FQ\\-1WO,O,Y3G+.;>[RZ8JHC_9*T\[.'.1-"S4P.DQHBA M:@K)![F[UQ;L>]3 S^4:AWUBL]"!'D92_?A4A%+"(?., 4V_ZM7J/]UVF?#0 M0(E929JR0&VAXP$W?YRP*W=N?7A6)QSI;9M2V=*/IV+/K0;&Z"D\N??!5VOLD^E:4VW#!\J.L$\=* M?,KSKYCL=:*EW?SK#P1LL,$_X*R7)4CW_&2&]TH*KNTS\MYVI(9\8_;&-7E( MPUIF7]+CX1;8T0L0<_]"'>?JJ'V> <7)T-+!CY_G"1FH2RPI"GNT,4V>:1K! MCF_$,>.: AD'K\.48JF*EM%#%BWK#0"BJPHURA+)\X6R%T9/W%9N"=HZ7@MG M:&&D0U'J9G0A( )SV&^'"OU5/RHZ]"QFG]Z^2,:D,K/1\M'9EOT-'[>MU>[Y[DT>_K;''ID=OA=EN;))6H MMR/IT1^.V4&X9PN./.H>O_U(]O$DI+O$- M/R86^T_]C-SQQ!RAU2BC%VVUHTF-*A>CV',@,LORP8&;*9%8>IJFVGF^1F.] M"NMZ56&;$ "LQE,+&%RG)&X^8HA&]5Z%?Z(J2 L!=13?,Y_FX]Y'9$K>88.^ M$\C"^FS=7#AVW>;IM&*-HA5#.\KGQ[56X_W33GUW[.FN44&]BT%VWR8;QIO) M$1;#]U\5 KRPD5J8?+K 9 3713P<<')/[G,68O=%EGZC5GBC1763I=CYX_2" MT;M35YF7 JVSSQQOI/LA/9\UAP'5&1_N;&+X(69NVC!'52\/Q*"6(HNE$?8Z/TC4\VY2?Z07H'D%A__1MQA\N(26:J_'] M,7$/>><-].(&8E+[V";+CF?, E\-?L1Z6>VX8TN]4** NY%(5[/;,V'0NDL= M9*[Y)P].\MIB^$]Y3@PW3\L(S-] %O,&+ F=)$,GTS K-P+;]2?'(U*G^F_@ MM1B^"ATG;-\X9%@DJ&K+;2%5F&G+%#[I6;90?R%#^-Z3+@UH'QM\?C'S-]D[A&/!.*@1!0/@C3 M R:,!6&IR9GVZ/P/2SJ?@?VY^7.+=S12V+C2B;:X=TM^&@F#_8(/@8N0QK6D MZ#DU#6LA0&^XQ33%MCQN]]FX][6O*9I5UVF[8FCH1_*7'[$TDG,4XV>J559W M[N$_)9X7',!_[WE M_E%R/%.@JG#Z]+8VZB#%@DJ5Q./I"G#[R5MZ79@EL6_ MM8G1N\@L:7C7L2>LT3W(SX]9C%'S2SQ6:;;G?BOYJ4?KPS>VR>;G$]ZBL3.$ M1/#J$Y^JI:G]IO)T>C)B=HG);@Y,G@IHNZX=F2%=G9A=?$XN*2:T03L.GOGQ M>8)MAD-(^-W,$NG03$D#=/V?S,/5?FEZ,5FW?&L$8WZS\MZP]!@R&3-T_I00 M8%=RP/=F>D1E11:__-E(<5!INM;>^B)6T4.[LA--KL!CT8RB8RU#5Y<^]A9 M->8%=1&AN0?\\EX>RM=%BI&*SQJ7-!. X7 MANZUA7S_UT?F&VRPP08;;+#!!AMLL,$&&VRPP08;;+#!!AMLL,$&&VRPP08; M;+#!!AMLL,$&&VRPP08;;+#!!AMLL,$&&VRPP08;;+#!!AM\@? WS''!,*X$ M^Q9[<(8H;G2,YR@$/(0W#\L*/@BH75CZ=YSX G0TU]V,O,+7$2A"MCXH=U6< MF-.SSK\2*(C$@N(G/N_Y['3*:@<&*P1(F/!#09-5V/$S')(0T+YVUTCPLGZ3 M$!#^4M" 6[Y,7-K/NR($3*#->(8R[+U"P,LQ(>!9QZB$$* _#>"N17&V"N2C MN=NQ7;>$@ ^>K' A('4%R%R&]ML+HI,$[J!'(-Y"SN:%:941("=88_:$$ M*@2P6\I@[]_$AP4@A8JO]%@IA#N(NE3Q)?X?DR&KQF[#[L M9YKMQC WAKDQS(UA;@SSRS![9H2 +=@;Q(%2=@3+2@BX7[^39R;R :1&*C1\ MOM8>G8UM ([2)#[+2B5F9,%TG&@W6.#092LCJ(I-[W(-MH04>&R4G]\6.S02 MQKAPUPCWSSLN,R5BL>7 -X2!4H$DEN/JIBOZ$QJ"/> Y(L>4R'C.BHL0 LJ( M] ."7P4#0L!C,&EMH5_0PJ_)PK8( 0.8+C9A&0KZM6KQ!T/!_P^SLC',C6'^ MWQXF.G5$ LC1820]0!FRMM)7(_R% "FD3A,DV#M8NB;;((RZV/].88^9PID6 M\:&P]"N!XLVI^3"]F+KL_ SOBJ1DQWQ/SUSG(4C#IOZOW]@I:&LS(0ZZ30CP MQ(I=0O:-RD0) 70)9GLN0PPJ=FD:V^]VC+455S0\12TJA+NS06)>:\/I,BGX MR>2L%FIV66R;4>N8^@/ZQWG^XWS\ ,3:0@%"P#].=,8?IP. YF^,XLZP@#RL2TC;V+-1]_8HYG[M5.E$6'9NK( MQA;F>^M()SO&9$'(\\^%@.DT#AH*Z-QDLM?F/P*W>\Q\!C2J7IQG MQH0V ;>X\N,;A[>RMH01LQ$XV\K2>JY"QERR.H$?C\V:EG$#LKY+6PV6B2@; M1!N3N4[&E("#IYT3Q:K.3"S;;%VU9[HS5A]@#%$GF>%-1(!5CA4=O']J:1@V MDW_)/'NZPDE;-G0\K@"FEYJB6:R8_G(F^$Y&IINYQVULUN6/ ^8!&=/!V0E: M:>FWIU9XW=BWA['>,Z P@3X%='UA7^LGCB=C(>)(#T\LWRHP'48-#*\_VI)1 MESJOH'@9(^6/G#*]^[V MXR__3SZ?9W?SD]6$ &_:W>%#G"OB;%PFLJC/AESKPN2Z]L3F^1<>;88FIRS5 MZ8>> $,Q5[*6N(Q+5X!8F]*EKA6X2JJ^0W> J]ZXI>'YGRC+W%_I-:\HJNKT MY-[%]NE]13Z^5Y]L&S6W?>K9-X?@2+3&< M.,^DG'RHLK@"&BEP2R_JYZ1= #K!?+4D@)-_\^[(%P>2V!"4+.$!0HL?8E/+ MDHFYECS*LOCC]_YWX/-$@<@93#=M44O0FJ;:0YQ8;:%MPY9I$#^*XH:EMQ!/ M=F*=$. VK-M9JTLGB-:\+EN6=FF0H(@(F.DTDD)9LIS>$B,$8IR,D7QB"3+E MC>#0J[[EMJ5I;78@[=I3=*E)CQ!0@EBN,YXA"0Z1AQ>,6=(IB!P(UGL2$IN1 M;7GZ;:#B#Z":*)6[' >61@-MO]$!I 8C[GZ1H(^..X#$D*!DG0[\9;=+_*+# M[#89)\$[8H\F%[H+B;6QK!-KA/C4IP?R$XJFJ+'/5=L,,Y\M3'[5VVL(8S*" M[95<$R&@89*?452[^>7'H/IMG&U\PHB+Q,=9+B)VHKI"" A-RL-F308[%OJP M?5PLR"@I]GZ"5HP\@F,,HA_M5&^JC/1< F%!OG%4#<'^.+8?*RFN;##N:#.U M)6D$&H:K6KJ#7&BLJ*3]W /"IL^L66(;3F3VS[AI<7<2/:7CBD1_74L(^/Y3 MW\W+,](I0L CR%=.4-;'\>-!GGPG=C)G:00:J@W+,7GIK7>WIS:P #9SZPDR MY(W>"H/Z-%M[M9H:>Q^N)M<]\JV(]&VXC\ 2XE, M,XV!$ NR@5R>@.*FT:7)I4DB<384E XS=GI1+*0&)X'T-'TB!!BSPB.7G]-[ MYAFE% .'PE3+AM-BQ=Q8^Q.SC1;CO#Q?4>W?ZK*#]UE;6+& M9$V^S(]=_EQ#);.NY105M+Y%MW^A'E7?$/0369-[EE[VBCRK=CBLM[V]=U]A MH<_+V.^/7GA\T>NO7YK_P]FZ*"8$;!$]YO$SG/7K+CJ$@(NKI&G.=_4"T0+Q M4@AXM\(329)J3R$@+X2^@MK\UU\N^K\A*VM=F#0\#&F3:BO\8-OQ;:2RBL3L M!%N-GS7WF^\ !? M? =&OKJO7.0[*+XIG I"YP)'L6/._C97FQ=$]D<'VI)GC?;PW"B:H&T\TQ2; MRNZ7<695#Z<3Z[>S[O4%&)J91O] YFD4SI!U(A=\R[>5Y?#D6QW!Y:RMX2O?EO6A]',OPU:Q Y#Y5+RWGS&9:A;'D%O_'"F4 M'"?N]\]1BJR58(A]^9R,+:FK \?^_CD:-M5,(2!"<_7W#V+CJ-72&>L?],JU M!3?/(.XECKRBE;#S1X6 [SB>[&BF460.7/X(QQ/_D8-@J!4]W]*VTHHZN:0E M?J>EHF!)ZSV07GA+[D)0#6492Z:SV""#/44%PX2DJA=P38EO65GQ9@ M)9%IBA"MQ)*$@QP"&]8WKST%DJP?'"6(Y'95Q^/1NLUF8([%,G%9;6?(P[N5MRUC.4XT7XF^RCVU#H*$,N!T+>@ASS[(@ZPR4B610@E$$MX M5B-"P"ZOX1/,>3S;19\V.Q=(6HNI*,R$HN-L*VO(\X)W.1"7C^C$M>[I=JS& M^^K*Y*W(06X09PLKVIC_BY$XSY!#HO^*>8?GC)*8TSJRGL^#_/CA152P43P# MMY-?PK7LPE-$,;D<2QN7/PFB3F5#G&> S1J\BUM7"#\Z-U@_ED MN@CVM[+]^HBOM!"S0D D<:\1>00H,M:U>JYB<980X 6IY!W#:!5SI>O2.?=; M!9(:$N]TV-"(9>B$!%=T7;G"J '9FD 9S.\K2+KF!, ADH,_8R)J$?J2B^N[(FH6J-@8G MUM'GC ??%G/R27H/+G%>.B8MF7[E&^L(,W#!MA3N"3=,&VCSIUZ>BTP"2V=4 M@W=4<)+E$$^%5WM,A)8=UXQ7>FBP)7\J^<.K(+=#S#YV>QV:<<+I?->"6CEM ME[>17!7Z:BL)XEAXFR.RU+=M_*<%0@ ,$;L;CE&+;N-X,.$"22%@'S+OW9RF MFG5'D][L6G%\@_PW/HY*1*JZHAQ4SL$W&WV[9U#T!NF/YE9.)6/9X6PL^Z';]K[Y M[J5&O;<4?[1.(^9DSQY[5GLJFTBF"HX1KW50-SOPG]<;<&08Y2G3NR>3[_RB MB3LXN19RN3;M,'-GF5U'X]K/9$:OOYR5BTUYF0H!>;7C$L7>Y$$S1"-LQ?N-C*-3-F?9?JDP^3 MH;E3?.:TQ,#E4ZMW5H$>]67EM0\^+!85TE/EM0"3_RA&54".(DF'M: LJP7^ M1%XIW ,A+VBFNIOU%!2N'%1Q["Z7@ZFNB)^Q)R\<3>X6 L#$LF2X2ZM^CD=% M=47B!:48QAW[=!, 5II6D33;=9M[ A7$VDKZ'E$N#FU(@F!2&;1PZGR!?WK> MM$"\M^V#]%PN*?-CZVYO6?5*/+Q>NK8JK>/'>.>J3@66>-&#S"E(?:HW\;C3 MBLC<6Q3Y"84BTVOX/*39@U!EF/@ M!;F>6M!*F)8_WJ6YSXDD[5B-TBM(.TU&Z7A^5YH]N;K&DXU;5/FZ,@@S+ 2\ MW4_T(G),:P,9Q $\]/5@)L]4%*'4 P431F:QR^('0705D FO85[/'NZZ M!N%R-QF$) MUG5)/5_A6YD#JCA=GDT*RZE@%$H7K!Q"(O/S_H ME\"8NZ"Z*)4)B8$S[+O=1!CN[O 63N'U-11D. ,?H]02;)36.P4,KT6_?%C* M,GJFR2E/#5XP)\\7- -H YVH4M%0(J:[=E<&2X%FT:_JLM"Q.\O>'L1"$@[!;_1<#"K+@+ M%\1 -$F4<;;2A8 !C?IW!3 L55KTY&R#QMS -!&\,(=*1-:W)"U:\9,8AC+< M\]RM+<$M][!E!<.M-B@AX%#95\UF.8;%9TY7"_*SO2#2SW/@D.'R'.8YN??3>",B M COR-V*)&>]8_0D*"(:(E)?D@A_6'AN[Q#LHH)$-VO0OLS[J18O4,W+&9$GK M+(8L!&Q?X)XJ2]6>7SI'60XRL"^RPK[T3G13XP3J]-\%>8*N20R4&O,3!%LY M"'K:,PR9(893:0))KESKT=!R,40PC/(SI[3=CM5W*]24=->WT;F(V7PU.5)% M\>3:16(_Q#'U=K[+1\[]"2?*@@#W5Q?W_)<@.(?]8_:RCT9C7H1^-B+&0E=_ M$@)6P"@CPEVOO]IU_U&43=X6?+_ =7*>EI5JF7W.&$#%N!B+7J/X9N#V /WH MNNWM'3:=181#/;56(RHN(!5PSXK$+MA:13H!.=WL@)4<]I:5FH@R:9V$@.\O M9,ZUTK596Y=6TS]_7+V@F*]8;]2T4,%<3/+?WB'G1;A7W1S4AEA8%2DFR-J)5_"UK8V+#S20_=% M&IS*F#KITC_E=H"E_>CX@/>8,6+:._U$/I1.X9A8U^R'8]P%]SFBPV9;C M1-(+[N>X.42OO2>\ ,%! T* !3^[?C-RAF[%@+'@P;%I 8AOX++W!S,Q\BQV ME/P22?8YY5A7 +=."5Q=(_X+)VW)C(R#X-Y6]T5JUAE=R*)8VFQEJ9GXRZLR M*VI&$'LY26_=3A0+6EDZ#WCG"C@NC1!/ZHT%;&DY36):1\^:X,X>TF,L@&NX MBNDP/P0[7ZXF7S].HZW\=?)6>:=*K'*C= MP\IX+[)_X-SJL'7J2YY]]R_8V;BC7#.W5]W^-([UD(X%JE@;GL)"P>5>,YMRL*009MJQ5B0MF5.>9T96!8< MNXPV+.P&22"Y)ML\&>B3HJG06QF.QP^YAO;5GO(L\-8H!(\,P4G!V>D'[*8/ M>VV>7/NW\[^$#QH<9=JNP&Z39QU^_9^[Z! MVBU7D)0^76W50?5/=;)B.O5?K^U:B<#2=41&C/NA1L=(%M<*X&WF5X-$X@/6 M0=5O=C,B^QJ(@IY) ?0>1A8S\9XV A9W%>F+BWQ!^"_>K2)?Z%:(+D3VS>KQ M7U0WBY34-E%X%>_:X9-!O?'YFZ\:GVN=1@V- M0PP-R^'+9/]\%;BXT=*E7BT?:U:BLSVXR]]*W[9GX6A)!;''UZ<@L[QKN M(;D#7"6@UDNA-)F5;XGA\F(BW[%TFF@239E(&?-DLBNY'"B!.AMW*:2USLPNENVB9L052*NG9W)"H%UN M:HIL%:R8U]IWI1F<**3!E3Q8(JCTZTJ&_X?Y[]S8^]\SM;,(WFXE=FX5QX]E M!!X@-P7'XN!,+J,W'9W+@4!N*HFLUF!>%G*H2 )6 MGB-9;4YKL+4-Y%I>BC-G=L3Y$@R&SIN3>: &.-C]-N^D1#P X5]#@\._CNM?*3S* MA9 NDN=0Y^C\Y61QN,Q 5SY.M=P29Y;V>.A@=_*5H;6FK#U#]H[/[!:UQXDO;#'!.PU(WQ@ M4(80X"4$>$RK5X=F4;PV??H:HBQ=.YEA]11=/]XCSVQQ^O!F9!X<%HW09!R&#YRB(H@!7 MT!OQW&&8FUQ7@)5QWZ*%2 T*CA/^AKV"I6H(9&^S_9B(N'*5.% S%?1\!!J) MK5JLY"R0'"M B!Z07_JDK(40T."42?.JU^+NO.>I'I>.;;!4.83T=ATM3ZRJ8;9'8,=')6^WSS^R#".>::! M*O+X/JR,-M%\1<_*#%MGO.2I=N/!%0RZ_"#93%.I'HE M9GE28]WNF=:J"@O!E:^L80E"P!7L 'G=WK%,Q-T %2SHK1[H^2@A$ELOLO<> MDI,C""&*T/V*O&1+U@V>#_6JW\[UO1>D7OR;P;<=T(X?]!(9_ ?"S(Q@6QU7 M4P@@Z6+:]238@G@^CJ7#"!^H1;,VS]T!7NO5),Z).8B^M_U;)YI/IS]HES.V MX1C]\V$!A3E>SD_G/QBM>0H_F T_V_OLGW%1_[_=;"'B'^,NN + M"QQE#1X.VJ+!S<:NX>N!3F\T_VJ'^4]Q&J(QP6!J-HU]B;/D68 DV%+4,'LX M,V#L-IY%6#?-H>?HJXIC1;4ZH]^7J8%LRZ*6;)A%%4==HGO)*W..K6^K.V)N M\/0SW&9DRVMWHXZ*[('=ZS0FP]L=SRXJY;0Q??M&\!%9BYBCJ!U,P>-,EW>W M ]--1$\_@A0Q444V4,N9I%H]@MSYA]@J=2GA.P-J54J]#8Z0NQ% M70GPQ N*_NB_H;%0IA-B $)C@$C?BU;LCNVPZM"^1N##:G3L<\8S'Z4>Q-$> M@63,>?OJNB=JV\G6%(:@DVE=663.@,W:JWD#)@6(0/).@W*)X.D=SH9]Z M?#-GZ\OZ=GX-R&/.B>W*66(@=@Y,)H?B&A:DO&6&%3CF!>9;WG43#,[<\5E0 M1YWRS''U7EL9&D]GKBW80K=[>UZBA$<@"@LU<5+>LNC4N*BRL"I.\U>M\@"! MB2-/<650W@DL5:_OC5Y/2\((+@X[(+^%R&\7 HJ1\V+Y.(YC,GY-,3QON@\$ MZREWM7P+O1*V9-9%%ZT?-,%N0\SL(-);0F.MFC B3RPE]$-_7ZU?H.1&YRQ& M.U@5<>-(&09T?;769_84Q@VN@#]Z!7_W1+1:3^E0-42K]2_.K1F3OZ_6XA]7 M]0R'WT@0O.RZQX2\H.7C?JF'H+8\IV+>738# MT] 2!]M3-!3"NDG@5V5A\/S6UMR7%>454>83CX^87DF'_DWT,!"H+@(IW-LZ MT(AG:#FB5!3^F*6('C29?HW:5#,3CG.6-8XJP++OU%W)GR(R4Z=;$?00<"5, MEA". M/A&I'!Q_J2;M]XNHFCQ'46=,H2YLZP)EJ@4@2@3?2/E(#-F9P]9A39 M,07FZEU_.S9F'WDG3KV4 ('IA?;\XA/2R XV>KFF*CC=6VN>!V,U2;]TK+_Y M59,^U1+;."ZNK(XHE-8(0>S2>H8NI5G^4%>M&GWHS)SV'2A5;R%"2\Y'Z4(Q MUS?##X:GH@DV-9657(>5H<)4XO/QHB@M8#K:UV+5]"$+1\S"R8%?&_>.E >@OY3Y+( M(?R_?#G_;^*_W/6LQW!S0D IH25N/Z:-)F.@Q')ZFU1]W_+EM'0Q,LFXE++' MNH)5^<"CO@S7B-G>D_WZ54_A=S@"%1*145/5';!?T\I1[4QCLDM26"KL[:Z;Z6V,CK!2UXXLV"WHQ[L5]0I,5/5\.MZUU1//R?_QM%;=DVG9[Q)"1M7D MWCJE'>F]48969""%@#B(0*#R^9IHD(7KJ8?O,*==47#F)[= $BXV[5#/2DC$ M7*'6 )&^FQ.G($W%1?G/>3K6)]F2!P5[8HQ'G5BXL,=:*B>N#3+:9*R9W0LCL/^,1\K"?O-">=C0#P?N"ZK@YHHC6X MQE-8^EY6X>I@P)P$B0UE1B+O7\"6&Y@58KVP/W/V7&+UL7U2AJ>WX>YZ_2*Q MP%@_@B$2RI98DJG@BTXNY*>S=.C8@=K-(IT<2(/W:H%GN5]TOO&.7 MV_IJ1N?0!126?#D?QZ\;K0.*A'(%S .?;23XE[[:3FQ3VHG.6@DZ8C>GKTF' M-H#9S\2&K^#VXT\IZYNU.H."P@" M)8U!!MOT,WUXEI@NJ+R!!_<"[S++LPFZ?WA:0KT\Q]6$7KA]R<;*=/"MD7C4 MVCQV)U+%/'F89%ZFA[D'\[_Z9'[0G)S9N^(< -KM?6>A< :2U=,RC^!)>ZY[ M\8?P-VE[^ \Z9ZR9=;LZ"3 A#KP4!%*AQ&F&*0'8UV,%?F*LISIFRFBY&"0?NN M>)WL:\X=3[ M-V1<7/:;+^T9:TD2^5(K M_=I'FSK_ Y;0_R;^ZU-V7W#=^E4*Q7 B.?\:-] WVO( "P,^% 5=^2.M0X:, MWC+NI5K+=.?IW=XZ1MM83QVUXSEQ;R%EY'Z8CJ=-I_K\0]NACU-Z_L'#">K/ M&5:GAY:MX);5K]EK E?02#RPW(KXEA:=A-M2ZYDSO6T$'%,=%IF-A+E7]@18 M^NQA?*KLI8+"%2S/:@%+O-:P,3X:X'"#\_DN7GHQ*^WY>,ZFFX. M1 BP]?]CO!@A6K1$Z]91EF<#8?\ ;$&Z'#]D22^\LV0=;UO%!#]Z65SS M@)2FU7U%--OF-7IA]P+]/9YT#SJ2,WJ7M^G$S.J20.S,>A;EUURN+0=L+@3@- \B*!#I&BQ@ET@V6GL0+4$ M'\61O2O0XI]#**GEGDN8._B($(*9I T+ MCOKCZ)0WH%U&?6BV%=!2T%D-Y9@8P-'LH9#S3'X2[XC;H2? .;#D#)0*[#?Z MMM<@@)]R?;7ZON?:VGJ@5D#@'.N;.Y\GZ!1)B"*4X2@:8=,G.,Z3IZBA=!EH M=\>T<:X#"Q@6\!@=- +>,QU\KUM539&B6/:JAW<"J4 I7]@U+6,D'M_DIDB1 MY39):OX"S*+\2;TIU<$I%0FL>SPU!E26D\WE:I",))B"4@9./J=[..RK2!HV8GMY@ M3"B"JXBT@((<^[!T.59XDX_U\()Q;2EY6<7EW0IB!V?[=,=[BA8:U"@;5HB? M--*K3\"1DI(QH9[T*S?6YN-'K8P-#3:SQ$87FM4"V7,& M(!,C"PWZ'3%&9\C^RRQ:\Q#H1PI/LZLCRSM)#]B@>\.G/&ZG:5+BVLV:KA4) MV:%AG"0GW+RBKUQ.+E4%S/QF^DZP4Z2FJSVXG._S'U#(\-_&?W/AQ?^1P)Y5 M$6R;XE[\^"4D*5B)DYK6^RTDD:"#(FVH+E.0RTFKA[3ZPGA7I$/QTSJW!J8$ MRET[X'[!5,R#+#=.JRFK$!?N#U<#FE?>!XWVUK?S'PH!W@>_),[HN%W#\.#? M$F?21@4 50/#^GR64)GC.=!^Q%I%ST+A?:^_.SZ7C]B&QSLS*B.6.LF%GK->DVR%R MD7^J6\M<=4!3=CJ,76K*; _79,/M%@67&M!1UNROPDP6ED M!AT8Y?M;PJ(E%QG8='(*$AN/1Y(:J&7?S%SH6QY$FX+6.%TK.3<06C[Z%BSK M>,*D=O5ZPF*5C$5H?381 K:X\)\6",Z@Y*HY??3^6EP$[1L>*']Z57(0XF6S M'H$P&;ISY:"]4]3V0K1Z:HX&[] :NIXP"A(_XNU4;%;3E*R>2A_D>S9+5R8C MMRZ^^ZH:'"IH$ +*H+PSP+F#(S2@MY.\V?V N#-OB+N%@-OCLTRE2-\"#"T/ M,WJ^;^7Z>NSD6-R%@K,/?M.NYNZZ'E,()'_U':GH55_EW?LMO3O^);TKBC=" MN[AGJ9RMD-=+*!_F'N[1-Y5"0-4 F_8-&'Y;"-A.OBCRL9W+A8J#LU3KA%RD MRNS)8;AL(XWY$-M@1AB*QNU^.XY)^U-";^LFEA,#&EHOSCO+PC>90#)XE!>(23Y,%89LV56#A+)];@')8P':)$\56=Q?2=X,I'9V+A MT.GD4$(X#X3/R@ZE#VF/VM0(WG>6S>G_%'7]?KA@;919FS$)=BQ6[G#2.39R^[N2"O M+MF4]ZS,6+:!Z"O9+X?WDG?&Y4I(0"]3O8>5R;DR4$?!O*3\;2 MKZ.N48QT.7AS+O@^1NPSE!G+KR>UD\L)4<$%$OS'GT0OGC7OU=\TB=_ MO(:[DY"%C";)GZCCP JIGQ/[-*#DH;\\6?;?R']_@N]_(C^^H2CR.[Q>J^N, M^VY%XE[:B9YZ\BCBOL")=Y2(J%\J/PBG7\_7%P*N!0&I>BL"0BZV85N^5DOH MO("4"7,[R&P))6!DO1+K/=I:^V;FL#MH@/I3<&*I$- ,#B?N0^E+4%:W4C;*GTRJ@L. /LIX\A;3](BFYE>NJV5K3!N2:<>VM M32AJ:M? <_#U^L$OAZ]^KQ_\[?#5E_K!5+_UPH/PO] M>M=*-=E/?MY,_&=52YP5D=P-%;SO%;F8EI:4-F!#LF\ZG(EK@00C2^D%?;>G MJS/O2#<6$B(-@.HU.;#>QV[>\E*]C3&(:]5AQ+P!I(XSTV$BHCQER-WQ=1KX M(9RK_&6/2H7]DB/^VQX5>J()N'UJ]?<]JM<]-WA67FK_LT,F\5Q,->3]A MW>.?ZF1=]:3#AJQE:+1XUG=62TSL]?7RVM+J,)44EV>9]Y'=%ST ^Y>_XE./ MAG*E!=VKH)*D%IP$#YS<8B,*80+PTT:[.0_284[?[>_>[2[?=-C_NZVJ] M'N::S,QZUKJ?M=:].MN/MF&^*OQ2P&9--JQ'BY.=@Y'V'@[)*=/1)@%XC://PNM9Z8WT$('WC5#+;OHM25+T M#PE^6,F8/,&-&!2!M\_G>S?5N"QPV9D-GHZ$4]5 YW<<#:-;4Q\5&?N@?E&O M$":++/G0L= M*N=SC.T]L>NZG_7,&)7_LV2RN*(+735DH)P)'1"K@3@J.GE7;'GJ'&YG,<_< MXT["Y\V$8X11(U>$>U-8K4/P=8J;7\NHI?.VO$OR[HKM^?=++O;MXXV4K%Y2 MM[F-V_>R4O,9_@PW@M)+T% Y/6_GZ:^+/*#C:/JL8L:L.P;U]A?^2K- M3I[1\]7^*LV&SC]#/,7*?KLQ2GTLM+52D^93S7F M+&P/W>CRY["AY!JK91S^J&M"KZ/9"33^KRK:EB8T.W?4:S._ D9PF[B;I8/) M7V=J@HK#P7XG4C*VK-^$LW*!IS*LW0CME7*KL(M1RR&D*/P,$\47$Y:2SE1L MY#J69=8''9+?=V]S8&HLN>(+#7%&BU2N:T>%\T.\Q[4E1-$:0_[A#LOLTJ'Z MOO&EFJ?E##_RUG#4KQ6^4#Y2QU%72,'RE'5B[B1'_OI D;QFN^Y6C]G7, MO'MNSP1'%2=\DZ3EJ"@OEQFC8YWF9>U&SM6R/''C6 M3<\1M)9ED9(?>.=3O=-N2F $SSX%'2AKOG ;7IJG^3OTHKA$/I%@@9-)-$$^ M\3^B2\A4^0@L"^ @\P=8].UY"=N@'\-4 M.WOEVUBV7LX[$A7H:H%UK,VY'(?#=&QIJ>RO5@XAB>H@0-]^0F:Y^A?B3UTM]D>-XJ$ MMBJ]&!*+,;E;[XDKD37R<'G@]0%&>_O63D2%@VD/PI1J0\Z9E!EY=3EP@W'0'[KRHVAG#R'&OHTY7>>93- 0MW\@P2NDH0&'QB0B5J M6LMY7XB^PX+L]S@*EQ5BEA]-')KCVV=Q/O@.J7:+M.-6IOL:OZ_\7I:?!^!Q M^Q3_[?P1YOJ !K:KMG.>B:KW;AR-MWXAW-W$#K7=G7]Q&,,;J=O\V(.)'%$H M/-(*\XK92?[X+-RAU%E6-MY.IMI63@VQ2.=HB,42'LJ Q/!68.)+)XF%XC&/ MF!N=E#VD(Q9]_/%2';'(YEN9:XC%]^FD\ HK,PVQN.[W,M$1BTTX>(^2>3/ MX]IPT9IG'Z\)%T=JBUQUX>+N+=R!M3;FG1TO0^Z1#%:Z;GU>"\X^Q'@X,,9/%$;1=#=GDCU<,W5R3/QY[ M*LQC],OFBS2Q43N*XE/MDV10PFB%XLH^=R- Z5/;6N\./Z3GP5D*+W*$%%F> M;,_[H-'!A]#Q?73LM%Z<_/C7Z5ZGSQI9QHQV'R3M*K[+@,5 MA[[ SC661'[[_9;,F-P!FW*J64.QL8A@3+(M;T%/I$M'"$:DXSL47J_2I6T> M36NH;9F_!$RD2^T&X&9*.#'BZV*B"NOD M:U LYK[LKZFFL@VI!1WFYPZJUK[QMN#_5)@\-8=GQZD!&[ZL%I;0X5M#L:&<$VHGC[.L3A M8F[A.W/?LPS?PR->):KYI8+>OQ[2PO/"8XB9B M/,+[7@$OC.F_G1=Z,X]G7X?!%%_$>ZI0*X5(_-2 M^,+UX[G]M=I2NMF$A;L2/^.R9V21%N[CF3U[*C,Y1;P^EOH>[W':VKAK?B&" M:&9:J&'E6!+JAZ0U5NL:R1[IDA>>9C_XG4)]-54,0?NL^/ T\D$^&*0&+M!- MJ!]!)Q#L7BM#V3M.\=57NWW;U,"Q8)^O,#,F M\D)<8G@26DZ39_P0E^GG]Q.]K?Y;Y9XT4E=YQT0RF.VROLO$I*=CE;2;(?>O M10Y8&E5:$%_E@ED\.Q2?T=ZFRP6WO#!9_ZBP(":,Q(=L :KB_Y$I:5L&!3.VJZYJ.P;%["[)"PV+3@VC3P\> MC_(OIKXOD[.LZBLL#G"?M80M*?''L(OLZ\/7Y1987(J$\/<\_S M&T>5Y6!9($=WLK/87@V<3C5K+N5VTL_ !.4*[%]*AUD#>'%JUG00_U(-M I& MX03MT862&%<-:MOL)!QD23 M) CN,3X<"_N$+Q0N8QGCS8C;XW=1=]^R?5@]Z'; 23;LN>;>2,#1^Q MC&QKP;6?2VWN%7)%33>EQY+%GI^.ICCNXS0LXU&G-86E^&";P[2U^0[&>/\6 MMM%D;7Z*^]YF=L#6[E>U^=U%'!YRL%M7F[_XV+&*_&BMGTCE-78?CO;G?>;F8/D3<>S>L,[$9C&/P"E^0_%VU'1\O_DBWS@ M*@ZKI+X_7?:\0@TL[+[+M&9 MP4DM]$E-+T*FQ"__V-".\A4'\#>C$NRZ(VR'APM?T6?ITTY2FYO+ 9C 8 M/-72\8%TZ[E,O!I81#4),0]<(:VFW2P[3KD-T2JYA,C-$D(6 M^NW#6=GF?2PI'#M+-*(;U(BPN[V^3/?^\ MQ=[.$7,'PLC 77P77VFW)8JR^I.1DW_;F4CLPAK&&^W@LH)9QNCR\8Z2V=#! M1WQ,\G9:66%B3']G"]'N8 4V:J=2-G7Q7 FH[791]Z5T6.SF:P ][VQV^-JQIQ2[R59QZ5)Y(B2O_Y_[7@X=B!(L1&'S7-\ M0+ D>Q=34 &$G=S'"9U>B%WX<%HE"M42U0H=VN%$+GP<%9Z%DQ<<9@\M;.T9 M/X_?17+<(K.^Q:A94_BU'[R*'>J_ES\:@ G@$UVU![+,S+0[Q?B^>[VXF MAOKLOG]I>!=OU'7S"X^RT-.NJDV(>8 ; Z4^HSX/:R.&NS07*-25[5$BW)C:>D!$"%:G3]@5>Z*OOHR:RE*6:^35$&XB8VHN+2KSID]D3 ]4+-\G50W245E=MJ[@)MX:Y9;.S.X"^%+?*>VI;[G0 %Y*FCCU?2BB:\B] M[M27L2F"(M\6.WGJZ\D=+-XD-MXT.'GJRY#G%&7V.OUP)WOLFR#.&V=6_\EX M"UFA%J[HSIJJH<7DF1!=9!)'!9(QL574.3R;8B[?^XZ7Y_:2? YWR)YRR(/7 MWWK]\H@*_QF/:/G!"T_;9&-O@4#NR43L:1K==W34B#"0-35IQD/0UER!$%I> M/^"63C*L#K16I9"_9DK&T;%4ZQ"SCN40D7BKGG#H*&=A920UFB(Z^]SK_?0? M>2Z4ZYMN9EPBTN;YXJ0AI<9Y#?:6J.'*0(>+2TZ92-:^[HW^#:WQ?UIUG]LH M0RA!E)I!K1,;$1RKT',=@IJ1]EFN"\6HRS=[6P(M2IN?LNXU4[DB!7W OWU) MI?>]X/%LSA._G!O';[:UD/UH^-"_3V:PXQ]=(1R5R.QQ'S7)*&\SV4' MV.SEYGSYBE N*3+>7#ZX6$W=*]:EFI_>;'[6".VCC&5,LR=,V3;I](& M-FJUCZNP!O!R:$+[^*&8, ,ZH],^SFQK%5(N[9[4/FX:-UCW&J MK+00IXM7U]3._.4JW$$U)7M*"ZHQ6GT*K2 S&PJJL4+H!)DE?/,K:/S95X+, MHUXH?J45@K=@4I!9FU[#%YZXD>&Y'H.S1G\;,N7M++JNO:>(R3[O0ZH?R+H^ M[Y]D^7%>NB32ZG*6/R79 MNXDEG$F)P=<=RXH_X MQ'F4G!>6"U"GLWO@#U)-W@M).DP3T_O]%?;[X6:.%1DM+<_ O>2U/&W.(D-*->*U7 MX/U]IJ! ?ORFQ,G[=#HNR2PZ S>^]MQUB3QR)^V&9(/W^(G+-R5^1-:)2.K5 M#)S\ZPK< <83/S=C9DI*]L?^?FU;EL[;^OT'F4##/T."]?C'9TEO0)BRR"2V M='8S=25)\4 -S&79QJ.X_IH@^(*+0R?3JL_[2K?QZK:],F_VX33 M0@$O92KV@ TJZ0PU,)M^EJ/LU=4OS MOXC^H3Q*@3S 6V<[\)6)X7!>XY&(U@4LE M;3I.#;!H4=>'B[VD<14O)%9.30=8?**E>R5Z[HJ6!2^XN[F'[ET9PVA^>30Q M,Z3C??XH(]'CWOFN>XZZ&G*4(#$S 26&EQLKTG\ -NZ*@1 M9B# :#N? <2X7=!/.]UC75[X,?PSSN]RQ%D2^" M/U$DMYZJ"47C24-58-Y.SM<%'E"\7&A)1JL>DVF6/19.8+E/NAI("S[^BU;^ M#GDFC$0D%.#]1B_2-)]3>:G"(!FW@2DN& 9O%+XV=)[H!O_B%[@6,2W7@38[ MQ(F26T6S#)DE0L?<:6^3^-V\8K["CG_.Y<#:Z,R0#9ACOOX8>V;*\0U52JTFRRHDD2<-;KO:>- FD4Z_TRQ59@=9F=C>H.# MB5%/TDBM^*0M$Q7JC5X<$K@BC^[+8YTTGF[L/.+TYL/(_W2\B3#X]=&K=/:8 M&FA%PSN3Y2$:=JP&I 0UX(V,_7"&(N)-/J#?KH6N/$058/.VZ!(SE8@Y[Y=. MYF7"XZ@(?.'=R;R,XT?^^8RY"<A*"\?S&N^INO)X3.$< M((5OO,HC#(XH./="S*[H\@B%>?3:%SG,[M,=&^ .ZC3RP09.L$D4J$WV?X.X MAX,_D2IUR?[ _:"VP*_^5:Y_!#>*UA7X]>IR_5U*3J=4A M5ZFP-I%[>8[TH*8T2]YN61[ ;O'L-)^"HMRPZP62O.+ MNC3N&5\6:'87YLD<+[ALND'RKR@,$ASMY["(PGDA&P0[OS\D;]\JYF)8BL"T M< )!GM57Y.\,KJ\K_#'FG0ASA8=NZ)6M_#!DK!MZQ:AE2@2DB:%7QV10;(V@ MX=70JX:UHZ&HEOZ,QGH?M,/23O;[K1B!5B!)G^9 M4-,Q74J3(\O0YQ%'2IO0=\/J[Y'\RTJ=/]H/EKMW[CL1$JF=+!(K)YW>J*H.HQ6T8%JW/RJJ+HD M_*9DS.? 1%%U7-\>R-%/5U2]J/"LWSB*\S?,5"J;]_P_4<>PT:N9AXFJ'X[I M9AX&;H#&)F8>#BG,3R]C_]?,PYR$X_(4F[T3,P_M*0<1D"9XUPX]K*N/8;Q0 M W_=/JX)N7I4FC!/Q$ '#RTF*;Q^'%8NO/&2.A/"*>BVX&D7!R)%;KQG;-SJ M=!92N3*2+6=W8>_TR;_ILS!7KN!(+WJ%N^;3<'E/9T]91[ZMMIK/D@\&FVB+ M^4Q()PCW0JP^D;WC1*QF/&NM5\6F^6U",<7T^92+BB\:K_$XHB72Q_2L/F'K MK%N"0#RB5=@:>3P_+1R_Y.5,<#( M ESMM?5?"S:%!AU=<2GBYB7A?5.>SM[B8 ME[LV)Z/_#Y )?1N _@[[=_T^#F-C2E-S&)/;E:CBHE5[A"99G193\VV^UF'D M KF@*D$-/)5PCN0JD&K 0 V,'H2^.84N2'K3CP@FJ8'.NXA[E[OI.6UP"W5! M7'T34:@)B1$R_QT%+#X!::\ZT?*88E.!2$=9C+S)_U$KR/&VB:Z.;T66TM4WXVGM'?KFN@R"WO- M$GJ(72J(P<;[\G)$45&__VA)1G.NAW900T* O<$FS MP[OBQ-U&V$HV-4/SD:W6T!.?SJ&:E.4BF[,.)6ZP:7@U(YR22&T2M1*'CHK7*I$9TG,%_@']'RN\3(KI6*/ 5;]HEZG MQPD4LQN9CDH;"_(X)\K%7I+1NL5::(;W"S^;[4 W%+3V(FX5YC/3@RV\&3E] MA:GTZSU):^D167B+:F8$@8'SVWF9X>\1D1D2F9H6L6)B"/KZ@,# "]3-I/U M.<;EW(+U)N)D>9[JF@-6$-15?['4-A"59G8NL]?00VI-RW1XY"$: GK2^Y4? M9UBB H("64U$HZR-@C'-[Z9L&?%5'F:2$K[@=IVW^XP)D$53R5NG3O2'\Z29 M[*:807WD#=ZC/U!I_)!XF&H-#2G65R,6(8_9V:\LYA);1Y+W=4I-A?FVX-_<3>K#@1^J M@1=APCP?5:(:B +'[Y(_#9P6J 84-FK@(9=:AY5C86,UT%LE?0: A*GDZ/\J MJ)NT?0%'Z%K%AQ$U<)%JUD3523[H^@+N3$H^.$WV!1B_DGS@G+=#M6=))B4? M5O:%!QZN>^0S/ LKK (M. 5!_26WX5J.%=E+U.:Z<%<>%"!F;E94TF&\*2]^GJ5*H$TH[]L_[NR:4=L!X%CBIM/.,(!/&,(].*.TTV%_61/>Y M'J632CL!"&VS3J)6:>?Y_<9!.86"?81\);*#5+C[:45V7FA8P="DR(Y0CK0L M(_Z7R,YH@-_S :?\K F1G>!Q%[0T6;,?N^>V)Q.,-VDXLL\7FGL\#J^1[8SN M!(U(B=6EJTKA6FE]E!*=#3$J(^FM!"28QT*:2/A.^;D4N:M3Q]"N(H4U'??U MUW+_)9Y9#Y6"M9<[ =]CD-8Z:-P;)KK#%7GLP M%S]D+V /1T_9M_MJ4,=E)OPQ>7\QQ.UR==P%3B? M'V_;)WV*BS#X(=0A'EWF?<6]DOI^4RA[P&F\;2_/!2A,2"_X YR/BJ> MUFFRF/RY+#&V%$%&2>5IXMS%I*Q=7NLW-[ JW8Y'?'-H@@E,BIQ/$@'N]D96 MEJ>6".1QCP[FI,$"JH;N-'""M)N EN]\0V!+8$.I4L=W.C:I[N>TU__*=UJ" MN*!HA6Q#V@3?:6_5/FNTAO#DT'%X"V *YPOK@?@)^?G5U'RA0VK@ M'JA,<>QO5@.'-5&[$,[&SO4Y]5I/L1'15O<'>$0S-<$,&=8$,^R@!RJWS[@? MO"BUAA8J,-4(HZ'0 7OK8A[[B7URYG.I:0N#Z7E E:P)9BP'\NZ67G$][IYW MCW_4Q4[LY3MJBS3>D'!2/KIHFG)&(Y;)D7J#K7["SJ&J6G0\:@Z7^([4IKK= MS9^GW-Z$N=U[18"H>DC((=+F5X\E2,JY$P-U7-Q% ];/ R<&ZM3T9?A* I\Z*?YEB;4 MKS^E-@ITZM=T::UV2LR$^O67C2.< :/T7]6O66B35K!\I7C6^Q/BUVFJJ$XO M[928?,+)3.N-Z-S;2K=7BC#QI(43BC %WE#\I"(,F38]V*+B5T&8XVW:H37( M>%;$A"#,Q;N3V>YTW(8$,6L8#'+Q%:<8/8#-9,AX\AZ**E%$-X1 7QGF["CZ M7H MQDOA +:"D*,:R#*ON-SY>E>QRU ^_ =X5+K'-96BTC*[*'3RV@N^R7BH(73W\P*=F%]^\TB>R.ZVK-K^A>),87+!)[&5>N:%C MG=3DG-T@RT'*B0OK+E3>FT*=7-OQK,G"'Y\RX2G!1.$/J+1#Q/N1=84__O6W M>\ Y#A__5^$/,]A>16UJF2C\<>.M/49LUQ7^N(Z=":MFZSI CVK>!9J56).B M*_M!J0$1NMS835OW$TR<-7)K>G;F+GFAG.@556R%: MR'9B5XWOOH(5.)F?M>]+L?'1^.Z4KW&9?I1<3-&/&M\=W\Y\QKG:+?C%S6E% M7(-F/ZAT''!6N)*RY%CHH9CV+775?9@//U18I8N$BRK20YQVIG29&(4T&#&7 M8[FAH^^I@;XN]Y:TN\7-K ';*J>=G&N"/K\"N:?0J]-46[-7YJWQ%+;H"T*# MP5('Z 321NSX@&/2.UY2>:(E:1%:>D7YR<63H9@JIQ-Y65A/1HC&W;V+HA.R MH/J*;4F7^W>^,^YN_@9[$SX7;?>,[5M&"_(VE, M?&1+6M#-GG%4PN'CF;V%^5F9O]0$,21)1^A!2_GAX]&J7QH$K:V""KNZYI_O MEKU#L+W]P[BN&'&SEM L< F?&/_[6%I?CIRW96+\[V9>V- \I7N"^\3XWW'_ M]LW:MG1Z%FEB_.\C?]JB/@O=^-]92L1M7.(#!)M^E]#?2%"L(AM(U4#%K%R6 M"EL5[A=S0RP\ZS1XB;@[/01>UU+%,C?.<+O]2^UJ;=L/(SC0+._^F?K/:+[Y M#L")KL,9HRL0!*Z&T M+%T38^__]82UI=A4WDY]\>J$=<&G3)O[C0,; / ]EG<,\V9OH4'6K1Z_P:L3 MJ;M G%,U+ING6^OQ1$&H\-],G774G E?%>5-G7W'<9B^X4;J#>>T/Z_ MX3I#Y%.!,25_"=$Z.=$=LUD*[+GBK\5&QC-V" UNN*;0!,\01UO88'^R\9Y= M;,WV$CLR4L0G;[GE+]'V(IBE9/9^4][@YT$;>*Z]D!%YB;9367YV\]H?TAPAH>7U_R6UH1EFI MM>JZ\NOK(1;HLZ76.'G'$HB(OU5V_- WG#DN=>B 4IG+5]8YC?MQ,+JELPGA M85$3V\]^US[7H+5O?&Y:A$AH4>-0,Q#ZQC_IMQ'Z'>U_][C6T7639Y^+:BJA MRBKB#Y,;H* 5RZAU M24,#NV45%>"X)[.3?[^R_4J6G#YO MOR:4;NWIL&33W)L/PNW-87TI?AUM%7)!*>/ \$PP "OUHK?Z">6AD'%&G\5@ ME5>.]SE=H1VXMHD!4%2_M1&[X0\PV^9MQ+][7L_K*[N*=3W;#LU4 M"TC;LST_3"N*XR\UN>#BT!5@Q?<^WTU9_7RO-(=].$O\[<_-;"]./[+19.B#\_ !M&@4S794O8L&-$0,TM#M^L]I$ 4S MH.%MFTT>F"A7EGZ@!H9YUTPD@_K5^M7ZU6_G:LXAL#.5PS:D_9"Q M5J,4M7]YI*$:(*7X1[),3%.^0E_3"P1JW9A>WVY) 6ZZ9&M@5 M55$Z\UX,?VQ=WFBHC59C7#>.9$)C?'(!GB08GI"#@0I$#WA7?X3LN=Q':1#>YR^ M+5Q[>D+VG(58V!$\_HU.]EQFGJG&K&)Q\7TR=$ MM"T#TY18T&=B+:M M/!8:GA#1IG*D19V:Y1,BVF9C I^S2J_LY%]%M ^$;Z [M,=,B&CGDD[NRI<> MU8EHMZ ^/'<8OI>ED_L'FSA'L%JY_SU'DLB%'2F,>/^:R.K4_"'$63*%^4ZQ M#)7A\"XK8/J0-W?@V*,>U'O%+?9/6ZY)C\6)2I"[+OF&=3:_1NY?C_](@O=[ MPF=D3 V\XZT&$GQE8UKZN$@3U!5">[$_KP0QH'0+X:4#'0&V@C(,G)4;_<6T M<<6_FI*<>C'0IRTKQVU:]4Q145 +DNQP MNY>_#/'#FV;(IHK[FI<2KOIKKH/QB2YYGNQHX-:$-+#&JZR?V=OYET62DV*? MFC] 1A7J:D!$0V5#<^LF:D!B=_[(4Q9]J@;NC-ANLVDNWB-&WA6&)-E;)"J7 M4Q=S1RDG%>\[.'O6'5(X*Y [3VAVP$.@=K;7%!QE?3<7?M/9HK<8;YMTI&Y@ MV'GA"SP*I9:L ZKVM(@817J8%FHO3V*30V^%_- MLW>;"-2 _&@#)X1V&EX!!=VBYY'.M-7),!7QOJ.>=:OK/X-HZ3@G=F),+CO" M;@T;RX*HSQ7>8UMEIME)J"RDW"PK\Q?)!GG'LOPF!V<31L\UDTZL=Q,Q8,9> MG58!SSZ L(6'G- JR D;\/%H#NN[^DJK(&:P8M>=HAB=5,'!^^S[Y[?9Q*_< MNIN.97.D^PBM)[=+#2\4KU=L@1"?<4? N9CNI6JLW+R)BB M0^*(990 K3XE>'U3%BK;'C1IU>E3%O-'!S9K]2DOX6E5J]_@*<+$:%OMZ)'K MVM&VVJ:S&!H M)V$V+M:=1SM[-#1GE&"*&Z<\HT433^0#*J8N;5B'EF;#QKV(IMSH<_ND%FA6VQ!BK803?#GG[TQ8%J&)]FLG.8M#(EVS? M,D N2@[*Y0O>O/V^S=#O3?_JWJ1%)VJUTGY"QW1"T6I"QU2G:(7C=NQ3Y2R? M5+1JME=@YY' 79Z3BE;AJLLY$L$)QB([UYLD>"5UO?)]6>(#[#D8";EW0?80 MV:>S;K.1ZR96\@B/E=6&5Z'J]S6.AJZ3>:_":H>5N.]L[N\JR;_3',K,/<1N ML:]#[HT9QN3#O7A9'#Q[5+$JD+Q-:DU7;(.+T6N_[V):+_$*W\TC MNTG%7@>0=@Z6&YQ7$<(4",C'+X8IM@3](L*2/\QQL$:@!' A\DYZXY>CAA?\N:(6*;)J*%$CPH&VHKLVZV4E>!9=;HPWCP M M8ZHK/0V/-W\@]+\%I=/+0(W,99X'<)(]Z9_ M+T.<#4L./;FS-+^9: *L903=A@A^FM>9V[OVS7_N;SG^O?W,OR=LQT]JO*(M M^# ;4FC+MFJV(VV&' MQ_#(-M+#7]*W\XX=R(_;RVE4@EV&>:%.O4,;><8=E\B+17UMH?B=S4>:TF6J M?,8-U#EF<&0T9-@WU-\G191Q\L++T;.4JZ6'KZ1^'UQ(R2Y=R3\Z(K'OHR\A M/?)?LLW%O2O ;_'0*/YN)G[LQ/5] VN)H5M=%VZ/VR'MN/I5DG5D M$@!F@>7!3]8&-;'0Y\:OEA3+Z#%(!Z,4[*020'B7ZJ..L@DE &8:R1^C50)( M]M-LNT3=C!2T!,OB:V>DK"KVTHG>/)XX4I\0O7%[=:3.F1"]F3A2/ZX3O=$= MJ2\J/!<"P"LSL^%R9J\@/$II=_/!,38%_+R >T,-Y%(0 M6V+&ASVX;.RB7H%!%)&)0PL>4DSD>9I],CC00#LC1[M/]G/F0.B*<+(537NV3:T>-./=P\BL3^V1AL;9)(>L<(_Q[SD>T@:[5J./?8 M)=&/+VMBA/5>/*L _"YNL8WLZB'Z7EYHVOVX[7<:E=.ZWLD+<.KE;N3695QR M62Q>TI:"W]F4T7Q8.C/_Z@U4 1.?%*VY4@H88866&D915Y$<*]$FI3F%R4-7%M0(HPJ'^M6 MH>Q;&B^E[S$[0&\+'EG 4]9] FZP-[VQV7- MQ79BY-TGO4D_6Q"4*U(7\^SC3RK>'W4NJM/.&D;N)FJVNQL;39;]EC#W?P/M MR+ID81Y&:4\8L+RF!@@2M QI]1#0X_V#QRXTMW;O:_S MC./E9HQ\K\((?DR7_@SFT:+(,V[YO[3:T.)2;TGV5(TEY]505[+O*JB)BOCC MV"9_>+Z7==I"INA:)JO0XSFEIEH5$JY0.=\?]@JJ$@EC9. M!7EZ:JXT[=-2P.BK4@(&>BX*M1E ;8"0W6J@?(O0\ZAJU*N M"7O'$Y7+DO+\H>O< 4'I99%P#LEO3!Q80.S>_TNZYI8V(AZXFLK'!H85JP*I MC\"E#L8+=\3508>[. /H]\C(D@(6W[O>JX'1G'.#_L#'+Y5MIP;DB6==9A4^ MKA[?-UIW\,789HZTX)Q#$)= WB[P2JS\=R2(M=KP,:FKH8=:;7BC8E.<^BK[$2 $061[H-V[J]7NQ^<=1$X%[]<43'8FB+^%T6;;IDO5^PW\44,>+L MB^"AB/#,WMU"SY.9^S1/NI [2C#!C]M6W6SU_%J<F%O-%;1R?D+/)/.#;5Y 3KY"RBBSVR4.F'11E-!/"B'PS;O@S3\/D\G9B_ M(76MKQ(G/9*<:7,:M:'7HH,A]KY$\?DBOP%>ZTDYGDVZZ%A,WVF6A*)W^7LV MBM$F.$_N&JS LO?!+VG09\5VF=0F MX0*7Y7*"&53PZ"[DK.)D1$1>C.WT8#V'>;*6N.Z0XY1DV,Q&GHQS"FWOCLK MSX?\W9+4P&?-2/)*V0)"/OPQ]2=$WI$BQ1?DKZ3""M>/5,D5\@Z?\]3EO0]O M^TI\DFPJXFV]FXX6>U)N>H0?OJUB5)JC!?F1CK&AAQI']W$*B %.S[T+\J6J M_-Q;3T"KJEQ0E-OLJGQE::>^ZNFQ@E-O8]T38U:3;W=9>_@%JP^ M9?S&V<2?"/KC^]^^'OOZ4Z*"Q,K_ :Z4ZQO'.^D M+]YR*-PPU@5_LV(F/#%>I*=V97H^D^'.E'S>2UW"&T1\UL+V]*<1-&\D"D1 M,ZJQ1N3#8D2LL" M7EB*_\X?BYK8*:L'Z_,W'UZQI0+'>6? MYZG22S_Q8$+Y2$=18EDNY*X\(,ZR836PG=&+^O)ZJS'ODHQ\N Y7@X;):#&V M/S124?EY3FRV[R\]@0@>V?&;<=>AEO?EGF MV(54+H<_DNU-$. +#S^/9GUHGV#SK"&K)?+L.^@2DTKJ5J M(,[%+HWTO+QCI=3G_%&0[;*^R\2D#V4FL[HJ3ZY%#E@:55H0'R=D/5$5[/R1 MQ;-#\1GMO_BK;ENS]E 5;X%4JJ,8O(RV5>]7*. M'/-D%#D7RK"TW=T4-O0>R=_[5 #. DXF9-:H :P%BFTKN MFL\0ISC[-N>F<]DSU<"W"$Q!LS)(=--KN_S#,5+>%FZQ,Y@-E;<,8P#8]_=R M*@U-82D^V.8PK5BZ@S'>OX5MY&KCWCB2;)OBOK>9';"UV]D5O8-KK_BDNXC# M0PYVQ[0\?MRR^-BQG,,7WUT>$?"%&L"C[P7UJX%TZL^<:<5&THPZ^Y?$$F>, M1<'%T7C7T [T/$CA-RM"3-D1,C^X<&8'DR%HO]Q _C@B&_>0N:FSW;PB,C!M MQ3U)698L3CN-'AE22+_ Q@KBJL:MTPYK&#=NG!8#SP\(W'0<%RI&+,1_+.P) M_$B&2G!Q*KE9D 1&AVVZ1=JZB9+6FVK53,2:]N(/9&X2(Z=W5.!59F_>./YD MT"<6?WMB\;]#VUSP.:*5 2^NE5_D<^[8TS7F%H-=A.)V#<6J@2_O**QIZ6H@ M.,!1N9(Z^Z["+"H-HM;"\Y'S/!SEV%A[[(!)/V(ZWFHFW%1\LGW3L-08#,(6 MN/=+U(#QIXI/H-H'3J$<>E"8ILFPCL MW)F4 FQQHGL#1[12LUE=Q'L,AIWTHE?G_$:!AVLS4%.=_BD!.\VU&O:GH(?2 ML&F) MZKNDE/3NNZH452+#.<3\Q%W.=SXC?,UK/J=5J5U*_BA!?D$6F)SII]P$L1E" M7*I9S"#%^['KWQB_8UU4=0'\03%WB;=4:4$;X0<>D-%%)E%4 M5_)',K O=$K."S.OFN==KTO\D1* M5FO-R5 P??\OK>[X;%Q2QF6';OHWTY2VNP-/RWQ$C/.EQDIW&:-\R$) 2:CL M,)3-A$_?ZH_:?48[195^M\_/735%58 OM>3EV"MT4U2Y[$_2]JWMJJH6M%VGE8*_)Z45O=PEW%4( H8'--)=UL]&SG?8N]])A0XZIG!=JZ MDP#LIJ(\'FI9NZ1.Y/51S_CW,N-X=@=3S$1CBN]*L45;_S'WOJI0#?3$J('N'9"&H=8;T"!B_8#&S7_F MJ ;6!94-P23[:5)C4\UO=WHN[U,#UY>H@:OK.S7QGHL%6L1'%V!5\X3*AW1# MSLO.!L,']CZ:_;^/WI8+GR7 7]9'"9728#40NQ]N!T?!ZU$0'H M;U1_HW_2&WT=A](.-/[[O^>$HSO_AIA&74-]K 8 94!G[H5 #;7Z%ETI8%2I MP*H-3D'RH1CEIN<]/J5&4H,$/$4N-,);=-#-DS.#D](YK4>*+LI0==T/CWWG M15AQ#7&#]SMDJ*B+U4#9(?#P@.T>Z;'+BMTDM\^X_<5;1/%N.Z7"JMJL3^P& MUI+=1"E'/(V-RF";9D:R#^O\\"YI3KZ]\-WJ-6&N>RJ=Z#%Y&4QB\'"QMBT!' M%V_*P,&KI(GRDB:)WXH%T!GDG+[(':@/%%:)>(9UD=4-JZO/<9+0KS\T/#55 MYYT^O4/:.2N?%T-ULDO\+NQ9\0OJ4J61S.#[K+::X[B<"C4PBU!)ZKS/4]HQ M@@7L"X4G4CG2J%ZS@IIL801PGL!@3@U\+? *1EIZZOZ M&R(K[*8SAX\\@%QBM]Q8E;?^.72%(3J M9,_X&D=^4OZ-=)*_1X/]$B;>&W[H*3GEJF]=?C/0JR'_'N#\?2@X.HK]N]JS MS!F=%E,4?+J^=M(\W(&'8EZG]L4I2'KC1P%_5OQ1]-Y*7OO) '!'\!_@(?UO M8*L-A/[^:!S$[GU=EO 4:MI4/%4-9KQ^=.I -^],?U+HW=SO M ;V;T^,?0N_FIAAZ-Z?'_P"]F_L]H'=S>OQ#Z-W<%$/OYO3X'Z!W<[\']&Y. MCW\(O9N;8NC=G![_ _1N[O> WLWI\0^A=W-3#+V;T^-_P)MP2Y+NG+[L?EJX AX%"Q?*;9SQ,*U<)/".DU%5VD@QQ10 MSHSUIX;3Y9YTY$,0??T4&D2+7M)'\9R7R6CE[D8U8/*S&L@*4 ,_MZH!\44. MT'/-1%@/48-4?D/P$_G@\ 80NI'[P.G#&6/#,$*SVW@7J8&K M>6J@RA(A5=:/LX7*.CK\89]T[GE I50#L=U@I@9K@;6 M:RSJO)-RAOY.]'>BOY,_]IUH^X(.UT.KZY7V]!KL#+*I9@V=0C@;.]='/HRM=.RG:WR!E\(!; 4A1\U;,*^XK"J>TO8?/?[4_VN@MSB]Q>FAMSB]Q>DM M[FV%WN+T%J>'WN+T%J>WN+<5>HO36YP>>HO36YS>XMY6Z"U.;W%ZZ"U.;W%Z MBWM;H;YMA=[B]!:GQQ_"XCC,7!I6NL/D%,ARKZ*9*@_* M+2A#E+> !=G/Q-&;O_(A"ZCF< U_@ MX,D^\+L'E@ M89V&O,SH"S_NIZ)_P6Z-L"R^]+)AQ947,.U_'TG^O51(UOAX[F/$U(60\PQ? M>&[1#GQY1F@-@F.':&H ^D+II :>[W57?NHO]U4#:8HN-0";HN=R7C;O,AR> MI5^N7ZY?_@^6=R)>2\3YSQ(KA- *;'^[E%_380C%I9':NB@=!9TF[Y'PU86N M.4PQ9EI]^O[>4M.6;'8[2KCG3+V(&?V+@,P_,:\FPI0YFO+SE;H/-H435ODF MC&Z8&F$*/?300P\]]-!##SWTT$,//?300P\]]-!##SWTT$,//?300P\]]-!# M#SWTT$,//?300P\M;%\8P8@]BC5JH"%*IBV\GD6(Q2I'/U0#L3RX%CVR3 FJ M@7)_$5\-N&X'5)3KG&4\B-?"MOP(/ M+V3:5A0&"3@B.\T_Q"D<%4C%C*I ZV$E#=I*@-OEG+L15"+C>SE]'2'O%(7R M=]78Y!D*3[!L&QB$:*U5^&^$.]1 =)K,$:.@,)2V:@#X1="+:(VL8LA'$Y\4 MX\4E322P''M09A"KBA.[(A^WN(1?4P/!OKU8:52(&:88G@8W":6?(P3.\GBX MI0%=P!'Y*-?Q4$*>D2N4J MN\<-6Y?.Z.NU?;E%=5T-=&:!K/!J&BNX=%JAYLG,ZKQ*IH^83._E[X$&QX+D MED*E%VJE*GE[,[.T+@OGD[!/\VI,,Z#ECQM'XTIF5(+22VTF*$QO[Y_@2_I/ M!#E*L05N1^31^FOD\8XU'>O@)S*6%4;ICYE>A1=C+1G)JEBTTFL-JOW036C/ MB83*BY(KZ&WF'U&^ATM_Q^E^MN@=S2QFB,"S#K&'.XK? M1C3V]TCJVU%YY_3^[OW],;Q>)##+Y_,\[^?]K..[ MR]][8\NHVMNG.;\UX5'&K2>AM/'STFBZY_))6?]P$<(&%$47K])(F:4% X?C MDJZ%E\3V\/+I=L)?Q!G9-(_@#,:RGJR; X<3GGVK"*'IYGY;%Q43$^4:W%+4 MX.OY?.GFGZT=@QN%1J>#Z@&*"-U2XHK :@%)W0WSN>;==J3,Q-\<9T/_IU1 M!O9FY;;>J0\"&WXR0X;TH=;6A$GW +KR@0CFQ*=48-;HMK?A/%Q>@D,6,=**A+>9\*G[)<[<._0,3C)AZA:P)K]LRO_] M[5Q'[*2Z'!/F^L67[4>)J2H7$\8UJG-.@*4$O8>0N";EZ#<2,TX]9V\T87K. MIIJ:&0\5GXA; ]K(-S?B&L -TV[8" M3YMK+*"RP7@FYGH3 RSTW,AEB@3%?O7"?G7T[J@7THV8N!Z6$V(%=@]:?ZC" MG9)@##@5CR&51V"1(&3EL&ML]$;X8O3!7)]#:;+:FS4% M"K(_XP M(OV+6:UU,>#$ B@:F9:M7\JFR/=!ZOI3AO50:@">JMM;4^UD/;M" M,?=.DM>7$^,/M5M35< L5M@FI/[X%U^E(K/:J5*.PCW]4AHW'%!,)%1>N@TN M%018CC?<&% $2[)IZ<,)-_LG6D[S:+K#12GY-/=+$^I\+=NSO@EO[&-0O:;#VW6>MQYS.]JZ\*J5VA[.YU_GLU>"M_LQDXA M>>=2!^JZ]%Z^?,.\([<&2%_V%:=G\CH9.]UP4P9)Q_OOD-#[;H E6HE2"';7&'V$* M^^5*Z,)VFEVU4%6VZ5T1P(KHW-F7?N4+5;N7HOH]RHEI&%&T9!C(! M!1F9YJWWB6N0*!26NG'#AZ@:D!+;U$ 7%9[2,TA FAJ&39CB?'%5-]5F.*72 MWEG/3!RK'Z+.[(\[E-+I?T2/K_\2M?+S"&7^G1;C([I+*,A\BSP""M-T14>- M92:,E;=J/T>G)\!$9-)]81-P=RR)H!YTN<.25QVY :'_*JY266/UMI6'J1GY M+,UZY'%ADZ1K2M-*3HS!PI@MZ;P!"*+5\XR\JR 3K.##>W-CQ3+$QH2)W[]? M8,*H_>TU^L.U0Z%NVM ^PWJ5L@@&=R!56ONTWG#D';FD<&C,!5XOT#=UX">] MXDV Y,P_Y>G\[P%:O6*D4SET.2N\1%+EIYSAE\OBZGV0F2Y6+/)Z#E'.]C>> MCKE*&E3NO'<_S1]ZQ#$F6YYV56\:1&:YS SGT MMI]X :1$SG<_&XPCR/XQ1 MXB"L#H6F8SRD06F';[@&3QE$YC@>V_LV$.9V=V)8?R9FVOS%* M[Q57@\RFT*74MA)/XD'60?VN'NQ=H!.G1FW99++QNM@U]OI&R%IN6$YXIQ:5 MFZLLV^ 23DUT*7 ;U4\53>LRI CF,70,\A91>@TR@^=>;G\H)9_29[\$5;%+ M3V*>HS 2UP 6^PQUZS\V7O?7CI^5%'DR+%--F+FR!W=(<%H-K<>$V5EOPLSV MPQ:']./GM-\8U!TVIA@<2N0G)<61K((>J%=7]3-N#_@ 4+@@TXKU/NQP_::D MSGE\."!S:AKZA)]!JWA1P#G-(7!G.RK-,A6U5< CM0VAM##&+<6PB,0\YJG& MA90^]O1!9=OY]L@S0_G;9.:/._CQ((T)K\"BC_TI2 _'M2DA =ZAWX1AHN"1 M ';.NT+QUKN$")".NWK;9#:QA("%_89"%SXV8>ZP?;)?*&K.C>+45EY^R S& MAH?CWV(E>9VX5ZCY"?*(^@HUG;&G2\ WH"D/0&I;G($WF)DJ16;I;4^Y J\P M\TYWF:5^PRO,#+@;VXNJ\RO(;% *F*\A8>5UK MF137UF4\^ HRK\.S0Y'ZEY ITP2QX"GQ>.2/1$T !,S#H'9Q7@V#ZH*/4W]T M!JE4R(__XF/"47[6^(K&#PKX+JMRSBA:%"L<,S\__4'B MLS0UZD9./@R[0_5ZDCDI *G#T@B&O#+VG;4W(T'R%&HBCQVY1$H\B@O8&.# M*P4_$MSBEDQZKMS:*,APVEIT822@:JO-^TI$HI)T)SHY_$9F MS*RE^W 7J *4R0UV*J6 FFG%?@_=GZY(EJ)-K<-!YV,*^ZE6KI1-.+5Z73TB M?U)2?,Z$*8RB6R_6#V7:%M^%^*<-ZVX9\SZ'TQ@'[7\RS#9>!>A "B!X=&N< M8R.*RHWP6$HZ'F$'''6]H'")9WLMWC'X97_O%U#5E20_GK>O0#ZVP+Z^>)R"V7? M_S;>_AO'6X:043%RI1+EBB_PDG/4\2],F#$"&\^/#\=<.[/\GQT6NG%D*JJX MDQ>A:FVAMT1A,RM* Q>;,'T*0$HX?;BJWG *=\@*:\FJ1@Z9,.X!K:0L\/ M25WUTV'+S4(1QOCSO_ (?_?18,LWO_&5]? BCJ'=UM@ & V8A5D+G+NQ.G7V@_UX1I3M(&2Q;FC8V_]?/<7Z^F MA__9/?$? /"J,(-"8VRI-SY#Z0,U'H1VU+\0*O4\CO['/@MH^IN AT1R!IDT MJ(=_#8%@.^U__0[%M9/@2"1U_',39KR V+D@#@'+WT,=S3[)\&D31K/C*E;Y MT_]VL/C?/0R[4)M2SHZ#'T+,#?"*+F4".$.TOM,:4+D85H*PWWY/9U>[K:6Q M*(]+[I4ZJ2V'\"N*CGKZ=Z&J77\K8D44^L4P_X8)$]':\92FD+0)7M@U(8_D MG3B#[1J$$8T,AB'//3 &BU]W1:.2Q!]&D'];SMZ^US.,-_#N_=3"E'(7'#N\ MQ=7+N[(H<,LC;Y%%U+E(/FQ_2QM>K9((7465T@EU13I$B MX=&5[-B[$_6^+:O4G8W#1K%XTNOXQQGVZ_A'7F+7&";N#XTSFR<9OG+NC+$O M9Z94X=_,3)%JITB^)2%BR6_LZ63#(G50#%5'7@+^9$S>0A9W!>*E1GV M\N#$ZKG(I 9U%(/4^T6C()88#'&3QMJ!2H\?YAZ*MCT\S.&VPQ'O:SP!>NS5 M'0.'Y%\NM5_4F)V\CUF8]]SJI>(Y%***YX*8%2]*&QP/O&/"A&,5]=WUZC6W MRGJKF LB[,Z=GGM5<1)U[986)77BL)O3/)I*8F2>'^]3-0X&-#+F2X;BV?/,=]#U M$V9\XG];5?Z- _B6"G_H8N!0:UST.> $5XPC/G ;'__M()I.N]?VI@S4'8&* M$KHY*1P+@XWJ"DY-> \V!_BD!"M6RA=Z_U_2=.<25%B[\)*M_-VZ=@^5+$"@ M#^5$'V#J\N:5DFO!-77">R=8_+BJGH ].3% AL@ M\"S>KEV:NS'&H;23CX-1"K2MM.B<8MBR2O%9#,+0JBQM^8<":VX>L:_2FAT[2OI=RD+>1F[RF4A?.<(ZR M)LD^:XI* MZCUUZ#?[*V6=+D1IA.:]AR+1[_EU\AZ3-XF]:EBCH%60*[J%*. M%2 /54P+^)B4*G.OSVUK5<9>"-35V1*1AY+&,2L^%CY..%)F54EBB+-HQKRL M"(]SEU?63GYZ>60"-78WX15:[RUP,Y3255\5NR 29GC&=AJQE0=I$_N$3-4\ MAM4VR9W30N5[OOFDL(^_G-2=M#=I3?ZH^^)$^/37BZIK6\?\P\ M1/.=77#9052LXCO<8=_M\=V:3:<%X:_@[-Z_=A,:O-2M; MW9Q] I*J22XI8[%;_7>U/BLJDKM>(3MO'6ATDXV"3Q3_/K6:U(?J.O(!8![] ME&%0, -699\3TH+[^J0@G?0SZ-P3S*"J%& -V M73'GI7[^!0<]-%LCXSSB ZQA#3A=\N*'JUB4AO[&< ]J#*M!<_YJ4S-D8<*\ MIY3RD3"GQYY6$*A3Q!?M93=4P= M5S?E"A>%01 U".%48Z(Z+KH5WQ;]+ :D76%9@F_&E8Y,1>G=313 =1O]TVH7_KYU_].I'6:/AG@=2V^K>LV/*W;0$&G-'\EB E%>Q*-6'VC13NH)$\8*;XN2!K!" -,ZL8E@&V &4IJO1 MA:&_%8)"X+9K.Z#WU@-ZE-H. ?01\4-=FV1)K?Z+M@?K_O]H$EZQ+G0UC_6 M=06HQ?_:A.GPH4I0EHS*Q\_H\E'0Y6LU843GX@',&Y?)20_S.^U1FOJ'.C=. MG3BS>?J>^\H\W8O#$97-$-9LGKX(>F6>=@#87+.)> -JJ$V9BNZXPPK('1D( M0PIPI]P,Q^1C8^C6EZ"R/0=&[744*@1$;*4=1C_QV\RB9*&D4P@\I^-14;N+ MNL-,(Y%J0Q_3O?5SU#:=^/7";V4%R*(\?8P1%;%G+> ^OGXA#J508Q36-_%> MR/]8;O1_[L ^LT6F):%.CUQ;B_1SD)N:Q&;(.M;X]O''KR1IW(1!6=36*R]9 ME ECIE'!+HE.#YR4)HS9-_=@HKYYK0F#.NJ>WUZX<(SAN$4^RB-L MD$?6 :0&-QY^Q+?%-9;TDS*P4]'BBX:&OU;.0G(NOL4R8D))S3I_FK]J4Q\C9*F?2K)N3>Y_3_YHZO2.!-BX@;TO4G8-K MYRI:>)/SSV_,[5BIE%' Q1)H2SMYFTRRW^7$H<-QW-P0$GT"K$QVI @+1?>% M12V"W+@/X%)*XA?-5X]]GA0H4[6,4G AYQYI]Q7Y$WUE;I//4IZ0ZFS'FO_8 M[/#/CH:Y7%08'@"ZSSR=S0/35+RX]6;#]Y:/_VH9QK5OS=';U,/-R!?FQ[+58Q9E?K-HPIV M^.B2:O..A!37NX8_6##9IA,'M>!0JS.?CUH=3PYJ=:[S/X-"V"<, *ZRZ7:;#Q7J+0,T2OO*GW^'K9[CXR#?)-*.!"&%1^_C? M3\H1<=W44Z&38'HV>5 RDWV@TX3!A*<=/D'R+[C339W5)[9I+(C:KB[0+)0Y MCUD?TE4T,C;0_:P&<_.[+Q?L*2HLS5CR,?GGASV_7XZK6/#:/>R?#"'P=JVW M/@BQX59*,.S/$:D>JY,;%HI70YHD\(X)(T#DQBO&F\:C-R-PJ(U0X%I1 -BI MIZ;J)'0V*38^]&]P.4;L*\IA9[(UP*21]8-?>P9G+HU^' MY34=9D/1_G +W$H'WAFY@-U"X[$I>;12,C%''K)7"YWD.0@Y+8.*/!W;G20!SR" M>=D1:QLZ:!.9EW.W/W3+1C@@S=4]./I2H1\CBK'R8/F2RH%*BPW_$9IV&^A: MJP> =61>;+3*Y9PGKM-ZEB8@R5?8XDE746PK2K8]RO,2MC^SVRO.*NAX0O+/ M]:?MC(VR^>&@V\^76J(/WMCG%'/94VHN/=C^LO1@DKGRP,R-7",G:4:)\: T M) ZEJ-](4(KZG&VFJ.?*@'+J#)&%UFG+/7G< E9W.0(T.+M-C;S"VUT>NJR! MO2V;''&;3 HEY.R(L+-1&V]XG%B;IG/_LO7AZJSJ"]>78W033C]Z.NLWL"VTU:6[ MNYB3V7^!UW=C9T=P(M[4HKA4V@U?USFM2]XT,N2Q*95'&; %]\C4JS0%XGJF M8^N0>O^J[-9W5GM,&/\O*.%]E)FR"BLZ/GF#:%4[Y!%B]X=I3MR&E\?0S] 7_6PZ[SMU;>+ MY=LC2[%&*N;5&S"J\*_?@"&%)LP^]!N^^/M8T+^:6W%Z:SQ'0J7_G3C/]UM^ MO68'^,<%]U&2\9\E4S!V<]ZN].K,!:PE?\]"XZ3B([2.M2'H>31VJ*6ML&UH+[ M&]T8$:^C-+18NBZ)A32$13&CYL(.R4\LY/]7\?/_*ELU7_A[@$&%-TJZ+@#A M2O@+L N'H$YMPOKNE+M@A9\QPYAAPDPEZ):A=E.RSRP6FU"_\C@RFPG[2+IF M/Y>H=K_\WET'&/S%4FJ5&TBF0MLT<_I"<<;3XB4TC[+Q5C?L?-;Q+F6"R)FI M(Z-G%[JU$>:'9[K=NS/"8/08=W-Z'CTWHF/.8_S"_L8(A;\DC9F] MEIL=X7Y)2_^6-("345YQFN=8=;_6IP:<_'(=SRAG(79T#I3,:I-2H>/@KD%J M:SK^CLY%G7(:/_VQFPM\:7 B+N_&4R/7MYFI!AJ'')^S31@\]L.>Y?M2!@=@ MRY<[Z[#BU]; 7B;,HXD4^+"+&K6)&]$]^YA3 MKD&B41%X^>!>MKI!$^8:*@/?UW>BV[YN .CJDQ13C;8NAFK04O)"27S@&F"I M5$*CU#8^DI2&[ :.*PV:O E/XS%D.:SI]AGB0%P5M;+L(#*+.H^5ALSFJ'ET M_1J?!J3-F*)UK/:8CP>^1LC^J,+_&&]VDX$* M4+O /D 7!=P-_MC:98P> G[-,F7D/: MP=$=DI$/#/8F3&^LSUL6")YR!J/7(_9)>A0"&E#[\',8=,2$R1C#_7:-.NV6 M6V@TOU][8^QOF"VX4/*;_\W]_;U0,0WF%SQ)&\#]DHE5U!=G$2PX(K[^EAMA M6VS$F!7\=W(@H8*=WRF%N!JJ@H#8UAM6\>>_6K]WJ88/-? FB>HR%)T(%()= M2] U3C(6FC"+.8FC+D6QA7JK+29,"JIAL9PA29_8AW.P%_SHXC^L]4%V N9@ M062'.5@PJ8MI#)'8T)]/,]_$6S[^:S#^-^5<_&J7MEYDVE%TQZF4)OQ[2/TL M%EB)FRE0JKW<:Y!/FQB2HDB7Q(FDUO:0FJNL0PVK%LO&)*?L'+)6>ISCK[V5 MSDT0N<1PN2>CDFTKT^ODIR(E4S%Q*7&/)0)-N:05K&CI6 '?5X%#'#53'<)V M[FI?^RB67(7_J"DRP\-_4[?_8]>DG29,Z*$U=%)5=6H7ZFHW"\B4(]1&4)@? MRJP$SBHA$O_4A%)W+A5RZ4I+-%AQ42B:NC:#J5(NH/AU8^?4AD7=;:OH6-PX M.@\WE/(>3*ZT^_I/L5OUFUOVP)>S_'+K:/OJCW#[Y?X\Y%/40ZY!5L/9W2XS M#.OAXZH%WE6AJ[7!5R?,-=C[3_8\?U8S?T;-_(]\K+-/9,&1P'P=>66\X MQG;4!\)!"-M<"$(.G81:G-O3KQBYW51SH?&=XY7B)7*V]4$4^ Z[GXRS!6NW M&"Q0,2GEG.38Q,UG[X&$W.0X6U:]%/D$JE-^RU$XQIAJ"#*LZ).$?D(=*"_)18A5_0E-_9+'+NME[GV[2[B3':#FXN MP8V]V#U=>/TI#;^B4: FDX2/HXR.>M*+'OT19!J@)[(_,?+P\^-J[=V@KR2M MH0L;)5U_>0*;, ]LY0=V#(HMY?MWP0':MJ>;SY/!"!C"BRIKITJ\?0,&6/Z&-?YMF-'I1R"<, <]%VRIE5:+YXJ16JW[<60& MVT]+2(P"[K9VF#!A=#$."A7FT6R5Z)T/C^HE=R/F7AK'[14+2@HYM<\+>#U' M.]:.34!8A=3,&B^:=5.;:F:-I_HL7ISX_PH:S='W=W*,N8@'T@A"8K KBM6+ MS"; &TR8+B)8X6;"S*D_+OK4B)J4J3C#2JJ:\V*. M>G/C;$H?O)NE?O(FF=.$,/U55H[^"[.X/PA=.#+6IK1#]=*W1*P/.\-V>?UBB>PVXZ5Y]X9D0^*O M#_5[RF?YO9"^!7/+3)BWETB\[?F;?@OO_/APU%N0_,8F![[E.N))+Z%S!)ND MM,._SYX,?8T **P9@?+,.8D!MQN) :+C 9+[9K3.T:=A:&P!D]1D MO[R N:>PT76P[0KC0VE0RZKKB5L:QZQJF=\"#!=X.56*;0W;HK4\$>E4!U2; M,+A4@NR*#QQW?F!6?ZA]*J7H_CW9F 8WT$)_A4?O>>1GSA(V_UE[Z3XC%V:M M9USKLU]$?;^?\Q._4G)&,A-9S_2<;J\9E& @$*J'?N+XA22]OS])M>\=PJ;!4RKOHE"5I T/3'1C=BL M4'@=#("3L^G:G)28V!Q:@T/6-4K<3G:HD0_0F.=TLGY4NL0?P])*CV4=G)TY M5%;HHQY9A=BZ22VHVR8LG>K&G QOD'T&Y?!R20,Y3C^.,?Q\2IK9M5X?DZ"J M;-I-VDC"ZP30SD[^J5 \3+_UE"Z9+CK0C<70HP^S2_Q;[J"^ZF"H3?/^R)O# M#!='V2HWZVFZBF$&GEYJ->_FU\\N\V[<+Q1D=*]NJWA8@]K[FQ(K$Z:3SQ%R MC[L%7ZE)Z\#"TFN4 ;N5:27@:4^7&RSBMKN-^?O#&+OJI78U\2L-;C3N@)TZ MN^;;*&!6>.CJ(MG^KT?U>?Y+*TN2,V_JU^F=P')?L45<8[#B4$)^! FLP"79 M3IR88 /3V=L+IO*$IYO^:TZ "ZH2R MEOI.B0-*Z=X%3TMRRO[XUB&;&MAL7:UAQ^32/+9F,*-O#7KPVC,O9F_OB"!>*BH$/^(4X0PVMJI$ M]51&OMDM*,J"TCIUJ ]H-Z64F\3#CU=39XSFU1$CU[!20XY5[84*.#'72-M; M(^RMH:+K7H*&@5#'!H.W*N6#/H\,7L8IRR&-VAWEI*N,F9)]QN#>"JL#N>Q@ M^/ATCFHVD(BW#^VSG2">%'E?W_&4=D@\'[WU[<) VX0HJ[K]C<]K F6C1O?* M#@?H%V%",W*GZU1P[X;B%E2S7X>; T^J[C%U-^X?'PGD,QY3- M29O-E;T>V#EP857H)W*F**B;.@L^7FWOT(RO-7)5+G,&/5).N;7[# 4?FHCB MM EC23V:@%*] X=&VXWZTZ?Q]6%T)GWNCXN2;3EFJ^7MVRRD6&R3N;5;!36Y M4I@;FU:.,7 ACN=ONU^\+[ M9S[M/+]LXTZ.F>5"IDPES_RT%]@=G2"9R.8PA2SHD\@D/Q]FL0 M9;CA?B;,;.7[:AGB,(!K'2]);!/4PP4[]8Y/!$:7\4Q<$5(#MBE;9>8JZ$\, MX7I\4O>@N0IZ;=HC$^8S;0N/#AQU.03N1_V%2O[+*FB'MB'%UHMA;N,&AQ)S M%?3N$,%CST_-5= _CCQ# E$'6*.27"(H9B/3UNGWP;CNWAKL9!:YVU%'/L$,';CA@SLEA@=7I+ZHT08V$@Y-:1%:WSQS=V*-5$>30Q]44< MH[E25OICS9"UN2912WS@%4V F=K"4*WE6?R4"$YK.B7S>N[3 ?Q">=R,V#./ MY)MEJPP>%\SGZ;1"3_2HG@@Y'WMH3 V+2%<>6YGZ56(PI$G&3S)F>09EL;K- MMV8'D_3Z("G^(UBB=:G"SV]":F/V&J]GL8ZC]\6[08U-"2P6-#GCY=SVMJ>Q MER8:6YYCU_Q44GPRDM5D@2+G'V[+LNIA!TMUFMX7:<#A/"F=_+/4F2@+^ AZ ME 8=IVK]SUTV T6\"'A&+PIUA::DTF-U]58LZN=-RYX+C,ROBO4KY=]LERA$ MK$*FO(X>TN-%K8]=M:8SD>2C\ZKR#FL:L'BX2W)8-.2]*'WC^?""< MQV-&E0( M]5;8'*^1>UP4ZFXIR#Z6IR/UN7&XD(BY5M8M7/#&H'A-HUN(("_J_LE',5$+ M[)5?&LKA+%0NB[1C+;=N&VSA3SN-V,\%36ZY;0%P%LACY6V3C_(%#\0+1!1< M17K:<9[GDERKS<-A+0)I :QX\K1C/7UWWKN"ARYN3*G'($]!T]+6 MEM0DL_W,]U;4>/5^J>CX%\5-;FUM^GN1\'Z-IN!:X;F]1>=ZG@]'GO4[L ; M_36L>!@\)G9GA\/T[!WAU.GB508"-.5T=*Y?'B411R:W;V7*4]E"[66TE-1\Y(/ M6;OXRH)J2+M($7,Y=-EP9XO; GI5Z'2(DR!XGQ?%$CK'+KQ;*&X&@B(SR.9$ M\QK*8Z'7JT1S?7##6++#\S>)YG,CA*;1N@V/?%\EFK-*"D7"='.B>7?F5'O' M8.!!62R@7QN'HL%\8&]LY #XGL%7Q\$^-6$B\#RHNVKU@((O3=X_LJWPKB"5 M*(::,WG9L5:-7,C;U2L<],L_'33+F-U!G(#]1 MB^L?F#"*NX^!'2] U^Q;776X&UAZ9>-?Y9'.54_SFX1KN-/(BQH-&$J MHKN,[D-VS[Y1AK2&T(N"#Z\;Z%@*%9_,%SHOX\=U_./(J02#\J[_XA9J?OE- M^O(J]H''KS'XE^TN?6MTJ/-Q+(_FO47K7LYOI0"HIC83RWV0!!BM3 M*JBZ1MA:OX(<(M4"E78)\C-CL9X1"ENI9BI-2M9>XF=;![=MN1)$CAF.5,_> M*&O\!$7:_OT%>U%0C*%\W_O8YD=ZL;B!@^ELU\GAP9#/VQF M"')7[7^3'$*&%^#GE>I?)H<8U^^+2C.6S'KZ17U-PT:,3=:- 47!T5O]Y@;5 M@9?YL;FO&E33/ [EW1@HB?KY38.J]ZOLV,L&U09S=FP^M/G"M=OUJ+'Q%L\P MIW8D7V-/%#VF%<*]!#CO&HDVKCMTF%BE7@W:["@_"-XJN*40(*MD8]:6JNFH M#W"GY/;M%(HV[F;V]GYB\N[IWR^^T_#H\H1>#Z#GHHHMV%\V!TDY-@)G[\ZU MQ;&YSCDI-R,4][1@/'/)_?L-7T?"0L"VM4]AHSPIM$HJ\PZ\)[HG%[GM[6R? MM['A6;,;P:[-[YLB]+Y6??2F14E"<^"TX^UD@7I]>9P#[A=:]-[3,C8 MI3MR&K@E.0HNP,^/:P"GNS+/X*S&.&HJ=J"4QUPY?,F)$2VU4PL"?&_"Y"J/ M/0=1S=W+.KY%_X7U@?V%3UL[6I\^&20YZ_*ZC"A1X\=[Q?U^,L&/> ]V)'Q M[\'^I"5N.3N@!;PK K(9PL)"84A!E'+V8/''!(?+74PKV@4"PYBGLB8.R81E MI01&V-XP1BR/3E00$T=YY. [F+$)V+*;:Y@CU7T%8PL&\3.:1?XJ[ *X31JZ MD#J=E5I!M3;@%54]":RB@T^57CUE!:$L>OD:$V;WTRK[9%Z_(NP,?ZS=D9(A MR*M;[)3A3J:X:+&Z8E13K[+W&*^"7:L@V_@]*'>D0@02(FL [ZYD7+5?ITU) M*$ -\>R'6ODI<4/NRVI",*S#J^-HY\W(V$_ZD$7-GCB5EU^-QRXPO!WY\V/+ M06:5!E[)5#MWDR^KD;G]H5C8Z=JJK)TQN]TR,VC=F@]BTZU7\)BC&6149CCN M"2AX&H-I42'/9'&X_; (*31@!4#B$;]<1'-7@+L&( MH;[0N["^[]5^E %=8+4DB3,Y*K@%/X>]29L8O[\')=V$@$3IX5_&3EXL> H? M[CG"LP=F]_FM:/#WBB]%IQ=E7>]/EQ_?*QM5 MNPU'LD;KECRP6U;W,RTGM#VBD:(8L,Z/>X34X8JY0V/ZH!W*<,12[H:=!O\D M#UA[* X#)QN/=FD^8)U\0B-Z2",Z;&0HPY]!OY2Y3*96NQHIPN6CL1LTVQYW M-W)%5-V7Z!Z7L31=93^$3C?>B$3_F4V!?@;V M)/IJ'YU?E8*K!+$TU UV_N[P_NLT5OI6CM96K4BXE.HT2#)A3D6"<]IJCZB< M=V^7&W9Z3NQ+VVVT@2W,WF-VIQ++7@_'HMYC5:BU-C@S/3.AH#]E49&H:+7O M.PT/W].^SL,?X$8HMEYGTF[U*7C9/1=OM;8.!$<'WXX_](9,Q*&,MIR NB@2 M!4$7#;_HPDUF+X!3S,3V9!3AA)WE&2;JIG@;)JNP *5,RTT9O9*G*6)Q*R8Z MLFROXVW-#I']W%K92<44(78,=*22NGC>1B6*BT%H!%J.P-VL5)#&_%4F3(-+YX@H93&X5K$]*_79M/^2O>$CMG$='&%B.?BG<*HUWHX= M;,*4:>#PG["<*I0? '<- M:SI-F"039I;!N:M]#6+36Y&G'%);21'7%D'&XAIU>LK1@C$KR5V:[I(.Y3GB MTA(1IW9D?X%#1L>FY]C?7[ 3)TQ$/1&UT\MP9;1VCQ#UW:W->MZV1P12WHJ#:EWY"',SA M#5Q"SYX^[.>N)UY95EIO+3K/+O\KD[71C9] 9>.ZI(AY%'TJ_E^=TR[CO(J. M!3*@*Y3]81GRZ+$(0.F)Q\:4-C>NZ$&Y:Y49#IH$RNP)S-7:.=R=>1U+NH%T97V5@U1 MC%#]T.&HLM<35%3=0T5K+Q7])29S&T_TT>)-8DGH)+VC"?,P'ZFCZC[#HX[T M0 GTRY'_4LT2',?+HY&F7+PY6#+,Y?:5."1Q.R(4U7?R0LG]BN#4;%I+8VB$ M728W-]3W=:Q33DQ+"]K(H#/FI-8O_ORL],6(,0_LO&,WG!7CM":/D$OS !/'K!T)AR[I:TC6/:6YV^%D M=6*"R#8O/'# +MYRB*F>I-]NF&*\+."*8%XW#]C:\HNL+:#!,/7&>1Y+7_EQ M6='K_L_[I4+9&+W,XG7_9U+G$[<;+_L_N7X?IAN.P>9>QJ+FT)XCN'B.I:N> MO#G*:JJSB* ]C/0@O8&-Y[ZK"2KD/,A\KTG0)Z"L=[L?N-+M$V3QH*ZQ/]AZ M676J=4?^X@;PW3$&>9M\C/*R.L2;U#+&V_"Z.J0WL#F*00R\_Z8ZQ+= ,V:E MOY_SLCJ$?"7O\I[,&'OBOD]'S1F=.6 $7[&NVTICW1%G)#Z2_TY;;'KOEMM-D@;7=SW5N[#JFX9VTG;^'NAU M?]+TXQ4=*[7$HV-MN#FP4Z5X(02>%DB$X#Y64H7BT?4N8_16/2.C.B-&MX#J M>_]U */]27MLI@H0;&_?0:H53[VQR6@/HX1A,LUX"_D #*-E?M0D K0SQ0(&C. M%I9F^HFH#8H!YF,@GNH) QW>CS=/5&\A(8LA'$J1E#D:@I\ADR=P?XD M,?">_,^-HQENGE$YRW*R4,'%#UOO#FP1;>O43(7)Z\_(B4E?RANMG-:I@\8. M2>(/ZTMU*' >2S#$&"\Y"S33PL?3P7/BV8J!V>VHX:TZ?Z?H=LI7S9%J;TI: M.;)4&,B#B0&B,[( LM.AU.T0XU(>?Q"_6 0%\_)#ZP\LM-39;&1WZ5WCFH&I M0(1FBI(EZ=I_/7=IR:JKD?6S63Z5EW0>T6=%S@=7ICGZI9(;\]T6D![3)HS9 M^<4*>U[. .G<17 ^L<6*E=Z1Q.\G$1M&_]H"T8LUIU>ZY54IK]%\RE:&L> $<1-ZW_N(Y[ M6K03.M[%/>--XZ5&MWH>BM3PV2B$3Q7K[#":-JXCE!Y3>NZ=W3L[F_6 ? M=I'.?._=\WRHCMK2&->LG [LD3SQTS&U_.2]2+-V2AYDT>66$N\Y:7>T35%I M=_*AMBY^0H??D1A[)\X0']M/I0GN:0EG]CNO^GITWKHK(=>$S>SUM^ C4L43 MRS;4)"$?&CZ!W;OH$CM#H):3:,!V72%X 8(Q/DQ<5YM*4E2I.HV,J)O H?=EYMPFS6QM;V M]T<7;,RC*2[=#-O95?\S+@4G(%;5*WRJB>(U<)ZJSIMT<6Z( M]P)4B68*:R?6NIYX:YTR:\()E'N% M(OF?F\?6Y0&GM%+4=!<;EN+V(8\;(_TTLP?B5CT6D+W6[\;/;7(6U#DTUNI& M7M+6RVRL,9NY&+I4C#.LD)R^:SR_TN#4C9U!6],7ND+4--8:R5BS&;)->F;G M;E@J7IA6_UA!G:X,Q^/D^YENB4501X:*[(P+;F9(+I!>-F&+UQN/NF)M6'2= MNS%S5//^(+5M0E@?OW),[Z=1._ML>^[IK"I%+?<[8?@Q5NG1F[ MI1WSD;K3\[8VH'HGN>L:4Q!Y99[3Z;C_N:EV?VB]&JKO89(Y?:&6\ L(J!:O M$"/FBC#$Q>"J)9P: ^YVA*)_$!Z*T^8DY46,*W?+>,.O2%R:+6[O'8&9PSWG M,7HR&M=BD)YP?CR(8L-M[BML>!]\$[Q. %Z12ZF97)KKEL2O2HDJ.*_8S,Y? M\^5SWE"C;JR9&ID[;V!+,X1- U\AF+G[\Q6"/0EZA6!G 90<66@&S$U AUW, MS9^O$*P:]QK!=A)>(9BY^5.,XE<>$-PLX%EL:1IKCPZ2C5)F;Y1IW!B[0YKY MSJ-J)]]&P2#-Q_-:D;#HC&_O^<6;=K[8JW5! MK&;J/V0!ZD.9DXOAHUIF !['"6S4N&*MBQ-$S@XE<G>"YB$OK[AHO7^!='3LYQ<9%NR1$-D,!=RX,])@P6[:S-X*Y3G0=@H-Z M>Y)_+;9'86[HJ'XM72+TJ<%:&];(L*TB@/$+BZO"YZ=G9UZ,N<;^I%'(<*BM M+%9\GG:(Q%>PUQ\TYH5=9QUJ\<)M2])';Y,51-&/,+%M$1,9\9:CT2;,.T+8 M-@P"=5]!::==7)E#)LP\]K[ZRI19'3O6)L3$',B*L'8%IZ]41WDMQJ+>;06 MNGX$7=CIH4A_IW(9%N\5H:+HJJE)I+W(14.P=%+ M(_6X$0!MV"P)#.+1S_KYL4N:_[Y+L$SQ:EP_L0_[AC\VP*A!P =^\*-HR B/UI6 M$XS$T"5\D(\QY@//6D :5;\0]P$P1F&=,_?NO@EI_[_V;U7ZN;O^Q3_&6 M+JNX(I1ZHZ1D?QVQ,^6L@'J4,T?DSY5"N*KTA*'#^^ZHC@Q>.<(\T>$@.3?P M7#%":)I<]C0X#JL-+MIU1^MP^:9;8J+ B[@-[\4@2R'O[K5:EV<77P8(J-]3 M(3\31J%$["P[G\9-TFJ2)$7BM6P7O?\EOE%XT\BOPG\,+ MAN70'XNA8,FAM,Q%+=.O7^\7+]&>S$WGG(O4")',O_8![0!3#&"G,D%LK<56 MXD[A%\D,3IW*:?T:LT>:\]R*OF[GTK]XS_]+^?Q70M$R<2CU1G_+^.&"PEOM MK?VD;1D]V3%TNOM.ZB..P:9-5UFL#<[##=V!!D-D&L.ZKKH--23X?D%?>O6M MYQ2XUN]^4V<13(VUYK>Z^M4!%7>3<#-9%Z8Z:-_;7>V;U?](/%]K&Q]UA/P M>PK<#[2E5%.%O6Q!32_<.']TOLSZV@HL>$GQSUT;4E# M/I((TED,YT69FBW0_HO1![+"B;9IMIE+M8YGQ#/_2:NK,185.R?PH8RE1V7U M##BVR_ AOW_XOYVYY2^$]5#T!N-5O+5A ^RE^E3\D MW2T=H+1.-W^6/6TY2Z0NB[T$V\++#" MO=.$.:/86Y:3$!:6&TXDIO;C/]"JFWNO< - M5%2WNCH[EA\^D9XX4O-W^PP7),9[@MTN">+5T'@E+K%C49.G4[?+M(&I-_M( MP]_WK?IZ^/-OUKM^X^UYD$3M']>E[J IBE)SV]K[28\N1L=D1Q1%IS-^:_ C&@>ZP H+:![%J2-EJS2N MH!JG]O_4-D @/(\![J<[Q9MG-U0H/\#/9[V:W2#OXLQGQ;VG9#LZN>.H,%!OB]GMT0;;Q8T*\X=WEEG=>-[S7_0)#^]>:MMW82<8S?22(T MIU#PHU:R1/3.FZ"0#=PR7JBI03#BTDMM&[35"8R5_ 5EE:=MZG7$4ZY\0?M3 MU#=9JTMS3[?^I:[I2\6 &-?,]NY2,WNFH53^,FRKE775J&VA[DUP%B39CC1# M2%Y)R_-'_;N*Y.R/"]HVOI/.21 %Y?AXO3[A _G<0:^Z#'5&W3GA-64$>KK( M#))>/OAB&:IL^Y#F%K"06#/5E3"W]A?V:O@A2D',HXJWL<8/S[T:3A"K')S(?#@Z>*16<_?SN)IK_3B%?"*4 M$Z7"SHC TK)8T?[WFIP!852[SU;9XLMAI2D+[0%],/+*;TZ.D['+] M1C9+FZ9>HCU8Q;%AAQW)]2QIR8JR/2EPJEOO-H_Y#KS6:?"^X=-.G@/]B+7# MX_Z)R=D-9_Q*&8Y;4\G->YL,OC?;Q,6\B#2B_:*WJW%LNWYZW-.XU<9O#7MT MQ;ZYK+Q.R1GANWNUO?&JR]9UV0_/O=&]+,%M;4+"C8_,NJ=+)YX5Y/F9=:_P M7B&D/.WI!"6C]NL9ZP_)7^AL# JP?*GD:S_..ZR?<*U)JNEWPW&L4\< T MIIO7[BW'-T*.9].]4 K+_M1N@+.OU!]0;7MZ":)YQ&7<(LP/Q9/7,1REMG9I M*4+UKK8)OU>>W[\[9.QW(\Y>#AVS@$^:&4Z_!&4X+BC> &.[X'.B/Y69,+K; MYO$>QFQP2&+88SZ;R@.:]O?GG[RMP<5KN@U@MPDSQ> ,,4_% M+32LUTY'07,*3"3$FFF.^[?D[6U3EQQ[O_ODNSVO$N3%,D&&X];BTN:HC.#A M^BV-^1HWIUKR]M)I2"#8F4,M2C2XD2AA )34#@2$G2<>%(JW:HI8QG:?= F8 __T2#KDL_$>G);KC;H< MX^">)F<'K75B@B!$/>J\)+!,X+]EL-J.>](5.[O\A?3M U F#9HP?T(\V#[& M#/R2/N4QA>WK4Z?*?4X.@XC.1/_86O00P7;B=JCVL M2'175'2G14!6.U7:!:?FA9@P5.K=-#4%ZM8)X .VR6P;EY>8=C?D;VOH+W87 MWSN_^/6IZ*4I5JR5_( M+!5LX. O++(*?R&=DID7PS-\@O).AY'*(H_/HZ-+B*VB]0SCQ;!\^- *MBH MD[=%QA/2DSC8IP,3>V%+7>'&L'Z/HHO\?M*^_\?>NX]GK7N59$=$L427*.2F%G5.7DANP/*2\#K5MX M4"35OJS=MZ7>99'+[J*P7UN<[(BZ]*:3R,*$_-':^UJ2GOG6MQ&X_0;KWU2G M)>L.JV?W;RU7LQ/"35CD>1"A&L: +=W.QC2CJDJ3ENQFW2;EZ*K[W1M?MFWN M:EG)7WBO8$@8E55Q_5XD=TB>GQU1W_Q[WW,":QIC=D.W4SUY"K8.]K-DY@N1 M5?T^@UI%VB+CVOUBZ5-6J.*&-+A*GSIL&AG%/55*E17B.,][M*/T]8?*]ML8 M>YYSK=8Q66R@ZB,7$W3>Q.C%:\C:D+,[#!BP4#>C5VS-3$$@ /P(?E B@"CZ MM'Y]<:=V ]HG>$XOT"A6[WE&*#%@2ED_L>58^BT,? .Q$[1!=8/K W[CRP;5 M)H_FY\Q5/[]N4+W01)3:-^+OO[K2@VC%01S:H)IS>D[+"A_+_TW9_Y]P?Y0, MTVK?DL[Z9YI7%2!6$_XR3#54L>>)5D^'*4['<.7*5-GK, 6KK/WK*I>?;GD5 MI@H/R-T_G@Y3Q?9-)H/ILC)->8FC$::DFG M*>GFL?D?664TI"Q-:5R10ESAF&K)C,UULKS +0QQ,D_W30BD6T;*69DFW9QU MZ6>[L2"+':T_=75U2N[^KA>DM/,$I76S WO)<-GX<0,&>; CL\ 4S>Z6N*LE M@P;,HLIU7@4!W42U?P#8EA17F-OI02L8/%%./,4?Y#GD+2;9FUO9[1-6_YKR]@?^R+;)B?>GC+!P-N"7]L1*H1V.@"X M=SX&6:OE5]#(7,IT0OW"2X8]RHEJ2[C2O7?&V MMW\]W)CJS>&2R)VEFNPV( 27C$>\?):P(#!F/<+LF,JFL^DN*8^2UC9)'..Z M[_?7:**8LHM7NSJ&L N./7^B#LQW2+*'XNKD8Q[(GQ<$[H/\OO"G#X9J8$A- MU^+A!O'"&"^3I]F'56(+RB3V/1CKE3MD69QXHQ-JJ(LZDD>E%PVF/[U\D+D^ MN8#A]CF"6^E!H2[I!R+2\!\D?R&0V8]Z?RGE8.NXOS$(<@7[EI%ND06\*--8 M BQ"(*"U6XT-]HSWN(!*.!VUB_Q0/BB]],Q#)#6J(2S\8GS($O&3*5"T_\0*!,K9X'T^)B5^A+] M%8UX1#%*'#%Q(L(/X";X@5AK*M>-W6*6C?TT#DL=81B55K?5_J3F2108W!5 9G)XCV6C_9%T[@2Y&N&[HSVP? M:#\W9 - #\&[:W9HVD1S]7F%Y$%S A6\4SL6&_.ILLMVI'RUQ#/CBM,#HV=S MMT<9,/7$4\!" R:(F##55(WP54LG-!9SA;X195R[^[$JYKR^_;U2%V\E;?<7 M=N)IGI,>+OPQV(ZWCF?'XP>$U.]4S[Y<2''$;_O5;P* F6YF^Z3ZY4\,H]&# MJ-J!=JVVFNQ2W3;U2N<&O.VA1X/_7JR'!NWCO;A M9U!AG7G4RD?I@\WFP\BSI*41XVL"5X"]C#.2\9"MV/?;MRGILO1Y%B1 MF9*W@"&ID7/DXE*7S4J:U5[U[(H"_?G[O7M%VOD7$?;Q=^0X#)@ \AR@)P,- MD]7&P>]AC>T-F(0I^>#DU.'^!!AG;T.XW2 [4%+&T-7"C(?#7YPOOL(\1/>F$IT1D4>T8.$WM7R MQU .F''79F/K>AV!$"L6"@P8XT$GUIJ2!\7X;L7!YAA_S3=JIWBX 7^]() B M))ES.8$44M(C>=:5XY0")_E6([!Q.ZN/]1 O\CTJRZ3U]>0.[[VI&%R>5;;_Z8K+DY_03 MMWO'%C(NM']1JMOPJU<4BGLR#1CK=? ,5AM@*O+@40D/67/5],Y**^BINMWU MPOTMQK6%[T7Y]/&N0Z=1XBN9LD@JTJU4 0NI)^2QEY]6DG2R#VYJ_?" M=860$6^4HW&#[H2J%1H*M$GMN2=C3X5,Y]:CI1*6D(=.6/I>";T.-50+(U@+ MU/EH_,CE-4S'!S,'7JOHX?^D+P&" MR= 1TPYMG<+\Z*B(<(.1081_;HXQN\I(](%_*6V/\5:9[.[TXL=^>$[5ZB > M\<('$&NG+IS*;: 6#$59Q$TP>EOYP8MZ25)Q(LW?MRU<[S"[I3*_2N\%/*M*![:M]0W_[56>Z7.Y)'Z3KSPEXGC:(& MB"._\SS3_1>ISEBIY5DSRA2[U4[RHB=JXKN_C4U/,^V'9ZE,X:2M=MU[LV5%CI<,^)4 MMMUX6BZZ4TZA\7'O!?NV5-EP5.PE0\>K0O4('+$=_<2NMKHJ-#(Z,O30M8$R M9UZ"0\!JCTHXC1!$A%:N'ND%R2-3BF0NH&1"M+W(YMU;"OUM"H) MQ'%L2EM8!IL_Z,S]P4D!I@\%.HV')]E(R6"_;KG?ZI^^G?GB&U!X5N?3FW2B MOKI['MB>X')01?,>)7=D68-E2070F8!65FW0\8)N9OP7+;17-6%I$>WD(&'* MB.:$T.++D=,?6$>96L>LACB@&!5U(4N("=CY!HP0WZ5'<,O<]C,QVY6XT>21 MIEL !3ALP- 'RU$Q%$ 3&]]9>:^?F3):E@6D:?X:8<"$6^Y.R0M&UE)V,.D( M^]I ^GIV4.[ %#[E,)U#(>V^S/%W#^(,IA]A!RU]B>T^D7=TR"5F BY_;]6[ ME$5KD^:]4OA4)8]PT=8GN"M#1:Y*QC#2?-4X39"F_;P!<],NC&[=;< < H+R M,PP8BYE;+?V2N)6-M+Q]%/% NL[F1+*19AU\+&6=[$O6A[!4#+I[1=P--%>[ M)P-!O ^@,ZK/+5<_',N&O'D#)_X"/>UU%4KC-?JZ1!7-G&I'J+-9%K\G:<+: MJ5K6_1XX\01.7H\NO!I2CF8JTN,2N0/EL7TI M1<%3@LOW,V\,.A=GAJ[,RLX/B6(^_G/7PQ!SBS\W4B.#PM_S[W:!MA=7(.O.J] M>&H'MQV*H$;2^R++A ONG_O(@#%7"-@C2+2#?Q';Q(2#^6J'N6%>F_]>J>NTL:M(#V2M**+6% M6@JO$0NM\1NAAFJ]=)_<5#M)Z,:4*79]\CM#EE\%VJ0[M?#O^-5FF=QI72%H M=S&++!Y&@D@\WS. L"O-![ :3$/P]??IS/M)A10;K/ 6NRY*-(G!WN.&V9B# M[/.BX\4/(?^J0$NUT;8A=H-DDKS9@%V ;4\^6'14P>KIIN#EEZ"5QUL MTX/,QIE9]V6JH8#OW);SGO:/2 V8=X\8,-\1$PDA!#,#IBD.Q29I=YW$FAFM M2/BC]C:R-9\PJ#51%J>XXOZF_6!3+?9%$%D@-H;GQ:R ;/,+MD]5GP.P1 MW1:E/X7'(^\BV!F!:J 'KW.F"O^]O(YSE4%0>N7*68G7!_?H]JC7:2R+>;2B M3F+8H0#C:F?BMP*QZ9#EKKV=ZP6Y4!,1O%]X*!28]=?2]*>=/F=V:RN4'-W" MQ=4RQ3<54*U:4F-9SU9"^"[E6%R6C53DH+^LNL*JLFOO<#FD2E.3-WL[AK4-D%P6'V9/82O1P67>(,*8,WVB M6KCP^WMO66CL +ARQG=<'LR"!J\2!A$7Z5UXT!H9-OR[;9W'RW8JB" MU+RRU7XP@+ZN5V;/]-\9_==# 6Z[Q/P-I(8I:^00FT(4X'9L1SG-UCO>%;JL M%J.%A6/+FR=,_/U &T'>OA >[:/!R?2LY* >DW?&?*6CQW[9T$U)+7^:& H< MO42J*J2T_"S\3G=(G0C/J5"G5$TM<197C25D8:'& K<^@ +Y[VV^"ATLOM<7 M2#E1!H 7'H5TKU$;Q85[?7=@*.H"3W]'A9O+/-_D^7D+XO<$)JZ;WP?RRC^> M":U6$Q'OVL,\H:WN=D"]*U9%PXV(Y2QK]6[$NP(!TLK.('I!A[[BBS8NU\&8 M*!B19#!ENA+> 0J96 M@D;)([2/;K?'F!8_JEWD<9QNU4#3HXT,([)4> THJ.T29-T)HE'7^9'0/),I M(_YS>%/E6IV]VJ]*G #;0P&]_L1;C(R[\#+Q X%D:DRLT+(_4IZMGW9>.4IS&$/ :P4SVKZ:S WWJ1W'KM>'^ MFG,^/#: /.HT3B%77$8' %9M8JU$,"!/?PMO'.)DP5H6[Z&F)ZR"*(4/!Q:_ M #JQ8,FZ8S%VRDZOD+:QYUJ:FV0*2!*8&C,2OSP]^)1U3Q\_GW?H8'0A)3V\ M O'T7_T[Y(VG7ZQ\N)X->O+.8_DKRY)[#9ASD\[QU>0S\GQVSO"4^55:F%;Q M08Q;"\\AH-1-><D,/%\4X031.\@GC [R/_!]_OO1)6S$?F,4((JE]"VD(NJ<$X3G'.0.^?I-_'@2[% _E#9$K M;&G6C4]R39>EJLQBT/(I8FV@43M=9-=+-F&HY2L61 GAP_T;5Y MM.S$5!*[DY]$DO\=M;%.[<,BO;\'VOON_4#0M>%E[[NH)3P)ZWOK=>][;FFK M?2.1*+KPLO>=@K;M9*.][_N793F=Z_C"",1M!_P /EFW*$5S'&K6)-'O.HK! M;!<:+@5F]P1\) />"1R!)7SD:7 D1/X@R4O8P<]<.VZ%A5P%N'#LG, M!^H,SPH.J3ET4#@Z@?%A[.V;*C% MF[<^/MVI]9-,\3HX_M%QI^7C/X_+M=ME16&(]9'*4KZ>\?A-];D^ %FS:PC! M8B@ 6YK$.QE>F.Q4IYA!N.5B#&@SV31PA49( +D.Q.=>ICM;:)6-N8.DM-.5 M$I.^DB(O V:.NVY%E/[A;?4ZFZ#Q<^1L!>C)3I0AZ DX:CISVW4OCCR8;1:F M)RKG%T9&'KRA>%05JKK^7.]6_0G%-N]3:H";+W3F*L/-]1(,RY[M+&T1>.VF M/BE),#FT"P.7OQ%:095/3I? [6Q0R%INP$@(C+63C5 H>*;& @NF;JD[H[%J M/-2[ZAPNP65SD3YM[YU4+U>Z*40@WJD ]V('CG;>_2! MIIV*SAQT1%O<(?T/,8=[1QU[?U*7E3R!+)2L4B@7^2L;+] ME.Y@K_Z8E)CF6]ZL,U-F4FM)W+++LQKS?IC*K&-G[R=W23B2". 0U>[Q=UQ^ MA%/J=RZG_1-\X/OZ!.!//&M8-C7*2QA;C4[_[3ER3F7&=TQ8 M?]3DUG9,9ZVDS=]?+'A7/?LZ!SJS*QI8,"3?!A8G!]EI>^;72C]'XA28;W 67K&T]I2.C)PGIA%E E8T!<]34C.)G&5>! ME9C&"?\\M*BC/IO17B=5# E/-'>2=J<+1(KY?!PV.)'39%7N0?I0C_9 ?;55X7P(OY6J]@0=Z5"Q]'CM!K!M"4![BE2^2$]%5U#E3:<>?^MYF MMA1>.Y":SHQ]TE<(QGNS:_T^.: 8XN:M3S$Z&VY"V J=*0PQ+Z+1QQX_$'UX M@^(;Y:-2>%U/* H_E1\SLY#B7'SJQE"4>45^R&]$.V5^KYL24Z/BKEP?1,?P MOE6R$YZR?8R5"S5K("^CMDAC2%$7(-L51>^*TV*D.!ICTF9 MNQ>4U-)@;NC?B;Y&>M>4"&4""]D>E;+[PN/%]?-T'W='"A62WO( M-4"'5(4O!<6JN"0]JBU$:\L<+?0,S6:P76^G,IXW+8'\O2\9T]%N0/&13-I3 M2V-J@VT#==2"5-(BVI87(O=*_NY5UN6AGVZQ5'/]MOXZ/'/_L(UM:YB6EV@S MJQ5;#2S*Y@M;^+=Q3[=2>290M9TQL?78DU*ISN?:^S+5!%]OM/...C6IUY\P M?T!&PJ?0WP7JN:PTH&HMR\5?MU1?P$]^;UA8?A:_!.K@U(/W5>]/F/C8%](_ M0(BS']E4D-%HO/MFZ];BQ]<1"B-597U[&PY<(2 MH03.@FL-F-@(=+\"S<9L5W$!K;?6$U[,?N^%#:!;H?A&:_%PU3ANGP[&G)9/0 M_YX!K^%!/@KPXK2V9O6F7NP"!A%V(X E82^%W48-F/%Y BU!7MF@-6"6CVY M(.A>-*/62Y@JQR'W#W9"1Y!_@/"D9J!OL0&COHWJ-/N-]>LV-L'%B"O[A&W M)/U,4-8!$V%DU&7JCKW*N&%KG-"$WFJOZ80>@";T"BUJPGO,]#8Q^Q#7Z@A4 M/X X:IR*K+.G:["Z=<0$F\_4[1J<;JWI*&$$@#QCME^GHA^5DT$^%2]$M7-G@\5DN%6&/'99_MKN@'DQLUIZL#7:N;$-)6],&"H MR2/=7G>-^DQ^G2\_.E8-0,N#=':FL6P3/ +#)#L,&.2ZJVM HS,QX2BKGW=& M2]1BX46*^8/E!HR&K$G3V9F\')G@-L*F:6>ER75LPDAJ=]"ED]B$K_[1W>VQ MGIXV.W\#,6!HS'CM!NTA>"$..4TC#4=#ET^\O./(%X$^<712 M_,TS4;+@T0M6Z"3:[O$O3PC'$%:(>XH 0;]N+2X>"S9US[LS7KD\A@SJZW4K MDX]?U9MZXIUA$.::+MCS,VN K77$=66@9+#7;:?B\"QN# #QBQF;ZFT M)WD?)%1Y+HQ041N_Z@S1E,?VQ]GQUCM8$>/ES"?Y=ZX']^\"7\4(UX1C@$S;XA"[/@./'3F*AKW2("^SWF1XIE R4&<6&%3+=7).5 M\36%MP5SBI#@:=9+&7'P]Z38%?'>H4#P M TH*:>5$&WO";SL&F T[0-&]8W'EW,I8M<5=^!-PMC""4UM(&H =P/L"98!O M_\ZLOJ?W378KB.U'B];W2?LJ;E8*SH]O),D],S;_N,C-3O3S#TP@@K (-HO9 M"-U34L6S8O:"Y'C=<66&>(L!4^J@Q]N*;W8?H+1/$365B=%G6UT(*N, PE>M M=L\5"P?\HDY4Y#&+*6&-.UI./#,:'S1@9B'F8(C)-2J5TS%HGM[-YLHIEF4EVKII! <'H3J\W)22/GC>3U;G$G?L$/(.Q5!U6E M7E+LE!8?*4OS$R[$<577QXH<>LG& M9""$$51G@VT6>2L;B2/"5+++9 (+U/; R&PM$UGM_JT#IL=,";Z,9IP$XKP!847'$PVCTQ%DTA=S)Q: M9XY\[,,?*Q-']@2X.H(0>T!GUW^%3DKJ]]F*_66EF?8V$H?FG%,5 MT@5=.FM(J=0?:E*_B\0.<+)&;!J"MX1_!OEB>FK[*.M3L!3B:8$:\\UA%1_H MV.] U-UM,9WZ+Y$H^9'"_;;N&M2F70<_()>*'ZZ :D%QC8VI=()X*^_"G3Y* MUC*0/YDFEG.IN4"UOY*JITL^99S>9^_UY3-XX3U!\$2KE"OF/Y:F$-.[^_:8 M8GB#='A.(2B%%QHPIPR8Q:R/N^2,TPU[H(OJ=]JWEL+-9T:FS*\KZ?$DHL[3 M@3?_1>J"IN@^1D:=C<,# 7.GG:MV=W23Z:HK=),+V;E#BA"88JO=KT]D60+5 MU_27\>]"YI[$!11Y+.>D/1<(;-%Y&W4X=&%K\1LING!5E_G4O2+[>VBE#GTQ M(\6W932LLV%[:]CP9L]HZ]W4.Z[=?4__;,KYWQQ3^N\<)\HK1(!7EGW3;&]%7G"O$*'HQ3^(/T8PU4._$2[B;XPA$ZWWH\'N)X_)T^V NW4RHP.4$V@BZU[3ZGXN+O^]_9=I0K][*J\ROW/54$ MG7]61=J=?'A+#1#A!^+^50D5.)'0DX$.7800J'L3".+)+0(-F,13<%*.SAY* M*SJ H%<#9O)/-\&(;^G]]!G^\'8*;&O =%%(16+P)OY>1"]HVOGS M_ZOB^&]5<9CV$V%CFMK-IUP]6=5T&BS.IEP+9IF*H>P"^ZBV)HVO^ 942&K5 MKY6W^_5:NDE#B-@D9M.U&.?V8\L]_2M^NL".0#N, MRUL.4R[U,==2-XW9K5O_.*M.T?MZ4F*YZ5S(/T#==#[&H8=GC"#^$-1)+&L6 MH2H*HXXGD QEN!@15O]18GV6,[Q5YVS0J'69Z*+FRF^TM=UP.T=E_,SM,B# M?/>2/C&,&R+'RGFJM/CG>E*+]=;5=Z.-N3ODL-S.;VM;. U7DT5H"YLSFG?. MP<3"7WJM131W55Y!8N9FGYMJHW-6D@==[ZS[+2^'4\SY1I0JJ[LO]TR] MV,,7)A2M>?AKU]%W,6&0!=BK282.O\J0H6J^TQFR9G]JY?OMM&MO,F3]6K0@ M41Z$9LCZ[FON]Z$9LG"$;Y>7I3!U(7 S>8;NL-8IYH ZJ)KW04?(W/6)!0&> M2NZ)9[N]G#OKNDU2IYZ:SF>T>\1U(PN#;\D24T(.7VKI]&W]IMEAGX!@,A0Q MESM0GL<53R[^9Y>P:.9T5>Q^M"KV9 Q:%1NN[0J;@/#H'(=F!4_A$ MDXF^%$Y(Y9HVOLGL85(+(+@TA1U=?=<& ]*K%;.A:.6D9,R4 IN!]-BPYU)[ M.^-='K,$F3?1=\N"\VNJF)KG[M@FL$N_X[6\[-N80X#O^[$M1>7F&N@F- MCE3M8F5]C>)">EGFDR$;9_4LWJF8E<<+H$,CPHL,_RHULR*PS66S*B-MPU @ M5DT\)V \IP4V[#IM[6P7H4RW>]*=4[#?KOB<-O(WQ3 (Y9&[>#G'RMK+E,* Y<>9@[J 8S!RTI:L2B<*0*5Z" MB*C*P)V+ZFI/HQV]K-_2_@NV+$U"A/S%MSCU]'?J*2H3]ST5X.Q"WH S.?:J M-K"BB,&Y.VIT0;3RVL,.NS@./EM?JJ*;##H'R#*"@N47C1[8U:PC6 WN':JT!NGG MPAJM:IUCTE)3C]=>Q[.YC(:]"!2]4DA]1^79D$'SWW5+%.TU]RC?@'G2(J8# M/0E9SG 3Q%%+E!P-&1T/03_ILJ67-\HK>P&@):/%NL^GC!#J3._ CJ(;&GQ\ MNV9,V(EJ,QU\@?WF#BQ]Q@=-!YZ^E*!Z8MJ9@_BRD\ A T:^/$!F-V&!%_\:_E/-J"BQ0\_\H(*"CQE[K1:\E,67V&E[;!Q@5M$[]C[U*SE\<36B4+V@D<#)!_]]#M$78]<(8(]EWR_;E:;F+K65I6BHI#GKYO^LGK.'459,<*%$LA MCB1P'BA(GM844)E,ZZ[@I4&']3G%T)F]92UAB=BR(2?S5U.[H@$!.4#>T?DB MB]96\\GRGT3ZZ4ZWI94+'D'MFM0VUIH#VPK6GP/]JJ:2'CO)(J:^,E> 5QAH M*J/:TCRE<%_ .CD79@-*C\IE0WOOY=;2K5,+LRE)!4-_WNYB>>SF#&W&OZW" MD\G\347XB\,H8$$B>)UD:3O/AOU]E]>*&I.M!.=,F60KM6!G+./_7>ZF4< +J/7T=;3!F2Q 45POYD*5=J(UMI[]PIF.!#HR:B'PLUD>_ MY9^8QO4W+W(C1V=>H8R[K!Q+9,]EV0[V$\LJH"L]^@A)U%-VT+7.AX^ZD'A) MYZ?&UTR5E;P+'[M=$!*U.HD/S-^!6W>I?U>+R"K??WUV)&4E-^NR?N7?G<4] M$UDJY\,5,]&EX@ *)C7D]OKOSF?31N-W& D )VF ]5WX2I] M-A <8 3;&3!3CB6@5)E?0C-@EB,?S)+4X3^]F0D\WHJ M5#EF.D!CNZ :5=( M>1$9Y,'W*+T&3,U:>,K^7RSLQEB^V5D:CQ^-U]HRG#3%D'L1PVV?- S215P; MG*KC@#FU[8OO<0Y _G5?/E3]O/F.;^?NMN+Z,Q/:B@!\?5WYSL'R;Q&CV4ON MZ."@XYY'Q(L9A!K+IEC1]GQF_OU)[>8 M$,X)S1W2$&C2XO4OU?73D% 64E)17OKCN*[3_]S5L(NWI]"9-Z=_T1F+0&$= M<5X,H\6>CI,0EL00#BL52X9DC<7=AU2$,SW1MA&R;\I/!QA_#G>"2P*7W@)E MF1RR9#W/@)GCE^A@U/)1UL]:[U;Q^[\&2>T5/;L2W?]]#&'!#-6W:2QL1:O+ M\1Y3X^&I2=U'4GV.:XG:JSL%>2ASCR4>*C=@OLIJ1^G=XE7<[ "*,#VV.R82S 3GWC1-3NFKD7#]G#,.+% \5VQ\0;ADPI:@*OVZK6G&*U:Y1" R8 M8T PF:3SA%O'\?=H^BN/T8PG7*LUS2R(9#]$O"Z92APUO;F?];+)U>C9&L0+ M).FO.I _B*&U5&(H8P7[&=X]3]F<$/EH45(HC<:#M'51UG$5\_/!;45=E/)B MMG)L]E 4GJT<;FBTVB7C9_H=4.NOW0O/"_$M]8">!)Y2'ZHG(X%@C-1 6B5T;>B<'VB1O&W*>1OWO3CXN]IQF[N9_+N/8/OT?HBU_2_U*[Q0QL4 M-Q?##[!H?Z(-.*+X!KF+JCEAPTG$AE*VUM25?QH=#O*1UEIS/6?;=:#:29E) M\&L7WUKLS1?)"*7B6\_[::Y/94[C\^ SA)YSA#DTZ4ZH7OUTR@1/K>"Z2I2F M<>N7B]MV%'+\]_E3LC:H'UFD_VD?WUTZ<3T<&_\E)>WIY%21G_-L+MURT#%E M9_A5T\XF#&-FE=@XQDHY%J\P%6WA0'Y5E692Z:X'?+M/5YC+3E1[K$[W6)7U MJD.ZV,':W[?UV/J)@""?"E%;N']#X\[QH:%CU;_ID%)BH8_)(]Q0K;=NMJA9 MMR9_<))L[F)@=9*M9LECEG+ M6AST&SR_L!_VW(*%%R?/A8!ZO_3U%P_G/J2DL]A*O=4>]X&&OMZ@CG:C(W7]O2Z,NPE&VMXLT%)67^R#$ M J\@7R*#.WC81U"&)J!=]$$!A$" ];"ECMC^O!$K45=>MBE4(O R;5>SR)MS M+Y(2M)24,CC5_JT BWTTF%YV<_T*T6W$53?8UO,?I#80];3_JR;.V8Y[PO/T MVJTA8F/6S&#RO)B-4[$7A.KA/3+[3,]]?&I&\(ANIG)&3B!#O"MQ3XDL3%O! M=*L11HW%\:T2-ST?/;1=%F,5W1N ^^J"W#]C=L9$F?A[,F0KOB!6VNEO.7!G M:G%: FP&G'29VT,6Z(4(2F3+S9W(BPP8@4OR+7_@2"0!+"&4L"3](39!&H(F M32[5NHV8;\7^U?Y-74(LZRZY!+ZL71VS?'OK[&RGVN1S)"!.H#@O[0[HO$?+ M'2HS=TJA=!NUT,+NN'LW$TIUB]??+J*,4T]$I$WB5[<="]]RD"=US]CV@(_M M;X+G)H$5L'G\Z$50,AIEH>F/AZT-F*,Q>]6FNEV(2T4+MY6+2NB0FT#1%6+) M?)JM9ZN=]H XG>E&X["QW>O5. U;F[4."L\&#A$+@(Z]8E@JM>=-A;>' MF[ZPH!6"\U^MK7P#IN<[L34.OQJ^[QPO82\8)LBS5D%8U1S1)LK2AN)'(9_H M-JIG%0ZQ9C$]?=M65TB?PO<*2(SZZO+UF3E--/,S2OK< $:MUU6V#F,=5UH1=S2Y,L+K7.]Y5Q%QKS%X$-50YPRGX6)L4 MA]9#/N6M]NQY2,18$/Z!?>:JWH8?6]*\V\*M-B?P-ZY'^,5@\31]_I^.R+YV M7K\>,?:O=$9"J%Z[EV*SJOVH8*YH#4@D)JL.US0/R@L'_?"?W6P=X;*PP>WI M3S,!SO9K0W.Y#4Y)SQNHUW&]ZEG"DP+:1TR;2<\,GZR?9DX(X;EWM(@]871V M5W5'H8L:ZXH*0 M0*PXJUUR71G@*ZFV#"/A,Y5Z)TFE)=R244LB#HW^-_'Z?_-E-&[\=LFI2OB5 MJY[0O7+5-Z*5$S$S7X+H,)O%8%E%+WL)1*T*-"^!6]5.W[ILRV'X2\J#Y$=' MQ/QPQ8(01_GNBX4**GB798(%A]F=/#B!#G_3=$:A M ZE34]>0($&&PIM0Q;O/G0R8SX*JQF"&/2 I1A7O/A2_2,&; L^J>,-#T\EN M93M!2-8O4.CNL8W$+WJ:#9CYMZ=%4^,,F+Y=J&IJTVPQ[\;',U_,,F#B#Z Z MG6[ LU4QJ$[GF< /"UGU; $K\<90U);^D2YU)?7.ZCTBZ?K\%M;[D(3(-5(D5,^!G2&B MFJ@$-&3=.G$<>P$>\9;'F!5:"W@Q;S:46$WNQ':POX%;X 98(0U[71!@;"ID MIMS7KNZDN1@PN-%/QIY-P;"M"GN!#>Y&H)]W[VA?*8^1HD2@<*!CN^.=_@NP ME<+IK* #MZ(]2#V;4]A-V2N)[,F,J+$<;>S+IG&AY!IX4;M#Y_!FF7=!?>CA MW"[*76R]G9DF8C1\N@GH.T& ,V!6R58UQ73R)> M2JPO)RC#&23"*0/F?=%A?;:Z5$*@H JO7\JNC3M@S]F\*WT^')ER7Y97R887 MT1-L/AAWV-&N&PX@[&O3VU/C=@;(8U;)Y MURW%DI3\WQNFV<.]VQ*CM' MQ1X^W/9 8.V^*_7PZ:=(G*(3YE6NA/Q[5TN29^GV@CX*N6Y#;[+I0^K4D1?/ MAQ,;L((:?,>U(>1>.TWELZDJ4].AN1'9C$0O82OB[6X)NC;OE:Z\PN&G8%X. M _]_"E;_4,'*[#&6OQHE_KJ9D')Z=_4PE%&%4$#\2H@C*6=W'!T#2@4*4PA' M^@?<'P,LZ%ZGWEW1F[P$2IN6P7OIEHH@3@T)^3^OW)*3"MB7*6IVH!) M"G\XMO+VA;ZQG6+P29.D@/;\^],MJC43LV0Z(*?+P^RQS%RRLZRUWU]8$2>K M>_9LASB"T!//,G]0K//6?@[)5/6_J)WB=02PMUJ^@Z/)J-&NBNTU<:^S%":, ML&K2C#F/@. AF]F@H%Y>S%TEXL,-XT7'[/YTI_50!0:._QW !4UAXRL&C&.% M 1..4+Y(:Q;L]_=R+!C>F$I\,@J&7_WT1W&L._!;4^08^,,WQ:*3S^ YR()U M0I9U&-& B7K"FM$^UJ];T 0?2X0'V/#$SQB][C4#FZXL;446NI1AA,#H6/'$ MUSH?WD]KIQ60WO+^KWN3+UQOH M#C\/B1==I2>4CXKH5$K0 NFH@]@LQ+Q\EY?QHZH\MZ!93[KTCT(5!YCDOU%M M0+S%/M!)M]: .0\L@BV!$. 84%T!G>K%_:XP:&$(Z1\4!KW0,\G:,(:M#V@T M>DK[>3"IMHX=&@&H"36!#G%>G_E?X:;MA"X[Z[8_X#Z.+O36GIWJ?O%3EL'U[P\ZRPN<5\-PUO0%^U>*RY#//[? * M8KI4Y7=&!_1P3WC^5/S-;7Y+D9-M C%F0'/+,])$7])2 M'+[1O'E]GZ"R% /?*IAF)XFP\8>JS @)XK%V9.0.6BB^D>J.JX&J2G.UE[CC M:#_<^H!K3[2 9-WUC>7"]&@.[ @F)7RJ@GP6 M \0EPR799GK,T5F=.83**C&9AF4K,HD[]+:9>AY 2 KLT>_6B)4'(T^T;H, MOH\<2Y4!W))W28(B]-?[%/Y=Q,,)!3FMKGF>&UMMK$6-DJF[I%I-"76)ZALC"R]3GG[U.UA_(. M#*8(Y &-X8>"=#?\-*5:,X:_*PB,7-1NHN"7EB G\!1>P,#6.B&DCR*J>.:@ M6#J06HDJWF8PCX<[ R&,C!K+2H[FJXM'1RK;-7:HHQ *^&=G#D[]=F(K_*&8 M:OK"F2[W0V=$UQ'U^RJ7\T;[Q ETN005Z;P\#8S1S21?7,+ S+O_;NVOZ5?E MI_IB\3'"6?8M\\N<;2I^J\M^M5%-%"N;J:3'!UJEUSKL'^6.\BXU'%!OF7A4 MC9L'X9_Y\Y-=+3M)0^7:.DGWDP2)-[+4/E]6Q3N3_/AX7#VF6[[I/;DV;6< M(><0_^!Q2KKXI$-%1K#"^XZ@+:>B7-KIKOO+M9-XGIHWVJS]$T/K(Y0Y*.3+ M5V=H0^5E#80#E64AI MY\J\'R8OD?;MJZ(_F\TM#"F'"Z=EU NHI&Y!0>!+&?4#0\[%W!M#3I^]EE%W MZ(*S@0C[:1EUS]#PT'4I3O\$;B&#LP^6P@_$E6W*5H<@82M-O#'XJNG LYXFG7FALDZHS\S5 MA4&'5:;O#"T"JC=P#C"$=X5[&9+JENX >IF:F"#PFJW5+J_I-@?AC(UGO$M: M["GX5=1;@]* CL+N((^XM_9FPLE$ULF]JT_ZF"\.6/CL1'< MLC/JG7]/!O*M0I'_0I!\'B9U;/5F][HZ6+M>-09<')_'+DMT[=*?; M)R^JC:M(?C4\#-2KE%4<+R %9Q% X%R,65$ Y;/.JAN=E,"US?0P.]?>75GC M+7"+M:N5YXO EQE$@82:L,TF!U*\6=Y(/CWEJBEJ!U&HT"Y+""-C'!VC9= MKBY#\?%A Z9:,55ZF* > M#E3DPE(R_\*I/%0'1KM-1V\.\[(@EK:$,;$>$*^W\=6(N\U;"+ND]MHM+"M/ M$WQUR_NTHR.C!\_+9?*/>T[;GS/;:C2Y>#NP0 '*L (G_5(>\K1U+NR%P(N< M'-A2HLDW8'(N0P8,0AQ35 B7M0^;H1H:,AP\ M8,#$W=1?%P\\8:'-CX^A1 .FT1H#T.W]U CC-3FH]0::?]8!!HSDGMK"@$EW M)BB+""'TJ4UDM+0N$O^1 ?/,?2NVLQ&P9X/^.&-J&1N+7\) <&4#V)2 7^"N MI"WWUGI-AU\@R<6[D'&^?L3CS_)8L>8$NY=M?(!Y8ZC%:K-XE+BV3C44;;=C M,_$^%J*:RC/@"WZ]"/VV(2:(=W9U Y2FGJE:K<%VBDL MI;,Z+4'DKT_6%3ON0>5^X";;FHC.ES8 OUY:=,S?./\NZ:$US:D M01#.N5[>"(J]EN(M@<,O%& J-%/2[0S+M?0T/=N F3=60[R*'NZ(_B+BE'"9B)\8?B%&1)'?8?DQ9G:XS'+2Z436URKI60I MO(+B/,K-?-+(+1/DN8%-M?(1YR/<=Q>M(%U@FPNO#4S5G(A(=+@54K[[2L&Z MKY]6RX+%Q3=>.@G$PM?B='_EU..T^<#4CRRLGZ(--$6UCG9YO]0Z.D P+9CY M8M8;1S$\#,\-1XNW0"=X* @NQB8X(+8],8&@E_)ITF>%^)L-*.FKL415L/]V M^MK_-+G&&^W7$*=!>CJ"%F*L4)"N_!G^L% ;^1:]MI-;X-\=]2R0:.-LP,1F MJXDJJ(6W:%>Q]=EZY*4A"IFG M&T991+;&D[[A'G&D_RU4 6$*;WSF9"D\AYX[Z!TBYA=7.%[A-' 'Y4 U;351 MMN*6D.DKV2DK9BT/I%H>SKK:G%$10/"M>&!OR]U]?^XE.=R_O26H_,+^L&'' M>,0E*;%WQ>;X-3H;D,/3@&KC7B2$>6H/:3>, AUB.?NA M9>JK,T:6C."%XALM37'QB3Z?ID=L]FWF.%,;>0T!;G\T@.:W&B,&[@[FJ:S> M;O: 9!^K5?'\+V*L 0..QR LJ>_"28(PW1:*>ZO58__H4-#0"\\;ZZ%#GL A M)A7MTFA")W>I9][-:DV!OYS[B ME_JR7].?]"K53"*3]->ZB:7=I,ZN[;<8A\+'7[&480/FX>*7,>!HT+%[O"(8 B @0#@:8@.59 G[]/?^ZI%5$(WV]U"55E) M(/SF]I>EA(GA2L*DQ;%.YPH\$;!R MJDTTMRC$^"_CC/B[SLW13>^%!.U)V_[ SH'F*GM0=D85W8C=[65N^D%PY8J6 MYR]6)NZV(W=ZL3Y$3CJDT@2@Z39"A]52#ZFHT>UNY;)R$)=XS'[L/>:-<;(Q MHQHG#';F)(B\CZJ83A+87.UX<552[OZ0/WMQ/(MUN\)+*Z0"8YE =I?PPZ^3 M,"\9,#WG"4LB>:1O11IW+^(F=F/HKP2^<]HY#S%* 'T7*HTDS/ MC\%F4S13,3+V(A&Z_36+>BMP>^C*QOS+!Y4-[(2;CRBX65VB/2$F7,C(77#) M_R?ZZ(7+H=?OEIV+<.!._-5HXO(T?GK+CFHES#LY7?#]-?M5P;<28F[%_F3W MIB[O#SNJO,?F8AX/6MF.A,6["NUU-A(6ESTP4K3^1L3/##)"SO(7 R8CP( I M[S!@1!?$P!\1-X8UXPV_GU23[VX!@-\D96:^^=WO4TFZF;^OO?Q^AO;%:\2+ MMB'.NH[6/H&F^N],C8&A6JB0_)T/6A/UEO??;"N^'(&&\3O)DF''J00^#_FC M;]E3Q2+W0 ,F<(9V'W"O"&X1:[;B/P.&RM4(+EO0^J8XL-,'=WO8_*-S2BV#DUB#/M]0/N8(S M /)\-Y%K' ZX1:@2V\::4,;97L4<"%O_AXC3_T5]6C!RF>Z$8YO9'9Y5Y>YG\=A5[$AU MC@K/ON&9'=#EE4?VC]D,3N1>W._5&^ G>=;X,KW@4)M\RL[!VAX*VML6EKR M/"2T3!+''A/9J; \ R:8EVQCHL^H7 B5JGC?CH4]3]PN?7H-E,5&%GAP#D"= M=5\^[&I2-LVB;-AVL# @R8U<(?C4(X*6._3I0/I7)/8YA\UAS?8!7PXIH#*H M4(VK)7^ 7PY)5#1_H?Z8F_-%HLO8)FXS<&8; H! M1$\O8TDYK0X5(\^FR$]<6=(X*Y>!:4( &"KHZED7^"%T1FU4XQQ_7G18Q=TV M@0[<[3)I?'+OPL8/+VS\TX67?,R*N=FC)6PXVLMV1PMWW7/NVOM-7J4"07SR M/VAR^8]D!S O#P'/^(W\DA,\9[(WP+9:7/9NE'DVO< K0FVKC$\2F65[!)F) M4F7IW+-3%C7[BQV"LIYV[[/7-+O,+"+5V_W@-+G:Y[9T&?5S?OK05--4(0^) MZ2C+6-W^DF5<'TMPT#,1^XD#0'\#QG*HS 9Q(."0%7,+GVC&D-1E.;2NSSW_ M>.CF4.6,YK 8W=A:>:QEI8M^#ZIRK=B%6>)QLEBPP$Y!4>-"%IB\9T"[OO[ M5_M?O-!A8TA@8)-?!@9.Y3*$^2"$=X0]W0GM '0 D!-J!Y++>M$KD__/1:5I M'X#NXTZ[L?V(&T.,%O%CY8@?XPG>_@NT5^W-4=_B)Q#'0.YL0J\/\;[(]6'0 MZ[LQ+/E^QMCSWQPVYHR6"0W#9HH1NM9UNB2O$RNWP8A 7 >^4\]&RP&_)/=/R&L MNQV#Q%*1R:M "' 4"&:\ MTU1/IFI--0#*0URG#!@564.^J*E0;-":PHL4"*M\<4_/00A9GL:+, K\J0S^ ME/K/4-7_4]'R_[@03JO]@RMX><+3Q&/X-?'X:A(A'G!EP7\\J_$_F"<_IGJS MIT(X&?6?'LQ#$)]'OWM; ]"P8O@D5(*L=1+6&+]29X^P< FJV-UC^@'# C%7 M@AQXB"R 5"CBRP<$ :&4UUX^XY]_>[?\2? MQF5!0]>U4CPM#:)@Q=^ O2FW_HT^'C?_J+.L?<>:;RZ%,@^2_R31HZJZK M\"'EGZQK$[D\JSG[.J\1?@^N[DDN6WB- NPQ:^4*- MH;T9\:2^KU--_'"M=H6UDV&!!SNCYN_;.Z&QT.=Y$C_P:Y**S?X11A["6^RUCBO-NO ML5,B>]=YY=#T5_K'X\W?SDW_Z87*1X'V+FVI^=A6')P?XFX[@<[Y5%U )VNV MM::&E.$Q\?J O^@G#\_H6"+2 (1/I9A1A*H[J-ZD= M"LL&+A/,&$.V.SHOAO)FJ,>2PZZUE)FCFR>2[!TXYAM$.!$GM7U^J!V3\F/< MLF<=3OP%A(\^;>)'H:"]!J[-:72=>OS%UF53 M,&^>28OVG,Z5^O%;+=I;7%3)69,6;6A5A&S)4.U'NW[1HB5-:X,,/S)IT9)" M3H60IK5H Q+'F!OWW1R?A(%MC3@U&EJQ=ZV8K3<+J3!UG*'G(=WARCJD]IP&IU5-P03H9?J=(+H2!P$QX/-!/HFCD7WE!(>2?8B@'&C.P7F3K0E\ M:8U8\FH*5J+W1M\8LLJ1]O44=PFNN@RI(":86E^-'< <>U:$;/Z@%=#: M/L^CC+!(<$[]T-UW"M;J+SU,J+&*C(^^KD?6W4K%QGE@4@^E*U\<4'_:ZUZC MUD=:-4_RF NR3LVNC'U=9*H*N$%HGS\7Q.Z5T& 4QCZU)'&,OX0B,%JP].MY M:T1LDNO]( U:OU8+S!U3S3$NM@^62NT]L,9FT<_?MNTUBF[7&1]47U:=X7YO M\\UYVJ(_K<7\*T*(?^@H>_,N]/EAJ+^HR0N8W_%KR>$_//SVEC+-(M0:H;LV M-YA-R%Z7%Z>U-H5K!A $??O>;DO\3R?"$SHWV MT/@Q1,],OJR& B2,\'MC]RG8/&]Y1(XVO5X!GS50-]V7MJ,I^^T89&K&K2=2 M3%?C\VC_&O7=9*OSP$IV@!9:=//INBU3L,<<*I25!"XFY=0K/Z+D$&HY19_< MSCJ/ $\;;8!7G^Q$-#LO,W"A:S8:[Z/&2#@82OW I,KQ_,L,$(KS72'&M,J^ M.<85_$2<_N%!D] \Q'K^N-6*C"M0VJ-3L"(""*&H!+)<,@7;]IVIX 0E+/U6 M8!@"%GLZ33)S\V4"EC'D ^@BM"$;&)#R8( \#X2PY$\_FXIH_Y4W_Y*H,P/M M_#13,-57NAT#&/=6.BGJN 8EX#GG^OABOR?E[0>).ZB>$E)_+-;[GF]AU#5* MP$&.\//0P](X?^+'C@[#]NL*)F6Z?:Q5ZMKA"37\[J0J(X6Z3(V2S[FH]RDQ M5.JV-0=;@/@^/GRH+JK[S(C34/L-Y:1OZEN]E_J;=3KW9B"TNNXV)X>Z9&_: MT-MAJ[LH$PCY"/T6A'RA1[+XE7^ Y:96[%]WC$2B7SP$ ?0^LJ&C'0+H"XFO M9[T#ESO-F!C_0_WH/TWM_A1]O'J'P!8LUO![3YCE$!KRH"ZK *=@6@?HE\+0 M":LX3D_B1165Z)3[C]H/N[=GJ27-,1N;@R)[73AL[G=*RYB-\1%F01LVQ-LS M.D]77W@YTB3<-\J<@J5AC+W 'ZP\%5:_DTR?U@K:174U%/ VZRU!>A$X(4\4 MP)-P"ZF;-&Z$J&J*1,[[2A$7X*TFIU W796"F!UQ4KOW]_AVC&ZG+(D<)Y$:W8&^0H#C _$=S?-7@>K2 MHK(@ZD:U0T'!$I!HWL.K+&D#SLSKH62V+A[ )!1%+2LH5##/_% S4O$XJH+.D H_8L6E(Z8B@4?O[+*)P7Z)PJ"=; M2Z7!^R/,&I8TU<5792[9G2U25A]MC(XZCE\W(8; 8L#WU+-J_TJ-71^_19:( M6=9*QS.AR"A/S'@CO_*TL01+X&U6ES(+\1-6_]!&YKS16Q:L?U93XY+S4?>6 MC%DES87'OX#+,;\^)@8?7#.1BN) WQO.BH(9;>9+D-JI[0U7K$RK#*F24^_+RCO$TU+YJ;G6( M*%R%Q,T>"D9UCG_BG'HR_?D+#R'I#&<']HXE6@Q#E=;]FP;9HZB^6[:;'G%W MZ;"#=;Z7XTS3=A#D<[.6DY=V&[)?PH<;(D>Q&B"--$SMKJ3\O>&5V[9^^ (" M0! 5UU>C58B;#4U*BQQQ-K^C!U@@8]-;AN@9.%O:9CTVE[2;B%X!"@YSU9-* ML95_7D479?O=THP^TL8CU8\Q0<[.YI:-=9'QQ<'[9CW0Y[AL/QP41(@I>2I2 M6JZR7?T_:P!BZ;3Q[HF[,G6ET33?C3>4&^Z8&J%,\]UF!HX6,=RNR@ _Y7J6 MAR*D]"X^L6-ZMAM5;91H'6M[#9D/7R(E83^_;G\Q/C&AAU!P$Z!.H76CEM/: MY2QP#YN^&'K+6O%@[;W'_)MC*D!WXJYI.//KU.:ZL_>)1%* +J!5W+O)*!63 MJ%.P6DJI.:"2;%4^)NR@O0U$O(=0[(JF2/:KX:HB]:.D:[7GP%,::UV(+J2Y7:YS7$#U_/;4(R9G.7(M>%8L.Z )4V+0B2$YZ,>H MFO'W^?+-C\-'U_IDZ>T5YC,/&W\0]G6LJDX=G/S_!:^_NN#U(;^ORG0R^W6M MUD4,A1L5>G@*9BIA+72;V\^Z%9-1."-MB*]'Q.LE">FA;>;#6!R\7NDKUJ] M=O+HC5]Z;:]=Y^J74'A<<3O8M8IIBS6H)$X]:?>/ M+]MV/QI?S(PEK1=GEIT'3GSV^Y.H=QT>X[H?_%^1=SDZ6<,TF>O,U\WBMX6N^\ M3MIZJB58KQ[:?=NTO1'Z#S43%]BQ3 SV>Z=*4D!+\-+.7Y3$C",V2.MZ<%I) M[.7S':[KLM9T^"7V*/X(/1JI+KQ2&:K5AS.Z> M>V78(+VSY&2'HJ"U5VI-;%BO.CNZON"E-0PNE?X^A?VAP0#'S_ICM\MY%&S@ MVO_%P^8WK>@0H(-VXYM>="+]"6T5F&S(4-<+9)HM1I'Q";1S:TR]Z(_XL0RE M!0;0)@KL46TXS;8&G667&QW,4EKTKLKTDNDO2%2C_S7.5B;_C]6R>$XWVHSV M&.E\^^9+_38%?"'U8W7-Y7)#Z0.CI I$^6H2F H[Q,WU H(%!&NE0#K5_IRV MLG+OF1&3FD&E=6KY,&>Y"A5E]\K+.'=3'].NB7\SZN)X#[+_8.ZH(N"2&] ? M%+GC'NE9#;OSC)M7F.D@?/TJ=FVVN3L;#0N=..P9[6RXUWDVXA.QRGX#YV:U MP0%*:*NA+S:-ZF3J5=19Z_$BILH-M9TI=X0+-(Y[>9*^:4-6>9 ,2V$T!\38 M"P,)EJY DC/\O4'C)O7S//<*;!Q+]R5IS:3Q_KZ.<>NO=3'5XZ2-^R5C3/1N M2?@#%.:Q,Q/Y:I_8*0[SH^R0D$.R.U3S;?M!D;,[\N4G3, M)5;B3UZ@]&X\M0IQMV'9(TIUDW3T*^X1DYU+:9O.-'FEF5TM)R_"T_'5#<:' M$BJJ[.F@:T-&=_A0:@-R=#@WOJ2%+[U^=N3ZB!M_NU@1:K/N+.UM@*SA]WV' MG$9@2ZB?",-31SE*VSF:.2#[QO J;,JHGV@65!MRY/1T M6T2J(/OR3W7+>/DNS0"\!\GH"^C@D ['^NP6J6+B9)>H=M<&I6X36X=Z-VE. M?U5ZOSCXH=8E-W#.N,N_*SWUUW4+F&!S+<0;,R >!3),O+&I F:(>Q=5^DMI MIQCXG+5T(/A#P[>H$'NL($G3QD!62>8I<-HBIR2KKWA=2AL\MH$>O%.=,QAF*129+:@][3B?[UBXW M\I);=#E"87F!@TO@(35M F9DOZDH,J,?OABT"ZP3GKI#WW^GDVK'#![ Q+=> M;OI1BEI(+-BNSDFA>I6C M"9.)6KJVV;5A7*>4)A21S\PP>6V_@<0JB)AX*=[(CEGPEA+,&-U!^@-J6KS" MW>P@5\P*#S3M&L&@N M^UOEJ_W&;X? T^ LDUHZW;B5Z@X*Y$]HDC(*HGFATL4JY$H(V7"G,*@1F:F@ M+S#I'Q96#J"D@Z5!O:%3,"E*FONE0R&>N 8@FW24X_LSS"C$ M5IX%S]BA;K_DABJB, 2Y]"[R%CX[W'$A7BRM@2B/._1(WAC@D,]IL4/>V!_< MVCU<\[C^XX,+_KCWAOV4\3%$A\#G1"4. Y! 4T7EYZ MU#8C,VH*M@U"_RFN)I!O.B66OZ:/$_FO\U#Z0X^G8' (*%1"0.$G""@HTDWM M"J;#$UJ( 3-J/ W]H$O# <$KE%("O-H.@$4FP=P7^B,*B,,C=O,TZ#2JMWP* M-@<,\=8Y:NE)W"/7!WL1C]BC-;W803%PMG.=:24*T/,H,^7(3 !Z**GE<2E#;;0=CY#W#?3M)5.P M)&B:9W94]>>H0)Q2"D6\;JK=M!+ZI]<2,##!$ TB]"I2>44[ GKGOR M#3>C0W/3R[4-NXKKOH"+1KM?&.=]-04S*]K=@9QO;%],N2B8@BV(<%2YN[09 M/^D@\6]R9$E67P8'!;9=I40^=EC?X82&$6.H!Y6N7&D%GK99XUEPM6"%V EG M/B#FK1;JL6#+[\^JID_*NT /LOJB%@4>G7$1'416( MDEEROZ%*%DA%)C;F6C"/EV*Z!P\1ZCR?B1^4W7=OO5D.;*??X \/ M3L',/]%Y45SNNF;QZ7WYB)\TDF:^+!JKGRNOK$34#@*W)4[F1P&Y72>+C9L5 M5[N3FQ/XB"]?#P&P=.M]*G9L [WKP6]-6?-E;+@ #1X!5B*WZ!W21,5,AAZKGI,PKGMPY-!%UZ4%F]2W MVON"T)YJU7"DQ0V4%I= 1?4QCP2(3M5W<*SMVA>5C#>+)VFL8JG':\]?U5TT MOO5]P%+P37R[KW&YJ-]EBF^_G=0IM_\2WT;1];H-A?@W\:WR$ST?BF^A-OUG M:1!'50 A.%/G:3%M$8A6L"XZAD^D8D2JSS4.\2%E^\J>@AM;#P5*T0K4+((( M?;RX)]]C9WW=(J^HL.+!QT,QG]6%)#O=CX*@E(.ROWL(S#;DH@CT5/JMC$LL M+DY=>TC4:T]$NX8D<]^Q0[-XL8MP4 @+6 2:QHVZRN%XL9HJVJ399 FG:X.:/6OB^D9LET. MEE<,%M@*L_?:LP^5> MS/U7$84=_K3,2CS&F%5*K+-@,(8P&SB,+J44>;.X%ZMT]6>6$+8_[L5/%ER9 MGDPTT@&\DXM_5':U-RF"M"6L<6VSLFWW^7EV&1I6LR-,[RQDCLN2>!^K@?-. MW@V[[3=( C6LY'#,=_N=^DFS%'NUY M>/E[YO.3^A.&,FA=\,Q%3DQR$^+62%89A=X<4$?51O(MW?8Q]A510@02ETCI MIX\(O?NYBX&N"UZN9SYEZH7_"OSQ _;M:X_^<5C+3 M[^@HT+ZVR?J[3MH":NS-BP=SA4-H/NBAB$UV'"LLP4NV6[K2+^GGSBKXWM^> M-&Y.L/=2;,G-GW0W9BVK^:JX^X/;8@0LV73N\E][NTJ&YV3?B](+NK" M3]"VNL;5)NMADMS(K.@PQ"6N793%309^TN?Y3: $0P$.:DZ5\ K[]KGME>;_ M(V9/EH+I&RN(*LWK0;X":W[+Q!TR<+U$E4S6N>O1=\#C_883:*$13L5TV.\I MK!J:;*T,*:&Z:;*RZ7&S,Q0?'\=Q!K)C@)02UZAX[JFRX*[!FP+2G'B]QW4* M_< CZHIH8IS!3Z*&XUC\FVC],J\@<):V^6;2SML/-4S[4/B?TI=(_LE;:FW9" MSIH?>AVJ4H<^0V<&9S76TR /WKF]1-!CZQ"!R9T"%T MN\8=P=K)UT(NB:0EDC9/P0Y/P;P?K7K%IJ!JKKX*OW*\(5,V +MV&VY##02/ MOO4E;N;#J#N,3W516D?]QN"MZM&O^36H:N0]0XDAQ\ OQT/8#P'E;ZD%XJQN M8[X672.--N*DQV6O+^J\@<9@GKE^FU&LKKW[ &6T]$IC\F3'33K6><@L=;5G MQW%CKX@[!5/%I5921G4N_C>$CKQ[\MA8QWD@75#'DK+1R9&2CX:OPOG\4)PT MJD\VS)<3R4OUQS0H+5I;J[V.M%"/Y(4@F0KZ-Z9@K!TK M.,S/^_>I(<"OE-I7-; &45*QHXOFOD;4SWCCX5.M\5 D5$_WZ9"8^?D5]]]Z M^$0[F_BHB!B>R<-'*>5H_J+/F?CF=YSN_\^W_-E\ MB^DD05"KVJA.>-'GV$9/X;___.+!!%%CP8<=U_5(*<>854ZHY9GS-UVG6/MW MC#KYI?K$>6#49XL*"1.7&TG'UW,>#&?78D[G1,V?C*M-"AAYH;>H[ LJR*K2 M;S44CME8#\O4W\55ROG-/KX];#OO'?E1^ZN-8C N.N+4?(O>5:9O"Z1UM]3Y M:6O#ME>&0%^Q8Y-TQ_;+6N+[X[@FU]\JS[?X?;FHFO5\%4*=+FNTW29VFH*! M00@S)YV]Y='JVV+G((]FI(OZ[)43)?A)KQ:S&HG;T+32_(DB4!Q+PA[[UG&) MAT5#>4T\N9\,#QV<#,(U\L^[ ?V.\;RMZHEF1&+OZ@XWNW['>\' M',Z,?/KE+J3]PBIG66(P ME)(SQKQ]=@=M& I4!T I>1G>7WK=0IR3.9ACE1 ?"^ 7%)J7&-(Z:KX\4/M1 M=S#&5Y-4M3IDV*36\L6;]A0'_4W69=J"K80 MPNP(<(O+)6Y<"9$VQY!/W59&W:8>N 7WD>:_MR0YD9_.=W3WW0_KART(3L CS MP5QB("710\@YU-_9R46Y(>>3(5+F\-WO>D18_'>4K"6F+?K.$O>?#S; Q@(Z M(;;G=8&#@]&>(-A[XJ\?PT^X0%QLB=ZS/_"D:/V=W*YP5O(15G/0O%ZO.G;U M=P2+W(TI;%T09GV\ZFKG<>Z%AR-&X<>.50F78V$)S_*RV M\^]'(YB1]P5U#FEQMLPX4O$0_9O/I@_X:,=I31!I/01/1-A0Y_;)9E&/@AC4A M7-&)SKBYO6YM M><)+U^>XSSIH#!@4/7V84 \(85Z5$Z>.1#0NPD"B!"TGX+-'P1. M&44:RY2(_!V"28M\;??].-=VE93'#'OK/,*^R=%Y-@.AW+I:3BKUU9Y+,QX% MO(3"X2Q_0P756N>A/Z9F?(VT4KH"2?JY:B):L^ *(O4ZZ=GVWK6:G&066ZZX MX^3N%V&=ZA/5.!G'2."ZG+A&$$^>I=L65K0IO W(5\'JGA>)$4?C9FJ'36T/ M2K[5&&L)U1)<0BJC!,@CGA?&%8.IBO=R K87; !+Y)=)Y+/24P69Z].R9!>X MB.M!^0>4D5$N+K35&G)B>N8)9IL<:]V^#-QQ1/_E[VHD_VQ/\\3TVI?8KU+@O"'NX^M_PZPY%C7/SD[ M[&QF=ON,4Y9&'SF95L,DE3564%Z/'0W'+:1TXXS4@6GW&N,^X)0CN"FG#=Y5 M\=!Q+O'U-O \ULYFSZ^5$]VV[<_:(G#)F4'B[KD,7.,M!;IIY MB5JEO:@PGR=M]XHEFP_V6C6(G4G^+R:JY7#]TCR(W3:08!<5!71U/Y:$G((= MX:I?M/Q\\:Z+*XF37E&':4,E1YB5\Q XI>60/% \+;.\:/AE0EWI,#XGKH4T!-7VRKGHY(A6Y&7PX83)>0RH=S4,#^*CHA&YI]@!%,F/*K%U"5R MUN;G(@E_,&]#Q[!^Q_5CO:&YIV_JA;1./B<*0B$BA1O/67.=/]U7 M+3G1!X<%]MP/*Z0@=M_)WOAM;Z]72K>I'9O5Q71P.Z+(2_4F/HAY*15_P R' MD$FPK5J;-.,98AEM/5C9O[$9L*(>TC!E4KU/?\9"W-!DP;UQZ]0=",Z/M+9K M@PBI9+*TD&C:I8.#^$)*E,_M:75'MOT.7]&:*U?9&;; ;XYLB5"6IRWLUF,, M-]S,D26SZ5'7J)M%XZA4*3/_9V/E\3#W]O@0T9C)7;.XYKO"*H[Y1L4"OMP\ MTMM,5^F^^=5^X?C'Y-S)-4YQ!V9.IAKH/"N@*<^D;B\/SRY L#O.W"S4\!HFX_FL:HD8SDEF\"^(>7PP>Z36&3D\" MS5IMR 7D14"(3:QNYC[C(S!/S5C#J>R:;XEDB-]-LP%^@!J-!C\(SM)YX_V!><;- MP?A)QS:5)3KR0D1ZMZ^09X_'1%3[1+!"M]^XOCW;]L,;[ 3O=@MP_\./F24U M*2]::$MK?&8X]Y@U(LHY>K-!UYK*JX2ZT_6%A)B$5.9 77P!LVC(RN?GA_D5 M@ZY5^6$VS^GE@[GQ__BFYPG!PO(+041(--$I8'OM1UYNB]>574>% *=&I_/K MS)+0@CF&:UPHOQY0CV0P&DLQ>D]UCRF_BJ4_=@=0UFGMGY7.@[$[G$87HN6D([L> M.?MKVE+"XR)%JJ'8$TR*]]T;E,QFJ8N6.DGJ*2B)J,!OSXZ)O'9C,$>RD& 9 MF2TZ'X>"4/ENHX@_>_I(V@Q+82A>)$/+'^#P."@D/"\$%G MZS27G4+[1$/TDP=,HJ45.I[-]/)_3(I0 ?N,XIO1_)7\4#AH[_RPJ 29J'.B M(CN8&+_% P!WE?D7.)Z:.8HX$D1\&64^RV8B\J8D?KR M.NN\^YDKO_!8^47CRC?GV-LG(S.+!\7:7/^T$LS108Q??D%>")'X_ASEZ 5^ MWTV^-8GG]I3";\OUIP-J1&#'^FJZW#:1$1KBIXY*+-W^C539:ZWY6DJ[P@03 M6ZT^\^>?Y64TUWV'7*%Q?S!2>QQ?2MEL9I@WT81[+(/0:Y\L)=C\+7H5Z?WZ M9,OP@]/H]:4U\?Z)==_XK/RF?>4;(1,7JTAFL7*[-KFM5OOUDHVRTYNV5DB]Y%@9YW'CC^60"B#XX I]73W35SY!-) MX6_5TV,()L=NMVGU]'5+O-9M:WNKGMZ:7XEW36N85D_/R?6O# DI/]J#$3SY M'8'[@-9C.T_(!70(XV,KBYOG3-YIU \UEFG',P]D]UIG=]*L[O(7A=M%VRJ% M+]H9HRT2JB-#LI7?H^W-?FNVH-[NSBE<[R>->U'X]K2%]'ECIMDQ.1*C0 M2R@"^9QFOADEZH#.)_]M6_P0YG^O(KUT)GCZU[,/J0Q<:]F6"LS3HS7\NS:1 M$P5?8DH# V*7!BARIID)%3Q>17'Q5;]0><65 M4>P4"Y(9[383S>;;FB836'TR:Z]3&_+)QZ,W9,K-W-%8]<0EY\"JJA%GTE:1 M *=.>)WK^;R\5"E=,V1%OLAN%XZ"1'A7B#$]H&^.T1:=B-,_?C2'#X48"D,K M-GSKABC$45+]#47(A4&#DU%=M,=D.7EE:,''DI.ZH)\;+N&@[7RABKM+03IR M_'@<8@DQ/T7/(PF4F<@DGI)I.M2N,JRI(VW$D=7&HZ.&([5O%,>F30 MC=48?WH)R#\'2'&U]SK!8=FMC=K$[N'SJ.]^IL/9!KN;D\94545,P6!@^S&^Y'2'<.YX'M/;K\/-O=\>'2C2 M>T2'%.%S'3)+B 4P-MZ!$[1?B4==V0^E:.C.M(E@H6X;Y35RC7Y39[AA!S8' M'00/Y'2RXU 8(==#GB-F!T4=5/XMP8? MTYN_A>D, \XY!;R W^6#FP.&RS47VO=4:S:FHN0'P.Z#/>1H.2MY!MLPK_=E M^^Z+ 1TCUXUKV^#ZU2AUAH&A\]CWV)&++@>]@L0LI_%+(!9]IV,LSUO&F(+) MKZ-.T2<_P9U'@-%(&^"5UT[;*9@G]6(_JWM4ZP)&F>IENMT0QS0^T45UH>2S MN#RP\)E)SR>S_8UPUW&%;!BU377#D*@CZE Z]"F9E@Q] =6CQ@>OBS2Q1C-2 MR7JV%C4#N8!@&1"&UR[&4NB*<0,GOB:_(LTOG1&"^LIM13EAZQ F=N#RFD#" M.;WG(X?/.\E2[[0-1)]UGDP837L(]Z/C\$5-@ *EPNEBC>T2.GMCFMLNS4;= MQF;;=1K?9(;2Y>6@JV7BN&P.=4>G&[I01HD2%%B[.B;JW3,64JR;ZFI8Q&N# MV1:T]5SA8?3B;J6,P+/$=7;"EH$ET![.!^%A"E:"[?N@H? H'EHR8$"9CSQC MY0/;_))=%3V@2VM=PA6BW+#[55"!401!,[U=_^H%5THI9\5M@=\G-%TO$. MA5I+KQB*\H\1UQ8K;1$:BZQS840 F1%RE6B[1A)1+Y.U?XU2'R8_F8(IQME_ M@Z?$ ((T$EMG\'TEH%MFPV%/!VO$KA6#Q)7&]1T.I6 <4(:[+J[+3\@LI+0' M=)X25ED])WZ\7L1)C7.:.:*T0^WK9#.!_=/Z5:)QYA*,:/B-)8_]N(V=OY!C M'?J+)4^N< IF]N0IJ:FKR?ZD[[(BXD3ASEG+GMLZ@SUJG+RJDEQ(]03K MU8*[5CV]= LFL0B4M/4N55=5AI6@PZ)"9C/(C*$ZSIM."TOQS6 O,^R^L)"H MO^T]57OER*LYB@F]152?R]<.(2+>(G!M*V)YE8IC]GYW(/=[JK.:I,T**W'^ M^>?GF65$J].<_DT1YCL.QY)L?;8%J&.JNDJ=> M"O12\&R05Q!8:)%I/]#))+,-OA24?(5Z3C)7%ZHZ<^;,&#UI,(2!5;:U("T: M.EEN'Q490XV/$!QZ&UT:XA?;GM+K"@73Q?:[..:(N[G[2)9WD;:7'2+*PU^5 M4CY_T%(B+BR6$B?3,T(4<=$#[R0/E\XP7#?^B.-$"3*D M(GDSE+H_@WCC*B'OW@F3H0PNJ"6L"D0$W4D)2.]5?&HBCH))5E?5B)N](B_6 MF^@>\U"JW$0*9RW$!Z]6:Y/'#,!\V=^,KE0O0SYR[8!L*=)R"&7ZO%I37\V6 M6E?+Y#&[*W_//**N30G_X46-L5-MK-2&6BEZ0FJXM[@U-\5L+,1VK/PS*P.G M8#COKSF M[4<1ZS/,**6]0FE[<'5-70HVR.2LFD1UOP:+0_T*S/YSON+OGNX"%G:^2S]I M.MS_UQJ2_ 7F)/_N*V!L!137R@U?FP[C$!S'5MQ\)9S)*[2!EK.C&26A56J_ M6;(_1?KCJ"_8L/Z[G"5!,J7E1-@QK[Y9G=>=AD@;NGW1"/P7Q,-#P7,UL\_/ M&)_0+Q[2!G<"(1GG)<@U&EYR62AB*>U#I05OG0:94;DK[$0%&"9P_9!7K=Z8 MX.SNIIS0?J-<*,4IC7;%*XCKYBGQRW!#\4)Z=D.PJ5O^N9:4> F_C# M4[ 2ZEE##O5$505>R]L*VC&4_&5N'UT/8G(7.V3)55MCVVW R*"=H74U%4X& MH"F[-L=_<@]]>Q:I@G)_M_JSR=:BV7FE^^_K4R03&ER;H^J5;E,P[4=@I;/Y MD@.I#\!3_7P5:CG5L:&6+?%O]WG$Z*PJHM\-P!1P["%,DI/D-K?N8>MDX/B# MSU].[.:K:Y.=0T1DZGZISS=SFIU^5YP-Q?^+I-L=U8)B;VR3K0P-Z+70L-K@ MJ<8/U0_+M3@5:@'(4."@3%Y(0'W.K>TX8^PI)D@[>^E16I_=0N&D1&7Q,J[@ MI;A7:9\IL&9]\XZO'@#^R1X2<=?]U\')?[*O9MUU_<)P1#QL]J@Q;*#ZO>JI8,J1FA CO]C M\+2N"=,LKEM+U$!!6[L,M] H0]W*HJN.JE$''SO]P&4E\]XSBC2)3;KN6)^Y M+&?[2/,-RD_TLR+*APX_ 4Z#0%OLF6%R2<:QQ\/#G&ZX&273/V[_?8%/<:]I MVOC?41A:9M 'J.$X6,OM\3AS$AF<(>I&//7HI M)XZX?EWGP(\J'IP(.,Y&+.D-G0P;.@*Z8#0;0*N M@#I0UA7K)W([54+K"%[XV-E,M@"DHT5<%TVD\J%97CT93LG;DR[8K0:2Q_'/ M.T=^KA;I_:[9N#1]E&H#]U9KLRK (P>PAMW (HKR1^NK<('K!^]6]/BU'P(' M]*7(7H;W(DW]$@JZ(9 _KW(R]L_5Q?^L9=Y(A;A6C>S]LT?\P$\T(ZWFNXG> M3.A#Y?#DD75\84(6X]B38TK:-O4ZBYCC@9S:#N[J=\=:>:^BYWWVJG'_\?G@H/5 MT,/%'N#Z9:\S63'ZBCBQ'X^26&.5>7D?J"+2MGTF+.6*1H!D<@K?W,U/35:@ MTI"6%+%HN&"#&I7D.&:./FEUR2)*=O([0P9&B.)<=VK8/20PKA+UBH+4(R7G M&%* ,(!)SR]OF=<89;O3[=<&3+X7;P&4@3[C$X&O,4M[;>YH$(E&^\'^^\:? M;H,MQYD@(^CQJ^@*7' TO HXPVW M9H,(S-][-4"1JVZ03,D.]"GABLK0^ MS7Z)8AN[7;3 JT1/&.VAWANZK4[J%YHY4A72DKI5/4<0AYP0O!J4G9&,<,A) MO$W"\>Z,VC:(M%NDED_!6A#R[XTM[TFI=6G"OG,1DRX*34 M&*@_"$HT8?W^%75M+4!2[X>:\:>N"9SR0368>8S'%[+MZ N?-D9<]Y*GS2VQ MVA@?KKM'VO+=('*E:*QALQG1'/E0^M#:V^SC5:_F_5,_^#NU_O[-%?]&"R-" M]_K/G>C_](RJG ^NHP]W5>DM0<1UZ@$-7N>2A$1!CWFM(M]N7VWGEG'K'8Z) M$'J,C>WS'BI3GB,1]?1SMYSE>H:K?CFMU:A2B(Z.Z]^Z(_)QT^ Z.,V5*#Z.*M MTO1VW[=><5+B%'O??IZ@!;E.B#O 43W/ MWU 4UD=?X7DB:DZB&[%8,,OXIJ-OX/[ZDAHFPXLY>%A)L^X807PJYGACS\/E MTI2Q*=BE*=C[U%-J2P60:EP$&LV1B&7@MH,7V@^2-AB<[3=KI1!7^V6#IP28 MB-VA-QO\NC.62'QBVN#>G<>Y(A6WZ4\C&W+$D(@ZBUI!^X&V-19;W %% 5P+ MYNNMX*N[YPXD/!<^:S-GZ#?PYNF./9(&4IJ:A,M7U[-S8WWL6C%^);SXJJ=' MGQX%R: MX>K5A$O$V!;VCR88D1UK^>!E^5P'*W.[QKK/9O\H. (VA)3[VHH$N8F)]K:M MYCXGNTG]NE-"ZD+U,-0-'>-*!RVX5G M@ C%G!0G\SG&Q=^[I47JFL2YG';]&DRGMMOM6QIRT8_1TA_Q@IXTRFFU3.[QJDJUPVZ3IW_N8RY^O/Z0VY"12CU1BM]=' M9R09X5\-,V5'OU7.#;=?HB/?/43Y\KX $YD/S*_CZU<';^E [$V)M5.A#^L_ M_V.;>=$4[,2#C7YB/@'" W7M7B)G<\P((FT*-C\"SPR_;Y>G^Y[-G-EJM:>^ M2OGE+N+*6Z6FL;C(PNL$R:5KW;["ZX[.9O=6LSD%)XU2XANC 0BZ%IF,!KBB ML0>[C:*=(N,Z@E35F9_UH+,FM<3'9#2PU+6 Z;:(BXFD.]0R0R?=HG+2S*N5 M=357&-<31HSB%< O1@-W401ZO$Q=API!0,O5?+6I7;B3Z]UG#A@7^5CJT#IK M%6_'8Z8O'Z+FQ@WH,KR_6'9:4Y-U-6@*UORCT=R6O/8',;=G _;)R8G)#V:" MK%_=5YDZNEFL6.Y(;9\/"IIC0KHB MEH\,BW1>JO*S=?$E:3VL<1=<.T*_<+1)NDR6 H32K9X&OH8RYQ0LT;B2@MW; M8111Z"- MJ-2")1IZXR> M=J%CE5MS*PCEI02:;9V(NX\1.EF2HQ7)W;V".O7VE?4)C^+W[]QWL5__2U[!$%VT3;K&FM/R$GSZ(0 MFVT_U&POU[*&VQ> V#T=U%U52M3GU;<[R$A!,7Z[)"9>UN6D\ZX?8E5WW]/& M[L"FED?NFI]^=:4A%._J6\E2UDVKPB1PF$.8^+>J, ^+*I32JJ*P7U1APMY4 M6SRF56%J70*VMKVWB%M5 6"!TW1PG6,K.IG>A=P$OB@#FG+4/NU/'"$DM/+E MU4[:IB%,N.R):\9EP^4&-OUO ![O,MF0(=4?.A>KH,^GI.[7.=2JA<^E/N.Z M*SHG6@M_!O^4'7&0MYP"'*S3!+,8^1N#P(N*GD^)M*V=8X453Y4W!M/.S:K) MOQ9:%^-M_P_+[32+1VPSTFGW);OJ-/-C>)7%4N7F&:]_UEE"CWL]VW&6RM3? MART%@5;>!O+PCE$SJN/-#I8SPHR""02J(RI3,VS01*T]JM5V5>+!=!P\",1L M&U ME5.B6CXR5AWW![4)/AXO.P,V2G?RT]=PV0-;*\39QJN M3SS2&:"586W:P+9;06R_XT(]$KPH5WDT\;:JJZY.FBHVH1>>/WSF]<90^\V0 M@O-;0^W>K.N# 9$F0^WHTEY,CT^;1!NA\S>VH&9/P8@^\W#@ 7;[,#I)2DX< M&<%./L!,/B10-MT3ZXW(PXOWGLJM$([EKRSBP"&AR+*=@ MCXI'G)],P;Y#2RVUGX/W=(Y@:7>3S-+-T9!I8!DJ7>*Y7J6]NRI!;,MD9&;9 M/<8Q F8VBP ,/9PD60;6"JE'2O#2FM0(5J@56LM).3"C[P^5BH >V8T7PY_T M.TI?M:(CPB<3XVEF8,#!!$=;RLL/#A[K>9HDKX=BB%TCCIA -*E:X*0^[TFB MPG9%E5!<]M?72B*Z8^^GMIN#Y!8<#OJFL;SYU ]!LSY9%^XNXGW]:@:XK>D; M)<)V_+1H^$6'XP@Y(F@_^FO[Z'*EM/5F=-E0C/BJQI-TRN8YJZSW:3?>W^IT M!G&=JW\.HZL;1MOT:R'V?X0IPB]_ KV@R_<;OF+;-9BU\#DA338HG:F"[ ,YMS2YF,T%R'@F_O,Y2'P"5^*8+](F9B$E9 6\5A)PJ0[^V$OWB8 M\JB3G1^PLS/"W2P( GF6V,<19@\V!CX>)]KE[_ 31@2Y/O=V]SC0,:;[X2V MSA6_?*A<7D4Z^_FW<_OW'?HNY)\"8%R^;HU10+=$$7L"#M&;,A@@6CZ1Z&R. M;&M!+:+N,W^%/WCLZ;$G#2.)\E3KO0=XFS7Q!N$[$KL*9%<8YGL M]G'O*K4^-\=TT.R7\16P !6"3D3A)%VU XA@+#)($Y-3Z+'M8KXB+ M?.YX\>9;X5 +F92WJI/VP"0<:B&.](\4FX1#2RC ?F%XWD)XZ^9WC[S\B8#Q M7=0_ZZA=A2NL?F6>_U;2)J#/YI_+<::)Q%\0X/=HTQ!TOLMY8/@\!6N:PFS! MZ"^P)+)WO?T;%A]5_ 5#H/]QW>MIH)T!Q>/S;M8:[T;>:C!.,T<@!5*XU@JF M^]B#J-T=0@]2])F3Z923Z:'K$D8$!V_4)\@."2-(K@J1W[3F2,!^;G7'==79 MPF'HKOLEVGY#HMLIW6KPG@,3=U 3T @L(RSQ[$/9>L^SSO/.7"D!U/$4R? W M OSQ?C.SO2&YPI'E]DZL%7C_'*N1>'+(N1 %VAP,D%L97[H!??!IUI=$0U!W MJ;5O65_V8,7:W+FKWRS:VH[P?*SO[3>LK]U/R-H"L3YL&9"- MZX8;YQ9IPK1?W!&[A?3%QGDHZ(V ROQS1?O1QV=8'-0*"D(@I649;DN I4YI MJ/T)0@'Z!CO1OX;>6O=)GF!K6V$-@^79EY<6Y:5^=9X6^@>4@KO)OT'7+Q[R M [M**"']7FW$?(\FOADKPLP&*^##^SEWV!J7%L?YJ<34^(Y1Y]#1ZU7Z97V& MST=U'^)SLL62-QV\S+AK^TP=O/,H;4?TO,+K:S$L2Z,?Q\[?71$;>:"$124N_V&7U M:Y>?;)1%*( MGEG^RS%*,IZE.P=EGH_UUCK_IXQFQ/N$24"0D6810Q77Q@S7'S06V"6B;W3FH+ET-+^F0RKSA1SA<[6 MW422O^#(XY'B1#_AN-F.O\,__,/#Y!D-*<#?R4D0%<.EA#_ 8D3Z77WDK[+S M(FP A=/DR1JZ^MNNQK+>P6I*E+QX,JMRT+A*,^MA88D2<\K(FA^3'M]'OQ74 M2QR,JG!(E>,6QP%0=/@*]%/W]\GB^:<<9U$=U+A$/5R>AP:/L0Q7KN(UF+BZ MES)?<%,QA$>& F['>33;KJH3C34@98MOI/ MT^Z_HG_KNK3J3=XL#;24/[]4,YTWCSZA(/:9\B9V .D$,U(&_EE!1F(T:31GZ#SU M7F\UFCG4714C)HUF/(GM.#_47]CXBT9SF"%+;K!3?6C2: Z+CHT.F]9H9B4Y M!VWN_;LLZ^O^YSS^[[^\7I=ZLK*RGK?9[C? M]WGN6Q/@0CRO_R0E6%#]841Z1E#6U6<97N,7CHYFH16>J^[I1:V]'.7+U/!; M@]7!#"+C0+^X"U'>-A8''V"HO727*+,TJT"3 &7:.9+U]CII]P6.&1*CHOTP M=A_I528B,8.;O4J%P9*-[-[B2QA\]9\DA-RKJ^_>35U[ M3_^+4G]5G5D)0*EVU_#+YJUE][C7,$QC0?AYRG:F#OD/"$F5IB!I%E'6Z%A1 M3#? O#I'ACSO^:%PS!1A2O%2/MMD?ZN&<)Q 48<@+@P=DVTD,VK4L9W/8OM: MK09WB0C'T'N2^-5KE'+P;-W22.Q#>B/J-# -O9NA()]LY3J)O2N"H\N9T]A[ M?Z_0(U!&\-]I/XV]215W(^R-V)O%#HUL-&)O!FX3\ED3V41AJME(6:DK\K G MR(@IV99ZL?YGO2BSMFNUD&@K@.YBYATLS!>6N-C/0I7 G;#*-95_^1D:2,U3HBK=#/SU3QU;BR]'KN&IKR'G6%E[JB2H4^JT4R MMI: (WE9>U"E[59:0ELDBI MMKON:67OV<.V4[NJ@R$/_*5V#YAV@DYFJ5.N[ %]E1.#J.QAA"DN74H&[S$> MQA3@)+'+[^P/Q66\O-"3A6QJ>T4(Z:YK;>ZU6ZF8^89?H5\@P 2>K;/ZSJ06 M:9QZ%4+-!M.FIMZ8,KV;^LO/^L),6DH.3TU]N5ZDFFONF;L*IRX]3; M\2?0T-3G FCL[[>.)I)J$6<1"SUG@IO@,,IJ92*MQTCLC1UHHK M(#@TXQD_58B=4452%JJ<06]G%U75?H MG:&)+1143%Y_,Q/5TXFORPBCK=D[L)8!%OZ?1AL@WOSM6LC=.NO.C;)2N\S$ MU9NU]LHG.:Z-:?/[U7LC8Y&)&P@E#M0-X)%:7XQ[YI;M*%>+RUUD?BUWU34- M/S8[HT+_D22*N9X\/XJV&.5ZUI+_!>)1@7D. ^=6,!Z;/Z-M;_[[ M-/)I-_CQQ2NWFC0[M;LD!X4N\Z/\W'L26?D#5G4GT8X%^R*YDC2/&= ;2L\X MTT" HG2(\ O),?:CS2]],S4$R^!L\>9OA"PK1'\);[8!UI,XX<]8=%6S:[ , MEW$N9%U>$66=($KWC:_=CP+66*A%A]SE96GA_@&S#]C<-N=,/V ;MVVHY_KP M47L.\KOM7 (IK52 MBF77IC;IX-NOC*=1?T&!G\"UR^+T4)*B'H<B8+#_"(!_Q7\N4(*Q M/"KK4T1[I3RXCUS +ER+-YVCWCUG0H_R,)WM5),>DR;$+NKVBPV1I/H M_:ZQ^DI2X?YFIXY]!P9#V.K2>H<\LI#:('F5IEU:X2-@CSR-EEF_I!7BU):Q M^AS5ZF#)L>(AIN(8% <0%[(=6G+:QG ]J6O;2//8?I;>K;U55;B20 CI-&WY MUN*:Q>WZ">NIW-X<2H Q]A^79?*V&&!E+CI/.][MK@,X MR01*79T2=Z[- RDW#45^U68_VKVD#QU[LK(@O@07U;1# % VQX%0CC M=D [O,&'%#F1E%QM"C+V9#C. %_OV_-,>N"GEY/; 0V\;Q-7^L(_V!>RW4.< M_ET-KH#\:!?[KB3*+LX]!;F43*SES9.,E\II\T%,HY7Y>$(57L:"@WR^&[T= M8&O=Y5DK_55S$XITR:^[ \HT)R\Q,*']X\"W;?;VCDQJ*]&V?<2>,)S;[K$1 MPC"> >N7?*H(>0(@PGRU*&B* -L&7AR?$_V:XD,<<'E@U'B,G*L=/C5SD0S M6[[-9Q+BDPMRIN<3S/WOP8=RA6]M1LE5F<(1=9N :@S[.!O?83R@M[NA0IW3 M!O7$GS1*ORHEYST01$6:PB(Z>#R >":B\][$KTGL;BM-3GE,:K?9@/%*#5\ZK=WFW 0E]$LF MM=M\7E[VH5^>UFY+]0X6<5:F3&JW.;J$!K]N]BOCKFP M"IW7WJ^? Z)(12B<:QW+PMT4#X[>1_L+QYY6(625P6[=R1S3/Y6,S;US-V*4 M.!?RM7/+9!W-5OUN]3^J(:3G0X,JM M0\/=1BY4,1Z2W.]&*3PQ'9W(&CTB<\]EZXRYIU_$ES3O5(YHUUJE)Y.REG:' M_GG6*SAH2]58 M#H[IJ#T(X)RO4>U5A+]<[O BV#'SR_<2L0>Y(J@$6&/&.3_#,-,UG,6AB M%(E*X(V%4H)8$NG[_^,&_.72OV+U"EH[THCPC31(,XPL2$&2)#LP\?UT3[#Q MB7]2G?%[#N0\ ^PH#UQGTM@M7:V^ J:I4FK"',"M!6!X T*99( =V0?2L:J" M:Y4FVM7ZF4I> LNS$Y\/SL((Y6](9DN'\=BR@73,T/.*R]AUT9>['']"RG[I MYKCJX-TPI/*F42?YB;%"9(H_-B7E%F M='N)B*/Y]U(YIEN<]E6!J2PISBU!="/#=(O_X#8QL]@AS/WF:-:.]1E/B%V_ MK)_U)DE&URZE&1L#U+ZIWC5AJ\ <(] [BRT5Z=>"A9H]KZD/U2:K!-\U;/V+6T3Q/-5]L5&,;P([-.!-Y%6OAW]XNYHLIULY!35JA]M9?GY)"1&NQRBJ7, /N0?&2D&1AJ E#) M(T.NZ58D_14=*[=+Y@*'@VH4P,ZJJNEN_0)Q M!F";:)<4%#8Q-5W,[0@\,HD_PDBC$')R; MN,*!1O]R8E%J/CFNSM-&Q$&7)P6(QHB([LZ?CA[67@;3-19Z$3"O6F)[D3I; M^P5;.#H";Y9G!8:U.!>HFA/8\0N$"D5\/)-<\: ,O,)W<_,OM@>AR)0YR[DX0/':>)+H&HCW=0)2R3)ZDQFHW\!*S8> %79)Z9 @+ M^E>ME'5;3,K XW17-+X:1PW@]XYU>LBS4XVR50#?L-]HF\NVES4;8/^2DL#] M60]X\_46E&DI=Z7P 6*1 5;AR==Q#+!YCF?T0GTWTK52ONM'DR$_O U<)KO_/&RC+I\$AVM#5<[(;S-]E Z7+$H1_#1XI-O) M2OO1V&MYT;$3_CDJ2X4T_MJ597U0#$]B Z:8^CBY/6)_B\?!V1-';A[2N'O! M_H_U$)#.O)Y\1"FZ'MEAHE\NT=KY 0^L$%H['KB/UH%59D56?RST%!D;G+2K MNMMY[:>RW5^)IH^I)>J-?^Y T\/L*A9\! MMGW\ 5S[*?5C ^S-+5;_\.]RM=$__4?:_G*9_D.F)A!HT1G%*Q;0SO.T T7O M=77Z[+[?Y7+&J$8_GZGBKO\M.55*YI;[* M"H*@WA$3<5+RQ88_%5R>L+MV+UEAT_KQSB,T&>+?. F_>?4_YG9OMZO3=2G4 M6511N=B)@E+J<_#R^ZM15OX)*I/:D/.M'H?S<=Y!Y:(C0@MY','[2S%[_)K= MS_;%VL [Q65C^YM/C8SHM^L]DNCH.-.E-/:FI]W0!$L\%QN^HT:\3Z$6ZZW)'4PKT M'4ECG>Z*\F@KTJNGI'A;+W:;O:>$WMGYM#,^6XYD[^\\$/*H>G[^#IA^"W6Q M_F> 7=$8%^$"3^"9>!R46R\=0?':AB@!,02<##MWX*3TR"WN6FTL*M4#&WV# M'!C<9D\*M/]+AG]F<6AD]>'LPD='OA%P;-DZIBX+V?-#UVREI'W, )-BZ@%E M*>?P&YZ\&[08W]?B,7\N4+&!)\?)[V<@4ZM\7W:@;@P&(]L_TWKJ&\4;CHUV M&&#@KM'K%8\T,7\XM[]Q;E7\WN@S'.P%[!R]@]:MI<19XT=L-, 6>L3W,&T& M@Z^]-/NT(TB%3G AF*+NMKTJ8_,JDU")P_H5CFLYI57W+K9_2[9W6&MJ.A$/ M+?1:@'^5%TF<0!C5? )5E@985A!"^8(HS=0GC4!1]BNMEP'VRDB3\WM<3*4! M-:X&V#>L9*!T7.N !??'&F"G7)JA.5"6&&"E@&R.B.)U4Y>N7^((^@-L'@=9 MH;63T59#L?]/UYYULH8K^6:;S[%7]SD/S" )NS (JJL=H(77&U M,_F0W)'/6J;]K#7*SQ)RE3T,!M9J,,Q.R-GO$NI>3W61A-^M.+M-B3ZO0*#B M4$N>-BZ_@_7Z7K(Q-$^ZQF>A4+O: %L4K+O)ZZ,:32T!58?5DX)T6UHG93@V M8]2%!EB.IL=$;XY< KP5!?P^5_]CN17B'%".U2Z;U3NB6*+QT7J#]3TL2\HJ M@=:I%PYN-\#*-E "6:#@4>A9_1(#; 896RNA'>,(*#.8_:H8;N*%:!=6^Y@O M4_T]YJ'C%?>'1,O'_[[)C4=JK(":SSP]]4^@_(W&3_LAS$4576L6R/>$0]/' MU_@WUDH-L%1'4CN4R:U26B9[V(>K5X9B'EBMHSE>+<*?O!(:G_<5ISWH*:%CXG[0S;;R8Q M<"N_EXZ'*I]R(K>.(@Z-V8#DC]C9U)V0DE_1E3 MG4DOKQ1'3'"NONM,6IN=4Q@9&__\NZG.I"9\3#AIH;$SR6>V*K_H%R=C"<,J M%/C=BI]JGC2*PRW&<].>%BNFNB?+4Z*+0G574.PI MQB5:>!FG@I/R[>*&Y!E:)_16&7$^R(!NE99092YC+2;SZZ1T*:_,PUU&6!F@ MFEM9I$M^TAM0I5ET*;\C=, 2^%:HNLB9L>8=MDG:MVG%Q!- 1 M]J'((^M08RQN2###3948]')(N1=VM0 X!H"_DD";%U:78;X63P 3Z MP_.A>N3V_GC6PS?ZAX27,>MGO'HGS$X5&V U2RGFM[JU$6#C.^E'[6>WE<$Y M^#45JX,RC=J!R:--_U3[$? A@>$&V.POE,&,@SV(--J2(W>%'5^JT#]X6/8P M/<6;C_DS%C%ZS"Q#)*24E)^M6NU7"X<)GFLC OHOU\0?/^'25%B<'GSM^-9P M%P-L^/!_WF'U@.)K//7LM4THT9JKO&NH"%5CXC'MN/ZQ9!0LT?-CCM.Q_4CI MA/WPLCV3A]%1NL ]%4**=TYHOW3XJOI>@=!EI4_'8VN=L:9')=3/8^1$5F0\ MN:_QH$ Q[AQ6X7[,N3D)6&I/= E=('T]$IJ-?X1!GG=#22E;C54G2MWC3=*U M%QDR1RM\A6O&WI)2>29-$>,XROK%T9KZ@%;NS><-\1301(S(Y^;H2M4C=X!: MT_!#JNT/]MY3:GA'C@:NED!0+OL1;Z@; GCAW;I,S>9) MNE8[S<\J%K_;R+/'''4\7VTRS;-G'R+Q5K$2W_'L24Y^%WER@EIY>)IG;ZP8 M?:G6R+,7^N#RO))UZ#?P]ZOLA5CY7[DU.%%R/2B)!]ZQ%VMXNY=LWB1Z7ULPFVMVB*>CO3?+Z M;.884;0,4-.U=B@CBH[6W5,C%"QP*P5"T?.!H\"1>);&51.HF>7WUX7JJ.>K M>>Y#-$+E:P\>NZEJUMLU( Y:5"]T=SS7QU_N]0?MY?#Y."?R&;.9&C28[I(& MO6; :0A.8H:")^I=W8!4#AS>KY:>"47=)$?72E])]4W H?SM-P?$:*OOJ4_T M34CE3NQ98"'D&2B!JN8]D/&W]N*)M[&0O6Y^@2J@;&@E?0#<)B%6:U;'#G2Y MZYM$Q2YQ" Z8*W]46VVK'&:H0XFR L[CN,$Q*+%J%D1EV7TA8#>]J]B(TFRQ M]6X=S;2+=]\EB&*Z2=VW('<+G35_DK%O"X?L/TH4/WDB_H#)).1>G+=ZYZ6O MJ#B@9B?2F&*4P[6?L,#@#"C%<$:":,"H&L23N4$91F$\0[^T&]S**P/N0*[% MPTY.1/X,K=(C!IBB&Z^Q3'\5$H/ O5FG0?8K_MN3) 5]9\T%1MI1O[___,0 MJ_2MP&W>4*_&/SYOKVK\+%!:14!>,< L'1_<"0'QC<07P,$: VR9+_3\W3A/ MNX[\/HO8.6G:=5S'"\!M=LPQF?*5>LMC*"BA'B!_Z%;Z$*4L6;KZ(KU'YPJ! MOQ5:)VB5SW=Y'0I:[L6@EG?TA5@\2G7K_0K*]Z"%.F8*!<&SJ.C+C;5=,ZO MTV27E;[WU]DQ[CT7K(4P ./6^EF@[>]SIJ%7>P3*D*;DWFW5RHI4BHO,R$,< M_I61:#^)$IB'ZUK5PD&4AF$&-@''!"YX_+342L$82VK_7+/E!?-^&\8VT16[ MZE_6W81 ERD95=METE),L>]AF9&!&OV*250HZS:-D$8GC=J[*RK2K5)?/8U* M72>=ICV*CB>IX\CZUAC2<9+#VY>7GLX"7X).&A.J"+!&EK$H".65.BMT(@D! M[CAVI:':+95B)CO24H6NAI)JM]#N\TW7Y45WR;^T M[QGJ5K_%./1N>3,-L)YDKL75F#Q\-QM9UPWN\FSB]@:"TY>G MZ\HX5>!91GQFG14K:0P+[_ C,)_VARU5AE428F[=Z=-_4J[_^:(!%J1[EGMJ M\^_R0SMN_):24@]"BM'/OZ_YD[Z5)X4R6#4$UPRP"]RDCF$HD?V:/%G; MQ X&6 6+VMF+74!(X^OM-<3S+LT*UI*!;/^TWOMQ&L]F8QP<1-WQ.SLR8-Q' M!^]#?O@@^$9FBAM#G,MV50(-=KX$S]H=K2,?$1.K/Z\6'2,%EU65":)TAP+% M52L=:'0E1#6HQ2D94*(#:"0X]@<7I "HJGD9A+737C>I(G*T% Y89!'$"(W)3;$D6 M;A.]\$!H_Z#ZBNYQJ[%9W5SWG"PQ;H.OQ05/;8$@&R?6%N:\VP)Q3&8S",&F M^'=;(#QVTIY$@7YR"P3SDX+ET.,S&[W,[FW2^R1D9X&)N;P*VJ\#*)H%8FJI M%DK/A*DN +X>KGR2_JX+0%B%S,%U$ZK>=0&(I_6K)[L &M4ICQ@I-Z.;G2\^ M0-2[UHZT8]07P59=@BL?=1:QV,,W'X1R9XUE/?#4,L3UM"-0RF,OVVN I9QF MI=K5;.H^O4^%N^\[J[& NP9?6_D)$E4-Q;4:<^KJ0:!=6M&(NE"- M4#K0;+6KW5(;SU69XAU_\ BTSQ)K:,O!Z*\D+-X=#R<9<3'N]CSG1];8'6GR M(PD.>2Z=\H)A&CVDI$)GW6KT?$]HDYYOHXZV5PD_"Y13""991L_7N#<$3&_$ MO33 CFTUP)960J[O:;_G\L[\P?&,.>/:CT(<$WD5463F1RJ$NOXQ @^PBGZC M;W")[C;R:\=S-,[%'TESTU @7O6-]3;!:WBRU#*QF#@6&B)U)[C[<@64$_3M M,3F/>@E(S;+=966M:]I<4@AHON4F"[.\@>_Z1DKZW,;?O%(Q]/.O:S!:2\V< M1NTJK++<&4JO[_!U+&60"\]:EQ+ U8N H0X(TP('<6&;RC4NY5?5#"9>OR1< MR49*0X+2U)I(":V]U0##?C5U)!!CXP+&]2 NA 15)Z@L'^CA*OT%7)$7(Z1/ M[Z)\DB)G?MH1=$8Z_,3,OQLE.7;C6O^T5_ M\/V.;[(@Z3>VROKU"XQ?G,@-:DA0#D)?K)Q[(;K(EQ$:H5\ ?;$L]--70=E2 MP9-X_UY42W&Q_;JV=>S;I9QKKW>&O/3%N^^TV6Y>]>DI1&-%#>VINYH!]NNR MXGH@N\Y>):AR*H)2'J>H;!=5&[Z':+HI07[_=7_7)X)A[8ZC'+B1?=[35<0J M\9A32"YY;;^9N2:Y01Z/WEG!T_D9L?QL'\%EJ>E(&O#!F"GC'EL##E,V*A-K MI;4=_J(=M_)V5YUMI#H)75:0F%M&=V:-C#[TM(ZPW!A9,6A=S70IO'Q8S(M; M?P/^&;A=>4B6] [MZ8'?HZZ6*A=(=M),M7M9VLVCYEJ,CO1>R^%O D4<5*_ M>1,@'F-NE2=+?W%OP@; M^4@'!:]! K5(Y5FY,^]I\(@,65:?2UDIWC!$Z;#?,:A9R<]&W&^#(N9\]ML- M)9Z=,HTOTS2 ]N5K5I6]19G<#]NPF+I"2]9=0.*([0W2\7W@)67''ALS=IN+ MJ0L$CQ(="!Y!/9+R,M%1Y[@MF#UM43'''+2V=/#,2)#0DG\<'$$I2QB,A^0- M,N'< ES1?FB><=.G321/%W"U$BL/9A!+M%Z@EY+?.-%92+.X@B\F2Q[8+%<% M,P@%6T]$Q\R]3BS"<_UTS]PHKM'CDH#]C9]W>)^(B7;;L?;N=5K:;\1;44X^ MA.%YM_HS+!(*(ZW$%\+6["X4)NOWKJML$3 M)Z_F]X>0V.]NR\<=I#\-V3YYVXV8D XOZ+:7/BZ"Z;VH"R!GY83$ ZD(XEUH M49KJS3VO'%07 1R]R[J*'E3YP"9>.TJ7>5#6/&2/;I @<>4BJ@C/!&HW9%MD M:ER#2O7=H2'-&C>4N/L<4KD#<:IK\;VS >"]7N #RC>5Y6V.ST-MGBQ12FHJ MI$%/?BP_>3*VG)8W$"OYH:#-6>$S3#H_MF5UXX0UY_&%POVAN,]#0@9,BZD- MK5]\")SRF-'3G5!MIASGCR1UV0BU=CW="_K["R-"+'ZZ;(IW/[CF2M.:*Z@U M4YA(8G61R8ATM8PM*;O5V17)9;YX61!#(KD>_(=:HC=)BAF:=92YND(VO0QD M]H0B \1R80>J51N=?SH7U/!;"\HY%MG.SC1TF3MF*^;=^ 6*;>5@CL:,*J:9 M1!5(*#%*]P8+[L?]$V)F7#'Y:+\-4L#>8L<7MX3AK6@7QN"P2*HM6UE(P^&0 MTH17%]8)F"4$YMA\Q9IL>Z< //9'.PTXC5ICWK<@$;_>D3$V7E3"YU"VJ,;K MF,&]VT!2#_ !V0##L(4O1"5L8 XY/&3:!G#AGO3C]+Y@])0@]%/IHY@U=@3K MIA?Y\%77Y.; L.WO=8(Z/CI#RZ48Q1 W4P5=+O?.],JO,2"_>8;[\8"E.KJE M*W)3-E+UY_*SNS ,,XQ/2]5'@&N"XZA&%QS!OKFZK7I57PCSQY,3V;G2;U5; M"VN*J72**?1I?^ICGLE8Y\KZZC5&]:)>U_/.!AB\/"NF@+*S0MF0HY3WAE:5 MG9$$JLQIIU?0<7MQ(=$)'O@<%)'HF0"E M]DLZJV^,4U>77EZ?7YK'P& ]&^4P)/\-)8:[#7!]E9*%KJY<+HNRW]>[.?BVH'29XXBOGYY==&VAX M\M+W2.HK=L6/[$_Z1__;B+C^&/]IC^QSA+6G&^5/NBS/#_'(Y9[K\4@C27FY M<0.I&.TV.JGPK%FQ #S2$; /0FSZK!\"WJ?,NT\"=_T MJ<\U VP/#XQW/?=1ZLBK*T%"-L//:5OUQ2>A:W!J6C0:"2'ZB+"YRHK$*B.C M\!!O(8CD3[@F5&TNC"]\/:YQWZ;49Q'R^RV0A+9C#F.FO#LX]34UY"*K*[E5 M=U]K.Q@7Z-&7N M^DXKHC_''^-\S[L*3*Q!+AO0?D@4:F1DK:0Q^@0LDC8PA MYN \/RE-W]/"Z8Q&G>\*(9^<^%-58 _O#F3+WL\W)>$9S7(_S^9M56WV8Y6C M;1O8FM3/E;-XN<:&N7B4,9)M@T.1;&VU,9*U%>LP>E-W#7K +9A.;P>Q/8FG MHP%ZUW[I(!=UCG)P$R/W62?&9[95N;'NT#2D=6V;GSYZV[_ M,LU)%N. %+)I?)N#8@.!VGH<(75T8"J^Z?9HS0-657\".8X_4SO"/FMA5;DS M*'&J.86T(EVZPM+& LHF3FOA)8UJWT=Q?=5\.6T.&[/N>TN9AM9(\LC&?Q MN\S*[@E<,*9V#UW@B$&KW5-\(=*L5XECQ)D1>C & ML!T5[JHKZALJOXIDJ@.9IL%H;#7!"%-RM%_961]EQ=E1!2;@2L!=8939QVV M).L'J;CT.(-,AYQBEH4D3#)&',JT3'KPMT131*#GA^XRNG9-M;L*J[!G=0P+ MJ!_J*A[PX 98?!JR,59_D::\.D#K"WENN1&H=>G).F)M.Q0B/AN?-XA0WJ9V M%W;R&>0 +:O1$4:>U8!=7G58-I+4#:_:4D1F-(1]VK9L=PO;?N/B9UT'?GJ> MC5N3$?/1U%G W382 1-PERU@$SX5O D2$3>,=K@SB@ VK3U%':NL&.(IB;50 MZJJU/Z%CZ:ZHFWSKPC[)W 7]$N\&FT]$=->0:MY-3'^K 2:I3LOEQ\RL65NY8@YQZ,?JGV9U]_V/F^,?XX_Q7QOZK4!//K(,I75*5UBS('QF)"U: M6+T^GM[8#=<_/*CV0_CJ6[A$<)?6_)#:WF2[4I>N_3ALU67B$&]1!$^*>.HY M6^QAJBL@CW//ONJQTI<88#T, #)MA[3VAL%&J3TOLY=XBB;5N]W6J9O+P:5Q M&"*X/Q8[$7:O +>I^X@@BNG:P"-D-.\3KX,0VFK]DJ:9+0? :X#3VR__H;MO MR&-&#WP%9:\J/:D:0?%4JG/DK!5DQAXH\6IAUVT_$?/]H'2[)T4.IVT$DN Y[ECJO/VP%6*!J]A)J]ZOD MUML:ZR8\KZ\=2M>O /U.$ G?.>N,A'Q]?=F?JA+^4H&_&4E=4YT2)& C%S_% MV?>L7JA'8%> /\[:KI\/:)9#(>V4<@VP0O\1+GN5H'H3Q5>I>Y))DC7A@#) M!E.N?5)*+'K:MPQG,5[V%G+OCFK/!#F!2HAU)QSB@T+*&F[R#D[OR.(&M;2- M&R/TV'CDY;10@[=WFMG41]+ M [LHP2HQC8[_OE]1%*&?+=@IKHJ7?]#5$9*.<@M/W/"L4]H_P>DZ7=2GIMI* M,KV41ZT$WO2![-7"@JM^U/EZ0;<2S?J!M@S)J;)7.J$,L 3'GDQ:Q5.@UNME MS2UMH)C=SZM@CR UV$,XS]EZ@8 XFC)RAQS6-5[O^8'*XJJ:N4P>VL3.M'OM M&RSBA )!;6.=T8%M+DQB2)NC"^'0/A'+@62-#A:15EYW=#%#!;8YKLD8-L*R MR@P\X]&CFP7WN/>N^;RZ].+D-S,F.J844C^G['ZGD+J<=^88=5HA=2Y#A0H1 M%KY32$W-!Y=I?'UXTPJIW'JE4Q,X\2Z',>K],&3?^Z,S_,M;X^QKCL>T[(F>NE;$ZTGW7@2 MDF/2:X#IEW8OXKT=,'*1_8J7&*;/-L!D8\@[S;IY2(0!IKQFW&5LWIL&9>O& M0[QM\$8##$K7K8$W;:R72Y-_Z_K[0(^C%O*8/0C%$M6A6IH)Q5R&2)G 7J@Z MJ*O478^79\VJ.1FR'*%, XG[5'ZO.DK8-,1@[+FP8[3<4#Y>'>_P*O[Y-=6C MYP]>'_#27I9T=RM]66\]>:=YXX'(,11EZPWXX, _HSO]5P;O E':K 9$P!%L MFJ<;&$C..,==EU5DC7F0T7"CPM'V/&46T[)*V5!(FA\5.E,8W&9/,(WPM*UJ M'7W>^K7J6HK1];+M*Q)<_3M>9.:A.#PR[0ABNQM5+@ G45B-PC MIFQD]0?PSE4A;PW:F$D(5X)NMSEZA,H)P!?)?L@:;M>5$X1"\M&L;3X.%( 1 M>7(U"A._9V"5L:EYPCK? *NQ X[9>P<)G37-YV*IIW% T?[V3CRWHBXM\00N MQ)XC>OP=BA'Y75^8@YAS+TKG9HM_]/-H/")8%"9=88D2.@X_WG1' _RZ''6/ MR7-SGY&ENIU@ ;XH'!UWB+M",*))NO'E&P%&F.&D^AQE6#C#? M.KY 7O6S]1&1=&ACJN^T1\RYC]]3-L7<*0T ";G0 ^5#EI;.N1'X[!P;WZ^?E,(>RE+0I1ILLH,C)5"6M@2'/2S66QWH M\*GFY37/U-I.:CD'ZLWI?-24EC-<+8'>C]D[+6>)+E-W4W>ZL/^=EK,E9+ : MK%',N?.M#59ZI+N[Q>0) K*EH>N01S\LN-PL0YV>5M]![E-U%<^=]N@;0DZU M:5'DQ&F/[KX/6GYGN),>W6^[K_)EUH9BN[Z)W]$&_NW##ADL8C-G[9IT],+1 MT&5>PI$I1V\_JK#S$; '<>\<_72*-^GG<\LYYE,>%I4[P MAXY2C'[!F)(HHZDK$JKG&IOEN1X$@EH#!W=6M8^R$C(<\N!J==8K PP_%(II M!-JYG,1+\6J4:4<[&5VGMQ911;D4W_)[:8>A,/B["(FTF(R$*^PACQ\+NBJ; M-9C:[EF32L!QCMIX%K>-*9'*3;*:2G9MGJQD4(R(0">4.5>V%Z3 M#V)J)DXRB[38MF/.G;-V;J98!%07$^]@6,JO^O$412#U); 640K[VQAR=UQL(Z@5J-BAV&FC Y M3<+O\YA_F*=9-*)?1UNJ;[K5[XK$"4B8A\6 ;(&00GP^:+6EZ[0<">XH0=$^ M,.E7_%[W0D!!R5(316WM9K^2.GKG NCH?A0H=:U<&OX?#:G MS07O-RO@XA--6'4K9&LX!$R09"P4%2HA;=D>(AYC;GOS=YGH MO?K\#MO1/$2;%+QW M =IAH*N1:)9_5;O]_X 5H\(TAB3FY7H5;")GS!VB<U4R#EUW&!.D/R]_RA,)TV]SKD!='-A"GJL': M\BRHRP4>AT_0P:2M;1Y.\B*M(X6Y 5L@TFXW2L%$=;-9NG0#[ ?:1"G%^PN; MTQHO?2>"':W8K$YU;>SZ7-^HW*U':3&HF?4D&6LF\JHN":GUV^#9&<\@LXXQ M;^P?5".5&8-A:_6UXK65F7S:4[50=\GSBVF,]GMQ ?XQ_NN#];.CD0,TH_D4 M ,$'C!%.UX?HXM_[SS#]P7=PVDX3H[MB@#T7 T=8FE6(N0;86"CY>][Y2'T7 M\*T!!OGO=@8TAS4\'3KLPQMPX)\\QJRW<]ZO"H8%@%^384]%G4DAL5 ^@3D M7KG7C9^0FTU]PH$'?0)ZIL[=QH^HYIY"LF[]-W*J_&\>R%.Q[_[V*[$F["F2 M!D*=LZ$7G0G-!1>*8/>_/X4$_MF6N!V8J"M&/N_GX; :1P-L!7+L&_ BKR)# M_Q$/#W_K1I2BC;PX#2C=ONK5-^!_G?.Q\?>+"?V1J_T;!V\5KX>#?(WWG &] M7 -,1M2AL>;X,?5[_SUBUMMS?W44[R4KTG_$>*\G.+5%_T^>!/X[=6.F-+^7 MJ$2?#%.^IYTLX/WES48IC@?(7Y>0AIHD\,)YIZ@FDJ.4P![6:0-LWF3/B@+; MGOVQLH*/FC/=M'*<'A:?A!9$8?RV"16Q\9V=J9+VX=4:KRQ1?7%E3\:71.S_ MO.G_;QE_N*#_@:$G&V 1"/#3<86?DMB;5$]+:-5N O]."8AF0O&JD!"K['&, M Q X7\O$$L#4@AH(2\PW2<3Z2 @DNRV>0G_1T;&5\:C="5&:RJ-3^^#&G4\3 MR,26=B\!W@[L,1D=]S**_4W0I)GZ!#E MF ADN0?!,2D*SV#];^\.8KI@WGCK4<$&HELSAH;=.83S_.T8^MG M3<3]1I%.WK]T-:N]^ZFI.E^%5D ^,P!,ZL6:@0"?:E3AJ3.+>\#-(.\?6][" MP0[I;/G5'Y>)-D0I0@;WMCG_@--_PA8,%Q]S888W5PF&72)*%%^W]0J<'\ K MBO[6FE@O XV,L!*JP"F2^Q>I)1][QNKD!8>@X\X>.9-(*>%C<%K?KP\8&;KGQQ4EH3\=[X&P0AH:ZO(4>6I M:T74#4TJR]W@P1L1M$7.!IB)-YX.VO%M[$I%)#]T ]IS=82C@TMJM-SDO+W] MJ.Y386UTBV^A=X[/B9L'!M3I/@Q<*\YI_T /XN;?J6;^7J>$^->F1@7HCJ"X MZT/4F90/A0K"1VT;UI2KD/6#FDQ-EO MH>C2$,S6-W-@ !&I%"/N-.L^9$'OUH.VB/1 V/"J;=A99QH\388RR=>&B1@FVJ^*F5VQF&& +6B;T@N? M.>'/O-5G57*]I"\D.R=W,-8A)YP1,=%P)>8$/9+KSZ ?:(RA#\1"-KQFBOS\ ML\[]72%-YDW,QP'-LR]\:@?G52\VRN+PCL+/E;?@RL!7*)"1&X(;5Y^,1=T%/&FU&%/3$W2W6BQN8ST#WZ1!&V@5O_%[XA.E7>NM"E29IVDFA AOP MK%)3YS8M5.!BI/&UF10JN#P_[_**WFFA@EY_$3MK1]>44$&375!965OQ,/,@ M;.A7@8TU15*UW*[7>RC32%*UJ-J:?$B6R,G%8Q M=JJ2A"WWJR8L4RF;(S)B0\C?-^S,O=R N7KOFJ)+(20;L#[AY.- MQ>YC2(ZK;AX2RJ&N&8O=IXXH_^M7WT?VI&G-A>I+X%55GLR2SXRN0-#=<)S*I U8DZ*)U#2KNEMT$,GTOXRT1%,N5@ M4;];5$9J0^8-G 5?7S5T1,Q)2;6ME0;G,2+*N6J>D5)^7]4#H_@UX$"SY/64 M\M@5JFY#PX@=Q+(F>5G58'>%<&1L M?X'HT!4_,#XGLCR@HS_C^X$3]7,+/$O?)O1BSX=Y@E=O=0SREE".]\(1@R L6;?Z50>O%)"YJ=*3*&MUI;KK:I3"<8BGT/FB M]"WZ9GW+;4UTN\?(G?AR8?-KO7"11K\ 3)AL_&NH5 XVVDPU_OGF=^)M%J@< MWC7^"5['?]Z[IX4UO=53RKWVQ.>:L?'/IVNC>9TQTMZ?%)+!UKG6CD@9ZHN@ MHRX!SD?]8( M]G#)!_'&3L]:6L=X2./I#;QR)!MA[/0$6%GH&EG\F8+N/IHF$VP4GKWQJ@*%XX2AP0_-%K8LZ?I;ZFI*NW4!82QD![]K,N=,Z M"K>NH2D>=8,9Y$!J6@]MZ=L*ISXW^S3U[FXXKW0T;N7]7<:C]?LAA,NG .\H M]'F*B2ZW>BE5X&EV1T6K95G@)MI0]/[QC)'$ FYI2D/8_'MMW_(JDGQ4K*15 ME=S*%I=9T?D#8O'E78<%G+NC@ZDH?FPV)W=+RKLLWVD(^U'\,N/8 _6;T0IDO]7<+HOQATC1JRCAUOU H=TW-U M?0]K#L4#G&&D&M&L'4_3 O$]K MH-\O3HW;7#^\<=EB-2MDT+8D3390133&= M'6%XR37)WDK#X\E1<*NPP3(H0=W:XV@*%KY12$)0::-^GEB[/>)A&4?CF4ZX M\\2=_.(-W<=A[=NS_^;7<0@%0K!AFCSWN#*ZH7K)._+BX+OJB?-7?OHV7\ ['7G0R+QQH+Y,C&QSG MX/0(D8=?CP'VCJ4*7]35%VA\$;W=IF#(&X48"J6YD4O?AE KIDBJ".F7.AXZ M9LWT(3K*$/^V3/VW+J;4:*PHD5"BND2SB?(GL+XW%,F?+%B!7FV2.BLM@4E: M:;\ #GIKX^1IIOMUB9)@$>G^-D=75*O].JYFQ\T3U:]]+WS\^FNR0C[Q.QQT M>U&W4B=+K":95?Y:8V5D5IFJL6J>)E:9JK'Z9II8Q7FJQNH=L8JQQHKS.,[N MM2^4U)FOG&1H\LPTN1@US=!T,#RF@/*1T':*H8D1R6!LE2NV[Y%43S$T84S! M44?+_DF&IG(G7**=XNN!KQ&2H.]LW,#222H:(Z'K!>H4%OA=U0TTW2N M>_]*1;/!R.=JI*)AO]'RV'P>&"SB$-!8$6E+=&C;F!D>(^:8-F'VB5WPC[*\ M@T2='3DBGFQDI_(R^ZD=O*2T8(?\>+WNM?I5G$RG_6.<6+[C!TK+KYN)$7 M_9C]X7:/SS\>-=?.DFPUWHGQ8$(Q=:?%9&2=%/ON3@%*?24]OOS)NSM)(RUH M>.'P\.2=$-(-PR7VA[MG"U;#@+CEZ->^2J%^0:GF6XJ[9FUU7B\6KMTC@-XY MO.;&OG[$4JW]H:(8Y+>:F2&#:.K'2G;V4E7Y/?D\17&V.-Y8D"Y&LHW,/2,< M,LELOV)L)5'. M(@>?-!#P^^X**/8%D6[E*7@6?@*EYJ0T@2]4<7I3PJW[C]7(&9Z+<.KR/P]8 M+,60:?(Q79/N25Z!]2<7Z>'(TQXK;N):([AG\-_G[HL\KO62* H$Q5:^J>M6 MWM_GE7L*V/HC6F7?:X!US%+G@5DGY"NJPE6#\G@=/7ET7$#9*M,YUAU-O:"@ZK95CKU)97#2L1Y6H<-]NG20:]*E64R@0-?"3G*-GOV*(?F MIQQ)CD+>B2_4:W9F[A:QCKE8ZN)U/_)Z6&&SP4LQEF=Y.&LD'PHL57ZN[1\) M*"?R?8M]E+UU;A?S2AX=MLDLDH85,HLH;II%M+C\7R;$/+GUH5K)DOWDE'UB M$A2<:N9>+^B&49^T[H< CE%L=A+@3(G-3@.<=V*SWN\ SE3S2,LDP#&*S98V MSTY;QD#\_'MF^J=FJ3?]'CG]OW8UC\[][3TZ5A,"7-^M ""\_J6@>AF>9UJU M$@IEB_NR/V_S.)0/LO9!:5L5FH$+\6048LC?OZGE'J[.D8TL(T<*46TN';YI M%J%>X3?]2"=N=D18GNAO;;2X>M.)NA_@#P"1Q(G%5!@@LS>R(647P !4%-JH MI0B_:>2#W&KDJCA748?5Q_[X^UQ]GMI$LV3JMU#F@D&J8RO8;TNTX3VZ36_J M3/.?1G*/73W<:P>;0%Z,ROJ\.01'6B,+Y>U1U 0?/DSMP%FD\+,ZICRS9A@(CHLC+>:?=UDFGE40/, _AUJ/X" M(>PT-U)(_>J'(?Z5B^.Q&LBJ:_;HG:DM/#;Z;+49Q4MIRS<-7=8@!9)[.2** M>;C\/CRH=0P+)V.#55&6Z;-"5:@4>Y=03[F0/R[=S?WVY$30+\\&3F;D1G8% M7]]T]=8IZLN_%Z_[$:L, #K&&[KOH).I*T [V9&L'OABMB9:&ODR2.YKVO])@]P@IQXGQD)/T[D\$O0"B;F/.=[F;U>DH@B(-\UA+L*2N$=@/JO(V9TE$MT7Z$6$*: MIC\L[$-(:>T\Y5UG TP!'S+^P=$E*=18_&M*&JG-/YJ=HWU!N]]0$2$\%Z8=GK MJC6GJQE@IBZOD(S6=;O\*D0=>CE3X M;>NHLT$(6WM+5:A3Q7I$E_6.X9'@9+& /'J>G7;. Z^J[/6N8W[:O0U,447+ M_Y9%,*T*_?<4-B2\9B=I'L%QA/E-U47S>Q>EKX=G_]GK^.=W3<:=&)'2X-,% MD;'#E3?[)XD_QC/*2XLC)=?>$7^D9R32;PY87MX^1?SA(GKQHJW52/RQYLW/ MEU9_]MS#5'5(%EX/5Z# 8-I2[0S5,@U\"-F!59X!'_&K[?6->J$&JR:JZ>JY M!45 N $6 81W0Q-(14GU]='/8VA',L.5J5/Q2XGZ/;*@^% E3[\ KOF:\JD( MLT?HZ4KFUXO3W1)38F[U89>[S->OQ844E*><\.CUV5\5NH[.!.-0HF^X]\K$ M^?=R@KROQYN-C;C,Q0Y\3_&2#!\6';7PC5^WTF]? M?:Z^6KM8E^\YG]HJ#;Y73+%4#=-Z,2BS2(N)([R%L=1[.0-/XR9^\/F>>Z082MZ&F+M>H43%0T0'A]'XO:9?P(FY_U@;4/VU[H[> MA3S_1\(%X\1I?0&ECFU%5$6/LG@*]0B"\#,*83X% SY M_\A[T["F[G5M/*U5JA2# Z!8B'6 *F):)=(B)@Y5BHA!V8($(;4.D,28N@$) M$+*< !6!W5JAA4**"$%#B$@2*H1$"4-;B@QAD""$!!49 BL"84F2Q;N"V)ZS M=]_]OZZS>[WGP_]#OF1:6;\\P_U,]]-QX%[3C\BW '72#T$1YS$]BAX8W+IJ M+-*TN(4F$%(SMHZN^>D;K)-%:@\V;X(>O+?)C3_3N4;8W>P6@I_M7%/M;Q%F MN^P7O^E<^YR^P(5@720Y1,FX^L!VCJK$QKH!<-'9FXOHR^U&YX'WF:^+Z MC=>CBI@NU>5OB.M]?AFO3]FULW*6N+YV,/A3)S-QO=:9^9L8O!=O N/@!14& M$@O7%FFCB[Z*&/YK>*L6H0G[63E8EQ*9LJKCT/V6HM.1#[=-R%+'7;?(:R*8 M5?3U5?W$Y.H<5XGNAC##([NG1!#._J U?;G?G*E?;\H\@9-$:%WT\(3A];C+*>0(EVN<[^L%6@9X\![^\1*K?3*[-HNS(-M;_H2_WFQL."!Q[_4;;=C M9-_^R^[N_C2M.R)G&TTYLI.F@/XJRS.%K #HXD*.9@DA">\8^L)N*C!1LBOO MR!/*6>G[T$5-D.B 74*49^._F#.57&0*#F@16KGX=T1U$XEF M7G.BI$V49O/T*_YO9SLROEIS MP>7*#6/5.4(Y9R[K-(35N1SZJ4GJP J!CO:93BN(&0'ES4:;OM$%3-XA</[IXB<[!0,3?VWDG0R&P0L4AD/&3? C MA>?1VTR@CY!()ZB7E\01'2@\BB8KWG*GBE'8-<#&@?WZT-P(#=J:,O*UBLFM M$P/6V'EY% K/AQ;MF2DAR;3]Y@&2N1^8?@#"5;R%_"09>G?123Z-L3675]OUZ;)*;;*N7KJ?2Q(FY#519<3N= MP+1%'?JQ/Z>HCOQCR3Q;:N8AE#T=D,2; MD[8UA*D2MDW@^"3Y-V?CHF!X?U:=2K_=T]_\,;698O5_NW?U?]SSBF#XAR?9 M=D#5.H,7TU\3DIB@MW+6-)[;(!.*!%J""&! HP\RB#_2R#K7++_[]UMD]R1+ M(L 6Q:2M_>FT>%FCT'"RJ-Q8_VHNN55EM%VMYAJ=,/?R9:E\5T\\#GV)8^WI M+NBA9EY;UG$,++M* MX>C,4F,8[=+<\FB#Q]->BYU$QIEFM/%C>T$SJ#+7;Z MJ=4MQ:F%\>R;UZG.%Y[.FNSH!_ ZL".%Y1IORM P+*"+>W3$I"C"O:508 M38III8OHJPS#L2F5/9QHO>_.EIZ^X;+VC("(5^Q#;9*FK;5/3$O?,@TSB34> M=JF>KFJ!/40R&/SE^(] .$7#64@%3DCNPL&W2, .4:V/[]?V7\0[3J%.LC3JTT8=0 M2BA!(K7%4@:T2XCMIDS%I^>:.&"]'X@U[AN6=NEE6V&GS(3&RZO;M\2;W@R= M8G26M>6!0L$KK!H1:2!CX,;[SP9"+5I9D1U[U3MN_!R MI*J%OI/F,S^O].K@U".E3WJ*'/;QDS$:G=S_X0 =E-IGMX9]/U(_ 3 MQ'^;.:83>ARG45?"]&%Z@G%5 *(/\U,3#-T$8F4KH11V&G3T0%[-GNQB=_0# MU0*_^Z Q%M]XCK;K/QT6/<:9=12/9H@]UR(_C:"3:QA50Q4R="=E&K78\RV: MH!,!R8WZ^.B_Z8AR?C"\-A.;Q*J'OJ@<\]S?BU#<5 E;D6I9EW'KFY4)'I>U.)'OLVS6[7 M=@AY9G&K8B(XBR.$G ]U: F:X*/X$C2G_X4T@&_S;?,Y@.'VIHHS9J'-UV%A M&[OAV[JNN@/=T,7]K:Z>;]UY8;_PMIH"_U+\ EZGD^_H)<^G!;C7 P6-YDP_ M$GIF[K\==3NHNSB/&Z0\$CKPC^Y!ZV 2<=S$_AAX2)7.W#A(4&=4#?G(K(.H MF,7XE2&T24ZGPL39V>;I"@YY(W] 3K(&NQ%>/LIJ7,*4/R2-?%U0SU51&F/4 M_:TC3B6M;MG.VI68AK5OO"\03 ;W HDSRSR. 7.I[K8Y*Q43C*N.*W7$ZLK0 M.O+%X1RB/F&<;0MJ>Y*I>MO CR'@"$B\)''5;-L2QVTU9S[%3FW##)5WJ]M0 M'..9717;MH,5H>%8,5VJV@G*'"==TF4WAB4S>I_!-SM#GUJAL=K3Y=VR@=U5 M^(0T2^2BA=OBHVEAC.#C1>-A#QF ML#PS3,G J5"+'J@7;G_ZV/Z[CV:4;\*@Q.'PF#H>4,5O/HT;$/Y3YG1,5C]IQZ]%Z-%C/[U7!+$I1Q\TD#G4LNO]CA?-+Y51)D2_:B8,/B$V#ZOK\9O M7D2].T!*+2TX LW9W:X@=FS 'S!5 KUY]J/: T]9GA"#HD'/,;XGA!NEK9'9 M7W0JF5S-O J+Z\P,QX_3/F_%^>([Y#"F=1&@=@1%.;<+.Y\,;OF:61%<7M%F M)R\/NPA\%#[G1QTQV?/0[/(C'?:RYU$-W=],HKU*M[^T$+H8TLJN"6-P@TP5 M@6W%IV>)LM*WR,)_NCZL/RO6EYRZL*PYYI_''"MEO02MC2Y"?UIW(^,:;,,L M]6L^X;N+*.E@X5S;QJ56.I$XV\$D\2"FL#Z=V\TOD'&3?8,#Q,)O_&UY-[T+ MGU#9*UK'0^BN43Z ]]>'-!WU+Q$%PE?'A-*.[26 J#FP31J3S-LS_)IWP@\!0QW#S.WUKJ/ ME1F_1=^GJT>MGR!^WV8:-2+D!Y"APYCC%3K(0OOLO\[<(.[>EHNX^P<$Q-V[ MFMV]AL_>$3@T^F=/OY[[,3>GF>=[%.P&LIX,F^=[:L!GS+F1CDMT^RMZ@:40 MK59J*X7K=>X7C3ORF%QY.:?SU"A0*E*A![LQM?)\Q5HNZ9C:^??)#ZR1>ILQM?X[=ZMT0.Q